ID	Gene Name	Species	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	PIR_SUPERFAMILY	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
AGPAT1	1-acylglycerol-3-phosphate O-acyltransferase 1(AGPAT1)	Homo sapiens	GO:0001819~positive regulation of cytokine production,GO:0001961~positive regulation of cytokine-mediated signaling pathway,GO:0006644~phospholipid metabolic process,GO:0006654~phosphatidic acid biosynthetic process,GO:0008654~phospholipid biosynthetic process,GO:0016024~CDP-diacylglycerol biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0003841~1-acylglycerol-3-phosphate O-acyltransferase activity,GO:0005515~protein binding,	IPR002123:Phospholipid/glycerol acyltransferase,IPR004552:1-acyl-sn-glycerol-3-phosphate acyltransferase,	hsa00561:Glycerolipid metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04072:Phospholipase D signaling pathway,hsa04975:Fat digestion and absorption,			SM00563:PlsC,	KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,KW-0594~Phospholipid biosynthesis,KW-1208~Phospholipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,		DOMAIN:PlsC,MOTIF:EGTR motif,MOTIF:HXXXXD motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ACCS	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)(ACCS)	Homo sapiens	GO:0006520~cellular amino acid metabolic process,GO:0009058~biosynthetic process,GO:0042218~1-aminocyclopropane-1-carboxylate biosynthetic process,		GO:0003824~catalytic activity,GO:0005515~protein binding,GO:0008483~transaminase activity,GO:0030170~pyridoxal phosphate binding,GO:0042802~identical protein binding,	IPR004839:Aminotransferase, class I/classII,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,									KW-0663~Pyridoxal phosphate,			DOMAIN:Aminotran_1_2,REGION:Disordered,
HMGCLL1	3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1(HMGCLL1)	Homo sapiens	GO:0006552~leucine catabolic process,GO:0006629~lipid metabolic process,GO:0046951~ketone body biosynthetic process,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004419~hydroxymethylglutaryl-CoA lyase activity,GO:0046872~metal ion binding,	IPR000891:Pyruvate carboxyltransferase,IPR013785:Aldolase-type TIM barrel,	hsa00280:Valine, leucine and isoleucine degradation,hsa00650:Butanoate metabolism,hsa01100:Metabolic pathways,hsa04146:Peroxisome,				KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,			KW-0479~Metal-binding,	KW-0456~Lyase,	KW-0449~Lipoprotein,KW-0519~Myristate,	DOMAIN:Pyruvate carboxyltransferase,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Abolishes myristoylation and induces a subcellular location change.,MUTAGEN:H->R: Abolishes catalytic activity.,MUTAGEN:L->S: Abolishes catalytic activity.,MUTAGEN:R->Q: Abolishes catalytic activity.,
HPD	4-hydroxyphenylpyruvate dioxygenase(HPD)	Homo sapiens	GO:0006559~L-phenylalanine catabolic process,GO:0006572~tyrosine catabolic process,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003868~4-hydroxyphenylpyruvate dioxygenase activity,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR004360:Glyoxalase/fosfomycin resistance/dioxygenase domain,IPR005956:4-hydroxyphenylpyruvate dioxygenase,	hsa00130:Ubiquinone and other terpenoid-quinone biosynthesis,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,	140350~Hawkinsinuria,276710~Tyrosinemia, type III,	PIRSF009283:4-hydroxyphenylpyruvate dioxygenase,		KW-0585~Phenylalanine catabolism,KW-0828~Tyrosine catabolism,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:VOC,DOMAIN:VOC 1,DOMAIN:VOC 2,
HTR2A	5-hydroxytryptamine receptor 2A(HTR2A)	Homo sapiens	GO:0001659~temperature homeostasis,GO:0006096~glycolytic process,GO:0006874~cellular calcium ion homeostasis,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007208~phospholipase C-activating serotonin receptor signaling pathway,GO:0007210~serotonin receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0007613~memory,GO:0008219~cell death,GO:0008284~positive regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0010513~positive regulation of phosphatidylinositol biosynthetic process,GO:0014059~regulation of dopamine secretion,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0014824~artery smooth muscle contraction,GO:0014832~urinary bladder smooth muscle contraction,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030431~sleep,GO:0042493~response to drug,GO:0043267~negative regulation of potassium ion transport,GO:0043406~positive regulation of MAP kinase activity,GO:0044380~protein localization to cytoskeleton,GO:0045600~positive regulation of fat cell differentiation,GO:0045821~positive regulation of glycolytic process,GO:0045907~positive regulation of vasoconstriction,GO:0046718~viral entry into host cell,GO:0048148~behavioral response to cocaine,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050965~detection of temperature stimulus involved in sensory perception of pain,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0098664~G-protein coupled serotonin receptor signaling pathway,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0030424~axon,GO:0030425~dendrite,GO:0031410~cytoplasmic vesicle,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043198~dendritic shaft,GO:0045211~postsynaptic membrane,GO:0070852~cell body fiber,GO:0098666~G-protein coupled serotonin receptor complex,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001587~Gq/11-coupled serotonin receptor activity,GO:0001618~virus receptor activity,GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0030594~neurotransmitter receptor activity,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0051378~serotonin binding,GO:0071886~1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000455:5-Hydroxytryptamine 2A receptor,IPR002231:5-Hydroxytryptamine receptor family,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04540:Gap junction,hsa04726:Serotonergic synapse,hsa04750:Inflammatory mediator regulation of TRP channels,	103780~Alcohol dependence, susceptibility to,164230~Obsessive-compulsive disorder, susceptibility to,181500~Schizophrenia, susceptibility to,606788~Anorexia nervosa, susceptibility to,608516~Major depressive disorder, response to citalopram therapy in,608516~Seasonal affective disorder, susceptibility to,		SM01381:SM01381,	KW-0085~Behavior,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,MOTIF:DRY motif; important for ligand-induced conformation changes,MOTIF:NPxxY motif; important for ligand-induced conformation changes and signaling,MOTIF:PDZ-binding,MUTAGEN:C->S: No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-465.,MUTAGEN:G->V: Loss of interaction with PATJ.,MUTAGEN:L->A: Strongly increases dissociation of bound lysergic acid diethylamine, without affecting binding affinity. Reduces signaling via arrestins, but has no effect on signaling via the phosphatidylinositol-calcium second messenger system.,MUTAGEN:N->S: No effect on interaction with PATJ. Acquires the binding properties of HTR2C; when associated with S-470.,MUTAGEN:S->A: Increased ability of hallucinogens to desensitize the receptor.,MUTAGEN:S->D: Reduced receptor desensitization by nonhallucinogenic agonists.,MUTAGEN:V->A: Loss of interaction with PATJ, CASK, APBA1, DLG1 and DLG4.,REGION:Disordered,SITE:Hydrophobic barrier that decreases the speed of ligand binding and dissociation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADAM12	ADAM metallopeptidase domain 12(ADAM12)	Homo sapiens	GO:0006508~proteolysis,GO:0007155~cell adhesion,GO:0007520~myoblast fusion,GO:0045766~positive regulation of angiogenesis,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0008237~metallopeptidase activity,GO:0017124~SH3 domain binding,GO:0046872~metal ion binding,	IPR000742:Epidermal growth factor-like domain,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR001762:Blood coagulation inhibitor, Disintegrin,IPR002870:Peptidase M12B, propeptide,IPR006586:ADAM, cysteine-rich,IPR018358:Disintegrin, conserved site,IPR024079:Metallopeptidase, catalytic domain,				SM00050:DISIN,SM00608:ACR,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0729~SH3-binding,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0401~Integrin,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Disintegrin,DOMAIN:EGF-like,DOMAIN:Peptidase M12B,MOTIF:Cysteine switch,MOTIF:SH3-binding; class I,MOTIF:SH3-binding; class II,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ADAM33	ADAM metallopeptidase domain 33(ADAM33)	Homo sapiens	GO:0006508~proteolysis,GO:0007229~integrin-mediated signaling pathway,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004222~metalloendopeptidase activity,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,	IPR000742:Epidermal growth factor-like domain,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR001762:Blood coagulation inhibitor, Disintegrin,IPR002870:Peptidase M12B, propeptide,IPR006586:ADAM, cysteine-rich,IPR018358:Disintegrin, conserved site,IPR024079:Metallopeptidase, catalytic domain,				SM00050:DISIN,SM00608:ACR,		KW-0472~Membrane,	KW-1058~Asthma,	KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0401~Integrin,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Disintegrin,DOMAIN:EGF-like,DOMAIN:Pep_M12B_propep,DOMAIN:Peptidase M12B,MOTIF:Cysteine switch,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ADAMTS14	ADAM metallopeptidase with thrombospondin type 1 motif 14(ADAMTS14)	Homo sapiens	GO:0006508~proteolysis,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030574~collagen catabolic process,	GO:0005576~extracellular region,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0046872~metal ion binding,	IPR000884:Thrombospondin, type 1 repeat,IPR001590:Peptidase M12B, ADAM/reprolysin,IPR002870:Peptidase M12B, propeptide,IPR006586:ADAM, cysteine-rich,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,IPR013273:Peptidase M12B, ADAM-TS,IPR024079:Metallopeptidase, catalytic domain,				SM00209:TSP1,SM00608:ACR,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Disintegrin,DOMAIN:PLAC,DOMAIN:Peptidase M12B,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,REGION:Disordered,REGION:Spacer,
ADAMTSL4	ADAMTS like 4(ADAMTSL4)	Homo sapiens	GO:0002064~epithelial cell development,GO:0006915~apoptotic process,GO:0030198~extracellular matrix organization,GO:0043065~positive regulation of apoptotic process,GO:0070285~pigment cell development,	GO:0005576~extracellular region,GO:0005614~interstitial matrix,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0002020~protease binding,GO:0004222~metalloendopeptidase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000884:Thrombospondin, type 1 repeat,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,		225100~Ectopia lentis, isolated, autosomal recessive,225200~Ectopia lentis et pupillae,		SM00209:TSP1,	KW-0053~Apoptosis,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PLAC,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,DOMAIN:TSP type-1 5,DOMAIN:TSP type-1 6,REGION:Disordered,
ADCYAP1R1	ADCYAP receptor type I(ADCYAP1R1)	Homo sapiens	GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007283~spermatogenesis,GO:0009410~response to xenobiotic stimulus,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0019933~cAMP-mediated signaling,GO:0030154~cell differentiation,GO:0032355~response to estradiol,GO:0033555~multicellular organismal response to stress,GO:0042493~response to drug,GO:0043950~positive regulation of cAMP-mediated signaling,GO:0045471~response to ethanol,GO:0046545~development of primary female sexual characteristics,GO:0051057~positive regulation of small GTPase mediated signal transduction,GO:0060548~negative regulation of cell death,GO:0060732~positive regulation of inositol phosphate biosynthetic process,	GO:0005768~endosome,GO:0005791~rough endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0005923~bicellular tight junction,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0043231~intracellular membrane-bounded organelle,GO:0043235~receptor complex,	GO:0004930~G-protein coupled receptor activity,GO:0004999~vasoactive intestinal polypeptide receptor activity,GO:0005515~protein binding,GO:0008179~adenylate cyclase binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0017046~peptide hormone binding,GO:0031267~small GTPase binding,GO:0038023~signaling receptor activity,GO:0042923~neuropeptide binding,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR002285:GPCR, family 2, pituitary adenylate cyclase activating polypeptide type 1 receptor,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04911:Insulin secretion,hsa04924:Renin secretion,			SM00008:HormR,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F2_3,DOMAIN:G_PROTEIN_RECEP_F2_4,MUTAGEN:E->R: Reduced affinity for ADCYAP1.,MUTAGEN:P->A: Reduced affinity for ADCYAP1.,MUTAGEN:V->A: Reduced affinity for ADCYAP1.,MUTAGEN:Y->A: Strongly reduced affinity for ADCYAP1.,REGION:Important for ligand binding and specificity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
AEBP1	AE binding protein 1(AEBP1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:1904026~regulation of collagen fibril organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0004180~carboxypeptidase activity,GO:0004181~metallocarboxypeptidase activity,GO:0005201~extracellular matrix structural constituent,GO:0005516~calmodulin binding,GO:0005518~collagen binding,GO:0008270~zinc ion binding,	IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000834:Peptidase M14, carboxypeptidase A,IPR008969:Carboxypeptidase-like, regulatory domain,IPR008979:Galactose-binding domain-like,		618000~Ehlers-Danlos syndrome, classic-like, 2,		SM00231:FA58C,SM00631:Zn_pept,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0732~Signal,		KW-0112~Calmodulin-binding,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:F5/8 type C,DOMAIN:Peptidase_M14,REGION:Disordered,REGION:Interaction with MAPK1 and MAPK3,REGION:Interaction with PTEN,REGION:Required for DNA-binding and interaction with NFKBIA,REGION:Required for transcriptional repression,
AFF2	ALF transcription elongation factor 2(AFF2)	Homo sapiens	GO:0006397~mRNA processing,GO:0007420~brain development,GO:0007611~learning or memory,GO:0008380~RNA splicing,GO:0010468~regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0035063~nuclear speck organization,GO:0043484~regulation of RNA splicing,	GO:0016607~nuclear speck,	GO:0002151~G-quadruplex RNA binding,GO:0005515~protein binding,	IPR007797:Transcription factor AF4/FMR2,		309548~Intellectual developmental disorder, X-linked 109,			KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,	KW-0991~Intellectual disability,			KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
ALX3	ALX homeobox 3(ALX3)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0042981~regulation of apoptotic process,GO:0048701~embryonic cranial skeleton morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,		136760~Frontonasal dysplasia 1,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
APCDD1L	APC down-regulated 1 like(APCDD1L)	Homo sapiens	GO:0030178~negative regulation of Wnt signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0017147~Wnt-protein binding,		hsa04310:Wnt signaling pathway,			SM01352:SM01352,		KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:APCDDC,TRANSMEM:Helical,
ABCC3	ATP binding cassette subfamily C member 3(ABCC3)	Homo sapiens	GO:0006805~xenobiotic metabolic process,GO:0006855~drug transmembrane transport,GO:0015698~inorganic anion transport,GO:0015721~bile acid and bile salt transport,GO:0015779~glucuronoside transport,GO:0042908~xenobiotic transport,GO:0055085~transmembrane transport,GO:0071716~leukotriene transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,	GO:0005524~ATP binding,GO:0008559~xenobiotic-transporting ATPase activity,GO:0015164~glucuronoside transmembrane transporter activity,GO:0015431~glutathione S-conjugate-exporting ATPase activity,GO:0015432~bile acid-exporting ATPase activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0042910~xenobiotic transporter activity,GO:0043225~ATPase-coupled anion transmembrane transporter activity,GO:0071714~icosanoid transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR005292:Multi drug resistance-associated protein,IPR011527:ABC transporter, transmembrane domain, type 1,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa01523:Antifolate resistance,hsa02010:ABC transporters,hsa04976:Bile secretion,			SM00382:AAA,	KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transmembrane type-1 1,DOMAIN:ABC transmembrane type-1 2,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=11,TRANSMEM:Helical; Name=12,TRANSMEM:Helical; Name=13,TRANSMEM:Helical; Name=14,TRANSMEM:Helical; Name=15,TRANSMEM:Helical; Name=16,TRANSMEM:Helical; Name=17,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
ABCF1	ATP binding cassette subfamily F member 1(ABCF1)	Homo sapiens	GO:0006412~translation,GO:0006413~translational initiation,GO:0006954~inflammatory response,GO:0045727~positive regulation of translation,	GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0016020~membrane,GO:0042788~polysomal ribosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008135~translation factor activity, RNA binding,GO:0008494~translation activator activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0043022~ribosome binding,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00382:AAA,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:ABC transporter,DOMAIN:ABC transporter 1,DOMAIN:ABC transporter 2,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-477.,MUTAGEN:E->Q: Does not inhibit ribosome binding. Reduces protein synthesis; when associated with Q-768.,MUTAGEN:G->D: Does not inhibit ribosome binding.,MUTAGEN:H->L: Does not inhibit ribosome binding.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-342. Shows a reduced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:K->M: Does not inhibit ribosome binding. Reduces ATP-binding. Inhibits ATP-binding and reduces protein synthesis; when associated with M-664. Shows an enhanced association with polyribosomes; when associated with M-664. Does not inhibit IRES-mediated protein synthesis; when associated with M-664.,MUTAGEN:Q->E: Does not inhibit ribosome binding.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-109. Does not inhibits interaction with EIF2; when associated with S-109. Does not inhibit association with ribosomes; when associated with S-109. Reduces EIF2 interaction with ribosomes; when associated with S-109. Does not inhibit protein synthesis; when associated with A-109.,MUTAGEN:S->A: Reduces phosphorylation. Inhibits strongly phosphorylation by CK2; when associated with S-140. Does not inhibit interaction with EIF2; when associated with S-140. Does not inhibit association with ribosomes; when associated with S-140. Reduces EIF2 interaction with ribosomes; when associated with S-140. Does not inhibit protein synthesis; when associated with A-140.,REGION:Disordered,
ATP6V1B1	ATPase H+ transporting V1 subunit B1(ATP6V1B1)	Homo sapiens	GO:0001503~ossification,GO:0003091~renal water homeostasis,GO:0003096~renal sodium ion transport,GO:0006693~prostaglandin metabolic process,GO:0006885~regulation of pH,GO:0007035~vacuolar acidification,GO:0007588~excretion,GO:0007605~sensory perception of sound,GO:0010468~regulation of gene expression,GO:0016241~regulation of macroautophagy,GO:0030534~adult behavior,GO:0035812~renal sodium excretion,GO:0042048~olfactory behavior,GO:0042472~inner ear morphogenesis,GO:0045851~pH reduction,GO:0046034~ATP metabolic process,GO:0055064~chloride ion homeostasis,GO:0055074~calcium ion homeostasis,GO:0055075~potassium ion homeostasis,GO:0070072~vacuolar proton-transporting V-type ATPase complex assembly,GO:0097254~renal tubular secretion,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005902~microvillus,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0033180~proton-transporting V-type ATPase, V1 domain,GO:0070062~extracellular exosome,GO:0098850~extrinsic component of synaptic vesicle membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0016787~hydrolase activity,GO:0044877~macromolecular complex binding,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR000194:ATPase, F1/V1/A1 complex, alpha/beta subunit, nucleotide-binding domain,IPR004100:ATPase, alpha/beta subunit, N-terminal,IPR005723:ATPase, V1 complex, subunit B,IPR020003:ATPase, alpha/beta subunit, nucleotide-binding domain, active site,IPR022879:V-type ATP synthase regulatory subunit B/beta,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	267300~Distal renal tubular acidosis 2 with progressive sensorineural hearing loss,			KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,			DOMAIN:ATP-synt_ab,DOMAIN:ATP-synt_ab_N,MOTIF:PDZ-binding,MUTAGEN:L->G: Loss of interactions with SLC9A3R1 and SCL4A7.,
ATP6V1G2	ATPase H+ transporting V1 subunit G2(ATP6V1G2)	Homo sapiens	GO:0016241~regulation of macroautophagy,GO:0097401~synaptic vesicle lumen acidification,GO:1902600~hydrogen ion transmembrane transport,	GO:0000221~vacuolar proton-transporting V-type ATPase, V1 domain,GO:0005829~cytosol,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030285~integral component of synaptic vesicle membrane,GO:0030665~clathrin-coated vesicle membrane,GO:0042470~melanosome,GO:0098850~extrinsic component of synaptic vesicle membrane,	GO:0005515~protein binding,GO:0016887~ATPase activity,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0046961~proton-transporting ATPase activity, rotational mechanism,	IPR005124:Vacuolar (H+)-ATPase G subunit,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04145:Phagosome,hsa04150:mTOR signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,				KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,						COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
ATP1A3	ATPase Na+/K+ transporting subunit alpha 3(ATP1A3)	Homo sapiens	GO:0006883~cellular sodium ion homeostasis,GO:0010248~establishment or maintenance of transmembrane electrochemical gradient,GO:0021987~cerebral cortex development,GO:0030007~cellular potassium ion homeostasis,GO:0036376~sodium ion export from cell,GO:0060075~regulation of resting membrane potential,GO:0071300~cellular response to retinoic acid,GO:0071383~cellular response to steroid hormone stimulus,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0097067~cellular response to thyroid hormone stimulus,GO:1902600~hydrogen ion transmembrane transport,GO:1903416~response to glycoside,GO:1904646~cellular response to beta-amyloid,GO:1990535~neuron projection maintenance,GO:1990573~potassium ion import across plasma membrane,	GO:0001917~photoreceptor inner segment,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005890~sodium:potassium-exchanging ATPase complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0031090~organelle membrane,GO:0032809~neuronal cell body membrane,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043209~myelin sheath,GO:0044305~calyx of Held,GO:0044326~dendritic spine neck,GO:0044327~dendritic spine head,GO:0045202~synapse,GO:0060342~photoreceptor inner segment membrane,GO:0098984~neuron to neuron synapse,GO:1903561~extracellular vesicle,	GO:0001540~beta-amyloid binding,GO:0005391~sodium:potassium-exchanging ATPase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008556~potassium-transporting ATPase activity,GO:0016887~ATPase activity,GO:0019829~cation-transporting ATPase activity,GO:0031748~D1 dopamine receptor binding,GO:0046872~metal ion binding,GO:0051087~chaperone binding,GO:0099520~ion antiporter activity involved in regulation of presynaptic membrane potential,GO:1990239~steroid hormone binding,	IPR001757:Cation-transporting P-type ATPase,IPR004014:Cation-transporting P-type ATPase, N-terminal,IPR005775:Sodium/potassium-transporting P-type ATPase, subfamily IIC,IPR006068:Cation-transporting P-type ATPase, C-terminal,IPR008250:P-type ATPase, A  domain,IPR018303:P-type ATPase, phosphorylation site,IPR023214:HAD-like domain,IPR023298:P-type ATPase,  transmembrane domain,IPR023299:P-type ATPase, cytoplasmic domain N,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04911:Insulin secretion,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04964:Proximal tubule bicarbonate reclamation,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa04974:Protein digestion and absorption,hsa04976:Bile secretion,hsa04978:Mineral absorption,	128235~Dystonia-12,601338~CAPOS syndrome,614820~Alternating hemiplegia of childhood 2,619606~Developmental and epileptic encephalopathy 99,		SM00831:SM00831,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0740~Sodium/potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-0887~Epilepsy,KW-0908~Parkinsonism,KW-0991~Intellectual disability,KW-1023~Dystonia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,KW-0915~Sodium,	KW-1278~Translocase,	KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,DOMAIN:Cation_ATPase_N,REGION:Disordered,REGION:Interaction with phosphoinositide-3 kinase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ATP2B2	ATPase plasma membrane Ca2+ transporting 2(ATP2B2)	Homo sapiens	GO:0003407~neural retina development,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0007420~brain development,GO:0007605~sensory perception of sound,GO:0030182~neuron differentiation,GO:0034220~ion transmembrane transport,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0070588~calcium ion transmembrane transport,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,GO:1903779~regulation of cardiac conduction,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0032591~dendritic spine membrane,GO:0032809~neuronal cell body membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0048787~presynaptic active zone membrane,GO:0070062~extracellular exosome,GO:0098688~parallel fiber to Purkinje cell synapse,GO:0098793~presynapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0005388~calcium-transporting ATPase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0016887~ATPase activity,GO:0019829~cation-transporting ATPase activity,GO:0030165~PDZ domain binding,GO:0035254~glutamate receptor binding,GO:0046872~metal ion binding,GO:1905056~calcium-transporting ATPase activity involved in regulation of presynaptic cytosolic calcium ion concentration,GO:1905059~calcium-transporting ATPase activity involved in regulation of postsynaptic cytosolic calcium ion concentration,	IPR001757:Cation-transporting P-type ATPase,IPR004014:Cation-transporting P-type ATPase, N-terminal,IPR006068:Cation-transporting P-type ATPase, C-terminal,IPR006408:Calcium-transporting P-type ATPase, subfamily IIB,IPR008250:P-type ATPase, A  domain,IPR018303:P-type ATPase, phosphorylation site,IPR022141:Calcium transporting P-type ATPase, C-terminal, plasma membrane,IPR023214:HAD-like domain,IPR023298:P-type ATPase,  transmembrane domain,IPR023299:P-type ATPase, cytoplasmic domain N,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04925:Aldosterone synthesis and secretion,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,hsa04978:Mineral absorption,	601386~Deafness, autosomal recessive 12, modifier of,619804~Deafness, autosomal dominant 82,		SM00831:SM00831,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-1278~Translocase,	KW-0597~Phosphoprotein,	ACT_SITE:4-aspartylphosphate intermediate,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ATP_Ca_trans_C,DOMAIN:Cation_ATPase_C,DOMAIN:Cation_ATPase_N,REGION:Calmodulin-binding subdomain A,REGION:Calmodulin-binding subdomain B,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ARAP3	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3(ARAP3)	Homo sapiens	GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0016192~vesicle-mediated transport,GO:0043547~positive regulation of GTPase activity,	GO:0001726~ruffle,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030027~lamellipodium,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0046872~metal ion binding,	IPR000159:Ras-association,IPR000198:Rho GTPase-activating protein domain,IPR001164:Arf GTPase activating protein,IPR001660:Sterile alpha motif domain,IPR001849:Pleckstrin homology domain,IPR008936:Rho GTPase activation protein,IPR011993:Pleckstrin homology-like domain,IPR013761:Sterile alpha motif/pointed domain,	hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04144:Endocytosis,			SM00105:ArfGap,SM00233:PH,SM00324:RhoGAP,SM00454:SAM,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Arf-GAP,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:PH 3,DOMAIN:Ras-associating,DOMAIN:Rho-GAP,DOMAIN:SAM,MUTAGEN:RR->AA: Loss of PtdIns(3,4,5)P3 binding.,REGION:Disordered,ZN_FING:C4-type,
BCL2L12	BCL2 like 12(BCL2L12)	Homo sapiens	GO:0006915~apoptotic process,GO:0042981~regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:1990001~inhibition of cysteine-type endopeptidase activity involved in apoptotic process,GO:2000773~negative regulation of cellular senescence,GO:2001236~regulation of extrinsic apoptotic signaling pathway,	GO:0005634~nucleus,GO:0016020~membrane,	GO:0002039~p53 binding,						KW-0053~Apoptosis,						KW-0488~Methylation,KW-0597~Phosphoprotein,	MOTIF:BH2,REGION:Disordered,
BCL3	BCL3 transcription coactivator(BCL3)	Homo sapiens	GO:0002268~follicular dendritic cell differentiation,GO:0002315~marginal zone B cell differentiation,GO:0002455~humoral immune response mediated by circulating immunoglobulin,GO:0002467~germinal center formation,GO:0006606~protein import into nucleus,GO:0006974~cellular response to DNA damage stimulus,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0009615~response to virus,GO:0010225~response to UV-C,GO:0019730~antimicrobial humoral response,GO:0030198~extracellular matrix organization,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032717~negative regulation of interleukin-8 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032733~positive regulation of interleukin-10 production,GO:0042088~T-helper 1 type immune response,GO:0042742~defense response to bacterium,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0042832~defense response to protozoan,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045064~T-helper 2 cell differentiation,GO:0045727~positive regulation of translation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046426~negative regulation of JAK-STAT cascade,GO:0048536~spleen development,GO:0051101~regulation of DNA binding,GO:0070231~T cell apoptotic process,GO:0070233~negative regulation of T cell apoptotic process,GO:1901222~regulation of NIK/NF-kappaB signaling,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030496~midbody,GO:0032991~macromolecular complex,GO:0032996~Bcl3-Bcl10 complex,GO:0033257~Bcl3/NF-kappaB2 complex,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0030674~protein binding, bridging,GO:0042826~histone deacetylase binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa04625:C-type lectin receptor signaling pathway,hsa04668:TNF signaling pathway,	Leukemia/lymphoma, B-cell, 3~Leukemia/lymphoma, B-cell, 3,		SM00248:ANK,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0040~ANK repeat,KW-0677~Repeat,		KW-0010~Activator,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
BEND4	BEN domain containing 4(BEND4)	Homo sapiens			GO:0003677~DNA binding,	IPR018379:BEN domain,				SM01025:SM01025,				KW-0175~Coiled coil,				COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BEN,REGION:Disordered,
BRINP1	BMP/retinoic acid inducible neural specific 1(BRINP1)	Homo sapiens	GO:0001662~behavioral fear response,GO:0007049~cell cycle,GO:0007614~short-term memory,GO:0008219~cell death,GO:0022008~neurogenesis,GO:0035176~social behavior,GO:0035640~exploration behavior,GO:0042711~maternal behavior,GO:0045666~positive regulation of neuron differentiation,GO:0045786~negative regulation of cell cycle,GO:0045930~negative regulation of mitotic cell cycle,GO:0050768~negative regulation of neurogenesis,GO:0071300~cellular response to retinoic acid,GO:0071625~vocalization behavior,	GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0030425~dendrite,GO:0043025~neuronal cell body,	GO:0005515~protein binding,	IPR020864:Membrane attack complex component/perforin (MACPF) domain,				SM00457:MACPF,	KW-0131~Cell cycle,KW-0338~Growth arrest,	KW-0963~Cytoplasm,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MACPF,
BTBD17	BTB domain containing 17(BTBD17)	Homo sapiens	GO:0009615~response to virus,GO:0045071~negative regulation of viral genome replication,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,		IPR000210:BTB/POZ-like,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,				SM00225:BTB,SM00875:SM00875,		KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BACK,DOMAIN:BTB,
BUB1B	BUB1 mitotic checkpoint serine/threonine kinase B(BUB1B)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0006915~apoptotic process,GO:0007091~metaphase/anaphase transition of mitotic cell cycle,GO:0007093~mitotic cell cycle checkpoint,GO:0007094~mitotic spindle assembly checkpoint,GO:0016310~phosphorylation,GO:0051301~cell division,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051754~meiotic sister chromatid cohesion, centromeric,GO:0071459~protein localization to chromosome, centromeric region,	GO:0000776~kinetochore,GO:0000940~condensed chromosome outer kinetochore,GO:0005680~anaphase-promoting complex,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0033597~mitotic checkpoint complex,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR011009:Protein kinase-like domain,IPR013212:Mad3/BUB1 homology region 1,IPR015661:Mitotic checkpoint serine/threonine protein kinase Bub1/Mitotic spindle checkpoint component Mad3,	hsa04110:Cell cycle,hsa05166:Human T-cell leukemia virus 1 infection,	114500~Colorectal cancer, somatic,176430~Premature chromatid separation trait,257300~Mosaic variegated aneuploidy syndrome 1,		SM00777:Mad3_BUB1_I,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0043~Tumor suppressor,KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:BUB1 N-terminal,DOMAIN:Protein kinase,MOTIF:D-box,MOTIF:Nuclear localization signal,MUTAGEN:A->W: Loss of interaction with KNL1.,MUTAGEN:D->E: Abolishes the cleavage by caspase-3.,MUTAGEN:F->A: Loss of interaction with KNL1.,MUTAGEN:K->A: Does not abolish the capacity to inhibit APC/CDC20.,MUTAGEN:K->R: Inhibits kinase activity.,MUTAGEN:T->A: Induces chromosome congression defects and mitotic delay.,REGION:Disordered,REGION:Necessary for interaction with KNL1,SITE:Cleavage; by caspase-3,
BUB1	BUB1 mitotic checkpoint serine/threonine kinase(BUB1)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007063~regulation of sister chromatid cohesion,GO:0007093~mitotic cell cycle checkpoint,GO:0007094~mitotic spindle assembly checkpoint,GO:0008283~cell proliferation,GO:0051301~cell division,GO:0051754~meiotic sister chromatid cohesion, centromeric,GO:0051983~regulation of chromosome segregation,	GO:0000776~kinetochore,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016301~kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013212:Mad3/BUB1 homology region 1,IPR015661:Mitotic checkpoint serine/threonine protein kinase Bub1/Mitotic spindle checkpoint component Mad3,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,	114500~Colorectal cancer with chromosomal instability, somatic,		SM00220:S_TKc,SM00777:Mad3_BUB1_I,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:BUB1 N-terminal,DOMAIN:Protein kinase,MOTIF:KEN box 1,MOTIF:KEN box 2,MOTIF:Nuclear localization signal,MUTAGEN:A->D,W: Loss of interaction with KNL1.,MUTAGEN:A->S: Partial rescue of the spindle-assembly checkpoint activity. Increased rate of chromosome congression errors. Impaired localization to kinetochores and loss of kinetochore binding of CENPF, SGO1 and BUBR1 but not of MCAK, MAD1L1 or MAD2L1.,MUTAGEN:E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-537.,MUTAGEN:E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-627.,MUTAGEN:K->A: Loss of activity.,MUTAGEN:K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-536 and A-537.,MUTAGEN:K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-626 and A-627.,MUTAGEN:L->G: Loss of interaction with KNL1.,MUTAGEN:N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-536.,MUTAGEN:N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-626.,MUTAGEN:T->A: Diminished interaction with PLK1.,REGION:Disordered,REGION:Essential for loading of BUBR1, MAD1L1 and MAD2L1 to kinetochores,REGION:Necessary for interaction with BUB3,REGION:Necessary for interaction with KNL1,REGION:Necessary for kinetochore localization,
CCL20	C-C motif chemokine ligand 20(CCL20)	Homo sapiens	GO:0002548~monocyte chemotaxis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0042742~defense response to bacterium,GO:0043547~positive regulation of GTPase activity,GO:0048247~lymphocyte chemotaxis,GO:0060326~cell chemotaxis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0072678~T cell migration,GO:0072679~thymocyte migration,GO:2000406~positive regulation of T cell migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0031731~CCR6 chemokine receptor binding,GO:0048020~CCR chemokine receptor binding,	IPR000827:CC chemokine, conserved site,IPR001811:Chemokine interleukin-8-like domain,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa05323:Rheumatoid arthritis,			SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0044~Antibiotic,KW-0202~Cytokine,KW-0929~Antimicrobial,	KW-1015~Disulfide bond,
CCR2	C-C motif chemokine receptor 2(CCR2)	Homo sapiens	GO:0001974~blood vessel remodeling,GO:0002407~dendritic cell chemotaxis,GO:0002548~monocyte chemotaxis,GO:0002724~regulation of T cell cytokine production,GO:0002827~positive regulation of T-helper 1 type immune response,GO:0002829~negative regulation of type 2 immune response,GO:0006874~cellular calcium ion homeostasis,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0006968~cellular defense response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007259~JAK-STAT cascade,GO:0009611~response to wounding,GO:0010574~regulation of vascular endothelial growth factor production,GO:0010820~positive regulation of T cell chemotaxis,GO:0016525~negative regulation of angiogenesis,GO:0019221~cytokine-mediated signaling pathway,GO:0019233~sensory perception of pain,GO:0019722~calcium-mediated signaling,GO:0019725~cellular homeostasis,GO:0030097~hemopoiesis,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035696~monocyte extravasation,GO:0035705~T-helper 17 cell chemotaxis,GO:0043310~negative regulation of eosinophil degranulation,GO:0045580~regulation of T cell differentiation,GO:0046641~positive regulation of alpha-beta T cell proliferation,GO:0048873~homeostasis of number of cells within a tissue,GO:0050727~regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0050870~positive regulation of T cell activation,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060326~cell chemotaxis,GO:0061756~leukocyte adhesion to vascular endothelial cell,GO:0070098~chemokine-mediated signaling pathway,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090265~positive regulation of immune complex clearance by monocytes and macrophages,GO:0090594~inflammatory response to wounding,GO:0097350~neutrophil clearance,GO:1903238~positive regulation of leukocyte tethering or rolling,GO:1904783~positive regulation of NMDA glutamate receptor activity,GO:1905517~macrophage migration,GO:1905521~regulation of macrophage migration,GO:2000412~positive regulation of thymocyte migration,GO:2000439~positive regulation of monocyte extravasation,GO:2000451~positive regulation of CD8-positive, alpha-beta T cell extravasation,GO:2000464~positive regulation of astrocyte chemotaxis,GO:2000473~positive regulation of hematopoietic stem cell migration,	GO:0001650~fibrillar center,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,	GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0016493~C-C chemokine receptor activity,GO:0019957~C-C chemokine binding,GO:0031727~CCR2 chemokine receptor binding,GO:0035715~chemokine (C-C motif) ligand 2 binding,GO:0035716~chemokine (C-C motif) ligand 12 binding,GO:0035717~chemokine (C-C motif) ligand 7 binding,GO:0042802~identical protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000355:Chemokine receptor family,IPR002237:CC chemokine receptor 2,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,	HIV infection, susceptibility/resistance to~HIV infection, susceptibility/resistance to,		SM01381:SM01381,	KW-0395~Inflammatory response,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CCR5	C-C motif chemokine receptor 5(CCR5)	Homo sapiens	GO:0000165~MAPK cascade,GO:0002407~dendritic cell chemotaxis,GO:0006816~calcium ion transport,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007267~cell-cell signaling,GO:0014808~release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0019722~calcium-mediated signaling,GO:0023052~signaling,GO:0046718~viral entry into host cell,GO:0060326~cell chemotaxis,GO:0070098~chemokine-mediated signaling pathway,GO:0070723~response to cholesterol,GO:0071222~cellular response to lipopolysaccharide,GO:2000110~negative regulation of macrophage apoptotic process,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0001618~virus receptor activity,GO:0003779~actin binding,GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004950~chemokine receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0016493~C-C chemokine receptor activity,GO:0019957~C-C chemokine binding,GO:0042802~identical protein binding,GO:0071791~chemokine (C-C motif) ligand 5 binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000355:Chemokine receptor family,IPR002240:CC chemokine receptor 5,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa03250:Viral life cycle - HIV-1,hsa03260:Virion - Human immunodeficiency virus,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04144:Endocytosis,hsa05145:Toxoplasmosis,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,	609532~Hepatitis C virus, resistance to,610379~West nile virus, susceptibility to,612522~Diabetes mellitus, insulin-dependent, 22,HIV infection, susceptibility/resistance to~HIV infection, susceptibility/resistance to,		SM01381:SM01381,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0219~Diabetes mellitus,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) serine,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreases to 40% surface expression. Disrupts conformational integrity. Disrupts binding of CCL4. Decreases HIV cell infection.,MUTAGEN:C->A: Decreases to 40% surface expression. No effect on conformational integrity. Disrupts binding of CCL4. Decreases cell HIV infection.,MUTAGEN:C->A: Small reduction in palmitoylation. Cell surface expression reduced by 50%. Greatly reduced palmitoylation. Cell surface expression greatly reduced; when associated with A-321 or A-323. No palmitoylation. Cell surface expression greatly reduced. HIV entry reduced by 50%; when associated with A-321 and A-323.,MUTAGEN:C->A: Small reduction in palmitoylation. Cell surface expression reduced by 50%. Greatly reduced palmitoylation. Cell surface expression greatly reduced; when associated with A-321 or A-324. No palmitoylation. Cell surface expression greatly reduced. HIV entry reduced by 50%; when associated with A-321 and A-324.,MUTAGEN:C->A: Small reduction in palmitoylation. Cell surface expression reduced by 50%. Greatly reduced palmitoylation. Cell surface expression greatly reduced; when associated with A-323 or A-324. No palmitoylation. Cell surface expression greatly reduced. HIV entry reduced by 50%; when associated with A-323 and A-324.,MUTAGEN:S->A: APO-RANTES-stimulated phosphorylation reduced by 15%; APO-RANTES-stimulated phosphorylation reduced by 30-50%; when associated with A-337 or A-342 or A-349; APO-RANTES-stimulated phosphorylation reduced by 80%; when associated with A-337 and A-342 or A-349; No APO-RANTES-stimulated phosphorylation; when associated with A-337; A-342 and A349; abolishes interaction with ARRB2; when associated with S-337; S-342 and S-349.,MUTAGEN:S->A: APO-RANTES-stimulated phosphorylation reduced by 18%; APO-RANTES-stimulated phosphorylation reduced by 30-50% on APO-RANTES stimulation; when associated with A-336 or A-342 or A-349; APO-RANTES-stimulated phosphorylation reduced by 80%; when associated with A-336 and A-342 or A-349; No APO-RANTES-stimulated phosphorylation; when associated with A-336; A-342 and A349; abolishes interaction with ARRB2; when associated with S-336; S-342 and S-349.,MUTAGEN:S->A: APO-RANTES-stimulated phosphorylation reduced by 42%. Phosphorylation reduced by 50% on APO-RANTES stimulation; when associated with A-336 or A-337 or A-349; APO-RANTES-stimulated phosphorylation reduced by 80% when associated with A-336 and A-337 or A-349; No APO-RANTES-stimulated phosphorylation; when associated with A-336; A-337 and A349; abolishes interaction with ARRB2; when associated with S-336; S-337 and S-349.,MUTAGEN:S->A: APO-RANTES-stimulated phosphorylation reduced by 43%; APO-RANTES-stimulated phosphorylation reduced by 30-50%; when associated with A-336 or A-337 or A-342; APO-RANTES-stimulated phosphorylation reduced by 80%; when associated with A-336 and A-337 or A-342; No APO-RANTES-stimulated phosphorylation stimulation; when associated with A-336; A-337 and A347; abolishes interaction with ARRB2; when associated with S-336; S-337 and S-342.,MUTAGEN:S->A: No change in glycosylation status and binds CCL4 as efficiently as wild type. Loss of molecular mass of about 2 kDa as compared to wild type. Dramatically reduced binding of CCL4; when associated with A-6; A-16; A-17. Similar molecular mass loss. Dramatically reduced binding of CCL4; when associated with A-6 only.,MUTAGEN:S->A: No change in glycosylation status and greatly decreased CCL4 binding. Loss of molecular mass of about 2 kDa as compared to wild type. Dramatically reduced binding of CCL4; when associated with A-7; A-16; A-17. Similar molecular mass loss. Dramatically reduced binding of CCL4; when associated with A-7 only.,MUTAGEN:S->A: Similar decrease in molecular mass when treated with O-glycosidase as for wild type; when associated with A-16.,MUTAGEN:T->A: Similar decrease in molecular mass when treated with O-glycosidase as for wild type; when associated with A-17.,MUTAGEN:Y->D: No sulfation and greatly decreased binding of CCL4 and CCL5; when associated with D-10; D-14 and D-15. Restored most CCL4 binding; when associated with D-10 and D-15.,MUTAGEN:Y->D: No sulfation and greatly decreased binding of CCL4 and CCL5; when associated with D-3; D-10 and D-14. No restoration of CCL4 binding; when associated with D-10 and D-15.,MUTAGEN:Y->D: No sulfation and greatly decreased binding of CCL4 and CCL5; when associated with D-3; D-10 and D-14. Restored most CCL4 binding; when associated with D-3 and D-10.,MUTAGEN:Y->F: No sulfation and greatly decreases binding of CCL4 and CCL5; when associated with F-10; F-14 and F-15.,MUTAGEN:Y->F: No sulfation and greatly decreases binding of CCL4 and CCL5; when associated with F-3; F-10 and F-14. Small loss of sulfation; when associated with F-10 and F-14.,MUTAGEN:Y->F: No sulfation and greatly decreases binding of CCL4 and CCL5; when associated with F-3; F-10; and F-15. Small loss of sulfation; when associated with F-10 and F-15.,MUTAGEN:Y->F: No sulfation and greatly decreases binding of CCL4 and CCL5; when associated with F-3; F-14 and F-15. Small loss of sulfation; when associated with F-14 and F-15.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CXCL10	C-X-C motif chemokine ligand 10(CXCL10)	Homo sapiens	GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007517~muscle organ development,GO:0008015~blood circulation,GO:0008284~positive regulation of cell proliferation,GO:0009409~response to cold,GO:0010332~response to gamma radiation,GO:0010818~T cell chemotaxis,GO:0010819~regulation of T cell chemotaxis,GO:0010996~response to auditory stimulus,GO:0016525~negative regulation of angiogenesis,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0033280~response to vitamin D,GO:0034605~cellular response to heat,GO:0042118~endothelial cell activation,GO:0042127~regulation of cell proliferation,GO:0042981~regulation of apoptotic process,GO:0045662~negative regulation of myoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050790~regulation of catalytic activity,GO:0050918~positive chemotaxis,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:0090026~positive regulation of monocyte chemotaxis,GO:0097398~cellular response to interleukin-17,GO:0098586~cellular response to virus,GO:1901509~regulation of endothelial tube morphogenesis,GO:1901740~negative regulation of myoblast fusion,GO:2000406~positive regulation of T cell migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008201~heparin binding,GO:0008603~cAMP-dependent protein kinase regulator activity,GO:0042056~chemoattractant activity,GO:0045236~CXCR chemokine receptor binding,GO:0048248~CXCR3 chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04620:Toll-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa05160:Hepatitis C,hsa05164:Influenza A,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,			SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0164~Citrullination,KW-1015~Disulfide bond,
CXCL11	C-X-C motif chemokine ligand 11(CXCL11)	Homo sapiens	GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0010818~T cell chemotaxis,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0042127~regulation of cell proliferation,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008201~heparin binding,GO:0045236~CXCR chemokine receptor binding,GO:0048248~CXCR3 chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,IPR027221:CXC chemokine 11,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04620:Toll-like receptor signaling pathway,			SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0164~Citrullination,KW-1015~Disulfide bond,
CXCL8	C-X-C motif chemokine ligand 8(CXCL8)	Homo sapiens	GO:0001525~angiogenesis,GO:0002237~response to molecule of bacterial origin,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0019722~calcium-mediated signaling,GO:0030155~regulation of cell adhesion,GO:0030593~neutrophil chemotaxis,GO:0031328~positive regulation of cellular biosynthetic process,GO:0031623~receptor internalization,GO:0031640~killing of cells of other organism,GO:0034976~response to endoplasmic reticulum stress,GO:0035556~intracellular signal transduction,GO:0042119~neutrophil activation,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045091~regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045744~negative regulation of G-protein coupled receptor protein signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0048566~embryonic digestive tract development,GO:0050930~induction of positive chemotaxis,GO:0051726~regulation of cell cycle,GO:0060354~negative regulation of cell adhesion molecule production,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090023~positive regulation of neutrophil chemotaxis,GO:2000535~regulation of entry of bacterium into host cell,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005153~interleukin-8 receptor binding,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008201~heparin binding,GO:0045236~CXCR chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04218:Cellular senescence,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04622:RIG-I-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05144:Malaria,hsa05146:Amoebiasis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05219:Bladder cancer,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,			SM00199:SCY,	KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0164~Citrullination,KW-1015~Disulfide bond,	DOMAIN:SCY,MUTAGEN:K->A: Decreases heparin-binding activity. Impairs heparin-binding activity and leukocyte transendothelial migration; when associated with A-94 and A-95.,MUTAGEN:K->A: Impairs heparin-binding activity and leukocyte transendothelial migration; when associated with A-91 and A-95.,MUTAGEN:R->A: Impairs heparin-binding activity and leukocyte transendothelial migration; when associated with A-91 and A-94.,SITE:Cleavage; by MMP9,SITE:Cleavage; by thrombin,
CXCL9	C-X-C motif chemokine ligand 9(CXCL9)	Homo sapiens	GO:0006935~chemotaxis,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0042127~regulation of cell proliferation,GO:0045663~positive regulation of myoblast differentiation,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051607~defense response to virus,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:1901741~positive regulation of myoblast fusion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0045236~CXCR chemokine receptor binding,GO:0048248~CXCR3 chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,hsa04620:Toll-like receptor signaling pathway,			SM00199:SCY,	KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,	COMPBIAS:Basic residues,REGION:Disordered,
CLEC5A	C-type lectin domain containing 5A(CLEC5A)	Homo sapiens	GO:0001819~positive regulation of cytokine production,GO:0002076~osteoblast development,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0030099~myeloid cell differentiation,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0045087~innate immune response,GO:0046718~viral entry into host cell,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0035579~specific granule membrane,GO:0070821~tertiary granule membrane,	GO:0001618~virus receptor activity,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,MUTAGEN:K->I: Abolishes interaction with TYROBP.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CLEC9A	C-type lectin domain containing 9A(CLEC9A)	Homo sapiens	GO:0001819~positive regulation of cytokine production,GO:0006898~receptor-mediated endocytosis,	GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,				SM00034:CLECT,	KW-0254~Endocytosis,	KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,MOTIF:ITAM-like,MUTAGEN:W->A: Abolishes binding to damaged cells; when associated with A-131.,MUTAGEN:W->A: Abolishes binding to damaged cells; when associated with A-227.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CLEC12A	C-type lectin domain family 12 member A(CLEC12A)	Homo sapiens	GO:0007165~signal transduction,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0035579~specific granule membrane,GO:0070821~tertiary granule membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0030545~receptor regulator activity,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,MOTIF:ITIM motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CLEC18B	C-type lectin domain family 18 member B(CLEC18B)	Homo sapiens		GO:0005615~extracellular space,GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0016529~sarcoplasmic reticulum,	GO:0030247~polysaccharide binding,	IPR000742:Epidermal growth factor-like domain,IPR001283:Allergen V5/Tpx-1-related,IPR001304:C-type lectin,IPR014044:CAP domain,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,				SM00034:CLECT,SM00181:EGF,SM00198:SCP,		KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0964~Secreted,KW-0967~Endosome,		KW-0245~EGF-like domain,KW-0732~Signal,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,DOMAIN:EGF-like,DOMAIN:SCP,
CASKIN1	CASK interacting protein 1(CASKIN1)	Homo sapiens	GO:0007165~signal transduction,	GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001452:Src homology-3 domain,IPR001660:Sterile alpha motif domain,IPR002110:Ankyrin repeat,IPR013761:Sterile alpha motif/pointed domain,IPR020683:Ankyrin repeat-containing domain,IPR027013:Caskin,				SM00248:ANK,SM00326:SH3,SM00454:SAM,		KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SAM,DOMAIN:SAM 1,DOMAIN:SAM 2,DOMAIN:SH3,REGION:CASK-binding,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,
CEBPD	CCAAT enhancer binding protein delta(CEBPD)	Homo sapiens	GO:0002244~hematopoietic progenitor cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0045444~fat cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,IPR016468:CCAAT/enhancer-binding,			PIRSF005879:CCAAT/enhancer-binding protein,	SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:bZIP,MUTAGEN:K->A: Loss of sumoylation.,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
CD101	CD101 molecule(CD101)	Homo sapiens	GO:0002763~positive regulation of myeloid leukocyte differentiation,GO:0007166~cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0016812~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides,	IPR002195:Dihydroorotase, conserved site,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IG,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,MOTIF:EWI motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD14	CD14 molecule(CD14)	Homo sapiens	GO:0006898~receptor-mediated endocytosis,GO:0006909~phagocytosis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007166~cell surface receptor signaling pathway,GO:0009408~response to heat,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0031666~positive regulation of lipopolysaccharide-mediated signaling pathway,GO:0032026~response to magnesium ion,GO:0032481~positive regulation of type I interferon production,GO:0032729~positive regulation of interferon-gamma production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034142~toll-like receptor 4 signaling pathway,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0034612~response to tumor necrosis factor,GO:0045087~innate immune response,GO:0045471~response to ethanol,GO:0045807~positive regulation of endocytosis,GO:0051602~response to electrical stimulus,GO:0071219~cellular response to molecule of bacterial origin,GO:0071222~cellular response to lipopolysaccharide,GO:0071223~cellular response to lipoteichoic acid,GO:0071726~cellular response to diacyl bacterial lipopeptide,GO:0071727~cellular response to triacyl bacterial lipopeptide,GO:1901224~positive regulation of NIK/NF-kappaB signaling,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0030667~secretory granule membrane,GO:0031362~anchored component of external side of plasma membrane,GO:0045121~membrane raft,GO:0046696~lipopolysaccharide receptor complex,GO:0070062~extracellular exosome,	GO:0001530~lipopolysaccharide binding,GO:0001847~opsonin receptor activity,GO:0005515~protein binding,GO:0016019~peptidoglycan receptor activity,GO:0070891~lipoteichoic acid binding,GO:0071723~lipopeptide binding,	IPR001611:Leucine-rich repeat,IPR016337:Monocyte differentiation antigen CD14,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04145:Phagosome,hsa04620:Toll-like receptor signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04936:Alcoholic liver disease,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,hsa05417:Lipid and atherosclerosis,		PIRSF002017:monocyte differentiation antigen CD14,		KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,LIPID:GPI-anchor amidated asparagine,PROPEP:Removed in mature form,REGION:Required for response to bacterial lipopolysaccharide (LPS),REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
CD163	CD163 molecule(CD163)	Homo sapiens	GO:0006897~endocytosis,GO:0006953~acute-phase response,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,	GO:0005044~scavenger receptor activity,GO:0005515~protein binding,GO:0097110~scaffold protein binding,	IPR001190:Speract/scavenger receptor,IPR017448:Speract/scavenger receptor-related,				SM00202:SR,	KW-0011~Acute phase,KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SRCR,DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,DOMAIN:SRCR 4,DOMAIN:SRCR 5,DOMAIN:SRCR 6,DOMAIN:SRCR 7,DOMAIN:SRCR 8,DOMAIN:SRCR 9,MOTIF:Internalization signal,MUTAGEN:S->A: Impaired phosphorylation by PRKCA.,MUTAGEN:T->A: Impaired phosphorylation by PRKCA.,MUTAGEN:Y->A: Massive decrease of endocytotic activity.,SITE:Cleavage; in calcium-free condition,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD2	CD2 molecule(CD2)	Homo sapiens	GO:0001766~membrane raft polarization,GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0030101~natural killer cell activation,GO:0030887~positive regulation of myeloid dendritic cell activation,GO:0032729~positive regulation of interferon-gamma production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034113~heterotypic cell-cell adhesion,GO:0042110~T cell activation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0045580~regulation of T cell differentiation,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,GO:0045121~membrane raft,GO:0046658~anchored component of plasma membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0043621~protein self-association,	IPR008424:Immunoglobulin C2-set,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,IPR015632:T-cell adhesion molecule CD2,	hsa04514:Cell adhesion molecules,hsa04640:Hematopoietic cell lineage,				KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:C2-set,DOMAIN:IGv,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,MUTAGEN:D->H: Loss of CD58 and CD59 binding.,MUTAGEN:K->R: Loss of CD58 binding.,MUTAGEN:Q->K: Loss of CD58 binding.,MUTAGEN:Y->D: Loss of CD58 and CD59 binding.,REGION:CD58 binding region 1,REGION:CD58 binding region 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD248	CD248 molecule(CD248)	Homo sapiens	GO:0008284~positive regulation of cell proliferation,GO:0010761~fibroblast migration,GO:0016477~cell migration,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048535~lymph node development,GO:0060033~anatomical structure regression,GO:0072577~endothelial cell apoptotic process,GO:2000353~positive regulation of endothelial cell apoptotic process,	GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0050840~extracellular matrix binding,GO:1990430~extracellular matrix protein binding,	IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018097:EGF-like calcium-binding, conserved site,				SM00034:CLECT,SM00179:EGF_CA,SM00181:EGF,		KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:C-type lectin,DOMAIN:EGF-like; calcium-binding,DOMAIN:Sushi,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD3E	CD3 epsilon subunit of T-cell receptor complex(CD3E)	Homo sapiens	GO:0001954~positive regulation of cell-matrix adhesion,GO:0002250~adaptive immune response,GO:0002669~positive regulation of T cell anergy,GO:0002870~T cell anergy,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007172~signal complex assembly,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007224~smoothened signaling pathway,GO:0007584~response to nutrient,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016358~dendrite development,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019722~calcium-mediated signaling,GO:0021549~cerebellum development,GO:0031295~T cell costimulation,GO:0032729~positive regulation of interferon-gamma production,GO:0032743~positive regulation of interleukin-2 production,GO:0032753~positive regulation of interleukin-4 production,GO:0033634~positive regulation of cell-cell adhesion mediated by integrin,GO:0035739~CD4-positive, alpha-beta T cell proliferation,GO:0042102~positive regulation of T cell proliferation,GO:0042110~T cell activation,GO:0042981~regulation of apoptotic process,GO:0045059~positive thymic T cell selection,GO:0045060~negative thymic T cell selection,GO:0045879~negative regulation of smoothened signaling pathway,GO:0046629~gamma-delta T cell activation,GO:0046631~alpha-beta T cell activation,GO:0046641~positive regulation of alpha-beta T cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050850~positive regulation of calcium-mediated signaling,GO:0050852~T cell receptor signaling pathway,GO:0065003~macromolecular complex assembly,GO:0097190~apoptotic signaling pathway,GO:2000563~positive regulation of CD4-positive, alpha-beta T cell proliferation,	GO:0001772~immunological synapse,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042101~T cell receptor complex,GO:0042105~alpha-beta T cell receptor complex,GO:0042106~gamma-delta T cell receptor complex,GO:0043197~dendritic spine,GO:0044297~cell body,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,GO:0019901~protein kinase binding,GO:0030159~receptor signaling complex scaffold activity,GO:0042608~T cell receptor binding,GO:0042802~identical protein binding,GO:0046982~protein heterodimerization activity,	IPR003110:Phosphorylated immunoreceptor signaling ITAM,IPR003598:Immunoglobulin subtype 2,IPR013783:Immunoglobulin-like fold,IPR015484:CD3 protein, gamma/delta subunit,	hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa05142:Chagas disease,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05340:Primary immunodeficiency,	615615~Immunodeficiency 18,615615~Immunodeficiency 18, SCID variant,		SM00077:ITAM,SM00408:IGc2,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:IGc2,DOMAIN:ITAM,DOMAIN:Ig-like,REGION:Disordered,REGION:NUMB-binding region,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD300LB	CD300 molecule like family member b(CD300LB)	Homo sapiens	GO:0002376~immune system process,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0391~Immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:Ig-like,DOMAIN:Ig-like V-type,MUTAGEN:K->L: Abolishes interaction with TYROBP, and strongly reduces activation properties.,MUTAGEN:Y->F: No effect on interaction with TYROBP, but strongly reduces activation properties.,SITE:Interaction with TYROBP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD38	CD38 molecule(CD38)	Homo sapiens	GO:0001666~response to hypoxia,GO:0007165~signal transduction,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007565~female pregnancy,GO:0009410~response to xenobiotic stimulus,GO:0010977~negative regulation of neuron projection development,GO:0014824~artery smooth muscle contraction,GO:0019674~NAD metabolic process,GO:0030307~positive regulation of cell growth,GO:0030890~positive regulation of B cell proliferation,GO:0032024~positive regulation of insulin secretion,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032570~response to progesterone,GO:0033194~response to hydroperoxide,GO:0042100~B cell proliferation,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0045779~negative regulation of bone resorption,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045907~positive regulation of vasoconstriction,GO:0050853~B cell receptor signaling pathway,GO:0060292~long term synaptic depression,GO:0070555~response to interleukin-1,GO:0097190~apoptotic signaling pathway,	GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0003953~NAD+ nucleosidase activity,GO:0016740~transferase activity,GO:0016849~phosphorus-oxygen lyase activity,GO:0042802~identical protein binding,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,	IPR003193:ADP-ribosyl cyclase (CD38/157),	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa04020:Calcium signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04921:Oxytocin signaling pathway,hsa04970:Salivary secretion,hsa04972:Pancreatic secretion,					KW-0472~Membrane,	KW-0219~Diabetes mellitus,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,KW-0521~NADP,	KW-0378~Hydrolase,KW-0675~Receptor,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:C->A: Loss of cADPr hydrolase and ADP-ribosyl cyclase activity.,MUTAGEN:C->D,K,A: Loss of cADPr hydrolase and ADP-ribosyl cyclase activity.,MUTAGEN:C->E: Loss of cADPr hydrolase activity.,MUTAGEN:C->K: Loss of cADPr hydrolase activity.,MUTAGEN:C->R,E,A: Loss of cADPr hydrolase and ADP-ribosyl cyclase activity.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CD48	CD48 molecule(CD48)	Homo sapiens	GO:0002819~regulation of adaptive immune response,GO:0006952~defense response,GO:0042110~T cell activation,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031225~anchored component of membrane,GO:0031226~intrinsic component of plasma membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04650:Natural killer cell mediated cytotoxicity,			SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,TRANSMEM:Helical,
CD58	CD58 molecule(CD58)	Homo sapiens	GO:0032757~positive regulation of interleukin-8 production,GO:0034113~heterotypic cell-cell adhesion,GO:0071346~cellular response to interferon-gamma,GO:0071356~cellular response to tumor necrosis factor,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR013783:Immunoglobulin-like fold,IPR015714:Lymphocyte function associated antigen 3,	hsa04514:Cell adhesion molecules,hsa05169:Epstein-Barr virus infection,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,MUTAGEN:F->S: No effect on CD2-binding.,MUTAGEN:L->G: No effect on CD2-binding.,MUTAGEN:T->S: No effect on CD2-binding.,MUTAGEN:V->K: No effect on CD2-binding.,MUTAGEN:V->Q: No effect on CD2-binding.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CD69	CD69 molecule(CD69)	Homo sapiens	GO:0071466~cellular response to xenobiotic stimulus,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0042802~identical protein binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:C-type lectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CD93	CD93 molecule(CD93)	Homo sapiens	GO:0006909~phagocytosis,GO:0042116~macrophage activation,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0035579~specific granule membrane,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0001849~complement component C1q binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0038023~signaling receptor activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,				SM00034:CLECT,SM00179:EGF_CA,SM00181:EGF,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:C-type lectin,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CELF5	CUGBP Elav-like family member 5(CELF5)	Homo sapiens	GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006376~mRNA splice site selection,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0036002~pre-mRNA binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,				SM00360:RRM,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,		COMPBIAS:Polar residues,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,REGION:Disordered,
CITED1	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1(CITED1)	Homo sapiens	GO:0000578~embryonic axis specification,GO:0001570~vasculogenesis,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001890~placenta development,GO:0003340~negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006913~nucleocytoplasmic transport,GO:0006915~apoptotic process,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007420~brain development,GO:0010628~positive regulation of gene expression,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030318~melanocyte differentiation,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0032496~response to lipopolysaccharide,GO:0032868~response to insulin,GO:0034097~response to cytokine,GO:0034341~response to interferon-gamma,GO:0042438~melanin biosynthetic process,GO:0042981~regulation of apoptotic process,GO:0043473~pigmentation,GO:0043524~negative regulation of neuron apoptotic process,GO:0043627~response to estrogen,GO:0045668~negative regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051591~response to cAMP,GO:0060231~mesenchymal to epithelial transition,GO:0060395~SMAD protein signal transduction,GO:0060711~labyrinthine layer development,GO:0060712~spongiotrophoblast layer development,GO:0070555~response to interleukin-1,GO:0070669~response to interleukin-2,GO:0070670~response to interleukin-4,GO:0070741~response to interleukin-6,GO:0071104~response to interleukin-9,GO:0071105~response to interleukin-11,GO:0071107~response to parathyroid hormone,GO:0071559~response to transforming growth factor beta,GO:1902462~positive regulation of mesenchymal stem cell proliferation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003682~chromatin binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0042803~protein homodimerization activity,GO:0050693~LBD domain binding,GO:0070410~co-SMAD binding,	IPR007576:CITED,					KW-0053~Apoptosis,KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0010~Activator,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:Nuclear export signal,MUTAGEN:EE->AA: Does not inhibit interaction with ESR1 and ER-coactivation activity.,MUTAGEN:GL->AA: Does not inhibit interaction with ESR1 and ER-coactivation activity. Localizes mainly in the nucleus; when associated with A-165.,MUTAGEN:L->A: Does not change subcellular localization; when associated with A-176.,MUTAGEN:L->A: Does not change subcellular localization; when associated with A-178.,MUTAGEN:L->A: Does not change subcellular localization; when associated with A-95.,MUTAGEN:L->A: Does not inhibit interaction with ESR1 and ER-coactivation activity. Localizes mainly in the nucleus; when associated with A-167.,MUTAGEN:LV->AA: Does not inhibit interaction with ESR1 and ER-coactivation activity.,MUTAGEN:M->A: Does not change subcellular localization; when associated with A-91.,MUTAGEN:MS->AA: Does not inhibit interaction with ESR1 and ER-coactivation activity.,MUTAGEN:S->A: Reduces strongly phosphorylation but does not interfere with its NES-dependent nuclear export; when associated with A-16; A-63; A-67 and A-137.,MUTAGEN:S->A: Reduces strongly phosphorylation but does not interfere with its NES-dependent nuclear export; when associated with A-16; A-63; A-71 and A-137.,MUTAGEN:S->A: Reduces strongly phosphorylation but does not interfere with its NES-dependent nuclear export; when associated with A-16; A-67; A-71 and A-137.,MUTAGEN:S->A: Reduces strongly phosphorylation but does not interfere with its NES-dependent nuclear export; when associated with A-63; A-67; A-71 and A-137.,MUTAGEN:S->A: Reduces strongly phosphorylation; when associated with A-16; A-63; A-67 and A-71.,MUTAGEN:VE->AA: Does not inhibit interaction with ESR1 and ER-coactivation activity.,MUTAGEN:VL->AA: Inhibits interaction with ESR1 and ER-coactivation activity.,REGION:Disordered,
DCAF4L2	DDB1 and CUL4 associated factor 4 like 2(DCAF4L2)	Homo sapiens		GO:0080008~Cul4-RING E3 ubiquitin ligase complex,		IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,				SM00320:WD40,				KW-0677~Repeat,KW-0853~WD repeat,				REPEAT:WD 1,REPEAT:WD 2,
DDX12P	DEAD/H-box helicase 12, pseudogene(DDX12P)	Homo sapiens	GO:0006139~nucleobase-containing compound metabolic process,GO:0006259~DNA metabolic process,GO:0032508~DNA duplex unwinding,GO:0034085~establishment of sister chromatid cohesion,	GO:0005634~nucleus,	GO:0003677~DNA binding,GO:0003678~DNA helicase activity,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR006554:Helicase-like, DEXD box c2 type,IPR006555:ATP-dependent helicase, C-terminal,IPR010614:DEAD2,IPR013020:DNA helicase (DNA repair), Rad3 type,IPR014013:Helicase, superfamily 1/2, ATP-binding domain, DinG/Rad3-type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00488:DEXDc2,SM00491:HELICc2,	KW-0131~Cell cycle,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,		COMPBIAS:Basic and acidic residues,DOMAIN:Helicase ATP-binding,MOTIF:DEAH,REGION:Disordered,
DHX16	DEAH-box helicase 16(DHX16)	Homo sapiens	GO:0000398~mRNA splicing, via spliceosome,GO:0008380~RNA splicing,	GO:0005622~intracellular,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0071005~U2-type precatalytic spliceosome,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,	IPR001650:Helicase, C-terminal,IPR002464:DNA/RNA helicase, ATP-dependent, DEAH-box type, conserved site,IPR007502:Helicase-associated domain,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR011709:Domain of unknown function DUF1605,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03040:Spliceosome,	618733~Neuromuscular disease and ocular or auditory anomalies with or without seizures,		SM00487:DEXDc,SM00490:HELICc,SM00847:SM00847,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,	KW-0225~Disease variant,KW-0622~Neuropathy,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,MOTIF:DEAH box,MUTAGEN:D->A: Impairs pre-mRNA splicing activity.,MUTAGEN:G->N: Dominant-negative mutant. Impairs pre-mRNA splicing activity.,MUTAGEN:H->A: No loss of pre-mRNA splicing activity.,MUTAGEN:K->A: Impairs pre-mRNA splicing activity.,MUTAGEN:S->L: Dominant-negative mutant. Impairs pre-mRNA splicing activity.,REGION:Disordered,
DDX39B	DExD-box helicase 39B(DDX39B)	Homo sapiens	GO:0000245~spliceosomal complex assembly,GO:0000398~mRNA splicing, via spliceosome,GO:0001889~liver development,GO:0006405~RNA export from nucleus,GO:0006406~mRNA export from nucleus,GO:0008380~RNA splicing,GO:0010501~RNA secondary structure unwinding,GO:0032786~positive regulation of DNA-templated transcription, elongation,GO:0045727~positive regulation of translation,GO:0046784~viral mRNA export from host cell nucleus,GO:0061051~positive regulation of cell growth involved in cardiac muscle cell development,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000002~negative regulation of DNA damage checkpoint,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0000346~transcription export complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005687~U4 snRNP,GO:0005688~U6 snRNP,GO:0005737~cytoplasm,GO:0016363~nuclear matrix,GO:0016607~nuclear speck,GO:0032991~macromolecular complex,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003724~RNA helicase activity,GO:0004386~helicase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008186~RNA-dependent ATPase activity,GO:0016787~hydrolase activity,GO:0016887~ATPase activity,GO:0017070~U6 snRNA binding,GO:0030621~U4 snRNA binding,GO:0042802~identical protein binding,GO:0043008~ATP-dependent protein binding,GO:0044877~macromolecular complex binding,	IPR001650:Helicase, C-terminal,IPR011545:DNA/RNA helicase, DEAD/DEAH box type, N-terminal,IPR014001:Helicase, superfamily 1/2, ATP-binding domain,IPR014014:RNA helicase, DEAD-box type, Q motif,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa03013:Nucleocytoplasmic transport,hsa03015:mRNA surveillance pathway,hsa03040:Spliceosome,			SM00487:DEXDc,SM00490:HELICc,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0509~mRNA transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0347~Helicase,KW-0378~Hydrolase,KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Helicase ATP-binding,DOMAIN:Helicase C-terminal,DOMAIN:Q_MOTIF,MOTIF:DECD box,MOTIF:Q motif,MUTAGEN:C->A: No effect on ATPase activity.,MUTAGEN:D->A: Increased ATPase activity and loss of helicase activity.,MUTAGEN:E->A: Loss of ATPase and helicase activity.,MUTAGEN:GKT->AAA: Loss of ATPase and helicase activity.,MUTAGEN:K->A: Loss of ATPase and helicase activity.,MUTAGEN:SAT->AAA: Decreased ATPase activity and loss of helicase activity.,REGION:Disordered,
DIRAS3	DIRAS family GTPase 3(DIRAS3)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0006349~regulation of gene expression by genetic imprinting,GO:0007264~small GTPase mediated signal transduction,	GO:0005886~plasma membrane,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR020849:Small GTPase superfamily, Ras type,IPR027417:P-loop containing nucleoside triphosphate hydrolase,						KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,
DLGAP1	DLG associated protein 1(DLGAP1)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0098962~regulation of postsynaptic neurotransmitter receptor activity,	GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0045202~synapse,GO:0098978~glutamatergic synapse,GO:0099572~postsynaptic specialization,	GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0060090~binding, bridging,	IPR005026:Guanylate-kinase-associated protein,	hsa04724:Glutamatergic synapse,					KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,MOTIF:PDZ-binding,REGION:Disordered,REGION:Interaction with DYL2,
DLGAP3	DLG associated protein 3(DLGAP3)	Homo sapiens	GO:0023052~signaling,GO:0098962~regulation of postsynaptic neurotransmitter receptor activity,GO:0099563~modification of synaptic structure,	GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0031594~neuromuscular junction,GO:0098978~glutamatergic synapse,GO:0098981~cholinergic synapse,GO:0099572~postsynaptic specialization,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0060090~binding, bridging,	IPR005026:Guanylate-kinase-associated protein,						KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
DLGAP5	DLG associated protein 5(DLGAP5)	Homo sapiens	GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007079~mitotic chromosome movement towards spindle pole,GO:0007346~regulation of mitotic cell cycle,GO:0023052~signaling,GO:0045842~positive regulation of mitotic metaphase/anaphase transition,GO:0051382~kinetochore assembly,GO:0051642~centrosome localization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0031616~spindle pole centrosome,GO:0034451~centriolar satellite,	GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR005026:Guanylate-kinase-associated protein,					KW-0131~Cell cycle,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
DMRTA2	DMRT like family A2(DMRTA2)	Homo sapiens	GO:0002052~positive regulation of neuroblast proliferation,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007405~neuroblast proliferation,GO:0007548~sex differentiation,GO:0021796~cerebral cortex regionalization,GO:0035914~skeletal muscle cell differentiation,GO:0048665~neuron fate specification,GO:0048866~stem cell fate specification,GO:0071542~dopaminergic neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001275:DM DNA-binding,IPR005173:DMRTA motif,IPR009060:UBA-like,IPR026607:DMRT/protein doublesex/protein male abnormal 3,				SM00301:DM,		KW-0539~Nucleus,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:DM,DOMAIN:DM,DOMAIN:DMA,REGION:Disordered,
DDIT4L	DNA damage inducible transcript 4 like(DDIT4L)	Homo sapiens	GO:0009968~negative regulation of signal transduction,	GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR012918:RTP801-like,						KW-0963~Cytoplasm,
TOP2A	DNA topoisomerase II alpha(TOP2A)	Homo sapiens	GO:0000712~resolution of meiotic recombination intermediates,GO:0000819~sister chromatid segregation,GO:0002244~hematopoietic progenitor cell differentiation,GO:0006265~DNA topological change,GO:0006266~DNA ligation,GO:0006974~cellular response to DNA damage stimulus,GO:0007059~chromosome segregation,GO:0007143~female meiotic division,GO:0030263~apoptotic chromosome condensation,GO:0040016~embryonic cleavage,GO:0042752~regulation of circadian rhythm,GO:0043065~positive regulation of apoptotic process,GO:0045870~positive regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:1905463~negative regulation of DNA duplex unwinding,	GO:0000228~nuclear chromosome,GO:0000775~chromosome, centromeric region,GO:0000793~condensed chromosome,GO:0001673~male germ cell nucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0009330~DNA topoisomerase complex (ATP-hydrolyzing),GO:0032991~macromolecular complex,GO:1990904~ribonucleoprotein complex,	GO:0000287~magnesium ion binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003918~DNA topoisomerase type II (ATP-hydrolyzing) activity,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0008094~DNA-dependent ATPase activity,GO:0008301~DNA binding, bending,GO:0019899~enzyme binding,GO:0042803~protein homodimerization activity,GO:0042826~histone deacetylase binding,GO:0043130~ubiquitin binding,GO:0046872~metal ion binding,GO:0046982~protein heterodimerization activity,	IPR001241:DNA topoisomerase, type IIA,IPR002205:DNA topoisomerase, type IIA, subunit A/C-terminal,IPR003594:Histidine kinase-like ATPase, ATP-binding domain,IPR006171:Toprim domain,IPR012542:DTHCT,IPR013506:DNA topoisomerase, type IIA, subunit B, domain 2,IPR013758:DNA topoisomerase, type IIA, subunit A/ C-terminal, alpha-beta,IPR013759:DNA topoisomerase, type IIA, central domain,IPR013760:DNA topoisomerase, type IIA-like domain,IPR014721:Ribosomal protein S5 domain 2-type fold, subgroup,IPR018522:DNA topoisomerase, type IIA, conserved site,IPR020568:Ribosomal protein S5 domain 2-type fold,	hsa01524:Platinum drug resistance,	DNA topoisomerase II, resistance to inhibition of, by amsacrine~DNA topoisomerase II, resistance to inhibition of, by amsacrine,		SM00433:TOP2c,SM00434:TOP4c,	KW-0090~Biological rhythms,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0413~Isomerase,KW-0799~Topoisomerase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:O-(5'-phospho-DNA)-tyrosine intermediate,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:HATPase_c,DOMAIN:Toprim,MOTIF:Nuclear export signal,MUTAGEN:D->A,C: Impairs bending of target DNA. Strongly reduced DNA cleavage.,MUTAGEN:D->A,C: Strongly reduced DNA cleavage.,MUTAGEN:E->A,C: Impairs bending of target DNA. Strongly reduced DNA cleavage.,MUTAGEN:KKK->AAA: Reduced enzyme activity; abolishes stimulation of ATPase activity upon DNA binding.,MUTAGEN:KKK->EEE: Strongly reduced enzyme activity; abolishes stimulation of ATPase activity upon DNA binding.,MUTAGEN:S->A: Abolishes binding to the antibody MPM2.,REGION:Disordered,REGION:Interaction with DNA,REGION:Interaction with PLSCR1,SITE:Important for DNA bending; intercalates between base pairs of target DNA,SITE:Interaction with DNA,SITE:Transition state stabilizer,
DGCR6	DiGeorge syndrome critical region gene 6(DGCR6)	Homo sapiens	GO:0007155~cell adhesion,GO:0009887~animal organ morphogenesis,	GO:0005634~nucleus,GO:0031012~extracellular matrix,	GO:0005515~protein binding,	IPR010849:DiGeorge syndrome critical 6,						KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	REGION:Disordered,
E2F7	E2F transcription factor 7(E2F7)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001890~placenta development,GO:0002040~sprouting angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008285~negative regulation of cell proliferation,GO:0030330~DNA damage response, signal transduction by p53 class mediator,GO:0032466~negative regulation of cytokinesis,GO:0032877~positive regulation of DNA endoreduplication,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060707~trophoblast giant cell differentiation,GO:0060718~chorionic trophoblast cell differentiation,GO:0070365~hepatocyte differentiation,GO:0071930~negative regulation of transcription involved in G1/S transition of mitotic cell cycle,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0016607~nuclear speck,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003316:Transcription factor E2F/dimerisation partner (TDP),IPR015633:E2F Family,				SM01372:SM01372,	KW-0131~Cell cycle,KW-0227~DNA damage,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:E2F_TDP,MUTAGEN:LG->EE: Loss of DNA-binding and E2F-dependent repression.,MUTAGEN:R->A: Loss of DNA-binding and inhibition of E2F1-dependent activation. Impairs DNA-binding and dimerization; when associated with A-185.,MUTAGEN:R->A: Loss of DNA-binding and inhibition of E2F1-dependent activation. Impairs DNA-binding and dimerization; when associated with A-334.,REGION:Disordered,
E2F8	E2F transcription factor 8(E2F8)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001890~placenta development,GO:0002040~sprouting angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008283~cell proliferation,GO:0032466~negative regulation of cytokinesis,GO:0032877~positive regulation of DNA endoreduplication,GO:0033301~cell cycle comprising mitosis without cytokinesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048144~fibroblast proliferation,GO:0060707~trophoblast giant cell differentiation,GO:0060718~chorionic trophoblast cell differentiation,GO:0070365~hepatocyte differentiation,	GO:0000785~chromatin,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001217~bacterial-type RNA polymerase transcriptional repressor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR003316:Transcription factor E2F/dimerisation partner (TDP),IPR015633:E2F Family,				SM01372:SM01372,	KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:R->A: Loss of DNA-binding and inhibition of E2F1-dependent activation. Impairs DNA-binding and dimerization; when associated with A-156.,MUTAGEN:R->A: Loss of DNA-binding and inhibition of E2F1-dependent activation. Impairs DNA-binding and dimerization; when associated with A-314.,REGION:Disordered,
EFEMP2	EGF containing fibulin extracellular matrix protein 2(EFEMP2)	Homo sapiens	GO:0035904~aorta development,GO:0048251~elastic fiber assembly,GO:0060414~aorta smooth muscle tissue morphogenesis,GO:0097084~vascular smooth muscle cell development,GO:1904026~regulation of collagen fibril organization,GO:1904028~positive regulation of collagen fibril organization,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1904831~positive regulation of aortic smooth muscle cell differentiation,GO:1905609~positive regulation of smooth muscle cell-matrix adhesion,	GO:0001527~microfibril,GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,GO:0071953~elastic fiber,GO:1903561~extracellular vesicle,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0042803~protein homodimerization activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,IPR026824:EGF-containing fibulin-like extracellular matrix protein 1/2,		614437~Cutis laxa, autosomal recessive, type IB,		SM00179:EGF_CA,SM00181:EGF,		KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1; atypical,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF_CA,REGION:Disordered,SITE:Cleavage,SITE:Cleavage; by ELANE,SITE:Cleavage; by MMP2, MMP3, MMP7, MMP9, MMP12,
EGFL8	EGF like domain multiple 8(EGFL8)	Homo sapiens	GO:0048856~anatomical structure development,	GO:0005576~extracellular region,GO:0009986~cell surface,	GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR011489:EMI domain,IPR018097:EGF-like calcium-binding, conserved site,				SM00179:EGF_CA,SM00181:EGF,		KW-0964~Secreted,		KW-0175~Coiled coil,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EMI,
EHD2	EH domain containing 2(EHD2)	Homo sapiens	GO:0006897~endocytosis,GO:0016197~endosomal transport,GO:0030866~cortical actin cytoskeleton organization,GO:0032456~endocytic recycling,GO:0060271~cilium assembly,GO:0072659~protein localization to plasma membrane,GO:0097320~plasma membrane tubulation,GO:1901741~positive regulation of myoblast fusion,GO:2001137~positive regulation of endocytic recycling,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0010008~endosome membrane,GO:0015630~microtubule cytoskeleton,GO:0019898~extrinsic component of membrane,GO:0030139~endocytic vesicle,GO:0043231~intracellular membrane-bounded organelle,GO:0045171~intercellular bridge,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,	GO:0003676~nucleic acid binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0016787~hydrolase activity,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,	IPR000261:EPS15 homology (EH),IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR022812:Dynamin,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,			SM00027:EH,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	DOMAIN:Dynamin-type G,DOMAIN:EF-hand,DOMAIN:EH,MOTIF:KPF loop; caveolar targeting,MUTAGEN:F->A: Complete loss of localization to CAV1 positive caveolae.,MUTAGEN:F->A: No effect on caveolae targeting.,MUTAGEN:H->D: Distorded caveolae.,MUTAGEN:K->D: Distorded caveolae.,MUTAGEN:K->N: Complete loss of localization to CAV1 positive caveolae.,MUTAGEN:T->A: Incapable of binding membranes and localizing to caveolae.,MUTAGEN:T->A: Lowers the level of CAV1; distorded caveolae.,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,REGION:Mediates membrane-binding,
EPHB6	EPH receptor B6(EPHB6)	Homo sapiens	GO:0001806~type IV hypersensitivity,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0007411~axon guidance,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021952~central nervous system projection neuron axonogenesis,GO:0032092~positive regulation of protein binding,GO:0033674~positive regulation of kinase activity,GO:0048013~ephrin receptor signaling pathway,GO:0050798~activated T cell proliferation,GO:2000525~positive regulation of T cell costimulation,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0043235~receptor complex,	GO:0004672~protein kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005003~ephrin receptor activity,GO:0005005~transmembrane-ephrin receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0038023~signaling receptor activity,	IPR000719:Protein kinase, catalytic domain,IPR001090:Ephrin receptor ligand binding domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001426:Tyrosine-protein kinase, receptor class V, conserved site,IPR001660:Sterile alpha motif domain,IPR003961:Fibronectin, type III,IPR008979:Galactose-binding domain-like,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR011641:Tyrosine-protein kinase ephrin type A/B receptor-like,IPR013761:Sterile alpha motif/pointed domain,IPR013783:Immunoglobulin-like fold,IPR016257:Tyrosine-protein kinase, ephrin receptor,	hsa04360:Axon guidance,		PIRSF000666:tyrosine-protein kinase, ephrin receptor type,	SM00060:FN3,SM00454:SAM,SM00615:EPH_lbd,		KW-0472~Membrane,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Eph LBD,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:SAM,MOTIF:PDZ-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EPS8L1	EPS8 like 1(EPS8L1)	Homo sapiens	GO:0007266~Rho protein signal transduction,GO:0035023~regulation of Rho protein signal transduction,GO:0050790~regulation of catalytic activity,GO:1900029~positive regulation of ruffle assembly,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0042608~T cell receptor binding,GO:0045296~cadherin binding,	IPR001452:Src homology-3 domain,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,IPR013625:Tensin phosphotyrosine-binding domain,IPR013761:Sterile alpha motif/pointed domain,				SM00326:SH3,SM00462:PTB,		KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0728~SH3 domain,KW-0732~Signal,		KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:PTB,DOMAIN:SH3,REGION:Disordered,
ERMARD	ER membrane associated RNA degradation(ERMARD)	Homo sapiens		GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,		IPR025209:Domain of unknown function DUF4209,		615544~Periventricular nodular heterotopia 6,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,		DOMAIN:DUF4209,TRANSMEM:Helical,
ETV2	ETS variant transcription factor 2(ETV2)	Homo sapiens	GO:0001824~blastocyst development,GO:0001890~placenta development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0010628~positive regulation of gene expression,GO:0016055~Wnt signaling pathway,GO:0030154~cell differentiation,GO:0030218~erythrocyte differentiation,GO:0045603~positive regulation of endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048514~blood vessel morphogenesis,GO:0060803~BMP signaling pathway involved in mesodermal cell fate specification,GO:2000382~positive regulation of mesoderm development,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,				SM00413:ETS,		KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Polar residues,DNA_BIND:ETS,DOMAIN:ETS,REGION:Disordered,
ETV7	ETS variant transcription factor 7(ETV7)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0009887~animal organ morphogenesis,GO:0030154~cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000418:Ets domain,IPR003118:Pointed domain,IPR013761:Sterile alpha motif/pointed domain,	hsa05202:Transcriptional misregulation in cancer,			SM00251:SAM_PNT,SM00413:ETS,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,KW-0678~Repressor,		DNA_BIND:ETS,DOMAIN:PNT,REGION:Disordered,
EYA4	EYA transcriptional coactivator and phosphatase 4(EYA4)	Homo sapiens	GO:0006281~DNA repair,GO:0006325~chromatin organization,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0009653~anatomical structure morphogenesis,GO:0016576~histone dephosphorylation,GO:0030154~cell differentiation,GO:0045739~positive regulation of DNA repair,GO:0048839~inner ear development,GO:0048856~anatomical structure development,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR006545:EYA,		601316~Deafness, autosomal dominant 10,605362~Cardiomyopathy, dilated, 1J,			KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,		KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0010~Activator,KW-0156~Chromatin regulator,KW-0217~Developmental protein,KW-0378~Hydrolase,KW-0904~Protein phosphatase,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
EVC	EvC ciliary complex subunit 1(EVC)	Homo sapiens	GO:0001501~skeletal system development,GO:0003416~endochondral bone growth,GO:0007224~smoothened signaling pathway,GO:0007517~muscle organ development,GO:0045880~positive regulation of smoothened signaling pathway,GO:0051216~cartilage development,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005929~cilium,GO:0016021~integral component of membrane,GO:0036064~ciliary basal body,GO:0060170~ciliary membrane,GO:0098797~plasma membrane protein complex,		IPR026501:Limbin/Ellis-van Creveld protein,IPR026582:Ellis-van Creveld protein,	hsa04340:Hedgehog signaling pathway,	193530~Weyers acrofacial dysostosis,225500~Ellis-van Creveld syndrome,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0242~Dwarfism,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EVC2	EvC ciliary complex subunit 2(EVC2)	Homo sapiens	GO:0007224~smoothened signaling pathway,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005929~cilium,GO:0016021~integral component of membrane,GO:0060170~ciliary membrane,GO:0098797~plasma membrane protein complex,		IPR022076:Limbin,IPR026501:Limbin/Ellis-van Creveld protein,	hsa04340:Hedgehog signaling pathway,	193530~Weyers acrofacial dysostosis,225500~Ellis-van Creveld syndrome,				KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,KW-0242~Dwarfism,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FBXL16	F-box and leucine rich repeat protein 16(FBXL16)	Homo sapiens	GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,	GO:0005829~cytosol,GO:0019005~SCF ubiquitin ligase complex,		IPR001611:Leucine-rich repeat,IPR006553:Leucine-rich repeat, cysteine-containing subtype,				SM00367:LRR_CC,	KW-0833~Ubl conjugation pathway,			KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0488~Methylation,	COMPBIAS:Pro residues,DOMAIN:F-box,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
FBXO39	F-box protein 39(FBXO39)	Homo sapiens	GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,	GO:0019005~SCF ubiquitin ligase complex,	GO:0005515~protein binding,	IPR001611:Leucine-rich repeat,IPR001810:F-box domain, cyclin-like,					KW-0833~Ubl conjugation pathway,							DOMAIN:F-box,
FAM20A	FAM20A golgi associated secretory pathway pseudokinase(FAM20A)	Homo sapiens	GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0009617~response to bacterium,GO:0031214~biomineral tissue development,GO:0044691~tooth eruption,GO:0055074~calcium ion homeostasis,GO:0070166~enamel mineralization,GO:0071902~positive regulation of protein serine/threonine kinase activity,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0043539~protein serine/threonine kinase activator activity,	IPR009581:Domain of unknown function DUF1193,IPR024869:FAM20,		204690~Amelogenesis imperfecta, type IG (enamel-renal syndrome),			KW-0091~Biomineralization,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0964~Secreted,	KW-0225~Disease variant,KW-0986~Amelogenesis imperfecta,	KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fam20C,MUTAGEN:Q->E: Able to hydrolyze ATP and display some protein kinase activity.,REGION:Disordered,
FAM20C	FAM20C golgi associated secretory pathway kinase(FAM20C)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0019538~protein metabolic process,GO:0030501~positive regulation of bone mineralization,GO:0031214~biomineral tissue development,GO:0036179~osteoclast maturation,GO:0040036~regulation of fibroblast growth factor receptor signaling pathway,GO:0043687~post-translational protein modification,GO:0044267~cellular protein metabolic process,GO:0045669~positive regulation of osteoblast differentiation,GO:0046034~ATP metabolic process,GO:0046777~protein autophosphorylation,GO:0051174~regulation of phosphorus metabolic process,GO:0070166~enamel mineralization,GO:0071895~odontoblast differentiation,GO:0097187~dentinogenesis,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016773~phosphotransferase activity, alcohol group as acceptor,GO:0030145~manganese ion binding,GO:0043621~protein self-association,	IPR009581:Domain of unknown function DUF1193,IPR024869:FAM20,		259775~Raine syndrome,			KW-0091~Biomineralization,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0464~Manganese,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,MUTAGEN:C->S: No effect on homodimer formation. Complete disruption of homodimer formation but no effect on secretion; when associated with S-46.,MUTAGEN:C->S: No effect on homodimer formation. Complete disruption of homodimer formation but no effect on secretion; when associated with S-48.,MUTAGEN:D->A: Abrogates kinase activity.,MUTAGEN:D->A: Unable to bind manganese. Abrogates kinase activity. Loss of ERO1A phosphorylation. Loss of autophosphorylation. Loss of ability to promote osteoblast differentiation.,MUTAGEN:DLLP->AAAA: Loss of membrane localization with more efficient secretion and loss of propeptide cleavage. Reduced oligomerization.,MUTAGEN:E->A,Q: Strongly reduced kinase activity.,MUTAGEN:E->A: Reduced kinase activity.,MUTAGEN:I->A: No effect on secretion.,MUTAGEN:K->A: Reduced kinase activity.,MUTAGEN:L->S: Impaired secretion.,MUTAGEN:LQD->AAA: No effect on secretion or activity.,MUTAGEN:N->A: Impaired secretion; when associated with A-101 and A-335.,MUTAGEN:N->A: Impaired secretion; when associated with A-101 and A-470.,MUTAGEN:N->A: Impaired secretion; when associated with A-335 and A-470.,MUTAGEN:Q->A: Impaired secretion. Loss of ability to promote osteoblast differentiation; when associated with A-89.,MUTAGEN:R->A: Impaired secretion. Loss of ability to promote osteoblast differentiation; when associated with A-92.,MUTAGEN:R->A: Reduced kinase activity.,MUTAGEN:S->A: Abolishes phosphorylation.,REGION:Disordered,REGION:Kinase domain,SITE:Cleavage; by MBTPS1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FRMPD2B	FERM and PDZ domain containing 2B, pseudogene(FRMPD2B)	Homo sapiens	GO:0070830~bicellular tight junction assembly,	GO:0005923~bicellular tight junction,GO:0016323~basolateral plasma membrane,	GO:0005545~1-phosphatidylinositol binding,	IPR001478:PDZ domain,				SM00228:PDZ,				KW-0677~Repeat,				DOMAIN:PDZ 1,DOMAIN:PDZ 2,REGION:Disordered,
FKBP9	FKBP prolyl isomerase 9(FKBP9)	Homo sapiens	GO:0006457~protein folding,	GO:0005783~endoplasmic reticulum,	GO:0003755~peptidyl-prolyl cis-trans isomerase activity,GO:0005509~calcium ion binding,	IPR001179:Peptidyl-prolyl cis-trans isomerase, FKBP-type, domain,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,		KW-0256~Endoplasmic reticulum,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0413~Isomerase,KW-0697~Rotamase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:PPIase FKBP-type,DOMAIN:PPIase FKBP-type 1,DOMAIN:PPIase FKBP-type 2,DOMAIN:PPIase FKBP-type 3,DOMAIN:PPIase FKBP-type 4,MOTIF:Prevents secretion from ER,
FOSL1	FOS like 1, AP-1 transcription factor subunit(FOSL1)	Homo sapiens	GO:0001701~in utero embryonic development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006935~chemotaxis,GO:0006968~cellular defense response,GO:0007296~vitellogenesis,GO:0007565~female pregnancy,GO:0007612~learning,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009615~response to virus,GO:0009629~response to gravity,GO:0031668~cellular response to extracellular stimulus,GO:0032570~response to progesterone,GO:0034097~response to cytokine,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0045787~positive regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051412~response to corticosterone,GO:0051591~response to cAMP,GO:0060674~placenta blood vessel development,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000144~positive regulation of DNA-templated transcription, initiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,	hsa04310:Wnt signaling pathway,hsa04380:Osteoclast differentiation,hsa04657:IL-17 signaling pathway,hsa05166:Human T-cell leukemia virus 1 infection,			SM00338:BRLZ,		KW-0539~Nucleus,				KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
FREM2	FRAS1 related extracellular matrix 2(FREM2)	Homo sapiens	GO:0001654~eye development,GO:0001822~kidney development,GO:0002009~morphogenesis of an epithelium,GO:0007154~cell communication,GO:0007155~cell adhesion,GO:0007507~heart development,GO:0009653~anatomical structure morphogenesis,GO:0042733~embryonic digit morphogenesis,GO:0048839~inner ear development,	GO:0005604~basement membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR003644:Na-Ca exchanger/integrin-beta4,	hsa04512:ECM-receptor interaction,	123570~Cryptophthalmos, unilateral or bilateral, isolated,617666~Fraser syndrome 2,		SM00237:Calx_beta,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Calx-beta 1,DOMAIN:Calx-beta 2,DOMAIN:Calx-beta 3,DOMAIN:Calx-beta 4,DOMAIN:Calx-beta 5,REGION:Disordered,REPEAT:CSPG 1,REPEAT:CSPG 10,REPEAT:CSPG 11,REPEAT:CSPG 12,REPEAT:CSPG 2,REPEAT:CSPG 3,REPEAT:CSPG 4,REPEAT:CSPG 5,REPEAT:CSPG 6,REPEAT:CSPG 7,REPEAT:CSPG 8,REPEAT:CSPG 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FAIM2	Fas apoptotic inhibitory molecule 2(FAIM2)	Homo sapiens	GO:0002931~response to ischemia,GO:0006915~apoptotic process,GO:0021549~cerebellum development,GO:0021680~cerebellar Purkinje cell layer development,GO:0021681~cerebellar granular layer development,GO:0021702~cerebellar Purkinje cell differentiation,GO:0043066~negative regulation of apoptotic process,GO:0043523~regulation of neuron apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0051402~neuron apoptotic process,GO:0097190~apoptotic signaling pathway,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,GO:0045211~postsynaptic membrane,	GO:0005515~protein binding,	IPR006214:Bax inhibitor 1-related,					KW-0053~Apoptosis,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
FCGBP	Fc gamma binding protein(FCGBP)	Homo sapiens		GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000742:Epidermal growth factor-like domain,IPR001007:von Willebrand factor, type C,IPR001846:von Willebrand factor, type D domain,IPR002919:Trypsin Inhibitor-like, cysteine rich domain,IPR003645:Follistatin-like, N-terminal,IPR014853:Uncharacterised domain, cysteine-rich,IPR025615:TILa domain,				SM00181:EGF,SM00214:VWC,SM00215:VWC_out,SM00216:VWD,SM00274:FOLN,SM00832:SM00832,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TIL 1,DOMAIN:TIL 10,DOMAIN:TIL 11,DOMAIN:TIL 12,DOMAIN:TIL 2,DOMAIN:TIL 3,DOMAIN:TIL 4,DOMAIN:TIL 5,DOMAIN:TIL 6,DOMAIN:TIL 7,DOMAIN:TIL 8,DOMAIN:TIL 9,DOMAIN:VWFD,DOMAIN:VWFD 1,DOMAIN:VWFD 10,DOMAIN:VWFD 11,DOMAIN:VWFD 12,DOMAIN:VWFD 13,DOMAIN:VWFD 2,DOMAIN:VWFD 3,DOMAIN:VWFD 4,DOMAIN:VWFD 5,DOMAIN:VWFD 6,DOMAIN:VWFD 7,DOMAIN:VWFD 8,DOMAIN:VWFD 9,REGION:IgGFc-binding,
FCGR3A	Fc gamma receptor IIIa(FCGR3A)	Homo sapiens	GO:0001788~antibody-dependent cellular cytotoxicity,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0019722~calcium-mediated signaling,GO:0030101~natural killer cell activation,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0038094~Fc-gamma receptor signaling pathway,GO:0042116~macrophage activation,GO:0042267~natural killer cell mediated cytotoxicity,GO:0043320~natural killer cell degranulation,GO:0050776~regulation of immune response,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0033001~Fc-gamma receptor III complex,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019772~low-affinity IgG receptor activity,GO:0019864~IgG binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04666:Fc gamma R-mediated phagocytosis,hsa05140:Leishmaniasis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05322:Systemic lupus erythematosus,	615707~Immunodeficiency 20,		SM00409:IG,	KW-0391~Immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IG,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,MUTAGEN:C->A: Has no effect on complex formation with CD247 or FCER1G. Decreases cell surface expression; when associated with A-210 and A-211.,MUTAGEN:D->A: Decreases the association with either CD247 or FCER1G. Strongly increases cell surface expression.,MUTAGEN:D->E,K: Strongly decreases complex formation with CD247 or FCER1G.,MUTAGEN:D->N: Has little effect on complex formation with CD247 or FCER1G.,MUTAGEN:F->A: Decreases the association with either CD247 or FCER1G. Decreases cell surface expression.,MUTAGEN:F->A: Decreases the association with either CD247 or FCER1G. Decreases cell surface expression; when associated with A-210 and A-212.,MUTAGEN:F->A: Decreases the association with either CD247 or FCER1G. Decreases cell surface expression; when associated with A-226 and A-228.,MUTAGEN:F->P: Disrupts transmembrane anchoring.,MUTAGEN:F->T,Y,N,E,A,D,K: Enables membrane anchoring via glycosylphosphatidylinositol. Disrupts transmembrane anchoring.,MUTAGEN:F->V,I,L: Enables only transmembrane anchoring.,MUTAGEN:Missing: Impairs the interaction with S100A4.,MUTAGEN:Q->A: Decreases the association with either CD247 or FCER1G.,MUTAGEN:S->A: Has little effect on complex formation with CD247 or FCER1G. Decreases cell surface expression; when associated with A-226 and A-227.,MUTAGEN:S->A: Has no effect on complex association with CD247 or FCER1G. Decreases cell surface expression; when associated with A-211 and A-212.,MUTAGEN:S->P: Impairs receptor shedding. Impairs the detachment of NK cells from opsonized target cells upon sequential activation.,MUTAGEN:SST->AAA: Loss of PKC-dependent phosphorylation. Abolishes pro-inflammatory cytokine production while enhancing cell degranulation.,MUTAGEN:T->A: Decreases the association with either CD247 or FCER1G. Decreases cell surface expression.,MUTAGEN:Y->A: Decreases the association with either CD247 or FCER1G. Decreases cell surface expression; when associated with A-227 and A-228.,SITE:Cleavage; by ADAM17,SITE:Important for receptor turnover,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCGR3B	Fc gamma receptor IIIb(FCGR3B)	Homo sapiens	GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0050776~regulation of immune response,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0031225~anchored component of membrane,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0019864~IgG binding,GO:0034235~GPI anchor binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04666:Fc gamma R-mediated phagocytosis,hsa05140:Leishmaniasis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05322:Systemic lupus erythematosus,			SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,LIPID:GPI-anchor amidated serine,MUTAGEN:S->P: Abolishes membrane anchoring via glycosylphosphatidylinositol.,MUTAGEN:S->T,Y,A,D,K: Has no effect on membrane anchoring via glycosylphosphatidylinositol.,PROPEP:Removed in mature form,TRANSMEM:Helical,
FCGR2A	Fc gamma receptor IIa(FCGR2A)	Homo sapiens	GO:0002376~immune system process,GO:0007166~cell surface receptor signaling pathway,GO:0050776~regulation of immune response,	GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019864~IgG binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa04611:Platelet activation,hsa04613:Neutrophil extracellular trap formation,hsa04666:Fc gamma R-mediated phagocytosis,hsa05130:Pathogenic Escherichia coli infection,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	152700~Lupus nephritis, susceptibility to,219700~Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis,611162~Malaria, severe, susceptibility to,		SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCGR2B	Fc gamma receptor IIb(FCGR2B)	Homo sapiens	GO:0001811~negative regulation of type I hypersensitivity,GO:0001814~negative regulation of antibody-dependent cellular cytotoxicity,GO:0001818~negative regulation of cytokine production,GO:0002266~follicular dendritic cell activation,GO:0002313~mature B cell differentiation involved in immune response,GO:0002316~follicular B cell differentiation,GO:0002436~immune complex clearance by monocytes and macrophages,GO:0002605~negative regulation of dendritic cell antigen processing and presentation,GO:0002622~regulation of B cell antigen processing and presentation,GO:0002638~negative regulation of immunoglobulin production,GO:0002819~regulation of adaptive immune response,GO:0002865~negative regulation of acute inflammatory response to antigenic stimulus,GO:0002922~positive regulation of humoral immune response,GO:0002924~negative regulation of humoral immune response mediated by circulating immunoglobulin,GO:0006898~receptor-mediated endocytosis,GO:0006911~phagocytosis, engulfment,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0009617~response to bacterium,GO:0010469~regulation of receptor activity,GO:0016064~immunoglobulin mediated immune response,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0021549~cerebellum development,GO:0030889~negative regulation of B cell proliferation,GO:0032693~negative regulation of interleukin-10 production,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0043031~negative regulation of macrophage activation,GO:0043318~negative regulation of cytotoxic T cell degranulation,GO:0045088~regulation of innate immune response,GO:0046330~positive regulation of JNK cascade,GO:0050765~negative regulation of phagocytosis,GO:0050766~positive regulation of phagocytosis,GO:0050776~regulation of immune response,GO:0050777~negative regulation of immune response,GO:0050859~negative regulation of B cell receptor signaling pathway,GO:0050869~negative regulation of B cell activation,GO:0071219~cellular response to molecule of bacterial origin,GO:0090264~regulation of immune complex clearance by monocytes and macrophages,GO:1901216~positive regulation of neuron death,GO:1902564~negative regulation of neutrophil activation,GO:1902950~regulation of dendritic spine maintenance,GO:1904646~cellular response to beta-amyloid,GO:1905898~positive regulation of response to endoplasmic reticulum stress,GO:2001199~negative regulation of dendritic cell differentiation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0043197~dendritic spine,GO:0044297~cell body,	GO:0001540~beta-amyloid binding,GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019772~low-affinity IgG receptor activity,GO:0019864~IgG binding,GO:0044877~macromolecular complex binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05162:Measles,	152700~Systemic lupus erythematosus, susceptibility to,611162~Malaria, resistance to,		SM00408:IGc2,SM00409:IG,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,KW-0772~Systemic lupus erythematosus,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,MOTIF:ITIM motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCGR2C	Fc gamma receptor IIc (gene/pseudogene)(FCGR2C)	Homo sapiens	GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0050776~regulation of immune response,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0019864~IgG binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04145:Phagosome,hsa04380:Osteoclast differentiation,hsa05140:Leishmaniasis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,			SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0390~IgG-binding protein,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FCRLA	Fc receptor like A(FCRLA)	Homo sapiens	GO:0007166~cell surface receptor signaling pathway,GO:0030154~cell differentiation,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0004888~transmembrane signaling receptor activity,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0221~Differentiation,	KW-0963~Cytoplasm,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,
FOS	Fos proto-oncogene, AP-1 transcription factor subunit(FOS)	Homo sapiens	GO:0001661~conditioned taste aversion,GO:0006306~DNA methylation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006954~inflammatory response,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007399~nervous system development,GO:0007565~female pregnancy,GO:0007568~aging,GO:0009409~response to cold,GO:0009410~response to xenobiotic stimulus,GO:0009416~response to light stimulus,GO:0009629~response to gravity,GO:0009636~response to toxic substance,GO:0014823~response to activity,GO:0014856~skeletal muscle cell proliferation,GO:0030316~osteoclast differentiation,GO:0030431~sleep,GO:0031668~cellular response to extracellular stimulus,GO:0032496~response to lipopolysaccharide,GO:0032570~response to progesterone,GO:0032868~response to insulin,GO:0032870~cellular response to hormone stimulus,GO:0034097~response to cytokine,GO:0034224~cellular response to zinc ion starvation,GO:0034614~cellular response to reactive oxygen species,GO:0035902~response to immobilization stress,GO:0035914~skeletal muscle cell differentiation,GO:0035994~response to muscle stretch,GO:0042493~response to drug,GO:0045471~response to ethanol,GO:0045672~positive regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051412~response to corticosterone,GO:0051450~myoblast proliferation,GO:0051591~response to cAMP,GO:0060395~SMAD protein signal transduction,GO:0071276~cellular response to cadmium ion,GO:0071277~cellular response to calcium ion,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0071456~cellular response to hypoxia,GO:1901216~positive regulation of neuron death,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903131~mononuclear cell differentiation,GO:1904628~cellular response to phorbol 13-acetate 12-myristate,GO:1990646~cellular response to prolactin,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0032993~protein-DNA complex,GO:0035976~transcription factor AP-1 complex,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070412~R-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,	hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04024:cAMP signaling pathway,hsa04210:Apoptosis,hsa04380:Osteoclast differentiation,hsa04620:Toll-like receptor signaling pathway,hsa04657:IL-17 signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04668:TNF signaling pathway,hsa04713:Circadian entrainment,hsa04725:Cholinergic synapse,hsa04728:Dopaminergic synapse,hsa04915:Estrogen signaling pathway,hsa04917:Prolactin signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04932:Non-alcoholic fatty liver disease,hsa04935:Growth hormone synthesis, secretion and action,hsa05031:Amphetamine addiction,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05161:Hepatitis B,hsa05162:Measles,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05224:Breast cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05323:Rheumatoid arthritis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,			SM00338:BRLZ,		KW-0256~Endoplasmic reticulum,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,MUTAGEN:K->R: Abolishes sumoylation. No change in nuclear location nor on protein stability. Increased AP1 transactivation activity when heterodimerized with cJUN.,MUTAGEN:K->R: No change in sumoylation.,MUTAGEN:S->A: Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-374.,MUTAGEN:S->A: No change in sumoylation levels. Loss of protein stability. Reduced MOS/MAPK-mediated transforming ability; when associated with A-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-362.,MUTAGEN:S->D: Increased protein stability. Increased MOS/MAPK-mediated transforming ability and no change in sumoylation levels; when associated with D-374.,MUTAGEN:T->D: Decreased sumoylation levels.,MUTAGEN:T->D: No change in sumoylation levels.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-10.,MUTAGEN:Y->E: Loss of activation of phospholipid synthesis; when associated with E-30.,MUTAGEN:Y->F: No effect on Tyr-phosphorylation. Loss of endoplasmic reticulum localization in quiescent cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-10 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,MUTAGEN:Y->F: Overall loss of Tyr-phosphorylation, including that of Y-30 phosphorylation. Localizes to the endoplasmic reticulum in quiescent cells. Activates phospholipid synthesis in growing cells.,REGION:Basic motif; required for the activation of phospholipid synthesis, but not for CDS1-binding,REGION:Disordered,REGION:Leucine-zipper,
GNAL	G protein subunit alpha L(GNAL)	Homo sapiens	GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007191~adenylate cyclase-activating dopamine receptor signaling pathway,GO:0007606~sensory perception of chemical stimulus,	GO:0005834~heterotrimeric G-protein complex,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019001~guanyl nucleotide binding,GO:0031683~G-protein beta/gamma-subunit complex binding,GO:0046872~metal ion binding,	IPR000367:G-protein alpha subunit, group S,IPR001019:Guanine nucleotide binding protein (G-protein), alpha subunit,IPR011025:G protein alpha subunit, helical insertion,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04020:Calcium signaling pathway,hsa04728:Dopaminergic synapse,hsa04740:Olfactory transduction,hsa05012:Parkinson disease,hsa05142:Chagas disease,hsa05146:Amoebiasis,	615073~Dystonia 25,		SM00275:SM00275,			KW-0225~Disease variant,KW-1023~Dystonia,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0807~Transducer,	KW-0013~ADP-ribosylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:G-alpha,LIPID:N-palmitoyl glycine,LIPID:S-palmitoyl cysteine,REGION:Disordered,REGION:G1 motif,REGION:G2 motif,REGION:G3 motif,REGION:G4 motif,REGION:G5 motif,
GNG12	G protein subunit gamma 12(GNG12)	Homo sapiens	GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0021987~cerebral cortex development,GO:0032496~response to lipopolysaccharide,	GO:0005834~heterotrimeric G-protein complex,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0031680~G-protein beta/gamma-subunit complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0030165~PDZ domain binding,GO:0031681~G-protein beta-subunit binding,GO:0042301~phosphate ion binding,	IPR001770:G-protein, gamma subunit,IPR015898:G-protein gamma-like domain,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04062:Chemokine signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04810:Regulation of actin cytoskeleton,hsa04926:Relaxin signaling pathway,hsa05032:Morphine addiction,hsa05034:Alcoholism,hsa05163:Human cytomegalovirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05200:Pathways in cancer,			SM00224:GGL,		KW-0472~Membrane,KW-1003~Cell membrane,				KW-0807~Transducer,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,PROPEP:Removed in mature form,
GPR139	G protein-coupled receptor 139(GPR139)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0008188~neuropeptide receptor activity,GO:0042802~identical protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR156	G protein-coupled receptor 156(GPR156)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007214~gamma-aminobutyric acid signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0038039~G-protein coupled receptor heterodimeric complex,	GO:0004888~transmembrane signaling receptor activity,GO:0004965~G-protein coupled GABA receptor activity,	IPR002455:GPCR, family 3, gamma-aminobutyric acid receptor, type B,IPR017978:GPCR, family 3, C-terminal,	hsa04080:Neuroactive ligand-receptor interaction,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GPR158	G protein-coupled receptor 158(GPR158)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0072659~protein localization to plasma membrane,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,	IPR017978:GPCR, family 3, C-terminal,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:G_PROTEIN_RECEP_F3_4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR22	G protein-coupled receptor 22(GPR22)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0030030~cell projection organization,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0042277~peptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,					KW-0970~Cilium biogenesis/degradation,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR26	G protein-coupled receptor 26(GPR26)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-1015~Disulfide bond,	MUTAGEN:R->A,Q: No effect on constitutive activity.,MUTAGEN:R->A: No effect on constitutive activity; when associated with E-236.,MUTAGEN:R->E: No effect on constitutive activity; when associated with A-104. No effect on constitutive activity; when associated with Q-104.,MUTAGEN:R->Q,E: No effect on constitutive activity.,MUTAGEN:R->Q: No effect on constitutive activity; when associated with E-236.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR27	G protein-coupled receptor 27(GPR27)	Homo sapiens	GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:1900738~positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR61	G protein-coupled receptor 61(GPR61)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0043950~positive regulation of cAMP-mediated signaling,	GO:0005768~endosome,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:1990763~arrestin family protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,MUTAGEN:N->S: Does not affect subcellular location.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GPR84	G protein-coupled receptor 84(GPR84)	Homo sapiens	GO:0007218~neuropeptide signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0035579~specific granule membrane,GO:0043235~receptor complex,GO:0070821~tertiary granule membrane,	GO:0001604~urotensin II receptor activity,GO:0008528~G-protein coupled peptide receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR017452:GPCR, rhodopsin-like, 7TM,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
G0S2	G0/G1 switch 2(G0S2)	Homo sapiens	GO:0097191~extrinsic apoptotic signaling pathway,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005739~mitochondrion,GO:0005811~lipid particle,	GO:0005515~protein binding,	IPR016821:G0/G1 switch protein 2, putative,			PIRSF023925:G0/G1 switch protein 2,		KW-0053~Apoptosis,	KW-0496~Mitochondrion,						MUTAGEN:D->A: Reduced BCL2-binding and reduced pro-apoptotic activity; when associated with A-57. No effect on mitochondrial localization; when associated with A-57.,MUTAGEN:E->A: No effect on BCL2-binding; when associated with A-43.,MUTAGEN:F->A: No effect on BCL2-binding; when associated with A-35.,MUTAGEN:F->A: Reduced BCL2-binding; when associated with A-51.,MUTAGEN:L->A: No effect on BCL2-binding; when associated with A-36.,MUTAGEN:M->A: No effect on BCL2-binding; when associated with A-44.,MUTAGEN:R->A: Reduced BCL2-binding and reduced pro-apoptotic activity; when associated with A-58. No effect on mitochondrial localization; when associated with A-58.,MUTAGEN:R->A: Reduced BCL2-binding; when associated with A-54.,MUTAGEN:R->A: Reduced BCL2-binding; when associated with A-55.,MUTAGEN:T->A: No effect on BCL2-binding; when associated with A-46.,MUTAGEN:T->A: Reduced BCL2-binding; when associated with A-50.,MUTAGEN:V->A: No effect on BCL2-binding; when associated with A-38.,MUTAGEN:V->A: No effect on BCL2-binding; when associated with A-39.,MUTAGEN:V->A: No effect on BCL2-binding; when associated with A-45.,REGION:Disordered,
GATA3	GATA binding protein 3(GATA3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0001709~cell fate determination,GO:0001764~neuron migration,GO:0001806~type IV hypersensitivity,GO:0001817~regulation of cytokine production,GO:0001822~kidney development,GO:0001823~mesonephros development,GO:0002088~lens development in camera-type eye,GO:0002520~immune system development,GO:0002572~pro-T cell differentiation,GO:0003180~aortic valve morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003281~ventricular septum development,GO:0006338~chromatin remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0006952~defense response,GO:0006959~humoral immune response,GO:0007165~signal transduction,GO:0007411~axon guidance,GO:0008283~cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009615~response to virus,GO:0009653~anatomical structure morphogenesis,GO:0009791~post-embryonic development,GO:0009967~positive regulation of signal transduction,GO:0010332~response to gamma radiation,GO:0010595~positive regulation of endothelial cell migration,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010975~regulation of neuron projection development,GO:0014065~phosphatidylinositol 3-kinase signaling,GO:0030101~natural killer cell activation,GO:0030217~T cell differentiation,GO:0030218~erythrocyte differentiation,GO:0030856~regulation of epithelial cell differentiation,GO:0031929~TOR signaling,GO:0032689~negative regulation of interferon-gamma production,GO:0032703~negative regulation of interleukin-2 production,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0033600~negative regulation of mammary gland epithelial cell proliferation,GO:0035162~embryonic hemopoiesis,GO:0035457~cellular response to interferon-alpha,GO:0035799~ureter maturation,GO:0035898~parathyroid hormone secretion,GO:0042421~norepinephrine biosynthetic process,GO:0042472~inner ear morphogenesis,GO:0042493~response to drug,GO:0043370~regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043523~regulation of neuron apoptotic process,GO:0043583~ear development,GO:0043627~response to estrogen,GO:0045061~thymic T cell selection,GO:0045064~T-helper 2 cell differentiation,GO:0045087~innate immune response,GO:0045165~cell fate commitment,GO:0045471~response to ethanol,GO:0045582~positive regulation of T cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045622~regulation of T-helper cell differentiation,GO:0045786~negative regulation of cell cycle,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048469~cell maturation,GO:0048485~sympathetic nervous system development,GO:0048538~thymus development,GO:0048568~embryonic organ development,GO:0048589~developmental growth,GO:0048646~anatomical structure formation involved in morphogenesis,GO:0050728~negative regulation of inflammatory response,GO:0050852~T cell receptor signaling pathway,GO:0051569~regulation of histone H3-K4 methylation,GO:0051897~positive regulation of protein kinase B signaling,GO:0060017~parathyroid gland development,GO:0060037~pharyngeal system development,GO:0060065~uterus development,GO:0060231~mesenchymal to epithelial transition,GO:0060374~mast cell differentiation,GO:0060676~ureteric bud formation,GO:0061085~regulation of histone H3-K27 methylation,GO:0061290~canonical Wnt signaling pathway involved in metanephric kidney development,GO:0071353~cellular response to interleukin-4,GO:0071356~cellular response to tumor necrosis factor,GO:0071442~positive regulation of histone H3-K14 acetylation,GO:0071599~otic vesicle development,GO:0071773~cellular response to BMP stimulus,GO:0072107~positive regulation of ureteric bud formation,GO:0072178~nephric duct morphogenesis,GO:0072179~nephric duct formation,GO:0072182~regulation of nephron tubule epithelial cell differentiation,GO:0072197~ureter morphogenesis,GO:0072676~lymphocyte migration,GO:0090102~cochlea development,GO:1901536~negative regulation of DNA demethylation,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000114~regulation of establishment of cell polarity,GO:2000146~negative regulation of cell motility,GO:2000352~negative regulation of endothelial cell apoptotic process,GO:2000553~positive regulation of T-helper 2 cell cytokine production,GO:2000607~negative regulation of cell proliferation involved in mesonephros development,GO:2000611~positive regulation of thyroid hormone generation,GO:2000617~positive regulation of histone H3-K9 acetylation,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2000683~regulation of cellular response to X-ray,GO:2000703~negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation,GO:2000734~negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005134~interleukin-2 receptor binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Zinc finger, GATA-type,IPR013088:Zinc finger, NHR/GATA-type,IPR016374:Transcription factor, GATA-1/2/3,	hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05321:Inflammatory bowel disease,	146255~Hypoparathyroidism, sensorineural deafness, and renal dysplasia,	PIRSF003027:transcription factor, GATA-1/2/3 types,	SM00401:ZnF_GATA,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MOTIF:YxKxHxxxRP,REGION:Disordered,REGION:Flexible linker,REGION:Interaction with TBX21,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GATA4	GATA binding protein 4(GATA4)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001947~heart looping,GO:0003162~atrioventricular node development,GO:0003180~aortic valve morphogenesis,GO:0003190~atrioventricular valve formation,GO:0003197~endocardial cushion development,GO:0003208~cardiac ventricle morphogenesis,GO:0003215~cardiac right ventricle morphogenesis,GO:0003281~ventricular septum development,GO:0003289~atrial septum primum morphogenesis,GO:0003290~atrial septum secundum morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007267~cell-cell signaling,GO:0007492~endoderm development,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010507~negative regulation of autophagy,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0030513~positive regulation of BMP signaling pathway,GO:0033189~response to vitamin A,GO:0035054~embryonic heart tube anterior/posterior pattern specification,GO:0036302~atrioventricular canal development,GO:0042060~wound healing,GO:0042493~response to drug,GO:0045165~cell fate commitment,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048617~embryonic foregut morphogenesis,GO:0051891~positive regulation of cardioblast differentiation,GO:0051896~regulation of protein kinase B signaling,GO:0060290~transdifferentiation,GO:0060413~atrial septum morphogenesis,GO:0060575~intestinal epithelial cell differentiation,GO:0061026~cardiac muscle tissue regeneration,GO:0061049~cell growth involved in cardiac muscle cell development,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071333~cellular response to glucose stimulus,GO:0086004~regulation of cardiac muscle cell contraction,GO:1903202~negative regulation of oxidative stress-induced cell death,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0008270~zinc ion binding,GO:0019901~protein kinase binding,GO:0043565~sequence-specific DNA binding,GO:0051525~NFAT protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070410~co-SMAD binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000679:Zinc finger, GATA-type,IPR008013:GATA-type transcription activator, N-terminal,IPR013088:Zinc finger, NHR/GATA-type,IPR016375:Transcription factor GATA-4/5/6,	hsa04022:cGMP-PKG signaling pathway,hsa04218:Cellular senescence,hsa04530:Tight junction,hsa04919:Thyroid hormone signaling pathway,	187500~Tetralogy of Fallot,607941~Atrial septal defect 2,614429~Ventricular septal defect 1,614430~Atrioventricular septal defect 4,615542~Testicular anomalies with or without congenital heart disease,	PIRSF003028:transcription factor GATA-4/5/6 types,	SM00401:ZnF_GATA,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0976~Atrial septal defect,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0488~Methylation,	COMPBIAS:Polar residues,DOMAIN:GATA-N,DOMAIN:GATA-type,REGION:Disordered,ZN_FING:GATA-type 1,ZN_FING:GATA-type 2,
GFRA1	GDNF family receptor alpha 1(GFRA1)	Homo sapiens	GO:0001822~kidney development,GO:0007166~cell surface receptor signaling pathway,GO:0007399~nervous system development,GO:0007568~aging,GO:0008584~male gonad development,GO:0016477~cell migration,GO:0031175~neuron projection development,GO:0035860~glial cell-derived neurotrophic factor receptor signaling pathway,GO:0038179~neurotrophin signaling pathway,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,	GO:0005771~multivesicular body,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0019898~extrinsic component of membrane,GO:0030424~axon,GO:0031225~anchored component of membrane,GO:0043025~neuronal cell body,GO:0043235~receptor complex,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0005030~neurotrophin receptor activity,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0016167~glial cell-derived neurotrophic factor receptor activity,GO:0038023~signaling receptor activity,	IPR003438:Glial cell line-derived neurotrophic factor receptor,IPR003503:Glial cell line-derived neurotrophic factor receptor, alpha 1,IPR016017:GDNF/GAS1,IPR017372:Glial cell line-derived neurotrophic factor receptor, alpha 1/2,		619887~Renal hypodysplasia/aplasia 4,	PIRSF038071:GDNF family receptor alpha,	SM00907:SM00907,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GDNF,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,REPEAT:1,REPEAT:2,REPEAT:3,
GAREM2	GRB2 associated regulator of MAPK1 subtype 2(GAREM2)	Homo sapiens				IPR013761:Sterile alpha motif/pointed domain,IPR025946:CABIT domain,											KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SAM,REGION:CABIT,REGION:Disordered,
GAPT	GRB2 binding adaptor protein, transmembrane(GAPT)	Homo sapiens	GO:0001782~B cell homeostasis,GO:0002322~B cell proliferation involved in immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,	GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,		IPR021082:Protein GAPT,					KW-0075~B-cell activation,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				MUTAGEN:P->A: Abolishes interaction with GRB2.,REGION:Disordered,TRANSMEM:Helical,
GRAP2	GRB2 related adaptor protein 2(GRAP2)	Homo sapiens	GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0007267~cell-cell signaling,GO:0043408~regulation of MAPK cascade,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0001784~phosphotyrosine binding,GO:0005515~protein binding,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,	hsa04660:T cell receptor signaling pathway,			SM00252:SH2,SM00326:SH3,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,REGION:Disordered,
GRAPL	GRB2 related adaptor protein like(GRAPL)	Homo sapiens	GO:0007165~signal transduction,GO:0016477~cell migration,	GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0035591~signaling adaptor activity,	IPR000980:SH2 domain,IPR001452:Src homology-3 domain,				SM00252:SH2,SM00326:SH3,				KW-0727~SH2 domain,KW-0728~SH3 domain,				DOMAIN:SH2,DOMAIN:SH3,REGION:Disordered,
GREB1L	GREB1 like retinoic acid receptor coactivator(GREB1L)	Homo sapiens	GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001822~kidney development,GO:0003231~cardiac ventricle development,GO:0007275~multicellular organism development,GO:0030539~male genitalia development,GO:0060065~uterus development,GO:0061205~paramesonephric duct development,GO:0072177~mesonephric duct development,	GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR024840:GREB1-like,		617805~Renal hypodysplasia/aplasia 3,619274~Deafness, autosomal dominant 80,				KW-0472~Membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
GSX2	GS homeobox 2(GSX2)	Homo sapiens	GO:0002087~regulation of respiratory gaseous exchange by neurological system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007219~Notch signaling pathway,GO:0021527~spinal cord association neuron differentiation,GO:0021575~hindbrain morphogenesis,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021889~olfactory bulb interneuron differentiation,GO:0021978~telencephalon regionalization,GO:0030334~regulation of cell migration,GO:0045747~positive regulation of Notch signaling pathway,GO:0048665~neuron fate specification,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0048853~forebrain morphogenesis,GO:0060163~subpallium neuron fate commitment,GO:0097154~GABAergic neuron differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		618646~Diencephalic-mesencephalic junction dysplasia syndrome 2,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1023~Dystonia,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic residues,DNA_BIND:Homeobox,REGION:Disordered,
HLF	HLF transcription factor, PAR bZIP family member(HLF)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0035914~skeletal muscle cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003690~double-stranded DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,				SM00338:BRLZ,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
HORMAD2	HORMA domain containing 2(HORMAD2)	Homo sapiens	GO:0051177~meiotic sister chromatid cohesion,GO:0051321~meiotic cell cycle,	GO:0000795~synaptonemal complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005813~centrosome,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR003511:DNA-binding HORMA,					KW-0469~Meiosis,	KW-0158~Chromosome,KW-0539~Nucleus,					KW-0597~Phosphoprotein,	DOMAIN:HORMA,
HTRA3	HtrA serine peptidase 3(HTRA3)	Homo sapiens	GO:0006508~proteolysis,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,	GO:0005576~extracellular region,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0008236~serine-type peptidase activity,GO:0042802~identical protein binding,	IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR001478:PDZ domain,IPR001940:Peptidase S1C,IPR002350:Kazal domain,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR009030:Insulin-like growth factor binding protein, N-terminal,				SM00121:IB,SM00228:PDZ,SM00280:KAZAL,		KW-0964~Secreted,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,DOMAIN:IGFBP N-terminal,DOMAIN:Kazal-like,DOMAIN:PDZ,MUTAGEN:S->A: Abolishes protease activity. Stabilizes the protein.,REGION:Serine protease,
IFI30	IFI30 lysosomal thiol reductase(IFI30)	Homo sapiens	GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0042590~antigen processing and presentation of exogenous peptide antigen via MHC class I,GO:0048147~negative regulation of fibroblast proliferation,GO:0050821~protein stabilization,	GO:0005576~extracellular region,GO:0005764~lysosome,GO:0005829~cytosol,GO:0030054~cell junction,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0016667~oxidoreductase activity, acting on a sulfur group of donors,GO:0016671~oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor,	IPR004911:Gamma interferon inducible lysosomal thiol reductase GILT,	hsa04612:Antigen processing and presentation,				KW-0391~Immunity,	KW-0458~Lysosome,KW-0964~Secreted,		KW-0676~Redox-active center,KW-0732~Signal,		KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Redox-active,MUTAGEN:C->S: Abolishes reducing activity, does not affect dimerization. Abolishes reducing activity; when associated with S-72.,MUTAGEN:C->S: Abolishes reducing activity, does not affect dimerization. Abolishes reducing activity; when associated with S-75.,PROPEP:Removed in mature form,
INSM2	INSM transcriptional repressor 2(INSM2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0010564~regulation of cell cycle process,GO:0030182~neuron differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0017053~transcriptional repressor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:SNAG domain,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
IQGAP1	IQ motif containing GTPase activating protein 1(IQGAP1)	Homo sapiens	GO:0001817~regulation of cytokine production,GO:0007165~signal transduction,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007346~regulation of mitotic cell cycle,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0010761~fibroblast migration,GO:0016477~cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0035305~negative regulation of dephosphorylation,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0043086~negative regulation of catalytic activity,GO:0043087~regulation of GTPase activity,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0045860~positive regulation of protein kinase activity,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0051894~positive regulation of focal adhesion assembly,GO:0071277~cellular response to calcium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0072015~glomerular visceral epithelial cell development,GO:1900006~positive regulation of dendrite development,GO:1900086~positive regulation of peptidyl-tyrosine autophosphorylation,GO:1903829~positive regulation of cellular protein localization,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,GO:1990138~neuron projection extension,GO:1990776~response to angiotensin,	GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0015630~microtubule cytoskeleton,GO:0016328~lateral plasma membrane,GO:0030424~axon,GO:0030426~growth cone,GO:0030496~midbody,GO:0030667~secretory granule membrane,GO:0030864~cortical actin cytoskeleton,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032991~macromolecular complex,GO:0036057~slit diaphragm,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043005~neuron projection,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0005078~MAP-kinase scaffold activity,GO:0005095~GTPase inhibitor activity,GO:0005096~GTPase activator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0019904~protein domain specific binding,GO:0031267~small GTPase binding,GO:0043539~protein serine/threonine kinase activator activity,GO:0044548~S100 protein binding,GO:0044877~macromolecular complex binding,GO:0045296~cadherin binding,GO:0051015~actin filament binding,GO:0051019~mitogen-activated protein kinase binding,GO:0060090~binding, bridging,	IPR000048:IQ motif, EF-hand binding site,IPR000593:RasGAP protein, C-terminal,IPR001202:WW domain,IPR001715:Calponin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR023152:Ras GTPase-activating protein, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04520:Adherens junction,hsa04810:Regulation of actin cytoskeleton,hsa05205:Proteoglycans in cancer,			SM00015:IQ,SM00033:CH,SM00323:RasGAP,SM00456:WW,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,		KW-0112~Calmodulin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Calponin-homology (CH),DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:IQ 4,DOMAIN:Ras-GAP,DOMAIN:WW,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->A: Abolishes neurite outgrowth promoting activity; when associated with A-1443.,MUTAGEN:S->D: Strongly enhances neurite outgrowth promoting activity; when associated with A-1441.,MUTAGEN:S->E: Strongly enhances neurite outgrowth promoting activity; when associated with A-1443.,REGION:C1,REGION:C2,REGION:Disordered,
IQGAP2	IQ motif containing GTPase activating protein 2(IQGAP2)	Homo sapiens	GO:0007165~signal transduction,GO:0032956~regulation of actin cytoskeleton organization,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0043086~negative regulation of catalytic activity,GO:0043087~regulation of GTPase activity,GO:0070493~thrombin-activated receptor signaling pathway,GO:2000249~regulation of actin cytoskeleton reorganization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0009986~cell surface,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005095~GTPase inhibitor activity,GO:0005096~GTPase activator activity,GO:0005516~calmodulin binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0031267~small GTPase binding,GO:0051015~actin filament binding,GO:0071933~Arp2/3 complex binding,	IPR000048:IQ motif, EF-hand binding site,IPR000593:RasGAP protein, C-terminal,IPR001202:WW domain,IPR001715:Calponin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR023152:Ras GTPase-activating protein, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04810:Regulation of actin cytoskeleton,			SM00015:IQ,SM00033:CH,SM00323:RasGAP,		KW-0472~Membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:Ras-GAP,DOMAIN:WW,TRANSMEM:Helical,
IQGAP3	IQ motif containing GTPase activating protein 3(IQGAP3)	Homo sapiens	GO:0000082~G1/S transition of mitotic cell cycle,GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0008361~regulation of cell size,GO:0010467~gene expression,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0032956~regulation of actin cytoskeleton organization,GO:0033598~mammary gland epithelial cell proliferation,GO:0033601~positive regulation of mammary gland epithelial cell proliferation,GO:0043087~regulation of GTPase activity,GO:0043410~positive regulation of MAPK cascade,GO:0070371~ERK1 and ERK2 cascade,GO:0071310~cellular response to organic substance,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005911~cell-cell junction,GO:0016328~lateral plasma membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0031267~small GTPase binding,GO:0051015~actin filament binding,GO:0070856~myosin VI light chain binding,	IPR000048:IQ motif, EF-hand binding site,IPR000593:RasGAP protein, C-terminal,IPR001715:Calponin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR023152:Ras GTPase-activating protein, conserved site,	hsa04810:Regulation of actin cytoskeleton,			SM00015:IQ,SM00033:CH,SM00323:RasGAP,				KW-0677~Repeat,		KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:IQ 4,DOMAIN:Ras-GAP,
ISL2	ISL LIM homeobox 2(ISL2)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007409~axonogenesis,GO:0021520~spinal cord motor neuron cell fate specification,GO:0021524~visceral motor neuron differentiation,GO:0031290~retinal ganglion cell axon guidance,GO:0045665~negative regulation of neuron differentiation,GO:0048665~neuron fate specification,GO:0048666~neuron development,GO:0048935~peripheral nervous system neuron development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0000987~core promoter proximal region sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00132:LIM,SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,REGION:LIM-binding domain (LID),
KANSL1	KAT8 regulatory NSL complex subunit 1(KANSL1)	Homo sapiens	GO:0006325~chromatin organization,GO:0043981~histone H4-K5 acetylation,GO:0043982~histone H4-K8 acetylation,GO:0043984~histone H4-K16 acetylation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0051571~positive regulation of histone H3-K4 methylation,GO:1900095~regulation of dosage compensation by inactivation of X chromosome,	GO:0000123~histone acetyltransferase complex,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0044545~NSL complex,GO:0071339~MLL1 complex,	GO:0005515~protein binding,GO:0035035~histone acetyltransferase binding,	IPR026180:KAT8 regulatory NSL complex subunit 1,		610443~Koolen-De Vries syndrome,		SM01300:SM01300,		KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0175~Coiled coil,		KW-0156~Chromatin regulator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PEHE,MUTAGEN:E->R: Abolishes interaction with KAT8.,MUTAGEN:F->R: No effect on interaction with KAT8.,MUTAGEN:FDIN->AAAA: Strongly reduces KAT8 histone acetyltransferase activity.,MUTAGEN:GESS->AAAA: Strongly reduces KAT8 histone acetyltransferase activity.,MUTAGEN:H->R: Abolishes interaction with KAT8.,MUTAGEN:NIVI->AAAA: Abolishes KAT8 histone acetyltransferase activity.,MUTAGEN:PMSV->AAAA: Reduces KAT8 histone acetyltransferase activity.,MUTAGEN:RRRR->AAAA: Abolishes KAT8 histone acetyltransferase activity.,REGION:Disordered,REGION:Required for activation of KAT8 histone acetyltransferase activity,REGION:Sufficient for interaction with KAT8,
KDELR3	KDEL endoplasmic reticulum protein retention receptor 3(KDELR3)	Homo sapiens	GO:0006621~protein retention in ER lumen,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0015031~protein transport,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005801~cis-Golgi network,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0030663~COPI-coated vesicle membrane,	GO:0005046~KDEL sequence binding,GO:0046923~ER retention sequence binding,	IPR000133:ER lumen protein retaining receptor,	hsa05110:Vibrio cholerae infection,				KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		REGION:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,REGION:Interaction with the K-D-E-L motif on target proteins,SITE:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum,SITE:Interaction with the K-D-E-L motif on target proteins,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
KIAA0040	KIAA0040(KIAA0040)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
KIAA0513	KIAA0513(KIAA0513)	Homo sapiens		GO:0005737~cytoplasm,								KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
KISS1R	KISS1 receptor(KISS1R)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005929~cilium,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008188~neuropeptide receptor activity,GO:0008528~G-protein coupled peptide receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR008103:KiSS-1 peptide receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,hsa04929:GnRH secretion,	176400~Precocious puberty, central, 1,614837~Hypogonadotropic hypogonadism 8 with or without anosmia,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1016~Hypogonadotropic hypogonadism,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
LEMD1	LEM domain containing 1(LEMD1)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003887:LEM domain,IPR011015:LEM/LEM-like domain,				SM00540:LEM,		KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:LEM,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
LHFPL1	LHFPL tetraspan subfamily member 1(LHFPL1)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR019372:Lipoma HMGIC fusion partner-like protein,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
LIF	LIF interleukin 6 family cytokine(LIF)	Homo sapiens	GO:0001974~blood vessel remodeling,GO:0006955~immune response,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0007275~multicellular organism development,GO:0007566~embryo implantation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0019827~stem cell population maintenance,GO:0030225~macrophage differentiation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033141~positive regulation of peptidyl-serine phosphorylation of STAT protein,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035019~somatic stem cell population maintenance,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043410~positive regulation of MAPK cascade,GO:0045595~regulation of cell differentiation,GO:0045651~positive regulation of macrophage differentiation,GO:0045835~negative regulation of meiotic nuclear division,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046697~decidualization,GO:0046888~negative regulation of hormone secretion,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048286~lung alveolus development,GO:0048644~muscle organ morphogenesis,GO:0048666~neuron development,GO:0048711~positive regulation of astrocyte differentiation,GO:0048861~leukemia inhibitory factor signaling pathway,GO:0048863~stem cell differentiation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0060426~lung vasculature development,GO:0060463~lung lobe morphogenesis,GO:0060707~trophoblast giant cell differentiation,GO:0060708~spongiotrophoblast differentiation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0072108~positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,GO:0072307~regulation of metanephric nephron tubule epithelial cell differentiation,GO:1900182~positive regulation of protein localization to nucleus,GO:1901676~positive regulation of histone H3-K27 acetylation,GO:1903025~regulation of RNA polymerase II regulatory region sequence-specific DNA binding,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,	GO:0005102~receptor binding,GO:0005125~cytokine activity,GO:0005146~leukemia inhibitory factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR001581:Leukemia inhibitory factor /oncostatin,IPR003624:Leukemia inhibitory factor,IPR009079:Four-helical cytokine-like, core,IPR019827:Leukemia inhibitory factor /oncostatin, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04630:JAK-STAT signaling pathway,hsa04668:TNF signaling pathway,			SM00080:LIF_OSM,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
LHX3	LIM homeobox 3(LHX3)	Homo sapiens	GO:0001890~placenta development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007275~multicellular organism development,GO:0008045~motor neuron axon guidance,GO:0009887~animal organ morphogenesis,GO:0021520~spinal cord motor neuron cell fate specification,GO:0021521~ventral spinal cord interneuron specification,GO:0021526~medial motor column neuron differentiation,GO:0021527~spinal cord association neuron differentiation,GO:0021983~pituitary gland development,GO:0030182~neuron differentiation,GO:0030324~lung development,GO:0043066~negative regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048839~inner ear development,GO:0060126~somatotropin secreting cell differentiation,GO:0060127~prolactin secreting cell differentiation,GO:0060129~thyroid-stimulating hormone-secreting cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,		221750~Pituitary hormone deficiency, combined, 3,		SM00132:LIM,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,
LHX5	LIM homeobox 5(LHX5)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0021527~spinal cord association neuron differentiation,GO:0021702~cerebellar Purkinje cell differentiation,GO:0021766~hippocampus development,GO:0021846~cell proliferation in forebrain,GO:0021879~forebrain neuron differentiation,GO:0021937~cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of granule cell precursor cell proliferation,GO:0030182~neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,	hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00132:LIM,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,
LHX6	LIM homeobox 6(LHX6)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0021799~cerebral cortex radially oriented cell migration,GO:0021800~cerebral cortex tangential migration,GO:0021853~cerebral cortex GABAergic interneuron migration,GO:0021884~forebrain neuron development,GO:0030182~neuron differentiation,GO:0048469~cell maturation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00132:LIM,SM00389:HOX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,REGION:Required for interaction with LDB1,
LHX9	LIM homeobox 9(LHX9)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008283~cell proliferation,GO:0008584~male gonad development,GO:0008585~female gonad development,GO:0030182~neuron differentiation,GO:0035262~gonad morphogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0097380~dorsal spinal cord interneuron anterior axon guidance,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001781:Zinc finger, LIM-type,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00132:LIM,SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,REGION:Disordered,
LRRN4CL	LRRN4 C-terminal like(LRRN4CL)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,		KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MAP7D2	MAP7 domain containing 2(MAP7D2)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,	GO:0015630~microtubule cytoskeleton,		IPR008604:E-MAP-115,								KW-0175~Coiled coil,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
MCF2	MCF.2 cell line derived transforming sequence(MCF2)	Homo sapiens	GO:0016358~dendrite development,GO:0035556~intracellular signal transduction,GO:0050771~negative regulation of axonogenesis,GO:0050790~regulation of catalytic activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0016020~membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000219:Dbl homology (DH) domain,IPR001251:CRAL-TRIO domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR018159:Spectrin/alpha-actinin,				SM00150:SPEC,SM00233:PH,SM00325:RhoGEF,SM00516:SEC14,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,		KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	DOMAIN:CRAL-TRIO,DOMAIN:DH,DOMAIN:PH,MUTAGEN:LLLKELL->IIIRDII: Transformation capability reduced; no stimulation of GDP dissociation.,REPEAT:Spectrin,
MICB	MHC class I polypeptide-related sequence B(MICB)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002429~immune response-activating cell surface receptor signaling pathway,GO:0006955~immune response,GO:0006979~response to oxidative stress,GO:0009408~response to heat,GO:0019835~cytolysis,GO:0032526~response to retinoic acid,GO:0046629~gamma-delta T cell activation,GO:0050689~negative regulation of defense response to virus by host,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0046703~natural killer cell lectin-like receptor binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04650:Natural killer cell mediated cytotoxicity,hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM00407:IGc1,	KW-0204~Cytolysis,KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MIA	MIA SH3 domain containing(MIA)	Homo sapiens	GO:0007165~signal transduction,GO:0030198~extracellular matrix organization,	GO:0005615~extracellular space,	GO:0008083~growth factor activity,	IPR001452:Src homology-3 domain,				SM00326:SH3,		KW-0964~Secreted,		KW-0728~SH3 domain,KW-0732~Signal,		KW-0339~Growth factor,	KW-1015~Disulfide bond,	DOMAIN:SH3,
MICALL2	MICAL like 2(MICALL2)	Homo sapiens	GO:0030041~actin filament polymerization,GO:0031175~neuron projection development,GO:0031532~actin cytoskeleton reorganization,GO:0032456~endocytic recycling,GO:0034446~substrate adhesion-dependent cell spreading,GO:0070830~bicellular tight junction assembly,GO:1903955~positive regulation of protein targeting to mitochondrion,	GO:0001725~stress fiber,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005923~bicellular tight junction,GO:0032432~actin filament bundle,GO:0043005~neuron projection,GO:0055037~recycling endosome,	GO:0005515~protein binding,GO:0031005~filamin binding,GO:0031267~small GTPase binding,GO:0042805~actinin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001715:Calponin homology domain,IPR001781:Zinc finger, LIM-type,IPR022735:Domain of unknown function DUF3585,	hsa04530:Tight junction,			SM00033:CH,SM00132:LIM,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0440~LIM domain,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Calponin-homology (CH),DOMAIN:LIM zinc-binding,DOMAIN:bMERB,REGION:Disordered,REGION:Forms an intramolecular interaction with the C-terminal coiled coil domain keeping the protein in a closed conformation,REGION:Forms an intramolecular interaction with the N-terminal Calponin-homology and LIM zinc-binding domains-containing region keeping the protein in a closed conformation,REGION:Mediates interaction with RAB13 and is required for transition from the closed to the opened conformation,REGION:Mediates targeting to the cell plasma membrane,REGION:Necessary and sufficient for interaction with actinins,
MN1	MN1 proto-oncogene, transcriptional regulator(MN1)	Homo sapiens	GO:0001957~intramembranous ossification,GO:0006355~regulation of transcription, DNA-templated,GO:0033689~negative regulation of osteoblast proliferation,GO:0070564~positive regulation of vitamin D receptor signaling pathway,GO:1902806~regulation of cell cycle G1/S phase transition,	GO:0005634~nucleus,	GO:0005515~protein binding,			607174~Meningioma,618774~CEBALID syndrome,			KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0991~Intellectual disability,			KW-0010~Activator,KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,
MYBL2	MYB proto-oncogene like 2(MYBL2)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0006355~regulation of transcription, DNA-templated,GO:0043525~positive regulation of neuron apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0090307~mitotic spindle assembly,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031523~Myb complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001005:SANT/Myb domain,IPR009057:Homeodomain-like,IPR015395:C-myb, C-terminal,IPR017930:Myb domain,	hsa04218:Cellular senescence,			SM00717:SANT,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,		KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:H-T-H motif,DOMAIN:HTH myb-type 1,DOMAIN:HTH myb-type 2,DOMAIN:HTH myb-type 3,MOTIF:Bipartite nuclear localization signal,MOTIF:Nuclear localization signal,REGION:Disordered,
MMD2	Miyoshi muscular dystrophy 2(MMD2)	Homo sapiens						Miyoshi muscular dystrophy 2~Miyoshi muscular dystrophy 2,
NECAB2	N-terminal EF-hand calcium binding protein 2(NECAB2)	Homo sapiens	GO:0042984~regulation of amyloid precursor protein biosynthetic process,GO:0060168~positive regulation of adenosine receptor signaling pathway,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1900451~positive regulation of glutamate receptor signaling pathway,GO:1904021~negative regulation of G-protein coupled receptor internalization,GO:1905477~positive regulation of protein localization to membrane,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0031687~A2A adenosine receptor binding,GO:0031802~type 5 metabotropic glutamate receptor binding,GO:0042802~identical protein binding,	IPR002048:EF-hand domain,IPR007138:Antibiotic biosynthesis monooxygenase,IPR011008:Dimeric alpha-beta barrel,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0488~Methylation,	DOMAIN:ABM,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
NDRG2	NDRG family member 2(NDRG2)	Homo sapiens	GO:0001818~negative regulation of cytokine production,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0010574~regulation of vascular endothelial growth factor production,GO:0016055~Wnt signaling pathway,GO:0021762~substantia nigra development,GO:0030154~cell differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0090361~regulation of platelet-derived growth factor production,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,GO:1990874~vascular smooth muscle cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0030426~growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR004142:Ndr,					KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0043~Tumor suppressor,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:L->D: Decreased interaction with CTNNB1. Abolishes down-regulation of Wnt signaling.,REGION:Disordered,TRANSMEM:Helical,
NDRG4	NDRG family member 4(NDRG4)	Homo sapiens	GO:0001947~heart looping,GO:0007165~signal transduction,GO:0007420~brain development,GO:0008542~visual learning,GO:0010642~negative regulation of platelet-derived growth factor receptor signaling pathway,GO:0010976~positive regulation of neuron projection development,GO:0014912~negative regulation of smooth muscle cell migration,GO:0030154~cell differentiation,GO:0035050~embryonic heart tube development,GO:0048278~vesicle docking,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0060038~cardiac muscle cell proliferation,GO:0060973~cell migration involved in heart development,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:2001135~regulation of endocytic recycling,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0031253~cell projection membrane,	GO:0005515~protein binding,	IPR004142:Ndr,						KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,TRANSMEM:Helical,
NFE2L3	NFE2 like bZIP transcription factor 3(NFE2L3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR004826:Basic leucine zipper domain, Maf-type,IPR004827:Basic-leucine zipper domain,IPR008917:Eukaryotic transcription factor, Skn-1-like, DNA-binding,				SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,
NFKBIZ	NFKB inhibitor zeta(NFKBIZ)	Homo sapiens	GO:0006954~inflammatory response,GO:0010468~regulation of gene expression,GO:0050729~positive regulation of inflammatory response,GO:0050852~T cell receptor signaling pathway,GO:2000321~positive regulation of T-helper 17 cell differentiation,	GO:0005634~nucleus,GO:0016607~nuclear speck,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,	hsa05202:Transcriptional misregulation in cancer,			SM00248:ANK,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0040~ANK repeat,KW-0677~Repeat,		KW-0010~Activator,KW-0678~Repressor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:OCA,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Interaction with NFKB1/p50,REGION:Required for transcriptional activity,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
NKX2-5	NK2 homeobox 5(NKX2-5)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001570~vasculogenesis,GO:0001947~heart looping,GO:0003007~heart morphogenesis,GO:0003148~outflow tract septum morphogenesis,GO:0003161~cardiac conduction system development,GO:0003162~atrioventricular node development,GO:0003166~bundle of His development,GO:0003168~Purkinje myocyte differentiation,GO:0003180~aortic valve morphogenesis,GO:0003211~cardiac ventricle formation,GO:0003221~right ventricular cardiac muscle tissue morphogenesis,GO:0003222~ventricular trabecula myocardium morphogenesis,GO:0003228~atrial cardiac muscle tissue development,GO:0003278~apoptotic process involved in heart morphogenesis,GO:0003285~septum secundum development,GO:0003342~proepicardium development,GO:0003350~pulmonary myocardium development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007507~heart development,GO:0007512~adult heart development,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010735~positive regulation of transcription via serum response element binding,GO:0010765~positive regulation of sodium ion transport,GO:0010832~negative regulation of myotube differentiation,GO:0030097~hemopoiesis,GO:0030154~cell differentiation,GO:0030855~epithelial cell differentiation,GO:0030878~thyroid gland development,GO:0035050~embryonic heart tube development,GO:0043066~negative regulation of apoptotic process,GO:0045666~positive regulation of neuron differentiation,GO:0045823~positive regulation of heart contraction,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048536~spleen development,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051891~positive regulation of cardioblast differentiation,GO:0055005~ventricular cardiac myofibril assembly,GO:0055007~cardiac muscle cell differentiation,GO:0055008~cardiac muscle tissue morphogenesis,GO:0055013~cardiac muscle cell development,GO:0055014~atrial cardiac muscle cell development,GO:0055015~ventricular cardiac muscle cell development,GO:0055117~regulation of cardiac muscle contraction,GO:0060037~pharyngeal system development,GO:0060038~cardiac muscle cell proliferation,GO:0060043~regulation of cardiac muscle cell proliferation,GO:0060048~cardiac muscle contraction,GO:0060261~positive regulation of transcription initiation from RNA polymerase II promoter,GO:0060347~heart trabecula formation,GO:0060412~ventricular septum morphogenesis,GO:0060413~atrial septum morphogenesis,GO:0060928~atrioventricular node cell development,GO:0060929~atrioventricular node cell fate commitment,GO:0060971~embryonic heart tube left/right pattern formation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1903779~regulation of cardiac conduction,GO:1904019~epithelial cell apoptotic process,GO:1904036~negative regulation of epithelial cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0042803~protein homodimerization activity,GO:0043565~sequence-specific DNA binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		108900~Atrial septal defect 7, with or without AV conduction defects,187500~Tetralogy of Fallot,217095~Conotruncal heart malformations, variable,225250~Hypothyroidism, congenital nongoitrous, 5,614432~Ventricular septal defect 3,614435~Hypoplastic left heart syndrome 2,		SM00389:HOX,		KW-0539~Nucleus,	KW-0225~Disease variant,KW-0976~Atrial septal defect,KW-0984~Congenital hypothyroidism,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,
NKX3-2	NK3 homeobox 2(NKX3-2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007368~determination of left/right symmetry,GO:0030154~cell differentiation,GO:0031016~pancreas development,GO:0032331~negative regulation of chondrocyte differentiation,GO:0042474~middle ear morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0048536~spleen development,GO:0048645~animal organ formation,GO:0048705~skeletal system morphogenesis,GO:0048706~embryonic skeletal system development,GO:0060576~intestinal epithelial cell development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		613330~Spondylo-megaepiphyseal-metaphyseal dysplasia,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0242~Dwarfism,	KW-0371~Homeobox,		KW-0238~DNA-binding,KW-0678~Repressor,		DNA_BIND:Homeobox,REGION:Disordered,
NKX6-1	NK6 homeobox 1(NKX6-1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0003309~type B pancreatic cell differentiation,GO:0003310~pancreatic A cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0009410~response to xenobiotic stimulus,GO:0009887~animal organ morphogenesis,GO:0021953~central nervous system neuron differentiation,GO:0030154~cell differentiation,GO:0030516~regulation of axon extension,GO:0031016~pancreas development,GO:0032024~positive regulation of insulin secretion,GO:0035094~response to nicotine,GO:0042493~response to drug,GO:0044342~type B pancreatic cell proliferation,GO:0045666~positive regulation of neuron differentiation,GO:0045686~negative regulation of glial cell differentiation,GO:0045687~positive regulation of glial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048709~oligodendrocyte differentiation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0050796~regulation of insulin secretion,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051594~detection of glucose,GO:0071345~cellular response to cytokine stimulus,GO:0071375~cellular response to peptide hormone stimulus,GO:0072560~type B pancreatic cell maturation,GO:2000078~positive regulation of type B pancreatic cell development,GO:2001222~regulation of neuron migration,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa04950:Maturity onset diabetes of the young,			SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0488~Methylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,REGION:Involved in DNA-binding,REGION:Repressor domain,
NSUN7	NOP2/Sun RNA methyltransferase family member 7(NSUN7)	Homo sapiens	GO:0032259~methylation,		GO:0003723~RNA binding,GO:0008168~methyltransferase activity,	IPR001678:Bacterial Fmu (Sun)/eukaryotic nucleolar NOL1/Nop2p,									KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0694~RNA-binding,KW-0808~Transferase,		ACT_SITE:Nucleophile,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
NUF2	NUF2 component of NDC80 kinetochore complex(NUF2)	Homo sapiens	GO:0007049~cell cycle,GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007094~mitotic spindle assembly checkpoint,GO:0008608~attachment of spindle microtubules to kinetochore,GO:0045132~meiotic chromosome segregation,GO:0051301~cell division,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051383~kinetochore organization,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0016020~membrane,GO:0031262~Ndc80 complex,	GO:0005515~protein binding,GO:0044877~macromolecular complex binding,	IPR005549:Kinetochore protein Nuf2,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0995~Kinetochore,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Nuf2,REGION:Interaction with the C-terminus of NDC80 and the SPBC24-SPBC25 subcomplex,REGION:Interaction with the N-terminus of NDC80,
PBX2	PBX homeobox 2(PBX2)	Homo sapiens	GO:0001654~eye development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007420~brain development,GO:0009887~animal organ morphogenesis,GO:0009954~proximal/distal pattern formation,GO:0030326~embryonic limb morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048568~embryonic organ development,GO:0048666~neuron development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,	IPR001356:Homeodomain,IPR005542:PBX,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,DNA_BIND:Homeobox; TALE-type,DOMAIN:Homeobox,DOMAIN:PBC,REGION:Disordered,REGION:PBC-A,REGION:PBC-B,
PDLIM1	PDZ and LIM domain 1(PDLIM1)	Homo sapiens	GO:0001666~response to hypoxia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006979~response to oxidative stress,GO:0007507~heart development,GO:0010761~fibroblast migration,GO:0030011~maintenance of cell polarity,GO:0030036~actin cytoskeleton organization,GO:0030950~establishment or maintenance of actin cytoskeleton polarity,GO:0043149~stress fiber assembly,GO:0045893~positive regulation of transcription, DNA-templated,GO:0061061~muscle structure development,GO:0098609~cell-cell adhesion,	GO:0001725~stress fiber,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0030018~Z disc,GO:0031941~filamentous actin,	GO:0003713~transcription coactivator activity,GO:0003779~actin binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051371~muscle alpha-actinin binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,IPR006643:ZASP,				SM00132:LIM,SM00228:PDZ,SM00735:ZM,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:LIM zinc-binding,DOMAIN:PDZ,
PDLIM4	PDZ and LIM domain 4(PDLIM4)	Homo sapiens	GO:0007507~heart development,GO:0030036~actin cytoskeleton organization,GO:0031532~actin cytoskeleton reorganization,GO:0061061~muscle structure development,GO:0098976~excitatory chemical synaptic transmission,	GO:0001725~stress fiber,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005912~adherens junction,GO:0030018~Z disc,GO:0030027~lamellipodium,GO:0031901~early endosome membrane,GO:0031905~early endosome lumen,GO:0031941~filamentous actin,GO:0034777~recycling endosome lumen,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0048471~perinuclear region of cytoplasm,GO:0055038~recycling endosome membrane,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0019903~protein phosphatase binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0051371~muscle alpha-actinin binding,GO:0051393~alpha-actinin binding,	IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,		166710~Osteoporosis, susceptibility to,		SM00132:LIM,SM00228:PDZ,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,		KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:PDZ,REGION:Disordered,
PDLIM7	PDZ and LIM domain 7(PDLIM7)	Homo sapiens	GO:0001503~ossification,GO:0006898~receptor-mediated endocytosis,GO:0007507~heart development,GO:0030036~actin cytoskeleton organization,GO:0030154~cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0061061~muscle structure development,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030018~Z disc,GO:0031941~filamentous actin,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0051371~muscle alpha-actinin binding,	IPR001478:PDZ domain,IPR001781:Zinc finger, LIM-type,				SM00132:LIM,SM00228:PDZ,	KW-0221~Differentiation,KW-0892~Osteogenesis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:PDZ,MUTAGEN:GF->AA: Loss of binding to TPM2.,MUTAGEN:H->A: Loss of binding to TPM2.,REGION:Disordered,
PBK	PDZ binding kinase(PBK)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0001933~negative regulation of protein phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0032435~negative regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032873~negative regulation of stress-activated MAPK cascade,GO:0034644~cellular response to UV,GO:0038066~p38MAPK cascade,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0050728~negative regulation of inflammatory response,GO:1904291~positive regulation of mitotic DNA damage checkpoint,	GO:0005634~nucleus,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004706~JUN kinase kinase kinase activity,GO:0004708~MAP kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,				SM00220:S_TKc,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Protein kinase,MUTAGEN:KK->AA: Loss of activity.,MUTAGEN:T->A: Decrease in the binding to DLG1.,MUTAGEN:T->E: TP53-binding.,MUTAGEN:V->A: Decrease in the binding to DLG1.,REGION:PDZ-interaction,
PHF24	PHD finger protein 24(PHF24)	Homo sapiens	GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0032228~regulation of synaptic transmission, GABAergic,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,		GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR011011:Zinc finger, FYVE/PHD-type,IPR011992:EF-hand-like domain,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR019786:Zinc finger, PHD-type, conserved site,								KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,LIPID:N-myristoyl glycine,REGION:Disordered,ZN_FING:PHD-type,
PITPNM3	PITPNM family member 3(PITPNM3)	Homo sapiens	GO:0006661~phosphatidylinositol biosynthetic process,GO:0015914~phospholipid transport,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0042995~cell projection,GO:0044297~cell body,	GO:0004620~phospholipase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005548~phospholipid transporter activity,GO:0008289~lipid binding,GO:0008526~phosphatidylinositol transporter activity,GO:0030971~receptor tyrosine kinase binding,GO:0046872~metal ion binding,	IPR001666:Phosphatidylinositol transfer protein,IPR004177:DDHD,IPR023214:HAD-like domain,		600977~Cone-rod dystrophy 5,		SM00775:LNS2,SM01127:SM01127,		KW-0472~Membrane,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,		KW-0106~Calcium,KW-0446~Lipid-binding,KW-0479~Metal-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:DDHD,DOMAIN:LNS2,REGION:Disordered,
POTEC	POTE ankyrin domain family member C(POTEC)	Homo sapiens				IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,				KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,
POTEI	POTE ankyrin domain family member I(POTEI)	Homo sapiens	GO:0001895~retina homeostasis,	GO:0005615~extracellular space,GO:0070062~extracellular exosome,		IPR002110:Ankyrin repeat,IPR004000:Actin-related protein,IPR004001:Actin, conserved site,IPR020683:Ankyrin repeat-containing domain,IPR020902:Actin/actin-like conserved site,				SM00248:ANK,SM00268:ACTIN,				KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,				COMPBIAS:Basic and acidic residues,REGION:Actin-like,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,
POU4F1	POU class 4 homeobox 1(POU4F1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001764~neuron migration,GO:0001967~suckling behavior,GO:0003223~ventricular compact myocardium morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007409~axonogenesis,GO:0007416~synapse assembly,GO:0007498~mesoderm development,GO:0007507~heart development,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0021535~cell migration in hindbrain,GO:0021559~trigeminal nerve development,GO:0021953~central nervous system neuron differentiation,GO:0021986~habenula development,GO:0031175~neuron projection development,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043069~negative regulation of programmed cell death,GO:0043524~negative regulation of neuron apoptotic process,GO:0043525~positive regulation of neuron apoptotic process,GO:0045672~positive regulation of osteoclast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048665~neuron fate specification,GO:0048880~sensory system development,GO:0048935~peripheral nervous system neuron development,GO:0050767~regulation of neurogenesis,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0051355~proprioception involved in equilibrioception,GO:0051402~neuron apoptotic process,GO:0051726~regulation of cell cycle,GO:0060384~innervation,GO:0071345~cellular response to cytokine stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0072332~intrinsic apoptotic signaling pathway by p53 class mediator,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2001208~negative regulation of transcription elongation from RNA polymerase I promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0043005~neuron projection,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0051020~GTPase binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000327:POU-specific,IPR001356:Homeodomain,IPR001387:Helix-turn-helix,IPR009057:Homeodomain-like,IPR010982:Lambda repressor-like, DNA-binding domain,IPR013847:POU domain,IPR015584:POU domain-containing protein, class 4-related,IPR017970:Homeobox, conserved site,		619352~Ataxia, intention tremor, and hypotonia syndrome, childhood-onset,		SM00352:POU,SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:POU-specific,MOTIF:POU-IV box,REGION:Disordered,
PERM1	PPARGC1 and ESRR induced regulator, muscle 1(PERM1)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0014850~response to muscle activity,	GO:0005634~nucleus,GO:0005737~cytoplasm,							KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,						COMPBIAS:Polar residues,REGION:Disordered,
PTTG1	PTTG1 regulator of sister chromatid separation, securin(PTTG1)	Homo sapiens	GO:0006281~DNA repair,GO:0007283~spermatogenesis,GO:0010951~negative regulation of endopeptidase activity,GO:0045143~homologous chromosome segregation,GO:0051276~chromosome organization,GO:0051301~cell division,GO:2000816~negative regulation of mitotic sister chromatid separation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0017124~SH3 domain binding,	IPR006940:Securin sister-chromatid separation inhibitor,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa05166:Human T-cell leukemia virus 1 infection,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0227~DNA damage,KW-0234~DNA repair,KW-0498~Mitosis,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0729~SH3-binding,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,MOTIF:D-box,MOTIF:SH3-binding,MOTIF:TEK-box 1,MOTIF:TEK-box 2,MUTAGEN:L->A: Abolishes ubiquitination and subsequent degradation; when associated with A-61.,MUTAGEN:P->A: Strongly reduces transforming capability; when associated with L-170; A-172 and L-173.,MUTAGEN:PSPP->LSAL: Strongly reduces transforming capability; when associated with A-163.,MUTAGEN:R->A: Abolishes ubiquitination and subsequent degradation; when associated with A-64.,MUTAGEN:S->A: Abolishes phosphorylation.,REGION:Disordered,
RAB34	RAB34, member RAS oncogene family(RAB34)	Homo sapiens	GO:0006897~endocytosis,GO:0016192~vesicle-mediated transport,GO:0019882~antigen processing and presentation,GO:0030030~cell projection organization,GO:0032418~lysosome localization,GO:0043001~Golgi to plasma membrane protein transport,GO:0045880~positive regulation of smoothened signaling pathway,GO:0072659~protein localization to plasma membrane,GO:0090382~phagosome maturation,GO:0090385~phagosome-lysosome fusion,	GO:0005730~nucleolus,GO:0005794~Golgi apparatus,GO:0005795~Golgi stack,GO:0005929~cilium,GO:0030670~phagocytic vesicle membrane,GO:0031982~vesicle,GO:0031985~Golgi cisterna,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0030742~GTP-dependent protein binding,GO:0031267~small GTPase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,KW-0970~Cilium biogenesis/degradation,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,REGION:13 x 9 AA approximate tandem-repeats of P-R-V-I-V-G-(S/T)-P-R,REGION:Disordered,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
RAB38	RAB38, member RAS oncogene family(RAB38)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0007005~mitochondrion organization,GO:0007264~small GTPase mediated signal transduction,GO:0015031~protein transport,GO:0016192~vesicle-mediated transport,GO:0032438~melanosome organization,GO:0035646~endosome to melanosome transport,GO:0048023~positive regulation of melanin biosynthetic process,GO:0060155~platelet dense granule organization,GO:0072657~protein localization to membrane,GO:0090383~phagosome acidification,GO:1903232~melanosome assembly,GO:1904377~positive regulation of protein localization to cell periphery,GO:2001247~positive regulation of phosphatidylcholine biosynthetic process,	GO:0005739~mitochondrion,GO:0005764~lysosome,GO:0005769~early endosome,GO:0005783~endoplasmic reticulum,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0030670~phagocytic vesicle membrane,GO:0031982~vesicle,GO:0033162~melanosome membrane,GO:0042470~melanosome,GO:0044233~ER-mitochondrion membrane contact site,GO:0044297~cell body,GO:0045335~phagocytic vesicle,GO:0048471~perinuclear region of cytoplasm,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0030742~GTP-dependent protein binding,GO:0035650~AP-1 adaptor complex binding,GO:0035651~AP-3 adaptor complex binding,GO:0036461~BLOC-2 complex binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,LIPID:S-palmitoyl cysteine,MOTIF:Effector region,REGION:Disordered,SITE:Not methylated,
RAB3A	RAB3A, member RAS oncogene family(RAB3A)	Homo sapiens	GO:0001778~plasma membrane repair,GO:0003016~respiratory system process,GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006904~vesicle docking involved in exocytosis,GO:0007005~mitochondrion organization,GO:0007274~neuromuscular synaptic transmission,GO:0007409~axonogenesis,GO:0009306~protein secretion,GO:0009791~post-embryonic development,GO:0010807~regulation of synaptic vesicle priming,GO:0014059~regulation of dopamine secretion,GO:0016079~synaptic vesicle exocytosis,GO:0016188~synaptic vesicle maturation,GO:0017156~calcium ion regulated exocytosis,GO:0017157~regulation of exocytosis,GO:0030324~lung development,GO:0031630~regulation of synaptic vesicle fusion to presynaptic membrane,GO:0032418~lysosome localization,GO:0036465~synaptic vesicle recycling,GO:0045054~constitutive secretory pathway,GO:0045055~regulated exocytosis,GO:0045921~positive regulation of exocytosis,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0048489~synaptic vesicle transport,GO:0048790~maintenance of presynaptic active zone structure,GO:0050975~sensory perception of touch,GO:0051602~response to electrical stimulus,GO:0060478~acrosomal vesicle exocytosis,GO:0061670~evoked neurotransmitter secretion,GO:0072659~protein localization to plasma membrane,GO:0097091~synaptic vesicle clustering,GO:1903307~positive regulation of regulated secretory pathway,GO:1905684~regulation of plasma membrane repair,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0001669~acrosomal vesicle,GO:0005764~lysosome,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0030424~axon,GO:0030667~secretory granule membrane,GO:0030672~synaptic vesicle membrane,GO:0032991~macromolecular complex,GO:0043195~terminal bouton,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,GO:0048786~presynaptic active zone,GO:0060201~clathrin-sculpted acetylcholine transport vesicle membrane,GO:0060203~clathrin-sculpted glutamate transport vesicle membrane,GO:0061202~clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane,GO:0070083~clathrin-sculpted monoamine transport vesicle membrane,GO:0098793~presynapse,GO:0098794~postsynapse,GO:0098993~anchored component of synaptic vesicle membrane,GO:1903561~extracellular vesicle,	GO:0001671~ATPase activator activity,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008022~protein C-terminus binding,GO:0030742~GTP-dependent protein binding,GO:0031489~myosin V binding,GO:0051021~GDP-dissociation inhibitor binding,GO:0051117~ATPase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04721:Synaptic vesicle cycle,hsa04911:Insulin secretion,				KW-0268~Exocytosis,KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:T->A: Loss of phosphorylation.,MUTAGEN:T->E: Phosphomimetic mutant. Loss of GDI1, GDI2, CHM and CHML binding.,REGION:Disordered,
RAB6B	RAB6B, member RAS oncogene family(RAB6B)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006891~intra-Golgi vesicle-mediated transport,GO:0007030~Golgi organization,GO:0031175~neuron projection development,GO:0042147~retrograde transport, endosome to Golgi,GO:1903292~protein localization to Golgi membrane,	GO:0000139~Golgi membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0012505~endomembrane system,GO:0031410~cytoplasmic vesicle,GO:0098793~presynapse,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0031489~myosin V binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0653~Protein transport,KW-0813~Transport,KW-0931~ER-Golgi transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:Q->L: Interacts with APBA1. Abolishes localization of VPS13B to the Golgi.,MUTAGEN:T->N: Loss of APBA1-binding. Abolishes localization of VPS13B to the Golgi.,
RASL10A	RAS like family 10 member A(RASL10A)	Homo sapiens	GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,	GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0003924~GTPase activity,GO:0005525~GTP binding,	IPR001806:Small GTPase superfamily,IPR027417:P-loop containing nucleoside triphosphate hydrolase,						KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,		KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-farnesyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,REGION:Disordered,REGION:Small GTPase-like,
RASAL1	RAS protein activator like 1(RASAL1)	Homo sapiens	GO:0007165~signal transduction,GO:0030154~cell differentiation,GO:0035556~intracellular signal transduction,GO:0043087~regulation of GTPase activity,GO:0046580~negative regulation of Ras protein signal transduction,GO:0071277~cellular response to calcium ion,GO:1903861~positive regulation of dendrite extension,	GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005096~GTPase activator activity,GO:0005543~phospholipid binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR001562:Zinc finger, Btk motif,IPR001849:Pleckstrin homology domain,IPR001936:Ras GTPase-activating protein,IPR008936:Rho GTPase activation protein,IPR011993:Pleckstrin homology-like domain,IPR023152:Ras GTPase-activating protein, conserved site,	hsa04014:Ras signaling pathway,			SM00107:BTK,SM00233:PH,SM00239:C2,SM00323:RasGAP,	KW-0221~Differentiation,			KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0343~GTPase activation,		DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:PH,DOMAIN:Ras-GAP,ZN_FING:Btk-type,
RASD2	RASD family member 2(RASD2)	Homo sapiens	GO:0001963~synaptic transmission, dopaminergic,GO:0007165~signal transduction,GO:0007626~locomotory behavior,GO:0031397~negative regulation of protein ubiquitination,GO:0033235~positive regulation of protein sumoylation,GO:0043949~regulation of cAMP-mediated signaling,GO:0051897~positive regulation of protein kinase B signaling,	GO:0005886~plasma membrane,GO:0045202~synapse,	GO:0003924~GTPase activity,GO:0005525~GTP binding,GO:0031624~ubiquitin conjugating enzyme binding,GO:0031681~G-protein beta-subunit binding,GO:0043548~phosphatidylinositol 3-kinase binding,	IPR001806:Small GTPase superfamily,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,						KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-farnesyl cysteine,MOTIF:Effector region,PROPEP:Removed in mature form,REGION:Interaction with GNB1, GNB2 and GNB3,
RERGL	RERG like(RERGL)	Homo sapiens	GO:0007165~signal transduction,	GO:0016020~membrane,	GO:0003924~GTPase activity,GO:0005525~GTP binding,	IPR001806:Small GTPase superfamily,IPR027417:P-loop containing nucleoside triphosphate hydrolase,									KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,		REGION:Small GTPase-like,
RIMBP2	RIMS binding protein 2(RIMBP2)	Homo sapiens	GO:0007274~neuromuscular synaptic transmission,	GO:0005886~plasma membrane,GO:0045202~synapse,		IPR001452:Src homology-3 domain,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,SM00326:SH3,		KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,DOMAIN:SH3 3,REGION:Disordered,
RBFOX2	RNA binding fox-1 homolog 2(RBFOX2)	Homo sapiens	GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0008380~RNA splicing,GO:0010724~regulation of definitive erythrocyte differentiation,GO:0016070~RNA metabolic process,GO:0021942~radial glia guided migration of Purkinje cell,GO:0030520~intracellular estrogen receptor signaling pathway,GO:0042127~regulation of cell proliferation,GO:0043484~regulation of RNA splicing,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048813~dendrite morphogenesis,GO:0050885~neuromuscular process controlling balance,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR000504:RNA recognition motif domain,IPR012677:Nucleotide-binding, alpha-beta plait,IPR017325:RNA binding protein Fox-1,IPR025670:Fox-1 C-terminal domain,			PIRSF037932:ataxin 2 binding protein, A2BP type,	SM00360:RRM,	KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:RRM,REGION:Disordered,SITE:Interaction with RNA,
RUNX1	RUNX family transcription factor 1(RUNX1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0002062~chondrocyte differentiation,GO:0002573~myeloid leukocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010755~regulation of plasminogen activation,GO:0030097~hemopoiesis,GO:0030099~myeloid cell differentiation,GO:0030182~neuron differentiation,GO:0030853~negative regulation of granulocyte differentiation,GO:0030854~positive regulation of granulocyte differentiation,GO:0032743~positive regulation of interleukin-2 production,GO:0032967~positive regulation of collagen biosynthetic process,GO:0043371~negative regulation of CD4-positive, alpha-beta T cell differentiation,GO:0043378~positive regulation of CD8-positive, alpha-beta T cell differentiation,GO:0045595~regulation of cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048935~peripheral nervous system neuron development,GO:0060043~regulation of cardiac muscle cell proliferation,GO:0061026~cardiac muscle tissue regeneration,GO:0071425~hematopoietic stem cell proliferation,GO:1903055~positive regulation of extracellular matrix organization,GO:1905203~regulation of connective tissue replacement,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016021~integral component of membrane,GO:0016513~core-binding factor complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003714~transcription corepressor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008134~transcription factor binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,	IPR000040:Acute myeloid leukemia 1 protein (AML1)/Runt,IPR002893:Zinc finger, MYND-type,IPR008967:p53-like transcription factor, DNA-binding,IPR012346:p53/RUNT-type transcription factor, DNA-binding domain,IPR013289:Eight-Twenty-One,IPR013290:Myeloid transforming gene on chromosome 8 (MTG8),IPR013524:Runt domain,IPR013711:Runx, C-terminal  domain,IPR014896:NHR2-like,IPR016554:Runt-related transcription factor RUNX,IPR027384:Runx, central domain,	hsa04530:Tight junction,hsa04659:Th17 cell differentiation,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05220:Chronic myeloid leukemia,hsa05221:Acute myeloid leukemia,	601399~Platelet disorder, familial, with associated myeloid malignancy,601626~Leukemia, acute myeloid,	PIRSF009374:runt-related transcription factor RUNX,		KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0812~Transmembrane,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0868~Chloride,	KW-0010~Activator,KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:MYND-type,DOMAIN:NHR2,DOMAIN:Runt,MUTAGEN:A->T: Loss of heterodimerization. Disrupts interactionof AML1-MTG8/ETO with CBFB, no effect on AML1-MTG8/ETO-mediated transformation activity.,MUTAGEN:D->A: Strongly reduces DNA-binding.,MUTAGEN:G->R: Loss of heterodimerization and impaired phosphorylation.,MUTAGEN:K->A: Reduces DNA-binding.,MUTAGEN:K->A: Strongly reduces DNA-binding.,MUTAGEN:K->E: Strongly reduces DNA-binding, impaired phosphorylation and reduced EP300 phosphorylation induction.,MUTAGEN:M->V: Disrupts interaction of AML1-MTG8/ETO with CBFB, no effect on AML1-MTG8/ETO-mediated transformation activity.,MUTAGEN:Missing: No DNA-binding.,MUTAGEN:R->A: Strongly reduces DNA-binding.,MUTAGEN:S->A: Reduced phosphorylation.,MUTAGEN:S->A: Reduced phosphorylation; when associated with A-273.,MUTAGEN:S->G: Disrupts AML1-MTG8/ETO DNA-binding, decreases AML1-MTG8/ETO transforming activity.,MUTAGEN:S->R: Loss of heterodimerization and reduced EP300 phosphorylation induction.,MUTAGEN:T->A: No effect on DNA binding.,MUTAGEN:T->A: Reduced phosphorylation; when associated with A-276.,MUTAGEN:T->A: Strongly reduces DNA-binding.,REGION:Disordered,REGION:Interaction with DNA,REGION:Interaction with FOXP3,REGION:Interaction with KAT6A,REGION:Interaction with KAT6B,SITE:Breakpoint for translocation to form AML1-EAP in T-MDS and CML, to form type II MACROD1-RUNX1 fusion protein and to form RUNX1-CBFA2T2 in acute myeloid leukemia,SITE:Breakpoint for translocation to form AML1-EMV-1 (or AML1-EAP) in CML and T-MDS, to form AML1-MTG8 (ETO) in AML-M2, to form AML1-CBFA2T3 in therapy-related myeloid malignancies, to form AML1-MECOM in CML and to form type I MACROD1-RUNX1 fusion protein,
RAPGEF4	Rap guanine nucleotide exchange factor 4(RAPGEF4)	Homo sapiens	GO:0002250~adaptive immune response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0007265~Ras protein signal transduction,GO:0017156~calcium ion regulated exocytosis,GO:0017157~regulation of exocytosis,GO:0019933~cAMP-mediated signaling,GO:0030073~insulin secretion,GO:0043547~positive regulation of GTPase activity,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0098686~hippocampal mossy fiber to CA3 synapse,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0030552~cAMP binding,GO:0031267~small GTPase binding,	IPR000591:DEP domain,IPR000595:Cyclic nucleotide-binding domain,IPR000651:Ras-like guanine nucleotide exchange factor, N-terminal,IPR001895:Guanine-nucleotide dissociation stimulator CDC25,IPR008937:Ras guanine nucleotide exchange factor,IPR014710:RmlC-like jelly roll fold,IPR018490:Cyclic nucleotide-binding-like,IPR019804:Ras guanine-nucleotide exchange factor, conserved site,IPR023578:Ras guanine nucleotide exchange factor, domain,	hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04670:Leukocyte transendothelial migration,hsa04911:Insulin secretion,			SM00049:DEP,SM00100:cNMP,SM00147:RasGEF,SM00229:RasGEFN,	KW-0268~Exocytosis,	KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,	KW-0344~Guanine-nucleotide releasing factor,		DOMAIN:Cyclic nucleotide-binding,DOMAIN:DEP,DOMAIN:N-terminal Ras-GEF,DOMAIN:Ras-GEF,
RASSF10	Ras association domain family member 10(RASSF10)	Homo sapiens	GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0050769~positive regulation of neurogenesis,GO:2000179~positive regulation of neural precursor cell proliferation,	GO:0000922~spindle pole,GO:0005815~microtubule organizing center,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR000159:Ras-association,					KW-0524~Neurogenesis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,				COMPBIAS:Polar residues,DOMAIN:Ras-associating,REGION:Disordered,
RASSF7	Ras association domain family member 7(RASSF7)	Homo sapiens	GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0070507~regulation of microtubule cytoskeleton organization,	GO:0005737~cytoplasm,GO:0034451~centriolar satellite,	GO:0005515~protein binding,	IPR000159:Ras-association,				SM00314:RA,	KW-0053~Apoptosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:Ras-associating,REGION:Disordered,
RASGRF1	Ras protein specific guanine nucleotide releasing factor 1(RASGRF1)	Homo sapiens	GO:0007165~signal transduction,GO:0007264~small GTPase mediated signal transduction,GO:0007265~Ras protein signal transduction,GO:0007616~long-term memory,GO:0008283~cell proliferation,GO:0031175~neuron projection development,GO:0034976~response to endoplasmic reticulum stress,GO:0035020~regulation of Rac protein signal transduction,GO:0035023~regulation of Rho protein signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0044342~type B pancreatic cell proliferation,GO:0046578~regulation of Ras protein signal transduction,GO:0046579~positive regulation of Ras protein signal transduction,GO:0048167~regulation of synaptic plasticity,GO:0048168~regulation of neuronal synaptic plasticity,GO:0090630~activation of GTPase activity,GO:2000310~regulation of NMDA receptor activity,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030426~growth cone,GO:0043005~neuron projection,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0035254~glutamate receptor binding,	IPR000048:IQ motif, EF-hand binding site,IPR000219:Dbl homology (DH) domain,IPR000651:Ras-like guanine nucleotide exchange factor, N-terminal,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001849:Pleckstrin homology domain,IPR001895:Guanine-nucleotide dissociation stimulator CDC25,IPR008937:Ras guanine nucleotide exchange factor,IPR011993:Pleckstrin homology-like domain,IPR019804:Ras guanine-nucleotide exchange factor, conserved site,IPR023578:Ras guanine nucleotide exchange factor, domain,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04510:Focal adhesion,			SM00147:RasGEF,SM00229:RasGEFN,SM00233:PH,SM00325:RhoGEF,				KW-0175~Coiled coil,KW-0677~Repeat,		KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:IQ,DOMAIN:N-terminal Ras-GEF,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:Ras-GEF,REGION:Disordered,
ARHGAP11A	Rho GTPase activating protein 11A(ARHGAP11A)	Homo sapiens	GO:0007165~signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005096~GTPase activator activity,	IPR000198:Rho GTPase-activating protein domain,IPR008936:Rho GTPase activation protein,				SM00324:RhoGAP,		KW-0539~Nucleus,				KW-0343~GTPase activation,	KW-0597~Phosphoprotein,	DOMAIN:Rho-GAP,REGION:Disordered,
ARHGAP36	Rho GTPase activating protein 36(ARHGAP36)	Homo sapiens	GO:0007165~signal transduction,GO:0050790~regulation of catalytic activity,		GO:0005096~GTPase activator activity,	IPR000198:Rho GTPase-activating protein domain,IPR008936:Rho GTPase activation protein,				SM00324:RhoGAP,				KW-0732~Signal,		KW-0343~GTPase activation,		COMPBIAS:Basic and acidic residues,DOMAIN:Rho-GAP,REGION:Disordered,
S100A11	S100 calcium binding protein A11(S100A11)	Homo sapiens	GO:0007165~signal transduction,GO:0008156~negative regulation of DNA replication,GO:0008285~negative regulation of cell proliferation,GO:0014911~positive regulation of smooth muscle cell migration,GO:0042127~regulation of cell proliferation,GO:0098609~cell-cell adhesion,	GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005912~adherens junction,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0044548~S100 protein binding,GO:0048306~calcium-dependent protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,SM01394:SM01394,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Interchain,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
S100A2	S100 calcium binding protein A2(S100A2)	Homo sapiens	GO:0043542~endothelial cell migration,		GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,				SM01394:SM01394,				KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,			DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:S_100,
S100A3	S100 calcium binding protein A3(S100A3)	Homo sapiens		GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0048306~calcium-dependent protein binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,				SM01394:SM01394,		KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0164~Citrullination,KW-1015~Disulfide bond,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:C->A: Abolishes calcium binding; when associated with Ala-30.,MUTAGEN:C->A: Abolishes calcium binding; when associated with Ala-68.,MUTAGEN:C->A: Increases affinity for calcium; when associated with Ala-81.,MUTAGEN:C->A: Increases affinity for calcium; when associated with Ala-99.,
S100A4	S100 calcium binding protein A4(S100A4)	Homo sapiens	GO:0001837~epithelial to mesenchymal transition,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046914~transition metal ion binding,GO:0048306~calcium-dependent protein binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,SM01394:SM01394,		KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,
S100A8	S100 calcium binding protein A8(S100A8)	Homo sapiens	GO:0002523~leukocyte migration involved in inflammatory response,GO:0002526~acute inflammatory response,GO:0002544~chronic inflammatory response,GO:0002790~peptide secretion,GO:0002793~positive regulation of peptide secretion,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006954~inflammatory response,GO:0010043~response to zinc ion,GO:0014002~astrocyte development,GO:0018119~peptidyl-cysteine S-nitrosylation,GO:0030307~positive regulation of cell growth,GO:0030593~neutrophil chemotaxis,GO:0032119~sequestering of zinc ion,GO:0032496~response to lipopolysaccharide,GO:0035425~autocrine signaling,GO:0042060~wound healing,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0045471~response to ethanol,GO:0050729~positive regulation of inflammatory response,GO:0050832~defense response to fungus,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051493~regulation of cytoskeleton organization,GO:0070488~neutrophil aggregation,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0034774~secretory granule lumen,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0035662~Toll-like receptor 4 binding,GO:0048306~calcium-dependent protein binding,GO:0050544~arachidonic acid binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04657:IL-17 signaling pathway,			SM01394:SM01394,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0145~Chemotaxis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0929~Antimicrobial,	KW-0702~S-nitrosylation,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:C->A: Loss of antifungal activity.,
S100A9	S100 calcium binding protein A9(S100A9)	Homo sapiens	GO:0002523~leukocyte migration involved in inflammatory response,GO:0002544~chronic inflammatory response,GO:0006914~autophagy,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006954~inflammatory response,GO:0007267~cell-cell signaling,GO:0010976~positive regulation of neuron projection development,GO:0014002~astrocyte development,GO:0018119~peptidyl-cysteine S-nitrosylation,GO:0030307~positive regulation of cell growth,GO:0030593~neutrophil chemotaxis,GO:0032119~sequestering of zinc ion,GO:0032496~response to lipopolysaccharide,GO:0035425~autocrine signaling,GO:0035606~peptidyl-cysteine S-trans-nitrosylation,GO:0035821~modification of morphology or physiology of other organism,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0045113~regulation of integrin biosynthetic process,GO:0050729~positive regulation of inflammatory response,GO:0050832~defense response to fungus,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051493~regulation of cytoskeleton organization,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070488~neutrophil aggregation,GO:0098869~cellular oxidant detoxification,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0030054~cell junction,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008270~zinc ion binding,GO:0016209~antioxidant activity,GO:0035662~Toll-like receptor 4 binding,GO:0048306~calcium-dependent protein binding,GO:0050544~arachidonic acid binding,GO:0050786~RAGE receptor binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR013787:S100/CaBP-9k-type, calcium binding, subdomain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04657:IL-17 signaling pathway,			SM00054:EFh,SM01394:SM01394,	KW-0053~Apoptosis,KW-0072~Autophagy,KW-0145~Chemotaxis,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0049~Antioxidant,KW-0929~Antimicrobial,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:C->A: Disrupts interaction with NOS2 and inhibits LDL(ox)-induced GAPDH S-nitrosylation; no effect on interaction with S100A8.,MUTAGEN:E->Q: Loss of resistance to bacterial invasion; when associated with Q-36.,MUTAGEN:E->Q: Loss of resistance to bacterial invasion; when associated with Q-78.,MUTAGEN:M->A: Loss of antifungal activity.,MUTAGEN:M->A: No effect on antifungal activity.,REGION:Disordered,
SEC61G	SEC61 translocon subunit gamma(SEC61G)	Homo sapiens	GO:0006605~protein targeting,GO:0031204~posttranslational protein targeting to membrane, translocation,GO:0045047~protein targeting to ER,	GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0071261~Ssh1 translocon complex,	GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,GO:0015450~P-P-bond-hydrolysis-driven protein transmembrane transporter activity,GO:0043022~ribosome binding,	IPR001901:Protein translocase complex, SecE/Sec61-gamma subunit,IPR008158:Protein translocase SEC61 complex,  gamma subunit,IPR023391:Protein translocase SecE domain,	hsa03060:Protein export,hsa04141:Protein processing in endoplasmic reticulum,hsa04145:Phagosome,hsa05110:Vibrio cholerae infection,				KW-0653~Protein transport,KW-0811~Translocation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SH2D4A	SH2 domain containing 4A(SH2D4A)	Homo sapiens	GO:0010923~negative regulation of phosphatase activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019902~phosphatase binding,	IPR000980:SH2 domain,				SM00252:SH2,		KW-0963~Cytoplasm,		KW-0727~SH2 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:SH2,REGION:Disordered,
SH2D5	SH2 domain containing 5(SH2D5)	Homo sapiens		GO:0014069~postsynaptic density,		IPR000980:SH2 domain,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,				SM00462:PTB,		KW-0770~Synapse,		KW-0727~SH2 domain,				DOMAIN:PID,DOMAIN:SH2,REGION:Disordered,
STAC	SH3 and cysteine rich domain(STAC)	Homo sapiens	GO:0003009~skeletal muscle contraction,GO:0007165~signal transduction,GO:0034605~cellular response to heat,GO:0035556~intracellular signal transduction,GO:1901387~positive regulation of voltage-gated calcium channel activity,GO:1903078~positive regulation of protein localization to plasma membrane,GO:2001259~positive regulation of cation channel activity,	GO:0005829~cytosol,GO:0030315~T-tubule,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0042383~sarcolemma,	GO:0005515~protein binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,	IPR001452:Src homology-3 domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,				SM00109:C1,SM00326:SH3,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0728~SH3 domain,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
SHANK1	SH3 and multiple ankyrin repeat domains 1(SHANK1)	Homo sapiens	GO:0007616~long-term memory,GO:0008306~associative learning,GO:0030534~adult behavior,GO:0032232~negative regulation of actin filament bundle assembly,GO:0035176~social behavior,GO:0035418~protein localization to synapse,GO:0042048~olfactory behavior,GO:0046959~habituation,GO:0050885~neuromuscular process controlling balance,GO:0050894~determination of affect,GO:0060013~righting reflex,GO:0060074~synapse maturation,GO:0060997~dendritic spine morphogenesis,GO:0060999~positive regulation of dendritic spine development,GO:0065003~macromolecular complex assembly,GO:0071625~vocalization behavior,GO:0099562~maintenance of postsynaptic density structure,GO:2000311~regulation of AMPA receptor activity,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0060076~excitatory synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0017124~SH3 domain binding,GO:0030160~GKAP/Homer scaffold activity,GO:0031877~somatostatin receptor binding,GO:0035255~ionotropic glutamate receptor binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0071532~ankyrin repeat binding,GO:0097110~scaffold protein binding,GO:0098919~structural constituent of postsynaptic density,	IPR001452:Src homology-3 domain,IPR001478:PDZ domain,IPR001660:Sterile alpha motif domain,IPR002110:Ankyrin repeat,IPR013761:Sterile alpha motif/pointed domain,IPR020683:Ankyrin repeat-containing domain,	hsa04724:Glutamatergic synapse,			SM00228:PDZ,SM00248:ANK,SM00326:SH3,SM00454:SAM,	KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0770~Synapse,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0728~SH3 domain,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PDZ,DOMAIN:SAM,DOMAIN:SH3,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,
SHANK2	SH3 and multiple ankyrin repeat domains 2(SHANK2)	Homo sapiens	GO:0007416~synapse assembly,GO:0007420~brain development,GO:0007584~response to nutrient,GO:0007612~learning,GO:0008284~positive regulation of cell proliferation,GO:0008306~associative learning,GO:0008344~adult locomotory behavior,GO:0009410~response to xenobiotic stimulus,GO:0030534~adult behavior,GO:0035176~social behavior,GO:0035331~negative regulation of hippo signaling,GO:0060291~long-term synaptic potentiation,GO:0060292~long term synaptic depression,GO:0071625~vocalization behavior,GO:0099562~maintenance of postsynaptic density structure,	GO:0001750~photoreceptor outer segment,GO:0001917~photoreceptor inner segment,GO:0005829~cytosol,GO:0005883~neurofilament,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030426~growth cone,GO:0031526~brush border membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0048786~presynaptic active zone,GO:0060170~ciliary membrane,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0017124~SH3 domain binding,GO:0030160~GKAP/Homer scaffold activity,GO:0035255~ionotropic glutamate receptor binding,GO:0098919~structural constituent of postsynaptic density,	IPR001452:Src homology-3 domain,IPR001478:PDZ domain,IPR001660:Sterile alpha motif domain,IPR013761:Sterile alpha motif/pointed domain,	hsa04724:Glutamatergic synapse,	613436~Autism susceptibility 17,		SM00228:PDZ,SM00326:SH3,SM00454:SAM,		KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-1268~Autism spectrum disorder,KW-1269~Autism,	KW-0040~ANK repeat,KW-0677~Repeat,KW-0728~SH3 domain,KW-0729~SH3-binding,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PDZ,DOMAIN:SAM,DOMAIN:SH3,MOTIF:SH3-binding,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,TRANSMEM:Helical,
SH3GL2	SH3 domain containing GRB2 like 2, endophilin A1(SH3GL2)	Homo sapiens	GO:0001933~negative regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0007417~central nervous system development,GO:0010629~negative regulation of gene expression,GO:0016191~synaptic vesicle uncoating,GO:0031175~neuron projection development,GO:0048488~synaptic vesicle endocytosis,GO:0060988~lipid tube assembly,GO:0097484~dendrite extension,GO:0097749~membrane tubulation,GO:0097753~membrane bending,GO:0099050~vesicle scission,GO:1903527~positive regulation of membrane tubulation,GO:1905604~negative regulation of maintenance of permeability of blood-brain barrier,GO:1990416~cellular response to brain-derived neurotrophic factor stimulus,GO:2000369~regulation of clathrin-dependent endocytosis,	GO:0000139~Golgi membrane,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0042995~cell projection,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,GO:0097441~basilar dendrite,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0008289~lipid binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,	IPR001452:Src homology-3 domain,IPR004148:BAR domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,	hsa04144:Endocytosis,			SM00326:SH3,SM00721:BAR,	KW-0254~Endocytosis,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,		KW-0175~Coiled coil,KW-0728~SH3 domain,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:BAR,DOMAIN:SH3,MUTAGEN:A->D: Loss of tubulation of liposomes, no effect on liposome binding.,MUTAGEN:A->S: Reduced tubulation of liposomes, 3-fold increase in tubule diameter, no effect on liposome binding; when associated with S-63 or with S-63 and Q-70.,MUTAGEN:A->S: Reduced tubulation of liposomes, 3-fold increase in tubule diameter, no effect on liposome binding; when associated with S-66 or with S-66 and Q-70.,MUTAGEN:A->W: Vesiculation of liposomes, no effect on liposome binding, indol ring located in hydrophobic core of the membrane.,MUTAGEN:F->W: No effect. Indol ring not associated with the membrane.,MUTAGEN:M->Q: Reduced tubulation of liposomes, 3-fold increase in tubule diameter, no effect on liposome binding; when associated with S-63 and S-66.,REGION:Binds and tubulates liposomes,REGION:Disordered,REGION:Membrane-binding amphipathic helix,REGION:Required for dimerization upon membrane association,
SIX3	SIX homeobox 3(SIX3)	Homo sapiens	GO:0001654~eye development,GO:0002070~epithelial cell maturation,GO:0002088~lens development in camera-type eye,GO:0003404~optic vesicle morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007420~brain development,GO:0007601~visual perception,GO:0009946~proximal/distal axis specification,GO:0014016~neuroblast differentiation,GO:0021537~telencephalon development,GO:0021798~forebrain dorsal/ventral pattern formation,GO:0021846~cell proliferation in forebrain,GO:0021978~telencephalon regionalization,GO:0021983~pituitary gland development,GO:0042127~regulation of cell proliferation,GO:0045665~negative regulation of neuron differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061074~regulation of neural retina development,GO:0070306~lens fiber cell differentiation,GO:0097402~neuroblast migration,GO:1901987~regulation of cell cycle phase transition,GO:1902692~regulation of neuroblast proliferation,GO:1902742~apoptotic process involved in development,GO:1990086~lens fiber cell apoptotic process,GO:2000177~regulation of neural precursor cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR009057:Homeodomain-like,		157170~Holoprosencephaly 2,269160~Schizencephaly,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0370~Holoprosencephaly,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:SIX1_SD,MUTAGEN:F->E: Decreased interaction with TLE5 and loss ineteraction with TLE1.,MUTAGEN:L->P: Loss of interaction with TLE1 and TLE5; when associated with P-95.,MUTAGEN:V->P: Loss of interaction with TLE1 and TLE5; when associated with P-99.,REGION:Bind to RHO promoter,REGION:Disordered,REGION:Interaction with TLE5,
SLAMF6	SLAM family member 6(SLAMF6)	Homo sapiens	GO:0032729~positive regulation of interferon-gamma production,GO:0032740~positive regulation of interleukin-17 production,GO:0042110~T cell activation,GO:0045087~innate immune response,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0072540~T-helper 17 cell lineage commitment,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,MOTIF:ITSM 1,MOTIF:ITSM 2,MUTAGEN:Q->A: Inhibits dimerization.,MUTAGEN:R->A: Inhibits dimerization.,MUTAGEN:S->A: Inhibits dimerization.,MUTAGEN:Y->F: Abolishes SLAMF6-mediated cytotoxity, disrupts interaction with SH2D1B and retains interaction with SH2D1A.,MUTAGEN:Y->F: Reduced SLAMF6-mediated cytotoxity.,MUTAGEN:Y->F: Retains reduced SLAMF6-mediated cytotoxity, disrupts interaction with SH2D1A and retains interaction with SH2D1B; when associated with F-273.,MUTAGEN:Y->F: Retains reduced SLAMF6-mediated cytotoxity, disrupts interaction with SH2D1A and retains interaction with SH2D1B; when associated with F-309.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLAMF8	SLAM family member 8(SLAMF8)	Homo sapiens	GO:0002232~leukocyte chemotaxis involved in inflammatory response,GO:0002336~B-1 B cell lineage commitment,GO:0010760~negative regulation of macrophage chemotaxis,GO:0033860~regulation of NAD(P)H oxidase activity,GO:0035690~cellular response to drug,GO:0042742~defense response to bacterium,GO:0043549~regulation of kinase activity,GO:0045577~regulation of B cell differentiation,GO:0060266~negative regulation of respiratory burst involved in inflammatory response,GO:0090027~negative regulation of monocyte chemotaxis,GO:0090383~phagosome acidification,GO:1902623~negative regulation of neutrophil migration,GO:2000509~negative regulation of dendritic cell chemotaxis,	GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,	IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,						KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLAMF9	SLAM family member 9(SLAMF9)	Homo sapiens	GO:0002373~plasmacytoid dendritic cell cytokine production,GO:0042110~T cell activation,	GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,		IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,						KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SMURF1	SMAD specific E3 ubiquitin protein ligase 1(SMURF1)	Homo sapiens	GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0006611~protein export from nucleus,GO:0007398~ectoderm development,GO:0016567~protein ubiquitination,GO:0030154~cell differentiation,GO:0030509~BMP signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030579~ubiquitin-dependent SMAD protein catabolic process,GO:0032801~receptor catabolic process,GO:0034394~protein localization to cell surface,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0045732~positive regulation of protein catabolic process,GO:0045773~positive regulation of axon extension,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0061736~engulfment of target by autophagosome,GO:0061753~substrate localization to autophagosome,GO:0071211~protein targeting to vacuole involved in autophagy,GO:0072659~protein localization to plasma membrane,GO:1903861~positive regulation of dendrite extension,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0016874~ligase activity,GO:0048185~activin binding,GO:0061630~ubiquitin protein ligase activity,GO:0070411~I-SMAD binding,GO:0070412~R-SMAD binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000569:HECT,IPR001202:WW domain,IPR024928:E3 ubiquitin-protein ligase, SMURF1 type,	hsa04120:Ubiquitin mediated proteolysis,hsa04144:Endocytosis,hsa04340:Hedgehog signaling pathway,hsa04350:TGF-beta signaling pathway,		PIRSF001569:E3 ubiquitin-protein ligase, SMURF1 type,	SM00119:HECTc,SM00239:C2,SM00456:WW,	KW-0221~Differentiation,KW-0833~Ubl conjugation pathway,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,		KW-0436~Ligase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Glycyl thioester intermediate,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:C2,DOMAIN:HECT,DOMAIN:WW,DOMAIN:WW 1,DOMAIN:WW 2,MUTAGEN:C->A: Loss of enzyme activity, without abolishing FBXL15-mediated ubiquitination.,MUTAGEN:K->A: Fails to ubiquitinate RHOA; when associated with A-28.,MUTAGEN:K->A: Fails to ubiquitinate RHOA; when associated with A-85.,MUTAGEN:K->R: Abolishes FBXL15-mediated ubiquitination and degradation; when associated with R-350 and R-381. Abolishes FBXL15-mediated ubiquitination and degradation; when associated with R-381.,MUTAGEN:K->R: Abolishes FBXL15-mediated ubiquitination and degradation; when associated with R-350 and R-383. Abolishes FBXL15-mediated ubiquitination and degradation; when associated with R-383.,MUTAGEN:K->R: Abolishes FBXL15-mediated ubiquitination and degradation; when associated with R-381 and R-381.,REGION:Disordered,
SPOCK1	SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1(SPOCK1)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0001764~neuron migration,GO:0007155~cell adhesion,GO:0007399~nervous system development,GO:0010812~negative regulation of cell-substrate adhesion,GO:0010951~negative regulation of endopeptidase activity,GO:0010977~negative regulation of neuron projection development,GO:0021953~central nervous system neuron differentiation,GO:0022008~neurogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0014069~postsynaptic density,GO:0016528~sarcoplasm,GO:0031594~neuromuscular junction,GO:0033268~node of Ranvier,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,	IPR000716:Thyroglobulin type-1,IPR002350:Kazal domain,IPR011992:EF-hand-like domain,IPR019577:SPARC/Testican, calcium-binding domain,				SM00211:TY,SM00280:KAZAL,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Xyl...) (glycosaminoglycan) serine,COMPBIAS:Acidic residues,DOMAIN:Kazal-like,DOMAIN:Thyroglobulin type-1,REGION:Disordered,
SMOC1	SPARC related modular calcium binding 1(SMOC1)	Homo sapiens	GO:0001654~eye development,GO:0030154~cell differentiation,GO:0030198~extracellular matrix organization,GO:0045667~regulation of osteoblast differentiation,GO:0060173~limb development,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0050840~extracellular matrix binding,	IPR000716:Thyroglobulin type-1,IPR002350:Kazal domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,IPR019577:SPARC/Testican, calcium-binding domain,		206920~Microphthalmia with limb anomalies,		SM00211:TY,SM00280:KAZAL,	KW-0221~Differentiation,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-1013~Microphthalmia,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Kazal-like,DOMAIN:Thyroglobulin type-1,DOMAIN:Thyroglobulin type-1 1,DOMAIN:Thyroglobulin type-1 2,REGION:Disordered,
SPHKAP	SPHK1 interactor, AKAP domain containing(SPHKAP)	Homo sapiens		GO:0005737~cytoplasm,GO:0005739~mitochondrion,	GO:0005515~protein binding,GO:0051018~protein kinase A binding,	IPR008382:SPHK1-interactor/A-kinase anchor 110kDa,IPR018292:A-kinase anchor 110kDa, C-terminal,						KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:PKA-RII subunit binding domain,
SPOCD1	SPOC domain containing 1(SPOCD1)	Homo sapiens	GO:0006306~DNA methylation,GO:0006351~transcription, DNA-templated,GO:0007283~spermatogenesis,GO:0010529~negative regulation of transposition,GO:0030154~cell differentiation,GO:0031047~gene silencing by RNA,	GO:0005634~nucleus,GO:0005694~chromosome,		IPR003618:Transcription elongation factor S-II, central domain,IPR012921:Spen paralogue and orthologue SPOC, C-terminal,				SM00510:TFS2M,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0943~RNA-mediated gene silencing,	KW-0158~Chromosome,KW-0539~Nucleus,						COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SPOC,DOMAIN:TFIIS central,REGION:Disordered,
SRCIN1	SRC kinase signaling inhibitor 1(SRCIN1)	Homo sapiens	GO:0006887~exocytosis,GO:0030334~regulation of cell migration,GO:0034446~substrate adhesion-dependent cell spreading,GO:0050709~negative regulation of protein secretion,GO:0061001~regulation of dendritic spine morphogenesis,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0098974~postsynaptic actin cytoskeleton organization,	GO:0005737~cytoplasm,GO:0014069~postsynaptic density,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0030424~axon,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,GO:0030234~enzyme regulator activity,	IPR022782:Actin interacting protein 3, C-terminal,IPR026727:SRC kinase signaling inhibitor 1,					KW-0268~Exocytosis,	KW-0206~Cytoskeleton,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,			KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:AIP3,REGION:Disordered,REGION:Interaction with SNAP25,
ST14	ST14 transmembrane serine protease matriptase(ST14)	Homo sapiens	GO:0001843~neural tube closure,GO:0006508~proteolysis,GO:0030163~protein catabolic process,GO:0030216~keratinocyte differentiation,GO:0060672~epithelial cell morphogenesis involved in placental branching,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016323~basolateral plasma membrane,GO:0019897~extrinsic component of plasma membrane,	GO:0004252~serine-type endopeptidase activity,GO:0008236~serine-type peptidase activity,	IPR000082:SEA domain,IPR000859:CUB domain,IPR001254:Peptidase S1,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR017051:Peptidase S1A, matripase,IPR018114:Peptidase S1, trypsin family, active site,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa05206:MicroRNAs in cancer,	602400~Ichthyosis, congenital, autosomal recessive 11,	PIRSF036370:suppressor of tumorigenicity 14,	SM00020:Tryp_SPc,SM00042:CUB,SM00192:LDLa,		KW-0472~Membrane,	KW-0225~Disease variant,KW-0977~Ichthyosis,KW-1063~Hypotrichosis,	KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:LDL-receptor class A 4,DOMAIN:Peptidase S1,DOMAIN:SEA,MUTAGEN:D->A: Abolishes catalytic activity.,MUTAGEN:H->A: Abolishes catalytic activity.,MUTAGEN:S->A: Abolishes catalytic activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ST6GALNAC1	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1(ST6GALNAC1)	Homo sapiens	GO:0006486~protein glycosylation,GO:0009312~oligosaccharide biosynthetic process,GO:0048874~homeostasis of number of cells in a free-living population,GO:0097503~sialylation,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0001665~alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase activity,GO:0008373~sialyltransferase activity,GO:0016740~transferase activity,	IPR001675:Glycosyl transferase, family 29,	hsa00512:Mucin type O-glycan biosynthesis,hsa01100:Metabolic pathways,					KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
STEAP3	STEAP3 metalloreductase(STEAP3)	Homo sapiens	GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0009306~protein secretion,GO:0015677~copper ion import,GO:0033572~transferrin transport,GO:0055072~iron ion homeostasis,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005771~multivesicular body,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008823~cupric reductase activity,GO:0016723~oxidoreductase activity, oxidizing metal ions, NAD or NADP as acceptor,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0052851~ferric-chelate reductase (NADPH) activity,	IPR013130:Ferric reductase transmembrane component-like domain,	hsa04115:p53 signaling pathway,hsa04216:Ferroptosis,	615234~Anemia, hypochromic microcytic, with iron overload 2,			KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0406~Ion transport,KW-0410~Iron transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0186~Copper,KW-0274~FAD,KW-0285~Flavoprotein,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	BINDING:axial binding residue,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:F420_oxidored,DOMAIN:Ferric oxidoreductase,MUTAGEN:L->F: Strongly inhibits RHBDL4/RHBDD1-induced cleavage.,MUTAGEN:N->I: Inhibits glycosylation and does not inhibit RHBDL4/RHBDD1-induced cleavage; when associated with A-256.,MUTAGEN:N->I: Inhibits glycosylation and does not inhibit RHBDL4/RHBDD1-induced cleavage; when associated with A-344.,REGION:Disordered,SITE:Cleavage; by RHBDL4/RHBDD1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,
TCIRG1	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3(TCIRG1)	Homo sapiens	GO:0000045~autophagosome assembly,GO:0001503~ossification,GO:0002158~osteoclast proliferation,GO:0006874~cellular calcium ion homeostasis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006968~cellular defense response,GO:0007035~vacuolar acidification,GO:0007039~protein catabolic process in the vacuole,GO:0007042~lysosomal lumen acidification,GO:0008284~positive regulation of cell proliferation,GO:0010155~regulation of proton transport,GO:0010272~response to silver ion,GO:0010467~gene expression,GO:0010468~regulation of gene expression,GO:0016064~immunoglobulin mediated immune response,GO:0016236~macroautophagy,GO:0021554~optic nerve development,GO:0030010~establishment of cell polarity,GO:0030183~B cell differentiation,GO:0030217~T cell differentiation,GO:0030316~osteoclast differentiation,GO:0031529~ruffle organization,GO:0033365~protein localization to organelle,GO:0035709~memory T cell activation,GO:0035711~T-helper 1 cell activation,GO:0043029~T cell homeostasis,GO:0044691~tooth eruption,GO:0045453~bone resorption,GO:0045667~regulation of osteoblast differentiation,GO:0045851~pH reduction,GO:0050796~regulation of insulin secretion,GO:0051650~establishment of vesicle localization,GO:0060041~retina development in camera-type eye,GO:0061484~hematopoietic stem cell homeostasis,GO:0070166~enamel mineralization,GO:0071345~cellular response to cytokine stimulus,GO:0090383~phagosome acidification,GO:0097188~dentin mineralization,GO:1902600~hydrogen ion transmembrane transport,	GO:0000220~vacuolar proton-transporting V-type ATPase, V0 domain,GO:0005634~nucleus,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0016471~vacuolar proton-transporting V-type ATPase complex,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0033176~proton-transporting V-type ATPase complex,GO:0033179~proton-transporting V-type ATPase, V0 domain,GO:0101003~ficolin-1-rich granule membrane,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0015078~hydrogen ion transmembrane transporter activity,GO:0046961~proton-transporting ATPase activity, rotational mechanism,GO:0051117~ATPase binding,	IPR002490:ATPase, V0 complex, subunit 116kDa,IPR026028:ATPase, V0 complex, subunit 116kDa, eukaryotic,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04142:Lysosome,hsa04145:Phagosome,hsa04721:Synaptic vesicle cycle,hsa04966:Collecting duct acid secretion,hsa05110:Vibrio cholerae infection,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05152:Tuberculosis,hsa05165:Human papillomavirus infection,hsa05323:Rheumatoid arthritis,	259700~Osteopetrosis, autosomal recessive 1,	PIRSF001293:V-type proton ATPase 116 kda subunit a isoform 1,		KW-0375~Hydrogen ion transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0987~Osteopetrosis,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vacuolar,TRANSMEM:Helical,
TRDC	T cell receptor delta constant(TRDC)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0046629~gamma-delta T cell activation,GO:0050852~T cell receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042101~T cell receptor complex,GO:0042106~gamma-delta T cell receptor complex,GO:0042571~immunoglobulin complex, circulating,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003597:Immunoglobulin C1-set,IPR013783:Immunoglobulin-like fold,					KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,KW-1279~T cell receptor,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IGc1,REGION:Disordered,TRANSMEM:Helical,
TAPBP	TAP binding protein(TAPBP)	Homo sapiens	GO:0002397~MHC class I protein complex assembly,GO:0002398~MHC class Ib protein complex assembly,GO:0002502~peptide antigen assembly with MHC class I protein complex,GO:0006890~retrograde vesicle-mediated transport, Golgi to ER,GO:0006955~immune response,GO:0010468~regulation of gene expression,GO:0015833~peptide transport,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0050776~regulation of immune response,GO:0050823~peptide antigen stabilization,GO:0061635~regulation of protein complex stability,GO:0065003~macromolecular complex assembly,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042824~MHC class I peptide loading complex,GO:0061779~Tapasin-ERp57 complex,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0015433~peptide antigen-transporting ATPase activity,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0046978~TAP1 binding,GO:0046979~TAP2 binding,GO:0051082~unfolded protein binding,	IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR008056:Tapasin,IPR013783:Immunoglobulin-like fold,	hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,	604571~Bare lymphocyte syndrome, type I,				KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-57 in PDIA3),DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,MUTAGEN:C->A: Abolishes the recruitment of PDIA3, CALR and B2M to the peptide-loading complex.,MUTAGEN:K->D: Restores interaction with TAP1-TAP2; when associated with TAP1 K-92 or TAP2 K-16.,MUTAGEN:N->Q: Reduces the recruitment of PDIA3 to TAP1-TAP2 transporter.,SITE:Inter-subunit salt bridge with TAP1-TAP2. Essential peptide loading complex assembly,SITE:May be involved in interaction with TAP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
TBC1D10C	TBC1 domain family member 10C(TBC1D10C)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0033173~calcineurin-NFAT signaling cascade,GO:0042113~B cell activation,GO:0042147~retrograde transport, endosome to Golgi,GO:0050869~negative regulation of B cell activation,GO:0070371~ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070885~negative regulation of calcineurin-NFAT signaling cascade,GO:0090630~activation of GTPase activity,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031527~filopodium membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005096~GTPase activator activity,GO:0005515~protein binding,	IPR000195:Rab-GTPase-TBC domain,				SM00164:TBC,						KW-0343~GTPase activation,		COMPBIAS:Polar residues,DOMAIN:Rab-GAP TBC,MUTAGEN:R->A: Loss of GAP activity.,REGION:Disordered,REGION:Interaction with calcineurin,SITE:Arginine finger,SITE:Glutamine finger,
TBC1D3D	TBC1 domain family member 3D(TBC1D3D)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0090630~activation of GTPase activity,	GO:0005886~plasma membrane,	GO:0005096~GTPase activator activity,	IPR000195:Rab-GTPase-TBC domain,				SM00164:TBC,		KW-0472~Membrane,KW-1003~Cell membrane,				KW-0343~GTPase activation,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0832~Ubl conjugation,	COMPBIAS:Pro residues,DOMAIN:Rab-GAP TBC,LIPID:S-palmitoyl cysteine,REGION:Disordered,
TEAD2	TEA domain transcription factor 2(TEAD2)	Homo sapiens	GO:0001570~vasculogenesis,GO:0001843~neural tube closure,GO:0003143~embryonic heart tube morphogenesis,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0030903~notochord development,GO:0035329~hippo signaling,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048339~paraxial mesoderm development,GO:0048368~lateral mesoderm development,GO:0048568~embryonic organ development,GO:0060548~negative regulation of cell death,GO:0065003~macromolecular complex assembly,GO:0071300~cellular response to retinoic acid,GO:2000736~regulation of stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0097718~disordered domain specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000818:TEA/ATTS,IPR016361:Transcriptional enhancer factor,	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,		PIRSF002603:transcriptional enhancer factor,	SM00426:TEA,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:TEA,DOMAIN:TEA,REGION:Disordered,REGION:Transcriptional activation,
TEAD3	TEA domain transcription factor 3(TEAD3)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007565~female pregnancy,GO:0035329~hippo signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048568~embryonic organ development,GO:0055059~asymmetric neuroblast division,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000818:TEA/ATTS,IPR016361:Transcriptional enhancer factor,IPR027253:Transcriptional enhancer factor TEF-5 (TEAD3),	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,		PIRSF002603:transcriptional enhancer factor,PIRSF500720:transcriptional enhancer factor TEF-5 (TEAD3) [Parent=PIRSF002603],	SM00426:TEA,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:TEA,DOMAIN:TEA,REGION:Disordered,REGION:Transcriptional activation,
TEAD4	TEA domain transcription factor 4(TEAD4)	Homo sapiens	GO:0001501~skeletal system development,GO:0001708~cell fate specification,GO:0001830~trophectodermal cell fate commitment,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0007566~embryo implantation,GO:0035329~hippo signaling,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048568~embryonic organ development,GO:1902459~positive regulation of stem cell population maintenance,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0032993~protein-DNA complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR000818:TEA/ATTS,IPR016361:Transcriptional enhancer factor,IPR027255:Transcriptional enhancer factor TEF-3 (TEAD4),	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,		PIRSF002603:transcriptional enhancer factor,PIRSF500722:transcriptional enhancer factor TEF-3 (TEAD4) [Parent=PIRSF002603],	SM00426:TEA,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0238~DNA-binding,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:TEA,DOMAIN:TEA,MUTAGEN:D->A: Reduced transforming ability.,MUTAGEN:E->A: Reduced transforming ability.,MUTAGEN:F->A: Reduced interaction with YAP1.,MUTAGEN:F->A: Reduced transforming ability.,MUTAGEN:H->A: Reduced transforming ability.,MUTAGEN:K->A: Important loss of interaction with YAP1 and complete loss of transforming ability.,MUTAGEN:L->A: Reduced transforming ability.,MUTAGEN:W->A: Important loss of interaction with YAP1 and complete loss of transforming ability.,MUTAGEN:Y->A,H: Loss of interaction with YAP1 and also activation by YAP1.,MUTAGEN:Y->A: Important loss of interaction with YAP1 and complete loss of transforming ability.,REGION:Disordered,
TIMP1	TIMP metallopeptidase inhibitor 1(TIMP1)	Homo sapiens	GO:0001775~cell activation,GO:0002248~connective tissue replacement involved in inflammatory response wound healing,GO:0007165~signal transduction,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0009725~response to hormone,GO:0010033~response to organic substance,GO:0010951~negative regulation of endopeptidase activity,GO:0034097~response to cytokine,GO:0043066~negative regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0043434~response to peptide hormone,GO:0051045~negative regulation of membrane protein ectodomain proteolysis,GO:0051216~cartilage development,GO:0071492~cellular response to UV-A,GO:1901164~negative regulation of trophoblast cell migration,GO:1905049~negative regulation of metallopeptidase activity,GO:2001044~regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008191~metalloendopeptidase inhibitor activity,GO:0008270~zinc ion binding,GO:0030414~peptidase inhibitor activity,GO:0046872~metal ion binding,	IPR001134:Netrin domain,IPR001820:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015611:Tissue inhibitor of metalloprotease 1,IPR027465:Proteinase inhibitor I35, tissue inhibitor of metalloproteinase, C-terminal domain,	hsa04066:HIF-1 signaling pathway,			SM00206:NTR,		KW-0964~Secreted,		KW-0176~Collagen,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0339~Growth factor,KW-0481~Metalloenzyme inhibitor,KW-0483~Metalloprotease inhibitor,KW-0646~Protease inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:NTR,MUTAGEN:H->A: Nearly abolishes metalloproteinase inhibition.,MUTAGEN:Q->A: Nearly abolishes metalloproteinase inhibition.,MUTAGEN:T->E,G,K,Q,R: Reduced interaction with metalloproteinase.,MUTAGEN:T->L: Decreases protein flexibility and increases affinity for MMP14.,MUTAGEN:T->V: Normal interaction with metalloproteinase.,REGION:Disordered,REGION:Involved in metalloproteinase-binding,SITE:Involved in metalloproteinase-binding,
TICAM2	TIR domain containing adaptor molecule 2(TICAM2)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007030~Golgi organization,GO:0034144~negative regulation of toll-like receptor 4 signaling pathway,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0035669~TRAM-dependent toll-like receptor 4 signaling pathway,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045087~innate immune response,GO:0071222~cellular response to lipopolysaccharide,GO:0071650~negative regulation of chemokine (C-C motif) ligand 5 production,GO:0071651~positive regulation of chemokine (C-C motif) ligand 5 production,GO:2000494~positive regulation of interleukin-18-mediated signaling pathway,	GO:0001891~phagocytic cup,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005783~endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0030134~ER to Golgi transport vesicle,GO:0030667~secretory granule membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0042995~cell projection,	GO:0005515~protein binding,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR015720:TMP21-related,	hsa04064:NF-kappa B signaling pathway,hsa04217:Necroptosis,hsa04620:Toll-like receptor signaling pathway,hsa05133:Pertussis,hsa05161:Hepatitis B,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,hsa05417:Lipid and atherosclerosis,				KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:TIR,LIPID:N-myristoyl glycine,MUTAGEN:C->H: Loss of ability to dimerize. Loss of RANTES-inducing activity and ability to induce NF-kappa-B activation. Inhibition of TLR4-dependent activation of IRF3 and IRF7. Loss of interaction with TLR4.,MUTAGEN:G->A: Results in relocalization from membrane to cytosol; Loss of ability to transduce TLR4-signal. Loss of TLR2-mediated activation of IRF7.,MUTAGEN:P->H: Loss of ability to dimerize. Significant loss of RANTES-inducing activity. Loss of ability to induce NF-kappa-B activation.,MUTAGEN:S->A: Loss of phosphorylation. Abolishes ability to activate IRF3 or NF-kappa-B and to transduce TLR4 signal.,MUTAGEN:S->A: Loss of phosphorylation. Significant reduction in the ability to activate IRF3 or NF-kappa-B.,MUTAGEN:S->A: No effect on phosphorylation and on the ability to activate IRF3 or NF-kappa-B.,MUTAGEN:S->E: Significant decrease of localization in the membrane.,MUTAGEN:Y->F: Complete loss of phosphorylation in response to LPS.,MUTAGEN:Y->F: No effect on phosphorylation.,REGION:Disordered,
TNFAIP6	TNF alpha induced protein 6(TNFAIP6)	Homo sapiens	GO:0001550~ovarian cumulus expansion,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0030212~hyaluronan metabolic process,GO:0030335~positive regulation of cell migration,GO:0030514~negative regulation of BMP signaling pathway,GO:0030728~ovulation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045671~negative regulation of osteoclast differentiation,GO:0050728~negative regulation of inflammatory response,GO:0090024~negative regulation of neutrophil chemotaxis,GO:1903911~positive regulation of receptor clustering,GO:1905590~fibronectin fibril organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0001968~fibronectin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005540~hyaluronic acid binding,GO:0052689~carboxylic ester hydrolase activity,	IPR000538:Link,IPR000859:CUB domain,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00042:CUB,SM00445:LINK,	KW-0130~Cell adhesion,	KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:Link,MUTAGEN:E->K: Has no significant effect on hyaluronan binding to CD44 or hyaluronan-dependent lymphocyte rolling.,MUTAGEN:E->S: Reduces the binding affinity to calcium ions. Abolishes the interaction with heavy chain ITIH1.,MUTAGEN:F->V: Impairs binding of hyaluronan to CD44. Decreases hyaluronan-dependent lymphocyte rolling.,MUTAGEN:H->K: Decreases binding of hyaluronan to CD44. Decreases hyaluronan-dependent lymphocyte rolling.,MUTAGEN:H->K: Increases binding of hyaluronan to CD44. Has no significant effect on hyaluronan-dependent lymphocyte rolling.,MUTAGEN:K->A: Decreases binding to heparin. Has normal binding to bikunin.,MUTAGEN:K->A: Decreases binding to heparin. Has normal binding to bikunin. Impairs binding to heparin and decreases the potentiation effect toward bikunin antiprotease activity; when associated with A-55 and A-69. Has no effect on CXCL8-induced neutrophil transmigration; when associated with A-55 and A-69.,MUTAGEN:K->A: Decreases binding to heparin. Has normal binding to bikunin. Impairs binding to heparin; when associated with A-55 and A-76. Has no effect on CXCL8-induced neutrophil transmigration; when associated with A-55 and A-76.,MUTAGEN:K->A: Decreases binding to heparin. Has normal binding to bikunin. Impairs binding to heparin; when associated with A-69 and A-76. Has no effect on CXCL8-induced neutrophil transmigration; when associated with A-69 and A-76.,MUTAGEN:K->E: Decreases binding of hyaluronan to CD44. Decreases hyaluronan-dependent lymphocyte rolling.,MUTAGEN:K->Q: Abolishes binding to bikunin.,MUTAGEN:Y->F: Abolishes binding to bikunin. Has no effect on transesterification reaction.,MUTAGEN:Y->F: Abolishes binding to bikunin. Impairs binding of hyaluronan to CD44. Decreases hyaluronan-dependent lymphocyte rolling. Has no effect on transesterification reaction.,MUTAGEN:Y->F: Abolishes binding to bikunin. Impairs binding to hyaluronan. Retains the ability to bind heavy chains but cannot transfer them onto hyaluronan. Impairs binding of hyaluronan to CD44. Decreases hyaluronan-dependent lymphocyte rolling.,
TNFRSF10C	TNF receptor superfamily member 10c(TNFRSF10C)	Homo sapiens	GO:0036462~TRAIL-activated apoptotic signaling pathway,GO:0043065~positive regulation of apoptotic process,	GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031225~anchored component of membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0045569~TRAIL binding,	IPR001368:TNFR/NGFR cysteine-rich region,IPR020465:Tumour necrosis factor receptor 10,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,			SM00208:TNFR,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,COMPBIAS:Polar residues,DOMAIN:TNFR-Cys,LIPID:GPI-anchor amidated alanine,PROPEP:Removed in mature form,REGION:Disordered,REPEAT:TAPE 1,REPEAT:TAPE 2,REPEAT:TAPE 3,REPEAT:TAPE 4,REPEAT:TAPE 5,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TRANSMEM:Helical,
TNFRSF11B	TNF receptor superfamily member 11b(TNFRSF11B)	Homo sapiens	GO:0001501~skeletal system development,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007584~response to nutrient,GO:0009410~response to xenobiotic stimulus,GO:0030198~extracellular matrix organization,GO:0032026~response to magnesium ion,GO:0042489~negative regulation of odontogenesis of dentin-containing tooth,GO:0042493~response to drug,GO:0043627~response to estrogen,GO:0045671~negative regulation of osteoclast differentiation,GO:0045779~negative regulation of bone resorption,GO:0046685~response to arsenic-containing substance,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0031012~extracellular matrix,GO:0043235~receptor complex,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR000488:Death domain,IPR001368:TNFR/NGFR cysteine-rich region,IPR011029:Death-like domain,IPR017371:Tumour necrosis factor receptor 11B,IPR022323:Tumour necrosis factor receptor 11,	hsa04060:Cytokine-cytokine receptor interaction,hsa04380:Osteoclast differentiation,	239000~Paget disease of bone 5, juvenile-onset,	PIRSF038065:tumor necrosis factor receptor superfamily member 11B,	SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Death 1,DOMAIN:Death 2,DOMAIN:TNFR-Cys,MUTAGEN:C->S: Abolishes dimerization.,MUTAGEN:DE->AA: Decreases inhibition of osteoclast differentiation.,MUTAGEN:E->A: Reduces affinity for TNFSF11. Decreases inhibition of osteoclast differentiation.,MUTAGEN:Missing: Abolishes dimerization.,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,SITE:Involved in dimerization,
TNFRSF12A	TNF receptor superfamily member 12A(TNFRSF12A)	Homo sapiens	GO:0001525~angiogenesis,GO:0006915~apoptotic process,GO:0007155~cell adhesion,GO:0030154~cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0061041~regulation of wound healing,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR022316:Tumour necrosis factor receptor 12,	hsa04060:Cytokine-cytokine receptor interaction,				KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0130~Cell adhesion,KW-0221~Differentiation,	KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:TNFR-Cys; atypical,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TNFRSF14	TNF receptor superfamily member 14(TNFRSF14)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002720~positive regulation of cytokine production involved in immune response,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0031295~T cell costimulation,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0045087~innate immune response,GO:0046642~negative regulation of alpha-beta T cell proliferation,GO:0046718~viral entry into host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:1905675~negative regulation of adaptive immune memory response,GO:2000406~positive regulation of T cell migration,	GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0001618~virus receptor activity,GO:0005031~tumor necrosis factor-activated receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0031625~ubiquitin protein ligase binding,	IPR001368:TNFR/NGFR cysteine-rich region,IPR022332:Tumour necrosis factor receptor 14,	hsa03266:Virion - Herpesvirus,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa05168:Herpes simplex virus 1 infection,			SM00208:TNFR,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TNFR-Cys,MUTAGEN:Y->A: Abolishes cis interactions with BTLA.,MUTAGEN:Y->F: Does not affect cis interactions with BTLA.,REPEAT:TNFR-Cys,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TICRR	TOPBP1 interacting checkpoint and replication regulator(TICRR)	Homo sapiens	GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0010212~response to ionizing radiation,GO:0030174~regulation of DNA-dependent DNA replication initiation,GO:0033314~mitotic DNA replication checkpoint,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0003682~chromatin binding,GO:0005515~protein binding,	IPR026153:Treslin,					KW-0131~Cell cycle,KW-0227~DNA damage,KW-0234~DNA repair,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
TPX2	TPX2 microtubule nucleation factor(TPX2)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0006915~apoptotic process,GO:0007020~microtubule nucleation,GO:0007026~negative regulation of microtubule depolymerization,GO:0032147~activation of protein kinase activity,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:0090307~mitotic spindle assembly,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005880~nuclear microtubule,GO:0015630~microtubule cytoskeleton,GO:0043203~axon hillock,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0061676~importin-alpha family protein binding,	IPR009675:TPX2,IPR015128:Aurora-A binding,IPR027329:TPX2, C-terminal domain,IPR027330:TPX2, central domain,					KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Aurora-A_bind,DOMAIN:TPX2,DOMAIN:TPX2_importin,REGION:Disordered,
TTK	TTK protein kinase(TTK)	Homo sapiens	GO:0007051~spindle organization,GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007094~mitotic spindle assembly checkpoint,GO:0008284~positive regulation of cell proliferation,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0016321~female meiosis chromosome segregation,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0033316~meiotic spindle assembly checkpoint,GO:0034501~protein localization to kinetochore,GO:0046777~protein autophosphorylation,GO:0051304~chromosome separation,GO:1903096~protein localization to meiotic spindle midzone,	GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005819~spindle,GO:0016020~membrane,	GO:0004674~protein serine/threonine kinase activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,GO:0043515~kinetochore binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR011990:Tetratricopeptide-like helical,IPR017441:Protein kinase, ATP binding site,IPR027084:Dual specificity protein kinase TTK,	hsa04110:Cell cycle,			SM00220:S_TKc,					KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Polar residues,DOMAIN:Protein kinase,MUTAGEN:D->A: Loss of kinase activity.,MUTAGEN:T->A: Loss of kinase activity.,REGION:Disordered,
TUB	TUB bipartite transcription factor(TUB)	Homo sapiens	GO:0006910~phagocytosis, recognition,GO:0007605~sensory perception of sound,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009725~response to hormone,GO:0042073~intraciliary transport,GO:0045494~photoreceptor cell maintenance,GO:0050766~positive regulation of phagocytosis,GO:0050896~response to stimulus,GO:0060041~retina development in camera-type eye,GO:0061512~protein localization to cilium,GO:0097500~receptor localization to non-motile cilium,GO:1903546~protein localization to photoreceptor outer segment,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005929~cilium,	GO:0001664~G-protein coupled receptor binding,GO:0044877~macromolecular complex binding,	IPR000007:Tubby, C-terminal,IPR005398:Tubby, N-terminal,IPR018066:Tubby, C-terminal, conserved site,IPR025659:Tubby C-terminal-like domain,		616188~Retinal dystrophy and obesity,			KW-0581~Phagocytosis,KW-0716~Sensory transduction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0550~Obesity,					COMPBIAS:Polar residues,DOMAIN:Tub,DOMAIN:Tub_N,REGION:Disordered,
TULP1	TUB like protein 1(TULP1)	Homo sapiens	GO:0001895~retina homeostasis,GO:0006910~phagocytosis, recognition,GO:0007601~visual perception,GO:0016358~dendrite development,GO:0042462~eye photoreceptor cell development,GO:0045494~photoreceptor cell maintenance,GO:0050766~positive regulation of phagocytosis,GO:0050908~detection of light stimulus involved in visual perception,GO:0060041~retina development in camera-type eye,GO:0061512~protein localization to cilium,GO:1903546~protein localization to photoreceptor outer segment,	GO:0001750~photoreceptor outer segment,GO:0001917~photoreceptor inner segment,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005929~cilium,GO:0042995~cell projection,GO:0043679~axon terminus,GO:0045202~synapse,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0051015~actin filament binding,	IPR000007:Tubby, C-terminal,IPR018066:Tubby, C-terminal, conserved site,IPR025659:Tubby C-terminal-like domain,		600132~Retinitis pigmentosa 14,613843~Leber congenital amaurosis 15,			KW-0581~Phagocytosis,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,KW-0901~Leber congenital amaurosis,					COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:Tub,REGION:Disordered,
B3GNT7	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7(B3GNT7)	Homo sapiens	GO:0006486~protein glycosylation,GO:0016266~O-glycan processing,GO:0018146~keratan sulfate biosynthetic process,GO:0030311~poly-N-acetyllactosamine biosynthetic process,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008194~UDP-glycosyltransferase activity,GO:0008375~acetylglucosaminyltransferase activity,GO:0008376~acetylgalactosaminyltransferase activity,GO:0008499~UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity,GO:0008532~N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity,GO:0016757~transferase activity, transferring glycosyl groups,	IPR002659:Glycosyl transferase, family 31,	hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
USH1C	USH1 protein network component harmonin(USH1C)	Homo sapiens	GO:0000086~G2/M transition of mitotic cell cycle,GO:0007605~sensory perception of sound,GO:0030046~parallel actin filament bundle assembly,GO:0032532~regulation of microvillus length,GO:0034622~cellular macromolecular complex assembly,GO:0042472~inner ear morphogenesis,GO:0042491~auditory receptor cell differentiation,GO:0045494~photoreceptor cell maintenance,GO:0046549~retinal cone cell development,GO:0050953~sensory perception of light stimulus,GO:0050957~equilibrioception,GO:0051017~actin filament bundle assembly,GO:0060122~inner ear receptor stereocilium organization,GO:0065003~macromolecular complex assembly,GO:1904106~protein localization to microvillus,GO:1904970~brush border assembly,	GO:0001750~photoreceptor outer segment,GO:0001917~photoreceptor inner segment,GO:0002142~stereocilia ankle link complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0005903~brush border,GO:0005929~cilium,GO:0032420~stereocilium,GO:0032426~stereocilium tip,GO:0045177~apical part of cell,GO:0045202~synapse,	GO:0005515~protein binding,GO:0030507~spectrin binding,GO:0051015~actin filament binding,	IPR001478:PDZ domain,		276904~Usher syndrome, type 1C,602092~Deafness, autosomal recessive 18A,		SM00228:PDZ,	KW-0221~Differentiation,KW-1009~Hearing,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0682~Retinitis pigmentosa,KW-0836~Usher syndrome,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	DOMAIN:PDZ,DOMAIN:PDZ 1,DOMAIN:PDZ 2,DOMAIN:PDZ 3,MUTAGEN:R->H: Strongly reduced affinity for USH1G.,REGION:Disordered,REGION:Mediates interaction with MYO7B,REGION:N-terminal domain,
VSIG4	V-set and immunoglobulin domain containing 4(VSIG4)	Homo sapiens	GO:0006957~complement activation, alternative pathway,GO:0032703~negative regulation of interleukin-2 production,GO:0042130~negative regulation of T cell proliferation,GO:0043031~negative regulation of macrophage activation,GO:0045957~negative regulation of complement activation, alternative pathway,	GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,	GO:0001851~complement component C3b binding,GO:0005515~protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04610:Complement and coagulation cascades,			SM00406:IGv,SM00408:IGc2,SM00409:IG,	KW-0179~Complement alternate pathway,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
WEE1	WEE1 G2 checkpoint kinase(WEE1)	Homo sapiens	GO:0000086~G2/M transition of mitotic cell cycle,GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030010~establishment of cell polarity,GO:0048812~neuron projection morphogenesis,GO:0051301~cell division,GO:2000134~negative regulation of G1/S transition of mitotic cell cycle,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0000287~magnesium ion binding,GO:0004672~protein kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017164:Wee1-like protein kinase,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa05170:Human immunodeficiency virus 1 infection,		PIRSF037281:Wee1-like protein kinase,	SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Protein kinase,MUTAGEN:EE->AA: Impairs binding of the SCF(BTRC) complex.,MUTAGEN:K->R: Abolishes activity.,MUTAGEN:S->A: Abolishes phosphorylation by BRSK1 and BRSK2.,MUTAGEN:S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-123.,MUTAGEN:S->A: Abolishes phosphorylation by PLK1 and CDK1 and binding of the SCF(BTRC) complex, leading to stabilization of the protein; when associated with A-53.,REGION:Disordered,
WWTR1	WW domain containing transcription regulator 1(WWTR1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001894~tissue homeostasis,GO:0001933~negative regulation of protein phosphorylation,GO:0003015~heart process,GO:0006355~regulation of transcription, DNA-templated,GO:0006469~negative regulation of protein kinase activity,GO:0006644~phospholipid metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016567~protein ubiquitination,GO:0017145~stem cell division,GO:0031146~SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,GO:0032835~glomerulus development,GO:0035264~multicellular organism growth,GO:0035329~hippo signaling,GO:0045599~negative regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048762~mesenchymal cell differentiation,GO:0060271~cilium assembly,GO:0060390~regulation of SMAD protein import into nucleus,GO:0060993~kidney morphogenesis,GO:0072307~regulation of metanephric nephron tubule epithelial cell differentiation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1900182~positive regulation of protein localization to nucleus,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016604~nuclear body,	GO:0003713~transcription coactivator activity,GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0016746~transferase activity, transferring acyl groups,GO:0042803~protein homodimerization activity,	IPR000872:Tafazzin,IPR001202:WW domain,IPR002123:Phospholipid/glycerol acyltransferase,	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,			SM00456:WW,SM00563:PlsC,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PlsC,DOMAIN:WW,MOTIF:PDZ-binding,MUTAGEN:Missing: No effect on binding to PRRG4.,MUTAGEN:Missing: Reduced binding to PRRG4.,MUTAGEN:S->A,D: Loss of interaction with TEAD4.,MUTAGEN:S->A: Partial resistance to inhibition by MST2 and LATS2.,MUTAGEN:S->A: Significant resistance to inhibition by STK3/MST2 and LATS2. No effect on binding to PRRG4.,REGION:Disordered,REGION:Required for interaction with PALS1,TRANSMEM:Helical,
WNT10B	Wnt family member 10B(WNT10B)	Homo sapiens	GO:0000086~G2/M transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0002062~chondrocyte differentiation,GO:0006366~transcription from RNA polymerase II promoter,GO:0006629~lipid metabolic process,GO:0007224~smoothened signaling pathway,GO:0008284~positive regulation of cell proliferation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0014835~myoblast differentiation involved in skeletal muscle regeneration,GO:0016055~Wnt signaling pathway,GO:0030182~neuron differentiation,GO:0030217~T cell differentiation,GO:0030501~positive regulation of bone mineralization,GO:0030855~epithelial cell differentiation,GO:0030858~positive regulation of epithelial cell differentiation,GO:0032434~regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0043065~positive regulation of apoptotic process,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045899~positive regulation of RNA polymerase II transcriptional preinitiation complex assembly,GO:0048627~myoblast development,GO:0048641~regulation of skeletal muscle tissue development,GO:0048741~skeletal muscle fiber development,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050821~protein stabilization,GO:0050909~sensory perception of taste,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051885~positive regulation of timing of anagen,GO:0060070~canonical Wnt signaling pathway,GO:0060346~bone trabecula formation,GO:0061196~fungiform papilla development,GO:0071300~cellular response to retinoic acid,GO:0071320~cellular response to cAMP,GO:0071374~cellular response to parathyroid hormone stimulus,GO:0071425~hematopoietic stem cell proliferation,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902035~positive regulation of hematopoietic stem cell proliferation,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR013302:Wnt-10 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,	225300~Split-hand/foot malformation 6,617073~Tooth agenesis, selective, 8,		SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,REGION:Disordered,
WNT7B	Wnt family member 7B(WNT7B)	Homo sapiens	GO:0001701~in utero embryonic development,GO:0003338~metanephros morphogenesis,GO:0007257~activation of JUN kinase activity,GO:0016055~Wnt signaling pathway,GO:0016332~establishment or maintenance of polarity of embryonic epithelium,GO:0021871~forebrain regionalization,GO:0022009~central nervous system vasculogenesis,GO:0030182~neuron differentiation,GO:0030324~lung development,GO:0032364~oxygen homeostasis,GO:0032536~regulation of cell projection size,GO:0042592~homeostatic process,GO:0044237~cellular metabolic process,GO:0045165~cell fate commitment,GO:0045669~positive regulation of osteoblast differentiation,GO:0046330~positive regulation of JNK cascade,GO:0048144~fibroblast proliferation,GO:0048568~embryonic organ development,GO:0048812~neuron projection morphogenesis,GO:0050808~synapse organization,GO:0051384~response to glucocorticoid,GO:0060070~canonical Wnt signaling pathway,GO:0060425~lung morphogenesis,GO:0060428~lung epithelium development,GO:0060482~lobar bronchus development,GO:0060535~trachea cartilage morphogenesis,GO:0060560~developmental growth involved in morphogenesis,GO:0060669~embryonic placenta morphogenesis,GO:0060710~chorio-allantoic fusion,GO:0061180~mammary gland epithelium development,GO:0070307~lens fiber cell development,GO:0071300~cellular response to retinoic acid,GO:0072053~renal inner medulla development,GO:0072054~renal outer medulla development,GO:0072060~outer medullary collecting duct development,GO:0072061~inner medullary collecting duct development,GO:0072089~stem cell proliferation,GO:0072205~metanephric collecting duct development,GO:0072207~metanephric epithelium development,GO:0072236~metanephric loop of Henle development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0030666~endocytic vesicle membrane,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005109~frizzled binding,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0048018~receptor agonist activity,	IPR005817:Wnt,IPR013300:Wnt-7 protein,IPR018161:Wnt protein, conserved site,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00097:WNT1,	KW-0879~Wnt signaling pathway,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,LIPID:O-palmitoleoyl serine; by PORCN,REGION:Disordered linker,
XG	Xg glycoprotein (Xg blood group)(XG)	Homo sapiens	GO:0034109~homotypic cell-cell adhesion,GO:0072683~T cell extravasation,GO:2000391~positive regulation of neutrophil extravasation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,		IPR022078:CD99 antigen-like protein 2,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,	KW-0325~Glycoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
YBX3	Y-box binding protein 3(YBX3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006915~apoptotic process,GO:0007283~spermatogenesis,GO:0008584~male gonad development,GO:0009566~fertilization,GO:0010468~regulation of gene expression,GO:0035234~ectopic germ cell programmed cell death,GO:0043066~negative regulation of apoptotic process,GO:0046622~positive regulation of organ growth,GO:0048642~negative regulation of skeletal muscle tissue development,GO:0060546~negative regulation of necroptotic process,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:0071356~cellular response to tumor necrosis factor,GO:0071474~cellular hyperosmotic response,GO:1902219~negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress,GO:2000242~negative regulation of reproductive process,GO:2000767~positive regulation of cytoplasmic translation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005923~bicellular tight junction,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:1905538~polysome binding,	IPR002059:Cold-shock protein, DNA-binding,IPR011129:Cold shock protein,IPR012340:Nucleic acid-binding, OB-fold,IPR019844:Cold-shock conserved site,	hsa04530:Tight junction,			SM00357:CSP,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0238~DNA-binding,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:CSD,REGION:Disordered,
ZFP36	ZFP36 ring finger protein(ZFP36)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0000288~nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:0000289~nuclear-transcribed mRNA poly(A) tail shortening,GO:0006402~mRNA catabolic process,GO:0009611~response to wounding,GO:0010837~regulation of keratinocyte proliferation,GO:0030099~myeloid cell differentiation,GO:0031086~nuclear-transcribed mRNA catabolic process, deadenylation-independent decay,GO:0032680~regulation of tumor necrosis factor production,GO:0032703~negative regulation of interleukin-2 production,GO:0032897~negative regulation of viral transcription,GO:0035278~miRNA mediated inhibition of translation,GO:0038066~p38MAPK cascade,GO:0042594~response to starvation,GO:0043488~regulation of mRNA stability,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045600~positive regulation of fat cell differentiation,GO:0045616~regulation of keratinocyte differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0050728~negative regulation of inflammatory response,GO:0051028~mRNA transport,GO:0060213~positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,GO:0060218~hematopoietic stem cell differentiation,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:0071222~cellular response to lipopolysaccharide,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:1900153~positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay,GO:1901835~positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA,GO:1902037~negative regulation of hematopoietic stem cell differentiation,GO:1902172~regulation of keratinocyte apoptotic process,GO:1904246~negative regulation of polynucleotide adenylyltransferase activity,GO:1904582~positive regulation of intracellular mRNA localization,GO:2000637~positive regulation of gene silencing by miRNA,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0030014~CCR4-NOT complex,GO:1990904~ribonucleoprotein complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0019957~C-C chemokine binding,GO:0031072~heat shock protein binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0070063~RNA polymerase binding,GO:0071889~14-3-3 protein binding,	IPR000571:Zinc finger, CCCH-type,	hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,			SM00356:ZnF_C3H1,	KW-0509~mRNA transport,KW-0813~Transport,KW-0943~RNA-mediated gene silencing,KW-0945~Host-virus interaction,	KW-0271~Exosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:C3H1-type,MUTAGEN:C->R: Inhibits binding to ARE-containing transcripts. Inhibits binding to and deadenylation activities of ARE-containing mRNAs. Inhibits localization of ARE-containing mRNAs to processing bodies (PBs).,MUTAGEN:C->R: Inhibits both ARE-binding and mRNA deadenylation activities.,MUTAGEN:F->A: Abolishes interaction with CNOT1 and impairs TNF mRNA deadenylation.,MUTAGEN:F->N: Inhibits ARE-containing RNA-binding, deadenylation and RNA decapping activities.,MUTAGEN:P->V: Inhibits interaction with SH3KBP1.,MUTAGEN:R->A: Abolishes interaction with CNOT1.,MUTAGEN:S->A: Inhibits PKM-induced ZFP36 degradation through a p38 MAPK signaling pathway.,REGION:Disordered,REGION:Interaction with CNOT1,REGION:Necessary and sufficient for the association with mRNA decay enzymes and mRNA decay activation,REGION:Necessary for RNA-binding,REGION:Necessary for interaction with PABPN1,REGION:Necessary for localization of ARE-containing mRNAs to processing bodies (PBs),REGION:Necessary for mRNA decay activation,REGION:Necessary for nuclear export,REGION:Necessary for nuclear localization,REPEAT:P-P-P-P-G,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,
ZIC3	Zic family member 3(ZIC3)	Homo sapiens	GO:0001501~skeletal system development,GO:0001840~neural plate development,GO:0001947~heart looping,GO:0003228~atrial cardiac muscle tissue development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007368~determination of left/right symmetry,GO:0007417~central nervous system development,GO:0009880~embryonic pattern specification,GO:0021766~hippocampus development,GO:0021772~olfactory bulb development,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0030324~lung development,GO:0030718~germ-line stem cell population maintenance,GO:0035108~limb morphogenesis,GO:0035283~central nervous system segmentation,GO:0035469~determination of pancreatic left/right asymmetry,GO:0035545~determination of left/right asymmetry in nervous system,GO:0042473~outer ear morphogenesis,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048318~axial mesoderm development,GO:0048339~paraxial mesoderm development,GO:0048863~stem cell differentiation,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0060324~face development,GO:0070986~left/right axis specification,GO:0071907~determination of digestive tract left/right asymmetry,GO:0071910~determination of liver left/right asymmetry,GO:0090009~primitive streak formation,GO:1904888~cranial skeletal system development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04550:Signaling pathways regulating pluripotency of stem cells,	306955~Congenital heart defects, nonsyndromic, 1, X-linked,314390~VACTERL association, X-linked,Heterotaxy, visceral, 1, X-linked 306955~Heterotaxy, visceral, 1, X-linked 306955,		SM00355:ZnF_C2H2,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1056~Heterotaxy,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal,MUTAGEN:C->S: Increases weakly its cytoplasmic localization.,MUTAGEN:H->R: Increases its cytoplasmic localization.,MUTAGEN:K->A: Does not increase its cytoplasmic localization.,MUTAGEN:K->A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-349 and A-350.,MUTAGEN:K->A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-341; A-346; A-349 and A-350.,MUTAGEN:K->A: Increases its cytoplasmic localization. Does not interacts with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-346 and A-350.,MUTAGEN:K->M: Does not increase its cytoplasmic localization.,MUTAGEN:K->M: Increases its cytoplasmic localization.,MUTAGEN:R->A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-346 and A-349.,MUTAGEN:R->A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-346; A-349 and A-350.,MUTAGEN:R->A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-337; A-341; A-346; A-349 and A-350.,MUTAGEN:R->M: Increases its cytoplasmic localization.,REGION:Disordered,ZN_FING:C2H2-type 1; atypical,ZN_FING:C2H2-type 2; atypical,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,
ABHD16A	abhydrolase domain containing 16A, phospholipase(ABHD16A)	Homo sapiens	GO:0006660~phosphatidylserine catabolic process,GO:0052651~monoacylglycerol catabolic process,GO:0098734~macromolecule depalmitoylation,GO:1905344~prostaglandin catabolic process,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004620~phospholipase activity,GO:0005515~protein binding,GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016787~hydrolase activity,GO:0047372~acylglycerol lipase activity,	IPR000073:Alpha/beta hydrolase fold-1,IPR026604:Abhydrolase domain-containing protein 16,	hsa00561:Glycerolipid metabolism,hsa01100:Metabolic pathways,	619735~Spastic paraplegia 86, autosomal recessive,			KW-0443~Lipid metabolism,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0890~Hereditary spastic paraplegia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,		ACT_SITE:Charge relay system,COMPBIAS:Polar residues,DOMAIN:AB hydrolase-1,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
ACTC1	actin alpha cardiac muscle 1(ACTC1)	Homo sapiens	GO:0007015~actin filament organization,GO:0010628~positive regulation of gene expression,GO:0030048~actin filament-based movement,GO:0030240~skeletal muscle thin filament assembly,GO:0031032~actomyosin structure organization,GO:0033275~actin-myosin filament sliding,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0045471~response to ethanol,GO:0055003~cardiac myofibril assembly,GO:0055008~cardiac muscle tissue morphogenesis,GO:0060047~heart contraction,GO:0060048~cardiac muscle contraction,GO:0090131~mesenchyme migration,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0005884~actin filament,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0030017~sarcomere,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0031674~I band,GO:0044297~cell body,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:0098978~glutamatergic synapse,	GO:0000146~microfilament motor activity,GO:0005524~ATP binding,GO:0016787~hydrolase activity,GO:0017022~myosin binding,	IPR004000:Actin-related protein,IPR004001:Actin, conserved site,IPR020902:Actin/actin-like conserved site,	hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa05410:Hypertrophic cardiomyopathy,hsa05414:Dilated cardiomyopathy,	612098~Cardiomyopathy, hypertrophic, 11,612794~Atrial septal defect 5,613424~Cardiomyopathy, dilated, 1R,613424~Left ventricular noncompaction 4,		SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0976~Atrial septal defect,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0558~Oxidation,KW-1017~Isopeptide bond,	CROSSLNK:Isoglutamyl lysine isopeptide (Glu-Lys) (interchain with K-52); by Vibrio toxins RtxA and VgrG1,CROSSLNK:Isoglutamyl lysine isopeptide (Lys-Glu) (interchain with E-272); by Vibrio toxins RtxA and VgrG1,
ABLIM2	actin binding LIM protein family member 2(ABLIM2)	Homo sapiens	GO:0006351~transcription, DNA-templated,GO:0030032~lamellipodium assembly,GO:0030036~actin cytoskeleton organization,	GO:0005737~cytoplasm,GO:0015629~actin cytoskeleton,	GO:0003779~actin binding,GO:0046872~metal ion binding,GO:0051015~actin filament binding,	IPR001781:Zinc finger, LIM-type,IPR003128:Villin headpiece,	hsa04360:Axon guidance,			SM00132:LIM,SM00153:VHP,		KW-0963~Cytoplasm,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AbLIM_anchor,DOMAIN:HP,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,REGION:Disordered,
ACTG2	actin gamma 2, smooth muscle(ACTG2)	Homo sapiens	GO:0010628~positive regulation of gene expression,GO:0090131~mesenchyme migration,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005869~dynactin complex,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0032982~myosin filament,GO:0044297~cell body,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0072562~blood microparticle,	GO:0005524~ATP binding,GO:0016787~hydrolase activity,	IPR004000:Actin-related protein,IPR004001:Actin, conserved site,IPR020902:Actin/actin-like conserved site,	hsa04270:Vascular smooth muscle contraction,	155310~Visceral myopathy 1,619431~Megacystis-microcolon-intestinal hypoperistalsis syndrome 5,		SM00268:ACTIN,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0558~Oxidation,KW-1017~Isopeptide bond,	CROSSLNK:Isoglutamyl lysine isopeptide (Glu-Lys) (interchain with K-51); by Vibrio toxins RtxA and VgrG1,CROSSLNK:Isoglutamyl lysine isopeptide (Lys-Glu) (interchain with E-271); by Vibrio toxins RtxA and VgrG1,MUTAGEN:I->A,D,K: Abolished methylation by SETD3.,MUTAGEN:I->L,M: Slightly decreased methylation by SETD3.,
ACTN4	actinin alpha 4(ACTN4)	Homo sapiens	GO:0001666~response to hypoxia,GO:0015031~protein transport,GO:0030036~actin cytoskeleton organization,GO:0030050~vesicle transport along actin filament,GO:0030335~positive regulation of cell migration,GO:0032417~positive regulation of sodium:proton antiporter activity,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0035357~peroxisome proliferator activated receptor signaling pathway,GO:0042981~regulation of apoptotic process,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048384~retinoic acid receptor signaling pathway,GO:0051272~positive regulation of cellular component movement,GO:0055001~muscle cell development,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1903506~regulation of nucleic acid-templated transcription,	GO:0001725~stress fiber,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0016604~nuclear body,GO:0030018~Z disc,GO:0030054~cell junction,GO:0030864~cortical actin cytoskeleton,GO:0031093~platelet alpha granule lumen,GO:0031143~pseudopodium,GO:0032991~macromolecular complex,GO:0042995~cell projection,GO:0043005~neuron projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001882~nucleoside binding,GO:0003713~transcription coactivator activity,GO:0003723~RNA binding,GO:0003779~actin binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0016922~ligand-dependent nuclear receptor binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0031490~chromatin DNA binding,GO:0042803~protein homodimerization activity,GO:0042974~retinoic acid receptor binding,GO:0044325~ion channel binding,GO:0047485~protein N-terminus binding,GO:0051015~actin filament binding,	IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR002017:Spectrin repeat,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR014837:EF-hand, Ca insensitive,IPR018159:Spectrin/alpha-actinin,IPR018247:EF-Hand 1, calcium-binding site,	hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05131:Shigellosis,hsa05146:Amoebiasis,hsa05203:Viral carcinogenesis,hsa05322:Systemic lupus erythematosus,	603278~Glomerulosclerosis, focal segmental, 1,		SM00033:CH,SM00054:EFh,SM00150:SPEC,	KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MOTIF:LXXLL motif,MUTAGEN:LL->AA: Reduced interaction with RARA. Loss of the transcriptional coac tivator activity toward RARA.,REGION:Actin-binding,REGION:Disordered,REGION:Interaction with VCL,REGION:Mediates interaction with MICALL2,REGION:Polyphosphoinositide (PIP2)-binding,REPEAT:Spectrin 1,REPEAT:Spectrin 2,REPEAT:Spectrin 3,REPEAT:Spectrin 4,
ATF3	activating transcription factor 3(ATF3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006094~gluconeogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008284~positive regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0034198~cellular response to amino acid starvation,GO:0035914~skeletal muscle cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0061394~regulation of transcription from RNA polymerase II promoter in response to arsenic-containing substance,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1903984~positive regulation of TRAIL-activated apoptotic signaling pathway,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0090575~RNA polymerase II transcription factor complex,GO:1990622~CHOP-ATF3 complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000837:Fos transforming protein,IPR004827:Basic-leucine zipper domain,				SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Leucine-zipper,
ATF6B	activating transcription factor 6 beta(ATF6B)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007165~signal transduction,GO:0030968~endoplasmic reticulum unfolded protein response,GO:0036500~ATF6-mediated unfolded protein response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1903892~negative regulation of ATF6-mediated unfolded protein response,GO:1990440~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0012505~endomembrane system,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0032993~protein-DNA complex,GO:0090575~RNA polymerase II transcription factor complex,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0035497~cAMP response element binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR004827:Basic-leucine zipper domain,	hsa04022:cGMP-PKG signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04151:PI3K-Akt signaling pathway,hsa04211:Longevity regulating pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04668:TNF signaling pathway,hsa04728:Dopaminergic synapse,hsa04911:Insulin secretion,hsa04915:Estrogen signaling pathway,hsa04918:Thyroid hormone synthesis,hsa04925:Aldosterone synthesis and secretion,hsa04926:Relaxin signaling pathway,hsa04927:Cortisol synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa04935:Growth hormone synthesis, secretion and action,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,hsa05207:Chemical carcinogenesis - receptor activation,			SM00338:BRLZ,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0010~Activator,KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BZIP,DOMAIN:bZIP,REGION:Basic motif,REGION:Disordered,REGION:Leucine-zipper,REGION:Transcription activation,SITE:Cleavage; by MBTPS1,SITE:Important for cleavage by MBTPS2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
ARC	activity regulated cytoskeleton associated protein(ARC)	Homo sapiens	GO:0006897~endocytosis,GO:0007010~cytoskeleton organization,GO:0007492~endoderm development,GO:0007612~learning,GO:0007616~long-term memory,GO:0009952~anterior/posterior pattern specification,GO:0016477~cell migration,GO:0022604~regulation of cell morphogenesis,GO:0048168~regulation of neuronal synaptic plasticity,GO:0050804~modulation of synaptic transmission,GO:0051028~mRNA transport,GO:0051260~protein homooligomerization,GO:0060291~long-term synaptic potentiation,GO:0060997~dendritic spine morphogenesis,GO:0061001~regulation of dendritic spine morphogenesis,GO:1900271~regulation of long-term synaptic potentiation,GO:1900452~regulation of long term synaptic depression,GO:2000969~positive regulation of AMPA receptor activity,	GO:0001669~acrosomal vesicle,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0031901~early endosome membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0045121~membrane raft,GO:0071598~neuronal ribonucleoprotein granule,GO:0098839~postsynaptic density membrane,GO:0098845~postsynaptic endosome,GO:0098978~glutamatergic synapse,GO:1903561~extracellular vesicle,	GO:0003729~mRNA binding,GO:0005515~protein binding,	IPR023263:Activity-regulated cytoskeleton-associated protein,	hsa05031:Amphetamine addiction,				KW-0254~Endocytosis,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with DNM2,REGION:Interaction with SH3GL1 or SH3GL3,
ACSL6	acyl-CoA synthetase long chain family member 6(ACSL6)	Homo sapiens	GO:0000038~very long-chain fatty acid metabolic process,GO:0001676~long-chain fatty acid metabolic process,GO:0006637~acyl-CoA metabolic process,GO:0007405~neuroblast proliferation,GO:0008610~lipid biosynthetic process,GO:0035338~long-chain fatty-acyl-CoA biosynthetic process,	GO:0005741~mitochondrial outer membrane,GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004467~long-chain fatty acid-CoA ligase activity,GO:0005524~ATP binding,GO:0016874~ligase activity,GO:0019899~enzyme binding,GO:0042803~protein homodimerization activity,GO:0047676~arachidonate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa00061:Fatty acid biosynthesis,hsa00071:Fatty acid degradation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04146:Peroxisome,hsa04216:Ferroptosis,hsa04714:Thermogenesis,hsa04920:Adipocytokine signaling pathway,	Myelodysplastic syndrome~Myelodysplastic syndrome,Myelogenous leukemia, acute~Myelogenous leukemia, acute,			KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0496~Mitochondrion,KW-0576~Peroxisome,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0547~Nucleotide-binding,	KW-0436~Ligase,		DOMAIN:AMP-binding,DOMAIN:AMP-binding_C,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type III membrane protein,
ACSS3	acyl-CoA synthetase short chain family member 3(ACSS3)	Homo sapiens	GO:0046951~ketone body biosynthetic process,	GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0043231~intracellular membrane-bounded organelle,	GO:0003987~acetate-CoA ligase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0047760~butyrate-CoA ligase activity,GO:0050218~propionate-CoA ligase activity,	IPR000873:AMP-dependent synthetase/ligase,IPR020845:AMP-binding, conserved site,IPR025110:Domain of unknown function DUF4009,	hsa00640:Propanoate metabolism,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,	KW-0496~Mitochondrion,		KW-0809~Transit peptide,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0436~Ligase,	KW-0007~Acetylation,	DOMAIN:ACAS_N,DOMAIN:AMP-binding,DOMAIN:AMP-binding_C,TRANSIT:Mitochondrion,
ACOT12	acyl-CoA thioesterase 12(ACOT12)	Homo sapiens	GO:0006084~acetyl-CoA metabolic process,GO:0006631~fatty acid metabolic process,GO:0006637~acyl-CoA metabolic process,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0045171~intercellular bridge,	GO:0003986~acetyl-CoA hydrolase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008289~lipid binding,GO:0036042~long-chain fatty acyl-CoA binding,GO:0042802~identical protein binding,GO:0047617~acyl-CoA hydrolase activity,GO:0052689~carboxylic ester hydrolase activity,	IPR002913:START domain,IPR006683:Thioesterase superfamily,IPR023393:START-like domain,	hsa00620:Pyruvate metabolism,hsa01100:Metabolic pathways,				KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0378~Hydrolase,KW-0719~Serine esterase,		DOMAIN:HotDog ACOT-type 1,DOMAIN:HotDog ACOT-type 2,DOMAIN:START,
ADARB2	adenosine deaminase RNA specific B2 (inactive)(ADARB2)	Homo sapiens	GO:0006382~adenosine to inosine editing,GO:0006396~RNA processing,GO:0006397~mRNA processing,	GO:0005730~nucleolus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003726~double-stranded RNA adenosine deaminase activity,GO:0003727~single-stranded RNA binding,GO:0004000~adenosine deaminase activity,GO:0008251~tRNA-specific adenosine deaminase activity,GO:0046872~metal ion binding,	IPR002466:Adenosine deaminase/editase,IPR014720:Double-stranded RNA-binding-like domain,				SM00358:DSRM,SM00552:ADEAMc,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0694~RNA-binding,		ACT_SITE:Proton donor,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:A to I editase,DOMAIN:DRBM 1,DOMAIN:DRBM 2,REGION:Disordered,REGION:R-domain (ssRNA-binding),
AK5	adenylate kinase 5(AK5)	Homo sapiens	GO:0006165~nucleoside diphosphate phosphorylation,GO:0006172~ADP biosynthetic process,GO:0006173~dADP biosynthetic process,GO:0009142~nucleoside triphosphate biosynthetic process,GO:0009220~pyrimidine ribonucleotide biosynthetic process,GO:0046034~ATP metabolic process,GO:0046940~nucleoside monophosphate phosphorylation,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0034451~centriolar satellite,	GO:0004017~adenylate kinase activity,GO:0004550~nucleoside diphosphate kinase activity,GO:0005524~ATP binding,	IPR000850:Adenylate kinase,IPR006267:Adenylate kinase, isozyme 1,IPR020618:Adenylate kinase, putative,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00230:Purine metabolism,hsa00730:Thiamine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa01240:Biosynthesis of cofactors,					KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		REGION:Adenylate kinase 1,REGION:Adenylate kinase 2,REGION:LID 1,REGION:LID 2,REGION:NMP 1,REGION:NMP 2,
ADGRA1	adhesion G protein-coupled receptor A1(ADGRA1)	Homo sapiens	GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0098978~glutamatergic synapse,	GO:0004930~G-protein coupled receptor activity,	IPR000832:GPCR, family 2, secretin-like,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADGRE1	adhesion G protein-coupled receptor E1(ADGRE1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000203:GPS domain,IPR000742:Epidermal growth factor-like domain,IPR000832:GPCR, family 2, secretin-like,IPR001740:GPCR, family 2, EMR1 hormone receptor,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,				SM00179:EGF_CA,SM00181:EGF,SM00303:GPS,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:GPS,DOMAIN:G_PROTEIN_RECEP_F2_4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADGRE4P	adhesion G protein-coupled receptor E4, pseudogene(ADGRE4P)	Homo sapiens	GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,	GO:0005576~extracellular region,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000203:GPS domain,IPR000742:Epidermal growth factor-like domain,IPR000832:GPCR, family 2, secretin-like,IPR001740:GPCR, family 2, EMR1 hormone receptor,IPR001881:EGF-like calcium-binding,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,				SM00179:EGF_CA,SM00303:GPS,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:GPS,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADGRE5	adhesion G protein-coupled receptor E5(ADGRE5)	Homo sapiens	GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0004888~transmembrane signaling receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000203:GPS domain,IPR000742:Epidermal growth factor-like domain,IPR000832:GPCR, family 2, secretin-like,IPR001881:EGF-like calcium-binding,IPR003056:GPCR, family 2, CD97 antigen,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,				SM00179:EGF_CA,SM00181:EGF,SM00303:GPS,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:GPS,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADRA2A	adrenoceptor alpha 2A(ADRA2A)	Homo sapiens	GO:0001819~positive regulation of cytokine production,GO:0002526~acute inflammatory response,GO:0006260~DNA replication,GO:0006940~regulation of smooth muscle contraction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007265~Ras protein signal transduction,GO:0007266~Rho protein signal transduction,GO:0007565~female pregnancy,GO:0008284~positive regulation of cell proliferation,GO:0010700~negative regulation of norepinephrine secretion,GO:0019229~regulation of vasoconstriction,GO:0030036~actin cytoskeleton organization,GO:0030168~platelet activation,GO:0030335~positive regulation of cell migration,GO:0032147~activation of protein kinase activity,GO:0032148~activation of protein kinase B activity,GO:0032811~negative regulation of epinephrine secretion,GO:0032870~cellular response to hormone stimulus,GO:0035624~receptor transactivation,GO:0042311~vasodilation,GO:0042593~glucose homeostasis,GO:0042596~fear response,GO:0043268~positive regulation of potassium ion transport,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0045741~positive regulation of epidermal growth factor-activated receptor activity,GO:0045955~negative regulation of calcium ion-dependent exocytosis,GO:0046676~negative regulation of insulin secretion,GO:0050892~intestinal absorption,GO:0050955~thermoception,GO:0050995~negative regulation of lipid catabolic process,GO:0051044~positive regulation of membrane protein ectodomain proteolysis,GO:0051926~negative regulation of calcium ion transport,GO:0061179~negative regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0070473~negative regulation of uterine smooth muscle contraction,GO:0071875~adrenergic receptor signaling pathway,GO:0071880~adenylate cyclase-activating adrenergic receptor signaling pathway,GO:0071881~adenylate cyclase-inhibiting adrenergic receptor signaling pathway,GO:0071882~phospholipase C-activating adrenergic receptor signaling pathway,GO:0090303~positive regulation of wound healing,GO:1901020~negative regulation of calcium ion transmembrane transporter activity,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016323~basolateral plasma membrane,GO:0043025~neuronal cell body,GO:0043235~receptor complex,GO:0043679~axon terminus,GO:0048787~presynaptic active zone membrane,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0004930~G-protein coupled receptor activity,GO:0004938~alpha2-adrenergic receptor activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0031692~alpha-1B adrenergic receptor binding,GO:0031696~alpha-2C adrenergic receptor binding,GO:0031996~thioesterase binding,GO:0032795~heterotrimeric G-protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0051379~epinephrine binding,GO:0051380~norepinephrine binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001946:Adrenergic receptor, alpha-2A,IPR002233:Adrenergic receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04022:cGMP-PKG signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,LIPID:S-palmitoyl cysteine,MUTAGEN:D->N: Lower affinity for agonists. Eliminates guanine nucleotide-sensitive agonist binding.,MUTAGEN:D->N: No binding to yohimbine. Increase in adenylate cyclase activity.,MUTAGEN:D->N: No change in binding affinity. eliminates guanine nucleotide-sensitive agonist binding.,MUTAGEN:F->N: 350-fold reduced affinity for alpha-2 antagonist yohimbine, 3000-fold increase for beta-antagonist alprenolol.,MUTAGEN:S->A: Lower affinity for agonists. No change in guanine nucleotide-sensitive agonist binding.,MUTAGEN:S->A: Lower affinity for agonists. Reduced guanine nucleotide-sensitive agonist binding.,REGION:Disordered,SITE:Implicated in catechol agonist binding and receptor activation,SITE:Implicated in ligand binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
ADM	adrenomedullin(ADM)	Homo sapiens	GO:0001570~vasculogenesis,GO:0001666~response to hypoxia,GO:0001843~neural tube closure,GO:0002026~regulation of the force of heart contraction,GO:0002031~G-protein coupled receptor internalization,GO:0003073~regulation of systemic arterial blood pressure,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007507~heart development,GO:0007565~female pregnancy,GO:0007568~aging,GO:0008209~androgen metabolic process,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009409~response to cold,GO:0009611~response to wounding,GO:0010460~positive regulation of heart rate,GO:0019731~antibacterial humoral response,GO:0019933~cAMP-mediated signaling,GO:0031100~animal organ regeneration,GO:0031102~neuron projection regeneration,GO:0031623~receptor internalization,GO:0032496~response to lipopolysaccharide,GO:0032868~response to insulin,GO:0035809~regulation of urine volume,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042594~response to starvation,GO:0043065~positive regulation of apoptotic process,GO:0043116~negative regulation of vascular permeability,GO:0045766~positive regulation of angiogenesis,GO:0045906~negative regulation of vasoconstriction,GO:0046879~hormone secretion,GO:0048589~developmental growth,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0051384~response to glucocorticoid,GO:0055074~calcium ion homeostasis,GO:0060670~branching involved in labyrinthine layer morphogenesis,GO:0060712~spongiotrophoblast layer development,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0097084~vascular smooth muscle cell development,GO:0097647~amylin receptor signaling pathway,GO:1990410~adrenomedullin receptor signaling pathway,GO:2000184~positive regulation of progesterone biosynthetic process,GO:2001214~positive regulation of vasculogenesis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0031700~adrenomedullin receptor binding,	IPR001710:Adrenomedullin,IPR021116:Procalcitonin/adrenomedullin,	hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,					KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,PEPTIDE:Adrenomedullin,PEPTIDE:Proadrenomedullin N-20 terminal peptide,PROPEP:PreproAM C-terminal fragment,REGION:Disordered,
AGER	advanced glycosylation end-product specific receptor(AGER)	Homo sapiens	GO:0001666~response to hypoxia,GO:0001774~microglial cell activation,GO:0001914~regulation of T cell mediated cytotoxicity,GO:0001934~positive regulation of protein phosphorylation,GO:0006897~endocytosis,GO:0006954~inflammatory response,GO:0007166~cell surface receptor signaling pathway,GO:0007611~learning or memory,GO:0009611~response to wounding,GO:0010255~glucose mediated signaling pathway,GO:0014002~astrocyte development,GO:0031175~neuron projection development,GO:0032693~negative regulation of interleukin-10 production,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032735~positive regulation of interleukin-12 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0042104~positive regulation of activated T cell proliferation,GO:0043507~positive regulation of JUN kinase activity,GO:0045056~transcytosis,GO:0046330~positive regulation of JNK cascade,GO:0048143~astrocyte activation,GO:0048167~regulation of synaptic plasticity,GO:0050727~regulation of inflammatory response,GO:0050930~induction of positive chemotaxis,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051101~regulation of DNA binding,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:0072657~protein localization to membrane,GO:0090647~modulation of age-related behavioral decline,GO:1900271~regulation of long-term synaptic potentiation,GO:1900272~negative regulation of long-term synaptic potentiation,GO:1900453~negative regulation of long term synaptic depression,GO:1900744~regulation of p38MAPK cascade,GO:1900745~positive regulation of p38MAPK cascade,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902961~positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process,GO:1903523~negative regulation of blood circulation,GO:1904472~positive regulation of endothelin secretion,GO:1904645~response to beta-amyloid,GO:1904646~cellular response to beta-amyloid,GO:2000439~positive regulation of monocyte extravasation,GO:2000514~regulation of CD4-positive, alpha-beta T cell activation,GO:2001200~positive regulation of dendritic cell differentiation,	GO:0001650~fibrillar center,GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0098794~postsynapse,	GO:0001540~beta-amyloid binding,GO:0004888~transmembrane signaling receptor activity,GO:0005044~scavenger receptor activity,GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0044548~S100 protein binding,GO:0044877~macromolecular complex binding,GO:0050785~advanced glycation end-product receptor activity,GO:0060090~binding, bridging,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa04613:Neutrophil extracellular trap formation,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,			SM00408:IGc2,SM00409:IG,	KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
AVIL	advillin(AVIL)	Homo sapiens	GO:0007015~actin filament organization,GO:0007399~nervous system development,GO:0008154~actin polymerization or depolymerization,GO:0010592~positive regulation of lamellipodium assembly,GO:0010976~positive regulation of neuron projection development,GO:0051014~actin filament severing,GO:0051016~barbed-end actin filament capping,GO:0060271~cilium assembly,GO:1900480~regulation of diacylglycerol biosynthetic process,	GO:0005737~cytoplasm,GO:0005884~actin filament,GO:0005925~focal adhesion,GO:0015629~actin cytoskeleton,GO:0030027~lamellipodium,GO:0030424~axon,GO:0042995~cell projection,GO:0043005~neuron projection,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0051015~actin filament binding,GO:0071933~Arp2/3 complex binding,	IPR003128:Villin headpiece,IPR007122:Villin/Gelsolin,IPR007123:Gelsolin domain,		618594~Nephrotic syndrome, type 21,		SM00153:VHP,SM00262:GEL,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,	KW-0225~Disease variant,	KW-0677~Repeat,	KW-0106~Calcium,	KW-0009~Actin-binding,KW-0117~Actin capping,	KW-0597~Phosphoprotein,	DOMAIN:Gelsolin-like,DOMAIN:HP,MUTAGEN:W->A: Reduces interaction with F-actin.,REGION:Core,REGION:Headpiece,REGION:Required for interaction with F-actin,REPEAT:Gelsolin-like 1,REPEAT:Gelsolin-like 2,REPEAT:Gelsolin-like 3,REPEAT:Gelsolin-like 4,REPEAT:Gelsolin-like 5,REPEAT:Gelsolin-like 6,
ANPEP	alanyl aminopeptidase, membrane(ANPEP)	Homo sapiens	GO:0001525~angiogenesis,GO:0006508~proteolysis,GO:0007165~signal transduction,GO:0008217~regulation of blood pressure,GO:0030154~cell differentiation,GO:0043171~peptide catabolic process,GO:0046718~viral entry into host cell,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0004177~aminopeptidase activity,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0038023~signaling receptor activity,GO:0042277~peptide binding,GO:0070006~metalloaminopeptidase activity,	IPR001930:Peptidase M1, alanine aminopeptidase/leukotriene A4 hydrolase,IPR014782:Peptidase M1, membrane alanine aminopeptidase, N-terminal,IPR024571:Domain of unknown function DUF3358,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa04614:Renin-angiotensin system,hsa04640:Hematopoietic cell lineage,				KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0217~Developmental protein,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:ERAP1_C,DOMAIN:Peptidase_M1,DOMAIN:Peptidase_M1_N,MUTAGEN:DYVEKQAS->QSVEETAQ: No change in receptor activity and HCoV-229E infection.,MUTAGEN:DYVEKQAS->QSVNEQAQ: No change in receptor activity and HCoV-229E infection.,MUTAGEN:DYVEKQAS->QSVNETAQ: Complete loss of receptor activity and blocks HCoV-229E infection. No loss of enzymatic activity.,MUTAGEN:E->N: No change of receptor activity and HCoV-229E infection.,MUTAGEN:EKQ->NKT: Complete loss of receptor activity and blocks HCoV-229E infection. No loss of enzymatic activity.,MUTAGEN:H->A: Loss of aminopeptidase activity.,MUTAGEN:N->E: Very low receptor activity and HCoV-229E infection.,MUTAGEN:Q->T: No change of receptor activity and HCoV-229E infection.,REGION:Cytosolic Ser/Thr-rich junction,REGION:Disordered,REGION:Metalloprotease,REGION:Necessary and sufficient to mediate interaction with HCoV-229E,SITE:Transition state stabilizer,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
AOX1	aldehyde oxidase 1(AOX1)	Homo sapiens	GO:0006629~lipid metabolic process,GO:0006805~xenobiotic metabolic process,GO:0017144~drug metabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004031~aldehyde oxidase activity,GO:0005506~iron ion binding,GO:0016491~oxidoreductase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043546~molybdopterin cofactor binding,GO:0046872~metal ion binding,GO:0050660~flavin adenine dinucleotide binding,GO:0051287~NAD binding,GO:0051537~2 iron, 2 sulfur cluster binding,GO:0071949~FAD binding,	IPR000674:Aldehyde oxidase/xanthine dehydrogenase, a/b hammerhead,IPR001041:2Fe-2S ferredoxin-type domain,IPR002346:Molybdopterin dehydrogenase, FAD-binding,IPR002888:[2Fe-2S]-binding,IPR005107:CO dehydrogenase flavoprotein, C-terminal,IPR006058:2Fe-2S ferredoxin, iron-sulphur binding site,IPR008274:Aldehyde oxidase/xanthine dehydrogenase, molybdopterin binding,IPR012675:Beta-grasp domain,IPR014313:Aldehyde oxidase,IPR016166:FAD-binding, type 2,IPR016167:FAD-binding, type 2, subdomain 1,IPR016169:CO dehydrogenase flavoprotein-like, FAD-binding, subdomain 2,IPR016208:Aldehyde oxidase/xanthine dehydrogenase,IPR022407:Oxidoreductase, molybdopterin binding site,	hsa00280:Valine, leucine and isoleucine degradation,hsa00350:Tyrosine metabolism,hsa00380:Tryptophan metabolism,hsa00750:Vitamin B6 metabolism,hsa00760:Nicotinate and nicotinamide metabolism,hsa00830:Retinol metabolism,hsa00982:Drug metabolism - cytochrome P450,hsa01100:Metabolic pathways,hsa04630:JAK-STAT signaling pathway,		PIRSF000127:xanthine dehydrogenase,	SM01008:SM01008,SM01092:SM01092,	KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0001~2Fe-2S,KW-0274~FAD,KW-0285~Flavoprotein,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0500~Molybdenum,	KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Proton acceptor; for azaheterocycle hydroxylase activity,DOMAIN:2Fe-2S ferredoxin-type,DOMAIN:Ald_Xan_dh_C2,DOMAIN:FAD-binding PCMH-type,MUTAGEN:C->W: Disrupts protein stability.,MUTAGEN:G->R: No effect on dimerization. Loss of oxidase activity.,
AKR1C2	aldo-keto reductase family 1 member C2(AKR1C2)	Homo sapiens	GO:0006693~prostaglandin metabolic process,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007586~digestion,GO:0008202~steroid metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0030855~epithelial cell differentiation,GO:0042448~progesterone metabolic process,GO:0044597~daunorubicin metabolic process,GO:0044598~doxorubicin metabolic process,GO:0051897~positive regulation of protein kinase B signaling,GO:0071395~cellular response to jasmonic acid stimulus,GO:0071799~cellular response to prostaglandin D stimulus,	GO:0005829~cytosol,	GO:0004032~alditol:NADP+ 1-oxidoreductase activity,GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0016229~steroid dehydrogenase activity,GO:0016655~oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor,GO:0018636~phenanthrene 9,10-monooxygenase activity,GO:0031406~carboxylic acid binding,GO:0032052~bile acid binding,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0047023~androsterone dehydrogenase activity,GO:0047026~androsterone dehydrogenase (A-specific) activity,GO:0047044~androstan-3-alpha,17-beta-diol dehydrogenase activity,GO:0047086~ketosteroid monooxygenase activity,GO:0047115~trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity,GO:0047718~indanol dehydrogenase activity,GO:0047834~D-threo-aldose 1-dehydrogenase activity,GO:0072582~17-beta-hydroxysteroid dehydrogenase (NADP+) activity,	IPR018170:Aldo/keto reductase, conserved site,IPR020471:Aldo/keto reductase subgroup,IPR023210:NADP-dependent oxidoreductase domain,	hsa00140:Steroid hormone biosynthesis,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05208:Chemical carcinogenesis - reactive oxygen species,	614279~46XY sex reversal 8,	PIRSF000097:aldo-keto reductase,		KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0521~NADP,	KW-0560~Oxidoreductase,		ACT_SITE:Proton donor,DOMAIN:Aldo_ket_red,MUTAGEN:K->A,M: Increases the low androstenedione reductase activity.,MUTAGEN:R->A: Decreases 3-alpha-hydroxysteroid reductase activity about 50-fold.,MUTAGEN:R->A: Decreases 3-alpha-hydroxysteroid reductase activity about 500-fold.,MUTAGEN:Y->A: Strongly decreases affinity for androstenedione. Decreases androstenedione reductase activity about 60-fold.,SITE:Lowers pKa of active site Tyr,
AKR1C3	aldo-keto reductase family 1 member C3(AKR1C3)	Homo sapiens	GO:0001523~retinoid metabolic process,GO:0006693~prostaglandin metabolic process,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007584~response to nutrient,GO:0008202~steroid metabolic process,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009267~cellular response to starvation,GO:0010942~positive regulation of cell death,GO:0016488~farnesol catabolic process,GO:0019371~cyclooxygenase pathway,GO:0030216~keratinocyte differentiation,GO:0034614~cellular response to reactive oxygen species,GO:0042448~progesterone metabolic process,GO:0042572~retinol metabolic process,GO:0042574~retinal metabolic process,GO:0043170~macromolecule metabolic process,GO:0044597~daunorubicin metabolic process,GO:0044598~doxorubicin metabolic process,GO:0048385~regulation of retinoic acid receptor signaling pathway,GO:0051897~positive regulation of protein kinase B signaling,GO:0061370~testosterone biosynthetic process,GO:0070293~renal absorption,GO:0071276~cellular response to cadmium ion,GO:0071277~cellular response to calcium ion,GO:0071379~cellular response to prostaglandin stimulus,GO:0071384~cellular response to corticosteroid stimulus,GO:0071395~cellular response to jasmonic acid stimulus,GO:0071799~cellular response to prostaglandin D stimulus,GO:1900053~negative regulation of retinoic acid biosynthetic process,GO:2000224~regulation of testosterone biosynthetic process,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0001758~retinal dehydrogenase activity,GO:0004032~alditol:NADP+ 1-oxidoreductase activity,GO:0004033~aldo-keto reductase (NADP) activity,GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0004745~retinol dehydrogenase activity,GO:0016229~steroid dehydrogenase activity,GO:0016655~oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor,GO:0018636~phenanthrene 9,10-monooxygenase activity,GO:0032052~bile acid binding,GO:0035410~dihydrotestosterone 17-beta-dehydrogenase activity,GO:0036130~prostaglandin H2 endoperoxidase reductase activity,GO:0036131~prostaglandin D2 11-ketoreductase activity,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0045550~geranylgeranyl reductase activity,GO:0045703~ketoreductase activity,GO:0047017~prostaglandin-F synthase activity,GO:0047020~15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity,GO:0047023~androsterone dehydrogenase activity,GO:0047024~5alpha-androstane-3beta,17beta-diol dehydrogenase activity,GO:0047035~testosterone dehydrogenase (NAD+) activity,GO:0047044~androstan-3-alpha,17-beta-diol dehydrogenase activity,GO:0047045~testosterone 17-beta-dehydrogenase (NADP+) activity,GO:0047086~ketosteroid monooxygenase activity,GO:0047787~delta4-3-oxosteroid 5beta-reductase activity,GO:0047834~D-threo-aldose 1-dehydrogenase activity,GO:0052650~NADP-retinol dehydrogenase activity,GO:0072582~17-beta-hydroxysteroid dehydrogenase (NADP+) activity,	IPR018170:Aldo/keto reductase, conserved site,IPR020471:Aldo/keto reductase subgroup,IPR023210:NADP-dependent oxidoreductase domain,	hsa00140:Steroid hormone biosynthesis,hsa00590:Arachidonic acid metabolism,hsa00790:Folate biosynthesis,hsa01100:Metabolic pathways,hsa04913:Ovarian steroidogenesis,hsa05208:Chemical carcinogenesis - reactive oxygen species,		PIRSF000097:aldo-keto reductase,		KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0520~NAD,KW-0521~NADP,	KW-0560~Oxidoreductase,		ACT_SITE:Proton donor,DOMAIN:Aldo_ket_red,MUTAGEN:K->E: No effect on 17beta-HSD activity.,MUTAGEN:R->P: Decreases in the retinaldehyde reductase activity. 3-fold decrease in the kcat value, whereas the KM value does not vary.,MUTAGEN:R->Q: Decrease in the retinaldehyde reductase activity. Exhibits changes in both KM and kcat values.,SITE:Important for substrate specificity,SITE:Involved in ligand recognition and product release,SITE:Lowers pKa of active site Tyr,
ALDOC	aldolase, fructose-bisphosphate C(ALDOC)	Homo sapiens	GO:0006000~fructose metabolic process,GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0030388~fructose 1,6-bisphosphate metabolic process,GO:0030855~epithelial cell differentiation,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004332~fructose-bisphosphate aldolase activity,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,	IPR000741:Fructose-bisphosphate aldolase, class-I,IPR013785:Aldolase-type TIM barrel,	hsa00010:Glycolysis / Gluconeogenesis,hsa00030:Pentose phosphate pathway,hsa00051:Fructose and mannose metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04066:HIF-1 signaling pathway,				KW-0324~Glycolysis,				KW-0704~Schiff base,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P,SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate,
ALPK2	alpha kinase 2(ALPK2)	Homo sapiens	GO:0003007~heart morphogenesis,GO:0003308~negative regulation of Wnt signaling pathway involved in heart development,GO:0006468~protein phosphorylation,GO:0010468~regulation of gene expression,GO:0030010~establishment of cell polarity,GO:0042981~regulation of apoptotic process,GO:0055013~cardiac muscle cell development,GO:1905223~epicardium morphogenesis,	GO:0016323~basolateral plasma membrane,	GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR004166:MHCK/EF2 kinase,IPR007110:Immunoglobulin-like domain,IPR011009:Protein kinase-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,SM00811:Alpha_kinase,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Alpha-type protein kinase,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,REGION:Disordered,
AZGP1	alpha-2-glycoprotein 1, zinc-binding(AZGP1)	Homo sapiens	GO:0001580~detection of chemical stimulus involved in sensory perception of bitter taste,GO:0001895~retina homeostasis,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,GO:0007155~cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0071806~protein transmembrane transport,GO:0090501~RNA phosphodiester bond hydrolysis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0009897~external side of plasma membrane,GO:0070062~extracellular exosome,	GO:0004540~ribonuclease activity,GO:0005515~protein binding,GO:0008320~protein transmembrane transporter activity,	IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,		KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,REGION:Disordered,
AREG	amphiregulin(AREG)	Homo sapiens	GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0010838~positive regulation of keratinocyte proliferation,GO:0014009~glial cell proliferation,GO:0031175~neuron projection development,GO:0032355~response to estradiol,GO:0038134~ERBB2-EGFR signaling pathway,GO:0042542~response to hydrogen peroxide,GO:0043434~response to peptide hormone,GO:0045668~negative regulation of osteoblast differentiation,GO:0045741~positive regulation of epidermal growth factor-activated receptor activity,GO:0051384~response to glucocorticoid,GO:0051591~response to cAMP,GO:0060598~dichotomous subdivision of terminal units involved in mammary gland duct morphogenesis,GO:0060744~mammary gland branching involved in thelarche,GO:0060749~mammary gland alveolus development,GO:0060750~epithelial cell proliferation involved in mammary gland duct elongation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005789~endoplasmic reticulum membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0005125~cytokine activity,GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0048018~receptor agonist activity,	IPR000742:Epidermal growth factor-like domain,IPR015497:Epidermal growth factor receptor ligand,	hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04390:Hippo signaling pathway,hsa05210:Colorectal cancer,					KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:EGF-like,REGION:Disordered,TRANSMEM:Helical,
ANG	angiogenin(ANG)	Homo sapiens	GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001556~oocyte maturation,GO:0001666~response to hypoxia,GO:0001878~response to yeast,GO:0001890~placenta development,GO:0001938~positive regulation of endothelial cell proliferation,GO:0006651~diacylglycerol biosynthetic process,GO:0007154~cell communication,GO:0007202~activation of phospholipase C activity,GO:0009303~rRNA transcription,GO:0009725~response to hormone,GO:0016078~tRNA catabolic process,GO:0016477~cell migration,GO:0017148~negative regulation of translation,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0030041~actin filament polymerization,GO:0032148~activation of protein kinase B activity,GO:0032431~activation of phospholipase A2 activity,GO:0042327~positive regulation of phosphorylation,GO:0042592~homeostatic process,GO:0045087~innate immune response,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050714~positive regulation of protein secretion,GO:0050830~defense response to Gram-positive bacterium,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0015629~actin cytoskeleton,GO:0030426~growth cone,GO:0031410~cytoplasmic vesicle,GO:0032311~angiogenin-PRI complex,GO:0043025~neuronal cell body,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003779~actin binding,GO:0004519~endonuclease activity,GO:0004521~endoribonuclease activity,GO:0004540~ribonuclease activity,GO:0005102~receptor binding,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0019843~rRNA binding,GO:0042277~peptide binding,GO:0042803~protein homodimerization activity,	IPR001427:Ribonuclease A,IPR023411:Ribonuclease A, active site,IPR023412:Ribonuclease A-domain,	hsa05014:Amyotrophic lateral sclerosis,	611895~Amyotrophic lateral sclerosis 9,		SM00092:RNAse_Pc,	KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0346~Stress response,	KW-0539~Nucleus,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0732~Signal,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0652~Protein synthesis inhibitor,KW-9996~Developmental protein,	KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,DOMAIN:RNAse_Pc,MOTIF:Nucleolar localization signal,MUTAGEN:D->H,S,A: 15- to 18-fold increase in RNase activity.,MUTAGEN:E->A: Slightly decreases binding affinity for RNH1.,MUTAGEN:GG->RR: Significantly decreases binding affinity for RNH1.,MUTAGEN:H->A: Significantly decreases binding affinity for RNH1.,MUTAGEN:IF->AA: 3- to 5-fold increase in RNase activity.,MUTAGEN:K->Q: Significantly decreases binding affinity for RNH1.,MUTAGEN:L->P: Homodimerization is similar to wild-type; causes mislocalization in the cytoplasm; reduces strongly ribonucleolytic activity.,MUTAGEN:N->A: Slightly decreases binding affinity for RNH1.,MUTAGEN:Q->A: Slightly decreases binding affinity for RNH1.,MUTAGEN:Q->G: Over 18-fold increase in RNase activity.,MUTAGEN:R->A: Significantly decreases binding affinity for RNH1.,
AMOT	angiomotin(AMOT)	Homo sapiens	GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0001702~gastrulation with mouth forming second,GO:0003365~establishment of cell polarity involved in ameboidal cell migration,GO:0006935~chemotaxis,GO:0007043~cell-cell junction assembly,GO:0008104~protein localization,GO:0016525~negative regulation of angiogenesis,GO:0030036~actin cytoskeleton organization,GO:0030334~regulation of cell migration,GO:0034260~negative regulation of GTPase activity,GO:0034613~cellular protein localization,GO:0035329~hippo signaling,GO:0040019~positive regulation of embryonic development,GO:0042074~cell migration involved in gastrulation,GO:0043116~negative regulation of vascular permeability,GO:0043534~blood vessel endothelial cell migration,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045793~positive regulation of cell size,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051496~positive regulation of stress fiber assembly,GO:0090162~establishment of epithelial cell polarity,	GO:0001725~stress fiber,GO:0001726~ruffle,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030139~endocytic vesicle,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,GO:0038023~signaling receptor activity,GO:0042802~identical protein binding,GO:0043532~angiostatin binding,	IPR009114:Angiomotin,IPR024646:Angiomotin, C-terminal,	hsa04390:Hippo signaling pathway,hsa04530:Tight junction,					KW-0796~Tight junction,KW-0965~Cell junction,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Angiomotin_C,MOTIF:PDZ-binding,REGION:Disordered,
ANGPT2	angiopoietin 2(ANGPT2)	Homo sapiens	GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0007165~signal transduction,GO:0007281~germ cell development,GO:0009314~response to radiation,GO:0009612~response to mechanical stimulus,GO:0009749~response to glucose,GO:0010467~gene expression,GO:0010812~negative regulation of cell-substrate adhesion,GO:0014070~response to organic cyclic compound,GO:0014823~response to activity,GO:0016525~negative regulation of angiogenesis,GO:0031100~animal organ regeneration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0048014~Tie signaling pathway,GO:0050928~negative regulation of positive chemotaxis,GO:0060135~maternal process involved in female pregnancy,GO:0071363~cellular response to growth factor stimulus,GO:0072012~glomerulus vasculature development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0042995~cell projection,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030971~receptor tyrosine kinase binding,GO:0046872~metal ion binding,	IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,IPR020837:Fibrinogen, conserved site,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa05167:Kaposi sarcoma-associated herpesvirus infection,	619369~Lymphatic malformation 10,		SM00186:FBG,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibrinogen C-terminal,
ANGPTL4	angiopoietin like 4(ANGPTL4)	Homo sapiens	GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0006629~lipid metabolic process,GO:0043066~negative regulation of apoptotic process,GO:0043335~protein unfolding,GO:0045766~positive regulation of angiogenesis,GO:0051005~negative regulation of lipoprotein lipase activity,GO:0070328~triglyceride homeostasis,GO:0072577~endothelial cell apoptotic process,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0072562~blood microparticle,	GO:0004857~enzyme inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,IPR020837:Fibrinogen, conserved site,	hsa03320:PPAR signaling pathway,hsa04979:Cholesterol metabolism,	615881~Plasma triglyceride level QTL, low,		SM00186:FBG,	KW-0037~Angiogenesis,KW-0443~Lipid metabolism,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibrinogen C-terminal,MUTAGEN:C->A: No effect on secretion and proteolytic cleavage. Loss of oligomerization; when associated with A-76.,MUTAGEN:C->A: No effect on secretion and proteolytic cleavage. Loss of oligomerization; when associated with A-80.,MUTAGEN:E->A: Loss of inactivation of lipoprotein lipase LPL.,MUTAGEN:E->D: Decreased inactivation of lipoprotein lipase LPL.,MUTAGEN:G->R: Impaired protein folding.,MUTAGEN:R->A: Loss of proteolytic cleavage.,MUTAGEN:R->A: Loss of proteolytic cleavage. Decreased ability to inactivate lipoprotein lipase LPL.,MUTAGEN:RRKR->GSGS: Loss of proteolytic cleavage. No effect on the ability to inactivate lipoprotein lipase LPL.,REGION:Disordered,SITE:Cleavage,
ANK1	ankyrin 1(ANK1)	Homo sapiens	GO:0006887~exocytosis,GO:0006888~ER to Golgi vesicle-mediated transport,GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0010638~positive regulation of organelle organization,GO:0045199~maintenance of epithelial cell apical/basal polarity,GO:0072659~protein localization to plasma membrane,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0014731~spectrin-associated cytoskeleton,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0030673~axolemma,GO:0031430~M band,GO:0042383~sarcolemma,GO:0043005~neuron projection,GO:0045211~postsynaptic membrane,	GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008093~cytoskeletal adaptor activity,GO:0019899~enzyme binding,GO:0019903~protein phosphatase binding,GO:0030507~spectrin binding,GO:0044325~ion channel binding,GO:0051117~ATPase binding,	IPR000488:Death domain,IPR000906:ZU5,IPR002110:Ankyrin repeat,IPR011029:Death-like domain,IPR020683:Ankyrin repeat-containing domain,	hsa05205:Proteoglycans in cancer,	182900~Spherocytosis, type 1,		SM00005:DEATH,SM00218:ZU5,SM00248:ANK,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0250~Elliptocytosis,KW-0360~Hereditary hemolytic anemia,	KW-0040~ANK repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Death,DOMAIN:ZU5,DOMAIN:ZU5 1,DOMAIN:ZU5 2,MUTAGEN:K->E: Abolishes interaction with OBSCN (in isoform Mu17).,MUTAGEN:R->G: Abolishes interaction with OBSCN (in isoform Mu17).,MUTAGEN:T->P: Abolishes interaction with OBSCN (in isoform Mu17).,REGION:55 kDa regulatory domain,REGION:89 kDa domain,REGION:Disordered,REGION:UPA domain,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 10,REPEAT:ANK 11,REPEAT:ANK 12,REPEAT:ANK 13,REPEAT:ANK 14,REPEAT:ANK 15,REPEAT:ANK 16,REPEAT:ANK 17,REPEAT:ANK 18,REPEAT:ANK 19,REPEAT:ANK 2,REPEAT:ANK 20,REPEAT:ANK 21,REPEAT:ANK 22,REPEAT:ANK 23,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,REPEAT:ANK 8,REPEAT:ANK 9,
ANKRD53	ankyrin repeat domain 53(ANKRD53)	Homo sapiens	GO:0007080~mitotic metaphase plate congression,GO:0031116~positive regulation of microtubule polymerization,GO:0051301~cell division,GO:0060236~regulation of mitotic spindle organization,GO:1902412~regulation of mitotic cytokinesis,	GO:0000922~spindle pole,GO:0005737~cytoplasm,GO:0005819~spindle,	GO:0005515~protein binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0040~ANK repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
ANXA1	annexin A1(ANXA1)	Homo sapiens	GO:0001780~neutrophil homeostasis,GO:0002250~adaptive immune response,GO:0002548~monocyte chemotaxis,GO:0002685~regulation of leukocyte migration,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0008360~regulation of cell shape,GO:0010165~response to X-ray,GO:0014839~myoblast migration involved in skeletal muscle regeneration,GO:0018149~peptide cross-linking,GO:0030073~insulin secretion,GO:0030216~keratinocyte differentiation,GO:0030850~prostate gland development,GO:0031018~endocrine pancreas development,GO:0031340~positive regulation of vesicle fusion,GO:0031394~positive regulation of prostaglandin biosynthetic process,GO:0031532~actin cytoskeleton reorganization,GO:0032355~response to estradiol,GO:0032508~DNA duplex unwinding,GO:0032652~regulation of interleukin-1 production,GO:0032717~negative regulation of interleukin-8 production,GO:0032743~positive regulation of interleukin-2 production,GO:0033031~positive regulation of neutrophil apoptotic process,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0042063~gliogenesis,GO:0042102~positive regulation of T cell proliferation,GO:0042119~neutrophil activation,GO:0042127~regulation of cell proliferation,GO:0042493~response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043434~response to peptide hormone,GO:0044849~estrous cycle,GO:0045087~innate immune response,GO:0045627~positive regulation of T-helper 1 cell differentiation,GO:0045629~negative regulation of T-helper 2 cell differentiation,GO:0045920~negative regulation of exocytosis,GO:0046632~alpha-beta T cell differentiation,GO:0046883~regulation of hormone secretion,GO:0050482~arachidonic acid secretion,GO:0050709~negative regulation of protein secretion,GO:0050727~regulation of inflammatory response,GO:0051179~localization,GO:0051238~sequestering of metal ion,GO:0070301~cellular response to hydrogen peroxide,GO:0070365~hepatocyte differentiation,GO:0070459~prolactin secretion,GO:0070555~response to interleukin-1,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071621~granulocyte chemotaxis,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090303~positive regulation of wound healing,GO:0097350~neutrophil clearance,GO:0098609~cell-cell adhesion,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1900138~negative regulation of phospholipase A2 activity,	GO:0001533~cornified envelope,GO:0001891~phagocytic cup,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0005929~cilium,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0019898~extrinsic component of membrane,GO:0031232~extrinsic component of external side of plasma membrane,GO:0031313~extrinsic component of endosome membrane,GO:0031514~motile cilium,GO:0031901~early endosome membrane,GO:0031966~mitochondrial membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0042383~sarcolemma,GO:0042629~mast cell granule,GO:0070062~extracellular exosome,GO:0097060~synaptic membrane,	GO:0003697~single-stranded DNA binding,GO:0003727~single-stranded RNA binding,GO:0004859~phospholipase inhibitor activity,GO:0005102~receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0005544~calcium-dependent phospholipid binding,GO:0008289~lipid binding,GO:0019834~phospholipase A2 inhibitor activity,GO:0036121~double-stranded DNA-dependent ATP-dependent DNA helicase activity,GO:0042802~identical protein binding,GO:0048306~calcium-dependent protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,GO:1990814~DNA/DNA annealing activity,	IPR001464:Annexin,IPR002388:Annexin, type I,IPR018252:Annexin repeat, conserved site,IPR018502:Annexin repeat,				SM00335:ANX,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,KW-1003~Cell membrane,		KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,KW-0479~Metal-binding,	KW-0593~Phospholipase A2 inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-?),MUTAGEN:S->A: Abolishes secretion and modulation of exocytosis.,MUTAGEN:S->A: Abolishes secretion and nearly abolishes modulation of exocytosis.,MUTAGEN:S->A: No effect on secretion and modulation of exocytosis.,PEPTIDE:Annexin Ac2-26,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,SITE:Cleavage; by CTSG,
ANXA2	annexin A2(ANXA2)	Homo sapiens	GO:0001525~angiogenesis,GO:0001765~membrane raft assembly,GO:0001921~positive regulation of receptor recycling,GO:0001934~positive regulation of protein phosphorylation,GO:0002091~negative regulation of receptor internalization,GO:0006900~membrane budding,GO:0007589~body fluid secretion,GO:0010756~positive regulation of plasminogen activation,GO:0010951~negative regulation of endopeptidase activity,GO:0030199~collagen fibril organization,GO:0031340~positive regulation of vesicle fusion,GO:0032804~negative regulation of low-density lipoprotein particle receptor catabolic process,GO:0036035~osteoclast development,GO:0042730~fibrinolysis,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0044090~positive regulation of vacuole organization,GO:0045921~positive regulation of exocytosis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048146~positive regulation of fibroblast proliferation,GO:0050767~regulation of neurogenesis,GO:0070588~calcium ion transmembrane transport,GO:0072659~protein localization to plasma membrane,GO:0097066~response to thyroid hormone,GO:0098609~cell-cell adhesion,GO:1905581~positive regulation of low-density lipoprotein particle clearance,GO:1905597~positive regulation of low-density lipoprotein particle receptor binding,GO:1905599~positive regulation of low-density lipoprotein receptor activity,GO:1905602~positive regulation of receptor-mediated endocytosis involved in cholesterol transport,GO:1905686~positive regulation of plasma membrane repair,	GO:0001533~cornified envelope,GO:0001726~ruffle,GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0005938~cell cortex,GO:0009986~cell surface,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016363~nuclear matrix,GO:0019897~extrinsic component of plasma membrane,GO:0030496~midbody,GO:0031902~late endosome membrane,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0035578~azurophil granule lumen,GO:0035749~myelin sheath adaxonal region,GO:0042383~sarcolemma,GO:0042470~melanosome,GO:0043220~Schmidt-Lanterman incisure,GO:0044354~macropinosome,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0090575~RNA polymerase II transcription factor complex,GO:0098797~plasma membrane protein complex,GO:1990665~AnxA2-p11 complex,GO:1990667~PCSK9-AnxA2 complex,	GO:0001786~phosphatidylserine binding,GO:0002020~protease binding,GO:0003723~RNA binding,GO:0004859~phospholipase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005262~calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0008092~cytoskeletal protein binding,GO:0019834~phospholipase A2 inhibitor activity,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0044548~S100 protein binding,GO:0044730~bone sialoprotein binding,GO:0046790~virion binding,GO:0048306~calcium-dependent protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR001464:Annexin,IPR002389:Annexin, type II,IPR018252:Annexin repeat, conserved site,IPR018502:Annexin repeat,	hsa05132:Salmonella infection,			SM00335:ANX,	KW-0945~Host-virus interaction,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,	KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,MUTAGEN:K->A: Strongly decreases interaction with PCSK9; when associated with 77-A--A-80.,MUTAGEN:KAYTNFDAE->SAYTNFNAS: No effect on interaction with PCSK9.,MUTAGEN:KKELA->GKPLD: No effect on interaction with PCSK9.,MUTAGEN:RDALNIETAIK->SDALNIHTAIM: Slightly decreases interaction with PCSK9.,MUTAGEN:RRTK->AATA: Decreases interaction with PCSK9. Strongly decreases interaction with PCSK9; when associated with K-88.,MUTAGEN:RRTKK->AATAA: Strongly decreases interaction with PCSK9.,MUTAGEN:S->E: Stronger interaction with S100A4.,MUTAGEN:Y->A: Abolishes heat stress-induced cell surface localization.,REGION:Disordered,REGION:S100A10-binding site,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ANXA8	annexin A8(ANXA8)	Homo sapiens	GO:0007032~endosome organization,GO:0007596~blood coagulation,GO:0016197~endosomal transport,GO:1900004~negative regulation of serine-type endopeptidase activity,GO:1900138~negative regulation of phospholipase A2 activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0031902~late endosome membrane,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0051015~actin filament binding,	IPR001464:Annexin,IPR009115:Annexin, type VIII,IPR018252:Annexin repeat, conserved site,IPR018502:Annexin repeat,				SM00335:ANX,	KW-0094~Blood coagulation,KW-0356~Hemostasis,			KW-0041~Annexin,KW-0677~Repeat,	KW-0106~Calcium,KW-0111~Calcium/phospholipid-binding,KW-0479~Metal-binding,			REGION:Disordered,REPEAT:Annexin 1,REPEAT:Annexin 2,REPEAT:Annexin 3,REPEAT:Annexin 4,
ANO3	anoctamin 3(ANO3)	Homo sapiens	GO:0016048~detection of temperature stimulus,GO:0034220~ion transmembrane transport,GO:0050982~detection of mechanical stimulus,GO:0051649~establishment of localization in cell,GO:0055085~transmembrane transport,GO:0061588~calcium activated phospholipid scrambling,GO:0061590~calcium activated phosphatidylcholine scrambling,GO:0061591~calcium activated galactosylceramide scrambling,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005229~intracellular calcium activated chloride channel activity,GO:0005254~chloride channel activity,GO:0017128~phospholipid scramblase activity,GO:0046983~protein dimerization activity,	IPR007632:Anoctamin/TMEM 16,		615034~Dystonia 24,			KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Anoct_dimer,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ANO9	anoctamin 9(ANO9)	Homo sapiens	GO:0006629~lipid metabolic process,GO:0006821~chloride transport,GO:0034220~ion transmembrane transport,GO:0051649~establishment of localization in cell,GO:0055085~transmembrane transport,GO:0061589~calcium activated phosphatidylserine scrambling,GO:0061590~calcium activated phosphatidylcholine scrambling,GO:0061591~calcium activated galactosylceramide scrambling,GO:1902476~chloride transmembrane transport,GO:1902939~negative regulation of intracellular calcium activated chloride channel activity,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005229~intracellular calcium activated chloride channel activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0017128~phospholipid scramblase activity,	IPR007632:Anoctamin/TMEM 16,					KW-0443~Lipid metabolism,KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
APOBEC3C	apolipoprotein B mRNA editing enzyme catalytic subunit 3C(APOBEC3C)	Homo sapiens	GO:0009972~cytidine deamination,GO:0010529~negative regulation of transposition,GO:0016554~cytidine to uridine editing,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045869~negative regulation of single stranded viral RNA replication via double stranded DNA intermediate,GO:0051607~defense response to virus,GO:0070383~DNA cytosine deamination,GO:0080111~DNA demethylation,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003723~RNA binding,GO:0004126~cytidine deaminase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016787~hydrolase activity,GO:0047844~deoxycytidine deaminase activity,	IPR002125:CMP/dCMP deaminase, zinc-binding,IPR016192:APOBEC/CMP deaminase, zinc-binding,IPR016193:Cytidine deaminase-like,	hsa03250:Viral life cycle - HIV-1,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,	ACT_SITE:Proton donor,DOMAIN:CMP/dCMP-type deaminase,MUTAGEN:A->K: Resistant to HIV-1 Vif.,MUTAGEN:C->K: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:E->K: Remains sensitive to HIV-1 Vif but abolishes Vif binding.,MUTAGEN:E->K: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:F->D: Resistant to HIV-1 Vif and abolishes Vif binding.,MUTAGEN:F->W: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:H->D: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:I->A: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:L->A: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:L->D: Resistant to HIV-1 Vif and abolishes Vif binding.,MUTAGEN:P->A: No effect on Vif binding.,MUTAGEN:S->P: Resistant to HIV-1 Vif and reduces Vif binding.,MUTAGEN:Y->A: Resistant to HIV-1 Vif and abolishes Vif binding.,REGION:(Microbial infection) Required for interaction with human foamy virus protein Bet,
AQP1	aquaporin 1 (Colton blood group)(AQP1)	Homo sapiens	GO:0003091~renal water homeostasis,GO:0003094~glomerular filtration,GO:0003097~renal water transport,GO:0006813~potassium ion transport,GO:0006833~water transport,GO:0006884~cell volume homeostasis,GO:0006972~hyperosmotic response,GO:0009992~cellular water homeostasis,GO:0010761~fibroblast migration,GO:0010763~positive regulation of fibroblast migration,GO:0015670~carbon dioxide transport,GO:0015696~ammonium transport,GO:0015793~glycerol transport,GO:0019233~sensory perception of pain,GO:0019725~cellular homeostasis,GO:0019934~cGMP-mediated signaling,GO:0021670~lateral ventricle development,GO:0030157~pancreatic juice secretion,GO:0030185~nitric oxide transport,GO:0030950~establishment or maintenance of actin cytoskeleton polarity,GO:0033326~cerebrospinal fluid secretion,GO:0033363~secretory granule organization,GO:0034644~cellular response to UV,GO:0035377~transepithelial water transport,GO:0035378~carbon dioxide transmembrane transport,GO:0042060~wound healing,GO:0042476~odontogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0044241~lipid digestion,GO:0045766~positive regulation of angiogenesis,GO:0046878~positive regulation of saliva secretion,GO:0048146~positive regulation of fibroblast proliferation,GO:0048593~camera-type eye morphogenesis,GO:0050829~defense response to Gram-negative bacterium,GO:0050891~multicellular organismal water homeostasis,GO:0051458~corticotropin secretion,GO:0051649~establishment of localization in cell,GO:0070295~renal water absorption,GO:0070301~cellular response to hydrogen peroxide,GO:0071241~cellular response to inorganic substance,GO:0071260~cellular response to mechanical stimulus,GO:0071280~cellular response to copper ion,GO:0071288~cellular response to mercury ion,GO:0071300~cellular response to retinoic acid,GO:0071320~cellular response to cAMP,GO:0071456~cellular response to hypoxia,GO:0071472~cellular response to salt stress,GO:0071474~cellular hyperosmotic response,GO:0071549~cellular response to dexamethasone stimulus,GO:0071732~cellular response to nitric oxide,GO:0071805~potassium ion transmembrane transport,GO:0072220~metanephric descending thin limb development,GO:0072230~metanephric proximal straight tubule development,GO:0072232~metanephric proximal convoluted tubule segment 2 development,GO:0072239~metanephric glomerulus vasculature development,GO:0072488~ammonium transmembrane transport,GO:0085018~maintenance of symbiont-containing vacuole by host,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005903~brush border,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0020003~symbiont-containing vacuole,GO:0030424~axon,GO:0031526~brush border membrane,GO:0031965~nuclear membrane,GO:0042383~sarcolemma,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,	GO:0005223~intracellular cGMP activated cation channel activity,GO:0005267~potassium channel activity,GO:0005372~water transmembrane transporter activity,GO:0005515~protein binding,GO:0008519~ammonium transmembrane transporter activity,GO:0015079~potassium ion transmembrane transporter activity,GO:0015168~glycerol transmembrane transporter activity,GO:0015250~water channel activity,GO:0015267~channel activity,GO:0022857~transmembrane transporter activity,GO:0030184~nitric oxide transmembrane transporter activity,GO:0035379~carbon dioxide transmembrane transporter activity,GO:0042802~identical protein binding,GO:0046875~ephrin receptor binding,	IPR000425:Major intrinsic protein,IPR022357:Major intrinsic protein, conserved site,IPR023271:Aquaporin-like,IPR023274:Aquaporin 1,	hsa04924:Renin secretion,hsa04964:Proximal tubule bicarbonate reclamation,hsa04976:Bile secretion,	110450~Aquaporin-1 deficiency,110450~Blood group, Colton,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0095~Blood group antigen,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,INTRAMEM:Helical; Name=Helix B,INTRAMEM:Helical; Name=Helix E,MOTIF:NPA 1,MOTIF:NPA 2,REGION:Disordered,SITE:Hg(2+)-sensitive residue,SITE:Substrate discrimination,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Helix 1,TRANSMEM:Helical; Name=Helix 2,TRANSMEM:Helical; Name=Helix 3,TRANSMEM:Helical; Name=Helix 4,TRANSMEM:Helical; Name=Helix 5,TRANSMEM:Helical; Name=Helix 6,
AQP5	aquaporin 5(AQP5)	Homo sapiens	GO:0006833~water transport,GO:0015670~carbon dioxide transport,GO:0030157~pancreatic juice secretion,GO:0042476~odontogenesis,GO:0046541~saliva secretion,GO:0048593~camera-type eye morphogenesis,GO:0051289~protein homotetramerization,GO:0055085~transmembrane transport,GO:0071476~cellular hypotonic response,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005902~microvillus,GO:0009925~basal plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0015250~water channel activity,GO:0042802~identical protein binding,	IPR000425:Major intrinsic protein,IPR022357:Major intrinsic protein, conserved site,IPR023271:Aquaporin-like,IPR023276:Aquaporin 5,	hsa04970:Salivary secretion,	600231~Palmoplantar keratoderma, Bothnian type,			KW-0813~Transport,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1007~Palmoplantar keratoderma,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,INTRAMEM:Discontinuously helical,MOTIF:NPA 1,MOTIF:NPA 2,MUTAGEN:S->A: No effect on location at the cell membrane.,MUTAGEN:S->E: Increased location at the cell membrane.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
AQP7	aquaporin 7(AQP7)	Homo sapiens	GO:0006833~water transport,GO:0015793~glycerol transport,GO:0071918~urea transmembrane transport,	GO:0005737~cytoplasm,GO:0005811~lipid particle,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0005938~cell cortex,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030659~cytoplasmic vesicle membrane,	GO:0005515~protein binding,GO:0015204~urea transmembrane transporter activity,GO:0015250~water channel activity,GO:0015254~glycerol channel activity,GO:0015267~channel activity,	IPR000425:Major intrinsic protein,IPR023271:Aquaporin-like,	hsa03320:PPAR signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,	614411~Glycerol quantitative trait locus,			KW-0813~Transport,	KW-0472~Membrane,KW-0551~Lipid droplet,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	INTRAMEM:Discontinuously helical,MOTIF:NPA 1,MOTIF:NPA 2,MUTAGEN:H->A: Decreased permeability to glycerol. Mildly decreased water permeability.,MUTAGEN:Missing: Decreased interaction with PLIN1.,MUTAGEN:Y->A: Strongly decreased permeability to glycerol. Mildly decreased water permeability.,SITE:Important for permeability to glycerol,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ALOX12B	arachidonate 12-lipoxygenase, 12R type(ALOX12B)	Homo sapiens	GO:0006497~protein lipidation,GO:0006665~sphingolipid metabolic process,GO:0010628~positive regulation of gene expression,GO:0019369~arachidonic acid metabolic process,GO:0019372~lipoxygenase pathway,GO:0034440~lipid oxidation,GO:0043410~positive regulation of MAPK cascade,GO:0043651~linoleic acid metabolic process,GO:0046513~ceramide biosynthetic process,GO:0051122~hepoxilin biosynthetic process,GO:0061436~establishment of skin barrier,GO:0070257~positive regulation of mucus secretion,	GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,	GO:0004052~arachidonate 12-lipoxygenase activity,GO:0005506~iron ion binding,GO:0016702~oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen,GO:0016829~lyase activity,GO:0016853~isomerase activity,GO:0046872~metal ion binding,GO:0047677~arachidonate 8(R)-lipoxygenase activity,GO:1990136~linoleate 9S-lipoxygenase activity,	IPR000907:Lipoxygenase,IPR001024:Lipoxygenase, LH2,IPR001885:Lipoxygenase, mammalian,IPR013819:Lipoxygenase, C-terminal,IPR020833:Lipoxygenase, iron binding site,IPR020834:Lipoxygenase, conserved site,	hsa00590:Arachidonic acid metabolism,hsa01100:Metabolic pathways,hsa04726:Serotonergic synapse,	242100~Ichthyosis, congenital, autosomal recessive 2,		SM00308:LH2,	KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0977~Ichthyosis,		KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0413~Isomerase,KW-0456~Lyase,KW-0560~Oxidoreductase,		DOMAIN:Lipoxygenase,DOMAIN:PLAT,
ALOX5AP	arachidonate 5-lipoxygenase activating protein(ALOX5AP)	Homo sapiens	GO:0002540~leukotriene production involved in inflammatory response,GO:0002675~positive regulation of acute inflammatory response,GO:0019370~leukotriene biosynthetic process,GO:0019372~lipoxygenase pathway,GO:0050790~regulation of catalytic activity,GO:0070207~protein homotrimerization,GO:0071277~cellular response to calcium ion,GO:0098869~cellular oxidant detoxification,	GO:0005635~nuclear envelope,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031965~nuclear membrane,	GO:0004051~arachidonate 5-lipoxygenase activity,GO:0004364~glutathione transferase activity,GO:0004464~leukotriene-C4 synthase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,GO:0008047~enzyme activator activity,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,GO:0047485~protein N-terminus binding,GO:0050544~arachidonic acid binding,	IPR001129:Membrane-associated, eicosanoid/glutathione metabolism (MAPEG) protein,IPR001446:5-lipoxygenase-activating protein,IPR018295:FLAP/GST2/LTC4S, conserved site,IPR023352:Membrane associated eicosanoid/glutathione metabolism-like domain,	hsa04664:Fc epsilon RI signaling pathway,	601367~Stroke, susceptibility to,			KW-0434~Leukotriene biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				MUTAGEN:A->V: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:D->A: Decreased affinity for the inhibitor MK-591.,MUTAGEN:F->A: Decreased affinity for the inhibitor MK-591.,MUTAGEN:I->A: Increased affinity for the inhibitor MK-591.,MUTAGEN:K->A: Strongly increased affinity for the inhibitor MK-591.,MUTAGEN:T->A: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:V->A: Increased affinity for the inhibitor MK-591.,MUTAGEN:V->A: Strongly decreased affinity for the inhibitor MK-591.,MUTAGEN:Y->A: Strongly decreased affinity for the inhibitor MK-591.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ARRDC5	arrestin domain containing 5(ARRDC5)	Homo sapiens	GO:0015031~protein transport,	GO:0005737~cytoplasm,	GO:0031625~ubiquitin protein ligase binding,GO:1990756~protein binding, bridging involved in substrate recognition for ubiquitination,	IPR011021:Arrestin-like, N-terminal,IPR011022:Arrestin C-terminal-like domain,IPR014752:Arrestin, C-terminal,IPR014756:Immunoglobulin E-set,				SM01017:SM01017,								DOMAIN:Arrestin_C,
ARSI	arylsulfatase family member I(ARSI)	Homo sapiens		GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,	GO:0004065~arylsulfatase activity,GO:0005515~protein binding,GO:0008484~sulfuric ester hydrolase activity,GO:0046872~metal ion binding,	IPR000917:Sulfatase,IPR017850:Alkaline-phosphatase-like, core domain,IPR024607:Sulfatase, conserved site,						KW-0256~Endoplasmic reticulum,KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0558~Oxidation,	ACT_SITE:Nucleophile,BINDING:via 3-oxoalanine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Sulfatase,MUTAGEN:C->S: No arylsulfatase activity in the media of retinal epithelium cell.,REGION:Disordered,
ARSJ	arylsulfatase family member J(ARSJ)	Homo sapiens		GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0015629~actin cytoskeleton,GO:0016021~integral component of membrane,	GO:0004065~arylsulfatase activity,GO:0008484~sulfuric ester hydrolase activity,GO:0046872~metal ion binding,	IPR000917:Sulfatase,IPR017850:Alkaline-phosphatase-like, core domain,IPR024607:Sulfatase, conserved site,						KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,	ACT_SITE:Nucleophile,BINDING:via 3-oxoalanine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Sulfatase,REGION:Disordered,TRANSMEM:Helical,
ASPM	assembly factor for spindle microtubules(ASPM)	Homo sapiens	GO:0001764~neuron migration,GO:0002052~positive regulation of neuroblast proliferation,GO:0007051~spindle organization,GO:0007283~spermatogenesis,GO:0008356~asymmetric cell division,GO:0008584~male gonad development,GO:0021873~forebrain neuroblast division,GO:0021987~cerebral cortex development,GO:0045665~negative regulation of neuron differentiation,GO:0045769~negative regulation of asymmetric cell division,GO:0048477~oogenesis,GO:0048589~developmental growth,GO:0051445~regulation of meiotic cell cycle,GO:0051653~spindle localization,GO:0051661~maintenance of centrosome location,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090306~spindle assembly involved in meiosis,GO:0097150~neuronal stem cell population maintenance,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0016324~apical plasma membrane,GO:0030496~midbody,GO:0036449~microtubule minus-end,GO:0072687~meiotic spindle,GO:0097431~mitotic spindle pole,	GO:0005516~calmodulin binding,	IPR000048:IQ motif, EF-hand binding site,IPR001715:Calponin homology domain,IPR011989:Armadillo-like helical,IPR013783:Immunoglobulin-like fold,IPR016024:Armadillo-type fold,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		608716~Microcephaly 5, primary, autosomal recessive,		SM00015:IQ,SM00033:CH,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0905~Primary microcephaly,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0112~Calmodulin-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:ASH,DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:IQ 1,DOMAIN:IQ 10,DOMAIN:IQ 11,DOMAIN:IQ 12,DOMAIN:IQ 13,DOMAIN:IQ 14,DOMAIN:IQ 15,DOMAIN:IQ 16,DOMAIN:IQ 17,DOMAIN:IQ 18,DOMAIN:IQ 19,DOMAIN:IQ 2,DOMAIN:IQ 20,DOMAIN:IQ 21,DOMAIN:IQ 22,DOMAIN:IQ 23,DOMAIN:IQ 24,DOMAIN:IQ 25,DOMAIN:IQ 26,DOMAIN:IQ 27,DOMAIN:IQ 28,DOMAIN:IQ 29,DOMAIN:IQ 3,DOMAIN:IQ 30,DOMAIN:IQ 31,DOMAIN:IQ 32,DOMAIN:IQ 33,DOMAIN:IQ 34,DOMAIN:IQ 35,DOMAIN:IQ 36,DOMAIN:IQ 37,DOMAIN:IQ 38,DOMAIN:IQ 39,DOMAIN:IQ 4,DOMAIN:IQ 5,DOMAIN:IQ 6,DOMAIN:IQ 7,DOMAIN:IQ 8,DOMAIN:IQ 9,REGION:Disordered,REGION:Sufficient for interaction with KATNA1:KATNB1,
ATOH7	atonal bHLH transcription factor 7(ATOH7)	Homo sapiens	GO:0003407~neural retina development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007623~circadian rhythm,GO:0010996~response to auditory stimulus,GO:0021554~optic nerve development,GO:0030182~neuron differentiation,GO:0043153~entrainment of circadian clock by photoperiod,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:1902336~positive regulation of retinal ganglion cell axon guidance,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0030424~axon,GO:0043204~perikaryon,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0046983~protein dimerization activity,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,		221900~Persistent hyperplastic primary vitreous, autosomal recessive,		SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0966~Cell projection,	KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DOMAIN:BHLH,DOMAIN:bHLH,MUTAGEN:A->G: Abolishes heterodimerization with TCF3 isoform E47; no effect on nuclear localization.,MUTAGEN:L->P: Loss of DNA-binding activity; loss of ability to restore retinal ganglion cell development in retinal explants from a mouse Atoh7 null mutant.,
BIRC3	baculoviral IAP repeat containing 3(BIRC3)	Homo sapiens	GO:0006915~apoptotic process,GO:0007166~cell surface receptor signaling pathway,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007283~spermatogenesis,GO:0016567~protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0034121~regulation of toll-like receptor signaling pathway,GO:0038061~NIK/NF-kappaB signaling,GO:0039535~regulation of RIG-I signaling pathway,GO:0042981~regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045088~regulation of innate immune response,GO:0050727~regulation of inflammatory response,GO:0051726~regulation of cell cycle,GO:0060544~regulation of necroptotic process,GO:0060546~negative regulation of necroptotic process,GO:0070424~regulation of nucleotide-binding oligomerization domain containing signaling pathway,GO:2000116~regulation of cysteine-type endopeptidase activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0045121~membrane raft,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0016740~transferase activity,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001315:Caspase Recruitment,IPR001370:Baculoviral inhibition of apoptosis protein repeat,IPR001841:Zinc finger, RING-type,IPR011029:Death-like domain,	hsa01524:Platinum drug resistance,hsa04064:NF-kappa B signaling pathway,hsa04120:Ubiquitin mediated proteolysis,hsa04210:Apoptosis,hsa04215:Apoptosis - multiple species,hsa04217:Necroptosis,hsa04390:Hippo signaling pathway,hsa04510:Focal adhesion,hsa04621:NOD-like receptor signaling pathway,hsa04668:TNF signaling pathway,hsa05132:Salmonella infection,hsa05145:Toxoplasmosis,hsa05168:Herpes simplex virus 1 infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05222:Small cell lung cancer,			SM00114:CARD,SM00184:RING,SM00238:BIR,	KW-0053~Apoptosis,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0832~Ubl conjugation,	DOMAIN:CARD,DOMAIN:RING-type,REPEAT:BIR 1,REPEAT:BIR 2,REPEAT:BIR 3,SITE:Breakpoint for translocation to form BIRC3-MALT1,ZN_FING:RING-type,
BSN	bassoon presynaptic cytomatrix protein(BSN)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0007416~synapse assembly,GO:0035418~protein localization to synapse,GO:0048790~maintenance of presynaptic active zone structure,GO:0097091~synaptic vesicle clustering,GO:0099526~presynapse to nucleus signaling pathway,GO:1904071~presynaptic active zone assembly,	GO:0005634~nucleus,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0030424~axon,GO:0030425~dendrite,GO:0030672~synaptic vesicle membrane,GO:0042995~cell projection,GO:0044306~neuron projection terminus,GO:0048786~presynaptic active zone,GO:0048788~cytoskeleton of presynaptic active zone,GO:0060076~excitatory synapse,GO:0098683~cochlear hair cell ribbon synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0098882~structural constituent of presynaptic active zone,	IPR008899:Zinc finger, piccolo-type,IPR011011:Zinc finger, FYVE/PHD-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,						KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0519~Myristate,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:zf-piccolo,LIPID:N-myristoyl glycine,REGION:3 X 7 AA tandem repeats of K-A-S-P-[LQ]-[APS]-[KST],REGION:5 X 2 AA tandem repeats of P-G,REGION:7 X 2 AA tandem repeats of P-G,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,ZN_FING:C4-type,
BST2	bone marrow stromal cell antigen 2(BST2)	Homo sapiens	GO:0002737~negative regulation of plasmacytoid dendritic cell cytokine production,GO:0009615~response to virus,GO:0010951~negative regulation of endopeptidase activity,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0032956~regulation of actin cytoskeleton organization,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0042113~B cell activation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0051607~defense response to virus,GO:0070665~positive regulation of leukocyte proliferation,GO:1901253~negative regulation of intracellular transport of viral material,	GO:0005737~cytoplasm,GO:0005771~multivesicular body,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031225~anchored component of membrane,GO:0035577~azurophil granule membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008191~metalloendopeptidase inhibitor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR024886:Bone marrow stromal antigen 2,	hsa03250:Viral life cycle - HIV-1,hsa05168:Herpes simplex virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,				KW-0051~Antiviral defense,KW-0075~B-cell activation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DISULFID:Interchain,LIPID:GPI-anchor amidated serine,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-63.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-53 and A-91.,MUTAGEN:C->A: Prevents homodimerization and inhibition of SARS-CoV, HCoV-229E, and HIV-1 viral particles production ex vivo; when associated with A-63 and A-91.,MUTAGEN:K->R: Abolishes redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:K->R: No effect on redistribution to late endosomes in cells expressing KSH virus E3 ubiquitin-protein ligase K5.,MUTAGEN:N->A: Loss of glycosylation site.,MUTAGEN:N->A: Loss of glycosylation site. Impairs anti-viral activity.,MUTAGEN:STS->AAA: Partial resistance to Vpu.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-6.,MUTAGEN:Y->A: Partial resistance to Vpu and significantly reduced activation of NF-kB; when associated with A-8.,PROPEP:Removed in mature form,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
BDKRB2	bradykinin receptor B2(BDKRB2)	Homo sapiens	GO:0006939~smooth muscle contraction,GO:0006954~inflammatory response,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008015~blood circulation,GO:0009612~response to mechanical stimulus,GO:0009651~response to salt stress,GO:0019229~regulation of vasoconstriction,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0042310~vasoconstriction,GO:0042311~vasodilation,GO:0043114~regulation of vascular permeability,GO:0050482~arachidonic acid secretion,GO:1902239~negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator,GO:1990127~intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator,	GO:0005768~endosome,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0002020~protease binding,GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004930~G-protein coupled receptor activity,GO:0004947~bradykinin receptor activity,GO:0005515~protein binding,GO:0031702~type 1 angiotensin receptor binding,GO:0046982~protein heterodimerization activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000496:Bradykinin receptor family,IPR001186:Bradykinin receptor B1,IPR001504:Bradykinin receptor B2,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04071:Sphingolipid signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04610:Complement and coagulation cascades,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04810:Regulation of actin cytoskeleton,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa05142:Chagas disease,hsa05200:Pathways in cancer,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
BEX5	brain expressed X-linked 5(BEX5)	Homo sapiens	GO:0007165~signal transduction,	GO:0005737~cytoplasm,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR007623:Brain-expressed X-linked protein,IPR021156:Transcription elongation factor A-like/Brain expressed X-linked-like,			PIRSF008633:brain-expressed X-linked protein,			KW-0963~Cytoplasm,					KW-0832~Ubl conjugation,	REGION:Disordered,
BCAT1	branched chain amino acid transaminase 1(BCAT1)	Homo sapiens	GO:0000082~G1/S transition of mitotic cell cycle,GO:0006629~lipid metabolic process,GO:0008652~cellular amino acid biosynthetic process,GO:0009082~branched-chain amino acid biosynthetic process,GO:0009098~leucine biosynthetic process,GO:0009099~valine biosynthetic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004084~branched-chain-amino-acid transaminase activity,GO:0042802~identical protein binding,GO:0050048~L-leucine:2-oxoglutarate aminotransferase activity,GO:0052654~L-leucine transaminase activity,GO:0052655~L-valine transaminase activity,GO:0052656~L-isoleucine transaminase activity,	IPR001544:Aminotransferase, class IV,IPR005786:Branched-chain amino acid aminotransferase II,IPR018300:Aminotransferase, class IV, conserved site,	hsa00270:Cysteine and methionine metabolism,hsa00280:Valine, leucine and isoleucine degradation,hsa00290:Valine, leucine and isoleucine biosynthesis,hsa00770:Pantothenate and CoA biosynthesis,hsa01100:Metabolic pathways,hsa01210:2-Oxocarboxylic acid metabolism,hsa01230:Biosynthesis of amino acids,hsa01240:Biosynthesis of cofactors,		PIRSF006468:branched-chain amino acid aminotransferase, BCAT1 type,		KW-0028~Amino-acid biosynthesis,KW-0100~Branched-chain amino acid biosynthesis,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,			KW-0663~Pyridoxal phosphate,	KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0007~Acetylation,
BTN2A3P	butyrophilin subfamily 2 member A3, pseudogene(BTN2A3P)	Homo sapiens	GO:0001817~regulation of cytokine production,GO:0050852~T cell receptor signaling pathway,	GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005102~receptor binding,	IPR001870:B30.2/SPRY domain,IPR003599:Immunoglobulin subtype,IPR003877:SPla/RYanodine receptor SPRY,IPR003879:Butyrophylin-like,IPR006574:SPRY-associated,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,SM00449:SPRY,SM00589:PRY,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:B30.2/SPRY,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDH22	cadherin 22(CDH22)	Homo sapiens	GO:0000902~cell morphogenesis,GO:0007043~cell-cell junction assembly,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007275~multicellular organism development,GO:0007420~brain development,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0034332~adherens junction organization,GO:0098742~cell-cell adhesion via plasma-membrane adhesion molecules,	GO:0005886~plasma membrane,GO:0005912~adherens junction,GO:0016021~integral component of membrane,GO:0016342~catenin complex,	GO:0005509~calcium ion binding,GO:0045296~cadherin binding,	IPR000233:Cadherin, cytoplasmic domain,IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,IPR027397:Catenin binding domain,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CELSR1	cadherin EGF LAG seven-pass G-type receptor 1(CELSR1)	Homo sapiens	GO:0001736~establishment of planar polarity,GO:0001764~neuron migration,GO:0001843~neural tube closure,GO:0001942~hair follicle development,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007266~Rho protein signal transduction,GO:0007417~central nervous system development,GO:0007626~locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0032956~regulation of actin cytoskeleton organization,GO:0042060~wound healing,GO:0042249~establishment of planar polarity of embryonic epithelium,GO:0042472~inner ear morphogenesis,GO:0045176~apical protein localization,GO:0048105~establishment of body hair planar orientation,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060488~orthogonal dichotomous subdivision of terminal units involved in lung branching morphogenesis,GO:0060489~planar dichotomous subdivision of terminal units involved in lung branching morphogenesis,GO:0060490~lateral sprouting involved in lung morphogenesis,GO:0090179~planar cell polarity pathway involved in neural tube closure,GO:0090251~protein localization involved in establishment of planar polarity,GO:0098609~cell-cell adhesion,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000203:GPS domain,IPR000742:Epidermal growth factor-like domain,IPR000832:GPCR, family 2, secretin-like,IPR001791:Laminin G domain,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR002126:Cadherin,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR015919:Cadherin-like,IPR017981:GPCR, family 2-like,IPR020894:Cadherin conserved site,		619319~Lymphatic malformation 9,		SM00008:HormR,SM00112:CA,SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00282:LamG,SM00303:GPS,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin 7,DOMAIN:Cadherin 8,DOMAIN:Cadherin 9,DOMAIN:EGF-like,DOMAIN:EGF-like 1; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:GPS,DOMAIN:G_PROTEIN_RECEP_F2_3,DOMAIN:G_PROTEIN_RECEP_F2_4,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin EGF-like,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CDHR1	cadherin related family member 1(CDHR1)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0008594~photoreceptor cell morphogenesis,GO:0035845~photoreceptor cell outer segment organization,GO:0045494~photoreceptor cell maintenance,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0042622~photoreceptor outer segment membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,		613660~Cone-rod dystrophy 15,613660~Retinitis pigmentosa 65,		SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0182~Cone-rod dystrophy,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CABP1	calcium binding protein 1(CABP1)	Homo sapiens	GO:0007601~visual perception,GO:0042308~negative regulation of protein import into nucleus,GO:0043086~negative regulation of catalytic activity,GO:0050896~response to stimulus,GO:1901385~regulation of voltage-gated calcium channel activity,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0014069~postsynaptic density,GO:0048471~perinuclear region of cytoplasm,	GO:0004857~enzyme inhibitor activity,GO:0005246~calcium channel regulator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008139~nuclear localization sequence binding,GO:0048306~calcium-dependent protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0716~Sensory transduction,KW-0844~Vision,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:D->A: Loss of binding to ITPRs; when associated with A-238; A-240; A-315; A-317 and A-354.,MUTAGEN:D->A: Loss of binding to ITPRs; when associated with A-238; A-240; A-317; A-352 and A-354.,MUTAGEN:D->A: Loss of magnesium-binding.,MUTAGEN:D->A: Loss of magnesium-binding. Loss of binding to ITPRs; when associated with A-238; A-315; A-317; A-352 and A-354.,MUTAGEN:D->A: Loss of magnesium-binding. Loss of binding to ITPRs; when associated with A-240; A-315; A-317; A-352 and A-354.,MUTAGEN:D->A: No effect on magnesium-binding.,MUTAGEN:N->A: Loss of binding to ITPRs; when associated with A-238; A-240; A-315; A-317 and A-352.,MUTAGEN:N->A: Loss of binding to ITPRs; when associated with A-238; A-240; A-315; A-352 and A-354.,MUTAGEN:S->A: Loss of phosphorylation and loss of calcium release by InsP(3).,REGION:Disordered,
CACNA2D2	calcium voltage-gated channel auxiliary subunit alpha2delta 2(CACNA2D2)	Homo sapiens	GO:0034765~regulation of ion transmembrane transport,GO:0070588~calcium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0016021~integral component of membrane,	GO:0005244~voltage-gated ion channel activity,GO:0005245~voltage-gated calcium channel activity,GO:0005262~calcium channel activity,GO:0046872~metal ion binding,	IPR002035:von Willebrand factor, type A,IPR013608:VWA N-terminal,IPR013680:Voltage-dependent calcium channel, alpha-2/delta subunit, conserved region,	hsa04010:MAPK signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04921:Oxytocin signaling pathway,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	618501~Cerebellar atrophy with seizures and variable developmental delay,		SM00327:VWA,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DISULFID:Interchain (between alpha-2-2 and delta-2 chains),DOMAIN:Cache,DOMAIN:VWFA,MOTIF:MIDAS-like motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CACNA1B	calcium voltage-gated channel subunit alpha1 B(CACNA1B)	Homo sapiens	GO:0006816~calcium ion transport,GO:0007268~chemical synaptic transmission,GO:0034765~regulation of ion transmembrane transport,GO:0050804~modulation of synaptic transmission,GO:0070509~calcium ion import,GO:0098703~calcium ion import across plasma membrane,GO:1904645~response to beta-amyloid,	GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0001540~beta-amyloid binding,GO:0005245~voltage-gated calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0008331~high voltage-gated calcium channel activity,	IPR002048:EF-hand domain,IPR002077:Voltage-dependent calcium channel, alpha-1 subunit,IPR005447:Voltage-dependent calcium channel, N-type, alpha-1 subunit,IPR005821:Ion transport domain,IPR014873:Voltage-dependent calcium channel, alpha-1 subunit, IQ domain,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04721:Synaptic vesicle cycle,hsa04723:Retrograde endocannabinoid signaling,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04930:Type II diabetes mellitus,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,hsa05207:Chemical carcinogenesis - receptor activation,	618497~Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements,		SM01062:SM01062,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:EF-hand,DOMAIN:GPHH,DOMAIN:Ion_trans,REGION:Binding to the beta subunit,REGION:Disordered,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=S1 of repeat I,TRANSMEM:Helical; Name=S1 of repeat II,TRANSMEM:Helical; Name=S1 of repeat III,TRANSMEM:Helical; Name=S1 of repeat IV,TRANSMEM:Helical; Name=S2 of repeat I,TRANSMEM:Helical; Name=S2 of repeat II,TRANSMEM:Helical; Name=S2 of repeat III,TRANSMEM:Helical; Name=S2 of repeat IV,TRANSMEM:Helical; Name=S3 of repeat I,TRANSMEM:Helical; Name=S3 of repeat II,TRANSMEM:Helical; Name=S3 of repeat III,TRANSMEM:Helical; Name=S3 of repeat IV,TRANSMEM:Helical; Name=S4 of repeat I,TRANSMEM:Helical; Name=S4 of repeat II,TRANSMEM:Helical; Name=S4 of repeat III,TRANSMEM:Helical; Name=S4 of repeat IV,TRANSMEM:Helical; Name=S5 of repeat I,TRANSMEM:Helical; Name=S5 of repeat II,TRANSMEM:Helical; Name=S5 of repeat III,TRANSMEM:Helical; Name=S5 of repeat IV,TRANSMEM:Helical; Name=S6 of repeat I,TRANSMEM:Helical; Name=S6 of repeat II,TRANSMEM:Helical; Name=S6 of repeat III,TRANSMEM:Helical; Name=S6 of repeat IV,
CACNA1I	calcium voltage-gated channel subunit alpha1 I(CACNA1I)	Homo sapiens	GO:0007165~signal transduction,GO:0019228~neuronal action potential,GO:0030317~flagellated sperm motility,GO:0030431~sleep,GO:0034765~regulation of ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0045956~positive regulation of calcium ion-dependent exocytosis,GO:0070509~calcium ion import,GO:0070588~calcium ion transmembrane transport,GO:0086010~membrane depolarization during action potential,	GO:0001518~voltage-gated sodium channel complex,GO:0005886~plasma membrane,GO:0005891~voltage-gated calcium channel complex,GO:0043005~neuron projection,	GO:0005245~voltage-gated calcium channel activity,GO:0005248~voltage-gated sodium channel activity,GO:0005515~protein binding,GO:0008332~low voltage-gated calcium channel activity,	IPR002077:Voltage-dependent calcium channel, alpha-1 subunit,IPR005445:Voltage-dependent calcium channel, T-type, alpha-1 subunit,IPR005821:Ion transport domain,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04010:MAPK signaling pathway,hsa04020:Calcium signaling pathway,hsa04713:Circadian entrainment,hsa04925:Aldosterone synthesis and secretion,hsa04927:Cortisol synthesis and secretion,hsa04929:GnRH secretion,hsa04934:Cushing syndrome,				KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,SITE:Calcium ion selectivity and permeability,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=S1 of repeat I,TRANSMEM:Helical; Name=S1 of repeat II,TRANSMEM:Helical; Name=S1 of repeat III,TRANSMEM:Helical; Name=S1 of repeat IV,TRANSMEM:Helical; Name=S2 of repeat I,TRANSMEM:Helical; Name=S2 of repeat II,TRANSMEM:Helical; Name=S2 of repeat III,TRANSMEM:Helical; Name=S2 of repeat IV,TRANSMEM:Helical; Name=S3 of repeat I,TRANSMEM:Helical; Name=S3 of repeat II,TRANSMEM:Helical; Name=S3 of repeat III,TRANSMEM:Helical; Name=S3 of repeat IV,TRANSMEM:Helical; Name=S4 of repeat I,TRANSMEM:Helical; Name=S4 of repeat II,TRANSMEM:Helical; Name=S4 of repeat III,TRANSMEM:Helical; Name=S4 of repeat IV,TRANSMEM:Helical; Name=S5 of repeat I,TRANSMEM:Helical; Name=S5 of repeat II,TRANSMEM:Helical; Name=S5 of repeat III,TRANSMEM:Helical; Name=S5 of repeat IV,TRANSMEM:Helical; Name=S6 of repeat I,TRANSMEM:Helical; Name=S6 of repeat II,TRANSMEM:Helical; Name=S6 of repeat III,TRANSMEM:Helical; Name=S6 of repeat IV,
CAMK2N2	calcium/calmodulin dependent protein kinase II inhibitor 2(CAMK2N2)	Homo sapiens	GO:0006469~negative regulation of protein kinase activity,	GO:0005654~nucleoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0045202~synapse,	GO:0008427~calcium-dependent protein kinase inhibitor activity,GO:0019901~protein kinase binding,	IPR026779:Calcium/calmodulin-dependent protein kinase II inhibitor,						KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,				KW-0649~Protein kinase inhibitor,		REGION:Disordered,REGION:Inhibitory domain,
CAMK4	calcium/calmodulin dependent protein kinase IV(CAMK4)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006468~protein phosphorylation,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007616~long-term memory,GO:0018105~peptidyl-serine phosphorylation,GO:0033081~regulation of T cell differentiation in thymus,GO:0035556~intracellular signal transduction,GO:0043011~myeloid dendritic cell differentiation,GO:0045670~regulation of osteoclast differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046777~protein autophosphorylation,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0070062~extracellular exosome,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0004672~protein kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0009931~calcium-dependent protein serine/threonine kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04211:Longevity regulating pathway,hsa04371:Apelin signaling pathway,hsa04380:Osteoclast differentiation,hsa04720:Long-term potentiation,hsa04722:Neurotrophin signaling pathway,hsa04725:Cholinergic synapse,hsa04921:Oxytocin signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05214:Glioma,			SM00220:S_TKc,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-1064~Adaptive immunity,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:O-linked (GlcNAc) serine,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Basic and acidic residues,DOMAIN:Protein kinase,MUTAGEN:FN->DD: Fully active Ca2+/CaM-independent kinase; when associated with 309-A--A-312. Loss of interaction with PPP2CA/PPP2CB.,MUTAGEN:HMDT->DEDD: Fully active Ca2+/CaM-independent kinase; when associated with 320-A-A-321.,MUTAGEN:K->E: Loss of activity; dominant negative form.,MUTAGEN:S->A: Increases phosphorylation of CREB1 2-fold. Decreases total O-linked glycosylation 2-fold. Increases ATP-binding affinity.,MUTAGEN:S->A: Loss of activity.,MUTAGEN:T->A: Loss of activation by CaMKK1 or CaMKK2.,MUTAGEN:TS->AA: Loss of phosphorylation of CREB1.,REGION:Autoinhibitory domain,REGION:Calmodulin-binding,REGION:Disordered,REGION:PP2A-binding,
CAMKK1	calcium/calmodulin dependent protein kinase kinase 1(CAMKK1)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0035556~intracellular signal transduction,GO:0045860~positive regulation of protein kinase activity,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004683~calmodulin-dependent protein kinase activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa05034:Alcoholism,			SM00220:S_TKc,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0112~Calmodulin-binding,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,REGION:Autoinhibitory domain,REGION:Calmodulin-binding,REGION:Disordered,REGION:RP domain,
CALY	calcyon neuron specific vesicular protein(CALY)	Homo sapiens	GO:0007212~dopamine receptor signaling pathway,GO:0008089~anterograde axonal transport,GO:0016197~endosomal transport,GO:0045807~positive regulation of endocytosis,GO:0048268~clathrin coat assembly,GO:0098884~postsynaptic neurotransmitter receptor internalization,GO:1905445~positive regulation of clathrin coat assembly,GO:2001019~positive regulation of retrograde axon cargo transport,	GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0098843~postsynaptic endocytic zone,GO:0098978~glutamatergic synapse,GO:1904115~axon cytoplasm,	GO:0005515~protein binding,GO:0032051~clathrin light chain binding,GO:0044877~macromolecular complex binding,	IPR009431:Calcyon neuron-specific vesicular protein,	hsa04728:Dopaminergic synapse,		PIRSF002383:neuron specific protein/calcyon,		KW-0254~Endocytosis,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CALD1	caldesmon 1(CALD1)	Homo sapiens	GO:0001525~angiogenesis,GO:0006936~muscle contraction,GO:0051017~actin filament bundle assembly,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0015629~actin cytoskeleton,GO:0030016~myofibril,GO:0030478~actin cap,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005523~tropomyosin binding,GO:0017022~myosin binding,GO:0045296~cadherin binding,	IPR006017:Caldesmon,IPR006018:Caldesmon/lymphocyte specific protein,	hsa04270:Vascular smooth muscle contraction,					KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0514~Muscle protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:3 X 14 AA tandem repeats of E-E-E-K-R-A-A-E-E-R-Q-R-I-K,REGION:Calmodulin-binding,REGION:Disordered,REGION:Myosin and calmodulin-binding,REGION:Strong actin-binding,REGION:Tropomyosin-binding,REGION:Weak actin-binding,REPEAT:1,REPEAT:2,REPEAT:3,
CALN1	calneuron 1(CALN1)	Homo sapiens		GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0032588~trans-Golgi network membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR001751:S100/Calbindin-D9k, conserved site,IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,		KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,			COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
CHST1	carbohydrate sulfotransferase 1(CHST1)	Homo sapiens	GO:0005976~polysaccharide metabolic process,GO:0006012~galactose metabolic process,GO:0006044~N-acetylglucosamine metabolic process,GO:0006790~sulfur compound metabolic process,GO:0006954~inflammatory response,GO:0018146~keratan sulfate biosynthetic process,GO:0042339~keratan sulfate metabolic process,	GO:0000139~Golgi membrane,GO:0005802~trans-Golgi network,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0001517~N-acetylglucosamine 6-O-sulfotransferase activity,GO:0005515~protein binding,GO:0008146~sulfotransferase activity,GO:0045130~keratan sulfotransferase activity,	IPR000863:Sulfotransferase domain,IPR016469:Carbohydrate sulfotransferase,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00533:Glycosaminoglycan biosynthesis - keratan sulfate,		PIRSF005883:carbohydrate sulfotransferase,		KW-0119~Carbohydrate metabolism,KW-0395~Inflammatory response,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MOTIF:Cell attachment site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
CA10	carbonic anhydrase 10(CA10)	Homo sapiens	GO:0006730~one-carbon metabolic process,GO:0007420~brain development,		GO:0004089~carbonate dehydratase activity,GO:0008270~zinc ion binding,GO:0016836~hydro-lyase activity,	IPR001148:Alpha carbonic anhydrase,IPR018423:Carbonic anhydrase-related protein, CA-X,IPR023561:Carbonic anhydrase, alpha-class,				SM01057:SM01057,				KW-0732~Signal,				DOMAIN:Alpha-carbonic anhydrase,REGION:Disordered,
CA3	carbonic anhydrase 3(CA3)	Homo sapiens	GO:0006730~one-carbon metabolic process,GO:0006979~response to oxidative stress,GO:0009617~response to bacterium,GO:0045471~response to ethanol,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004089~carbonate dehydratase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016151~nickel cation binding,GO:0016791~phosphatase activity,GO:0016836~hydro-lyase activity,	IPR001148:Alpha carbonic anhydrase,IPR018338:Carbonic anhydrase, alpha-class, conserved site,IPR018441:Carbonic anhydrase, CA-III,IPR023561:Carbonic anhydrase, alpha-class,	hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,			SM01057:SM01057,		KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0456~Lyase,	KW-0007~Acetylation,KW-0318~Glutathionylation,KW-0597~Phosphoprotein,	DOMAIN:Alpha-carbonic anhydrase,MUTAGEN:F->L: Enhanced activity by at least 10-fold.,MUTAGEN:K->H: Enhanced proton transfer in catalysis.,MUTAGEN:R->H: Enhanced proton transfer in catalysis.,REGION:Involved in proton transfer,
CA4	carbonic anhydrase 4(CA4)	Homo sapiens	GO:0006730~one-carbon metabolic process,GO:0015701~bicarbonate transport,	GO:0005791~rough endoplasmic reticulum,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030658~transport vesicle membrane,GO:0030667~secretory granule membrane,GO:0031225~anchored component of membrane,GO:0031362~anchored component of external side of plasma membrane,GO:0031526~brush border membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004089~carbonate dehydratase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016836~hydro-lyase activity,	IPR001148:Alpha carbonic anhydrase,IPR018338:Carbonic anhydrase, alpha-class, conserved site,IPR018343:Carbonic anhydrase, CA-IV,IPR023561:Carbonic anhydrase, alpha-class,	hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,hsa04964:Proximal tubule bicarbonate reclamation,			SM01057:SM01057,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0456~Lyase,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,DOMAIN:Alpha-carbonic anhydrase,LIPID:GPI-anchor amidated serine,MUTAGEN:S->F: Loss of C-terminal domain removal and abolishes carbonate dehydratase activity.,PROPEP:Removed in mature form,TRANSMEM:Helical,
CA9	carbonic anhydrase 9(CA9)	Homo sapiens	GO:0001666~response to hypoxia,GO:0002009~morphogenesis of an epithelium,GO:0006730~one-carbon metabolic process,GO:0009410~response to xenobiotic stimulus,GO:0033574~response to testosterone,GO:0042493~response to drug,GO:0046903~secretion,	GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0031528~microvillus membrane,	GO:0004089~carbonate dehydratase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016836~hydro-lyase activity,	IPR001148:Alpha carbonic anhydrase,IPR018338:Carbonic anhydrase, alpha-class, conserved site,IPR018429:Carbonic anhydrase, CA-IX,IPR023561:Carbonic anhydrase, alpha-class,	hsa00910:Nitrogen metabolism,hsa01100:Metabolic pathways,			SM01057:SM01057,		KW-0472~Membrane,KW-0539~Nucleus,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0456~Lyase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GlcNAc...) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:Alpha-carbonic anhydrase,REGION:Catalytic,REGION:Disordered,REGION:Proteoglycan-like (PG),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CPA6	carboxypeptidase A6(CPA6)	Homo sapiens	GO:0006508~proteolysis,	GO:0005615~extracellular space,	GO:0004181~metallocarboxypeptidase activity,GO:0008270~zinc ion binding,	IPR000834:Peptidase M14, carboxypeptidase A,IPR003146:Proteinase inhibitor, carboxypeptidase propeptide,		614417~Epilepsy, familial temporal lobe, 5,614418~Febrile seizures, familial, 11,		SM00631:Zn_pept,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Proton donor/acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,PROPEP:Activation peptide,
CPE	carboxypeptidase E(CPE)	Homo sapiens	GO:0003214~cardiac left ventricle morphogenesis,GO:0006464~cellular protein modification process,GO:0006518~peptide metabolic process,GO:0007218~neuropeptide signaling pathway,GO:0016055~Wnt signaling pathway,GO:0016485~protein processing,GO:0030070~insulin processing,GO:0030072~peptide hormone secretion,GO:0033366~protein localization to secretory granule,GO:0036211~protein modification process,GO:0072657~protein localization to membrane,	GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0030658~transport vesicle membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,	GO:0004180~carboxypeptidase activity,GO:0004181~metallocarboxypeptidase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042043~neurexin family protein binding,GO:0050839~cell adhesion molecule binding,	IPR000834:Peptidase M14, carboxypeptidase A,IPR008969:Carboxypeptidase-like, regulatory domain,	hsa04940:Type I diabetes mellitus,	619326~BDV syndrome,		SM00631:Zn_pept,		KW-0472~Membrane,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0550~Obesity,KW-0991~Intellectual disability,KW-1016~Hypogonadotropic hypogonadism,	KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0121~Carboxypeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,	ACT_SITE:Proton donor/acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase_M14,PROPEP:Activation peptide,
CMYA5	cardiomyopathy associated 5(CMYA5)	Homo sapiens		GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016529~sarcoplasmic reticulum,GO:0016607~nuclear speck,GO:0031430~M band,GO:0043231~intracellular membrane-bounded organelle,GO:0048471~perinuclear region of cytoplasm,		IPR001870:B30.2/SPRY domain,IPR003961:Fibronectin, type III,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,		KW-0539~Nucleus,KW-0703~Sarcoplasmic reticulum,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:B30.2/SPRY,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,REGION:Amphipathic helix H1,REGION:Amphipathic helix H2,REGION:Amphipathic helix H3,REGION:B-box coiled-coil; BBC,REGION:Disordered,REGION:Required for RYR2 clustering,
CLCF1	cardiotrophin like cytokine factor 1(CLCF1)	Homo sapiens	GO:0002639~positive regulation of immunoglobulin production,GO:0007166~cell surface receptor signaling pathway,GO:0007259~JAK-STAT cascade,GO:0008284~positive regulation of cell proliferation,GO:0019221~cytokine-mediated signaling pathway,GO:0030183~B cell differentiation,GO:0030890~positive regulation of B cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043524~negative regulation of neuron apoptotic process,GO:0048295~positive regulation of isotype switching to IgE isotypes,GO:0048711~positive regulation of astrocyte differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0097058~CRLF-CLCF1 complex,GO:0097059~CNTFR-CLCF1 complex,	GO:0005102~receptor binding,GO:0005125~cytokine activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR009079:Four-helical cytokine-like, core,IPR010681:Plethodontid receptivity factor PRF,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,	610313~Cold-induced sweating syndrome 2,				KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,
CRTAC1	cartilage acidic protein 1(CRTAC1)	Homo sapiens	GO:0007413~axonal fasciculation,	GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,	IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011519:ASPIC/UnbV,IPR013517:FG-GAP repeat,IPR018097:EGF-like calcium-binding, conserved site,IPR027039:Cartilage acidic protein 1,				SM00179:EGF_CA,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF_CA,DOMAIN:UnbV_ASPIC,REGION:Disordered,REPEAT:FG-GAP 1; atypical,REPEAT:FG-GAP 2; atypical,REPEAT:FG-GAP 3; atypical,REPEAT:FG-GAP 4; atypical,
CILP	cartilage intermediate layer protein(CILP)	Homo sapiens	GO:0010629~negative regulation of gene expression,GO:0016311~dephosphorylation,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0043569~negative regulation of insulin-like growth factor receptor signaling pathway,GO:0060392~negative regulation of SMAD protein import into nucleus,GO:0071560~cellular response to transforming growth factor beta stimulus,	GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,	IPR000884:Thrombospondin, type 1 repeat,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR008969:Carboxypeptidase-like, regulatory domain,IPR013783:Immunoglobulin-like fold,IPR025155:WxxW domain,		603932~Lumbar disc disease, susceptibility to,		SM00209:TSP1,SM00408:IGc2,SM00409:IG,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like C2-type,DOMAIN:TSP type-1,REGION:Disordered,
CASP1	caspase 1(CASP1)	Homo sapiens	GO:0001666~response to hypoxia,GO:0002221~pattern recognition receptor signaling pathway,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0007231~osmosensory signaling pathway,GO:0010506~regulation of autophagy,GO:0016540~protein autoprocessing,GO:0032730~positive regulation of interleukin-1 alpha production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0033198~response to ATP,GO:0042981~regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0046456~icosanoid biosynthetic process,GO:0050727~regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0051607~defense response to virus,GO:0051882~mitochondrial depolarization,GO:0060081~membrane hyperpolarization,GO:0070269~pyroptosis,GO:0071222~cellular response to lipopolysaccharide,GO:0071260~cellular response to mechanical stimulus,GO:0071310~cellular response to organic substance,GO:0071346~cellular response to interferon-gamma,GO:0097190~apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:0097300~programmed necrotic cell death,GO:1901998~toxin transport,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0061702~inflammasome complex,GO:0072557~IPAF inflammasome complex,GO:0072558~NLRP1 inflammasome complex,GO:0072559~NLRP3 inflammasome complex,GO:0097169~AIM2 inflammasome complex,GO:0097179~protease inhibitor complex,	GO:0004175~endopeptidase activity,GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0050700~CARD domain binding,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001315:Caspase Recruitment,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04217:Necroptosis,hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa05014:Amyotrophic lateral sclerosis,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05164:Influenza A,hsa05171:Coronavirus disease - COVID-19,hsa05417:Lipid and atherosclerosis,			SM00114:CARD,SM00115:CASc,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-0865~Zymogen,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:CARD,DOMAIN:CASPASE_P10,DOMAIN:CASPASE_P20,MUTAGEN:C->A,S: Loss of protease activity. Loss of SPHK2 cleavage and release in apoptotic cells.,MUTAGEN:D->N: In IDL(uncl); abolished cleavage in the interdomain region; when associated with 315-N-N-316.,MUTAGEN:DD->NN: In IDL(uncl); abolished cleavage in the interdomain region; when associated with N-297.,MUTAGEN:I->N: Mediates autoprocessing but is unable to interact with Gasdermin-D (GSDMD) and mediate its cleavage.,MUTAGEN:K->A: Abolishes cleavage of Gasdermin-D (GSDMD).,MUTAGEN:W->A: Mediates autoprocessing but is unable to interact with Gasdermin-D (GSDMD) and mediate its cleavage.,PROPEP:Interdomain linker,
CASP4	caspase 4(CASP4)	Homo sapiens	GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0016540~protein autoprocessing,GO:0042981~regulation of apoptotic process,GO:0045087~innate immune response,GO:0050727~regulation of inflammatory response,GO:0050729~positive regulation of inflammatory response,GO:0050830~defense response to Gram-positive bacterium,GO:0070059~intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070269~pyroptosis,GO:0097193~intrinsic apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:1904646~cellular response to beta-amyloid,GO:2000494~positive regulation of interleukin-18-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0072557~IPAF inflammasome complex,GO:0072559~NLRP3 inflammasome complex,GO:0097169~AIM2 inflammasome complex,	GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0050700~CARD domain binding,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001315:Caspase Recruitment,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04613:Neutrophil extracellular trap formation,hsa04621:NOD-like receptor signaling pathway,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,			SM00114:CARD,SM00115:CASc,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-1210~Necrosis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1271~Inflammasome,				KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0865~Zymogen,	DOMAIN:CARD,DOMAIN:CASPASE_P10,MUTAGEN:C->A: Loss of enzymatic activity. Loss of LPS-induced pyroptosis. No effect on the interaction with LPS. Decrease in cell death induced by TMEM214 overexpression. Does not support IL1B and IL18 secretion following UVB irradiation.,MUTAGEN:C->S: Loss of autocatalysis.,MUTAGEN:D->A: Abolished autoprocessing and ability to form a heterotetramer composed of Caspase-4 subunit p10 and Caspase-4 subunit p20, preventing ability to cleave GSDMD and induce pyroptosis.,MUTAGEN:R->A: Abolished ability to cleave Gasdermin-D (GSDMD).,MUTAGEN:V->N: Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.,MUTAGEN:W->L,N: Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.,REGION:Disordered,REGION:Required for LPS-binding,SITE:Cleavage; by autolysis,
CASP5	caspase 5(CASP5)	Homo sapiens	GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0021762~substantia nigra development,GO:0042981~regulation of apoptotic process,GO:0050727~regulation of inflammatory response,GO:0071260~cellular response to mechanical stimulus,GO:0097190~apoptotic signaling pathway,GO:0097194~execution phase of apoptosis,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0072558~NLRP1 inflammasome complex,	GO:0004197~cysteine-type endopeptidase activity,GO:0005515~protein binding,GO:0008234~cysteine-type peptidase activity,GO:0097199~cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	IPR001309:Peptidase C14, ICE, catalytic subunit p20,IPR001315:Caspase Recruitment,IPR002138:Peptidase C14, caspase non-catalytic subunit p10,IPR002398:Peptidase C14, caspase precursor p45,IPR011029:Death-like domain,IPR015917:Peptidase C14, caspase precursor p45, core,IPR016129:Peptidase C14, ICE, catalytic subunit p20, active site,	hsa04621:NOD-like receptor signaling pathway,hsa05132:Salmonella infection,			SM00114:CARD,SM00115:CASc,	KW-0053~Apoptosis,					KW-0378~Hydrolase,KW-0645~Protease,KW-0788~Thiol protease,	KW-0865~Zymogen,	DOMAIN:CARD,DOMAIN:CASPASE_P10,DOMAIN:CASPASE_P20,MUTAGEN:C->A: Abolishes protease activity.,
CARD16	caspase recruitment domain family member 16(CARD16)	Homo sapiens	GO:0010804~negative regulation of tumor necrosis factor-mediated signaling pathway,GO:0031665~negative regulation of lipopolysaccharide-mediated signaling pathway,GO:0032091~negative regulation of protein binding,GO:0032691~negative regulation of interleukin-1 beta production,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0071222~cellular response to lipopolysaccharide,GO:0071456~cellular response to hypoxia,GO:0071494~cellular response to UV-C,GO:0097340~inhibition of cysteine-type endopeptidase activity,	GO:0032991~macromolecular complex,GO:0097179~protease inhibitor complex,	GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0050700~CARD domain binding,GO:0089720~caspase binding,	IPR001315:Caspase Recruitment,IPR011029:Death-like domain,	hsa04621:NOD-like receptor signaling pathway,			SM00114:CARD,						KW-0646~Protease inhibitor,KW-0789~Thiol protease inhibitor,		DOMAIN:CARD,
CAV1	caveolin 1(CAV1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000165~MAPK cascade,GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001666~response to hypoxia,GO:0001935~endothelial cell proliferation,GO:0001937~negative regulation of endothelial cell proliferation,GO:0001960~negative regulation of cytokine-mediated signaling pathway,GO:0002067~glandular epithelial cell differentiation,GO:0002931~response to ischemia,GO:0003057~regulation of the force of heart contraction by chemical signal,GO:0006641~triglyceride metabolic process,GO:0006809~nitric oxide biosynthetic process,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006940~regulation of smooth muscle contraction,GO:0007260~tyrosine phosphorylation of STAT protein,GO:0007519~skeletal muscle tissue development,GO:0007595~lactation,GO:0008104~protein localization,GO:0009267~cellular response to starvation,GO:0009617~response to bacterium,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0010608~posttranscriptional regulation of gene expression,GO:0010628~positive regulation of gene expression,GO:0010875~positive regulation of cholesterol efflux,GO:0010952~positive regulation of peptidase activity,GO:0015031~protein transport,GO:0016050~vesicle organization,GO:0019065~receptor-mediated endocytosis of virus by host cell,GO:0019217~regulation of fatty acid metabolic process,GO:0019221~cytokine-mediated signaling pathway,GO:0019915~lipid storage,GO:0030154~cell differentiation,GO:0030193~regulation of blood coagulation,GO:0030301~cholesterol transport,GO:0030335~positive regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0030857~negative regulation of epithelial cell differentiation,GO:0030879~mammary gland development,GO:0031295~T cell costimulation,GO:0031397~negative regulation of protein ubiquitination,GO:0031398~positive regulation of protein ubiquitination,GO:0031623~receptor internalization,GO:0032091~negative regulation of protein binding,GO:0032092~positive regulation of protein binding,GO:0032507~maintenance of protein location in cell,GO:0032570~response to progesterone,GO:0033137~negative regulation of peptidyl-serine phosphorylation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033484~nitric oxide homeostasis,GO:0034141~positive regulation of toll-like receptor 3 signaling pathway,GO:0038016~insulin receptor internalization,GO:0042310~vasoconstriction,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0042632~cholesterol homeostasis,GO:0043085~positive regulation of catalytic activity,GO:0043407~negative regulation of MAP kinase activity,GO:0043409~negative regulation of MAPK cascade,GO:0043627~response to estrogen,GO:0044860~protein localization to plasma membrane raft,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0045907~positive regulation of vasoconstriction,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046716~muscle cell cellular homeostasis,GO:0048144~fibroblast proliferation,GO:0048147~negative regulation of fibroblast proliferation,GO:0048550~negative regulation of pinocytosis,GO:0051001~negative regulation of nitric-oxide synthase activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051592~response to calcium ion,GO:0051649~establishment of localization in cell,GO:0051899~membrane depolarization,GO:0052547~regulation of peptidase activity,GO:0055074~calcium ion homeostasis,GO:0060056~mammary gland involution,GO:0060355~positive regulation of cell adhesion molecule production,GO:0060546~negative regulation of necroptotic process,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0070836~caveola assembly,GO:0071360~cellular response to exogenous dsRNA,GO:0071375~cellular response to peptide hormone stimulus,GO:0071455~cellular response to hyperoxia,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0071711~basement membrane organization,GO:0072584~caveolin-mediated endocytosis,GO:0086091~regulation of heart rate by cardiac conduction,GO:0086098~angiotensin-activated signaling pathway involved in heart process,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097190~apoptotic signaling pathway,GO:0098903~regulation of membrane repolarization during action potential,GO:0098909~regulation of cardiac muscle cell action potential involved in regulation of contraction,GO:0098911~regulation of ventricular cardiac muscle cell action potential,GO:1900027~regulation of ruffle assembly,GO:1900085~negative regulation of peptidyl-tyrosine autophosphorylation,GO:1901380~negative regulation of potassium ion transmembrane transport,GO:1901844~regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1903071~positive regulation of ER-associated ubiquitin-dependent protein catabolic process,GO:1903361~protein localization to basolateral plasma membrane,GO:1903598~positive regulation of gap junction assembly,GO:1903609~negative regulation of inward rectifier potassium channel activity,GO:2000286~receptor internalization involved in canonical Wnt signaling pathway,GO:2000535~regulation of entry of bacterium into host cell,GO:2000811~negative regulation of anoikis,GO:2001238~positive regulation of extrinsic apoptotic signaling pathway,GO:2001244~positive regulation of intrinsic apoptotic signaling pathway,	GO:0000139~Golgi membrane,GO:0002080~acrosomal membrane,GO:0002095~caveolar macromolecular signaling complex,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005811~lipid particle,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0005925~focal adhesion,GO:0005929~cilium,GO:0005938~cell cortex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030666~endocytic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0031901~early endosome membrane,GO:0032991~macromolecular complex,GO:0042383~sarcolemma,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,	GO:0005102~receptor binding,GO:0005113~patched binding,GO:0005515~protein binding,GO:0015485~cholesterol binding,GO:0016504~peptidase activator activity,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0030674~protein binding, bridging,GO:0031267~small GTPase binding,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0044877~macromolecular complex binding,GO:0046982~protein heterodimerization activity,GO:0050998~nitric-oxide synthase binding,GO:0051117~ATPase binding,GO:0060090~binding, bridging,GO:0070320~inward rectifier potassium channel inhibitor activity,	IPR001612:Caveolin,IPR015504:Caveolin-1,IPR018361:Caveolin, conserved site,	hsa04144:Endocytosis,hsa04510:Focal adhesion,hsa05020:Prion disease,hsa05100:Bacterial invasion of epithelial cells,hsa05205:Proteoglycans in cancer,hsa05416:Viral myocarditis,hsa05418:Fluid shear stress and atherosclerosis,	606721~Lipodystrophy, familial partial, type 7,612526~Lipodystrophy, congenital generalized, type 3,615343~Pulmonary hypertension, primary, 3,			KW-0945~Host-virus interaction,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-1022~Congenital generalized lipodystrophy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,INTRAMEM:Helical,LIPID:S-palmitoyl cysteine,REGION:Disordered,REGION:Interaction with CAVIN3,REGION:Interacts with SPRY1, SPRY2, SPRY3 and SPRY4,REGION:Interacts with SPRY1, SPRY2, and SPRY4,REGION:Required for homooligomerization,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
CADM2	cell adhesion molecule 2(CADM2)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007420~brain development,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0032809~neuronal cell body membrane,GO:0045202~synapse,		IPR003585:Neurexin/syndecan/glycophorin C,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,				SM00294:4.1m,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CDC20	cell division cycle 20(CDC20)	Homo sapiens	GO:0007064~mitotic sister chromatid cohesion,GO:0007094~mitotic spindle assembly checkpoint,GO:0007346~regulation of mitotic cell cycle,GO:0007399~nervous system development,GO:0008284~positive regulation of cell proliferation,GO:0016567~protein ubiquitination,GO:0030154~cell differentiation,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031915~positive regulation of synaptic plasticity,GO:0040020~regulation of meiotic nuclear division,GO:0050773~regulation of dendrite development,GO:0051301~cell division,GO:0051444~negative regulation of ubiquitin-protein transferase activity,GO:0051445~regulation of meiotic cell cycle,GO:0090129~positive regulation of synapse maturation,GO:0090307~mitotic spindle assembly,GO:1904668~positive regulation of ubiquitin protein ligase activity,GO:1905786~positive regulation of anaphase-promoting complex-dependent catabolic process,	GO:0000922~spindle pole,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0033597~mitotic checkpoint complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0010997~anaphase-promoting complex binding,GO:0019899~enzyme binding,GO:0042826~histone deacetylase binding,GO:1990757~ubiquitin ligase activator activity,	IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR024977:Anaphase-promoting complex subunit 4, WD40 domain,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04120:Ubiquitin mediated proteolysis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05203:Viral carcinogenesis,			SM00320:WD40,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0498~Mitosis,KW-0524~Neurogenesis,KW-0833~Ubl conjugation pathway,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0853~WD repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:K->R: Does not affect its ability to bind the APC/C complex; when associated with R-485.,MUTAGEN:K->R: Does not affect its ability to bind the APC/C complex; when associated with R-490.,MUTAGEN:R->A: Loss of interaction with MAD2L1.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-72; A-153; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-92; A-153; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-157 and A-161.,MUTAGEN:S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-72; A-92; A-153; A-157 and A-161.,MUTAGEN:T->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-153 and A-161.,REGION:Disordered,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
CDC25C	cell division cycle 25C(CDC25C)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006470~protein dephosphorylation,GO:0007049~cell cycle,GO:0007088~regulation of mitotic nuclear division,GO:0007283~spermatogenesis,GO:0008283~cell proliferation,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0051301~cell division,GO:1902751~positive regulation of cell cycle G2/M phase transition,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005758~mitochondrial intermembrane space,GO:0005829~cytosol,GO:0016607~nuclear speck,GO:0048471~perinuclear region of cytoplasm,	GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0050699~WW domain binding,	IPR000751:M-phase inducer phosphatase,IPR001763:Rhodanese-like domain,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04914:Progesterone-mediated oocyte maturation,hsa05170:Human immunodeficiency virus 1 infection,hsa05206:MicroRNAs in cancer,			SM00450:RHOD,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Rhodanese,MUTAGEN:E->K: Partial loss of HIV-1 Vpr binding.,MUTAGEN:K->E: No effect on HIV-1 Vpr binding.,MUTAGEN:KKK->AAA: No effect on interaction with MARK3.,MUTAGEN:L->A: Abolishes interaction with MARK3. Reduces phosphorylation of S-216 by MARK3.,MUTAGEN:L->A: Reduces phosphorylation by MARK3 and CHEK1.,MUTAGEN:S->A: Facilitates nuclear exclusion.,MUTAGEN:S->A: No effect on interaction with MARK3. Abolishes phosphorylation by MARK3.,MUTAGEN:S->D: Mimicks phosphorylation state, leading to enhanced accumulation in the nucleus.,MUTAGEN:S->V: Loss of phosphorylation. Severely impairs PLK1-binding.,MUTAGEN:T->A: Loss of phosphorylation. Severely impairs PLK1-binding.,REGION:Disordered,REGION:HIV-1 Vpr binding site,
CDC45	cell division cycle 45(CDC45)	Homo sapiens	GO:0000076~DNA replication checkpoint,GO:0000727~double-strand break repair via break-induced replication,GO:0006268~DNA unwinding involved in DNA replication,GO:0006270~DNA replication initiation,GO:0007049~cell cycle,GO:0031938~regulation of chromatin silencing at telomere,GO:1902977~mitotic DNA replication preinitiation complex assembly,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0031261~DNA replication preinitiation complex,GO:0036064~ciliary basal body,GO:0071162~CMG complex,	GO:0003682~chromatin binding,GO:0003688~DNA replication origin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,	IPR003874:CDC45 family,	hsa04110:Cell cycle,	617063~Meier-Gorlin syndrome 7,			KW-0131~Cell cycle,KW-0235~DNA replication,	KW-0158~Chromosome,KW-0539~Nucleus,	KW-0225~Disease variant,KW-0242~Dwarfism,				KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,
CDCA2	cell division cycle associated 2(CDCA2)	Homo sapiens	GO:0007049~cell cycle,GO:0007059~chromosome segregation,GO:0007088~regulation of mitotic nuclear division,GO:0035307~positive regulation of protein dephosphorylation,GO:0051301~cell division,GO:0051983~regulation of chromosome segregation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,							KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:PP1-binding,MUTAGEN:VTF->ATA: Abolishes interaction with PPP1CC but not subcellular location.,REGION:Disordered,
CDCA8	cell division cycle associated 8(CDCA8)	Homo sapiens	GO:0000070~mitotic sister chromatid segregation,GO:0000278~mitotic cell cycle,GO:0000281~mitotic cytokinesis,GO:0001934~positive regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0007052~mitotic spindle organization,GO:0007080~mitotic metaphase plate congression,GO:0051256~mitotic spindle midzone assembly,GO:0051276~chromosome organization,GO:0051301~cell division,GO:0090267~positive regulation of mitotic cell cycle spindle assembly checkpoint,GO:1901970~positive regulation of mitotic sister chromatid separation,GO:1902425~positive regulation of attachment of mitotic spindle microtubules to kinetochore,GO:1903490~positive regulation of mitotic cytokinesis,	GO:0000775~chromosome, centromeric region,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005829~cytosol,GO:0010369~chromocenter,GO:0015630~microtubule cytoskeleton,GO:0030496~midbody,GO:0032133~chromosome passenger complex,GO:0032991~macromolecular complex,GO:0045171~intercellular bridge,GO:0051233~spindle midzone,	GO:0005515~protein binding,	IPR018851:Borealin-like, N-terminal,IPR018867:Cell division protein borealin,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MUTAGEN:F->E: Loss of binding to BIRC5; when associated with E-70.,MUTAGEN:K->E: Loss of localization to the central spindle and midbody in anaphase or cytokinesis; when associated with E-17 and E-19.,MUTAGEN:K->R: Fails to exhibit normal localization to the nucleolus in interphase depleted cells.,MUTAGEN:L->Y: Loss of binding to INCENP; when associated with E-35.,MUTAGEN:R->E: Loss of binding to INCENP; when associated with Y-46.,MUTAGEN:R->E: Loss of localization to the central spindle and midbody in anaphase or cytokinesis; when associated with E-17 and E-20.,MUTAGEN:R->E: Loss of localization to the central spindle and midbody in anaphase or cytokinesis; when associated with E-19 and E-20.,MUTAGEN:S->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-171, A-185, A-189, A-199 and A-204.,MUTAGEN:S->A: Results in reduction but not abolition of phosphorylation.,MUTAGEN:S->D,K: No effect on the structure.,MUTAGEN:T->A: Decrease in AURKB activity and almost no phosphorylation by TTK; when associated with A-88; A-169 and A-230.,MUTAGEN:T->A: Decrease in AURKB activity and almost no phosphorylation by TTK; when associated with A-88; A-94 and A-230.,MUTAGEN:T->A: Decrease in AURKB activity and almost no phosphorylation by TTK; when associated with A-94; A-169 and A-230.,MUTAGEN:T->A: Decrease in AURKB activity and dimer disruption. Decrease in AURKB activity and almost no phosphorylation by TTK; when associated with A-88; A-94 and A-230.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-171, A-185, A-189, A-199 and A-219.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-171, A-185, A-189, A-204, A-219.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-171, A-185, A-199, A-204 and A-219.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-171, A-189, A-199, A-204 and A-219.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-106, A-185, A-189, A-199, A-204 and A-219.,MUTAGEN:T->A: Decreases interaction with SOG1 and SOG2, abolishes localization to centromeres in prometaphase; when associated with A-171, A-185, A-189, A-199, A-204 and A-219.,MUTAGEN:T->D,K: Substantial loss of structure.,MUTAGEN:T->V: Decrease in AURKB activity and no effect on the structure.,MUTAGEN:W->E: Loss of binding to BIRC5; when associated with E-74.,REGION:Disordered,REGION:Required for centromere localization,REGION:Required for interaction with INCENP,REGION:Required for interaction with INCENP and BIRC5,REGION:Required for interaction with SENP3,REGION:Required to form a minimal CPC core complex that localizes to the central spindle and midbody and properly executes the role of the CPC during cytokinesis,
CREG2	cellular repressor of E1A stimulated genes 2(CREG2)	Homo sapiens		GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,		IPR012349:FMN-binding split barrel,IPR014631:Cellular repressor of E1A-stimulated genes (CREG),			PIRSF036911:cellular repressor of E1A-stimulated protein,			KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:NN->QQ: Abolishes N-glycosylation.,
CENPA	centromere protein A(CENPA)	Homo sapiens	GO:0000132~establishment of mitotic spindle orientation,GO:0000281~mitotic cytokinesis,GO:0034080~CENP-A containing nucleosome assembly,GO:0051382~kinetochore assembly,GO:0061644~protein localization to CENP-A containing chromatin,GO:0071459~protein localization to chromosome, centromeric region,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000779~condensed chromosome, centromeric region,GO:0000786~nucleosome,GO:0000939~condensed chromosome inner kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005829~cytosol,GO:0043505~CENP-A containing nucleosome,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0030527~structural constituent of chromatin,GO:0046982~protein heterodimerization activity,	IPR000164:Histone H3,IPR007125:Histone core,IPR009072:Histone-fold,				SM00428:H3,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0544~Nucleosome core,KW-0995~Kinetochore,				KW-0238~DNA-binding,	KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Histone,MUTAGEN:H->G: Reduces location at centromeres. Abolishes location at centromeres; when associated with C-112.,MUTAGEN:L->C: No effect on location at centromeres. Abolishes location at centromeres; when associated with G-104.,MUTAGEN:RG->AA: Impairs retention at centromeres, but not targeting to centromeres.,MUTAGEN:S->A: Impaired mitotic chromosome congression and chromosome segregation; when associated with A-17.,MUTAGEN:S->A: Impaired mitotic chromosome congression and chromosome segregation; when associated with A-19.,MUTAGEN:S->A: Induces a delay at the terminal stage of cytokinesis and chromosome misalignment during mitosis due to a defect in kinetochore attachment to microtubules.,MUTAGEN:S->A: No effect on interaction with HJURP. Impairs localization at centromeres.,MUTAGEN:S->E,Q: Impairs interaction with HJURP, association with chromatin and localization at centromeres.,REGION:CATD,REGION:Disordered,REGION:Important for flexibility of DNA ends that protrude from nucleosomes,
CENPE	centromere protein E(CENPE)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0007018~microtubule-based movement,GO:0007052~mitotic spindle organization,GO:0007059~chromosome segregation,GO:0007079~mitotic chromosome movement towards spindle pole,GO:0007080~mitotic metaphase plate congression,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0045860~positive regulation of protein kinase activity,GO:0051301~cell division,GO:0051310~metaphase plate congression,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051382~kinetochore assembly,GO:0099606~microtubule plus-end directed mitotic chromosome migration,GO:0099607~lateral attachment of mitotic spindle microtubules to kinetochore,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000779~condensed chromosome, centromeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0030496~midbody,GO:0043231~intracellular membrane-bounded organelle,GO:0045171~intercellular bridge,GO:0051233~spindle midzone,GO:0072686~mitotic spindle,GO:1990023~mitotic spindle midzone,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0043515~kinetochore binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		616051~Microcephaly 13, primary, autosomal recessive,		SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0225~Disease variant,KW-0905~Primary microcephaly,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0505~Motor protein,KW-9996~Developmental protein,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Kinesin motor,LIPID:S-farnesyl cysteine,PROPEP:Removed in mature form,REGION:Disordered,REGION:Globular autoinhibitory domain,REGION:Kinetochore-binding domain,
CENPF	centromere protein F(CENPF)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0001822~kidney development,GO:0007059~chromosome segregation,GO:0007094~mitotic spindle assembly checkpoint,GO:0007517~muscle organ development,GO:0009410~response to xenobiotic stimulus,GO:0010389~regulation of G2/M transition of mitotic cell cycle,GO:0015031~protein transport,GO:0016202~regulation of striated muscle tissue development,GO:0021591~ventricular system development,GO:0030154~cell differentiation,GO:0042493~response to drug,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051301~cell division,GO:0051310~metaphase plate congression,GO:0051382~kinetochore assembly,GO:0071897~DNA biosynthetic process,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0000785~chromatin,GO:0000922~spindle pole,GO:0000940~condensed chromosome outer kinetochore,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005930~axoneme,GO:0016363~nuclear matrix,GO:0030496~midbody,GO:0036064~ciliary basal body,GO:0045120~pronucleus,GO:0048471~perinuclear region of cytoplasm,GO:0097539~ciliary transition fiber,	GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0008022~protein C-terminus binding,GO:0042803~protein homodimerization activity,GO:0070840~dynein complex binding,	IPR018302:Centromere protein Cenp-F, Rb protein-binding domain,IPR018463:Centromere protein Cenp-F, N-terminal,IPR019513:Centromere protein Cenp-F, leucine-rich repeat-containing domain,		243605~Stromme syndrome,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,KW-0237~DNA synthesis,KW-0498~Mitosis,KW-0517~Myogenesis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,	KW-0990~Primary ciliary dyskinesia,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0677~Repeat,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0636~Prenylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,LIPID:S-farnesyl cysteine,MOTIF:Nuclear localization signal,PROPEP:Removed in mature form,REGION:2 X 177 AA tandem repeats,REGION:Disordered,REGION:Interaction with NDE1 and NDEL1,REGION:Interaction with SNAP25 and required for localization to the cytoplasm,REGION:Sufficient for centromere localization,REGION:Sufficient for nuclear localization,REGION:Sufficient for self-association,REPEAT:1,REPEAT:2,
CENPU	centromere protein U(CENPU)	Homo sapiens	GO:0043009~chordate embryonic development,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0034451~centriolar satellite,	GO:0005515~protein binding,	IPR025214:CENP-A nucleosome associated complex subunit CENP-U,					KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0137~Centromere,KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,		KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),MOTIF:Nuclear localization signal,MUTAGEN:S->A: Insensitive to PLK1-induced degradation.,MUTAGEN:T->A: Insensitive to PLK1-induced degradation.,MUTAGEN:T->D: Failed to enhance the PLK1-dependent degradation.,MUTAGEN:T->E: Failed to enhance the PLK1-dependent degradation.,REGION:Disordered,
CEP55	centrosomal protein 55(CEP55)	Homo sapiens	GO:0000281~mitotic cytokinesis,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0045184~establishment of protein localization,GO:1904888~cranial skeletal system development,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005814~centriole,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0034451~centriolar satellite,GO:0045171~intercellular bridge,GO:0090543~Flemming body,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR022008:TSG101 and ALIX binding domain of CEP55,		236500~Multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly,			KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:EABR,MUTAGEN:D->A: Diminishes interaction with PDCD6IP.,MUTAGEN:E->A: Abolishes interaction with PDCD6IP.,MUTAGEN:R->A: Abolishes interaction with PDCD6IP.,MUTAGEN:S->A: No effect on phosphorylation in mitotic cells.,MUTAGEN:S->A: No effect on phosphorylation in mitotic cells. Arrests mitotic cells at the midbody stage; when associated with A-425 and A-428.,MUTAGEN:S->A: Partial loss of phosphorylation in mitotic cells. Complete loss of phosphorylation in mitotic cells; when associated with A-425. Remains associated with the centrosome throughout mitosis; when associated with A-425. Arrests mitotic cells at the midbody stage; when associated with A-425 and A-436.,MUTAGEN:S->A: Partial loss of phosphorylation in mitotic cells. Complete loss of phosphorylation in mitotic cells; when associated with A-428. Remains associated with the centrosome throughout mitosis; when associated with A-428. Arrests mitotic cells at the midbody stage; when associated with A-428 and A-436.,MUTAGEN:W->A: Abolishes interaction with PDCD6IP.,MUTAGEN:Y->A: Abolishes interaction with PDCD6IP.,REGION:Disordered,REGION:Interaction with PDCD6IP,REGION:Interaction with TSG101,REGION:Required for localization to the interphase centrosome and to the midbody during cytokinesis,
CBLN1	cerebellin 1 precursor(CBLN1)	Homo sapiens	GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007268~chemical synaptic transmission,GO:0007399~nervous system development,GO:0007416~synapse assembly,GO:0009306~protein secretion,GO:0021707~cerebellar granule cell differentiation,GO:0050808~synapse organization,GO:0051649~establishment of localization in cell,GO:0051965~positive regulation of synapse assembly,GO:0090394~negative regulation of excitatory postsynaptic potential,GO:0099558~maintenance of synapse structure,GO:1900454~positive regulation of long term synaptic depression,GO:1905606~regulation of presynapse assembly,GO:1905703~negative regulation of inhibitory synapse assembly,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0043083~synaptic cleft,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098688~parallel fiber to Purkinje cell synapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001073:Complement C1q protein,IPR008983:Tumour necrosis factor-like domain,				SM00110:C1Q,		KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0730~Sialic acid,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:C1q,MUTAGEN:C->S: Abolishes hexamer formation; when associated with S-34. Abolishes interaction with NRXN1 isoform 3B; when associated with S-34. Abolishes GRID2 interaction.; when associated with S-34.,MUTAGEN:C->S: Abolishes hexamer formation; when associated with S-38. Abolishes interaction with NRXN1; when associated with S-38. Abolishes GRID2 interaction; when associated with S-38.,MUTAGEN:D->A: Abolishes GRID2 interaction.; when associated with A-122 and A-124.,MUTAGEN:R->A: Abolishes GRID2 interaction.; when associated with A-122 and A-147.,MUTAGEN:Y->A: Abolishes GRID2 interaction.; when associated with A-124 and A-147.,PEPTIDE:Cerebellin,PEPTIDE:[des-Ser1]-cerebellin,REGION:Essential for interaction with GRID2,REGION:Essential for interaction with NRXN1 and linker of two C1q trimers into disulfide-linked hexamers,REGION:Necessary for interaction with CBLN3, and homotrimerization,
CP	ceruloplasmin(CP)	Homo sapiens	GO:0006811~ion transport,GO:0006825~copper ion transport,GO:0006826~iron ion transport,GO:0006879~cellular iron ion homeostasis,GO:0055072~iron ion homeostasis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0004322~ferroxidase activity,GO:0005507~copper ion binding,GO:0016491~oxidoreductase activity,GO:0051087~chaperone binding,	IPR001117:Multicopper oxidase, type 1,IPR002355:Multicopper oxidase, copper-binding site,IPR008972:Cupredoxin,IPR011706:Multicopper oxidase, type 2,IPR011707:Multicopper oxidase, type 3,	hsa00860:Porphyrin metabolism,hsa04216:Ferroptosis,	604290~Cerebellar ataxia,604290~Hemosiderosis, systemic, due to aceruloplasminemia,604290~Hypoceruloplasminemia, hereditary,			KW-0187~Copper transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	BINDING:type 1 copper site,BINDING:type 2 copper site,BINDING:type 3 copper site,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:F5/8 type A 1,DOMAIN:F5/8 type A 2,DOMAIN:F5/8 type A 3,DOMAIN:Plastocyanin-like,DOMAIN:Plastocyanin-like 1,DOMAIN:Plastocyanin-like 2,DOMAIN:Plastocyanin-like 3,DOMAIN:Plastocyanin-like 4,DOMAIN:Plastocyanin-like 5,DOMAIN:Plastocyanin-like 6,
CHI3L1	chitinase 3 like 1(CHI3L1)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0006032~chitin catabolic process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0007250~activation of NF-kappaB-inducing kinase activity,GO:0009612~response to mechanical stimulus,GO:0010800~positive regulation of peptidyl-threonine phosphorylation,GO:0030324~lung development,GO:0032757~positive regulation of interleukin-8 production,GO:0034612~response to tumor necrosis factor,GO:0045766~positive regulation of angiogenesis,GO:0051216~cartilage development,GO:0051897~positive regulation of protein kinase B signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070555~response to interleukin-1,GO:0070741~response to interleukin-6,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0031012~extracellular matrix,GO:0035580~specific granule lumen,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008061~chitin binding,GO:0030246~carbohydrate binding,	IPR001223:Glycoside hydrolase, family 18, catalytic domain,IPR011583:Chitinase II,IPR017853:Glycoside hydrolase, superfamily,		181500~Schizophrenia, susceptibility to,611960~Asthma-related traits, susceptibility to, 7,		SM00636:Glyco_18,	KW-0053~Apoptosis,KW-0395~Inflammatory response,	KW-0256~Endoplasmic reticulum,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-1058~Asthma,KW-1211~Schizophrenia,	KW-0732~Signal,	KW-0430~Lectin,	KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GH18,REGION:Important for AKT1 activation and IL8 production,
CHI3L2	chitinase 3 like 2(CHI3L2)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0006032~chitin catabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0008061~chitin binding,GO:0016787~hydrolase activity,GO:0030246~carbohydrate binding,	IPR000677:2S globulin,IPR001223:Glycoside hydrolase, family 18, catalytic domain,IPR011583:Chitinase II,IPR017853:Glycoside hydrolase, superfamily,				SM00636:Glyco_18,		KW-0964~Secreted,		KW-0732~Signal,	KW-0147~Chitin-binding,KW-0430~Lectin,	KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:GH18,MUTAGEN:I->E: Confers chitinase activity; when associated with D-143.,MUTAGEN:S->D: Confers chitinase activity; when associated with E-145.,
CLIC1	chloride intracellular channel 1(CLIC1)	Homo sapiens	GO:0006749~glutathione metabolic process,GO:0006821~chloride transport,GO:0007165~signal transduction,GO:0034765~regulation of ion transmembrane transport,GO:0045669~positive regulation of osteoblast differentiation,GO:0051726~regulation of cell cycle,GO:0051881~regulation of mitochondrial membrane potential,GO:0070527~platelet aggregation,GO:1902476~chloride transmembrane transport,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0016020~membrane,GO:0031965~nuclear membrane,GO:0031982~vesicle,GO:0034707~chloride channel complex,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0005244~voltage-gated ion channel activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR002946:Intracellular chloride channel,IPR004045:Glutathione S-transferase, N-terminal,IPR010987:Glutathione S-transferase, C-terminal-like,					KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,KW-0869~Chloride channel,	KW-0007~Acetylation,KW-0318~Glutathionylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DISULFID:Alternate,DOMAIN:GST C-terminal,MUTAGEN:C->S: Loss of dimerization and of ion transport activity.,REGION:Required for insertion into the membrane,TRANSMEM:Helical; Note=After insertion into the membrane,
CCKBR	cholecystokinin B receptor(CCKBR)	Homo sapiens	GO:0001696~gastric acid secretion,GO:0007166~cell surface receptor signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008284~positive regulation of cell proliferation,GO:0038188~cholecystokinin signaling pathway,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0045851~pH reduction,GO:0048565~digestive tract development,GO:0048732~gland development,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004951~cholecystokinin receptor activity,GO:0005515~protein binding,GO:0015054~gastrin receptor activity,GO:0017046~peptide hormone binding,GO:0031741~type B gastrin/cholecystokinin receptor binding,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000314:Gastrin receptor,IPR009126:Cholecystokinin receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04971:Gastric acid secretion,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CHAT	choline O-acetyltransferase(CHAT)	Homo sapiens	GO:0006656~phosphatidylcholine biosynthetic process,GO:0006836~neurotransmitter transport,GO:0007274~neuromuscular synaptic transmission,GO:0008292~acetylcholine biosynthetic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043005~neuron projection,GO:0045202~synapse,	GO:0004102~choline O-acetyltransferase activity,GO:0016746~transferase activity, transferring acyl groups,	IPR000542:Acyltransferase ChoActase/COT/CPT,IPR023213:Chloramphenicol acetyltransferase-like domain,	hsa00564:Glycerophospholipid metabolism,hsa04725:Cholinergic synapse,	254210~Myasthenic syndrome, congenital, 6, presynaptic,			KW-0530~Neurotransmitter biosynthesis,		KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,			KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Carn_acyltransf,REGION:Disordered,
CHRM1	cholinergic receptor muscarinic 1(CHRM1)	Homo sapiens	GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007197~adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0007207~phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007274~neuromuscular synaptic transmission,GO:0007399~nervous system development,GO:0040012~regulation of locomotion,GO:0043270~positive regulation of ion transport,GO:0046541~saliva secretion,GO:0050890~cognition,GO:0060078~regulation of postsynaptic membrane potential,GO:0060251~regulation of glial cell proliferation,GO:0090316~positive regulation of intracellular protein transport,GO:0098664~G-protein coupled serotonin receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0030425~dendrite,GO:0042734~presynaptic membrane,GO:0043679~axon terminus,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0098981~cholinergic synapse,GO:0099056~integral component of presynaptic membrane,GO:0099061~integral component of postsynaptic density membrane,	GO:0004435~phosphatidylinositol phospholipase C activity,GO:0004993~G-protein coupled serotonin receptor activity,GO:0005515~protein binding,GO:0016907~G-protein coupled acetylcholine receptor activity,GO:0030594~neurotransmitter receptor activity,GO:0099529~neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000995:Muscarinic acetylcholine receptor family,IPR002228:Muscarinic acetylcholine receptor M1,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04725:Cholinergic synapse,hsa04810:Regulation of actin cytoskeleton,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,					KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,REGION:Disordered,SITE:Binds to snake venom muscarinic toxin 7,SITE:Subtype-specific residue that binds to snake venom muscarinic toxin 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CHRM4	cholinergic receptor muscarinic 4(CHRM4)	Homo sapiens	GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007187~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger,GO:0007197~adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway,GO:0007213~G-protein coupled acetylcholine receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0040012~regulation of locomotion,GO:0098664~G-protein coupled serotonin receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0030425~dendrite,GO:0045202~synapse,GO:0045211~postsynaptic membrane,	GO:0004993~G-protein coupled serotonin receptor activity,GO:0016907~G-protein coupled acetylcholine receptor activity,GO:0030594~neurotransmitter receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000995:Muscarinic acetylcholine receptor family,IPR001432:Muscarinic acetylcholine receptor M4,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,hsa04725:Cholinergic synapse,hsa04810:Regulation of actin cytoskeleton,			SM01381:SM01381,		KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CHRNA1	cholinergic receptor nicotinic alpha 1 subunit(CHRNA1)	Homo sapiens	GO:0003009~skeletal muscle contraction,GO:0006812~cation transport,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007271~synaptic transmission, cholinergic,GO:0007274~neuromuscular synaptic transmission,GO:0007528~neuromuscular junction development,GO:0019228~neuronal action potential,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0046716~muscle cell cellular homeostasis,GO:0048630~skeletal muscle tissue growth,GO:0050877~neurological system process,GO:0050881~musculoskeletal movement,GO:0050905~neuromuscular process,GO:0060079~excitatory postsynaptic potential,GO:0070050~neuron cellular homeostasis,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005892~acetylcholine-gated channel complex,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031594~neuromuscular junction,GO:0043005~neuron projection,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005216~ion channel activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0015464~acetylcholine receptor activity,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,GO:0042166~acetylcholine binding,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa03265:Virion - Lyssavirus,hsa04080:Neuroactive ligand-receptor interaction,	253290~Multiple pterygium syndrome, lethal type,601462~Myasthenic syndrome, congenital, 1A, slow-channel,608930~Myasthenic syndrome, congenital, 1B, fast-channel,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Associated with receptor activation,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,MUTAGEN:E->Q: Changed acetylcholine-gated cation-selective channel activity.,MUTAGEN:V->A: Increased length of channel opening.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHRNA4	cholinergic receptor nicotinic alpha 4 subunit(CHRNA4)	Homo sapiens	GO:0001508~action potential,GO:0001666~response to hypoxia,GO:0006281~DNA repair,GO:0006811~ion transport,GO:0006816~calcium ion transport,GO:0006979~response to oxidative stress,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007271~synaptic transmission, cholinergic,GO:0014059~regulation of dopamine secretion,GO:0019233~sensory perception of pain,GO:0034220~ion transmembrane transport,GO:0035094~response to nicotine,GO:0035095~behavioral response to nicotine,GO:0042113~B cell activation,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0050890~cognition,GO:0051899~membrane depolarization,GO:0060079~excitatory postsynaptic potential,GO:0060080~inhibitory postsynaptic potential,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005892~acetylcholine-gated channel complex,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0045211~postsynaptic membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0015464~acetylcholine receptor activity,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,GO:0042166~acetylcholine binding,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04725:Cholinergic synapse,hsa05033:Nicotine addiction,hsa05207:Chemical carcinogenesis - receptor activation,	188890~Nicotine addiction, susceptibility to,600513~Epilepsy, nocturnal frontal lobe, 1,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Associated with receptor activation,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHRNA9	cholinergic receptor nicotinic alpha 9 subunit(CHRNA9)	Homo sapiens	GO:0007165~signal transduction,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007268~chemical synaptic transmission,GO:0010996~response to auditory stimulus,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0042472~inner ear morphogenesis,GO:0050877~neurological system process,GO:0050910~detection of mechanical stimulus involved in sensory perception of sound,GO:0051899~membrane depolarization,GO:0060079~excitatory postsynaptic potential,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0070588~calcium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005892~acetylcholine-gated channel complex,GO:0043005~neuron projection,GO:0045202~synapse,GO:0098981~cholinergic synapse,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa05207:Chemical carcinogenesis - receptor activation,				KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:I->T: The CHRNA9-CHRNA10 receptor is 250-fold more potently inhibited by the alpha-conotoxin RgIA.,SITE:Key residue important for potent inhibition of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin RgIA (AC P0C1D0),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHRNB2	cholinergic receptor nicotinic beta 2 subunit(CHRNB2)	Homo sapiens	GO:0001666~response to hypoxia,GO:0006811~ion transport,GO:0006816~calcium ion transport,GO:0006939~smooth muscle contraction,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007271~synaptic transmission, cholinergic,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0007612~learning,GO:0007613~memory,GO:0007626~locomotory behavior,GO:0008306~associative learning,GO:0008542~visual learning,GO:0014059~regulation of dopamine secretion,GO:0019233~sensory perception of pain,GO:0021562~vestibulocochlear nerve development,GO:0021631~optic nerve morphogenesis,GO:0021771~lateral geniculate nucleus development,GO:0021952~central nervous system projection neuron axonogenesis,GO:0030890~positive regulation of B cell proliferation,GO:0032225~regulation of synaptic transmission, dopaminergic,GO:0033603~positive regulation of dopamine secretion,GO:0034220~ion transmembrane transport,GO:0035094~response to nicotine,GO:0035095~behavioral response to nicotine,GO:0035176~social behavior,GO:0042053~regulation of dopamine metabolic process,GO:0042113~B cell activation,GO:0042220~response to cocaine,GO:0042320~regulation of circadian sleep/wake cycle, REM sleep,GO:0042391~regulation of membrane potential,GO:0045471~response to ethanol,GO:0045759~negative regulation of action potential,GO:0048814~regulation of dendrite morphogenesis,GO:0050877~neurological system process,GO:0050890~cognition,GO:0051899~membrane depolarization,GO:0051963~regulation of synapse assembly,GO:0060079~excitatory postsynaptic potential,GO:0060084~synaptic transmission involved in micturition,GO:0095500~acetylcholine receptor signaling pathway,GO:1905144~response to acetylcholine,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005892~acetylcholine-gated channel complex,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0044853~plasma membrane raft,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098981~cholinergic synapse,GO:0099056~integral component of presynaptic membrane,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0015464~acetylcholine receptor activity,GO:0022848~acetylcholine-gated cation-selective channel activity,GO:0030594~neurotransmitter receptor activity,GO:0042166~acetylcholine binding,GO:0044877~macromolecular complex binding,GO:0050997~quaternary ammonium group binding,GO:1901363~heterocyclic compound binding,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR002394:Nicotinic acetylcholine receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04725:Cholinergic synapse,hsa05033:Nicotine addiction,hsa05207:Chemical carcinogenesis - receptor activation,	605375~Epilepsy, nocturnal frontal lobe, 3,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,MUTAGEN:F->Y: Increases ligand activation in LS and HS nAChR subtypes.,SITE:Key residue for a rapid dissociation (K(off)) from the conotoxin BuIA,SITE:Key residue that may interfere with effective access of the conotoxin BuIA to the channel binding site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHODL	chondrolectin(CHODL)	Homo sapiens	GO:0007399~nervous system development,GO:0007517~muscle organ development,GO:0050772~positive regulation of axonogenesis,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,	IPR001304:C-type lectin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,				SM00034:CLECT,	KW-0524~Neurogenesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:C-type lectin,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CHGB	chromogranin B(CHGB)	Homo sapiens	GO:0007165~signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0030141~secretory granule,	GO:0005179~hormone activity,GO:0005515~protein binding,	IPR001819:Chromogranin A/B,IPR001990:Chromogranin/secretogranin,IPR018054:Chromogranin, conserved site,						KW-0964~Secreted,		KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,PEPTIDE:CCB peptide,PEPTIDE:GAWK peptide,PEPTIDE:PE-11,REGION:Disordered,REGION:O-glycosylated at one site,
C15orf48	chromosome 15 open reading frame 48(C15orf48)	Homo sapiens	GO:0009617~response to bacterium,GO:0022900~electron transport chain,GO:1902600~hydrogen ion transmembrane transport,	GO:0005634~nucleus,GO:0005751~mitochondrial respiratory chain complex IV,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR010530:NADH-ubiquinone reductase complex 1 MLRQ subunit,						KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
C2orf66	chromosome 2 open reading frame 66(C2orf66)	Homo sapiens		GO:0005576~extracellular region,								KW-0964~Secreted,		KW-0732~Signal,
C21orf62	chromosome 21 open reading frame 62(C21orf62)	Homo sapiens												KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,
C6orf118	chromosome 6 open reading frame 118(C6orf118)	Homo sapiens												KW-0175~Coiled coil,				REGION:Disordered,
C6orf47	chromosome 6 open reading frame 47(C6orf47)	Homo sapiens		GO:0016021~integral component of membrane,	GO:0005515~protein binding,							KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
C7orf57	chromosome 7 open reading frame 57(C7orf57)	Homo sapiens												KW-0732~Signal,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,REGION:Disordered,
CFAP100	cilia and flagella associated protein 100(CFAP100)	Homo sapiens	GO:0003341~cilium movement,GO:0036159~inner dynein arm assembly,GO:2000574~regulation of microtubule motor activity,	GO:0031514~motile cilium,GO:0036064~ciliary basal body,GO:0097545~axonemal outer doublet,	GO:0070840~dynein complex binding,	IPR025252:Domain of unknown function DUF4200,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CFAP45	cilia and flagella associated protein 45(CFAP45)	Homo sapiens	GO:0030317~flagellated sperm motility,GO:0060287~epithelial cilium movement involved in determination of left/right asymmetry,GO:0060296~regulation of cilium beat frequency involved in ciliary motility,GO:0090660~cerebrospinal fluid circulation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005879~axonemal microtubule,GO:0005930~axoneme,GO:0097728~9+0 motile cilium,GO:0097729~9+2 motile cilium,	GO:0005515~protein binding,GO:0016208~AMP binding,			619608~Heterotaxy, visceral, 11, autosomal, with male infertility,				KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-1056~Heterotaxy,KW-1186~Ciliopathy,	KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:TPH,REGION:Disordered,
CFAP99	cilia and flagella associated protein 99(CFAP99)	Homo sapiens		GO:0031514~motile cilium,								KW-0282~Flagellum,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,
CLDN23	claudin 23(CLDN23)	Homo sapiens	GO:0007155~cell adhesion,GO:0016338~calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules,GO:0070830~bicellular tight junction assembly,	GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004031:PMP-22/EMP/MP20/Claudin,IPR006187:Claudin,IPR017974:Claudin, conserved site,	hsa04514:Cell adhesion molecules,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa05130:Pathogenic Escherichia coli infection,hsa05160:Hepatitis C,					KW-0472~Membrane,KW-0796~Tight junction,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CPSF4L	cleavage and polyadenylation specific factor 4 like(CPSF4L)	Homo sapiens	GO:0098789~pre-mRNA cleavage required for polyadenylation,	GO:0005847~mRNA cleavage and polyadenylation specificity factor complex,	GO:0003723~RNA binding,GO:0046872~metal ion binding,	IPR000571:Zinc finger, CCCH-type,	hsa03015:mRNA surveillance pathway,hsa05164:Influenza A,			SM00356:ZnF_C3H1,	KW-0507~mRNA processing,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0694~RNA-binding,		DOMAIN:C3H1-type,ZN_FING:C3H1-type,ZN_FING:C3H1-type 1,ZN_FING:C3H1-type 2,ZN_FING:C3H1-type 3,ZN_FING:C3H1-type 4,ZN_FING:C3H1-type 5,
F5	coagulation factor V(F5)	Homo sapiens	GO:0007596~blood coagulation,GO:0008015~blood circulation,GO:0032571~response to vitamin K,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0030134~ER to Golgi transport vesicle,GO:0031091~platelet alpha granule,GO:0031093~platelet alpha granule lumen,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:1903561~extracellular vesicle,	GO:0005507~copper ion binding,GO:0005515~protein binding,	IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR008972:Cupredoxin,IPR008979:Galactose-binding domain-like,IPR009271:Coagulation factor V, LSPD,IPR011707:Multicopper oxidase, type 3,IPR024715:Coagulation factor 5/8,	hsa04610:Complement and coagulation cascades,	188055~Thrombophilia 2 due to activated protein C resistance,188055~Thrombophilia, susceptibility to, due to factor V Leiden,227400~Factor V deficiency,600880~Budd-Chiari syndrome,601367~Stroke, ischemic, susceptibility to,614389~Pregnancy loss, recurrent, susceptibility to, 1,	PIRSF000354:coagulation factor V/coagulation factor VIII,	SM00231:FA58C,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0792~Thrombophilia,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0186~Copper,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0865~Zymogen,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:F5/8 type A 1,DOMAIN:F5/8 type A 2,DOMAIN:F5/8 type A 3,DOMAIN:F5/8 type C,DOMAIN:F5/8 type C 1,DOMAIN:F5/8 type C 2,DOMAIN:Plastocyanin-like 1,DOMAIN:Plastocyanin-like 2,DOMAIN:Plastocyanin-like 3,DOMAIN:Plastocyanin-like 4,DOMAIN:Plastocyanin-like 5,DOMAIN:Plastocyanin-like 6,PROPEP:Activation peptide (connecting region),REGION:2 X 17 AA tandem repeats,REGION:35 X 9 AA approximate tandem repeats of [TNP]-L-S-P-D-L-S-Q-T,REGION:B,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:2-1,REPEAT:2-10,REPEAT:2-11,REPEAT:2-12,REPEAT:2-13,REPEAT:2-14,REPEAT:2-15,REPEAT:2-16,REPEAT:2-17,REPEAT:2-18,REPEAT:2-19,REPEAT:2-2,REPEAT:2-20,REPEAT:2-21,REPEAT:2-22,REPEAT:2-23,REPEAT:2-24,REPEAT:2-25,REPEAT:2-26,REPEAT:2-27,REPEAT:2-28,REPEAT:2-29,REPEAT:2-3,REPEAT:2-30,REPEAT:2-31,REPEAT:2-32,REPEAT:2-33,REPEAT:2-34,REPEAT:2-35,REPEAT:2-4,REPEAT:2-5,REPEAT:2-6,REPEAT:2-7,REPEAT:2-8,REPEAT:2-9,SITE:Cleavage; by activated protein C,SITE:Cleavage; by thrombin,
F13A1	coagulation factor XIII A chain(F13A1)	Homo sapiens	GO:0007596~blood coagulation,GO:0018149~peptide cross-linking,GO:0072378~blood coagulation, fibrin clot formation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031093~platelet alpha granule lumen,GO:0072562~blood microparticle,GO:1990234~transferase complex,	GO:0003810~protein-glutamine gamma-glutamyltransferase activity,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001102:Transglutaminase, N-terminal,IPR002931:Transglutaminase-like,IPR008958:Transglutaminase, C-terminal,IPR013783:Immunoglobulin-like fold,IPR013808:Transglutaminase, conserved site,IPR014756:Immunoglobulin E-set,IPR023608:Protein-glutamine gamma-glutamyltransferase, eukaryota,	hsa04610:Complement and coagulation cascades,hsa05171:Coronavirus disease - COVID-19,	188050~Venous thrombosis, protection against,608446~Myocardial infarction, protection against,613225~Factor XIIIA deficiency,	PIRSF000459:protein-glutamine gamma-glutamyltransferase/erythrocyte membrane protein band 4.2,	SM00460:TGc,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,		KW-0106~Calcium,KW-0479~Metal-binding,	KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0865~Zymogen,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TGc,DOMAIN:Transglut_N,PROPEP:Activation peptide,REGION:Disordered,SITE:Cleavage; by thrombin; to produce active factor XIII-A,
CCHCR1	coiled-coil alpha-helical rod protein 1(CCHCR1)	Homo sapiens	GO:0006611~protein export from nucleus,GO:0030154~cell differentiation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR009800:Alpha helical coiled-coil rod,					KW-0221~Differentiation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,		KW-0217~Developmental protein,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CCDC177	coiled-coil domain containing 177(CCDC177)	Homo sapiens												KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CCDC85A	coiled-coil domain containing 85A(CCDC85A)	Homo sapiens		GO:0005912~adherens junction,	GO:0005515~protein binding,	IPR019359:Protein of unknown function DUF2216, coiled-coil,						KW-0965~Cell junction,		KW-0175~Coiled coil,			KW-0488~Methylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
CSDC2	cold shock domain containing C2(CSDC2)	Homo sapiens	GO:0006397~mRNA processing,GO:0043488~regulation of mRNA stability,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,	IPR002059:Cold-shock protein, DNA-binding,IPR011129:Cold shock protein,IPR012340:Nucleic acid-binding, OB-fold,IPR019844:Cold-shock conserved site,				SM00357:CSP,	KW-0507~mRNA processing,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	DOMAIN:CSD,REGION:Disordered,
CTHRC1	collagen triple helix repeat containing 1(CTHRC1)	Homo sapiens	GO:0001649~osteoblast differentiation,GO:0016477~cell migration,GO:0032092~positive regulation of protein binding,GO:0033687~osteoblast proliferation,GO:0033690~positive regulation of osteoblast proliferation,GO:0043932~ossification involved in bone remodeling,GO:0045669~positive regulation of osteoblast differentiation,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060122~inner ear receptor stereocilium organization,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090103~cochlea morphogenesis,GO:0090177~establishment of planar polarity involved in neural tube closure,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0016528~sarcoplasm,	GO:0005109~frizzled binding,GO:0005201~extracellular matrix structural constituent,GO:0017147~Wnt-protein binding,	IPR008160:Collagen triple helix repeat,		614266~Barrett esophagus/esophageal adenocarcinoma,				KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0176~Collagen,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Collagen-like,REGION:Disordered,
COL1A1	collagen type I alpha 1 chain(COL1A1)	Homo sapiens	GO:0001501~skeletal system development,GO:0001503~ossification,GO:0001568~blood vessel development,GO:0001649~osteoblast differentiation,GO:0001957~intramembranous ossification,GO:0001958~endochondral ossification,GO:0007155~cell adhesion,GO:0007601~visual perception,GO:0007605~sensory perception of sound,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010812~negative regulation of cell-substrate adhesion,GO:0015031~protein transport,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030335~positive regulation of cell migration,GO:0031960~response to corticosteroid,GO:0032355~response to estradiol,GO:0032868~response to insulin,GO:0032964~collagen biosynthetic process,GO:0034504~protein localization to nucleus,GO:0034505~tooth mineralization,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0042060~wound healing,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043434~response to peptide hormone,GO:0043588~skin development,GO:0043589~skin morphogenesis,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0044691~tooth eruption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048706~embryonic skeletal system development,GO:0051591~response to cAMP,GO:0055093~response to hyperoxia,GO:0060325~face morphogenesis,GO:0060346~bone trabecula formation,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071260~cellular response to mechanical stimulus,GO:0071300~cellular response to retinoic acid,GO:0071306~cellular response to vitamin E,GO:0071356~cellular response to tumor necrosis factor,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902618~cellular response to fluoride,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005584~collagen type I trimer,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0031012~extracellular matrix,	GO:0002020~protease binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001007:von Willebrand factor, type C,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,	114000~Caffey disease,130060~Ehlers-Danlos syndrome, arthrochalasia type, 1,166200~Osteogenesis imperfecta, type I,166210~Osteogenesis imperfecta, type II,166220~Osteogenesis imperfecta, type IV,166710~Bone mineral density variation QTL, osteoporosis,259420~Osteogenesis imperfecta, type III,619115~Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1,		SM00038:COLFI,SM00214:VWC,		KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0248~Ehlers-Danlos syndrome,KW-1065~Osteogenesis imperfecta,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Fibrillar collagen NC1,DOMAIN:VWFC,MOTIF:Cell attachment site,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,REGION:Nonhelical region (C-terminal),REGION:Nonhelical region (N-terminal),REGION:Triple-helical region,SITE:Cleavage; by collagenase,SITE:Cleavage; by procollagen C-endopeptidase,SITE:Cleavage; by procollagen N-endopeptidase,TRANSMEM:Helical,
COL1A2	collagen type I alpha 2 chain(COL1A2)	Homo sapiens	GO:0001501~skeletal system development,GO:0001568~blood vessel development,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007266~Rho protein signal transduction,GO:0008217~regulation of blood pressure,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030282~bone mineralization,GO:0032963~collagen metabolic process,GO:0042476~odontogenesis,GO:0043589~skin morphogenesis,GO:0070208~protein heterotrimerization,GO:0071230~cellular response to amino acid stimulus,GO:0085029~extracellular matrix assembly,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005584~collagen type I trimer,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0002020~protease binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0030674~protein binding, bridging,GO:0042802~identical protein binding,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05415:Diabetic cardiomyopathy,	166210~Osteogenesis imperfecta, type II,166220~Osteogenesis imperfecta, type IV,166710~Osteoporosis, postmenopausal,225320~Ehlers-Danlos syndrome, cardiac valvular type,259420~Osteogenesis imperfecta, type III,617821~Ehlers-Danlos syndrome, arthrochalasia type, 2,619120~Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2,		SM00038:COLFI,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0248~Ehlers-Danlos syndrome,KW-1065~Osteogenesis imperfecta,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Pro residues,DOMAIN:Fibrillar collagen NC1,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,
COL3A1	collagen type III alpha 1 chain(COL3A1)	Homo sapiens	GO:0001501~skeletal system development,GO:0001701~in utero embryonic development,GO:0001764~neuron migration,GO:0001894~tissue homeostasis,GO:0002062~chondrocyte differentiation,GO:0007160~cell-matrix adhesion,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007229~integrin-mediated signaling pathway,GO:0007507~heart development,GO:0009314~response to radiation,GO:0009612~response to mechanical stimulus,GO:0018149~peptide cross-linking,GO:0021819~layer formation in cerebral cortex,GO:0021987~cerebral cortex development,GO:0030168~platelet activation,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030324~lung development,GO:0032905~transforming growth factor beta1 production,GO:0034097~response to cytokine,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035264~multicellular organism growth,GO:0036022~limb joint morphogenesis,GO:0042060~wound healing,GO:0043588~skin development,GO:0048144~fibroblast proliferation,GO:0048251~elastic fiber assembly,GO:0048565~digestive tract development,GO:0050777~negative regulation of immune response,GO:0060350~endochondral bone morphogenesis,GO:0060414~aorta smooth muscle tissue morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071711~basement membrane organization,GO:0097435~supramolecular fiber organization,GO:1990776~response to angiotensin,GO:2001223~negative regulation of neuron migration,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005586~collagen type III trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0002020~protease binding,GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0046332~SMAD binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001007:von Willebrand factor, type C,IPR008160:Collagen triple helix repeat,	hsa04611:Platelet activation,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05415:Diabetic cardiomyopathy,	130050~Ehlers-Danlos syndrome, vascular type,618343~Polymicrogyria with or without vascular-type EDS,		SM00038:COLFI,SM00214:VWC,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,KW-0993~Aortic aneurysm,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Pro residues,DISULFID:Interchain,DISULFID:Interchain (with C-1268),DISULFID:Interchain (with C-1285),DOMAIN:Fibrillar collagen NC1,DOMAIN:VWFC,PROPEP:C-terminal propeptide,PROPEP:N-terminal propeptide,REGION:Disordered,REGION:Nonhelical region (C-terminal),REGION:Nonhelical region (N-terminal),REGION:Triple-helical region,
COL4A1	collagen type IV alpha 1 chain(COL4A1)	Homo sapiens	GO:0001569~branching involved in blood vessel morphogenesis,GO:0007420~brain development,GO:0007528~neuromuscular junction development,GO:0030198~extracellular matrix organization,GO:0030855~epithelial cell differentiation,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0048514~blood vessel morphogenesis,GO:0061304~retinal blood vessel morphogenesis,GO:0061333~renal tubule morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:0071711~basement membrane organization,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005587~collagen type IV trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0048407~platelet-derived growth factor binding,	IPR001442:Collagen IV, non-collagenous,IPR008160:Collagen triple helix repeat,IPR016187:C-type lectin fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	175780~Brain small vessel disease with or without ocular anomalies,180000~Retinal arteries, tortuosity of,611773~Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps,614519~Hemorrhage, intracerebral, susceptibility to,618564~Microangiopathy and leukoencephalopathy, pontine, autosomal dominant,		SM00111:C4,	KW-0037~Angiogenesis,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:S-Lysyl-methionine sulfilimine (Lys-Met) (interchain with M-1533),CROSSLNK:S-Lysyl-methionine sulfilimine (Met-Lys) (interchain with K-1651),DOMAIN:Collagen IV NC1,PROPEP:N-terminal propeptide (7S domain),REGION:Disordered,REGION:Triple-helical region,
COL4A2	collagen type IV alpha 2 chain(COL4A2)	Homo sapiens	GO:0001525~angiogenesis,GO:0006351~transcription, DNA-templated,GO:0007568~aging,GO:0014823~response to activity,GO:0016525~negative regulation of angiogenesis,GO:0030198~extracellular matrix organization,GO:0035987~endodermal cell differentiation,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0071560~cellular response to transforming growth factor beta stimulus,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005587~collagen type IV trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR001442:Collagen IV, non-collagenous,IPR008160:Collagen triple helix repeat,IPR016187:C-type lectin fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	614483~Brain small vessel disease 2,614519~Hemorrhage, intracerebral, susceptibility to,		SM00111:C4,	KW-0037~Angiogenesis,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0102~Bromination,KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Collagen IV NC1,PROPEP:N-terminal propeptide (7S domain),REGION:Disordered,REGION:Triple-helical region,
COL4A6	collagen type IV alpha 6 chain(COL4A6)	Homo sapiens	GO:0007155~cell adhesion,GO:0030198~extracellular matrix organization,GO:0038063~collagen-activated tyrosine kinase receptor signaling pathway,GO:0071230~cellular response to amino acid stimulus,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005587~collagen type IV trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR001442:Collagen IV, non-collagenous,IPR008160:Collagen triple helix repeat,IPR016187:C-type lectin fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04974:Protein digestion and absorption,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,	300914~Deafness, X-linked 6,		SM00111:C4,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DISULFID:Or C-1482 with C-1568,DISULFID:Or C-1515 with C-1571,DISULFID:Or C-1590 with C-1684,DISULFID:Or C-1624 with C-1687,DOMAIN:Collagen IV NC1,MOTIF:Cell attachment site,REGION:7S domain,REGION:Disordered,REGION:Triple-helical region,
COL9A3	collagen type IX alpha 3 chain(COL9A3)	Homo sapiens	GO:0008584~male gonad development,GO:0008585~female gonad development,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005594~collagen type IX trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04974:Protein digestion and absorption,hsa05165:Human papillomavirus infection,	600969~Epiphyseal dysplasia, multiple, 3, with or without myopathy,603932~Intervertebral disc disease, susceptibility to,				KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,MOTIF:Cell attachment site,REGION:Disordered,REGION:Nonhelical region 1 (NC1),REGION:Nonhelical region 2 (NC2),REGION:Nonhelical region 3 (NC3),REGION:Triple-helical region 1 (COL1),REGION:Triple-helical region 2 (COL2),REGION:Triple-helical region 3 (COL3),
COL5A1	collagen type V alpha 1 chain(COL5A1)	Homo sapiens	GO:0001568~blood vessel development,GO:0003007~heart morphogenesis,GO:0007155~cell adhesion,GO:0016477~cell migration,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0032964~collagen biosynthetic process,GO:0035313~wound healing, spreading of epidermal cells,GO:0035989~tendon development,GO:0043588~skin development,GO:0045112~integrin biosynthetic process,GO:0048592~eye morphogenesis,GO:0051128~regulation of cellular component organization,GO:0097435~supramolecular fiber organization,GO:1903225~negative regulation of endodermal cell differentiation,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005588~collagen type V trimer,GO:0005592~collagen type XI trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0043394~proteoglycan binding,GO:0046872~metal ion binding,GO:0048407~platelet-derived growth factor binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001791:Laminin G domain,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04974:Protein digestion and absorption,	130000~Ehlers-Danlos syndrome, classic type, 1,619329~Fibromuscular dysplasia, multifocal,		SM00038:COLFI,SM00210:TSPN,SM00282:LamG,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0358~Heparin-binding,	KW-0379~Hydroxylation,KW-0765~Sulfation,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain (with C-1645),DISULFID:Interchain (with C-1662),DOMAIN:Fibrillar collagen NC1,DOMAIN:Laminin G-like,PROPEP:C-terminal propeptide,REGION:Disordered,REGION:Interrupted collagenous region,REGION:Nonhelical region,REGION:Triple-helical region,
COL5A2	collagen type V alpha 2 chain(COL5A2)	Homo sapiens	GO:0001501~skeletal system development,GO:0001503~ossification,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0043588~skin development,GO:0048592~eye morphogenesis,GO:0071230~cellular response to amino acid stimulus,GO:1903225~negative regulation of endodermal cell differentiation,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005588~collagen type V trimer,GO:0005592~collagen type XI trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0046332~SMAD binding,GO:0046872~metal ion binding,	IPR000885:Fibrillar collagen, C-terminal,IPR001007:von Willebrand factor, type C,IPR008160:Collagen triple helix repeat,	hsa04974:Protein digestion and absorption,	130010~Ehlers-Danlos syndrome, classic type, 2,		SM00038:COLFI,SM00214:VWC,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Fibrillar collagen NC1,DOMAIN:VWFC,MOTIF:Cell attachment site,PROPEP:C-terminal propeptide,REGION:Disordered,
COL6A1	collagen type VI alpha 1 chain(COL6A1)	Homo sapiens	GO:0001649~osteoblast differentiation,GO:0007155~cell adhesion,GO:0035987~endodermal cell differentiation,GO:0071230~cellular response to amino acid stimulus,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005589~collagen type VI trimer,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0032991~macromolecular complex,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,	GO:0005518~collagen binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0048407~platelet-derived growth factor binding,	IPR002035:von Willebrand factor, type A,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04974:Protein digestion and absorption,hsa05165:Human papillomavirus infection,	158810~Bethlem myopathy 1,254090~Ullrich congenital muscular dystrophy 1,		SM00327:VWA,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:VWFA,DOMAIN:VWFA 1,DOMAIN:VWFA 2,DOMAIN:VWFA 3,MOTIF:Cell attachment site,REGION:C-terminal globular domain,REGION:Disordered,REGION:N-terminal globular domain,REGION:Triple-helical region,
COL6A2	collagen type VI alpha 2 chain(COL6A2)	Homo sapiens	GO:0007155~cell adhesion,GO:0009749~response to glucose,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0032991~macromolecular complex,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0005515~protein binding,GO:0005518~collagen binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR002035:von Willebrand factor, type A,IPR008160:Collagen triple helix repeat,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04974:Protein digestion and absorption,hsa05165:Human papillomavirus infection,	158810~Bethlem myopathy 1,254090~Ullrich congenital muscular dystrophy 1,255600~Myosclerosis, congenital,		SM00327:VWA,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:VWFA,DOMAIN:VWFA 1,DOMAIN:VWFA 2,DOMAIN:VWFA 3,MOTIF:Cell attachment site,REGION:Disordered,REGION:Nonhelical region,REGION:Triple-helical region,
COL6A3	collagen type VI alpha 3 chain(COL6A3)	Homo sapiens	GO:0007155~cell adhesion,GO:0007517~muscle organ development,GO:0010951~negative regulation of endopeptidase activity,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005589~collagen type VI trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0042383~sarcolemma,GO:0070062~extracellular exosome,GO:1903561~extracellular vesicle,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR002035:von Willebrand factor, type A,IPR002223:Proteinase inhibitor I2, Kunitz metazoa,IPR003961:Fibronectin, type III,IPR008160:Collagen triple helix repeat,IPR013783:Immunoglobulin-like fold,IPR020901:Proteinase inhibitor I2, Kunitz, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04974:Protein digestion and absorption,hsa05165:Human papillomavirus infection,	158810~Bethlem myopathy 1,254090~Ullrich congenital muscular dystrophy 1,616411~Dystonia 27,		SM00131:KU,SM00327:VWA,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,KW-1023~Dystonia,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Gal...) hydroxylysine; alternate,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:BPTI/Kunitz inhibitor,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Collagen-like 5,DOMAIN:Fibronectin type-III,DOMAIN:VWFA,DOMAIN:VWFA 1,DOMAIN:VWFA 10,DOMAIN:VWFA 11,DOMAIN:VWFA 12,DOMAIN:VWFA 2,DOMAIN:VWFA 3,DOMAIN:VWFA 4,DOMAIN:VWFA 5,DOMAIN:VWFA 6,DOMAIN:VWFA 7,DOMAIN:VWFA 8,DOMAIN:VWFA 9,MOTIF:Cell attachment site,REGION:Disordered,REGION:Nonhelical region,REGION:Triple-helical region,SITE:Reactive bond,
COL8A2	collagen type VIII alpha 2 chain(COL8A2)	Homo sapiens	GO:0001525~angiogenesis,GO:0030198~extracellular matrix organization,GO:0048593~camera-type eye morphogenesis,GO:0050673~epithelial cell proliferation,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0030674~protein binding, bridging,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,	hsa04974:Protein digestion and absorption,	136800~Corneal dystrophy, Fuchs endothelial, 1,609140~Corneal dystrophy, posterior polymorphous 2,		SM00110:C1Q,	KW-0037~Angiogenesis,KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-1212~Corneal dystrophy,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0379~Hydroxylation,	COMPBIAS:Pro residues,DOMAIN:C1q,REGION:Disordered,REGION:Nonhelical region (NC1),REGION:Nonhelical region (NC2),REGION:Triple-helical region,
COL13A1	collagen type XIII alpha 1 chain(COL13A1)	Homo sapiens	GO:0001501~skeletal system development,GO:0001763~morphogenesis of a branching structure,GO:0001958~endochondral ossification,GO:0007160~cell-matrix adhesion,GO:0030154~cell differentiation,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030903~notochord development,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005600~collagen type XIII trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0031012~extracellular matrix,GO:0045211~postsynaptic membrane,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR008160:Collagen triple helix repeat,	hsa04974:Protein digestion and absorption,	616720~Myasthenic syndrome, congenital, 19,			KW-0130~Cell adhesion,KW-0221~Differentiation,KW-0892~Osteogenesis,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-1004~Congenital myasthenic syndrome,	KW-0176~Collagen,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0358~Heparin-binding,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,REGION:Nonhelical region 1 (NC1),REGION:Nonhelical region 2 (NC2),REGION:Nonhelical region 3 (NC3),REGION:Nonhelical region 4 (NC4),REGION:Triple-helical region 1 (COL1),REGION:Triple-helical region 2 (COL2),REGION:Triple-helical region 3 (COL3),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
COL15A1	collagen type XV alpha 1 chain(COL15A1)	Homo sapiens	GO:0001525~angiogenesis,GO:0001886~endothelial cell morphogenesis,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005582~collagen type XV trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,	IPR001791:Laminin G domain,IPR008160:Collagen triple helix repeat,IPR010515:Collagenase NC10/endostatin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,	hsa04974:Protein digestion and absorption,			SM00210:TSPN,	KW-0037~Angiogenesis,KW-0130~Cell adhesion,KW-0221~Differentiation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like,REGION:4 X tandem repeats,REGION:Disordered,REGION:Nonhelical region 1 (NC1),REGION:Nonhelical region 10 (NC10),REGION:Nonhelical region 2 (NC2),REGION:Nonhelical region 3 (NC3),REGION:Nonhelical region 4 (NC4),REGION:Nonhelical region 5 (NC5),REGION:Nonhelical region 6 (NC6),REGION:Nonhelical region 7 (NC7),REGION:Nonhelical region 8 (NC8),REGION:Nonhelical region 9 (NC9),REGION:Triple-helical region 1 (COL1),REGION:Triple-helical region 2 (COL2),REGION:Triple-helical region 3 (COL3),REGION:Triple-helical region 4 (COL4),REGION:Triple-helical region 5 (COL5),REGION:Triple-helical region 6 (COL6),REGION:Triple-helical region 7 (COL7),REGION:Triple-helical region 8 (COL8),REGION:Triple-helical region 9 (COL9),REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,
COL18A1	collagen type XVIII alpha 1 chain(COL18A1)	Homo sapiens	GO:0001525~angiogenesis,GO:0001886~endothelial cell morphogenesis,GO:0007155~cell adhesion,GO:0007601~visual perception,GO:0008285~negative regulation of cell proliferation,GO:0009887~animal organ morphogenesis,GO:0030198~extracellular matrix organization,GO:0042493~response to drug,GO:0051599~response to hydrostatic pressure,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0030020~extracellular matrix structural constituent conferring tensile strength,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR001791:Laminin G domain,IPR008160:Collagen triple helix repeat,IPR010363:Domain of unknown function DUF959, collagen XVIII, N-terminal,IPR010515:Collagenase NC10/endostatin,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR020067:Frizzled domain,	hsa04974:Protein digestion and absorption,	267750~Knobloch syndrome, type 1,618880~Glaucoma, primary closed-angle,		SM00063:FRI,SM00210:TSPN,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0955~Glaucoma,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Collagen_trimer,DOMAIN:Endostatin,DOMAIN:FZ,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like,MOTIF:Cell attachment site,REGION:Disordered,REGION:Non-collagenous domain 1 association domain,REGION:Non-collagenous domain 1 hinge region,REGION:Nonhelical region 1 (NC1),REGION:Nonhelical region 10 (NC10),REGION:Nonhelical region 11 (NC11),REGION:Nonhelical region 2 (NC2),REGION:Nonhelical region 3 (NC3),REGION:Nonhelical region 4 (NC4),REGION:Nonhelical region 5 (NC5),REGION:Nonhelical region 6 (NC6),REGION:Nonhelical region 7 (NC7),REGION:Nonhelical region 8 (NC8),REGION:Nonhelical region 9 (NC9),REGION:Triple-helical region 1 (COL1),REGION:Triple-helical region 10 (COL10),REGION:Triple-helical region 2 (COL2),REGION:Triple-helical region 3 (COL3),REGION:Triple-helical region 4 (COL4),REGION:Triple-helical region 5 (COL5),REGION:Triple-helical region 6 (COL6),REGION:Triple-helical region 7 (COL7),REGION:Triple-helical region 8 (COL8),REGION:Triple-helical region 9 (COL9),
COL20A1	collagen type XX alpha 1 chain(COL20A1)	Homo sapiens		GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,		IPR001791:Laminin G domain,IPR002035:von Willebrand factor, type A,IPR003961:Fibronectin, type III,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,	hsa04974:Protein digestion and absorption,			SM00060:FN3,SM00210:TSPN,SM00327:VWA,		KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like,DOMAIN:VWFA,REGION:Disordered,
COL22A1	collagen type XXII alpha 1 chain(COL22A1)	Homo sapiens	GO:0001525~angiogenesis,GO:0001886~endothelial cell morphogenesis,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0031012~extracellular matrix,	GO:0005201~extracellular matrix structural constituent,	IPR001791:Laminin G domain,IPR002035:von Willebrand factor, type A,IPR008160:Collagen triple helix repeat,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04974:Protein digestion and absorption,			SM00210:TSPN,SM00327:VWA,		KW-0272~Extracellular matrix,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 10,DOMAIN:Collagen-like 11,DOMAIN:Collagen-like 12,DOMAIN:Collagen-like 13,DOMAIN:Collagen-like 14,DOMAIN:Collagen-like 15,DOMAIN:Collagen-like 16,DOMAIN:Collagen-like 2,DOMAIN:Collagen-like 3,DOMAIN:Collagen-like 4,DOMAIN:Collagen-like 5,DOMAIN:Collagen-like 6,DOMAIN:Collagen-like 7,DOMAIN:Collagen-like 8,DOMAIN:Collagen-like 9,DOMAIN:Laminin G-like,DOMAIN:VWFA,REGION:Disordered,
COL26A1	collagen type XXVI alpha 1 chain(COL26A1)	Homo sapiens	GO:0010811~positive regulation of cell-substrate adhesion,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,		IPR008160:Collagen triple helix repeat,IPR011489:EMI domain,	hsa04974:Protein digestion and absorption,					KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,DOMAIN:EMI,REGION:Disordered,
CSF3	colony stimulating factor 3(CSF3)	Homo sapiens	GO:0006955~immune response,GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0019221~cytokine-mediated signaling pathway,GO:0030838~positive regulation of actin filament polymerization,GO:0030851~granulocyte differentiation,GO:0032092~positive regulation of protein binding,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0045471~response to ethanol,GO:0045639~positive regulation of myeloid cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051897~positive regulation of protein kinase B signaling,GO:0071222~cellular response to lipopolysaccharide,GO:0071345~cellular response to cytokine stimulus,GO:1901215~negative regulation of neuron death,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0043202~lysosomal lumen,GO:0071682~endocytic vesicle lumen,	GO:0005125~cytokine activity,GO:0005130~granulocyte colony-stimulating factor receptor binding,GO:0008083~growth factor activity,GO:0019899~enzyme binding,	IPR009079:Four-helical cytokine-like, core,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04657:IL-17 signaling pathway,hsa05144:Malaria,hsa05171:Coronavirus disease - COVID-19,		PIRSF001935:interleukin-6,	SM00126:IL6,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (GalNAc...) threonine,REGION:Disordered,
C1QB	complement C1q B chain(C1QB)	Homo sapiens	GO:0006956~complement activation,GO:0006958~complement activation, classical pathway,GO:0045087~innate immune response,GO:0048839~inner ear development,GO:0098883~synapse disassembly,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005602~complement component C1 complex,GO:0045202~synapse,GO:0072562~blood microparticle,GO:0098794~postsynapse,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,	hsa04610:Complement and coagulation cascades,hsa04936:Alcoholic liver disease,hsa05020:Prion disease,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05150:Staphylococcus aureus infection,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	613652~C1q deficiency,		SM00110:C1Q,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	COMPBIAS:Pro residues,DISULFID:Interchain (with C-26 in chain A),DOMAIN:C1q,DOMAIN:Collagen-like 1,DOMAIN:Collagen-like 2,REGION:Disordered,
C1QC	complement C1q C chain(C1QC)	Homo sapiens	GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0030853~negative regulation of granulocyte differentiation,GO:0045087~innate immune response,GO:0045650~negative regulation of macrophage differentiation,GO:0098883~synapse disassembly,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005602~complement component C1 complex,GO:0005615~extracellular space,GO:0045202~synapse,GO:0072562~blood microparticle,GO:0098794~postsynapse,	GO:0005515~protein binding,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,	hsa04610:Complement and coagulation cascades,hsa04936:Alcoholic liver disease,hsa05020:Prion disease,hsa05133:Pertussis,hsa05142:Chagas disease,hsa05150:Staphylococcus aureus infection,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	613652~C1q deficiency,		SM00110:C1Q,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-1015~Disulfide bond,	CARBOHYD:O-linked (Gal...) hydroxylysine,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:C1q,DOMAIN:Collagen-like,REGION:Disordered,
C3	complement C3(C3)	Homo sapiens	GO:0001798~positive regulation of type IIa hypersensitivity,GO:0001934~positive regulation of protein phosphorylation,GO:0001970~positive regulation of activation of membrane attack complex,GO:0006631~fatty acid metabolic process,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006956~complement activation,GO:0006957~complement activation, alternative pathway,GO:0006958~complement activation, classical pathway,GO:0007165~signal transduction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0009617~response to bacterium,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010828~positive regulation of glucose transport,GO:0010866~regulation of triglyceride biosynthetic process,GO:0010884~positive regulation of lipid storage,GO:0010951~negative regulation of endopeptidase activity,GO:0016322~neuron remodeling,GO:0035846~oviduct epithelium development,GO:0045745~positive regulation of G-protein coupled receptor protein signaling pathway,GO:0045766~positive regulation of angiogenesis,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0097242~beta-amyloid clearance,GO:0097278~complement-dependent cytotoxicity,GO:1905114~cell surface receptor signaling pathway involved in cell-cell signaling,GO:2000427~positive regulation of apoptotic cell clearance,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0032991~macromolecular complex,GO:0034774~secretory granule lumen,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0004866~endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0031715~C5L2 anaphylatoxin chemotactic receptor binding,	IPR000020:Anaphylatoxin/fibulin,IPR001134:Netrin domain,IPR001599:Alpha-2-macroglobulin,IPR001840:Complement C3a/C4a/C5a anaphylatoxin,IPR002890:Alpha-2-macroglobulin, N-terminal,IPR008930:Terpenoid cyclases/protein prenyltransferase alpha-alpha toroid,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR009048:Alpha-macroglobulin, receptor-binding,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR011626:A-macroglobulin complement component,IPR013783:Immunoglobulin-like fold,IPR018081:Anaphylatoxin,IPR018933:Netrin module, non-TIMP type,IPR019742:Alpha-2-macroglobulin, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04145:Phagosome,hsa04610:Complement and coagulation cascades,hsa04613:Neutrophil extracellular trap formation,hsa04936:Alcoholic liver disease,hsa05131:Shigellosis,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05140:Leishmaniasis,hsa05142:Chagas disease,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05203:Viral carcinogenesis,hsa05322:Systemic lupus erythematosus,	611378~Macular degeneration, age-related, 9,612925~Hemolytic uremic syndrome, atypical, susceptibility to, 5,613779~C3 deficiency,		SM00104:ANATO,SM00643:C345C,SM01359:SM01359,SM01360:SM01360,SM01361:SM01361,	KW-0179~Complement alternate pathway,KW-0180~Complement pathway,KW-0276~Fatty acid metabolism,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,KW-0443~Lipid metabolism,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0913~Age-related macular degeneration,KW-1068~Hemolytic uremic syndrome,	KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0882~Thioester bond,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Isoglutamyl cysteine thioester (Cys-Gln),DISULFID:Interchain (between beta and alpha chains),DOMAIN:A2M_recep,DOMAIN:Anaphylatoxin-like,DOMAIN:MG1,DOMAIN:MG2,DOMAIN:NTR,DOMAIN:TED_complement,MUTAGEN:D->A: Impaired binding of C3d to CR2.,MUTAGEN:D->A: Minor effect on binding of C3d to CR2.,MUTAGEN:D->A: No effect on binding of C3d to CR2.,MUTAGEN:E->A: Impaired binding of C3d to CR2.,MUTAGEN:E->A: Minor effect on binding of C3d to CR2.,MUTAGEN:E->A: No effect on binding of C3d to CR2.,MUTAGEN:IL->RR: Impaired binding of C3d to CR2; when associated with A-1163.,MUTAGEN:K->A: Impaired binding of C3d to CR2.,MUTAGEN:N->A: No effect on binding of C3d to CR2. Impaired binding of C3d to CR2; when associated with 1108-R-R-1109.,MUTAGEN:N->R: Impaired binding of C3d to CR2.,MUTAGEN:R->M: Impaired binding of C3d to CR2.,PEPTIDE:Complement C3f fragment,REGION:Disordered,REGION:Interaction with CFP/properdin,SITE:Cleavage; by C3 convertase,SITE:Cleavage; by carboxypeptidases,SITE:Cleavage; by factor I,SITE:Coordinates Mg2+ for interaction with Complement factor B Bb fragment,
C4A	complement C4A (Rodgers blood group)(C4A)	Homo sapiens	GO:0006954~inflammatory response,GO:0006956~complement activation,GO:0006958~complement activation, classical pathway,GO:0010951~negative regulation of endopeptidase activity,GO:0045087~innate immune response,GO:2000427~positive regulation of apoptotic cell clearance,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0001849~complement component C1q binding,GO:0004866~endopeptidase inhibitor activity,	IPR000020:Anaphylatoxin/fibulin,IPR001134:Netrin domain,IPR001599:Alpha-2-macroglobulin,IPR001840:Complement C3a/C4a/C5a anaphylatoxin,IPR002890:Alpha-2-macroglobulin, N-terminal,IPR008930:Terpenoid cyclases/protein prenyltransferase alpha-alpha toroid,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR009048:Alpha-macroglobulin, receptor-binding,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR011626:A-macroglobulin complement component,IPR013783:Immunoglobulin-like fold,IPR018081:Anaphylatoxin,IPR018933:Netrin module, non-TIMP type,IPR019742:Alpha-2-macroglobulin, conserved site,	hsa04610:Complement and coagulation cascades,hsa04936:Alcoholic liver disease,hsa05133:Pertussis,hsa05150:Staphylococcus aureus infection,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	614374~Blood group, Rodgers,614380~C4a deficiency,		SM00104:ANATO,SM00643:C345C,SM01359:SM01359,SM01360:SM01360,SM01361:SM01361,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0770~Synapse,KW-0964~Secreted,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0772~Systemic lupus erythematosus,	KW-0732~Signal,		KW-0095~Blood group antigen,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0882~Thioester bond,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,CROSSLNK:Isoglutamyl cysteine thioester (Cys-Gln),DOMAIN:Anaphylatoxin-like,DOMAIN:NTR,DOMAIN:TED_complement,REGION:Disordered,SITE:Responsible for effective binding to form amide bonds with immune aggregates or protein antigens,
C4B	complement C4B (Chido blood group)(C4B)	Homo sapiens	GO:0006954~inflammatory response,GO:0006956~complement activation,GO:0006958~complement activation, classical pathway,GO:0008228~opsonization,GO:0010951~negative regulation of endopeptidase activity,GO:0032490~detection of molecule of bacterial origin,GO:0045087~innate immune response,GO:2000427~positive regulation of apoptotic cell clearance,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0001848~complement binding,GO:0004866~endopeptidase inhibitor activity,GO:0030246~carbohydrate binding,	IPR000020:Anaphylatoxin/fibulin,IPR001134:Netrin domain,IPR001599:Alpha-2-macroglobulin,IPR001840:Complement C3a/C4a/C5a anaphylatoxin,IPR002890:Alpha-2-macroglobulin, N-terminal,IPR008930:Terpenoid cyclases/protein prenyltransferase alpha-alpha toroid,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR009048:Alpha-macroglobulin, receptor-binding,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR011626:A-macroglobulin complement component,IPR013783:Immunoglobulin-like fold,IPR018081:Anaphylatoxin,IPR018933:Netrin module, non-TIMP type,IPR019742:Alpha-2-macroglobulin, conserved site,	hsa04610:Complement and coagulation cascades,hsa04936:Alcoholic liver disease,hsa05133:Pertussis,hsa05150:Staphylococcus aureus infection,hsa05171:Coronavirus disease - COVID-19,hsa05322:Systemic lupus erythematosus,	614379~C4B deficiency,		SM00104:ANATO,SM00643:C345C,SM01359:SM01359,SM01360:SM01360,SM01361:SM01361,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0770~Synapse,KW-0964~Secreted,KW-0966~Cell projection,	KW-0772~Systemic lupus erythematosus,	KW-0732~Signal,		KW-0095~Blood group antigen,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0882~Thioester bond,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Isoglutamyl cysteine thioester (Cys-Gln),DOMAIN:A2M_N_2,DOMAIN:Anaphylatoxin-like,DOMAIN:NTR,DOMAIN:TED_complement,MUTAGEN:H->A: 20% decrease in hemolytic activity, 2-fold increase in C1-dependent binding to IgG.,MUTAGEN:H->D: 2.5-3 fold-decrease in hemolytic activity, 3-fold increase in C1-dependent binding to IgG.,MUTAGEN:I->A: 50-60% decrease in hemolytic activity and C1-dependent binding to IgG.,MUTAGEN:L->P: No effect on hemolytic activity, nor on C1-dependent binding to IgG.,MUTAGEN:S->C: 30-40% decrease in hemolytic activity and C1-dependent binding to IgG.,REGION:Disordered,
CFB	complement factor B(CFB)	Homo sapiens	GO:0006508~proteolysis,GO:0006956~complement activation,GO:0006957~complement activation, alternative pathway,GO:0009617~response to bacterium,	GO:0005576~extracellular region,GO:0005601~classical-complement-pathway C3/C5 convertase complex,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0001848~complement binding,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,	IPR000436:Sushi/SCR/CCP,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR002035:von Willebrand factor, type A,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR011360:Complement B/C2,IPR018114:Peptidase S1, trypsin family, active site,	hsa04610:Complement and coagulation cascades,hsa05150:Staphylococcus aureus infection,hsa05171:Coronavirus disease - COVID-19,	612924~Hemolytic uremic syndrome, atypical, susceptibility to, 4,615489~Macular degeneration, age-related, 14, reduced risk of,615561~Complement factor B deficiency,	PIRSF001154:complement B/C2,PIRSF500181:complement factor B [Parent=PIRSF001154],	SM00020:Tryp_SPc,SM00032:CCP,SM00327:VWA,	KW-0179~Complement alternate pathway,KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0913~Age-related macular degeneration,KW-1068~Hemolytic uremic syndrome,	KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-0971~Glycation,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (Glc) (glycation) lysine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase S1,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,DOMAIN:VWFA,MUTAGEN:KLK->AAA: Decreases binding to the pro-C3-convertase complex. Does not affect Complement C3 beta chain binding.,
CFI	complement factor I(CFI)	Homo sapiens	GO:0006508~proteolysis,GO:0006897~endocytosis,GO:0006958~complement activation, classical pathway,GO:0045087~innate immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,GO:0005044~scavenger receptor activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,GO:0046872~metal ion binding,	IPR001190:Speract/scavenger receptor,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR002350:Kazal domain,IPR003884:Factor I / membrane attack complex,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR017448:Speract/scavenger receptor-related,IPR018114:Peptidase S1, trypsin family, active site,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa04610:Complement and coagulation cascades,hsa05150:Staphylococcus aureus infection,	610984~Complement factor I deficiency,612923~Hemolytic uremic syndrome, atypical, susceptibility to, 3,615439~Macular degeneration, age-related, 13, susceptibility to,		SM00020:Tryp_SPc,SM00057:FIMAC,SM00192:LDLa,SM00202:SR,	KW-0180~Complement pathway,KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,	KW-0964~Secreted,	KW-0225~Disease variant,KW-0913~Age-related macular degeneration,KW-1068~Hemolytic uremic syndrome,	KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (between heavy and light chains),DISULFID:Interchain (with C-327),DOMAIN:Kazal-like,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:Peptidase S1,DOMAIN:SRCR,
CPLX1	complexin 1(CPLX1)	Homo sapiens	GO:0006836~neurotransmitter transport,GO:0006887~exocytosis,GO:0007268~chemical synaptic transmission,GO:0016079~synaptic vesicle exocytosis,GO:0017157~regulation of exocytosis,GO:0030073~insulin secretion,GO:0031630~regulation of synaptic vesicle fusion to presynaptic membrane,GO:0046928~regulation of neurotransmitter secretion,GO:0098967~exocytic insertion of neurotransmitter receptor to postsynaptic membrane,	GO:0005829~cytosol,GO:0030425~dendrite,GO:0031201~SNARE complex,GO:0043195~terminal bouton,GO:0043204~perikaryon,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0070032~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex,GO:0070554~synaptobrevin 2-SNAP-25-syntaxin-3-complexin complex,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0000149~SNARE binding,GO:0005326~neurotransmitter transporter activity,GO:0005515~protein binding,GO:0017075~syntaxin-1 binding,GO:0019905~syntaxin binding,	IPR008849:Synaphin,	hsa04721:Synaptic vesicle cycle,	617976~Developmental and epileptic encephalopathy 63,			KW-0268~Exocytosis,KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,REGION:Disordered,REGION:Interaction with the SNARE complex,
CNTN6	contactin 6(CNTN6)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007219~Notch signaling pathway,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0045747~positive regulation of Notch signaling pathway,GO:0070593~dendrite self-avoidance,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0042734~presynaptic membrane,GO:0098688~parallel fiber to Purkinje cell synapse,GO:0099026~anchored component of presynaptic membrane,	GO:0098632~protein binding involved in cell-cell adhesion,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,KW-0914~Notch signaling pathway,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,REGION:Disordered,TRANSMEM:Helical,
CNTNAP3B	contactin associated protein family member 3B(CNTNAP3B)	Homo sapiens	GO:0007155~cell adhesion,	GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR008979:Galactose-binding domain-like,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00181:EGF,SM00231:FA58C,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:F5/8 type C,DOMAIN:Fibrinogen C-terminal,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CNTNAP5	contactin associated protein family member 5(CNTNAP5)	Homo sapiens	GO:0007155~cell adhesion,	GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR000421:Coagulation factor 5/8 C-terminal type domain,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR008979:Galactose-binding domain-like,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00181:EGF,SM00231:FA58C,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:F5/8 type C,DOMAIN:Fibrinogen C-terminal,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
CPNE9	copine family member 9(CPNE9)	Homo sapiens	GO:0030154~cell differentiation,GO:0071277~cellular response to calcium ion,GO:1903861~positive regulation of dendrite extension,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005544~calcium-dependent phospholipid binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR002035:von Willebrand factor, type A,IPR010734:Copine,				SM00239:C2,SM00327:VWA,	KW-0221~Differentiation,			KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:VWFA,REGION:Disordered,
CORO7	coronin 7(CORO7)	Homo sapiens	GO:0006895~Golgi to endosome transport,GO:0007015~actin filament organization,GO:0007030~Golgi organization,GO:0015031~protein transport,GO:0016477~cell migration,GO:0030010~establishment of cell polarity,GO:0030041~actin filament polymerization,GO:0035332~positive regulation of hippo signaling,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031410~cytoplasmic vesicle,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR001680:WD40 repeat,IPR015048:Domain of unknown function DUF1899,IPR015505:Coronin,IPR015943:WD40/YVTN repeat-like-containing domain,IPR019775:WD40 repeat, conserved site,IPR020472:G-protein beta WD-40 repeat,IPR027331:Coronin 7,				SM00320:WD40,SM01166:SM01166,	KW-0653~Protein transport,KW-0813~Transport,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,		KW-0677~Repeat,KW-0853~WD repeat,		KW-0009~Actin-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:DUF1899,MUTAGEN:K->R: Does not affect ability to regulate the anterograde Golgi to endosome transport.,MUTAGEN:K->R: Impaired ability to regulate the anterograde Golgi to endosome transport.,REGION:Disordered,REPEAT:WD,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,REPEAT:WD 8,
CRHR1	corticotropin releasing hormone receptor 1(CRHR1)	Homo sapiens	GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0007188~adenylate cyclase-modulating G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007565~female pregnancy,GO:0007567~parturition,GO:0009755~hormone-mediated signaling pathway,GO:0010578~regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway,GO:0030325~adrenal gland development,GO:0042596~fear response,GO:0048149~behavioral response to ethanol,GO:0051458~corticotropin secretion,GO:0051867~general adaptation syndrome, behavioral process,GO:0071376~cellular response to corticotropin-releasing hormone stimulus,GO:1901386~negative regulation of voltage-gated calcium channel activity,GO:2000852~regulation of corticosterone secretion,	GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031226~intrinsic component of plasma membrane,GO:0043005~neuron projection,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0015056~corticotrophin-releasing factor receptor activity,GO:0017046~peptide hormone binding,GO:0043404~corticotropin-releasing hormone receptor activity,GO:0051424~corticotropin-releasing hormone binding,	IPR000832:GPCR, family 2, secretin-like,IPR001879:GPCR, family 2, extracellular hormone receptor domain,IPR003051:GPCR, family 2, corticotropin releasing factor receptor,IPR003052:GPCR, family 2, corticotropin releasing factor receptor, type 1,IPR017981:GPCR, family 2-like,IPR017983:GPCR, family 2, secretin-like, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04730:Long-term depression,hsa04934:Cushing syndrome,			SM00008:HormR,		KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F2_3,DOMAIN:G_PROTEIN_RECEP_F2_4,MUTAGEN:F->A: Nearly abolishes antagonist binding.,MUTAGEN:F->A: Slightly reduces antagonist binding.,MUTAGEN:I->A: Strongly reduces antagonist binding.,MUTAGEN:L->A: Nearly abolishes antagonist binding.,MUTAGEN:L->A: Strongly reduces antagonist binding.,MUTAGEN:M->A: Strongly reduces antagonist binding.,MUTAGEN:N->A: Nearly abolishes antagonist binding.,MUTAGEN:Q->A: Increases antagonist binding.,MUTAGEN:Y->A: Strongly reduces antagonist binding.,REGION:Disordered,REGION:Important for antagonist binding,REGION:Important for peptide agonist binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
CRYM	crystallin mu(CRYM)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006554~lysine catabolic process,GO:0007605~sensory perception of sound,GO:0042403~thyroid hormone metabolic process,GO:0070327~thyroid hormone transport,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005782~peroxisomal matrix,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0003714~transcription corepressor activity,GO:0005515~protein binding,GO:0042562~hormone binding,GO:0042803~protein homodimerization activity,GO:0047127~thiomorpholine-carboxylate dehydrogenase activity,GO:0050661~NADP binding,GO:0070324~thyroid hormone binding,	IPR003462:Ornithine cyclodeaminase/mu-crystallin,IPR023401:Ornithine cyclodeaminase, N-terminal,		616357~Deafness, autosomal dominant 40,	PIRSF001439:ornithine cyclodeaminase,			KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,		KW-0520~NAD,KW-0521~NADP,	KW-0560~Oxidoreductase,
CNGB1	cyclic nucleotide gated channel subunit beta 1(CNGB1)	Homo sapiens	GO:0001895~retina homeostasis,GO:0006812~cation transport,GO:0007601~visual perception,GO:0007602~phototransduction,GO:0010628~positive regulation of gene expression,GO:0021630~olfactory nerve maturation,GO:0033365~protein localization to organelle,GO:0035845~photoreceptor cell outer segment organization,GO:0045494~photoreceptor cell maintenance,GO:0050908~detection of light stimulus involved in visual perception,GO:0050911~detection of chemical stimulus involved in sensory perception of smell,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051899~membrane depolarization,GO:0098655~cation transmembrane transport,GO:0099105~ion channel modulating, G-protein coupled receptor signaling pathway,GO:1990834~response to odorant,	GO:0001750~photoreceptor outer segment,GO:0005886~plasma membrane,GO:0017071~intracellular cyclic nucleotide activated cation channel complex,GO:0030660~Golgi-associated vesicle membrane,GO:0043195~terminal bouton,GO:0060170~ciliary membrane,GO:1902495~transmembrane transporter complex,	GO:0005221~intracellular cyclic nucleotide activated cation channel activity,GO:0005222~intracellular cAMP activated cation channel activity,GO:0005223~intracellular cGMP activated cation channel activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0030552~cAMP binding,GO:0030553~cGMP binding,GO:0044877~macromolecular complex binding,	IPR000595:Cyclic nucleotide-binding domain,IPR014710:RmlC-like jelly roll fold,IPR018488:Cyclic nucleotide-binding, conserved site,IPR018490:Cyclic nucleotide-binding-like,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04740:Olfactory transduction,hsa04744:Phototransduction,	613767~Retinitis pigmentosa 45,		SM00100:cNMP,	KW-0406~Ion transport,KW-0552~Olfaction,KW-0716~Sensory transduction,KW-0813~Transport,KW-0844~Vision,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,	KW-0407~Ion channel,KW-1071~Ligand-gated ion channel,		COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cyclic nucleotide-binding,MOTIF:IQ-like,MUTAGEN:L->E: Loss of calcium/calmodulin modulation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=H1,TRANSMEM:Helical; Name=H2,TRANSMEM:Helical; Name=H3,TRANSMEM:Helical; Name=H4,TRANSMEM:Helical; Name=H5,TRANSMEM:Helical; Name=H6,
CCNA2	cyclin A2(CCNA2)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000086~G2/M transition of mitotic cell cycle,GO:0006275~regulation of DNA replication,GO:0006351~transcription, DNA-templated,GO:0007265~Ras protein signal transduction,GO:0016572~histone phosphorylation,GO:0031100~animal organ regeneration,GO:0033762~response to glucagon,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0043687~post-translational protein modification,GO:0044320~cellular response to leptin stimulus,GO:0044772~mitotic cell cycle phase transition,GO:0044843~cell cycle G1/S phase transition,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048146~positive regulation of fibroblast proliferation,GO:0051301~cell division,GO:0071314~cellular response to cocaine,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071456~cellular response to hypoxia,GO:0071732~cellular response to nitric oxide,GO:0090102~cochlea development,GO:1990314~cellular response to insulin-like growth factor stimulus,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0001939~female pronucleus,GO:0001940~male pronucleus,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0097124~cyclin A2-CDK2 complex,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04110:Cell cycle,hsa04152:AMPK signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05161:Hepatitis B,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05221:Acute myeloid leukemia,		PIRSF001771:cyclin, A/B/D/E types,	SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0195~Cyclin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	REGION:Disordered,
CCNB2	cyclin B2(CCNB2)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0001701~in utero embryonic development,GO:0007057~spindle assembly involved in female meiosis I,GO:0008315~meiotic G2/MI transition,GO:0040008~regulation of growth,GO:0043029~T cell homeostasis,GO:0044772~mitotic cell cycle phase transition,GO:0048538~thymus development,GO:0051301~cell division,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,	GO:0005515~protein binding,GO:0016538~cyclin-dependent protein serine/threonine kinase regulator activity,GO:0045296~cadherin binding,	IPR004367:Cyclin, C-terminal domain,IPR006671:Cyclin, N-terminal,IPR013763:Cyclin-like,	hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04914:Progesterone-mediated oocyte maturation,hsa05166:Human T-cell leukemia virus 1 infection,hsa05170:Human immunodeficiency virus 1 infection,		PIRSF001771:cyclin, A/B/D/E types,	SM00385:CYCLIN,SM01332:SM01332,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,					KW-0195~Cyclin,	KW-0597~Phosphoprotein,	DOMAIN:Cyclin N-terminal,
CDK1	cyclin dependent kinase 1(CDK1)	Homo sapiens	GO:0000086~G2/M transition of mitotic cell cycle,GO:0000226~microtubule cytoskeleton organization,GO:0006260~DNA replication,GO:0006281~DNA repair,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0007098~centrosome cycle,GO:0007344~pronuclear fusion,GO:0007569~cell aging,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010971~positive regulation of G2/M transition of mitotic cell cycle,GO:0014038~regulation of Schwann cell differentiation,GO:0014070~response to organic cyclic compound,GO:0014075~response to amine,GO:0014823~response to activity,GO:0016477~cell migration,GO:0016570~histone modification,GO:0016579~protein deubiquitination,GO:0018105~peptidyl-serine phosphorylation,GO:0018107~peptidyl-threonine phosphorylation,GO:0030261~chromosome condensation,GO:0030855~epithelial cell differentiation,GO:0031100~animal organ regeneration,GO:0034501~protein localization to kinetochore,GO:0042307~positive regulation of protein import into nucleus,GO:0042493~response to drug,GO:0042752~regulation of circadian rhythm,GO:0043066~negative regulation of apoptotic process,GO:0045471~response to ethanol,GO:0045740~positive regulation of DNA replication,GO:0045995~regulation of embryonic development,GO:0046686~response to cadmium ion,GO:0046688~response to copper ion,GO:0046718~viral entry into host cell,GO:0048144~fibroblast proliferation,GO:0048511~rhythmic process,GO:0048678~response to axon injury,GO:0051301~cell division,GO:0055015~ventricular cardiac muscle cell development,GO:0060045~positive regulation of cardiac muscle cell proliferation,GO:0065003~macromolecular complex assembly,GO:0070301~cellular response to hydrogen peroxide,GO:0070371~ERK1 and ERK2 cascade,GO:0071407~cellular response to organic cyclic compound,GO:0090166~Golgi disassembly,GO:1900182~positive regulation of protein localization to nucleus,GO:1905448~positive regulation of mitochondrial ATP synthesis coupled electron transport,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0000781~chromosome, telomeric region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,GO:0005789~endoplasmic reticulum membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0016020~membrane,GO:0030496~midbody,GO:0070062~extracellular exosome,GO:0072686~mitotic spindle,GO:0097125~cyclin B1-CDK1 complex,	GO:0001618~virus receptor activity,GO:0003682~chromatin binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0030332~cyclin binding,GO:0030544~Hsp70 protein binding,GO:0035173~histone kinase activity,GO:0097472~cyclin-dependent protein kinase activity,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa04114:Oocyte meiosis,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04540:Gap junction,hsa04914:Progesterone-mediated oocyte maturation,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,			SM00220:S_TKc,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,KW-1183~Host cell receptor for virus entry,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Protein kinase,MUTAGEN:TY->AF: Abnormal cell cycle exhibiting only M-phase without completing either karyokinesis or cytokinesis.,MUTAGEN:Y->D,E: Constitutive polyubiquitination.,
CDK5R2	cyclin dependent kinase 5 regulatory subunit 2(CDK5R2)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0001764~neuron migration,GO:0007411~axon guidance,GO:0007420~brain development,GO:0021549~cerebellum development,GO:0021722~superior olivary nucleus maturation,GO:0021766~hippocampus development,GO:0021819~layer formation in cerebral cortex,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045956~positive regulation of calcium ion-dependent exocytosis,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016533~cyclin-dependent protein kinase 5 holoenzyme complex,GO:0030426~growth cone,GO:0043005~neuron projection,	GO:0003779~actin binding,GO:0008289~lipid binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,GO:0061575~cyclin-dependent protein serine/threonine kinase activator activity,	IPR004944:Cyclin-dependent kinase 5 activator,			PIRSF009324:cyclin-dependent kinase 5, regulatory subunit (activating),			KW-0472~Membrane,KW-1003~Cell membrane,			KW-0446~Lipid-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,LIPID:N-myristoyl glycine,MUTAGEN:G->A: Absent from the cell periphery.,REGION:Disordered,
CDK6	cyclin dependent kinase 6(CDK6)	Homo sapiens	GO:0000082~G1/S transition of mitotic cell cycle,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001954~positive regulation of cell-matrix adhesion,GO:0003323~type B pancreatic cell development,GO:0006468~protein phosphorylation,GO:0007219~Notch signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0009615~response to virus,GO:0010468~regulation of gene expression,GO:0010628~positive regulation of gene expression,GO:0014002~astrocyte development,GO:0021542~dentate gyrus development,GO:0021670~lateral ventricle development,GO:0033077~T cell differentiation in thymus,GO:0042063~gliogenesis,GO:0043697~cell dedifferentiation,GO:0045596~negative regulation of cell differentiation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045646~regulation of erythrocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045786~negative regulation of cell cycle,GO:0048146~positive regulation of fibroblast proliferation,GO:0048699~generation of neurons,GO:0050680~negative regulation of epithelial cell proliferation,GO:0051301~cell division,GO:0051726~regulation of cell cycle,GO:0060218~hematopoietic stem cell differentiation,GO:1902036~regulation of hematopoietic stem cell differentiation,GO:2000145~regulation of cell motility,GO:2000773~negative regulation of cellular senescence,	GO:0000307~cyclin-dependent protein kinase holoenzyme complex,GO:0001726~ruffle,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005829~cytosol,GO:0016592~mediator complex,GO:0097132~cyclin D2-CDK6 complex,	GO:0004693~cyclin-dependent protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008353~RNA polymerase II carboxy-terminal domain kinase activity,GO:0030332~cyclin binding,GO:0098770~FBXO family protein binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,	hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04934:Cushing syndrome,hsa05160:Hepatitis C,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05212:Pancreatic cancer,hsa05214:Glioma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,	616080~Microcephaly 12, primary, autosomal recessive,		SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0221~Differentiation,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0905~Primary microcephaly,		KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,
CDKN2C	cyclin dependent kinase inhibitor 2C(CDKN2C)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000082~G1/S transition of mitotic cell cycle,GO:0007049~cell cycle,GO:0008285~negative regulation of cell proliferation,GO:0030308~negative regulation of cell growth,GO:0042326~negative regulation of phosphorylation,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0048709~oligodendrocyte differentiation,GO:0051726~regulation of cell cycle,GO:0072089~stem cell proliferation,GO:2000045~regulation of G1/S transition of mitotic cell cycle,GO:2000647~negative regulation of stem cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0004861~cyclin-dependent protein serine/threonine kinase inhibitor activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019901~protein kinase binding,	IPR002110:Ankyrin repeat,	hsa01522:Endocrine resistance,hsa04110:Cell cycle,hsa04934:Cushing syndrome,hsa05166:Human T-cell leukemia virus 1 infection,hsa05202:Transcriptional misregulation in cancer,			SM00248:ANK,	KW-0131~Cell cycle,			KW-0040~ANK repeat,KW-0677~Repeat,		KW-0195~Cyclin,KW-0418~Kinase,KW-0808~Transferase,		REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,
CRIP1	cysteine rich protein 1(CRIP1)	Homo sapiens	GO:0006955~immune response,GO:0007507~heart development,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0010033~response to organic substance,GO:0010043~response to zinc ion,GO:0010468~regulation of gene expression,GO:0060741~prostate gland stromal morphogenesis,GO:0071236~cellular response to antibiotic,GO:0071493~cellular response to UV-B,	GO:0005737~cytoplasm,	GO:0008270~zinc ion binding,GO:0042277~peptide binding,	IPR001781:Zinc finger, LIM-type,				SM00132:LIM,				KW-0440~LIM domain,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0007~Acetylation,KW-0488~Methylation,	DOMAIN:LIM zinc-binding,
CYS1	cystin 1(CYS1)	Homo sapiens		GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005929~cilium,GO:0060170~ciliary membrane,	GO:0005515~protein binding,							KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0519~Myristate,	COMPBIAS:Basic and acidic residues,LIPID:N-myristoyl glycine,MOTIF:Ciliary targeting motif,REGION:Disordered,
CYP2D6	cytochrome P450 family 2 subfamily D member 6(CYP2D6)	Homo sapiens	GO:0006082~organic acid metabolic process,GO:0006805~xenobiotic metabolic process,GO:0008202~steroid metabolic process,GO:0008203~cholesterol metabolic process,GO:0008210~estrogen metabolic process,GO:0009804~coumarin metabolic process,GO:0009820~alkaloid metabolic process,GO:0009822~alkaloid catabolic process,GO:0016098~monoterpenoid metabolic process,GO:0017144~drug metabolic process,GO:0019369~arachidonic acid metabolic process,GO:0033076~isoquinoline alkaloid metabolic process,GO:0042178~xenobiotic catabolic process,GO:0042572~retinol metabolic process,GO:0042737~drug catabolic process,GO:0042738~exogenous drug catabolic process,GO:0042759~long-chain fatty acid biosynthetic process,GO:0046483~heterocycle metabolic process,GO:0051100~negative regulation of binding,GO:0070989~oxidative demethylation,GO:0090350~negative regulation of cellular organofluorine metabolic process,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0008395~steroid hydroxylase activity,GO:0016491~oxidoreductase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0016712~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen,GO:0020037~heme binding,GO:0070330~aromatase activity,	IPR001128:Cytochrome P450,IPR002401:Cytochrome P450, E-class, group I,IPR008069:Cytochrome P450, E-class, group I, CYP2D-like,IPR017972:Cytochrome P450, conserved site,	hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa01522:Endocrine resistance,hsa04726:Serotonergic synapse,	608902~Codeine sensitivity,608902~Debrisoquine sensitivity,			KW-0153~Cholesterol metabolism,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,KW-1207~Sterol metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
CYP26B1	cytochrome P450 family 26 subfamily B member 1(CYP26B1)	Homo sapiens	GO:0001709~cell fate determination,GO:0001768~establishment of T cell polarity,GO:0001822~kidney development,GO:0006766~vitamin metabolic process,GO:0006805~xenobiotic metabolic process,GO:0006954~inflammatory response,GO:0007140~male meiosis,GO:0007283~spermatogenesis,GO:0009954~proximal/distal pattern formation,GO:0010628~positive regulation of gene expression,GO:0016125~sterol metabolic process,GO:0030326~embryonic limb morphogenesis,GO:0033189~response to vitamin A,GO:0034653~retinoic acid catabolic process,GO:0042573~retinoic acid metabolic process,GO:0043587~tongue morphogenesis,GO:0045580~regulation of T cell differentiation,GO:0048384~retinoic acid receptor signaling pathway,GO:0048387~negative regulation of retinoic acid receptor signaling pathway,GO:0060349~bone morphogenesis,GO:0061436~establishment of skin barrier,GO:0070268~cornification,GO:0071300~cellular response to retinoic acid,GO:2001037~positive regulation of tongue muscle cell differentiation,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,	GO:0001972~retinoic acid binding,GO:0004497~monooxygenase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008401~retinoic acid 4-hydroxylase activity,GO:0016491~oxidoreductase activity,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0016709~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen,GO:0020037~heme binding,	IPR001128:Cytochrome P450,IPR002403:Cytochrome P450, E-class, group IV,IPR017972:Cytochrome P450, conserved site,	hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,	614416~Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies,			KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,	KW-0225~Disease variant,KW-0989~Craniosynostosis,		KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,
CYP27B1	cytochrome P450 family 27 subfamily B member 1(CYP27B1)	Homo sapiens	GO:0006766~vitamin metabolic process,GO:0006816~calcium ion transport,GO:0008285~negative regulation of cell proliferation,GO:0010956~negative regulation of calcidiol 1-monooxygenase activity,GO:0010980~positive regulation of vitamin D 24-hydroxylase activity,GO:0030282~bone mineralization,GO:0030308~negative regulation of cell growth,GO:0030500~regulation of bone mineralization,GO:0032496~response to lipopolysaccharide,GO:0033280~response to vitamin D,GO:0034341~response to interferon-gamma,GO:0036378~calcitriol biosynthetic process from calciol,GO:0042359~vitamin D metabolic process,GO:0042369~vitamin D catabolic process,GO:0043627~response to estrogen,GO:0045618~positive regulation of keratinocyte differentiation,GO:0046697~decidualization,GO:0055074~calcium ion homeostasis,GO:0070314~G1 to G0 transition,GO:0070564~positive regulation of vitamin D receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,	GO:0004497~monooxygenase activity,GO:0004498~calcidiol 1-monooxygenase activity,GO:0005506~iron ion binding,GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen,GO:0020037~heme binding,	IPR001128:Cytochrome P450,IPR002401:Cytochrome P450, E-class, group I,IPR017972:Cytochrome P450, conserved site,	hsa00100:Steroid biosynthesis,hsa01100:Metabolic pathways,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa05152:Tuberculosis,	264700~Vitamin D-dependent rickets, type I,			KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,	KW-0225~Disease variant,	KW-0809~Transit peptide,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0503~Monooxygenase,KW-0560~Oxidoreductase,		BINDING:axial binding residue,TRANSIT:Mitochondrion,
CRLF1	cytokine receptor like factor 1(CRLF1)	Homo sapiens	GO:0001657~ureteric bud development,GO:0008284~positive regulation of cell proliferation,GO:0019221~cytokine-mediated signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0043524~negative regulation of neuron apoptotic process,GO:2000672~negative regulation of motor neuron apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,GO:0009897~external side of plasma membrane,GO:0043235~receptor complex,GO:0097058~CRLF-CLCF1 complex,	GO:0004896~cytokine receptor activity,GO:0005125~cytokine activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005515~protein binding,GO:0019955~cytokine binding,	IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015152:Growth hormone/erythropoietin receptor, ligand binding,		272430~Cold-induced sweating syndrome 1,		SM00060:FN3,		KW-0964~Secreted,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Ig-like C2-type,MOTIF:WSXWS motif,REGION:Disordered,
DXO	decapping exoribonuclease(DXO)	Homo sapiens	GO:0000956~nuclear-transcribed mRNA catabolic process,GO:0006402~mRNA catabolic process,GO:0050779~RNA destabilization,GO:0071028~nuclear mRNA surveillance,GO:0090305~nucleic acid phosphodiester bond hydrolysis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0000166~nucleotide binding,GO:0000287~magnesium ion binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0004518~nuclease activity,GO:0004527~exonuclease activity,GO:0008409~5'-3' exonuclease activity,GO:0034353~RNA pyrophosphohydrolase activity,GO:0046872~metal ion binding,	IPR013961:RAI1-like,						KW-0539~Nucleus,			KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0269~Exonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:RAI1,MUTAGEN:D->A: Abolishes the decapping activity on incomplete m7G cap mRNAs; when associated with A-253.,MUTAGEN:E->A: Abolishes the decapping activity on incomplete m7G cap mRNAs; when associated with A-236.,MUTAGEN:KR->AA: Impaired subcellular location, leading to localization both in cytoplasm and nucleus.,REGION:Disordered,
DLL3	delta like canonical Notch ligand 3(DLL3)	Homo sapiens	GO:0001501~skeletal system development,GO:0001756~somitogenesis,GO:0007219~Notch signaling pathway,GO:0007386~compartment pattern specification,GO:0030154~cell differentiation,GO:0048339~paraxial mesoderm development,GO:0050768~negative regulation of neurogenesis,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005112~Notch binding,GO:0005509~calcium ion binding,	IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011651:Notch ligand, N-terminal,IPR013032:EGF-like, conserved site,	hsa01522:Endocrine resistance,hsa04330:Notch signaling pathway,hsa04658:Th1 and Th2 cell differentiation,hsa05200:Pathways in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05224:Breast cancer,	277300~Spondylocostal dysostosis 1, autosomal recessive,		SM00179:EGF_CA,SM00181:EGF,	KW-0221~Differentiation,KW-0914~Notch signaling pathway,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:DSL,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
DDN	dendrin(DDN)	Homo sapiens	GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0032591~dendritic spine membrane,GO:0042995~cell projection,GO:0043204~perikaryon,GO:0045211~postsynaptic membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR026500:Dendrin,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,REGION:Interaction with ACTN1,REGION:Interaction with CD2AP and NPHS1,REGION:Interaction with MAGI2,REGION:Nuclear localization,
DERL3	derlin 3(DERL3)	Homo sapiens	GO:0018279~protein N-linked glycosylation via asparagine,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0030968~endoplasmic reticulum unfolded protein response,GO:1904153~negative regulation of retrograde protein transport, ER to cytosol,	GO:0000839~Hrd1p ubiquitin ligase ERAD-L complex,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0005047~signal recognition particle binding,GO:0005515~protein binding,GO:0044877~macromolecular complex binding,GO:0051787~misfolded protein binding,GO:1990381~ubiquitin-specific protease binding,	IPR007599:Derlin,	hsa04141:Protein processing in endoplasmic reticulum,					KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
DES	desmin(DES)	Homo sapiens	GO:0006936~muscle contraction,GO:0007010~cytoskeleton organization,GO:0008016~regulation of heart contraction,GO:0045109~intermediate filament organization,GO:0060538~skeletal muscle organ development,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0005911~cell-cell junction,GO:0005916~fascia adherens,GO:0014704~intercalated disc,GO:0030018~Z disc,GO:0031594~neuromuscular junction,GO:0042383~sarcolemma,GO:0045111~intermediate filament cytoskeleton,GO:0070062~extracellular exosome,GO:0097512~cardiac myofibril,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0042802~identical protein binding,	IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,	hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	181400~Scapuloperoneal syndrome, neurogenic, Kaeser type,601419~Myopathy, myofibrillar, 1,604765~Cardiomyopathy, dilated, 1I,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-0911~Desmin-related myopathy,KW-0947~Limb-girdle muscular dystrophy,KW-1060~Myofibrillar myopathy,	KW-0175~Coiled coil,		KW-0514~Muscle protein,	KW-0013~ADP-ribosylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:IF rod,MUTAGEN:A->E,R: Results in impaired filaments formation.,MUTAGEN:A->K,L,V: Does not result in impaired filaments formation.,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Head,REGION:Interaction with CRYAB,REGION:Interaction with NEB,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,
DGKK	diacylglycerol kinase kappa(DGKK)	Homo sapiens	GO:0006979~response to oxidative stress,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0030168~platelet activation,GO:0035556~intracellular signal transduction,GO:0046339~diacylglycerol metabolic process,GO:0046834~lipid phosphorylation,	GO:0005886~plasma membrane,	GO:0003951~NAD+ kinase activity,GO:0004143~diacylglycerol kinase activity,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000756:Diacylglycerol kinase, accessory domain,IPR001206:Diacylglycerol kinase, catalytic domain,IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR011993:Pleckstrin homology-like domain,IPR016064:ATP-NAD kinase-like domain,IPR017438:Inorganic polyphosphate/ATP-NAD kinase, domain 1,	hsa00561:Glycerolipid metabolism,hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,hsa04070:Phosphatidylinositol signaling system,hsa04072:Phospholipase D signaling pathway,hsa05231:Choline metabolism in cancer,			SM00045:DAGKa,SM00046:DAGKc,SM00109:C1,SM00233:PH,	KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:DAGKc,DOMAIN:PH,MUTAGEN:Y->F: Does not affect phosphorylation.,MUTAGEN:Y->F: Induces a strong reduction in phosphorylation but is still sensitive to H(2)O(2).,REGION:33 X 4 AA approximate tandem repeats of E-P-A-P,REGION:Disordered,REGION:Required for localization to the plasma membrane,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
DPYS	dihydropyrimidinase(DPYS)	Homo sapiens	GO:0006208~pyrimidine nucleobase catabolic process,GO:0006210~thymine catabolic process,GO:0006212~uracil catabolic process,GO:0006248~CMP catabolic process,GO:0006249~dCMP catabolic process,GO:0019482~beta-alanine metabolic process,GO:0046050~UMP catabolic process,GO:0046079~dUMP catabolic process,	GO:0005829~cytosol,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0002058~uracil binding,GO:0002059~thymine binding,GO:0004157~dihydropyrimidinase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016597~amino acid binding,GO:0016810~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds,GO:0042802~identical protein binding,GO:0051219~phosphoprotein binding,	IPR006680:Amidohydrolase 1,IPR011059:Metal-dependent hydrolase, composite domain,IPR011778:Hydantoinase/dihydropyrimidinase,	hsa00240:Pyrimidine metabolism,hsa00410:beta-Alanine metabolism,hsa00770:Pantothenate and CoA biosynthesis,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,	222748~Dihydropyrimidinuria,					KW-0225~Disease variant,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	BINDING:via carbamate group,REGION:Disordered,
DPEP1	dipeptidase 1(DPEP1)	Homo sapiens	GO:0006508~proteolysis,GO:0006629~lipid metabolic process,GO:0006691~leukotriene metabolic process,GO:0006749~glutathione metabolic process,GO:0006751~glutathione catabolic process,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0016999~antibiotic metabolic process,GO:0030336~negative regulation of cell migration,GO:0030593~neutrophil chemotaxis,GO:0035690~cellular response to drug,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0050667~homocysteine metabolic process,GO:0071277~cellular response to calcium ion,GO:0071466~cellular response to xenobiotic stimulus,GO:0071732~cellular response to nitric oxide,GO:0072340~cellular lactam catabolic process,GO:1901749~leukotriene D4 catabolic process,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0031225~anchored component of membrane,GO:0031528~microvillus membrane,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008235~metalloexopeptidase activity,GO:0008270~zinc ion binding,GO:0008800~beta-lactamase activity,GO:0016805~dipeptidase activity,GO:0034235~GPI anchor binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0046872~metal ion binding,GO:0070573~metallodipeptidase activity,GO:0072341~modified amino acid binding,	IPR000180:Peptidase M19, renal dipeptidase, active site,IPR008257:Peptidase M19, renal dipeptidase,					KW-0443~Lipid metabolism,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0224~Dipeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,LIPID:GPI-anchor amidated serine,MUTAGEN:D->L: Loss of ability to hydrolyze cystinyl-bis-glycine.,MUTAGEN:E->A: Loss of zinc binding.,MUTAGEN:E->C: Complete loss of activity.,MUTAGEN:E->D: Abolished dipeptidase activity. Does not affect ability to bind neutrophils.,MUTAGEN:E->Q: Partial loss of activity.,PROPEP:Removed in mature form,
DAAM2	dishevelled associated activator of morphogenesis 2(DAAM2)	Homo sapiens	GO:0007368~determination of left/right symmetry,GO:0016055~Wnt signaling pathway,GO:0021516~dorsal spinal cord development,GO:0030036~actin cytoskeleton organization,GO:0030335~positive regulation of cell migration,GO:0030833~regulation of actin filament polymerization,GO:0048715~negative regulation of oligodendrocyte differentiation,GO:0051489~regulation of filopodium assembly,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0090521~glomerular visceral epithelial cell migration,GO:2000050~regulation of non-canonical Wnt signaling pathway,GO:2000251~positive regulation of actin cytoskeleton reorganization,	GO:0070062~extracellular exosome,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0031267~small GTPase binding,	IPR010472:Diaphanous FH3,IPR010473:Diaphanous GTPase-binding,IPR011989:Armadillo-like helical,IPR014767:Diaphanous autoregulatory,IPR014768:GTPase-binding/formin homology 3,IPR015425:Actin-binding FH2,IPR016024:Armadillo-type fold,	hsa04310:Wnt signaling pathway,	619263~Nephrotic syndrome, type 24,		SM00498:FH2,SM01139:SM01139,SM01140:SM01140,	KW-0879~Wnt signaling pathway,		KW-0225~Disease variant,	KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:DAD,DOMAIN:Drf_GBD,DOMAIN:FH1,DOMAIN:FH2,DOMAIN:GBD/FH3,REGION:Disordered,
DOK2	docking protein 2(DOK2)	Homo sapiens	GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007265~Ras protein signal transduction,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005068~transmembrane receptor protein tyrosine kinase adaptor activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR001849:Pleckstrin homology domain,IPR002404:Insulin receptor substrate-1, PTB,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,SM00310:PTBI,	KW-0945~Host-virus interaction,					KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:IRS-type PTB,DOMAIN:PH,REGION:Disordered,
DOK6	docking protein 6(DOK6)	Homo sapiens	GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0043410~positive regulation of MAPK cascade,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0005515~protein binding,	IPR001849:Pleckstrin homology domain,IPR002404:Insulin receptor substrate-1, PTB,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,SM00310:PTBI,							KW-0597~Phosphoprotein,	DOMAIN:IRS-type PTB,DOMAIN:PH,MOTIF:DKFBH motif,REGION:Disordered,
DOK7	docking protein 7(DOK7)	Homo sapiens	GO:0007528~neuromuscular junction development,GO:0061098~positive regulation of protein tyrosine kinase activity,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005886~plasma membrane,GO:0045202~synapse,	GO:0005515~protein binding,GO:0008289~lipid binding,GO:0019901~protein kinase binding,	IPR001849:Pleckstrin homology domain,IPR002404:Insulin receptor substrate-1, PTB,IPR011993:Pleckstrin homology-like domain,		254300~Myasthenic syndrome, congenital, 10,618389~Fetal akinesia deformation sequence 3,		SM00233:PH,		KW-0472~Membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,		KW-0446~Lipid-binding,			COMPBIAS:Polar residues,DOMAIN:IRS-type PTB,DOMAIN:PH,MUTAGEN:R->A: Reduced stimulation of MUSK autophosphorylation; when associated with Q-158.,MUTAGEN:S->W: Reduced stimulation of MUSK autophosphorylation.,MUTAGEN:V->A: Reduced stimulation of MUSK autophosphorylation.,REGION:Disordered,
DUSP26	dual specificity phosphatase 26(DUSP26)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006470~protein dephosphorylation,GO:0043409~negative regulation of MAPK cascade,GO:0044387~negative regulation of protein kinase activity by regulation of protein phosphorylation,GO:0045785~positive regulation of cell adhesion,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1902310~positive regulation of peptidyl-serine dephosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,	GO:0002039~p53 binding,GO:0004647~phosphoserine phosphatase activity,GO:0004721~phosphoprotein phosphatase activity,GO:0004725~protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008138~protein tyrosine/serine/threonine phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0033549~MAP kinase phosphatase activity,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,	IPR000340:Dual specificity phosphatase, catalytic domain,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR016130:Protein-tyrosine phosphatase, active site,IPR020405:Atypical dual specificity phosphatase, subfamily A,IPR020422:Dual specificity phosphatase, subgroup, catalytic domain,				SM00195:DSPc,		KW-0333~Golgi apparatus,KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0904~Protein phosphatase,		ACT_SITE:Phosphocysteine intermediate,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->A,S: Loss of activity.,
DNM1P46	dynamin 1 pseudogene 46(DNM1P46)	Homo sapiens			GO:0003924~GTPase activity,	IPR020850:GTPase effector domain, GED,IPR022812:Dynamin,												COMPBIAS:Basic and acidic residues,DOMAIN:GED,REGION:Disordered,
DNAAF3	dynein axonemal assembly factor 3(DNAAF3)	Homo sapiens	GO:0007368~determination of left/right symmetry,GO:0007507~heart development,GO:0044458~motile cilium assembly,GO:0070286~axonemal dynein complex assembly,					606763~Ciliary dyskinesia, primary, 2,			KW-0970~Cilium biogenesis/degradation,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0990~Primary ciliary dyskinesia,KW-1012~Kartagener syndrome,KW-1186~Ciliopathy,					DOMAIN:DUF4470,DOMAIN:DUF4471,REGION:Disordered,
DNAH11	dynein axonemal heavy chain 11(DNAH11)	Homo sapiens	GO:0003341~cilium movement,GO:0003356~regulation of cilium beat frequency,GO:0007018~microtubule-based movement,GO:0007368~determination of left/right symmetry,GO:0007611~learning or memory,GO:0030317~flagellated sperm motility,GO:0035545~determination of left/right asymmetry in nervous system,GO:0060287~epithelial cilium movement involved in determination of left/right asymmetry,GO:0060411~cardiac septum morphogenesis,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005929~cilium,GO:0005930~axoneme,GO:0030286~dynein complex,GO:0031514~motile cilium,GO:0097728~9+0 motile cilium,GO:0097729~9+2 motile cilium,	GO:0005524~ATP binding,GO:0008569~ATP-dependent microtubule motor activity, minus-end-directed,GO:0045505~dynein intermediate chain binding,GO:0051959~dynein light intermediate chain binding,	IPR003593:AAA+ ATPase domain,IPR004273:Dynein heavy chain domain,IPR013594:Dynein heavy chain, domain-1,IPR013602:Dynein heavy chain, domain-2,IPR024317:Dynein heavy chain, P-loop containing D4 domain,IPR024743:Dynein heavy chain, coiled coil stalk,IPR026983:Dynein heavy chain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	611884~Ciliary dyskinesia, primary, 7, with or without situs inversus,		SM00382:AAA,		KW-0206~Cytoskeleton,KW-0243~Dynein,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,	KW-0225~Disease variant,KW-0990~Primary ciliary dyskinesia,KW-1012~Kartagener syndrome,KW-1186~Ciliopathy,	KW-0175~Coiled coil,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,		DOMAIN:AAA,DOMAIN:AAA_6,DOMAIN:AAA_8,DOMAIN:AAA_9,DOMAIN:AAA_lid_1,DOMAIN:AAA_lid_11,DOMAIN:DHC_N1,DOMAIN:DHC_N2,DOMAIN:Dynein_AAA_lid,DOMAIN:Dynein_heavy,DOMAIN:MT,REGION:AAA 1,REGION:AAA 2,REGION:AAA 3,REGION:AAA 4,REGION:AAA 5,REGION:AAA 6,REGION:Stalk,REGION:Stem,
EGR1	early growth response 1(EGR1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0002931~response to ischemia,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009749~response to glucose,GO:0010628~positive regulation of gene expression,GO:0030217~T cell differentiation,GO:0030509~BMP signaling pathway,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032868~response to insulin,GO:0032922~circadian regulation of gene expression,GO:0033233~regulation of protein sumoylation,GO:0035914~skeletal muscle cell differentiation,GO:0042981~regulation of apoptotic process,GO:0044849~estrous cycle,GO:0045475~locomotor rhythm,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046886~positive regulation of hormone biosynthetic process,GO:0060086~circadian temperature homeostasis,GO:0061418~regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070498~interleukin-1-mediated signaling pathway,GO:0071480~cellular response to gamma radiation,GO:0071504~cellular response to heparin,GO:0071506~cellular response to mycophenolic acid,GO:0072110~glomerular mesangial cell proliferation,GO:0072303~positive regulation of glomerular metanephric mesangial cell proliferation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0098759~cellular response to interleukin-8,GO:1901216~positive regulation of neuron death,GO:1901875~positive regulation of post-translational protein modification,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1902949~positive regulation of tau-protein kinase activity,GO:2000182~regulation of progesterone biosynthetic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0010385~double-stranded methylated DNA binding,GO:0035035~histone acetyltransferase binding,GO:0043565~sequence-specific DNA binding,GO:0044729~hemi-methylated DNA-binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,GO:1990841~promoter-specific chromatin binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR021839:Protein of unknown function DUF3432,IPR021849:Protein of unknown function DUF3446,	hsa04371:Apelin signaling pathway,hsa04912:GnRH signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05020:Prion disease,hsa05166:Human T-cell leukemia virus 1 infection,			SM00355:ZnF_C2H2,	KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,SITE:Interaction with DNA,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
EMILIN1	elastin microfibril interfacer 1(EMILIN1)	Homo sapiens	GO:0003180~aortic valve morphogenesis,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0008217~regulation of blood pressure,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010811~positive regulation of cell-substrate adhesion,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030194~positive regulation of blood coagulation,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030948~negative regulation of vascular endothelial growth factor receptor signaling pathway,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033627~cell adhesion mediated by integrin,GO:0042127~regulation of cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0048251~elastic fiber assembly,GO:0050866~negative regulation of cell activation,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1900426~positive regulation of defense response to bacterium,GO:1901203~positive regulation of extracellular matrix assembly,GO:1901731~positive regulation of platelet aggregation,GO:1904027~negative regulation of collagen fibril organization,GO:1905522~negative regulation of macrophage migration,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0034668~integrin alpha4-beta1 complex,GO:0070062~extracellular exosome,GO:1990971~EMILIN complex,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0030023~extracellular matrix constituent conferring elasticity,GO:0042802~identical protein binding,GO:0060090~binding, bridging,GO:0098640~integrin binding involved in cell-matrix adhesion,	IPR001073:Complement C1q protein,IPR008160:Collagen triple helix repeat,IPR008983:Tumour necrosis factor-like domain,IPR011489:EMI domain,				SM00110:C1Q,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0176~Collagen,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C1q,DOMAIN:Collagen-like,DOMAIN:EMI,REGION:Disordered,
EMILIN2	elastin microfibril interfacer 2(EMILIN2)	Homo sapiens	GO:0007155~cell adhesion,GO:0008217~regulation of blood pressure,GO:0030194~positive regulation of blood coagulation,GO:0030336~negative regulation of cell migration,GO:0033627~cell adhesion mediated by integrin,GO:0042127~regulation of cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:1900426~positive regulation of defense response to bacterium,GO:1901731~positive regulation of platelet aggregation,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:1990971~EMILIN complex,	GO:0005515~protein binding,GO:0030023~extracellular matrix constituent conferring elasticity,	IPR001073:Complement C1q protein,IPR008983:Tumour necrosis factor-like domain,IPR011489:EMI domain,				SM00110:C1Q,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0176~Collagen,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:C1q,DOMAIN:Collagen-like,DOMAIN:EMI,REGION:Disordered,
EMILIN3	elastin microfibril interfacer 3(EMILIN3)	Homo sapiens		GO:0005576~extracellular region,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0030023~extracellular matrix constituent conferring elasticity,GO:0042802~identical protein binding,	IPR011489:EMI domain,						KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:EMI,REGION:Disordered,
ERP27	endoplasmic reticulum protein 27(ERP27)	Homo sapiens	GO:0006457~protein folding,GO:0006986~response to unfolded protein,GO:0034976~response to endoplasmic reticulum stress,	GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,	GO:0005515~protein binding,						KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Thioredoxin,MOTIF:Prevents secretion from ER,MUTAGEN:D->G: Greatly reduces PDIA3 binding in vivo and in vitro.,MUTAGEN:E->K,A: Greatly reduces PDIA3 binding in vivo and in vitro.,MUTAGEN:I->A,L,W: Decreases somatostatin-14 binding.,MUTAGEN:I->W: Conserved PDIA3 binding in vivo and in vitro.,MUTAGEN:M->W: Decreases somatostatin-14 binding.,MUTAGEN:W->A: Greatly reduces PDIA3 binding in vivo and in vitro.,REGION:PDIA3-binding site,
ESM1	endothelial cell specific molecule 1(ESM1)	Homo sapiens	GO:0001525~angiogenesis,GO:0002040~sprouting angiogenesis,GO:0008284~positive regulation of cell proliferation,GO:1902204~positive regulation of hepatocyte growth factor receptor signaling pathway,	GO:0005576~extracellular region,	GO:0005171~hepatocyte growth factor receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,	IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,				SM00121:IB,	KW-0037~Angiogenesis,	KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DOMAIN:IGFBP N-terminal,REGION:Disordered,
EDN3	endothelin 3(EDN3)	Homo sapiens	GO:0001755~neural crest cell migration,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0003100~regulation of systemic arterial blood pressure by endothelin,GO:0006874~cellular calcium ion homeostasis,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007275~multicellular organism development,GO:0007411~axon guidance,GO:0008015~blood circulation,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0010460~positive regulation of heart rate,GO:0010468~regulation of gene expression,GO:0010961~cellular magnesium ion homeostasis,GO:0014826~vein smooth muscle contraction,GO:0019229~regulation of vasoconstriction,GO:0030072~peptide hormone secretion,GO:0030182~neuron differentiation,GO:0030318~melanocyte differentiation,GO:0030593~neutrophil chemotaxis,GO:0042310~vasoconstriction,GO:0043406~positive regulation of MAP kinase activity,GO:0045597~positive regulation of cell differentiation,GO:0045840~positive regulation of mitotic nuclear division,GO:0046887~positive regulation of hormone secretion,GO:0048016~inositol phosphate-mediated signaling,GO:0048070~regulation of developmental pigmentation,GO:0048675~axon extension,GO:0051649~establishment of localization in cell,GO:0060585~positive regulation of prostaglandin-endoperoxide synthase activity,GO:0071805~potassium ion transmembrane transport,GO:1901381~positive regulation of potassium ion transmembrane transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0031708~endothelin B receptor binding,	IPR001928:Endothelin-like toxin,IPR019764:Endothelin-like toxin, conserved site,IPR020475:Bibrotoxin/Sarafotoxin-D,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04270:Vascular smooth muscle contraction,hsa04924:Renin secretion,	613265~Waardenburg syndrome, type 4B,613712~Hirschsprung disease, susceptibility to, 4,		SM00272:END,		KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-0367~Hirschsprung disease,KW-0897~Waardenburg syndrome,	KW-0732~Signal,		KW-0838~Vasoactive,KW-0839~Vasoconstrictor,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:END,PEPTIDE:Endothelin-3,REGION:Disordered,REGION:Endothelin-like,SITE:Cleavage; by KEL,
ENHO	energy homeostasis associated(ENHO)	Homo sapiens	GO:0007165~signal transduction,GO:0045747~positive regulation of Notch signaling pathway,	GO:0005576~extracellular region,GO:0005886~plasma membrane,	GO:0005179~hormone activity,							KW-0964~Secreted,		KW-0732~Signal,				REGION:Disordered,
EN1	engrailed homeobox 1(EN1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008344~adult locomotory behavior,GO:0009653~anatomical structure morphogenesis,GO:0009953~dorsal/ventral pattern formation,GO:0009954~proximal/distal pattern formation,GO:0021549~cerebellum development,GO:0030182~neuron differentiation,GO:0030901~midbrain development,GO:0030917~midbrain-hindbrain boundary development,GO:0035115~embryonic forelimb morphogenesis,GO:0035176~social behavior,GO:0035264~multicellular organism growth,GO:0042220~response to cocaine,GO:0042756~drinking behavior,GO:0043473~pigmentation,GO:0043524~negative regulation of neuron apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048666~neuron development,GO:0061743~motor learning,GO:0071542~dopaminergic neuron differentiation,GO:1990403~embryonic brain development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0016020~membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000747:Homeodomain engrailed,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR019549:Homeobox engrailed, C-terminal,IPR019737:Homeobox engrailed-type, conserved site,IPR020479:Homeodomain, metazoa,		619218~ENDOVE syndrome, limb-brain type,		SM00389:HOX,		KW-0539~Nucleus,	KW-0242~Dwarfism,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,REGION:Disordered,
EN2	engrailed homeobox 2(EN2)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0030182~neuron differentiation,GO:0030901~midbrain development,GO:0030902~hindbrain development,GO:0043524~negative regulation of neuron apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048666~neuron development,GO:0071542~dopaminergic neuron differentiation,GO:1990403~embryonic brain development,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0016020~membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000747:Homeodomain engrailed,IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR019549:Homeobox engrailed, C-terminal,IPR019737:Homeobox engrailed-type, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,		KW-0539~Nucleus,	KW-1268~Autism spectrum disorder,KW-1269~Autism,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
EGFR	epidermal growth factor receptor(EGFR)	Homo sapiens	GO:0000165~MAPK cascade,GO:0000902~cell morphogenesis,GO:0001503~ossification,GO:0001892~embryonic placenta development,GO:0001934~positive regulation of protein phosphorylation,GO:0001942~hair follicle development,GO:0006412~translation,GO:0006898~receptor-mediated endocytosis,GO:0006970~response to osmotic stress,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007173~epidermal growth factor receptor signaling pathway,GO:0007202~activation of phospholipase C activity,GO:0007275~multicellular organism development,GO:0007435~salivary gland morphogenesis,GO:0007494~midgut development,GO:0007611~learning or memory,GO:0007623~circadian rhythm,GO:0008284~positive regulation of cell proliferation,GO:0010750~positive regulation of nitric oxide mediated signal transduction,GO:0010960~magnesium ion homeostasis,GO:0014066~regulation of phosphatidylinositol 3-kinase signaling,GO:0016101~diterpenoid metabolic process,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0021795~cerebral cortex cell migration,GO:0022008~neurogenesis,GO:0030154~cell differentiation,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0032930~positive regulation of superoxide anion generation,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033590~response to cobalamin,GO:0033594~response to hydroxyisoflavone,GO:0033674~positive regulation of kinase activity,GO:0034614~cellular response to reactive oxygen species,GO:0035690~cellular response to drug,GO:0038083~peptidyl-tyrosine autophosphorylation,GO:0038134~ERBB2-EGFR signaling pathway,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042060~wound healing,GO:0042177~negative regulation of protein catabolic process,GO:0042311~vasodilation,GO:0042327~positive regulation of phosphorylation,GO:0042698~ovulation cycle,GO:0042743~hydrogen peroxide metabolic process,GO:0043006~activation of phospholipase A2 activity by calcium-mediated signaling,GO:0043066~negative regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043586~tongue development,GO:0045737~positive regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0045739~positive regulation of DNA repair,GO:0045740~positive regulation of DNA replication,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045907~positive regulation of vasoconstriction,GO:0045930~negative regulation of mitotic cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046328~regulation of JNK cascade,GO:0046718~viral entry into host cell,GO:0046777~protein autophosphorylation,GO:0048143~astrocyte activation,GO:0048146~positive regulation of fibroblast proliferation,GO:0048546~digestive tract morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048812~neuron projection morphogenesis,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050999~regulation of nitric-oxide synthase activity,GO:0051205~protein insertion into membrane,GO:0051592~response to calcium ion,GO:0051897~positive regulation of protein kinase B signaling,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060252~positive regulation of glial cell proliferation,GO:0060571~morphogenesis of an epithelial fold,GO:0061029~eyelid development in camera-type eye,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0070141~response to UV-A,GO:0070257~positive regulation of mucus secretion,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071230~cellular response to amino acid stimulus,GO:0071260~cellular response to mechanical stimulus,GO:0071276~cellular response to cadmium ion,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0071549~cellular response to dexamethasone stimulus,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:0097421~liver regeneration,GO:0098609~cell-cell adhesion,GO:1900020~positive regulation of protein kinase C activity,GO:1900087~positive regulation of G1/S transition of mitotic cell cycle,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1902722~positive regulation of prolactin secretion,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1905208~negative regulation of cardiocyte differentiation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031965~nuclear membrane,GO:0032587~ruffle membrane,GO:0032991~macromolecular complex,GO:0043235~receptor complex,GO:0045121~membrane raft,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070435~Shc-EGFR complex,GO:0097489~multivesicular body, internal vesicle lumen,GO:0097708~intracellular vesicle,	GO:0001618~virus receptor activity,GO:0003682~chromatin binding,GO:0003690~double-stranded DNA binding,GO:0004672~protein kinase activity,GO:0004709~MAP kinase kinase kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004888~transmembrane signaling receptor activity,GO:0005006~epidermal growth factor-activated receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019900~kinase binding,GO:0019901~protein kinase binding,GO:0019903~protein phosphatase binding,GO:0030235~nitric-oxide synthase regulator activity,GO:0030296~protein tyrosine kinase activator activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0031625~ubiquitin protein ligase binding,GO:0042802~identical protein binding,GO:0045296~cadherin binding,GO:0048408~epidermal growth factor binding,GO:0051015~actin filament binding,GO:0051117~ATPase binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR016245:Tyrosine protein kinase, EGF/ERB/XmrK receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01522:Endocrine resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04144:Endocytosis,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04520:Adherens junction,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa04912:GnRH signaling pathway,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04934:Cushing syndrome,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05160:Hepatitis C,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05219:Bladder cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,hsa05230:Central carbon metabolism in cancer,hsa05231:Choline metabolism in cancer,hsa05235:PD-L1 expression and PD-1 checkpoint pathway in cancer,	211980~Adenocarcinoma of lung, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in,211980~Nonsmall cell lung cancer, susceptibility to,616069~Inflammatory skin and bowel disease, neonatal, 2,	PIRSF000619:tyrosine-protein kinase, EGF receptor type,	SM00219:TyrKc,SM00261:FU,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0217~Developmental protein,KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,KW-1183~Host cell receptor for virus entry,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical; partial,CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Furin-like,DOMAIN:GF_recep_IV,DOMAIN:PK_Tyr_Ser-Thr,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Decreased palmitoylation.,MUTAGEN:D->A: Increased EGF binding; when associated with A-590 and A-609.,MUTAGEN:D->A: Strongly reduced phosphorylation.,MUTAGEN:DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding.,MUTAGEN:E->A: Reduced phosphorylation.,MUTAGEN:ED->RK: Constitutively activated kinase.,MUTAGEN:F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:H->A: Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:I->A: Abolishes phosphorylation.,MUTAGEN:K->A,M: Abolishes kinase activity.,MUTAGEN:K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609.,MUTAGEN:L->A,P: Strongly reduced phosphorylation.,MUTAGEN:L->A: Abolishes phosphorylation.,MUTAGEN:L->A: Strongly reduced phosphorylation.,MUTAGEN:Missing: Abolishes palmitoylation.,MUTAGEN:Missing: Increased EGF binding.,MUTAGEN:N->A: Abolishes phosphorylation.,MUTAGEN:P->A: Reduced phosphorylation.,MUTAGEN:P->A: Strongly reduced phosphorylation.,MUTAGEN:Q->G: No effect on interaction with CBLC.,MUTAGEN:R->A: Abolishes phosphorylation.,MUTAGEN:R->A: Reduced phosphorylation.,MUTAGEN:R->E: Abolishes autophosphorylation and activation of downstream kinases.,MUTAGEN:R->G: Strongly decreases interaction with CBLC.,MUTAGEN:R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287.,MUTAGEN:T->A: Increased phosphorylation.,MUTAGEN:T->D: Strongly reduced phosphorylation.,MUTAGEN:V->A: Reduced autophosphorylation.,MUTAGEN:V->M: Constitutively activated kinase.,MUTAGEN:Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309.,MUTAGEN:Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092.,MUTAGEN:Y->F: Abolishes interaction with CBLC.,MUTAGEN:Y->F: No change in interaction with PIK3C2B.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016.,MUTAGEN:Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016.,REGION:Disordered,REGION:Important for dimerization, phosphorylation and activation,REPEAT:Approximate,SITE:Important for interaction with PIK3C2B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
EMP1	epithelial membrane protein 1(EMP1)	Homo sapiens	GO:0008219~cell death,GO:0008544~epidermis development,GO:0032060~bleb assembly,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003932:Epithelial membrane protein EMP-1,IPR004031:PMP-22/EMP/MP20/Claudin,IPR004032:PMP-22/EMP/MP20,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
EMP3	epithelial membrane protein 3(EMP3)	Homo sapiens	GO:0008219~cell death,GO:0032060~bleb assembly,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003934:Epithelial membrane protein EMP-3,IPR004031:PMP-22/EMP/MP20/Claudin,IPR004032:PMP-22/EMP/MP20,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
ESPNL	espin like(ESPNL)	Homo sapiens	GO:0007605~sensory perception of sound,GO:0051017~actin filament bundle assembly,	GO:0005737~cytoplasm,GO:0032426~stereocilium tip,	GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-1009~Hearing,	KW-0966~Cell projection,		KW-0040~ANK repeat,KW-0175~Coiled coil,KW-0677~Repeat,		KW-0009~Actin-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,REPEAT:ANK 8,REPEAT:ANK 9,
ETNPPL	ethanolamine-phosphate phospho-lyase(ETNPPL)	Homo sapiens		GO:0005759~mitochondrial matrix,	GO:0003824~catalytic activity,GO:0008483~transaminase activity,GO:0030170~pyridoxal phosphate binding,GO:0050459~ethanolamine-phosphate phospho-lyase activity,	IPR005814:Aminotransferase class-III,IPR015421:Pyridoxal phosphate-dependent transferase, major region, subdomain 1,IPR015422:Pyridoxal phosphate-dependent transferase, major region, subdomain 2,IPR015424:Pyridoxal phosphate-dependent transferase,	hsa00564:Glycerophospholipid metabolism,hsa01100:Metabolic pathways,		PIRSF000521:4-aminobutyrate/lysine/ornithine transaminase,			KW-0496~Mitochondrion,			KW-0663~Pyridoxal phosphate,	KW-0032~Aminotransferase,KW-0456~Lyase,KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,REGION:Disordered,
EHMT2	euchromatic histone lysine methyltransferase 2(EHMT2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006275~regulation of DNA replication,GO:0006306~DNA methylation,GO:0006325~chromatin organization,GO:0007130~synaptonemal complex assembly,GO:0007286~spermatid development,GO:0007616~long-term memory,GO:0009267~cellular response to starvation,GO:0009566~fertilization,GO:0010424~DNA methylation on cytosine within a CG sequence,GO:0016571~histone methylation,GO:0018027~peptidyl-lysine dimethylation,GO:0031667~response to nutrient levels,GO:0034968~histone lysine methylation,GO:0035265~organ growth,GO:0035690~cellular response to drug,GO:0036166~phenotypic switching,GO:0044030~regulation of DNA methylation,GO:0045471~response to ethanol,GO:0048148~behavioral response to cocaine,GO:0048599~oocyte development,GO:0048665~neuron fate specification,GO:0051567~histone H3-K9 methylation,GO:0051569~regulation of histone H3-K4 methylation,GO:0051570~regulation of histone H3-K9 methylation,GO:0060992~response to fungicide,GO:0070734~histone H3-K27 methylation,GO:0071314~cellular response to cocaine,GO:0071466~cellular response to xenobiotic stimulus,GO:1902902~negative regulation of autophagosome assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016279~protein-lysine N-methyltransferase activity,GO:0018024~histone-lysine N-methyltransferase activity,GO:0046974~histone methyltransferase activity (H3-K9 specific),GO:0046976~histone methyltransferase activity (H3-K27 specific),GO:0070742~C2H2 zinc finger domain binding,GO:1990841~promoter-specific chromatin binding,	IPR001214:SET domain,IPR002110:Ankyrin repeat,IPR007728:Pre-SET domain,IPR020683:Ankyrin repeat-containing domain,	hsa00310:Lysine degradation,hsa01100:Metabolic pathways,hsa04211:Longevity regulating pathway,			SM00248:ANK,SM00317:SET,SM00468:PreSET,		KW-0158~Chromosome,KW-0539~Nucleus,		KW-0040~ANK repeat,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,KW-0949~S-adenosyl-L-methionine,	KW-0156~Chromatin regulator,KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Post-SET,DOMAIN:Pre-SET,DOMAIN:SET,MUTAGEN:D->R: Impairs binding to histone H3K9me.,MUTAGEN:E->A: Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.,MUTAGEN:E->R: Impairs binding to histone H3K9me.,MUTAGEN:W->A: Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.,REGION:Disordered,REGION:Histone H3K9me binding,REGION:Interaction with histone H3,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:ANK 6,REPEAT:ANK 7,SITE:Histone H3K9me binding,
EEFSEC	eukaryotic elongation factor, selenocysteine-tRNA specific(EEFSEC)	Homo sapiens	GO:0001514~selenocysteine incorporation,GO:0006414~translational elongation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:1990904~ribonucleoprotein complex,	GO:0000049~tRNA binding,GO:0003746~translation elongation factor activity,GO:0003924~GTPase activity,GO:0005525~GTP binding,GO:0035368~selenocysteine insertion sequence binding,GO:0043021~ribonucleoprotein complex binding,	IPR000795:Elongation factor, GTP-binding domain,IPR009000:Translation elongation/initiation factor/Ribosomal, beta-barrel,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0648~Protein biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Tr-type G,DOMAIN:tr-type G,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:G1,REGION:G2,REGION:G3,REGION:G4,REGION:G5,
EXOC3L1	exocyst complex component 3 like 1(EXOC3L1)	Homo sapiens	GO:0006887~exocytosis,GO:0030072~peptide hormone secretion,GO:0051601~exocyst localization,	GO:0000145~exocyst,GO:0030133~transport vesicle,GO:0030141~secretory granule,	GO:0000149~SNARE binding,GO:0005515~protein binding,	IPR010326:Exocyst complex component Sec6,					KW-0268~Exocytosis,	KW-0968~Cytoplasmic vesicle,		KW-0175~Coiled coil,				REGION:Disordered,REGION:Mediates interaction with EXOC2, EXOC4 and EXOC5,
ELFN2	extracellular leucine rich repeat and fibronectin type III domain containing 2(ELFN2)	Homo sapiens	GO:0043086~negative regulation of catalytic activity,	GO:0005615~extracellular space,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,	GO:0004864~protein phosphatase inhibitor activity,	IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00369:LRR_TYP,		KW-0472~Membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0650~Protein phosphatase inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:LRRCT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ECM2	extracellular matrix protein 2(ECM2)	Homo sapiens	GO:0007160~cell-matrix adhesion,GO:0010811~positive regulation of cell-substrate adhesion,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005614~interstitial matrix,GO:0031012~extracellular matrix,	GO:0005178~integrin binding,GO:0008201~heparin binding,GO:0070052~collagen V binding,	IPR001007:von Willebrand factor, type C,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00214:VWC,SM00369:LRR_TYP,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,DOMAIN:LRRNT,DOMAIN:VWFC,MOTIF:Cell attachment site,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
FAM120B	family with sequence similarity 120B(FAM120B)	Homo sapiens	GO:0035357~peroxisome proliferator activated receptor signaling pathway,GO:0045444~fat cell differentiation,	GO:0005634~nucleus,	GO:0005515~protein binding,	IPR026784:Constitutive coactivator of PPAR-gamma,					KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,	KW-0488~Methylation,	COMPBIAS:Polar residues,REGION:Disordered,
FAM133A	family with sequence similarity 133 member A(FAM133A)	Homo sapiens			GO:0005515~protein binding,	IPR026766:Protein FAM133,												COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,REGION:Disordered,
FAM177B	family with sequence similarity 177 member B(FAM177B)	Homo sapiens																COMPBIAS:Acidic residues,REGION:Disordered,
FAM180A	family with sequence similarity 180 member A(FAM180A)	Homo sapiens		GO:0005576~extracellular region,								KW-0964~Secreted,		KW-0732~Signal,
FAM180B	family with sequence similarity 180 member B(FAM180B)	Homo sapiens		GO:0005576~extracellular region,	GO:0005515~protein binding,							KW-0964~Secreted,		KW-0732~Signal,
FAM186B	family with sequence similarity 186 member B(FAM186B)	Homo sapiens		GO:0032991~macromolecular complex,	GO:0005515~protein binding,									KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
FAM72B	family with sequence similarity 72 member B(FAM72B)	Homo sapiens		GO:0005829~cytosol,GO:0016020~membrane,GO:0043231~intracellular membrane-bounded organelle,		IPR026768:Protein FAM72,
FAM81A	family with sequence similarity 81 member A(FAM81A)	Homo sapiens		GO:0098978~glutamatergic synapse,GO:0099092~postsynaptic density, intracellular component,	GO:0005515~protein binding,									KW-0175~Coiled coil,
FAM83H	family with sequence similarity 83 member H(FAM83H)	Homo sapiens	GO:0007165~signal transduction,GO:0030335~positive regulation of cell migration,GO:0031214~biomineral tissue development,GO:0044380~protein localization to cytoskeleton,GO:0045104~intermediate filament cytoskeleton organization,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0045095~keratin filament,	GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:1990254~keratin filament binding,	IPR012461:Protein of unknown function DUF1669,		130900~Amelogenesis imperfecta, type IIIA,			KW-0091~Biomineralization,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0986~Amelogenesis imperfecta,				KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:FAM83,MUTAGEN:F->A: Decreased interaction with CSNK1A1 and loss of function in keratin cytoskeleton organization.,MUTAGEN:F->A: No effect on interaction with CSNK1A1 and function in keratin cytoskeleton organization.,REGION:Disordered,REGION:Mediates interaction with CSNK1A1 and is required for FAM83H activity in keratin cytoskeleton organization,
FABP5	fatty acid binding protein 5(FABP5)	Homo sapiens	GO:0006006~glucose metabolic process,GO:0006629~lipid metabolic process,GO:0006656~phosphatidylcholine biosynthetic process,GO:0008544~epidermis development,GO:0010829~negative regulation of glucose transport,GO:0015908~fatty acid transport,GO:0015909~long-chain fatty acid transport,GO:0031392~regulation of prostaglandin biosynthetic process,GO:0035360~positive regulation of peroxisome proliferator activated receptor signaling pathway,GO:0042593~glucose homeostasis,GO:0051930~regulation of sensory perception of pain,GO:1990379~lipid transport across blood brain barrier,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0030667~secretory granule membrane,GO:0035578~azurophil granule lumen,GO:0045202~synapse,GO:0070062~extracellular exosome,	GO:0001972~retinoic acid binding,GO:0005324~long-chain fatty acid transporter activity,GO:0005504~fatty acid binding,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0042802~identical protein binding,	IPR000463:Cytosolic fatty-acid binding,IPR000566:Lipocalin/cytosolic fatty-acid binding protein domain,IPR012674:Calycin,	hsa03320:PPAR signaling pathway,				KW-0445~Lipid transport,KW-0813~Transport,	KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,			KW-0446~Lipid-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:FABP,DOMAIN:Lipocln_cytosolic_FA-bd_dom,MOTIF:Nuclear localization signal,MUTAGEN:K->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-33.,MUTAGEN:K->A: Loss of ligand-induced nuclear import; when associated with A-33 and A-34.,MUTAGEN:R->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-34.,
FBLL1	fibrillarin like 1(FBLL1)	Homo sapiens	GO:0000494~box C/D snoRNA 3'-end processing,GO:0001835~blastocyst hatching,GO:0031167~rRNA methylation,GO:1990258~histone glutamine methylation,	GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0015030~Cajal body,GO:0031428~box C/D snoRNP complex,GO:0032040~small-subunit processome,	GO:0003723~RNA binding,GO:0008649~rRNA methyltransferase activity,GO:1990259~histone-glutamine methyltransferase activity,	IPR000692:Fibrillarin,IPR020813:Fibrillarin, conserved site,	hsa03008:Ribosome biogenesis in eukaryotes,			SM01206:SM01206,	KW-0698~rRNA processing,	KW-0539~Nucleus,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0687~Ribonucleoprotein,KW-0694~RNA-binding,KW-0808~Transferase,	KW-0488~Methylation,	REGION:Disordered,
FAP	fibroblast activation protein alpha(FAP)	Homo sapiens	GO:0001525~angiogenesis,GO:0006508~proteolysis,GO:0007155~cell adhesion,GO:0010710~regulation of collagen catabolic process,GO:0010716~negative regulation of extracellular matrix disassembly,GO:0043542~endothelial cell migration,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:0051726~regulation of cell cycle,GO:0051917~regulation of fibrinolysis,GO:0060244~negative regulation of cell proliferation involved in contact inhibition,GO:0097325~melanocyte proliferation,GO:1900119~positive regulation of execution phase of apoptosis,GO:1902362~melanocyte apoptotic process,GO:1903054~negative regulation of extracellular matrix organization,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030027~lamellipodium,GO:0031258~lamellipodium membrane,GO:0032587~ruffle membrane,GO:0045177~apical part of cell,GO:0045178~basal part of cell,GO:1905368~peptidase complex,	GO:0002020~protease binding,GO:0004175~endopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008233~peptidase activity,GO:0008236~serine-type peptidase activity,GO:0008239~dipeptidyl-peptidase activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR001375:Peptidase S9, prolyl oligopeptidase, catalytic domain,IPR002469:Peptidase S9B, dipeptidylpeptidase IV N-terminal,IPR002471:Peptidase S9, serine active site,					KW-0037~Angiogenesis,KW-0053~Apoptosis,KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:DPPIV_N,DOMAIN:Peptidase_S9,MUTAGEN:A->D,N: Inhibits endopeptidase activity. Increases dipeptidyl peptidase activity.,MUTAGEN:A->F,V: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:A->Q: Inhibits endopeptidase activity. No change in dipeptidyl peptidase activity.,MUTAGEN:A->S,T: Reduces strongly endopeptidase activity. No change in dipeptidyl peptidase activity.,MUTAGEN:E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-203.,MUTAGEN:E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-204.,MUTAGEN:N->A: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:R->A,M,E: Reduces dipeptidyl peptidase and endopeptidase activities.,MUTAGEN:S->A: Reduces dipeptidyl peptidase and gelatinolytic activities. Does not inhibit cell adhesion, migration and invasion.,MUTAGEN:Y->F: Reduces dipeptidyl peptidase and endopeptidase activities.,REGION:substrate,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
FMOD	fibromodulin(FMOD)	Homo sapiens	GO:0007181~transforming growth factor beta receptor complex assembly,GO:0030199~collagen fibril organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005796~Golgi lumen,GO:0031012~extracellular matrix,GO:0043202~lysosomal lumen,	GO:0030021~extracellular matrix structural constituent conferring compression resistance,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR027215:Fibromodulin,	hsa04350:TGF-beta signaling pathway,			SM00013:LRRNT,SM00369:LRR_TYP,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (keratan sulfate) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,SITE:Not sulfated,
FN1	fibronectin 1(FN1)	Homo sapiens	GO:0001525~angiogenesis,GO:0001932~regulation of protein phosphorylation,GO:0006953~acute-phase response,GO:0007044~cell-substrate junction assembly,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007161~calcium-independent cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007399~nervous system development,GO:0007507~heart development,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0009611~response to wounding,GO:0010628~positive regulation of gene expression,GO:0010952~positive regulation of peptidase activity,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018149~peptide cross-linking,GO:0033622~integrin activation,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035987~endodermal cell differentiation,GO:0045773~positive regulation of axon extension,GO:0048146~positive regulation of fibroblast proliferation,GO:0051702~interaction with symbiont,GO:0070372~regulation of ERK1 and ERK2 cascade,GO:0070527~platelet aggregation,GO:0071635~negative regulation of transforming growth factor beta production,GO:0072378~blood coagulation, fibrin clot formation,GO:1901166~neural crest cell migration involved in autonomic nervous system development,GO:1904237~positive regulation of substrate-dependent cell migration, cell attachment to substrate,	GO:0005576~extracellular region,GO:0005577~fibrinogen complex,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0005886~plasma membrane,GO:0016324~apical plasma membrane,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0002020~protease binding,GO:0005102~receptor binding,GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008022~protein C-terminus binding,GO:0008201~heparin binding,GO:0016504~peptidase activator activity,GO:0019899~enzyme binding,GO:0042802~identical protein binding,GO:0043394~proteoglycan binding,GO:0051087~chaperone binding,GO:0097718~disordered domain specific binding,	IPR000083:Fibronectin, type I,IPR000562:Fibronectin, type II, collagen-binding,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR013806:Kringle-like fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04810:Regulation of actin cytoskeleton,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05100:Bacterial invasion of epithelial cells,hsa05135:Yersinia infection,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05222:Small cell lung cancer,	184255~Spondylometaphyseal dysplasia, corner fracture type,601894~Glomerulopathy with fibronectin deposits 2,		SM00058:FN1,SM00059:FN2,SM00060:FN3,	KW-0011~Acute phase,KW-0037~Angiogenesis,KW-0130~Cell adhesion,KW-0133~Cell shape,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0558~Oxidation,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-?),DISULFID:Interchain (with C-2458),DISULFID:Interchain (with C-2462),DOMAIN:Fibronectin type-I,DOMAIN:Fibronectin type-I 1,DOMAIN:Fibronectin type-I 10,DOMAIN:Fibronectin type-I 11,DOMAIN:Fibronectin type-I 12,DOMAIN:Fibronectin type-I 2,DOMAIN:Fibronectin type-I 3,DOMAIN:Fibronectin type-I 4,DOMAIN:Fibronectin type-I 5,DOMAIN:Fibronectin type-I 6,DOMAIN:Fibronectin type-I 7,DOMAIN:Fibronectin type-I 8,DOMAIN:Fibronectin type-I 9,DOMAIN:Fibronectin type-II,DOMAIN:Fibronectin type-II 1,DOMAIN:Fibronectin type-II 2,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 10,DOMAIN:Fibronectin type-III 11,DOMAIN:Fibronectin type-III 12,DOMAIN:Fibronectin type-III 13; extra domain A,DOMAIN:Fibronectin type-III 14,DOMAIN:Fibronectin type-III 15,DOMAIN:Fibronectin type-III 16,DOMAIN:Fibronectin type-III 17,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8; extra domain B,DOMAIN:Fibronectin type-III 9,MOTIF:Cell attachment site,MUTAGEN:D->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-691 and A-694.,MUTAGEN:E->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-694 and A-696.,MUTAGEN:F->A: Loss of ability to form fibronectin aggregates; when associated with A-695.,MUTAGEN:F->A: Loss of ability to form fibronectin aggregates; when associated with A-697.,MUTAGEN:I->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-682 and A-692.,MUTAGEN:I->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-684 and A-692.,MUTAGEN:I->A: Little effect on ability to form fibronectin aggregates; when associated with A-682; A-684 and A-692.,MUTAGEN:L->A: No effect on secondary structure nor on fibronectin binding nor on activation of p38 K but abolishes polymerization activity; when associated with A-666.,MUTAGEN:L->A: Severely compromised ability to form fibronectin aggregates; when associated with A-641 and A-683.,MUTAGEN:R->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-691 and A-696.,MUTAGEN:S->A: Severely compromised ability to form fibronectin aggregates; when associated with A-641 and A-681.,MUTAGEN:V->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-682 and A-684.,MUTAGEN:Y->A: No effect on secondary structure nor on fibronectin binding nor on activation of p38 kinase but abolishes polymerization activity; when associated with A-663.,MUTAGEN:Y->A: Severely compromised ability to form fibronectin aggregates; when associated with A-681 and A-683.,REGION:Binds to FBLN1,REGION:Cell-attachment,REGION:Collagen-binding,REGION:Critical for collagen binding,REGION:Disordered,REGION:Fibrin- and heparin-binding 1,REGION:Fibrin-binding 2,REGION:Heparin-binding 2,REGION:Required for binding to LILRB4,REGION:V region (type III connecting segment, IIICS),SITE:Important for superfibronectin formation,
FNDC11	fibronectin type III domain containing 11(FNDC11)	Homo sapiens			GO:0005515~protein binding,	IPR003961:Fibronectin, type III,												DOMAIN:Fibronectin type-III,
FNDC7	fibronectin type III domain containing 7(FNDC7)	Homo sapiens		GO:0005576~extracellular region,		IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,
FLNA	filamin A(FLNA)	Homo sapiens	GO:0001525~angiogenesis,GO:0001837~epithelial to mesenchymal transition,GO:0001974~blood vessel remodeling,GO:0003007~heart morphogenesis,GO:0007195~adenylate cyclase-inhibiting dopamine receptor signaling pathway,GO:0007597~blood coagulation, intrinsic pathway,GO:0010572~positive regulation of platelet activation,GO:0010977~negative regulation of neuron projection development,GO:0016479~negative regulation of transcription from RNA polymerase I promoter,GO:0021943~formation of radial glial scaffolds,GO:0021987~cerebral cortex development,GO:0030036~actin cytoskeleton organization,GO:0030334~regulation of cell migration,GO:0031532~actin cytoskeleton reorganization,GO:0032231~regulation of actin filament bundle assembly,GO:0032233~positive regulation of actin filament bundle assembly,GO:0034394~protein localization to cell surface,GO:0035855~megakaryocyte development,GO:0042177~negative regulation of protein catabolic process,GO:0042307~positive regulation of protein import into nucleus,GO:0042789~mRNA transcription from RNA polymerase II promoter,GO:0043066~negative regulation of apoptotic process,GO:0043113~receptor clustering,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0044319~wound healing, spreading of cells,GO:0045022~early endosome to late endosome transport,GO:0045184~establishment of protein localization,GO:0045216~cell-cell junction organization,GO:0048680~positive regulation of axon regeneration,GO:0050808~synapse organization,GO:0050821~protein stabilization,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051220~cytoplasmic sequestering of protein,GO:0051764~actin crosslink formation,GO:0060271~cilium assembly,GO:0070527~platelet aggregation,GO:0071526~semaphorin-plexin signaling pathway,GO:0072659~protein localization to plasma membrane,GO:0090042~tubulin deacetylation,GO:0090307~mitotic spindle assembly,GO:0097368~establishment of Sertoli cell barrier,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1901381~positive regulation of potassium ion transmembrane transport,GO:1902396~protein localization to bicellular tight junction,GO:1905000~regulation of membrane repolarization during atrial cardiac muscle cell action potential,GO:1905031~regulation of membrane repolarization during cardiac muscle cell action potential,GO:2000179~positive regulation of neural precursor cell proliferation,GO:2001046~positive regulation of integrin-mediated signaling pathway,GO:2001224~positive regulation of neuron migration,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005884~actin filament,GO:0005886~plasma membrane,GO:0005903~brush border,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0030018~Z disc,GO:0030863~cortical cytoskeleton,GO:0031523~Myb complex,GO:0032432~actin filament bundle,GO:0043198~dendritic shaft,GO:0043204~perikaryon,GO:0044295~axonal growth cone,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0097440~apical dendrite,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1990779~glycoprotein Ib-IX-V complex,	GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005080~protein kinase C binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0015459~potassium channel regulator activity,GO:0019900~kinase binding,GO:0031267~small GTPase binding,GO:0031852~mu-type opioid receptor binding,GO:0034988~Fc-gamma receptor I complex binding,GO:0042803~protein homodimerization activity,GO:0044325~ion channel binding,GO:0045296~cadherin binding,GO:0046332~SMAD binding,GO:0051015~actin filament binding,GO:0051020~GTPase binding,	IPR001298:Filamin/ABP280 repeat,IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR017868:Filamin/ABP280 repeat-like,	hsa04010:MAPK signaling pathway,hsa04510:Focal adhesion,hsa05132:Salmonella infection,hsa05205:Proteoglycans in cancer,	300048~Congenital short bowel syndrome,300048~Intestinal pseudoobstruction, neuronal,300049~Heterotopia, periventricular, 1,300244~Terminal osseous dysplasia,300321~FG syndrome 2,304120~Otopalatodigital syndrome, type II,305620~Frontometaphyseal dysplasia 1,309350~Melnick-Needles syndrome,311300~Otopalatodigital syndrome, type I,314400~Cardiac valvular dysplasia, X-linked,		SM00033:CH,SM00557:IG_FLMN,	KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Calponin-homology (CH),DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-42 and R-135.,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-42 and R-43.,MUTAGEN:K->R: Abrogates ASB2alpha-mediated degradation without altering ASB2alpha binding; when associated with R-43 and R-135.,REGION:Actin-binding,REGION:Disordered,REGION:Hinge 1,REGION:Hinge 2,REGION:Interaction with furin,REGION:Self-association site, tail,REPEAT:Filamin,REPEAT:Filamin 1,REPEAT:Filamin 10,REPEAT:Filamin 11,REPEAT:Filamin 12,REPEAT:Filamin 13,REPEAT:Filamin 14,REPEAT:Filamin 15,REPEAT:Filamin 16,REPEAT:Filamin 17,REPEAT:Filamin 18,REPEAT:Filamin 19,REPEAT:Filamin 2,REPEAT:Filamin 20,REPEAT:Filamin 21,REPEAT:Filamin 22,REPEAT:Filamin 23,REPEAT:Filamin 24,REPEAT:Filamin 3,REPEAT:Filamin 4,REPEAT:Filamin 5,REPEAT:Filamin 6,REPEAT:Filamin 7,REPEAT:Filamin 8,REPEAT:Filamin 9,SITE:Cleavage; by calpain,
FLNC	filamin C(FLNC)	Homo sapiens	GO:0030036~actin cytoskeleton organization,GO:0030154~cell differentiation,GO:0045214~sarcomere organization,GO:0055001~muscle cell development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016528~sarcoplasm,GO:0030018~Z disc,GO:0042383~sarcolemma,GO:0043034~costamere,	GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0030506~ankyrin binding,GO:0042802~identical protein binding,GO:0051015~actin filament binding,	IPR001298:Filamin/ABP280 repeat,IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR013783:Immunoglobulin-like fold,IPR014756:Immunoglobulin E-set,IPR017868:Filamin/ABP280 repeat-like,	hsa04010:MAPK signaling pathway,hsa04510:Focal adhesion,hsa05132:Salmonella infection,hsa05205:Proteoglycans in cancer,	609524~Myopathy, myofibrillar, 5,614065~Myopathy, distal, 4,617047~Cardiomyopathy, familial hypertrophic, 26,617047~Cardiomyopathy, familial restrictive 5,		SM00033:CH,SM00557:IG_FLMN,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1060~Myofibrillar myopathy,	KW-0677~Repeat,		KW-0009~Actin-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,MUTAGEN:M->D: Abolishes dimerization.,MUTAGEN:Missing: No effect on sarcomere structure or contractile performance in mutant induced pluripotent stem cell-derived cardiomyocytes.,REGION:Actin-binding,REGION:Disordered,REGION:Hinge 1,REGION:Hinge 2,REGION:Interaction with INPPL1,REGION:Intradomain insert; mediate targeting to Z lines,REGION:Self-association site, tail,REPEAT:Filamin,REPEAT:Filamin 1,REPEAT:Filamin 10,REPEAT:Filamin 11,REPEAT:Filamin 12,REPEAT:Filamin 13,REPEAT:Filamin 14,REPEAT:Filamin 15,REPEAT:Filamin 16,REPEAT:Filamin 17,REPEAT:Filamin 18,REPEAT:Filamin 19,REPEAT:Filamin 2,REPEAT:Filamin 20; mediates interaction with XIRP1,REPEAT:Filamin 21,REPEAT:Filamin 22,REPEAT:Filamin 23,REPEAT:Filamin 24,REPEAT:Filamin 3,REPEAT:Filamin 4,REPEAT:Filamin 5,REPEAT:Filamin 6,REPEAT:Filamin 7,REPEAT:Filamin 8,REPEAT:Filamin 9,
FLOT1	flotillin 1(FLOT1)	Homo sapiens	GO:0001765~membrane raft assembly,GO:0001819~positive regulation of cytokine production,GO:0001934~positive regulation of protein phosphorylation,GO:0002090~regulation of receptor internalization,GO:0007409~axonogenesis,GO:0022617~extracellular matrix disassembly,GO:0032092~positive regulation of protein binding,GO:0032226~positive regulation of synaptic transmission, dopaminergic,GO:0032728~positive regulation of interferon-beta production,GO:0033227~dsRNA transport,GO:0034116~positive regulation of heterotypic cell-cell adhesion,GO:0034141~positive regulation of toll-like receptor 3 signaling pathway,GO:0034976~response to endoplasmic reticulum stress,GO:0035023~regulation of Rho protein signal transduction,GO:0044854~plasma membrane raft assembly,GO:0044857~plasma membrane raft organization,GO:0045807~positive regulation of endocytosis,GO:0048643~positive regulation of skeletal muscle tissue development,GO:0050821~protein stabilization,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051580~regulation of neurotransmitter uptake,GO:0060355~positive regulation of cell adhesion molecule production,GO:0070528~protein kinase C signaling,GO:0071360~cellular response to exogenous dsRNA,GO:0072659~protein localization to plasma membrane,GO:1901741~positive regulation of myoblast fusion,GO:1901890~positive regulation of cell junction assembly,GO:1903044~protein localization to membrane raft,GO:2000049~positive regulation of cell-cell adhesion mediated by cadherin,	GO:0001931~uropod,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005769~early endosome,GO:0005815~microtubule organizing center,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0005911~cell-cell junction,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016323~basolateral plasma membrane,GO:0016600~flotillin complex,GO:0030027~lamellipodium,GO:0030864~cortical actin cytoskeleton,GO:0031410~cytoplasmic vesicle,GO:0034451~centriolar satellite,GO:0042383~sarcolemma,GO:0042470~melanosome,GO:0044291~cell-cell contact zone,GO:0045121~membrane raft,GO:0048786~presynaptic active zone,GO:0070062~extracellular exosome,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,	GO:0002020~protease binding,GO:0005515~protein binding,GO:0035255~ionotropic glutamate receptor binding,	IPR001107:Band 7 protein,	hsa04910:Insulin signaling pathway,			SM00244:PHB,		KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,					KW-0597~Phosphoprotein,	DOMAIN:Flot,DOMAIN:PHB,REGION:Disordered,
FLT3	fms related receptor tyrosine kinase 3(FLT3)	Homo sapiens	GO:0001776~leukocyte homeostasis,GO:0002318~myeloid progenitor cell differentiation,GO:0002328~pro-B cell differentiation,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0008284~positive regulation of cell proliferation,GO:0010243~response to organonitrogen compound,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0019221~cytokine-mediated signaling pathway,GO:0030097~hemopoiesis,GO:0030154~cell differentiation,GO:0030183~B cell differentiation,GO:0031100~animal organ regeneration,GO:0033674~positive regulation of kinase activity,GO:0035726~common myeloid progenitor cell proliferation,GO:0038084~vascular endothelial growth factor signaling pathway,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042981~regulation of apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0046651~lymphocyte proliferation,GO:0046777~protein autophosphorylation,GO:0071345~cellular response to cytokine stimulus,GO:0071385~cellular response to glucocorticoid stimulus,GO:0097028~dendritic cell differentiation,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004896~cytokine receptor activity,GO:0005021~vascular endothelial growth factor-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019838~growth factor binding,GO:0035259~glucocorticoid receptor binding,GO:0043621~protein self-association,GO:0044877~macromolecular complex binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001824:Tyrosine-protein kinase, receptor class III, conserved site,IPR007110:Immunoglobulin-like domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04640:Hematopoietic cell lineage,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05221:Acute myeloid leukemia,hsa05230:Central carbon metabolism in cancer,	601626~Leukemia, acute myeloid, reduced survival in, somatic,601626~Leukemia, acute myeloid, somatic,613065~Leukemia, acute lymphoblastic, somatic,		SM00219:TyrKc,	KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,KW-0656~Proto-oncogene,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:Protein kinase,MUTAGEN:K->A: Abolishes kinase activity.,MUTAGEN:Y->F: Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2.,MUTAGEN:Y->F: No significant effect on tyrosine phosphorylation. Abolishes activation of STAT5A.,MUTAGEN:Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A.,REGION:Important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
FOLR1	folate receptor alpha(FOLR1)	Homo sapiens	GO:0001947~heart looping,GO:0003147~neural crest cell migration involved in heart formation,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0006898~receptor-mediated endocytosis,GO:0007155~cell adhesion,GO:0007342~fusion of sperm to egg plasma membrane,GO:0015884~folic acid transport,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0031103~axon regeneration,GO:0035036~sperm-egg recognition,GO:0046655~folic acid metabolic process,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0061626~pharyngeal arch artery morphogenesis,GO:0061713~anterior neural tube closure,GO:0070293~renal absorption,GO:0071231~cellular response to folic acid,GO:1904447~folic acid import into cell,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005768~endosome,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030133~transport vesicle,GO:0030136~clathrin-coated vesicle,GO:0031362~anchored component of external side of plasma membrane,GO:0031526~brush border membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0046658~anchored component of plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005542~folic acid binding,GO:0038023~signaling receptor activity,GO:0051870~methotrexate binding,GO:0061714~folic acid receptor activity,	IPR004269:Folate receptor,IPR018143:Folate receptor-like,	hsa01523:Antifolate resistance,hsa04144:Endocytosis,	613068~Neurodegeneration due to cerebral folate transport deficiency,			KW-0813~Transport,	KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0523~Neurodegeneration,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0290~Folate-binding,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Folate_rec,LIPID:GPI-anchor amidated serine,MUTAGEN:D->A: Strongly reduced affinity for folate.,MUTAGEN:H->A: Moderately reduced affinity for folate.,MUTAGEN:R->A: Moderately reduced affinity for folate.,MUTAGEN:S->A: Moderately reduced affinity for folate.,MUTAGEN:W->A: Moderately reduced affinity for folate.,MUTAGEN:Y->A: Moderately reduced affinity for folate.,MUTAGEN:Y->A: Slightly reduced affinity for folate.,PROPEP:Removed in mature form,TRANSMEM:Helical,
FSTL1	follistatin like 1(FSTL1)	Homo sapiens	GO:0007275~multicellular organism development,GO:0030154~cell differentiation,GO:0030510~regulation of BMP signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043542~endothelial cell migration,GO:0045446~endothelial cell differentiation,GO:0061484~hematopoietic stem cell homeostasis,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0070062~extracellular exosome,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,	IPR002048:EF-hand domain,IPR002350:Kazal domain,IPR003645:Follistatin-like, N-terminal,IPR011992:EF-hand-like domain,IPR015369:Follistatin/Osteonectin EGF domain,				SM00274:FOLN,SM00280:KAZAL,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:Follistatin-like,DOMAIN:Kazal-like,DOMAIN:VWFC,
FOXD3	forkhead box D3(FOXD3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001701~in utero embryonic development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0030154~cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001766:Transcription factor, fork head,IPR018122:Transcription factor, fork head, conserved site,		607836~Autoimmune disease, susceptibility to, 1,		SM00339:FH,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DNA_BIND:Fork-head,REGION:Disordered,
FZD7	frizzled class receptor 7(FZD7)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0007186~G-protein coupled receptor signaling pathway,GO:0010812~negative regulation of cell-substrate adhesion,GO:0014834~skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration,GO:0019827~stem cell population maintenance,GO:0030182~neuron differentiation,GO:0033077~T cell differentiation in thymus,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035567~non-canonical Wnt signaling pathway,GO:0038031~non-canonical Wnt signaling pathway via JNK cascade,GO:0042327~positive regulation of phosphorylation,GO:0042666~negative regulation of ectodermal cell fate specification,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046330~positive regulation of JNK cascade,GO:0048103~somatic stem cell division,GO:0060054~positive regulation of epithelial cell proliferation involved in wound healing,GO:0060070~canonical Wnt signaling pathway,GO:0060071~Wnt signaling pathway, planar cell polarity pathway,GO:0060231~mesenchymal to epithelial transition,GO:0060828~regulation of canonical Wnt signaling pathway,GO:0071300~cellular response to retinoic acid,GO:2000726~negative regulation of cardiac muscle cell differentiation,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0055038~recycling endosome membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005109~frizzled binding,GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0017147~Wnt-protein binding,GO:0030165~PDZ domain binding,GO:0042813~Wnt-activated receptor activity,	IPR000539:Frizzled protein,IPR015526:Frizzled/secreted frizzled-related protein,IPR017981:GPCR, family 2-like,IPR020067:Frizzled domain,IPR026552:Frizzled-7,	hsa04150:mTOR signaling pathway,hsa04310:Wnt signaling pathway,hsa04390:Hippo signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,hsa04916:Melanogenesis,hsa04934:Cushing syndrome,hsa05010:Alzheimer disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05217:Basal cell carcinoma,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,			SM00063:FRI,SM01330:SM01330,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:FZ,MOTIF:Lys-Thr-X-X-X-Trp motif, mediates interaction with the PDZ domain of Dvl family members,MOTIF:PDZ-binding,MUTAGEN:K->A: Impaired SDCBP-mediated interaction with phosphatidylinositol-4,5-bisphosphate.,SITE:Essential for SDCBP-mediated plasma membrane phosphatidylinositol-4,5-bisphosphate recognition,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
FUT9	fucosyltransferase 9(FUT9)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0006486~protein glycosylation,GO:0006487~protein N-linked glycosylation,GO:0006493~protein O-linked glycosylation,GO:0006688~glycosphingolipid biosynthetic process,GO:0009312~oligosaccharide biosynthetic process,GO:0010976~positive regulation of neuron projection development,GO:0030182~neuron differentiation,GO:0033692~cellular polysaccharide biosynthetic process,GO:0036065~fucosylation,GO:0036071~N-glycan fucosylation,GO:0042355~L-fucose catabolic process,GO:1903037~regulation of leukocyte cell-cell adhesion,GO:1903236~regulation of leukocyte tethering or rolling,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0005802~trans-Golgi network,GO:0016021~integral component of membrane,GO:0032580~Golgi cisterna membrane,GO:0032588~trans-Golgi network membrane,	GO:0005515~protein binding,GO:0008417~fucosyltransferase activity,GO:0017083~4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity,GO:0046920~alpha-(1->3)-fucosyltransferase activity,	IPR001503:Glycosyl transferase, family 10,	hsa00515:Mannose type O-glycan biosynthesis,hsa00601:Glycosphingolipid biosynthesis - lacto and neolacto series,hsa00603:Glycosphingolipid biosynthesis - globo and isoglobo series,hsa01100:Metabolic pathways,				KW-0443~Lipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glyco_tran_10_N,MUTAGEN:Missing: Does not affect glycosylation. Does not affect 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity. Affects subcellular location.,MUTAGEN:N->Q: Almost complete loss of alpha 1,3-fucosyltransferase activity. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-62. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-101.,MUTAGEN:N->Q: Significantly decrease alpha 1,3-fucosyltransferase activity. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-62. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-153. Loss of catalytic efficiency.,MUTAGEN:N->Q: Weakly decreases alpha 1,3-fucosyltransferase activity. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-101. Almost complete loss of alpha 1,3-fucosyltransferase activity; when associated with Q-153. Loss of catalytic efficiency.,MUTAGEN:S->A: Does not affect glycosylation; when associated with A-3. Does not affect 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity; when associated with A-3. Does not affects subcellular location; when associated with A-3.,MUTAGEN:S->A: Does not affect glycosylation; when associated with A-5. Does not affect 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity; when associated with A-5. Does not affect subcellular location; when associated with A-5.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
LGALS3	galectin 3(LGALS3)	Homo sapiens	GO:0002548~monocyte chemotaxis,GO:0006397~mRNA processing,GO:0008380~RNA splicing,GO:0030593~neutrophil chemotaxis,GO:0030855~epithelial cell differentiation,GO:0031334~positive regulation of protein complex assembly,GO:0031640~killing of cells of other organism,GO:0042129~regulation of T cell proliferation,GO:0045087~innate immune response,GO:0045806~negative regulation of endocytosis,GO:0048245~eosinophil chemotaxis,GO:0048246~macrophage chemotaxis,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050918~positive chemotaxis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070232~regulation of T cell apoptotic process,GO:0071674~mononuclear cell migration,GO:0071677~positive regulation of mononuclear cell migration,GO:0090280~positive regulation of calcium ion import,GO:1902041~regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1903614~negative regulation of protein tyrosine phosphatase activity,GO:2000521~negative regulation of immunological synapse formation,GO:2001189~negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005681~spliceosomal complex,GO:0005737~cytoplasm,GO:0005743~mitochondrial inner membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0030667~secretory granule membrane,GO:0070062~extracellular exosome,GO:0101003~ficolin-1-rich granule membrane,	GO:0003723~RNA binding,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0019863~IgE binding,GO:0019903~protein phosphatase binding,GO:0030246~carbohydrate binding,GO:0042056~chemoattractant activity,GO:0043236~laminin binding,GO:0070492~oligosaccharide binding,	IPR001079:Galectin, carbohydrate recognition domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR015534:Galectin-3,				SM00276:GLECT,SM00908:SM00908,	KW-0221~Differentiation,KW-0391~Immunity,KW-0399~Innate immunity,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,KW-0747~Spliceosome,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,	KW-0430~Lectin,	KW-0389~IgE-binding protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:Galectin,MOTIF:Nuclear export signal,REGION:8 X 9 AA tandem repeats of Y-P-G-X(3)-P-G-A,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4; approximate,REPEAT:5,REPEAT:6; approximate,REPEAT:7; approximate,REPEAT:8; approximate,
GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3(GABRA3)	Homo sapiens	GO:0007165~signal transduction,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007268~chemical synaptic transmission,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0051932~synaptic transmission, GABAergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0060079~excitatory postsynaptic potential,GO:0099505~regulation of presynaptic membrane potential,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0032590~dendrite membrane,GO:0034707~chloride channel complex,GO:0043005~neuron projection,GO:0045202~synapse,GO:0048787~presynaptic active zone membrane,GO:0098794~postsynapse,GO:0098982~GABA-ergic synapse,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,GO:1902711~GABA-A receptor complex,	GO:0004890~GABA-A receptor activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005237~inhibitory extracellular ligand-gated ion channel activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0008503~benzodiazepine receptor activity,GO:0022851~GABA-gated chloride ion channel activity,GO:0030594~neurotransmitter receptor activity,GO:0099507~ligand-gated ion channel activity involved in regulation of presynaptic membrane potential,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001390:Gamma-aminobutyric-acid A receptor, alpha subunit,IPR005433:Gamma-aminobutyric-acid A receptor, alpha 3 subunit,IPR006028:Gamma-aminobutyric acid A receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04723:Retrograde endocannabinoid signaling,hsa04727:GABAergic synapse,hsa04742:Taste transduction,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0675~Receptor,KW-0869~Chloride channel,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GABRA4	gamma-aminobutyric acid type A receptor subunit alpha4(GABRA4)	Homo sapiens	GO:0006821~chloride transport,GO:0007165~signal transduction,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007268~chemical synaptic transmission,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0051932~synaptic transmission, GABAergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0060079~excitatory postsynaptic potential,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0032590~dendrite membrane,GO:0034707~chloride channel complex,GO:0043005~neuron projection,GO:0045202~synapse,GO:0098794~postsynapse,GO:0098982~GABA-ergic synapse,GO:0099060~integral component of postsynaptic specialization membrane,GO:0099634~postsynaptic specialization membrane,GO:1902711~GABA-A receptor complex,	GO:0004890~GABA-A receptor activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005237~inhibitory extracellular ligand-gated ion channel activity,GO:0005254~chloride channel activity,GO:0008503~benzodiazepine receptor activity,GO:0022851~GABA-gated chloride ion channel activity,GO:0030594~neurotransmitter receptor activity,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001390:Gamma-aminobutyric-acid A receptor, alpha subunit,IPR005434:Gamma-aminobutyric-acid A receptor, alpha 4 subunit,IPR006028:Gamma-aminobutyric acid A receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04723:Retrograde endocannabinoid signaling,hsa04727:GABAergic synapse,hsa04742:Taste transduction,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,				KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0675~Receptor,KW-0869~Chloride channel,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GABRB3	gamma-aminobutyric acid type A receptor subunit beta3(GABRB3)	Homo sapiens	GO:0006821~chloride transport,GO:0007165~signal transduction,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007268~chemical synaptic transmission,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0051932~synaptic transmission, GABAergic,GO:0060021~palate development,GO:0060079~excitatory postsynaptic potential,GO:0071420~cellular response to histamine,GO:1902476~chloride transmembrane transport,GO:1904862~inhibitory synapse assembly,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0034707~chloride channel complex,GO:0043005~neuron projection,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:1902711~GABA-A receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0004890~GABA-A receptor activity,GO:0005216~ion channel activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005254~chloride channel activity,GO:0022851~GABA-gated chloride ion channel activity,GO:0030594~neurotransmitter receptor activity,GO:0042802~identical protein binding,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR002289:Gamma-aminobutyric-acid A receptor, beta subunit,IPR006028:Gamma-aminobutyric acid A receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04723:Retrograde endocannabinoid signaling,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,	612269~Epilepsy, childhood absence, susceptibility to, 5,617113~Developmental and epileptic encephalopathy 43,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0675~Receptor,KW-0869~Chloride channel,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GABRD	gamma-aminobutyric acid type A receptor subunit delta(GABRD)	Homo sapiens	GO:0006821~chloride transport,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0034220~ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050877~neurological system process,GO:0060079~excitatory postsynaptic potential,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0034707~chloride channel complex,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:1902711~GABA-A receptor complex,	GO:0004890~GABA-A receptor activity,GO:0005216~ion channel activity,GO:0005230~extracellular ligand-gated ion channel activity,GO:0005231~excitatory extracellular ligand-gated ion channel activity,GO:0005254~chloride channel activity,GO:0005515~protein binding,GO:0030594~neurotransmitter receptor activity,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR006028:Gamma-aminobutyric acid A receptor,IPR006029:Neurotransmitter-gated ion-channel transmembrane domain,IPR006201:Neurotransmitter-gated ion-channel,IPR006202:Neurotransmitter-gated ion-channel ligand-binding,IPR008098:Gamma-aminobutyric-acid A receptor delta subunit,IPR018000:Neurotransmitter-gated ion-channel, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04723:Retrograde endocannabinoid signaling,hsa04727:GABAergic synapse,hsa05032:Morphine addiction,hsa05033:Nicotine addiction,	613060~Epilepsy, idiopathic generalized, 10,613060~Epilepsy, juvenile myoclonic, susceptibility to,613060~Generalized epilepsy with febrile seizures plus, type 5, susceptibility to,			KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,	KW-0407~Ion channel,KW-0675~Receptor,KW-0869~Chloride channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Neur_chan_LBD,DOMAIN:Neur_chan_memb,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GABBR1	gamma-aminobutyric acid type B receptor subunit 1(GABBR1)	Homo sapiens	GO:0001649~osteoblast differentiation,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0008285~negative regulation of cell proliferation,GO:0014049~positive regulation of glutamate secretion,GO:0014053~negative regulation of gamma-aminobutyric acid secretion,GO:0032811~negative regulation of epinephrine secretion,GO:0033602~negative regulation of dopamine secretion,GO:0035094~response to nicotine,GO:0045471~response to ethanol,GO:0050805~negative regulation of synaptic transmission,GO:0051932~synaptic transmission, GABAergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0060124~positive regulation of growth hormone secretion,GO:0099505~regulation of presynaptic membrane potential,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008021~synaptic vesicle,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0030673~axolemma,GO:0031966~mitochondrial membrane,GO:0038037~G-protein coupled receptor dimeric complex,GO:0038039~G-protein coupled receptor heterodimeric complex,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0045121~membrane raft,GO:0045211~postsynaptic membrane,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098978~glutamatergic synapse,GO:0098982~GABA-ergic synapse,GO:1902712~G-protein coupled GABA receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0004965~G-protein coupled GABA receptor activity,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,GO:0099579~G-protein coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential,GO:1990430~extracellular matrix protein binding,	IPR000436:Sushi/SCR/CCP,IPR001828:Extracellular ligand-binding receptor,IPR002455:GPCR, family 3, gamma-aminobutyric acid receptor, type B,IPR002456:GPCR, family 3, gamma-aminobutyric acid receptor, type B1,IPR017978:GPCR, family 3, C-terminal,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04727:GABAergic synapse,hsa04742:Taste transduction,hsa04915:Estrogen signaling pathway,hsa04929:GnRH secretion,hsa05032:Morphine addiction,			SM00032:CCP,		KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0964~Secreted,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:G_PROTEIN_RECEP_F3_4,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,MUTAGEN:H->A: Strongly reduces signaling via G-proteins. Abolishes antagonist binding.,MUTAGEN:W->A: Abolishes signaling via G-proteins. Abolishes antagonist binding.,MUTAGEN:W->A: Strongly reduces signaling via G-proteins. Strongly reduces antagonist binding.,MUTAGEN:Y->A: Decreases signaling via G-proteins.,MUTAGEN:Y->A: Slightly decreases signaling via G-proteins.,MUTAGEN:Y->A: Strongly reduces signaling via G-proteins. No effect on antagonist binding.,REGION:Disordered,REGION:Interaction with ATF4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GABBR2	gamma-aminobutyric acid type B receptor subunit 2(GABBR2)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0007194~negative regulation of adenylate cyclase activity,GO:0007214~gamma-aminobutyric acid signaling pathway,GO:0007268~chemical synaptic transmission,GO:0051932~synaptic transmission, GABAergic,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0038039~G-protein coupled receptor heterodimeric complex,GO:0043005~neuron projection,GO:0045211~postsynaptic membrane,GO:1902710~GABA receptor complex,GO:1902712~G-protein coupled GABA receptor complex,	GO:0004888~transmembrane signaling receptor activity,GO:0004965~G-protein coupled GABA receptor activity,GO:0005515~protein binding,GO:0046982~protein heterodimerization activity,	IPR000337:GPCR, family 3,IPR001828:Extracellular ligand-binding receptor,IPR002455:GPCR, family 3, gamma-aminobutyric acid receptor, type B,IPR002457:GPCR, family 3, gamma-aminobutyric acid receptor, type B2,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04727:GABAergic synapse,hsa04742:Taste transduction,hsa04915:Estrogen signaling pathway,hsa04929:GnRH secretion,hsa05032:Morphine addiction,	188890~Nicotine dependence, protection against,188890~Nicotine dependence, susceptibility to,617903~Neurodevelopmental disorder with poor language and loss of hand skills,617904~Developmental and epileptic encephalopathy 59,				KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ANF_receptor,DOMAIN:G_PROTEIN_RECEP_F3_4,MUTAGEN:Y->A: Impairs interaction with GABBR1. Decreases signaling via G-proteins.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GDAP1L1	ganglioside induced differentiation associated protein 1 like 1(GDAP1L1)	Homo sapiens	GO:0006749~glutathione metabolic process,	GO:0005737~cytoplasm,GO:0016021~integral component of membrane,		IPR004045:Glutathione S-transferase, N-terminal,IPR010987:Glutathione S-transferase, C-terminal-like,						KW-0472~Membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,TRANSMEM:Helical,
GJA3	gap junction protein alpha 3(GJA3)	Homo sapiens	GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0007601~visual perception,GO:0055085~transmembrane transport,GO:1990349~gap junction-mediated intercellular transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005922~connexin complex,GO:0016021~integral component of membrane,	GO:0005243~gap junction channel activity,GO:0055077~gap junction hemi-channel activity,	IPR000500:Connexin,IPR002262:Gap junction alpha-3 protein (Cx46),IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,		601885~Cataract 14, multiple types,		SM00037:CNX,SM01089:SM01089,		KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0898~Cataract,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:CNX,MUTAGEN:R->E,K: Abolishes formation of gap junctions. No significant effect on formation of functional hemichannels.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GJD3	gap junction protein delta 3(GJD3)	Homo sapiens	GO:0007154~cell communication,GO:0007267~cell-cell signaling,GO:0009749~response to glucose,GO:0010459~negative regulation of heart rate,GO:0016264~gap junction assembly,GO:0034220~ion transmembrane transport,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:1901845~negative regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1903780~negative regulation of cardiac conduction,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005922~connexin complex,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0005216~ion channel activity,GO:0005243~gap junction channel activity,GO:0005515~protein binding,GO:0086077~gap junction channel activity involved in AV node cell-bundle of His cell electrical coupling,	IPR000500:Connexin,IPR013092:Connexin, N-terminal,IPR017990:Connexin, conserved site,IPR019570:Gap junction protein, cysteine-rich domain,				SM00037:CNX,SM01089:SM01089,		KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Pro residues,DOMAIN:CNX,DOMAIN:Connexin_CCC,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GTF2H4	general transcription factor IIH subunit 4(GTF2H4)	Homo sapiens	GO:0006281~DNA repair,GO:0006289~nucleotide-excision repair,GO:0006366~transcription from RNA polymerase II promoter,GO:0070816~phosphorylation of RNA polymerase II C-terminal domain,	GO:0000438~core TFIIH complex portion of holo TFIIH complex,GO:0000439~core TFIIH complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005669~transcription factor TFIID complex,GO:0005675~holo TFIIH complex,GO:0016607~nuclear speck,	GO:0001671~ATPase activator activity,GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,	IPR004598:Transcription factor TFIIH subunit p52/Tfb2,	hsa03022:Basal transcription factors,hsa03420:Nucleotide excision repair,hsa05203:Viral carcinogenesis,				KW-0227~DNA damage,KW-0234~DNA repair,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,						DOMAIN:Tfb2_C,
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A(GRIN2A)	Homo sapiens	GO:0001964~startle response,GO:0001975~response to amphetamine,GO:0007215~glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007420~brain development,GO:0007611~learning or memory,GO:0007613~memory,GO:0008542~visual learning,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0019233~sensory perception of pain,GO:0019722~calcium-mediated signaling,GO:0022008~neurogenesis,GO:0030163~protein catabolic process,GO:0030431~sleep,GO:0033058~directional locomotion,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0042177~negative regulation of protein catabolic process,GO:0042417~dopamine metabolic process,GO:0042428~serotonin metabolic process,GO:0042493~response to drug,GO:0043065~positive regulation of apoptotic process,GO:0045471~response to ethanol,GO:0048167~regulation of synaptic plasticity,GO:0048168~regulation of neuronal synaptic plasticity,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060079~excitatory postsynaptic potential,GO:0060291~long-term synaptic potentiation,GO:0097202~activation of cysteine-type endopeptidase activity,GO:0097553~calcium ion transmembrane import into cytosol,GO:0098655~cation transmembrane transport,GO:0098976~excitatory chemical synaptic transmission,GO:1903539~protein localization to postsynaptic membrane,GO:1904062~regulation of cation transmembrane transport,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008021~synaptic vesicle,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0017146~NMDA selective glutamate receptor complex,GO:0030659~cytoplasmic vesicle membrane,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0097060~synaptic membrane,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099061~integral component of postsynaptic density membrane,	GO:0001540~beta-amyloid binding,GO:0004970~ionotropic glutamate receptor activity,GO:0004972~NMDA glutamate receptor activity,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0015276~ligand-gated ion channel activity,GO:0022849~glutamate-gated calcium ion channel activity,GO:0038023~signaling receptor activity,	IPR001320:Ionotropic glutamate receptor,IPR001508:NMDA receptor,IPR001828:Extracellular ligand-binding receptor,IPR018884:Glutamate [NMDA] receptor, epsilon subunit, C-terminal,IPR019594:Glutamate receptor, L-glutamate/glycine-binding,	hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04724:Glutamatergic synapse,hsa04728:Dopaminergic synapse,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05033:Nicotine addiction,hsa05034:Alcoholism,hsa05322:Systemic lupus erythematosus,	245570~Epilepsy, focal, with speech disorder and with or without impaired intellectual development,		SM00079:PBPe,SM00918:SM00918,	KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:ANF_receptor,DOMAIN:Lig_chan-Glu_bd,DOMAIN:PBPe,INTRAMEM:Discontinuously helical,MOTIF:PDZ-binding,MUTAGEN:P->A: Changed glutamate-gated calcium ion channel activity characterized by increased desensitization.,MUTAGEN:P->G: Changed glutamate-gated calcium ion channel activity characterized by accelerated response activation time and increased desensitization.,MUTAGEN:P->I: Changed glutamate-gated calcium ion channel activity characterized by increased desensitization.,MUTAGEN:P->K: Changed glutamate-gated calcium ion channel activity characterized by increased glutamate and glycine potency with delay in rise time and slower deactivation time course.,MUTAGEN:P->L: No effect on localization to the cell membrane. Changed glutamate-gated calcium ion channel activity characterized by increased desensitization.,MUTAGEN:P->Q: No effect on localization to the cell membrane. Changed glutamate-gated calcium ion channel activity characterized by decreased response amplitude and changed desensitization without effect on response rise time or deactivation time course.,REGION:Disordered,REGION:Pore-forming,SITE:Functional determinant of NMDA receptors,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C(GRIN2C)	Homo sapiens	GO:0007215~glutamate receptor signaling pathway,GO:0007420~brain development,GO:0009611~response to wounding,GO:0019722~calcium-mediated signaling,GO:0033058~directional locomotion,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0042177~negative regulation of protein catabolic process,GO:0048167~regulation of synaptic plasticity,GO:0048168~regulation of neuronal synaptic plasticity,GO:0050885~neuromuscular process controlling balance,GO:0051968~positive regulation of synaptic transmission, glutamatergic,GO:0060079~excitatory postsynaptic potential,GO:0060291~long-term synaptic potentiation,GO:0097553~calcium ion transmembrane import into cytosol,GO:0098655~cation transmembrane transport,GO:0098976~excitatory chemical synaptic transmission,GO:1903539~protein localization to postsynaptic membrane,GO:1904062~regulation of cation transmembrane transport,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0017146~NMDA selective glutamate receptor complex,GO:0045211~postsynaptic membrane,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,	GO:0004970~ionotropic glutamate receptor activity,GO:0004972~NMDA glutamate receptor activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0022849~glutamate-gated calcium ion channel activity,GO:0038023~signaling receptor activity,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001320:Ionotropic glutamate receptor,IPR001508:NMDA receptor,IPR001828:Extracellular ligand-binding receptor,IPR018884:Glutamate [NMDA] receptor, epsilon subunit, C-terminal,IPR019594:Glutamate receptor, L-glutamate/glycine-binding,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04724:Glutamatergic synapse,hsa05010:Alzheimer disease,hsa05014:Amyotrophic lateral sclerosis,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05033:Nicotine addiction,hsa05034:Alcoholism,			SM00079:PBPe,SM00918:SM00918,	KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,	KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:ANF_receptor,DOMAIN:Lig_chan-Glu_bd,DOMAIN:PBPe,INTRAMEM:Discontinuously helical,MOTIF:PDZ-binding,MUTAGEN:P->R: Changed glutamate-gated calcium ion channel activity characterized by increased glutamate and glycine potency.,REGION:Disordered,REGION:Pore-forming,SITE:Functional determinant of NMDA receptors,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GRIN3A	glutamate ionotropic receptor NMDA type subunit 3A(GRIN3A)	Homo sapiens	GO:0006816~calcium ion transport,GO:0016358~dendrite development,GO:0035235~ionotropic glutamate receptor signaling pathway,GO:0045471~response to ethanol,GO:0048511~rhythmic process,GO:0060078~regulation of postsynaptic membrane potential,GO:0060134~prepulse inhibition,GO:0061000~negative regulation of dendritic spine development,GO:0070588~calcium ion transmembrane transport,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0017146~NMDA selective glutamate receptor complex,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098793~presynapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,	GO:0004970~ionotropic glutamate receptor activity,GO:0004972~NMDA glutamate receptor activity,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0015276~ligand-gated ion channel activity,GO:0016594~glycine binding,GO:0038023~signaling receptor activity,GO:0042165~neurotransmitter binding,GO:0042802~identical protein binding,GO:0051721~protein phosphatase 2A binding,GO:1904315~transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR001320:Ionotropic glutamate receptor,IPR001508:NMDA receptor,IPR001828:Extracellular ligand-binding receptor,IPR019594:Glutamate receptor, L-glutamate/glycine-binding,	hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04724:Glutamatergic synapse,hsa05017:Spinocerebellar ataxia,hsa05020:Prion disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05033:Nicotine addiction,hsa05034:Alcoholism,			SM00079:PBPe,SM00918:SM00918,	KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,	KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Lig_chan-Glu_bd,DOMAIN:PBPe,REGION:Disordered,REGION:GIT1-binding,REGION:PPP2CB binding site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GRM1	glutamate metabotropic receptor 1(GRM1)	Homo sapiens	GO:0000186~activation of MAPKK activity,GO:0000187~activation of MAPK activity,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007626~locomotory behavior,GO:0019233~sensory perception of pain,GO:0043410~positive regulation of MAPK cascade,GO:0051482~positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway,GO:0051930~regulation of sensory perception of pain,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0071257~cellular response to electrical stimulus,GO:0098712~L-glutamate import across plasma membrane,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,	GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0038037~G-protein coupled receptor dimeric complex,GO:0038038~G-protein coupled receptor homodimeric complex,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008066~glutamate receptor activity,GO:0098872~G-protein coupled neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration,GO:0099530~G-protein coupled receptor activity involved in regulation of postsynaptic membrane potential,GO:0099583~neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration,	IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000337:GPCR, family 3,IPR001256:GPCR, family 3, metabotropic glutamate receptor 1,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,IPR019588:Metabotropic glutamate receptor, Homer-binding domain,	hsa04020:Calcium signaling pathway,hsa04068:FoxO signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04540:Gap junction,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04730:Long-term depression,hsa04742:Taste transduction,hsa04915:Estrogen signaling pathway,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,	614831~Spinocerebellar ataxia, autosomal recessive 13,617691~Spinocerebellar ataxia 44,		SM01229:SM01229,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Interchain,DOMAIN:G_PROTEIN_RECEP_F3_4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GRM2	glutamate metabotropic receptor 2(GRM2)	Homo sapiens	GO:0007194~negative regulation of adenylate cyclase activity,GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0010467~gene expression,GO:0014047~glutamate secretion,GO:0014048~regulation of glutamate secretion,GO:0014059~regulation of dopamine secretion,GO:0035095~behavioral response to nicotine,GO:0042220~response to cocaine,GO:0051896~regulation of protein kinase B signaling,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060292~long term synaptic depression,GO:0090461~glutamate homeostasis,GO:2001023~regulation of response to drug,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0042734~presynaptic membrane,GO:0097449~astrocyte projection,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0001641~group II metabotropic glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0008066~glutamate receptor activity,GO:0097110~scaffold protein binding,	IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000337:GPCR, family 3,IPR001458:GPCR, family 3, metabotropic glutamate receptor 2,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04724:Glutamatergic synapse,hsa05030:Cocaine addiction,					KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ANF_receptor,DOMAIN:G_PROTEIN_RECEP_F3_4,MUTAGEN:A->F: Impairs interaction with HTR2A.,MUTAGEN:A->G: Impairs interaction with HTR2A.,MUTAGEN:A->S: Impairs interaction with HTR2A.,REGION:Important for interaction with HTR2A,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GRM3	glutamate metabotropic receptor 3(GRM3)	Homo sapiens	GO:0007194~negative regulation of adenylate cyclase activity,GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0010467~gene expression,GO:0051966~regulation of synaptic transmission, glutamatergic,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0042734~presynaptic membrane,GO:0043197~dendritic spine,GO:0045211~postsynaptic membrane,GO:0097449~astrocyte projection,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0001641~group II metabotropic glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005246~calcium channel regulator activity,GO:0008066~glutamate receptor activity,GO:0097110~scaffold protein binding,	IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000337:GPCR, family 3,IPR001234:GPCR, family 3, metabotropic glutamate receptor 3,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04724:Glutamatergic synapse,hsa05030:Cocaine addiction,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ANF_receptor,DOMAIN:G_PROTEIN_RECEP_F3_4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GRM5	glutamate metabotropic receptor 5(GRM5)	Homo sapiens	GO:0001932~regulation of protein phosphorylation,GO:0002029~desensitization of G-protein coupled receptor protein signaling pathway,GO:0006355~regulation of transcription, DNA-templated,GO:0006417~regulation of translation,GO:0006448~regulation of translational elongation,GO:0006468~protein phosphorylation,GO:0007196~adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway,GO:0007205~protein kinase C-activating G-protein coupled receptor signaling pathway,GO:0007206~phospholipase C-activating G-protein coupled glutamate receptor signaling pathway,GO:0007216~G-protein coupled glutamate receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007611~learning or memory,GO:0007612~learning,GO:0007626~locomotory behavior,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0040013~negative regulation of locomotion,GO:0043410~positive regulation of MAPK cascade,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048170~positive regulation of long-term neuronal synaptic plasticity,GO:0050808~synapse organization,GO:0050890~cognition,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0061098~positive regulation of protein tyrosine kinase activity,GO:0090647~modulation of age-related behavioral decline,GO:0099553~trans-synaptic signaling by endocannabinoid, modulating synaptic transmission,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,GO:1902938~regulation of intracellular calcium activated chloride channel activity,GO:1904646~cellular response to beta-amyloid,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0043005~neuron projection,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0097449~astrocyte projection,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,	GO:0001640~adenylate cyclase inhibiting G-protein coupled glutamate receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008066~glutamate receptor activity,GO:0030296~protein tyrosine kinase activator activity,GO:0031687~A2A adenosine receptor binding,GO:0042802~identical protein binding,GO:0099530~G-protein coupled receptor activity involved in regulation of postsynaptic membrane potential,GO:0099583~neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration,GO:1990782~protein tyrosine kinase binding,	IPR000162:GPCR, family 3, metabotropic glutamate receptor,IPR000202:GPCR, family 3, metabotropic glutamate receptor 5,IPR000337:GPCR, family 3,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,IPR019588:Metabotropic glutamate receptor, Homer-binding domain,	hsa04020:Calcium signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04540:Gap junction,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa05010:Alzheimer disease,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,			SM01229:SM01229,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:ANF_receptor,DOMAIN:G_PROTEIN_RECEP_F3_4,MUTAGEN:E->A: Increased constitutive signaling activity.,MUTAGEN:K->A: Increased constitutive signaling activity.,MUTAGEN:S->A,K: Increased constitutive signaling activity.,MUTAGEN:S->D: Decreased constitutive signaling activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
GFPT2	glutamine-fructose-6-phosphate transaminase 2(GFPT2)	Homo sapiens	GO:0006002~fructose 6-phosphate metabolic process,GO:0006047~UDP-N-acetylglucosamine metabolic process,GO:0006048~UDP-N-acetylglucosamine biosynthetic process,GO:0006112~energy reserve metabolic process,GO:0006487~protein N-linked glycosylation,GO:0006541~glutamine metabolic process,GO:1901135~carbohydrate derivative metabolic process,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005829~cytosol,	GO:0004360~glutamine-fructose-6-phosphate transaminase (isomerizing) activity,GO:0005515~protein binding,GO:0097367~carbohydrate derivative binding,	IPR001347:Sugar isomerase (SIS),IPR005855:Glucosamine-fructose-6-phosphate aminotransferase, isomerising,IPR017932:Glutamine amidotransferase type 2 domain,	hsa00250:Alanine, aspartate and glutamate metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa01100:Metabolic pathways,hsa01250:Biosynthesis of nucleotide sugars,hsa04931:Insulin resistance,hsa05415:Diabetic cardiomyopathy,							KW-0315~Glutamine amidotransferase,KW-0677~Repeat,KW-0732~Signal,		KW-0032~Aminotransferase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:For GATase activity,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Glutamine amidotransferase type-2,DOMAIN:SIS,DOMAIN:SIS 1,DOMAIN:SIS 2,REGION:Disordered,
ENPEP	glutamyl aminopeptidase(ENPEP)	Homo sapiens	GO:0001525~angiogenesis,GO:0002003~angiotensin maturation,GO:0003081~regulation of systemic arterial blood pressure by renin-angiotensin,GO:0006508~proteolysis,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0008217~regulation of blood pressure,GO:0008283~cell proliferation,GO:0016477~cell migration,GO:0032835~glomerulus development,GO:0043171~peptide catabolic process,	GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005903~brush border,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,	GO:0004177~aminopeptidase activity,GO:0008270~zinc ion binding,GO:0042277~peptide binding,GO:0070006~metalloaminopeptidase activity,	IPR001930:Peptidase M1, alanine aminopeptidase/leukotriene A4 hydrolase,IPR014782:Peptidase M1, membrane alanine aminopeptidase, N-terminal,IPR024571:Domain of unknown function DUF3358,	hsa04614:Renin-angiotensin system,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0031~Aminopeptidase,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; atypical,COMPBIAS:Polar residues,DOMAIN:ERAP1_C,DOMAIN:Peptidase_M1,DOMAIN:Peptidase_M1_N,MUTAGEN:R->A: Reduced enzyme activity.,MUTAGEN:T->V: Reduced enzyme activity.,REGION:Disordered,SITE:Binds calcium which modulates its enzyme activity,SITE:Transition state stabilizer,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GSTT2	glutathione S-transferase theta 2 (gene/pseudogene)(GSTT2)	Homo sapiens	GO:0006749~glutathione metabolic process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004364~glutathione transferase activity,	IPR004045:Glutathione S-transferase, N-terminal,IPR004046:Glutathione S-transferase, C-terminal,IPR010987:Glutathione S-transferase, C-terminal-like,	hsa00480:Glutathione metabolism,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa00982:Drug metabolism - cytochrome P450,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01524:Platinum drug resistance,hsa05200:Pathways in cancer,hsa05204:Chemical carcinogenesis - DNA adducts,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,					KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0808~Transferase,		DOMAIN:GST C-terminal,DOMAIN:GST N-terminal,
GPX8	glutathione peroxidase 8 (putative)(GPX8)	Homo sapiens	GO:0006979~response to oxidative stress,GO:0034599~cellular response to oxidative stress,GO:0098869~cellular oxidant detoxification,	GO:0005788~endoplasmic reticulum lumen,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004601~peroxidase activity,GO:0004602~glutathione peroxidase activity,GO:0005515~protein binding,	IPR000889:Glutathione peroxidase,IPR013376:Glutathione peroxidase Gpx7, putative,	hsa00480:Glutathione metabolism,hsa01100:Metabolic pathways,hsa04918:Thyroid hormone synthesis,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,		PIRSF000303:glutathione peroxidase,			KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0007~Acetylation,	TRANSMEM:Helical,
PYGL	glycogen phosphorylase L(PYGL)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0005977~glycogen metabolic process,GO:0005980~glycogen catabolic process,GO:0006015~5-phosphoribose 1-diphosphate biosynthetic process,GO:0009617~response to bacterium,GO:0042593~glucose homeostasis,GO:0070266~necroptotic process,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0002060~purine nucleobase binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008184~glycogen phosphorylase activity,GO:0016208~AMP binding,GO:0019842~vitamin binding,GO:0030170~pyridoxal phosphate binding,GO:0032052~bile acid binding,GO:0042802~identical protein binding,	IPR000811:Glycosyl transferase, family 35,IPR011833:Glycogen/starch/alpha-glucan phosphorylase,	hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,hsa04217:Necroptosis,hsa04910:Insulin signaling pathway,hsa04922:Glucagon signaling pathway,hsa04931:Insulin resistance,	232700~Glycogen storage disease VI,	PIRSF000460:glucan phosphorylase,		KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,	KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0322~Glycogen storage disease,		KW-0547~Nucleotide-binding,KW-0663~Pyridoxal phosphate,	KW-0021~Allosteric enzyme,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:K->Q: Decreased glycogen phosphorylase activity.,MUTAGEN:K->R: Decreased acetylation; when associated with R-470.,MUTAGEN:K->R: Decreased acetylation; when associated with R-796.,REGION:Disordered,SITE:Involved in the association of subunits,SITE:May be involved in allosteric control,
GP1BB	glycoprotein Ib platelet subunit beta(GP1BB)	Homo sapiens	GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,GO:0007597~blood coagulation, intrinsic pathway,GO:0010572~positive regulation of platelet activation,GO:0030168~platelet activation,GO:0035855~megakaryocyte development,GO:0051209~release of sequestered calcium ion into cytosol,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:1990779~glycoprotein Ib-IX-V complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,	hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04640:Hematopoietic cell lineage,	231200~Bernard-Soulier syndrome, type B,231200~Giant platelet disorder, isolated,		SM00013:LRRNT,SM00082:LRRCT,	KW-0094~Blood coagulation,KW-0130~Cell adhesion,KW-0356~Hemostasis,	KW-0472~Membrane,	KW-0087~Bernard Soulier syndrome,KW-0225~Disease variant,	KW-0433~Leucine-rich repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-500 or C-501 in GP1BA),DOMAIN:LRRCT,DOMAIN:LRRNT,REPEAT:LRR,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
GLT1D1	glycosyltransferase 1 domain containing 1(GLT1D1)	Homo sapiens		GO:0005576~extracellular region,GO:0005829~cytosol,	GO:0016757~transferase activity, transferring glycosyl groups,	IPR001296:Glycosyl transferase, family 1,						KW-0964~Secreted,		KW-0732~Signal,		KW-0328~Glycosyltransferase,KW-0808~Transferase,		DOMAIN:Glycos_transf_1,
GOLGA6L10	golgin A6 family like 10(GOLGA6L10)	Homo sapiens				IPR026737:Golgin subfamily A member 6-like,								KW-0175~Coiled coil,				COMPBIAS:Polar residues,DOMAIN:GOLGA2L5,REGION:Disordered,
GOLGA6B	golgin A6 family member B(GOLGA6B)	Homo sapiens	GO:0007030~Golgi organization,	GO:0000137~Golgi cis cisterna,GO:0005801~cis-Golgi network,GO:0032580~Golgi cisterna membrane,		IPR024858:Golgin subfamily A,								KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,REGION:Disordered,
GOLGA7B	golgin A7 family member B(GOLGA7B)	Homo sapiens	GO:0006612~protein targeting to membrane,GO:0018230~peptidyl-L-cysteine S-palmitoylation,	GO:0000139~Golgi membrane,GO:0002178~palmitoyltransferase complex,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR019383:Golgin subfamily A member 7/ERF4,						KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,					KW-0449~Lipoprotein,KW-0564~Palmitate,	COMPBIAS:Polar residues,DOMAIN:Erf4,LIPID:S-palmitoyl cysteine,REGION:Disordered,
GADD45A	growth arrest and DNA damage inducible alpha(GADD45A)	Homo sapiens	GO:0000079~regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000185~activation of MAPKKK activity,GO:0006281~DNA repair,GO:0006915~apoptotic process,GO:0007098~centrosome cycle,GO:0016525~negative regulation of angiogenesis,GO:0033140~negative regulation of peptidyl-serine phosphorylation of STAT protein,GO:0042770~signal transduction in response to DNA damage,GO:0043065~positive regulation of apoptotic process,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0046330~positive regulation of JNK cascade,GO:0051726~regulation of cell cycle,GO:0071260~cellular response to mechanical stimulus,GO:0071479~cellular response to ionizing radiation,GO:0071901~negative regulation of protein serine/threonine kinase activity,GO:1900745~positive regulation of p38MAPK cascade,GO:2000379~positive regulation of reactive oxygen species metabolic process,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0047485~protein N-terminus binding,GO:1990841~promoter-specific chromatin binding,	IPR004038:Ribosomal protein L7Ae/L30e/S12e/Gadd45,IPR024824:Growth arrest and DNA damage-inducible protein GADD45,	hsa04010:MAPK signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04068:FoxO signaling pathway,hsa04110:Cell cycle,hsa04115:p53 signaling pathway,hsa04210:Apoptosis,hsa04218:Cellular senescence,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05210:Colorectal cancer,hsa05212:Pancreatic cancer,hsa05213:Endometrial cancer,hsa05214:Glioma,hsa05216:Thyroid cancer,hsa05217:Basal cell carcinoma,hsa05218:Melanoma,hsa05220:Chronic myeloid leukemia,hsa05222:Small cell lung cancer,hsa05223:Non-small cell lung cancer,hsa05224:Breast cancer,hsa05225:Hepatocellular carcinoma,hsa05226:Gastric cancer,				KW-0131~Cell cycle,KW-0227~DNA damage,KW-0338~Growth arrest,	KW-0539~Nucleus,					KW-0597~Phosphoprotein,	DOMAIN:Ribosomal_L7Ae,MUTAGEN:L->E: Abolishes dimerization.,
GDF15	growth differentiation factor 15(GDF15)	Homo sapiens	GO:0000187~activation of MAPK activity,GO:0002023~reduction of food intake in response to dietary excess,GO:0007165~signal transduction,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030509~BMP signaling pathway,GO:0035860~glial cell-derived neurotrophic factor receptor signaling pathway,GO:0040015~negative regulation of multicellular organism growth,GO:0043410~positive regulation of MAPK cascade,GO:0051897~positive regulation of protein kinase B signaling,GO:0060395~SMAD protein signal transduction,GO:0060400~negative regulation of growth hormone receptor signaling pathway,GO:1901741~positive regulation of myoblast fusion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0042803~protein homodimerization activity,GO:0070700~BMP receptor binding,	IPR001839:Transforming growth factor-beta, C-terminal,IPR015615:Transforming growth factor-beta-related,	hsa04060:Cytokine-cytokine receptor interaction,			SM00204:TGFB,		KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain,MUTAGEN:I->A: Reduces cellular signaling mediated by GFRAL and RET. Abolishes interaction with GFRAL and GDF15-mediated food-intake inhibition.,MUTAGEN:V->A: Reduces cellular signaling mediated by GFRAL and RET.,MUTAGEN:V->R: Abolishes interaction with GFRAL. Abolishes RET phosphorylation and cellular signaling mediated by GFRAL and RET.,MUTAGEN:W->A: No effect on interaction with GFRAL. Attenuates GDF15-mediated food-intake inhibition.,REGION:Disordered,
GDA	guanine deaminase(GDA)	Homo sapiens	GO:0000255~allantoin metabolic process,GO:0006139~nucleobase-containing compound metabolic process,GO:0006147~guanine catabolic process,GO:0006161~deoxyguanosine catabolic process,GO:0007399~nervous system development,GO:0046038~GMP catabolic process,GO:0046055~dGMP catabolic process,GO:0046098~guanine metabolic process,	GO:0005622~intracellular,GO:0005829~cytosol,	GO:0008270~zinc ion binding,GO:0008892~guanine deaminase activity,GO:0019239~deaminase activity,	IPR006680:Amidohydrolase 1,IPR011059:Metal-dependent hydrolase, composite domain,IPR014311:Guanine deaminase,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,								KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0597~Phosphoprotein,	DOMAIN:Amidohydro-rel,
GBP1	guanylate binding protein 1(GBP1)	Homo sapiens	GO:0032703~negative regulation of interleukin-2 production,GO:0050848~regulation of calcium-mediated signaling,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0051607~defense response to virus,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0072665~protein localization to vacuole,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:1903076~regulation of protein localization to plasma membrane,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0012506~vesicle membrane,GO:0015629~actin cytoskeleton,GO:0031410~cytoplasmic vesicle,	GO:0003779~actin binding,GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019003~GDP binding,GO:0019899~enzyme binding,GO:0019955~cytokine binding,GO:0030507~spectrin binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051879~Hsp90 protein binding,	IPR003191:Guanylate-binding protein, C-terminal,IPR015894:Guanylate-binding protein, N-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04621:NOD-like receptor signaling pathway,				KW-0051~Antiviral defense,KW-0391~Immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	DOMAIN:GB1/RHD3-type G,LIPID:S-farnesyl cysteine,MUTAGEN:K->A: Loss of GTPase activity. Constitutively monomeric. Expressed throughout the cytoplasm, loss of vesicular accumulation.,MUTAGEN:Missing: Loss of association with membranes.,MUTAGEN:RK->EE: Constitutively dimeric. Localizes at vesicle-like structures at the plasma membrane.,PROPEP:Removed in mature form,REGION:GTPase domain (Globular),
GBP2	guanylate binding protein 2(GBP2)	Homo sapiens	GO:0006955~immune response,GO:0034504~protein localization to nucleus,GO:0042832~defense response to protozoan,GO:0050830~defense response to Gram-positive bacterium,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,	GO:0000139~Golgi membrane,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0031410~cytoplasmic vesicle,GO:0048471~perinuclear region of cytoplasm,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,	IPR003191:Guanylate-binding protein, C-terminal,IPR015894:Guanylate-binding protein, N-terminal,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04621:NOD-like receptor signaling pathway,				KW-0391~Immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0968~Cytoplasmic vesicle,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,KW-0929~Antimicrobial,	KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	DOMAIN:GB1/RHD3-type G,LIPID:S-geranylgeranyl cysteine,MUTAGEN:Missing: No effect on subcellular location by confocal microscopy, but loss of membrane-association by subcellular fractionation.,PROPEP:Removed in mature form,REGION:GTPase domain (Globular),
HSPA1A	heat shock protein family A (Hsp70) member 1A(HSPA1A)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006402~mRNA catabolic process,GO:0006986~response to unfolded protein,GO:0007041~lysosomal transport,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0016192~vesicle-mediated transport,GO:0030308~negative regulation of cell growth,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031396~regulation of protein ubiquitination,GO:0031397~negative regulation of protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032757~positive regulation of interleukin-8 production,GO:0033120~positive regulation of RNA splicing,GO:0034599~cellular response to oxidative stress,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0045648~positive regulation of erythrocyte differentiation,GO:0046034~ATP metabolic process,GO:0046718~viral entry into host cell,GO:0050821~protein stabilization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051131~chaperone-mediated protein complex assembly,GO:0060548~negative regulation of cell death,GO:0070370~cellular heat acclimation,GO:0070434~positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071383~cellular response to steroid hormone stimulus,GO:0090063~positive regulation of microtubule nucleation,GO:0090084~negative regulation of inclusion body assembly,GO:0097201~negative regulation of transcription from RNA polymerase II promoter in response to stress,GO:1901029~negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:1901673~regulation of mitotic spindle assembly,GO:1902236~negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,GO:1902380~positive regulation of endoribonuclease activity,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016234~inclusion body,GO:0016235~aggresome,GO:0016607~nuclear speck,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0001618~virus receptor activity,GO:0001664~G-protein coupled receptor binding,GO:0003714~transcription corepressor activity,GO:0003723~RNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031249~denatured protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042826~histone deacetylase binding,GO:0044183~protein binding involved in protein folding,GO:0045296~cadherin binding,GO:0047485~protein N-terminus binding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,GO:0055131~C3HC4-type RING finger domain binding,GO:0097718~disordered domain specific binding,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	MUTAGEN:D->A: Reduces affinity for ADP.,MUTAGEN:K->Q: No loss of acetylation and ATPase activity. Exhibits normal protein refolding activity during the early phase but exhibits defects in ubiquitin-mediated protein degradation during the later phase.,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,MUTAGEN:K->R: Significant loss of acetylation and ATPase activity. Decreased binding to HOPX and HSP90 and increased binding to STUB1 and NAA10. Impaired capacity for protein refolding during the early phase after stress but shows normal protein degradation activity in the late phase.,REGION:Disordered,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPA1B	heat shock protein family A (Hsp70) member 1B(HSPA1B)	Homo sapiens	GO:0006402~mRNA catabolic process,GO:0008285~negative regulation of cell proliferation,GO:0010628~positive regulation of gene expression,GO:0016192~vesicle-mediated transport,GO:0030308~negative regulation of cell growth,GO:0031396~regulation of protein ubiquitination,GO:0031397~negative regulation of protein ubiquitination,GO:0032436~positive regulation of proteasomal ubiquitin-dependent protein catabolic process,GO:0032757~positive regulation of interleukin-8 production,GO:0034599~cellular response to oxidative stress,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0045648~positive regulation of erythrocyte differentiation,GO:0046034~ATP metabolic process,GO:0046718~viral entry into host cell,GO:0050821~protein stabilization,GO:0051085~chaperone mediated protein folding requiring cofactor,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060548~negative regulation of cell death,GO:0070370~cellular heat acclimation,GO:0070434~positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071383~cellular response to steroid hormone stimulus,GO:0090063~positive regulation of microtubule nucleation,GO:0090084~negative regulation of inclusion body assembly,GO:1901673~regulation of mitotic spindle assembly,GO:1903265~positive regulation of tumor necrosis factor-mediated signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005783~endoplasmic reticulum,GO:0005813~centrosome,GO:0005814~centriole,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016234~inclusion body,GO:0016235~aggresome,GO:0016607~nuclear speck,GO:0031982~vesicle,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:1904813~ficolin-1-rich granule lumen,GO:1990904~ribonucleoprotein complex,	GO:0001618~virus receptor activity,GO:0001664~G-protein coupled receptor binding,GO:0003723~RNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0042826~histone deacetylase binding,GO:0044183~protein binding involved in protein folding,GO:0047485~protein N-terminus binding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,GO:0055131~C3HC4-type RING finger domain binding,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0143~Chaperone,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	MUTAGEN:D->A: Reduces affinity for ADP.,MUTAGEN:K->Q: No loss of acetylation and ATPase activity. Exhibits normal protein refolding activity during the early phase but exhibits defects in ubiquitin-mediated protein degradation during the later phase.,MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,MUTAGEN:K->R: Significant loss of acetylation and ATPase activity. Decreased binding to HOPX and HSP90 and increased binding to STUB1 and NAA10. Impaired capacity for protein refolding during the early phase after stress but shows normal protein degradation activity in the late phase.,REGION:Disordered,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPA6	heat shock protein family A (Hsp70) member 6(HSPA6)	Homo sapiens	GO:0006986~response to unfolded protein,GO:0016192~vesicle-mediated transport,GO:0034605~cellular response to heat,GO:0034620~cellular response to unfolded protein,GO:0042026~protein refolding,GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005814~centriole,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0034774~secretory granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,GO:1904813~ficolin-1-rich granule lumen,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0019899~enzyme binding,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,	hsa03040:Spliceosome,hsa04010:MAPK signaling pathway,hsa04141:Protein processing in endoplasmic reticulum,hsa04144:Endocytosis,hsa04213:Longevity regulating pathway - multiple species,hsa04612:Antigen processing and presentation,hsa04915:Estrogen signaling pathway,hsa05020:Prion disease,hsa05134:Legionellosis,hsa05145:Toxoplasmosis,hsa05162:Measles,hsa05417:Lipid and atherosclerosis,				KW-0346~Stress response,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0488~Methylation,	MUTAGEN:K->R: Complete loss of in vitro methylation by METTL21A.,REGION:Disordered,REGION:Nucleotide-binding domain (NBD),REGION:Substrate-binding domain (SBD),
HSPA7	heat shock protein family A (Hsp70) member 7 (pseudogene)(HSPA7)	Homo sapiens	GO:0016192~vesicle-mediated transport,GO:0034620~cellular response to unfolded protein,GO:0042026~protein refolding,GO:0051085~chaperone mediated protein folding requiring cofactor,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0005524~ATP binding,GO:0016887~ATPase activity,GO:0031072~heat shock protein binding,GO:0031625~ubiquitin protein ligase binding,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0051787~misfolded protein binding,	IPR013126:Heat shock protein 70 family,IPR018181:Heat shock protein 70, conserved site,					KW-0346~Stress response,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,
HSPB6	heat shock protein family B (small) member 6(HSPB6)	Homo sapiens	GO:0006937~regulation of muscle contraction,GO:0009408~response to heat,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0042026~protein refolding,GO:0043066~negative regulation of apoptotic process,GO:0045766~positive regulation of angiogenesis,GO:0061077~chaperone-mediated protein folding,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,	GO:0005212~structural constituent of eye lens,GO:0042803~protein homodimerization activity,GO:0044183~protein binding involved in protein folding,GO:0051082~unfolded protein binding,GO:0051087~chaperone binding,	IPR001436:Alpha crystallin/Heat shock protein,IPR002068:Alpha crystallin/Hsp20 domain,IPR003090:Alpha-crystallin, N-terminal,IPR008978:HSP20-like chaperone,					KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,				KW-0143~Chaperone,	KW-0597~Phosphoprotein,	DOMAIN:Crystallin,DOMAIN:SHSP,DOMAIN:sHSP,MUTAGEN:I->G: Increases homodimer-based self-association properties; increases chaperone activity; when associated with G-5.,MUTAGEN:S->Q: Decreases heteromer formation with CRYAB.,MUTAGEN:V->G: Increases homodimer-based self-association properties; increases chaperone activity; when associated with G-3.,MUTAGEN:V->G: No effect on homodimer-based self-association properties; no effect on chaperone activity.,REGION:Disordered,REGION:Involved in stabilization of the HSPB1:HSBP6 heterodimer,
HSPB7	heat shock protein family B (small) member 7(HSPB7)	Homo sapiens	GO:0006986~response to unfolded protein,GO:0007507~heart development,GO:0008016~regulation of heart contraction,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0015030~Cajal body,GO:0015629~actin cytoskeleton,GO:0016235~aggresome,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0031005~filamin binding,	IPR001436:Alpha crystallin/Heat shock protein,IPR002068:Alpha crystallin/Hsp20 domain,IPR008978:HSP20-like chaperone,					KW-0346~Stress response,	KW-0539~Nucleus,KW-0963~Cytoplasm,				KW-0143~Chaperone,		COMPBIAS:Polar residues,DOMAIN:SHSP,DOMAIN:sHSP,REGION:Disordered,REGION:Required for localization to SC35 splicing speckles,
HMOX1	heme oxygenase 1(HMOX1)	Homo sapiens	GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001935~endothelial cell proliferation,GO:0002246~wound healing involved in inflammatory response,GO:0002686~negative regulation of leukocyte migration,GO:0006788~heme oxidation,GO:0006879~cellular iron ion homeostasis,GO:0006979~response to oxidative stress,GO:0007264~small GTPase mediated signal transduction,GO:0007588~excretion,GO:0008217~regulation of blood pressure,GO:0008219~cell death,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0014806~smooth muscle hyperplasia,GO:0016236~macroautophagy,GO:0016239~positive regulation of macroautophagy,GO:0016242~negative regulation of macroautophagy,GO:0031670~cellular response to nutrient,GO:0032722~positive regulation of chemokine production,GO:0032764~negative regulation of mast cell cytokine production,GO:0034101~erythrocyte homeostasis,GO:0034383~low-density lipoprotein particle clearance,GO:0034395~regulation of transcription from RNA polymerase II promoter in response to iron,GO:0034605~cellular response to heat,GO:0035094~response to nicotine,GO:0035556~intracellular signal transduction,GO:0042167~heme catabolic process,GO:0042493~response to drug,GO:0042542~response to hydrogen peroxide,GO:0043065~positive regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043305~negative regulation of mast cell degranulation,GO:0043392~negative regulation of DNA binding,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0043619~regulation of transcription from RNA polymerase II promoter in response to oxidative stress,GO:0043627~response to estrogen,GO:0045765~regulation of angiogenesis,GO:0045766~positive regulation of angiogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0051090~regulation of sequence-specific DNA binding transcription factor activity,GO:0055072~iron ion homeostasis,GO:0071243~cellular response to arsenic-containing substance,GO:0071276~cellular response to cadmium ion,GO:0071456~cellular response to hypoxia,GO:0072719~cellular response to cisplatin,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0097421~liver regeneration,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1904019~epithelial cell apoptotic process,GO:1904036~negative regulation of epithelial cell apoptotic process,GO:1904037~positive regulation of epithelial cell apoptotic process,GO:1904706~negative regulation of vascular smooth muscle cell proliferation,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005901~caveola,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004392~heme oxygenase (decyclizing) activity,GO:0004630~phospholipase D activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0020037~heme binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,	IPR002051:Haem oxygenase,IPR016053:Haem oxygenase-like,IPR016084:Haem oxygenase-like, multi-helical,IPR018207:Haem oxygenase conserved site,	hsa00860:Porphyrin metabolism,hsa01100:Metabolic pathways,hsa04066:HIF-1 signaling pathway,hsa04216:Ferroptosis,hsa04978:Mineral absorption,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05225:Hepatocellular carcinoma,hsa05418:Fluid shear stress and atherosclerosis,	606963~Pulmonary disease, chronic obstructive, susceptibility to,614034~Heme oxygenase-1 deficiency,	PIRSF000343:heme oxygenase (decyclizing),		KW-0053~Apoptosis,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0195~Cyclin,KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	BINDING:axial binding residue,COMPBIAS:Polar residues,MUTAGEN:D->A,H,N,F,L: Inactive as a heme oxygenase but active as a peroxidase.,REGION:Disordered,SITE:Important for catalytic activity,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
HMCN2	hemicentin 2(HMCN2)	Homo sapiens	GO:0007155~cell adhesion,GO:0050896~response to stimulus,	GO:0005615~extracellular space,GO:0016020~membrane,GO:0031012~extracellular matrix,GO:0032154~cleavage furrow,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR006605:G2 nidogen/fibulin G2F,IPR007110:Immunoglobulin-like domain,IPR009017:Green fluorescent protein,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR009138:Neural cell adhesion,IPR013098:Immunoglobulin I-set,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,				SM00179:EGF_CA,SM00181:EGF,SM00406:IGv,SM00408:IGc2,SM00409:IG,SM00682:G2F,	KW-0130~Cell adhesion,KW-0716~Sensory transduction,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0488~Methylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 13,DOMAIN:Ig-like C2-type 14,DOMAIN:Ig-like C2-type 15,DOMAIN:Ig-like C2-type 16,DOMAIN:Ig-like C2-type 17,DOMAIN:Ig-like C2-type 18,DOMAIN:Ig-like C2-type 19,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 20,DOMAIN:Ig-like C2-type 21,DOMAIN:Ig-like C2-type 22,DOMAIN:Ig-like C2-type 23,DOMAIN:Ig-like C2-type 24,DOMAIN:Ig-like C2-type 25,DOMAIN:Ig-like C2-type 26,DOMAIN:Ig-like C2-type 27,DOMAIN:Ig-like C2-type 28,DOMAIN:Ig-like C2-type 29,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 30,DOMAIN:Ig-like C2-type 31,DOMAIN:Ig-like C2-type 32,DOMAIN:Ig-like C2-type 33,DOMAIN:Ig-like C2-type 34,DOMAIN:Ig-like C2-type 35,DOMAIN:Ig-like C2-type 36,DOMAIN:Ig-like C2-type 37,DOMAIN:Ig-like C2-type 38,DOMAIN:Ig-like C2-type 39,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 40,DOMAIN:Ig-like C2-type 41,DOMAIN:Ig-like C2-type 42,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:Nidogen G2 beta-barrel,DOMAIN:VWFA,REGION:Disordered,
HSPG2	heparan sulfate proteoglycan 2(HSPG2)	Homo sapiens	GO:0001525~angiogenesis,GO:0006629~lipid metabolic process,GO:0006898~receptor-mediated endocytosis,GO:0006954~inflammatory response,GO:0007420~brain development,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0016525~negative regulation of angiogenesis,GO:0030154~cell differentiation,GO:0060548~negative regulation of cell death,GO:0072359~circulatory system development,GO:1905907~negative regulation of amyloid fibril formation,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0001540~beta-amyloid binding,GO:0005178~integrin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0030021~extracellular matrix structural constituent conferring compression resistance,GO:0050750~low-density lipoprotein particle receptor binding,	IPR000034:Laminin B type IV,IPR000082:SEA domain,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013106:Immunoglobulin V-set,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa04512:ECM-receptor interaction,hsa05161:Hepatitis B,hsa05205:Proteoglycans in cancer,	224410~Dyssegmental dysplasia, Silverman-Handmaker type,255800~Schwartz-Jampel syndrome, type 1,		SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00192:LDLa,SM00200:SEA,SM00281:LamB,SM00282:LamG,SM00406:IGv,SM00408:IGc2,SM00409:IG,	KW-0037~Angiogenesis,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0245~EGF-like domain,KW-0393~Immunoglobulin domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 13,DOMAIN:Ig-like C2-type 14,DOMAIN:Ig-like C2-type 15,DOMAIN:Ig-like C2-type 16,DOMAIN:Ig-like C2-type 17,DOMAIN:Ig-like C2-type 18,DOMAIN:Ig-like C2-type 19,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 20,DOMAIN:Ig-like C2-type 21,DOMAIN:Ig-like C2-type 22,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:LAM_G_DOMAIN,DOMAIN:LDL-receptor class A 1,DOMAIN:LDL-receptor class A 2,DOMAIN:LDL-receptor class A 3,DOMAIN:LDL-receptor class A 4,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 1; first part,DOMAIN:Laminin EGF-like 1; second part,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4; truncated,DOMAIN:Laminin EGF-like 5; first part,DOMAIN:Laminin EGF-like 5; second part,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9; first part,DOMAIN:Laminin EGF-like 9; second part,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin IV type A,DOMAIN:Laminin IV type A 1,DOMAIN:Laminin IV type A 2,DOMAIN:Laminin IV type A 3,DOMAIN:SEA,MUTAGEN:D->A: Retains proper folding. Reduced calcium ion binding.,MUTAGEN:D->I: Abolishes BMP1-mediated cleavage of endorepellin.,MUTAGEN:N->A: Retains proper folding. Reduced calcium ion binding.,REGION:Disordered,REGION:Mediates motor neuron attachment,SITE:Cleavage; by BMP1,
HS3ST3B1	heparan sulfate-glucosamine 3-sulfotransferase 3B1(HS3ST3B1)	Homo sapiens	GO:0001658~branching involved in ureteric bud morphogenesis,GO:0006024~glycosaminoglycan biosynthetic process,GO:0006477~protein sulfation,GO:0015012~heparan sulfate proteoglycan biosynthetic process,GO:0015015~heparan sulfate proteoglycan biosynthetic process, enzymatic modification,	GO:0000139~Golgi membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0008467~[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity,GO:0033872~[heparan sulfate]-glucosamine 3-sulfotransferase 3 activity,	IPR000863:Sulfotransferase domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00534:Glycosaminoglycan biosynthesis - heparan sulfate / heparin,					KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
HPSE2	heparanase 2 (inactive)(HPSE2)	Homo sapiens	GO:0006027~glycosaminoglycan catabolic process,GO:0008283~cell proliferation,GO:0008284~positive regulation of cell proliferation,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031012~extracellular matrix,	GO:0016798~hydrolase activity, acting on glycosyl bonds,GO:0030305~heparanase activity,GO:0043395~heparan sulfate proteoglycan binding,	IPR005199:Glycoside hydrolase, family 79,IPR017853:Glycoside hydrolase, superfamily,	hsa00531:Glycosaminoglycan degradation,hsa01100:Metabolic pathways,hsa05205:Proteoglycans in cancer,	236730~Urofacial syndrome 1,				KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
HK2	hexokinase 2(HK2)	Homo sapiens	GO:0001666~response to hypoxia,GO:0001678~cellular glucose homeostasis,GO:0002931~response to ischemia,GO:0006002~fructose 6-phosphate metabolic process,GO:0006006~glucose metabolic process,GO:0006096~glycolytic process,GO:0007595~lactation,GO:0008637~apoptotic mitochondrial changes,GO:0019318~hexose metabolic process,GO:0035795~negative regulation of mitochondrial membrane permeability,GO:0045766~positive regulation of angiogenesis,GO:0046324~regulation of glucose import,GO:0046835~carbohydrate phosphorylation,GO:0051156~glucose 6-phosphate metabolic process,GO:0061621~canonical glycolysis,GO:0072655~establishment of protein localization to mitochondrion,GO:0072656~maintenance of protein location in mitochondrion,GO:1904925~positive regulation of mitophagy in response to mitochondrial depolarization,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000378~negative regulation of reactive oxygen species metabolic process,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016529~sarcoplasmic reticulum,GO:0043231~intracellular membrane-bounded organelle,	GO:0004340~glucokinase activity,GO:0004396~hexokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008865~fructokinase activity,GO:0019158~mannokinase activity,	IPR001312:Hexokinase,IPR019807:Hexokinase, conserved site,IPR022672:Hexokinase, N-terminal,IPR022673:Hexokinase, C-terminal,	hsa00010:Glycolysis / Gluconeogenesis,hsa00051:Fructose and mannose metabolism,hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa00524:Neomycin, kanamycin and gentamicin biosynthesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01250:Biosynthesis of nucleotide sugars,hsa04066:HIF-1 signaling pathway,hsa04910:Insulin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04973:Carbohydrate digestion and absorption,hsa05131:Shigellosis,hsa05230:Central carbon metabolism in cancer,				KW-0324~Glycolysis,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-1000~Mitochondrion outer membrane,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,	DOMAIN:Hexokinase 1,DOMAIN:Hexokinase 2,DOMAIN:Hexokinase_1,DOMAIN:Hexokinase_2,MUTAGEN:D->A: Decreased hexokinase activity.,MUTAGEN:R->A: Induces a rapid dissociation of D-glucose.,REGION:Hexokinase large subdomain 1,REGION:Hexokinase large subdomain 2,REGION:Hexokinase small subdomain 1,REGION:Hexokinase small subdomain 2,REGION:Mitochondrial-binding peptide (MBP),
HK3	hexokinase 3(HK3)	Homo sapiens	GO:0001678~cellular glucose homeostasis,GO:0006002~fructose 6-phosphate metabolic process,GO:0006006~glucose metabolic process,GO:0006096~glycolytic process,GO:0019318~hexose metabolic process,GO:0046835~carbohydrate phosphorylation,GO:0051156~glucose 6-phosphate metabolic process,GO:0061621~canonical glycolysis,	GO:0005576~extracellular region,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0034774~secretory granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004340~glucokinase activity,GO:0004396~hexokinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0005536~glucose binding,GO:0008865~fructokinase activity,GO:0019158~mannokinase activity,	IPR001312:Hexokinase,IPR019807:Hexokinase, conserved site,IPR022672:Hexokinase, N-terminal,IPR022673:Hexokinase, C-terminal,	hsa00010:Glycolysis / Gluconeogenesis,hsa00051:Fructose and mannose metabolism,hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa00520:Amino sugar and nucleotide sugar metabolism,hsa00524:Neomycin, kanamycin and gentamicin biosynthesis,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01250:Biosynthesis of nucleotide sugars,hsa04066:HIF-1 signaling pathway,hsa04910:Insulin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04973:Carbohydrate digestion and absorption,hsa05131:Shigellosis,hsa05230:Central carbon metabolism in cancer,				KW-0324~Glycolysis,			KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0021~Allosteric enzyme,KW-0418~Kinase,KW-0808~Transferase,		DOMAIN:Hexokinase 1,DOMAIN:Hexokinase 2,DOMAIN:Hexokinase_1,DOMAIN:Hexokinase_2,REGION:Disordered,REGION:Hexokinase large subdomain 1,REGION:Hexokinase large subdomain 2,REGION:Hexokinase small subdomain 1,REGION:Hexokinase small subdomain 2,
HPCAL4	hippocalcin like 4(HPCAL4)	Homo sapiens	GO:0007165~signal transduction,GO:0007417~central nervous system development,		GO:0005246~calcium channel regulator activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0019904~protein domain specific binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,				KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:N-myristoyl glycine,
HPCA	hippocalcin(HPCA)	Homo sapiens	GO:0007420~brain development,GO:0019722~calcium-mediated signaling,GO:0031283~negative regulation of guanylate cyclase activity,GO:0031584~activation of phospholipase D activity,GO:0045762~positive regulation of adenylate cyclase activity,GO:0048839~inner ear development,GO:0060041~retina development in camera-type eye,GO:0071257~cellular response to electrical stimulus,GO:0071277~cellular response to calcium ion,GO:0090314~positive regulation of protein targeting to membrane,GO:1901385~regulation of voltage-gated calcium channel activity,GO:1901986~response to ketamine,GO:1902065~response to L-glutamate,GO:1904009~cellular response to monosodium glutamate,GO:1904010~response to Aroclor 1254,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0019898~extrinsic component of membrane,GO:0030424~axon,GO:0032590~dendrite membrane,GO:0032809~neuronal cell body membrane,GO:0032839~dendrite cytoplasm,GO:0043204~perikaryon,GO:0044327~dendritic spine head,GO:0098978~glutamatergic synapse,	GO:0003779~actin binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0042802~identical protein binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,		224500~Dystonia 2, torsion, autosomal recessive,		SM00054:EFh,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0519~Myristate,	DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:N-myristoyl glycine,
HAL	histidine ammonia-lyase(HAL)	Homo sapiens	GO:0006548~histidine catabolic process,GO:0019556~histidine catabolic process to glutamate and formamide,GO:0019557~histidine catabolic process to glutamate and formate,	GO:0005829~cytosol,	GO:0003824~catalytic activity,GO:0004397~histidine ammonia-lyase activity,GO:0016841~ammonia-lyase activity,	IPR001106:Aromatic amino acid lyase,IPR005921:Histidine ammonia-lyase,IPR008948:L-Aspartase-like,IPR021922:Protein of unknown function DUF3534,IPR022313:Phenylalanine/histidine ammonia-lyases, active site,IPR024083:Fumarase/histidase, N-terminal,	hsa00340:Histidine metabolism,hsa01100:Metabolic pathways,	235800~Histidinemia,			KW-0369~Histidine metabolism,		KW-0225~Disease variant,			KW-0456~Lyase,	KW-0597~Phosphoprotein,	CROSSLNK:5-imidazolinone (Ala-Gly),DOMAIN:Par3_HAL_N_term,
HDAC1	histone deacetylase 1(HDAC1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001975~response to amphetamine,GO:0006325~chromatin organization,GO:0006338~chromatin remodeling,GO:0006346~methylation-dependent chromatin silencing,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006476~protein deacetylation,GO:0007492~endoderm development,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009913~epidermal cell differentiation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0016575~histone deacetylation,GO:0021766~hippocampus development,GO:0030182~neuron differentiation,GO:0030336~negative regulation of cell migration,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0031000~response to caffeine,GO:0032496~response to lipopolysaccharide,GO:0032732~positive regulation of interleukin-1 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032922~circadian regulation of gene expression,GO:0034599~cellular response to oxidative stress,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042493~response to drug,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042659~regulation of cell fate specification,GO:0042733~embryonic digit morphogenesis,GO:0043044~ATP-dependent chromatin remodeling,GO:0043066~negative regulation of apoptotic process,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043524~negative regulation of neuron apoptotic process,GO:0043922~negative regulation by host of viral transcription,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046676~negative regulation of insulin secretion,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0048709~oligodendrocyte differentiation,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0052548~regulation of endopeptidase activity,GO:0055093~response to hyperoxia,GO:0060766~negative regulation of androgen receptor signaling pathway,GO:0060789~hair follicle placode formation,GO:0061029~eyelid development in camera-type eye,GO:0061198~fungiform papilla formation,GO:0070932~histone H3 deacetylation,GO:0070933~histone H4 deacetylation,GO:0071356~cellular response to tumor necrosis factor,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1900221~regulation of beta-amyloid clearance,GO:1902455~negative regulation of stem cell population maintenance,GO:1902459~positive regulation of stem cell population maintenance,GO:2000273~positive regulation of receptor activity,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,GO:2000676~positive regulation of type B pancreatic cell apoptotic process,GO:2000736~regulation of stem cell differentiation,GO:2000757~negative regulation of peptidyl-lysine acetylation,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,	GO:0000118~histone deacetylase complex,GO:0000785~chromatin,GO:0000792~heterochromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016580~Sin3 complex,GO:0016581~NuRD complex,GO:0017053~transcriptional repressor complex,GO:0032991~macromolecular complex,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0048471~perinuclear region of cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000979~RNA polymerase II core promoter sequence-specific DNA binding,GO:0001046~core promoter sequence-specific DNA binding,GO:0001222~transcription corepressor binding,GO:0002039~p53 binding,GO:0003714~transcription corepressor activity,GO:0004407~histone deacetylase activity,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019213~deacetylase activity,GO:0019899~enzyme binding,GO:0031492~nucleosomal DNA binding,GO:0032041~NAD-dependent histone deacetylase activity (H3-K14 specific),GO:0033558~protein deacetylase activity,GO:0035851~Krueppel-associated box domain binding,GO:0042826~histone deacetylase binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0047485~protein N-terminus binding,GO:0051059~NF-kappaB binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0070888~E-box binding,GO:1990841~promoter-specific chromatin binding,	IPR000286:Histone deacetylase superfamily,IPR003084:Histone deacetylase,IPR023696:Ureohydrolase domain,IPR023801:Histone deacetylase domain,	hsa04110:Cell cycle,hsa04213:Longevity regulating pathway - multiple species,hsa04330:Notch signaling pathway,hsa04613:Neutrophil extracellular trap formation,hsa04919:Thyroid hormone signaling pathway,hsa05016:Huntington disease,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,hsa05165:Human papillomavirus infection,hsa05169:Epstein-Barr virus infection,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05203:Viral carcinogenesis,hsa05206:MicroRNAs in cancer,hsa05220:Chronic myeloid leukemia,		PIRSF037913:histone deacetylase class I, eukaryotic type,		KW-0090~Biological rhythms,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,			KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0378~Hydrolase,KW-0678~Repressor,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Hist_deacetyl,MUTAGEN:AGG->VRPP: Impaired protein deacetylase activity without affecting the protein decrotonylase activity.,MUTAGEN:E->A: Decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:E->A: No effect on deacetylase activity, no effect on interaction with NuRD and SIN3 complexes.,MUTAGEN:E->A: Slightly decreases deacetylase activity, no effect on interaction with NuRD and SIN3 complexes.,MUTAGEN:EEE->AEA: Abolished histone deacetylase and decrotonylase activities.,MUTAGEN:F->Y: Abolishes interaction with CHFR; when associated with I-297.,MUTAGEN:H->A: Abolishes histone deacetylase and decrotonylase activities.,MUTAGEN:M->I: Abolishes interaction with CHFR; when associated with Y-287.,MUTAGEN:Missing: Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:S->A: Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.,MUTAGEN:S->D,E: Decreases deacetylase activity.,MUTAGEN:S->D,E: Slightly decreases deacetylase activity.,REGION:Disordered,REGION:Histone deacetylase,
HOXA1	homeobox A1(HOXA1)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007605~sensory perception of sound,GO:0007634~optokinetic behavior,GO:0009653~anatomical structure morphogenesis,GO:0021599~abducens nerve formation,GO:0042473~outer ear morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048702~embryonic neurocranium morphogenesis,GO:0048839~inner ear development,GO:0048844~artery morphogenesis,GO:0050795~regulation of behavior,GO:0050890~cognition,GO:0050905~neuromuscular process,GO:0060840~artery development,GO:0060876~semicircular canal formation,GO:0090102~cochlea development,GO:0090103~cochlea morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa04550:Signaling pathways regulating pluripotency of stem cells,	601536~Athabaskan brainstem dysgenesis syndrome,601536~Bosley-Salih-Alorainy syndrome,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-1268~Autism spectrum disorder,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,REGION:Interaction with OGT,
HOXA10	homeobox A10(HOXA10)	Homo sapiens	GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030326~embryonic limb morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060065~uterus development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0042826~histone deacetylase binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,			SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXA11	homeobox A11(HOXA11)	Homo sapiens	GO:0001501~skeletal system development,GO:0001656~metanephros development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0001759~organ induction,GO:0002063~chondrocyte development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0007501~mesodermal cell fate specification,GO:0008584~male gonad development,GO:0009653~anatomical structure morphogenesis,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0009954~proximal/distal pattern formation,GO:0010720~positive regulation of cell development,GO:0030326~embryonic limb morphogenesis,GO:0030850~prostate gland development,GO:0032332~positive regulation of chondrocyte differentiation,GO:0033574~response to testosterone,GO:0035115~embryonic forelimb morphogenesis,GO:0042733~embryonic digit morphogenesis,GO:0043627~response to estrogen,GO:0045893~positive regulation of transcription, DNA-templated,GO:0048589~developmental growth,GO:0048856~anatomical structure development,GO:0060065~uterus development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:1902761~positive regulation of chondrocyte development,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,GO:0032991~macromolecular complex,GO:0032993~protein-DNA complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR021918:Domain of unknown function DUF3528, homeobox protein, eukaryotic,	hsa05202:Transcriptional misregulation in cancer,	605432~Radioulnar synostosis with amegakaryocytic thrombocytopenia 1,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXA13	homeobox A13(HOXA13)	Homo sapiens	GO:0001501~skeletal system development,GO:0001570~vasculogenesis,GO:0001886~endothelial cell morphogenesis,GO:0001894~tissue homeostasis,GO:0003281~ventricular septum development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0030510~regulation of BMP signaling pathway,GO:0030539~male genitalia development,GO:0033574~response to testosterone,GO:0035115~embryonic forelimb morphogenesis,GO:0045840~positive regulation of mitotic nuclear division,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048619~embryonic hindgut morphogenesis,GO:0048839~inner ear development,GO:0048844~artery morphogenesis,GO:0060442~branching involved in prostate gland morphogenesis,GO:0060847~endothelial cell fate specification,GO:0097152~mesenchymal cell apoptotic process,GO:2001055~positive regulation of mesenchymal cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0045111~intermediate filament cytoskeleton,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		140000~Hand-foot-uterus syndrome,176305~Guttmacher syndrome,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:HoxA13_N,REGION:Disordered,
HOXA2	homeobox A2(HOXA2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001709~cell fate determination,GO:0002076~osteoblast development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007379~segment specification,GO:0008045~motor neuron axon guidance,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0021568~rhombomere 2 development,GO:0021658~rhombomere 3 morphogenesis,GO:0035284~brain segmentation,GO:0042474~middle ear morphogenesis,GO:0045665~negative regulation of neuron differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048703~embryonic viscerocranium morphogenesis,GO:0060037~pharyngeal system development,GO:0061061~muscle structure development,GO:0071300~cellular response to retinoic acid,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0043231~intracellular membrane-bounded organelle,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,		612290~Microtia with or without hearing impairment (AD),612290~Microtia, hearing impairment, and cleft palate (AR),		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA3	homeobox A3(HOXA3)	Homo sapiens	GO:0001525~angiogenesis,GO:0001974~blood vessel remodeling,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008284~positive regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0010159~specification of animal organ position,GO:0010467~gene expression,GO:0021615~glossopharyngeal nerve morphogenesis,GO:0030878~thyroid gland development,GO:0048538~thymus development,GO:0048645~animal organ formation,GO:0048704~embryonic skeletal system morphogenesis,GO:0051216~cartilage development,GO:0060017~parathyroid gland development,GO:0072089~stem cell proliferation,GO:2000648~positive regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0071837~HMG box domain binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR025281:Domain of unknown function DUF4074,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA4	homeobox A4(HOXA4)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0009952~anterior/posterior pattern specification,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0016604~nuclear body,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA5	homeobox A5(HOXA5)	Homo sapiens	GO:0003016~respiratory system process,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0010628~positive regulation of gene expression,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030878~thyroid gland development,GO:0033599~regulation of mammary gland epithelial cell proliferation,GO:0035264~multicellular organism growth,GO:0043065~positive regulation of apoptotic process,GO:0045639~positive regulation of myeloid cell differentiation,GO:0045647~negative regulation of erythrocyte differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048286~lung alveolus development,GO:0048704~embryonic skeletal system morphogenesis,GO:0060435~bronchiole development,GO:0060441~epithelial tube branching involved in lung morphogenesis,GO:0060480~lung goblet cell differentiation,GO:0060484~lung-associated mesenchyme development,GO:0060535~trachea cartilage morphogenesis,GO:0060574~intestinal epithelial cell maturation,GO:0060638~mesenchymal-epithelial cell signaling,GO:0060644~mammary gland epithelial cell differentiation,GO:0060749~mammary gland alveolus development,GO:0060764~cell-cell signaling involved in mammary gland development,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA6	homeobox A6(HOXA6)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0048704~embryonic skeletal system morphogenesis,GO:0048706~embryonic skeletal system development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA7	homeobox A7(HOXA7)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001953~negative regulation of cell-matrix adhesion,GO:0002686~negative regulation of leukocyte migration,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0045617~negative regulation of keratinocyte differentiation,GO:0045656~negative regulation of monocyte differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048863~stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0031965~nuclear membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXA9	homeobox A9(HOXA9)	Homo sapiens	GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007283~spermatogenesis,GO:0007338~single fertilization,GO:0008584~male gonad development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030850~prostate gland development,GO:0030879~mammary gland development,GO:0033574~response to testosterone,GO:0035115~embryonic forelimb morphogenesis,GO:0042118~endothelial cell activation,GO:0045638~negative regulation of myeloid cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0060065~uterus development,GO:0060216~definitive hemopoiesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019899~enzyme binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR006711:Hox9, N-terminal activation domain,IPR009057:Homeodomain-like,IPR017112:Homeobox protein Hox9,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05202:Transcriptional misregulation in cancer,		PIRSF037109:homeobox protein, Hox9 type,	SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0656~Proto-oncogene,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0488~Methylation,	DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:Hox9_act,MUTAGEN:R->A: Results in loss of methylation.,REGION:Disordered,SITE:Breakpoint for translocation to form MSI2/HOXA9 fusion protein,SITE:Breakpoint for translocation to form the NUP98-HOXA9 fusion protein,
HOXB13	homeobox B13(HOXB13)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008544~epidermis development,GO:0009611~response to wounding,GO:0033574~response to testosterone,GO:0040008~regulation of growth,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060743~epithelial cell maturation involved in prostate gland development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription factor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0008327~methyl-CpG binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		610997~Prostate cancer, hereditary, 9,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Interaction with 5-mCpG DNA,REGION:Interaction with DNA,
HOXB2	homeobox B2(HOXB2)	Homo sapiens	GO:0002011~morphogenesis of an epithelial sheet,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007399~nervous system development,GO:0008015~blood circulation,GO:0009952~anterior/posterior pattern specification,GO:0009953~dorsal/ventral pattern formation,GO:0021569~rhombomere 3 development,GO:0021570~rhombomere 4 development,GO:0021612~facial nerve structural organization,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048857~neural nucleus development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXB3	homeobox B3(HOXB3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0002244~hematopoietic progenitor cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0021546~rhombomere development,GO:0021615~glossopharyngeal nerve morphogenesis,GO:0030878~thyroid gland development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0050767~regulation of neurogenesis,GO:0051216~cartilage development,GO:0060216~definitive hemopoiesis,GO:0060324~face development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR025281:Domain of unknown function DUF4074,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXB4	homeobox B4(HOXB4)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002011~morphogenesis of an epithelial sheet,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008283~cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048103~somatic stem cell division,GO:0048536~spleen development,GO:0048539~bone marrow development,GO:0048704~embryonic skeletal system morphogenesis,GO:0060216~definitive hemopoiesis,GO:0060218~hematopoietic stem cell differentiation,GO:0071425~hematopoietic stem cell proliferation,GO:2000738~positive regulation of stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005813~centrosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXB5	homeobox B5(HOXB5)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0009952~anterior/posterior pattern specification,GO:0045446~endothelial cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXB6	homeobox B6(HOXB6)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0034101~erythrocyte homeostasis,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,
HOXB8	homeobox B8(HOXB8)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007625~grooming behavior,GO:0008344~adult locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0019233~sensory perception of pain,GO:0021516~dorsal spinal cord development,GO:0045638~negative regulation of myeloid cell differentiation,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXC10	homeobox C10(HOXC10)	Homo sapiens	GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008284~positive regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0021520~spinal cord motor neuron cell fate specification,GO:0030326~embryonic limb morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050905~neuromuscular process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXC11	homeobox C11(HOXC11)	Homo sapiens	GO:0001656~metanephros development,GO:0001759~organ induction,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007492~endoderm development,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0042733~embryonic digit morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048856~anatomical structure development,GO:0060272~embryonic skeletal joint morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR021918:Domain of unknown function DUF3528, homeobox protein, eukaryotic,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Homeobox,DOMAIN:DUF3528,REGION:Disordered,
HOXC13	homeobox C13(HOXC13)	Homo sapiens	GO:0001942~hair follicle development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009653~anatomical structure morphogenesis,GO:0009952~anterior/posterior pattern specification,GO:0035878~nail development,GO:0043587~tongue morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		614931~Ectodermal dysplasia 9, hair/nail type,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0038~Ectodermal dysplasia,KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXC4	homeobox C4(HOXC4)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0051216~cartilage development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXC5	homeobox C5(HOXC5)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0048706~embryonic skeletal system development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030054~cell junction,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXC6	homeobox C6(HOXC6)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0009952~anterior/posterior pattern specification,GO:0048706~embryonic skeletal system development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXC8	homeobox C8(HOXC8)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0030182~neuron differentiation,GO:0048705~skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0015630~microtubule cytoskeleton,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXC9	homeobox C9(HOXC9)	Homo sapiens	GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0045786~negative regulation of cell cycle,GO:0048704~embryonic skeletal system morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016235~aggresome,GO:0017053~transcriptional repressor complex,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR006711:Hox9, N-terminal activation domain,IPR009057:Homeodomain-like,IPR017112:Homeobox protein Hox9,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,			PIRSF037109:homeobox protein, Hox9 type,	SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXD10	homeobox D10(HOXD10)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007338~single fertilization,GO:0007519~skeletal muscle tissue development,GO:0008344~adult locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0021520~spinal cord motor neuron cell fate specification,GO:0030326~embryonic limb morphogenesis,GO:0035136~forelimb morphogenesis,GO:0035137~hindlimb morphogenesis,GO:0045786~negative regulation of cell cycle,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048935~peripheral nervous system neuron development,GO:0050905~neuromuscular process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0017053~transcriptional repressor complex,GO:0036464~cytoplasmic ribonucleoprotein granule,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,	192950~Charcot-Marie-Tooth disease, foot deformity of,192950~Vertical talus, congenital,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DNA_BIND:Homeobox,REGION:Disordered,
HOXD11	homeobox D11(HOXD11)	Homo sapiens	GO:0001658~branching involved in ureteric bud morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009953~dorsal/ventral pattern formation,GO:0048856~anatomical structure development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,IPR021918:Domain of unknown function DUF3528, homeobox protein, eukaryotic,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,REGION:Disordered,
HOXD12	homeobox D12(HOXD12)	Homo sapiens	GO:0001501~skeletal system development,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007389~pattern specification process,GO:0042733~embryonic digit morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DNA_BIND:Homeobox,REGION:Disordered,
HOXD13	homeobox D13(HOXD13)	Homo sapiens	GO:0001501~skeletal system development,GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006366~transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0009952~anterior/posterior pattern specification,GO:0030539~male genitalia development,GO:0033574~response to testosterone,GO:0042127~regulation of cell proliferation,GO:0042733~embryonic digit morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048619~embryonic hindgut morphogenesis,GO:0060527~prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,GO:0060571~morphogenesis of an epithelial fold,GO:0060602~branch elongation of an epithelium,GO:0060687~regulation of branching involved in prostate gland morphogenesis,	GO:0000785~chromatin,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022067:Homeobox protein Hox1A3 N-terminal,		113200~Brachydactyly, type D,113300~Brachydactyly, type E,186000~Synpolydactyly 1,186300~Syndactyly, type V,610713~Brachydactyly-syndactyly syndrome,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,REGION:Disordered,
HOXD4	homeobox D4(HOXD4)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0009952~anterior/posterior pattern specification,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048568~embryonic organ development,GO:0048704~embryonic skeletal system morphogenesis,GO:0048863~stem cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0030054~cell junction,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001827:Homeobox protein, antennapedia type, conserved site,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR017995:Homeobox protein, antennapedia type,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox,MOTIF:Antp-type hexapeptide,REGION:Disordered,
HOXD9	homeobox D9(HOXD9)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006351~transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007338~single fertilization,GO:0007519~skeletal muscle tissue development,GO:0008344~adult locomotory behavior,GO:0009952~anterior/posterior pattern specification,GO:0009954~proximal/distal pattern formation,GO:0030879~mammary gland development,GO:0035115~embryonic forelimb morphogenesis,GO:0035137~hindlimb morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0048935~peripheral nervous system neuron development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR006711:Hox9, N-terminal activation domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DNA_BIND:Homeobox,REGION:Disordered,
HGD	homogentisate 1,2-dioxygenase(HGD)	Homo sapiens	GO:0006559~L-phenylalanine catabolic process,GO:0006570~tyrosine metabolic process,GO:0006572~tyrosine catabolic process,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004411~homogentisate 1,2-dioxygenase activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR005708:Homogentisate 1,2-dioxygenase,IPR011051:RmlC-like cupin domain,IPR014710:RmlC-like jelly roll fold,	hsa00350:Tyrosine metabolism,hsa01100:Metabolic pathways,	203500~Alkaptonuria,			KW-0585~Phenylalanine catabolism,KW-0828~Tyrosine catabolism,		KW-0225~Disease variant,		KW-0408~Iron,KW-0479~Metal-binding,	KW-0223~Dioxygenase,KW-0560~Oxidoreductase,	KW-0007~Acetylation,
HAS2	hyaluronan synthase 2(HAS2)	Homo sapiens	GO:0001570~vasculogenesis,GO:0001822~kidney development,GO:0008284~positive regulation of cell proliferation,GO:0010838~positive regulation of keratinocyte proliferation,GO:0014911~positive regulation of smooth muscle cell migration,GO:0030213~hyaluronan biosynthetic process,GO:0030335~positive regulation of cell migration,GO:0035810~positive regulation of urine volume,GO:0036120~cellular response to platelet-derived growth factor stimulus,GO:0036302~atrioventricular canal development,GO:0044849~estrous cycle,GO:0045226~extracellular polysaccharide biosynthetic process,GO:0051549~positive regulation of keratinocyte migration,GO:0060349~bone morphogenesis,GO:0070295~renal water absorption,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0071498~cellular response to fluid shear stress,GO:0085029~extracellular matrix assembly,GO:0090500~endocardial cushion to mesenchymal transition,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,GO:1900127~positive regulation of hyaluronan biosynthetic process,GO:1900625~positive regulation of monocyte aggregation,GO:1901201~regulation of extracellular matrix assembly,	GO:0000139~Golgi membrane,GO:0005764~lysosome,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0044853~plasma membrane raft,GO:1903561~extracellular vesicle,	GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0050501~hyaluronan synthase activity,							KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MUTAGEN:K->R: Completely abolishes hyaluronan synthase activity. Cumulates at plasma membrane.,MUTAGEN:S->A: Prevents O-GlcNAcylation. Increases protein stability. Reduces hyaluronan synthase activity.,MUTAGEN:S->D: Increases protein degradation. Abolishes hyaluronan synthase activity. Does not affect subcellular location.,MUTAGEN:S->E: Increases protein degradation. Abolishes hyaluronan synthase activity. Does not affect subcellular location.,MUTAGEN:T->A: Abolishes hyaluronan synthase activity.,MUTAGEN:T->A: Completely abolishes hyaluronan synthase activity. Not detected in cytoplasmic vesicles nor at cell membrane. Inability to travel from ER to Golgi. Unresponsive to AMPK-mediated inactivation.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
HSD11B1	hydroxysteroid 11-beta dehydrogenase 1(HSD11B1)	Homo sapiens	GO:0006706~steroid catabolic process,GO:0030324~lung development,	GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0003845~11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity,GO:0005496~steroid binding,GO:0016491~oxidoreductase activity,GO:0042803~protein homodimerization activity,GO:0047022~7-beta-hydroxysteroid dehydrogenase (NADP+) activity,GO:0050661~NADP binding,GO:0070524~11-beta-hydroxysteroid dehydrogenase (NADP+) activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00140:Steroid hormone biosynthesis,hsa00980:Metabolism of xenobiotics by cytochrome P450,hsa01100:Metabolic pathways,hsa05204:Chemical carcinogenesis - DNA adducts,	614662~Cortisone reductase deficiency 2,			KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:E->K,Q: No effect on activity.,MUTAGEN:E->K: No effect on activity.,MUTAGEN:EE->KK: Inverted topology. Reduced Vmax.,MUTAGEN:EE->KQ: No effect on topology. Reduced Vmax.,MUTAGEN:EE->QQ: Reduced Vmax.,MUTAGEN:K->R: No effect on topology. Increased Km for corticosterone.,MUTAGEN:K->R: Predominantly inverted topology. No effect on activity.,MUTAGEN:K->S: Inverted topology. No effect on activity.,MUTAGEN:K->S: No effect on topology or activity.,MUTAGEN:KK->RR: Predominantly inverted topology. No effect on activity.,MUTAGEN:KK->SS: Complete loss of activity.,MUTAGEN:KK->SS: Inverted topology. Reduced Vmax.,MUTAGEN:YYY->AYA: No effect on topology. Reduced Vmax.,MUTAGEN:YYYY->AAAA: No effect on topology. Reduced Vmax.,MUTAGEN:YYYY->FFFF: No effect on topology or activity.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
HSD17B6	hydroxysteroid 17-beta dehydrogenase 6(HSD17B6)	Homo sapiens	GO:0006702~androgen biosynthetic process,GO:0006710~androgen catabolic process,GO:0008202~steroid metabolic process,GO:0022900~electron transport chain,GO:0042572~retinol metabolic process,	GO:0005783~endoplasmic reticulum,GO:0031901~early endosome membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0003824~catalytic activity,GO:0004303~estradiol 17-beta-dehydrogenase activity,GO:0004745~retinol dehydrogenase activity,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0044594~17-beta-hydroxysteroid dehydrogenase (NAD+) activity,GO:0047023~androsterone dehydrogenase activity,GO:0047024~5alpha-androstane-3beta,17beta-diol dehydrogenase activity,GO:0047035~testosterone dehydrogenase (NAD+) activity,GO:0047044~androstan-3-alpha,17-beta-diol dehydrogenase activity,GO:0047045~testosterone 17-beta-dehydrogenase (NADP+) activity,GO:0072582~17-beta-hydroxysteroid dehydrogenase (NADP+) activity,	IPR002347:Glucose/ribitol dehydrogenase,IPR020904:Short-chain dehydrogenase/reductase, conserved site,	hsa00140:Steroid hormone biosynthesis,hsa00830:Retinol metabolism,hsa01100:Metabolic pathways,hsa01240:Biosynthesis of cofactors,				KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0492~Microsome,KW-0967~Endosome,		KW-0732~Signal,	KW-0520~NAD,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,
HCN1	hyperpolarization activated cyclic nucleotide gated potassium channel 1(HCN1)	Homo sapiens	GO:0003254~regulation of membrane depolarization,GO:0019228~neuronal action potential,GO:0034765~regulation of ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0045176~apical protein localization,GO:0046549~retinal cone cell development,GO:0051289~protein homotetramerization,GO:0051867~general adaptation syndrome, behavioral process,GO:0051967~negative regulation of synaptic transmission, glutamatergic,GO:0060078~regulation of postsynaptic membrane potential,GO:0071320~cellular response to cAMP,GO:0071805~potassium ion transmembrane transport,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098907~regulation of SA node cell action potential,GO:2001257~regulation of cation channel activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0045211~postsynaptic membrane,GO:0048787~presynaptic active zone membrane,GO:0098855~HCN channel complex,GO:0098978~glutamatergic synapse,	GO:0005222~intracellular cAMP activated cation channel activity,GO:0005248~voltage-gated sodium channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0005267~potassium channel activity,GO:0005272~sodium channel activity,GO:0005515~protein binding,GO:0022843~voltage-gated cation channel activity,GO:0030552~cAMP binding,GO:0042802~identical protein binding,	IPR000595:Cyclic nucleotide-binding domain,IPR003938:Potassium channel, voltage-dependent, EAG/ELK/ERG,IPR005821:Ion transport domain,IPR013621:Ion transport N-terminal,IPR014710:RmlC-like jelly roll fold,IPR018488:Cyclic nucleotide-binding, conserved site,IPR018490:Cyclic nucleotide-binding-like,	hsa04929:GnRH secretion,	615871~Developmental and epileptic encephalopathy 24,618482~Generalized epilepsy with febrile seizures plus, type 10,		SM00100:cNMP,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,KW-0915~Sodium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,KW-0894~Sodium channel,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Cyclic nucleotide-binding,DOMAIN:Ion_trans,DOMAIN:Ion_trans_N,INTRAMEM:Pore-forming; Name=Segment H5,MOTIF:Selectivity filter,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
HCN4	hyperpolarization activated cyclic nucleotide gated potassium channel 4(HCN4)	Homo sapiens	GO:0002027~regulation of heart rate,GO:0003161~cardiac conduction system development,GO:0003163~sinoatrial node development,GO:0003254~regulation of membrane depolarization,GO:0006812~cation transport,GO:0006936~muscle contraction,GO:0008015~blood circulation,GO:0034765~regulation of ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0055117~regulation of cardiac muscle contraction,GO:0071320~cellular response to cAMP,GO:0071321~cellular response to cGMP,GO:0071805~potassium ion transmembrane transport,GO:0086012~membrane depolarization during cardiac muscle cell action potential,GO:0086015~SA node cell action potential,GO:0086046~membrane depolarization during SA node cell action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098719~sodium ion import across plasma membrane,GO:0098907~regulation of SA node cell action potential,GO:0098909~regulation of cardiac muscle cell action potential involved in regulation of contraction,GO:1990573~potassium ion import across plasma membrane,GO:2001257~regulation of cation channel activity,	GO:0005886~plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0031226~intrinsic component of plasma membrane,GO:0048471~perinuclear region of cytoplasm,GO:0098855~HCN channel complex,	GO:0005222~intracellular cAMP activated cation channel activity,GO:0005248~voltage-gated sodium channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0030552~cAMP binding,GO:0042802~identical protein binding,GO:0086041~voltage-gated potassium channel activity involved in SA node cell action potential depolarization,	IPR000595:Cyclic nucleotide-binding domain,IPR003938:Potassium channel, voltage-dependent, EAG/ELK/ERG,IPR005821:Ion transport domain,IPR013621:Ion transport N-terminal,IPR014710:RmlC-like jelly roll fold,IPR018488:Cyclic nucleotide-binding, conserved site,IPR018490:Cyclic nucleotide-binding-like,	hsa04024:cAMP signaling pathway,hsa04742:Taste transduction,	163800~Sick sinus syndrome 2,613123~Brugada syndrome 8,619521~Epilepsy, idiopathic generalized, susceptibility to, 18,		SM00100:cNMP,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0992~Brugada syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0114~cAMP,KW-0116~cAMP-binding,KW-0547~Nucleotide-binding,KW-0630~Potassium,KW-0915~Sodium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,KW-0894~Sodium channel,KW-1071~Ligand-gated ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,INTRAMEM:Pore-forming; Name=Segment H5,REGION:Disordered,REGION:Involved in subunit assembly,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
HILPDA	hypoxia inducible lipid droplet associated(HILPDA)	Homo sapiens	GO:0001819~positive regulation of cytokine production,GO:0008284~positive regulation of cell proliferation,GO:0010884~positive regulation of lipid storage,GO:0035425~autocrine signaling,GO:0071456~cellular response to hypoxia,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030141~secretory granule,	GO:0005102~receptor binding,GO:0005515~protein binding,	IPR026190:Hypoxia-inducible lipid droplet-associated protein,					KW-0346~Stress response,	KW-0472~Membrane,KW-0551~Lipid droplet,KW-0964~Secreted,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,MUTAGEN:S->K: No effect on lipid droplet targeting or protein expression; when associated with K-41.,MUTAGEN:T->K: No effect on lipid droplet targeting or protein expression; when associated with K-44.,MUTAGEN:YL->DD: Loss of targeting to lipid droplets and elimination of protein.,REGION:Disordered,REGION:Required for targeting to lipid droplets,TRANSMEM:Helical,
IER3	immediate early response 3(IER3)	Homo sapiens	GO:0001562~response to protozoan,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0006096~glycolytic process,GO:0006282~regulation of DNA repair,GO:0006915~apoptotic process,GO:0007095~mitotic G2 DNA damage checkpoint,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009653~anatomical structure morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0045732~positive regulation of protein catabolic process,GO:0045820~negative regulation of glycolytic process,GO:0046822~regulation of nucleocytoplasmic transport,GO:0050728~negative regulation of inflammatory response,GO:1901029~negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway,GO:2000377~regulation of reactive oxygen species metabolic process,GO:2001020~regulation of response to DNA damage stimulus,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR024829:Radiation-inducible immediate-early gene IEX-1,						KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
IGHA1	immunoglobulin heavy constant alpha 1(IGHA1)	Homo sapiens	GO:0001895~retina homeostasis,GO:0002250~adaptive immune response,GO:0003094~glomerular filtration,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0018298~protein-chromophore linkage,GO:0019731~antibacterial humoral response,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,GO:0060267~positive regulation of respiratory burst,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0071745~IgA immunoglobulin complex,GO:0071748~monomeric IgA immunoglobulin complex,GO:0071751~secretory IgA immunoglobulin complex,GO:0071752~secretory dimeric IgA immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,	KW-0157~Chromophore,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	BINDING:covalent; in form alpha-1-microglobulin complex,CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Pro residues,DISULFID:Interchain (with J chain); in oligomeric form,DISULFID:Interchain (with heavy chain of another subunit) (or with C-503 of PIGR/the secretory component),DISULFID:Interchain (with heavy chain),DISULFID:Interchain (with heavy chain) (or with C-180),DISULFID:Interchain (with light chain),DISULFID:Or C-123 with C-182,DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,REGION:Disordered,
IGHA2	immunoglobulin heavy constant alpha 2 (A2m marker)(IGHA2)	Homo sapiens	GO:0001895~retina homeostasis,GO:0002250~adaptive immune response,GO:0003094~glomerular filtration,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0019731~antibacterial humoral response,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,GO:0060267~positive regulation of respiratory burst,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071745~IgA immunoglobulin complex,GO:0071748~monomeric IgA immunoglobulin complex,GO:0071751~secretory IgA immunoglobulin complex,GO:0071752~secretory dimeric IgA immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0004866~endopeptidase inhibitor activity,GO:0034987~immunoglobulin receptor binding,	IPR002890:Alpha-2-macroglobulin, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010916:TonB box, conserved site,IPR011625:Alpha-2-macroglobulin, N-terminal 2,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with J chain),DISULFID:Interchain (with heavy chain of another subunit) (or with C-503 of PIGR/the secretory component),DISULFID:Interchain (with heavy chain),DISULFID:Interchain (with light chain),DOMAIN:A2M_N_2,DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,DOMAIN:MG2,
IGHG1	immunoglobulin heavy constant gamma 1 (G1m marker)(IGHG1)	Homo sapiens	GO:0001788~antibody-dependent cellular cytotoxicity,GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,GO:0097278~complement-dependent cytotoxicity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0034987~immunoglobulin receptor binding,GO:0034988~Fc-gamma receptor I complex binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,DISULFID:Interchain (with heavy chain),DISULFID:Interchain (with light chain),DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,MUTAGEN:G->A: Reduces the affinity for FCGR1A about 40-fold. Abolishes binding to FCGR2A and FCGR3A. Impairs ADCC of virus-infected cells by monocytes. Decreases binding to complement component C1q. Decreases complement-dependent cytotoxicity.,MUTAGEN:K->A: Does not affect binding to FCGR1A. Only slightly affects binding to FCGR2A and FCGR3A. Impairs binding to complement component C1q. Impairs complement-dependent cytotoxicity.,MUTAGEN:L->A: Reduces the affinity for FCGR1A about 5-fold. Abolishes binding to FCGR2A and FCGR3A. Impairs ADCC of virus-infected cells by monocytes. Impairs binding to complement component C1q. Impairs complement-dependent cytotoxicity.,MUTAGEN:L->E: Reduces the affinity for FCGR1A about 40-fold. Abolishes binding to FCGR2A and FCGR3A. Impairs ADCC of virus-infected cells by monocytes. Impairs binding to complement component C1q. Impairs complement-dependent cytotoxicity.,MUTAGEN:LL->AA: Abolishes binding to FCGR1A, FCGR2A and FCGR3A. Impairs ADCC of virus-infected cells by monocytes.,REGION:CH1,REGION:CH2,REGION:CH3,REGION:Disordered,REGION:Hinge,TRANSMEM:Helical,
IGHG2	immunoglobulin heavy constant gamma 2 (G2m marker)(IGHG2)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0005515~protein binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,		IgG2 deficiency, selective~IgG2 deficiency, selective,		SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,DISULFID:Interchain (with a heavy chain),DISULFID:Interchain (with a light chain),DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,REGION:CH1,REGION:CH2,REGION:CH3,REGION:Hinge,SITE:At or near the complement-binding site,TRANSMEM:Helical,
IGHG3	immunoglobulin heavy constant gamma 3 (G3m marker)(IGHG3)	Homo sapiens	GO:0001895~retina homeostasis,GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,DISULFID:Interchain (with heavy chain dimer),DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,REGION:CH1,REGION:CH2,REGION:CH3,REGION:Hinge,TRANSMEM:Helical,
IGHG4	immunoglobulin heavy constant gamma 4 (G4m marker)(IGHG4)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,DISULFID:Interchain (with a heavy chain),DISULFID:Interchain (with a light chain),DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,REGION:CH1,REGION:CH2,REGION:CH3,REGION:Hinge,TRANSMEM:Helical,
IGHM	immunoglobulin heavy constant mu(IGHM)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0019731~antibacterial humoral response,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050829~defense response to Gram-negative bacterium,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071753~IgM immunoglobulin complex,GO:0071756~pentameric IgM immunoglobulin complex,GO:0071757~hexameric IgM immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003697~single-stranded DNA binding,GO:0003823~antigen binding,GO:0031210~phosphatidylcholine binding,GO:0034987~immunoglobulin receptor binding,GO:0042834~peptidoglycan binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,		601495~Agammaglobulinemia 1,		SM00406:IGv,SM00407:IGc1,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0812~Transmembrane,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with heavy chain of another subunit),DISULFID:Interchain (with heavy chain),DISULFID:Interchain (with light chain),DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,DOMAIN:Ig-like 3,DOMAIN:Ig-like 4,REGION:CH1,REGION:CH2,REGION:CH3,REGION:CH4,
IGHV3-23	immunoglobulin heavy variable 3-23(IGHV3-23)	Homo sapiens	GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,
IGKC	immunoglobulin kappa constant(IGKC)	Homo sapiens	GO:0001895~retina homeostasis,GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0071738~IgD immunoglobulin complex,GO:0071742~IgE immunoglobulin complex,GO:0071745~IgA immunoglobulin complex,GO:0071753~IgM immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,		614102~Kappa light chain deficiency,		SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,			KW-1015~Disulfide bond,	DISULFID:Interchain (with a heavy chain),DOMAIN:Ig-like,
IGKV1-5	immunoglobulin kappa variable 1-5(IGKV1-5)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,REGION:Complementarity-determining-1,REGION:Complementarity-determining-2,REGION:Complementarity-determining-3,REGION:Framework-1,REGION:Framework-2,REGION:Framework-3,
IGKV1D-39	immunoglobulin kappa variable 1D-39(IGKV1D-39)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,REGION:Complementarity-determining-1,REGION:Complementarity-determining-2,REGION:Complementarity-determining-3,REGION:Framework-1,REGION:Framework-2,REGION:Framework-3,
IGKV3-11	immunoglobulin kappa variable 3-11(IGKV3-11)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,REGION:Complementarity-determining-1,REGION:Complementarity-determining-2,REGION:Complementarity-determining-3,REGION:Framework-1,REGION:Framework-2,REGION:Framework-3,
IGLC1	immunoglobulin lambda constant 1(IGLC1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006955~immune response,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0071738~IgD immunoglobulin complex,GO:0071742~IgE immunoglobulin complex,GO:0071745~IgA immunoglobulin complex,GO:0071753~IgM immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,		KW-0086~Bence-Jones protein,	KW-1015~Disulfide bond,	DISULFID:Interchain (with heavy chain),DOMAIN:Ig-like,
IGLC2	immunoglobulin lambda constant 2(IGLC2)	Homo sapiens	GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,		KW-0086~Bence-Jones protein,	KW-1015~Disulfide bond,	DISULFID:Interchain (with heavy chain),DOMAIN:Ig-like,
IGLC3	immunoglobulin lambda constant 3 (Kern-Oz+ marker)(IGLC3)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,GO:0071735~IgG immunoglobulin complex,GO:0071738~IgD immunoglobulin complex,GO:0071742~IgE immunoglobulin complex,GO:0071745~IgA immunoglobulin complex,GO:0071753~IgM immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,		KW-0086~Bence-Jones protein,	KW-1015~Disulfide bond,	DISULFID:Interchain (with heavy chain),DOMAIN:Ig-like,
IGLL5	immunoglobulin lambda like polypeptide 5(IGLL5)	Homo sapiens	GO:0006910~phagocytosis, recognition,GO:0006911~phagocytosis, engulfment,GO:0006958~complement activation, classical pathway,GO:0042742~defense response to bacterium,GO:0045087~innate immune response,GO:0050853~B cell receptor signaling pathway,GO:0050871~positive regulation of B cell activation,	GO:0009897~external side of plasma membrane,GO:0042571~immunoglobulin complex, circulating,GO:0070062~extracellular exosome,	GO:0003823~antigen binding,GO:0034987~immunoglobulin receptor binding,	IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,		KW-0964~Secreted,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,REGION:C region (By similarity to lambda light-chain),REGION:J region (By similarity to lambda light-chain),
IGLV1-40	immunoglobulin lambda variable 1-40(IGLV1-40)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	DOMAIN:Ig-like,
IGLV1-47	immunoglobulin lambda variable 1-47(IGLV1-47)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	DOMAIN:Ig-like,
IGLV2-23	immunoglobulin lambda variable 2-23(IGLV2-23)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:Ig-like,REGION:Disordered,
IGLV2-8	immunoglobulin lambda variable 2-8(IGLV2-8)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:Ig-like,REGION:Disordered,
IGLV3-21	immunoglobulin lambda variable 3-21(IGLV3-21)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002377~immunoglobulin production,GO:0006955~immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0019814~immunoglobulin complex,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003823~antigen binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,KW-1280~Immunoglobulin,		KW-0393~Immunoglobulin domain,KW-0732~Signal,			KW-1015~Disulfide bond,	DOMAIN:Ig-like,
IGSF1	immunoglobulin superfamily member 1(IGSF1)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0032926~negative regulation of activin receptor signaling pathway,	GO:0005576~extracellular region,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0034711~inhibin binding,GO:0038102~activin receptor antagonist activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,	hsa04350:TGF-beta signaling pathway,	300888~Hypothyroidism, central, and testicular enlargement,		SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,KW-0984~Congenital hypothyroidism,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ID3	inhibitor of DNA binding 3(ID3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001656~metanephros development,GO:0006275~regulation of DNA replication,GO:0007275~multicellular organism development,GO:0007417~central nervous system development,GO:0007507~heart development,GO:0007517~muscle organ development,GO:0009611~response to wounding,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0030855~epithelial cell differentiation,GO:0030903~notochord development,GO:0032922~circadian regulation of gene expression,GO:0042476~odontogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0045662~negative regulation of myoblast differentiation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0051726~regulation of cell cycle,GO:0072750~cellular response to leptomycin B,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0043425~bHLH transcription factor binding,GO:0046983~protein dimerization activity,GO:1901707~leptomycin B binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR026052:DNA-binding protein inhibitor,	hsa04350:TGF-beta signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00353:HLH,	KW-0090~Biological rhythms,KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0678~Repressor,		DOMAIN:BHLH,DOMAIN:bHLH,
IGF2BP2	insulin like growth factor 2 mRNA binding protein 2(IGF2BP2)	Homo sapiens	GO:0001817~regulation of cytokine production,GO:0007399~nervous system development,GO:0009653~anatomical structure morphogenesis,GO:0010468~regulation of gene expression,GO:0017148~negative regulation of translation,GO:0051028~mRNA transport,GO:0051252~regulation of RNA metabolic process,GO:0070934~CRD-mediated mRNA stabilization,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0010494~cytoplasmic stress granule,	GO:0003676~nucleic acid binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0045182~translation regulator activity,GO:0048027~mRNA 5'-UTR binding,GO:1990247~N6-methyladenosine-containing RNA binding,	IPR000504:RNA recognition motif domain,IPR004087:K Homology domain,IPR004088:K Homology domain, type 1,IPR012677:Nucleotide-binding, alpha-beta plait,		125853~Diabetes mellitus, noninsulin-dependent, susceptibility to,		SM00322:KH,SM00360:RRM,	KW-0509~mRNA transport,KW-0810~Translation regulation,KW-0813~Transport,	KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:KH,DOMAIN:KH 1,DOMAIN:KH 2,DOMAIN:KH 3,DOMAIN:KH 4,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,MUTAGEN:K->E: Significantly impaired binding to ACTB transcript but little effect on MYC transcript binding, accumulation in the nucleus and partial reduction in interaction with m6A-modified mRNA; when associated with E-211. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; 445-E-E-445 and 526-E-E-527.,MUTAGEN:K->E: Significantly impaired binding to ACTB transcript but little effect on MYC transcript binding, accumulation in the nucleus and partial reduction in interaction with m6A-modified mRNA; when associated with E-292. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-292; 445-E-E-446 and 526-E-E-527.,MUTAGEN:KG->EE: Significantly impaired binding to ACTB and MYC transcripts and loss of interaction with m6A-modified mRNA; when associated with 445-E-E-446. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; E-292 and 445-E-E-446.,MUTAGEN:KK->EE: Significantly impaired binding to ACTB and MYC transcripts and loss of interaction with m6A-modified mRNA; when associated with 527-E-E-528. Loss of homo- and heterooligomerization with IGF2BP1 and IGF2BP2, almost complete loss of ACTB and MYC transcript binding, almost complete loss of ELAVL1-, DHX9- and HNRNPU-binding and perturbed subcellular location, including accumulation in the nucleus and loss of localization to stress granules; when associated with E-211; E-292 and 527-E-E-528.,REGION:Disordered,
IGFBP2	insulin like growth factor binding protein 2(IGFBP2)	Homo sapiens	GO:0007165~signal transduction,GO:0007565~female pregnancy,GO:0007568~aging,GO:0007584~response to nutrient,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0010226~response to lithium ion,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032868~response to insulin,GO:0032870~cellular response to hormone stimulus,GO:0040008~regulation of growth,GO:0042104~positive regulation of activated T cell proliferation,GO:0042493~response to drug,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0043627~response to estrogen,GO:0051384~response to glucocorticoid,GO:0090090~negative regulation of canonical Wnt signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016324~apical plasma membrane,GO:0031410~cytoplasmic vesicle,GO:0070062~extracellular exosome,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0031994~insulin-like growth factor I binding,GO:0031995~insulin-like growth factor II binding,	IPR000716:Thyroglobulin type-1,IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR012210:Insulin-like growth factor binding protein 2,IPR017891:Insulin-like growth factor binding protein, N-terminal, Cys-rich conserved site,IPR022321:Insulin-like growth factor-binding protein family 1-6, chordata,				SM00121:IB,SM00211:TY,	KW-0341~Growth regulation,	KW-0964~Secreted,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,DOMAIN:IGFBP N-terminal,DOMAIN:Thyroglobulin type-1,MOTIF:Cell attachment site,MUTAGEN:D->E: Does not disrupt growth-inhibiting activity.,MUTAGEN:KKLR->NNLA: Does not disrupt growth-inhibiting activity.,REGION:Disordered,
IGFBP3	insulin like growth factor binding protein 3(IGFBP3)	Homo sapiens	GO:0000165~MAPK cascade,GO:0001558~regulation of cell growth,GO:0001649~osteoblast differentiation,GO:0001933~negative regulation of protein phosphorylation,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0008285~negative regulation of cell proliferation,GO:0009968~negative regulation of signal transduction,GO:0010906~regulation of glucose metabolic process,GO:0014912~negative regulation of smooth muscle cell migration,GO:0043065~positive regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0044342~type B pancreatic cell proliferation,GO:0045663~positive regulation of myoblast differentiation,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0050790~regulation of catalytic activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005788~endoplasmic reticulum lumen,GO:0016942~insulin-like growth factor binding protein complex,GO:0042567~insulin-like growth factor ternary complex,	GO:0001968~fibronectin binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0008160~protein tyrosine phosphatase activator activity,GO:0031994~insulin-like growth factor I binding,GO:0031995~insulin-like growth factor II binding,GO:0046872~metal ion binding,	IPR000716:Thyroglobulin type-1,IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR012211:Insulin-like growth factor binding protein 3,IPR017891:Insulin-like growth factor binding protein, N-terminal, Cys-rich conserved site,IPR022321:Insulin-like growth factor-binding protein family 1-6, chordata,	hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04935:Growth hormone synthesis, secretion and action,hsa05202:Transcriptional misregulation in cancer,			SM00121:IB,SM00211:TY,	KW-0053~Apoptosis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IGFBP N-terminal,DOMAIN:Thyroglobulin type-1,REGION:Disordered,REGION:IGF-binding,
IGFBP5	insulin like growth factor binding protein 5(IGFBP5)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0001649~osteoblast differentiation,GO:0007165~signal transduction,GO:0007565~female pregnancy,GO:0007568~aging,GO:0014912~negative regulation of smooth muscle cell migration,GO:0017148~negative regulation of translation,GO:0030336~negative regulation of cell migration,GO:0031069~hair follicle morphogenesis,GO:0035556~intracellular signal transduction,GO:0042593~glucose homeostasis,GO:0043567~regulation of insulin-like growth factor receptor signaling pathway,GO:0043568~positive regulation of insulin-like growth factor receptor signaling pathway,GO:0043569~negative regulation of insulin-like growth factor receptor signaling pathway,GO:0044342~type B pancreatic cell proliferation,GO:0045668~negative regulation of osteoblast differentiation,GO:0045926~negative regulation of growth,GO:0048009~insulin-like growth factor receptor signaling pathway,GO:0048286~lung alveolus development,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0051146~striated muscle cell differentiation,GO:0051897~positive regulation of protein kinase B signaling,GO:0060056~mammary gland involution,GO:0060416~response to growth hormone,GO:0071320~cellular response to cAMP,GO:0071407~cellular response to organic cyclic compound,GO:1901862~negative regulation of muscle tissue development,GO:1904205~negative regulation of skeletal muscle hypertrophy,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:1904754~positive regulation of vascular associated smooth muscle cell migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0016942~insulin-like growth factor binding protein complex,GO:0042567~insulin-like growth factor ternary complex,	GO:0001968~fibronectin binding,GO:0005515~protein binding,GO:0005520~insulin-like growth factor binding,GO:0031994~insulin-like growth factor I binding,GO:0031995~insulin-like growth factor II binding,	IPR000716:Thyroglobulin type-1,IPR000867:Insulin-like growth factor-binding protein, IGFBP,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR012213:Insulin-like growth factor binding protein 5,IPR017891:Insulin-like growth factor binding protein, N-terminal, Cys-rich conserved site,IPR022321:Insulin-like growth factor-binding protein family 1-6, chordata,				SM00121:IB,SM00211:TY,		KW-0964~Secreted,		KW-0732~Signal,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:O-linked (HexNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IGFBP N-terminal,DOMAIN:Thyroglobulin type-1,REGION:Disordered,
INSRR	insulin receptor related receptor(INSRR)	Homo sapiens	GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0007275~multicellular organism development,GO:0008286~insulin receptor signaling pathway,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030238~male sex determination,GO:0031532~actin cytoskeleton reorganization,GO:0033674~positive regulation of kinase activity,GO:0046777~protein autophosphorylation,GO:0071469~cellular response to alkaline pH,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005899~insulin receptor complex,GO:0030424~axon,GO:0043235~receptor complex,	GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0005009~insulin-activated receptor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0043548~phosphatidylinositol 3-kinase binding,GO:0043560~insulin receptor substrate binding,	IPR000494:EGF receptor, L domain,IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002011:Tyrosine-protein kinase, receptor class II, conserved site,IPR003961:Fibronectin, type III,IPR006211:Furin-like cysteine-rich domain,IPR006212:Furin-like repeat,IPR008266:Tyrosine-protein kinase, active site,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011009:Protein kinase-like domain,IPR013783:Immunoglobulin-like fold,IPR016246:Tyrosine-protein kinase, insulin-like receptor,IPR017441:Protein kinase, ATP binding site,IPR020635:Tyrosine-protein kinase, catalytic domain,	hsa04810:Regulation of actin cytoskeleton,hsa05215:Prostate cancer,		PIRSF000620:insulin receptor,	SM00060:FN3,SM00219:TyrKc,SM00261:FU,		KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain (between alpha and beta chains),DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Furin-like,DOMAIN:Protein kinase,DOMAIN:Recep_L_domain,MUTAGEN:YY->FF: Abolishes autophosphorylation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IBSP	integrin binding sialoprotein(IBSP)	Homo sapiens	GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0007155~cell adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0030198~extracellular matrix organization,GO:0030282~bone mineralization,GO:0031214~biomineral tissue development,GO:0045785~positive regulation of cell adhesion,GO:0071363~cellular response to growth factor stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016020~membrane,GO:0031982~vesicle,	GO:0005178~integrin binding,GO:0005515~protein binding,GO:0036094~small molecule binding,	IPR008412:Bone sialoprotein II,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05165:Human papillomavirus infection,				KW-0091~Biomineralization,KW-0130~Cell adhesion,	KW-0964~Secreted,		KW-0732~Signal,	KW-0730~Sialic acid,	KW-0401~Integrin,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Acidic residues,COMPBIAS:Polar residues,MOTIF:Cell attachment site,REGION:Disordered,
ITGA2	integrin subunit alpha 2(ITGA2)	Homo sapiens	GO:0001666~response to hypoxia,GO:0002687~positive regulation of leukocyte migration,GO:0006929~substrate-dependent cell migration,GO:0006971~hypotonic response,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007565~female pregnancy,GO:0007596~blood coagulation,GO:0008283~cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009887~animal organ morphogenesis,GO:0010634~positive regulation of epithelial cell migration,GO:0010694~positive regulation of alkaline phosphatase activity,GO:0014075~response to amine,GO:0014850~response to muscle activity,GO:0014911~positive regulation of smooth muscle cell migration,GO:0030879~mammary gland development,GO:0031346~positive regulation of cell projection organization,GO:0031589~cell-substrate adhesion,GO:0032967~positive regulation of collagen biosynthetic process,GO:0033343~positive regulation of collagen binding,GO:0033591~response to L-ascorbic acid,GO:0033627~cell adhesion mediated by integrin,GO:0038065~collagen-activated signaling pathway,GO:0042493~response to drug,GO:0043388~positive regulation of DNA binding,GO:0043589~skin morphogenesis,GO:0045184~establishment of protein localization,GO:0045727~positive regulation of translation,GO:0045785~positive regulation of cell adhesion,GO:0045987~positive regulation of smooth muscle contraction,GO:0046718~viral entry into host cell,GO:0048041~focal adhesion assembly,GO:0048333~mesodermal cell differentiation,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050729~positive regulation of inflammatory response,GO:0050927~positive regulation of positive chemotaxis,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0051971~positive regulation of transmission of nerve impulse,GO:0060100~positive regulation of phagocytosis, engulfment,GO:0070365~hepatocyte differentiation,GO:0071107~response to parathyroid hormone,GO:0071260~cellular response to mechanical stimulus,GO:0071392~cellular response to estradiol stimulus,GO:0098609~cell-cell adhesion,	GO:0005634~nucleus,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0034666~integrin alpha2-beta1 complex,GO:0043679~axon terminus,GO:0045178~basal part of cell,GO:0048471~perinuclear region of cytoplasm,	GO:0001540~beta-amyloid binding,GO:0001618~virus receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0038064~collagen receptor activity,GO:0043236~laminin binding,GO:0043395~heparan sulfate proteoglycan binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0098639~collagen binding involved in cell-matrix adhesion,	IPR000413:Integrin alpha chain,IPR002035:von Willebrand factor, type A,IPR013517:FG-GAP repeat,IPR013519:Integrin alpha beta-propellor,IPR013649:Integrin alpha-2,IPR018184:Integrin alpha chain, C-terminal cytoplasmic region, conserved site,	hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04611:Platelet activation,hsa04640:Hematopoietic cell lineage,hsa04810:Regulation of actin cytoskeleton,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05222:Small cell lung cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,			SM00191:Int_alpha,SM00327:VWA,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Integrin_alpha2,DOMAIN:VWFA,MOTIF:GFFKR motif,MUTAGEN:E->A: Significant reduction of RAB21-binding; when associated with A-1160; A-1161 and A-1165.,MUTAGEN:F->A: No significant reduction of RAB21-binding by co-immunoprecipitation assay; when associated with A-1160 and A-1162.,MUTAGEN:K->A: No effect on RAB21-binding. Significant reduction of RAB21-binding; when associated with A-1161. Shows defective cytokinesis on collagen, but not on fibronectin; when associated with A-1161.,MUTAGEN:K->A: No significant reduction of RAB21-binding by co-immunoprecipitation assay; when associated with A-1159 and A-1160.,MUTAGEN:K->A: Significant reduction of RAB21-binding; when associated with A-1160; A-1161 and A-1164.,MUTAGEN:K->P: Markedly weakens RAB21-binding. Shows defective cytokinesis on collagen, but not on fibronectin.,MUTAGEN:R->A: Significant reduction of RAB21-binding; when associated with A-1160. Shows defective cytokinesis on collagen, but not on fibronectin; when associated with A-1160.,REGION:Interaction with HPS5,REPEAT:FG-GAP,REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGA4	integrin subunit alpha 4(ITGA4)	Homo sapiens	GO:0003366~cell-matrix adhesion involved in ameboidal cell migration,GO:0007155~cell adhesion,GO:0007159~leukocyte cell-cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0030183~B cell differentiation,GO:0033627~cell adhesion mediated by integrin,GO:0033631~cell-cell adhesion mediated by integrin,GO:0034113~heterotypic cell-cell adhesion,GO:0034446~substrate adhesion-dependent cell spreading,GO:0035987~endodermal cell differentiation,GO:0043113~receptor clustering,GO:0050900~leukocyte migration,GO:0050901~leukocyte tethering or rolling,GO:0050904~diapedesis,GO:0060385~axonogenesis involved in innervation,GO:0071345~cellular response to cytokine stimulus,GO:0090074~negative regulation of protein homodimerization activity,GO:0098609~cell-cell adhesion,GO:0098657~import into cell,GO:1903238~positive regulation of leukocyte tethering or rolling,GO:1904646~cellular response to beta-amyloid,GO:1905564~positive regulation of vascular endothelial cell proliferation,GO:1990138~neuron projection extension,GO:1990771~clathrin-dependent extracellular exosome endocytosis,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000406~positive regulation of T cell migration,	GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030426~growth cone,GO:0034668~integrin alpha4-beta1 complex,GO:0034669~integrin alpha4-beta7 complex,GO:0043025~neuronal cell body,GO:0070062~extracellular exosome,	GO:0001968~fibronectin binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0019960~C-X3-C chemokine binding,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,GO:1990405~protein antigen binding,	IPR000413:Integrin alpha chain,IPR013517:FG-GAP repeat,IPR013519:Integrin alpha beta-propellor,IPR013649:Integrin alpha-2,IPR018184:Integrin alpha chain, C-terminal cytoplasmic region, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04514:Cell adhesion molecules,hsa04640:Hematopoietic cell lineage,hsa04670:Leukocyte transendothelial migration,hsa04672:Intestinal immune network for IgA production,hsa04810:Regulation of actin cytoskeleton,hsa05135:Yersinia infection,hsa05140:Leishmaniasis,hsa05165:Human papillomavirus infection,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,			SM00191:Int_alpha,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Integrin_alpha2,MOTIF:GFFKR motif,MOTIF:SG1,MUTAGEN:G->A: Blocks binding to PLA2G2A.,MUTAGEN:K->Q: Abolishes almost completely cleavage.,MUTAGEN:R->L: Abolishes completely cleavage.,MUTAGEN:S->A: Abolishes phosphorylation.,MUTAGEN:S->D: Reduces PXN binding.,MUTAGEN:T->A: Blocks binding to PLA2G2A.,MUTAGEN:Y->A: Disrupts PXN binding.,REGION:Disordered,REPEAT:FG-GAP,REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGA5	integrin subunit alpha 5(ITGA5)	Homo sapiens	GO:0001525~angiogenesis,GO:0007044~cell-substrate junction assembly,GO:0007155~cell adhesion,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007159~leukocyte cell-cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0007565~female pregnancy,GO:0007613~memory,GO:0010811~positive regulation of cell-substrate adhesion,GO:0023035~CD40 signaling pathway,GO:0030335~positive regulation of cell migration,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0031589~cell-substrate adhesion,GO:0033627~cell adhesion mediated by integrin,GO:0033631~cell-cell adhesion mediated by integrin,GO:0034113~heterotypic cell-cell adhesion,GO:0035313~wound healing, spreading of epidermal cells,GO:0035987~endodermal cell differentiation,GO:0046718~viral entry into host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0098609~cell-cell adhesion,GO:1903672~positive regulation of sprouting angiogenesis,GO:2000811~negative regulation of anoikis,	GO:0001726~ruffle,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031410~cytoplasmic vesicle,GO:0032587~ruffle membrane,GO:0034674~integrin alpha5-beta1 complex,GO:0045211~postsynaptic membrane,GO:0071062~alphav-beta3 integrin-vitronectin complex,GO:0098978~glutamatergic synapse,	GO:0001618~virus receptor activity,GO:0005154~epidermal growth factor receptor binding,GO:0005161~platelet-derived growth factor receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0046872~metal ion binding,	IPR000413:Integrin alpha chain,IPR013517:FG-GAP repeat,IPR013519:Integrin alpha beta-propellor,IPR013649:Integrin alpha-2,IPR018184:Integrin alpha chain, C-terminal cytoplasmic region, conserved site,	hsa03266:Virion - Herpesvirus,hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04640:Hematopoietic cell lineage,hsa04810:Regulation of actin cytoskeleton,hsa05100:Bacterial invasion of epithelial cells,hsa05131:Shigellosis,hsa05133:Pertussis,hsa05135:Yersinia infection,hsa05165:Human papillomavirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,			SM00191:Int_alpha,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0965~Cell junction,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0401~Integrin,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (between heavy and light chains),DOMAIN:Integrin_alpha2,MOTIF:GFFKR motif,REGION:Disordered,REGION:Interaction with HPS5,REPEAT:FG-GAP,REPEAT:FG-GAP 1,REPEAT:FG-GAP 2,REPEAT:FG-GAP 3,REPEAT:FG-GAP 4,REPEAT:FG-GAP 5,REPEAT:FG-GAP 6,REPEAT:FG-GAP 7,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGB4	integrin subunit beta 4(ITGB4)	Homo sapiens	GO:0006914~autophagy,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0009611~response to wounding,GO:0016477~cell migration,GO:0031581~hemidesmosome assembly,GO:0032290~peripheral nervous system myelin formation,GO:0033627~cell adhesion mediated by integrin,GO:0035878~nail development,GO:0043589~skin morphogenesis,GO:0046847~filopodium assembly,GO:0048333~mesodermal cell differentiation,GO:0048870~cell motility,GO:0061450~trophoblast cell migration,	GO:0005604~basement membrane,GO:0005730~nucleolus,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009925~basal plasma membrane,GO:0009986~cell surface,GO:0030054~cell junction,GO:0030056~hemidesmosome,GO:0031252~cell leading edge,GO:0031965~nuclear membrane,GO:0043235~receptor complex,GO:0070062~extracellular exosome,	GO:0001664~G-protein coupled receptor binding,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0031994~insulin-like growth factor I binding,GO:0038132~neuregulin binding,	IPR000742:Epidermal growth factor-like domain,IPR002369:Integrin beta subunit, N-terminal,IPR003644:Na-Ca exchanger/integrin-beta4,IPR003961:Fibronectin, type III,IPR012013:Integrin beta-4 subunit,IPR012896:Integrin beta subunit, tail,IPR013111:EGF, extracellular,IPR013783:Immunoglobulin-like fold,IPR015812:Integrin beta subunit,IPR016201:Plexin-like fold,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04810:Regulation of actin cytoskeleton,hsa05165:Human papillomavirus infection,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,	226730~Epidermolysis bullosa, junctional 5B, with pyloric atresia,619816~Epidermolysis bullosa, junctional 5A, intermediate,	PIRSF002513:integrin, beta-4 subunit,	SM00060:FN3,SM00187:INB,SM00237:Calx_beta,SM00423:PSI,SM01242:SM01242,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0263~Epidermolysis bullosa,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0401~Integrin,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Calx-beta,DOMAIN:EGF-like,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:INB,DOMAIN:PSI,DOMAIN:VWFA,REGION:Cysteine-rich tandem repeats,REGION:Disordered,REGION:Involved in NRG1- and IGF1-binding,REGION:Palmitoylated on several cysteines,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ITGBL1	integrin subunit beta like 1(ITGBL1)	Homo sapiens	GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007229~integrin-mediated signaling pathway,GO:0016477~cell migration,GO:0033627~cell adhesion mediated by integrin,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0008305~integrin complex,GO:0009986~cell surface,	GO:0005178~integrin binding,	IPR000742:Epidermal growth factor-like domain,IPR013111:EGF, extracellular,IPR015812:Integrin beta subunit,IPR027070:Integrin beta-like protein 1,				SM00181:EGF,		KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0401~Integrin,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF_2,REGION:Cysteine-rich tandem repeats,REPEAT:I,REPEAT:II,REPEAT:III,REPEAT:IV,REPEAT:IX,REPEAT:V,REPEAT:VI,REPEAT:VII,REPEAT:VIII,REPEAT:X,
ITIH3	inter-alpha-trypsin inhibitor heavy chain 3(ITIH3)	Homo sapiens	GO:0010951~negative regulation of endopeptidase activity,GO:0030212~hyaluronan metabolic process,	GO:0005576~extracellular region,GO:0031089~platelet dense granule lumen,GO:0070062~extracellular exosome,	GO:0004866~endopeptidase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,	IPR002035:von Willebrand factor, type A,IPR010600:Inter-alpha-trypsin inhibitor heavy chain, C-terminal,IPR013694:VIT domain,				SM00327:VWA,SM00609:VIT,		KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0654~Proteoglycan,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:VIT,DOMAIN:VWFA,REGION:Disordered,
ICAM1	intercellular adhesion molecule 1(ICAM1)	Homo sapiens	GO:0001541~ovarian follicle development,GO:0001910~regulation of leukocyte mediated cytotoxicity,GO:0001975~response to amphetamine,GO:0002291~T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:0002438~acute inflammatory response to antigenic stimulus,GO:0002457~T cell antigen processing and presentation,GO:0002693~positive regulation of cellular extravasation,GO:0007155~cell adhesion,GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0007159~leukocyte cell-cell adhesion,GO:0007569~cell aging,GO:0007605~sensory perception of sound,GO:0008360~regulation of cell shape,GO:0010212~response to ionizing radiation,GO:0010477~response to sulfur dioxide,GO:0022614~membrane to membrane docking,GO:0030838~positive regulation of actin filament polymerization,GO:0031669~cellular response to nutrient levels,GO:0032868~response to insulin,GO:0033627~cell adhesion mediated by integrin,GO:0034698~response to gonadotropin,GO:0042493~response to drug,GO:0043200~response to amino acid,GO:0043547~positive regulation of GTPase activity,GO:0044406~adhesion of symbiont to host,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0045471~response to ethanol,GO:0045907~positive regulation of vasoconstriction,GO:0046688~response to copper ion,GO:0046718~viral entry into host cell,GO:0046813~receptor-mediated virion attachment to host cell,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050900~leukocyte migration,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051926~negative regulation of calcium ion transport,GO:0061028~establishment of endothelial barrier,GO:0070234~positive regulation of T cell apoptotic process,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071222~cellular response to lipopolysaccharide,GO:0071312~cellular response to alkaloid,GO:0071333~cellular response to glucose stimulus,GO:0071346~cellular response to interferon-gamma,GO:0071347~cellular response to interleukin-1,GO:0071354~cellular response to interleukin-6,GO:0071356~cellular response to tumor necrosis factor,GO:0071456~cellular response to hypoxia,GO:0071549~cellular response to dexamethasone stimulus,GO:0072683~T cell extravasation,GO:0090557~establishment of endothelial intestinal barrier,GO:0097368~establishment of Sertoli cell barrier,GO:0098609~cell-cell adhesion,GO:1900027~regulation of ruffle assembly,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1904646~cellular response to beta-amyloid,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:1990830~cellular response to leukemia inhibitory factor,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0001772~immunological synapse,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,GO:0070062~extracellular exosome,	GO:0001618~virus receptor activity,GO:0004888~transmembrane signaling receptor activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR003599:Immunoglobulin subtype,IPR003987:Intercellular adhesion molecule/vascular cell adhesion molecule, N-terminal,IPR003988:Intercellular adhesion molecule,IPR013768:Intercellular adhesion molecule, N-terminal,IPR013783:Immunoglobulin-like fold,	hsa04064:NF-kappa B signaling pathway,hsa04514:Cell adhesion molecules,hsa04650:Natural killer cell mediated cytotoxicity,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05150:Staphylococcus aureus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05169:Epstein-Barr virus infection,hsa05323:Rheumatoid arthritis,hsa05416:Viral myocarditis,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	611162~Malaria, cerebral, susceptibility to,		SM00409:IG,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ICAM_N,DOMAIN:IG,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,MOTIF:Cell attachment site; atypical,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
ICAM5	intercellular adhesion molecule 5(ICAM5)	Homo sapiens	GO:0006909~phagocytosis,GO:0007155~cell adhesion,GO:0051963~regulation of synapse assembly,GO:0098609~cell-cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0098978~glutamatergic synapse,	GO:0005178~integrin binding,GO:0005515~protein binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003987:Intercellular adhesion molecule/vascular cell adhesion molecule, N-terminal,IPR003988:Intercellular adhesion molecule,IPR007110:Immunoglobulin-like domain,IPR013768:Intercellular adhesion molecule, N-terminal,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IFITM3	interferon induced transmembrane protein 3(IFITM3)	Homo sapiens	GO:0006955~immune response,GO:0009615~response to virus,GO:0032897~negative regulation of viral transcription,GO:0034341~response to interferon-gamma,GO:0035455~response to interferon-alpha,GO:0035456~response to interferon-beta,GO:0045071~negative regulation of viral genome replication,GO:0046597~negative regulation of viral entry into host cell,GO:0051607~defense response to virus,GO:0060337~type I interferon signaling pathway,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032991~macromolecular complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,	IPR007593:Interferon-induced transmembrane protein,		614680~Influenza, severe, susceptibility to,			KW-0051~Antiviral defense,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),INTRAMEM:Helical,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Loss of anti-HCV activity. Only localizes at the lysosome. No effect on SARS-CoV-2 infection; when associated with 71-A-A-72. Loss of anti-influenza A virus activity; when associated with 71-A-A-72.,MUTAGEN:CC->AA: Loss of anti-HCV activity. Only localizes at the lysosome. No effect on SARS-CoV-2 infection; when associated with A-105. Loss of anti-influenza A virus activity; when associated with A-105.,MUTAGEN:L->Q: Accumulates at the plasma membrane. Loss of anti-SARS-CoV-2 activity by enhancing Spike-mediated cell-to-cell fusion.,MUTAGEN:Missing: Slightly enhances infection by SARS-CoV-2.,MUTAGEN:SLFNT->ALFAA: Decreases anti-SARS-CoV-2 activity.,MUTAGEN:Y->A: Loss of phosphorylation. Accumulates at the plasma membrane. Increases anti-HCV properties. Loss of anti-SARS-CoV-2 activity by enhancing Spike-mediated cell-to-cell fusion.,REGION:Disordered,REGION:Interaction with SPP1,REGION:Interaction with VAPA,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL1RAP	interleukin 1 receptor accessory protein(IL1RAP)	Homo sapiens	GO:0006954~inflammatory response,GO:0006955~immune response,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032754~positive regulation of interleukin-5 production,GO:0032755~positive regulation of interleukin-6 production,GO:0038172~interleukin-33-mediated signaling pathway,GO:0045087~innate immune response,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051965~positive regulation of synapse assembly,GO:0065003~macromolecular complex assembly,GO:0099545~trans-synaptic signaling by trans-synaptic complex,GO:0099560~synaptic membrane adhesion,GO:1905606~regulation of presynapse assembly,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0098978~glutamatergic synapse,	GO:0002114~interleukin-33 receptor activity,GO:0004908~interleukin-1 receptor activity,GO:0005149~interleukin-1 receptor binding,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR003599:Immunoglobulin subtype,IPR004074:Interleukin-1 receptor, type I/II,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,IPR015621:Interleukin-1 receptor family,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04659:Th17 cell differentiation,hsa04750:Inflammatory mediator regulation of TRP channels,			SM00255:TIR,SM00409:IG,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0378~Hydrolase,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig_6,DOMAIN:TIR,REGION:Disordered,REGION:Essential for interaction with PTPRD,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL1RN	interleukin 1 receptor antagonist(IL1RN)	Homo sapiens	GO:0002437~inflammatory response to antigenic stimulus,GO:0006629~lipid metabolic process,GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007165~signal transduction,GO:0030073~insulin secretion,GO:0034115~negative regulation of heterotypic cell-cell adhesion,GO:0051384~response to glucocorticoid,GO:2000660~negative regulation of interleukin-1-mediated signaling pathway,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005149~interleukin-1 receptor binding,GO:0005150~interleukin-1, Type I receptor binding,GO:0005151~interleukin-1, Type II receptor binding,GO:0005152~interleukin-1 receptor antagonist activity,GO:0005515~protein binding,GO:0045352~interleukin-1 Type I receptor antagonist activity,GO:0045353~interleukin-1 Type II receptor antagonist activity,	IPR000975:Interleukin-1,IPR003297:Interleukin-1 receptor antagonist / Interleukin-36,IPR008996:Cytokine, IL-1-like,IPR020877:Interleukin-1 conserved site,	hsa04060:Cytokine-cytokine receptor interaction,	612628~Microvascular complications of diabetes 4,612852~Interleukin 1 receptor antagonist deficiency,613659~Gastric cancer risk after H. pylori infection,				KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0732~Signal,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
IL1R1	interleukin 1 receptor type 1(IL1R1)	Homo sapiens	GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0032729~positive regulation of interferon-gamma production,GO:0050727~regulation of inflammatory response,GO:0070498~interleukin-1-mediated signaling pathway,GO:0070555~response to interleukin-1,GO:2000391~positive regulation of neutrophil extravasation,GO:2000556~positive regulation of T-helper 1 cell cytokine production,GO:2000661~positive regulation of interleukin-1-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0002020~protease binding,GO:0004888~transmembrane signaling receptor activity,GO:0004908~interleukin-1 receptor activity,GO:0004909~interleukin-1, Type I, activating receptor activity,GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0019966~interleukin-1 binding,GO:0050135~NAD(P)+ nucleosidase activity,GO:0061809~NAD+ nucleotidase, cyclic ADP-ribose generating,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR003599:Immunoglobulin subtype,IPR004074:Interleukin-1 receptor, type I/II,IPR004076:Interleukin-1 receptor IL1R,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,IPR015621:Interleukin-1 receptor family,	hsa04010:MAPK signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04064:NF-kappa B signaling pathway,hsa04380:Osteoclast differentiation,hsa04640:Hematopoietic cell lineage,hsa04659:Th17 cell differentiation,hsa04750:Inflammatory mediator regulation of TRP channels,hsa05130:Pathogenic Escherichia coli infection,hsa05131:Shigellosis,hsa05146:Amoebiasis,hsa05163:Human cytomegalovirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05418:Fluid shear stress and atherosclerosis,			SM00255:TIR,SM00409:IG,	KW-0395~Inflammatory response,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0520~NAD,	KW-0378~Hydrolase,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:TIR,MUTAGEN:D->A: Reduces NF-kappa-B activation.,MUTAGEN:R->A: Reduces NF-kappa-B activation and receptor-associated kinase activation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL1R2	interleukin 1 receptor type 2(IL1R2)	Homo sapiens	GO:0006955~immune response,GO:0010955~negative regulation of protein processing,GO:0016485~protein processing,GO:0019221~cytokine-mediated signaling pathway,GO:0032690~negative regulation of interleukin-1 alpha production,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:2000660~negative regulation of interleukin-1-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004908~interleukin-1 receptor activity,GO:0004910~interleukin-1, Type II, blocking receptor activity,GO:0005515~protein binding,GO:0019966~interleukin-1 binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR004074:Interleukin-1 receptor, type I/II,IPR004077:Interleukin-1 receptor, type II,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR015621:Interleukin-1 receptor family,	hsa04060:Cytokine-cytokine receptor interaction,hsa04640:Hematopoietic cell lineage,hsa05146:Amoebiasis,hsa05166:Human T-cell leukemia virus 1 infection,hsa05202:Transcriptional misregulation in cancer,hsa05215:Prostate cancer,hsa05418:Fluid shear stress and atherosclerosis,			SM00408:IGc2,SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,REGION:Contains proteolytic cleavage site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL13RA2	interleukin 13 receptor subunit alpha 2(IL13RA2)	Homo sapiens	GO:0002638~negative regulation of immunoglobulin production,GO:0016064~immunoglobulin mediated immune response,GO:0019221~cytokine-mediated signaling pathway,GO:0043305~negative regulation of mast cell degranulation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0005515~protein binding,GO:0019955~cytokine binding,	IPR003532:Short hematopoietin receptor, family 2, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,IPR015321:Interleukin-6 receptor alpha chain, binding,	hsa04060:Cytokine-cytokine receptor interaction,hsa04630:JAK-STAT signaling pathway,					KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:IL6Ra-bind,MOTIF:WSXWS motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
IL17D	interleukin 17D(IL17D)	Homo sapiens	GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0032725~positive regulation of granulocyte macrophage colony-stimulating factor production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1903707~negative regulation of hemopoiesis,	GO:0005615~extracellular space,	GO:0005125~cytokine activity,GO:0042803~protein homodimerization activity,GO:0048018~receptor agonist activity,	IPR010345:Interleukin-17,IPR020440:Interleukin-17, chordata,	hsa04060:Cytokine-cytokine receptor interaction,hsa04625:C-type lectin receptor signaling pathway,hsa04657:IL-17 signaling pathway,					KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
IL4I1	interleukin 4 induced 1(IL4I1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002819~regulation of adaptive immune response,GO:0002841~negative regulation of T cell mediated immune response to tumor cell,GO:0006559~L-phenylalanine catabolic process,GO:0006569~tryptophan catabolic process,GO:0006572~tyrosine catabolic process,GO:0009063~cellular amino acid catabolic process,GO:0019440~tryptophan catabolic process to indole-3-acetate,GO:0042130~negative regulation of T cell proliferation,GO:0045577~regulation of B cell differentiation,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050868~negative regulation of T cell activation,	GO:0001669~acrosomal vesicle,GO:0001772~immunological synapse,GO:0005576~extracellular region,GO:0005764~lysosome,GO:0097225~sperm midpiece,	GO:0001716~L-amino-acid oxidase activity,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0046592~polyamine oxidase activity,	IPR001613:Flavin amine oxidase,IPR002937:Amine oxidase,	hsa00250:Alanine, aspartate and glutamate metabolism,hsa00270:Cysteine and methionine metabolism,hsa00280:Valine, leucine and isoleucine degradation,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa00380:Tryptophan metabolism,hsa00400:Phenylalanine, tyrosine and tryptophan biosynthesis,hsa01100:Metabolic pathways,				KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,	KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Amino_oxidase,MUTAGEN:E->A: Abolished L-amino-acid oxidase activity.,REGION:Disordered,
IL6	interleukin 6(IL6)	Homo sapiens	GO:0001781~neutrophil apoptotic process,GO:0002314~germinal center B cell differentiation,GO:0002384~hepatic immune response,GO:0002446~neutrophil mediated immunity,GO:0002548~monocyte chemotaxis,GO:0002639~positive regulation of immunoglobulin production,GO:0002675~positive regulation of acute inflammatory response,GO:0002690~positive regulation of leukocyte chemotaxis,GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0006959~humoral immune response,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0010573~vascular endothelial growth factor production,GO:0010574~regulation of vascular endothelial growth factor production,GO:0010575~positive regulation of vascular endothelial growth factor production,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010888~negative regulation of lipid storage,GO:0014823~response to activity,GO:0019221~cytokine-mediated signaling pathway,GO:0030168~platelet activation,GO:0031018~endocrine pancreas development,GO:0031175~neuron projection development,GO:0032494~response to peptidoglycan,GO:0032682~negative regulation of chemokine production,GO:0032722~positive regulation of chemokine production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032733~positive regulation of interleukin-10 production,GO:0032740~positive regulation of interleukin-17 production,GO:0032745~positive regulation of interleukin-21 production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032966~negative regulation of collagen biosynthetic process,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0042102~positive regulation of T cell proliferation,GO:0042531~positive regulation of tyrosine phosphorylation of STAT protein,GO:0042593~glucose homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045599~negative regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045727~positive regulation of translation,GO:0045765~regulation of angiogenesis,GO:0045779~negative regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046427~positive regulation of JAK-STAT cascade,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050768~negative regulation of neurogenesis,GO:0050796~regulation of insulin secretion,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050871~positive regulation of B cell activation,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051384~response to glucocorticoid,GO:0051607~defense response to virus,GO:0060252~positive regulation of glial cell proliferation,GO:0061470~T follicular helper cell differentiation,GO:0070050~neuron cellular homeostasis,GO:0070091~glucagon secretion,GO:0070092~regulation of glucagon secretion,GO:0070102~interleukin-6-mediated signaling pathway,GO:0070301~cellular response to hydrogen peroxide,GO:0071222~cellular response to lipopolysaccharide,GO:0072540~T-helper 17 cell lineage commitment,GO:0072574~hepatocyte proliferation,GO:0090091~positive regulation of extracellular matrix disassembly,GO:0097421~liver regeneration,GO:0098586~cellular response to virus,GO:1900017~positive regulation of cytokine production involved in inflammatory response,GO:1901731~positive regulation of platelet aggregation,GO:1902512~positive regulation of apoptotic DNA fragmentation,GO:1903800~positive regulation of production of miRNAs involved in gene silencing by miRNA,GO:1903978~regulation of microglial cell activation,GO:1904894~positive regulation of STAT cascade,GO:1904996~positive regulation of leukocyte adhesion to vascular endothelial cell,GO:2000553~positive regulation of T-helper 2 cell cytokine production,GO:2000635~negative regulation of primary miRNA processing,GO:2000660~negative regulation of interleukin-1-mediated signaling pathway,GO:2000676~positive regulation of type B pancreatic cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005896~interleukin-6 receptor complex,	GO:0005125~cytokine activity,GO:0005138~interleukin-6 receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR003574:Interleukin-6,IPR009079:Four-helical cytokine-like, core,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa01523:Antifolate resistance,hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04066:HIF-1 signaling pathway,hsa04068:FoxO signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04218:Cellular senescence,hsa04620:Toll-like receptor signaling pathway,hsa04621:NOD-like receptor signaling pathway,hsa04623:Cytosolic DNA-sensing pathway,hsa04625:C-type lectin receptor signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa04657:IL-17 signaling pathway,hsa04659:Th17 cell differentiation,hsa04668:TNF signaling pathway,hsa04672:Intestinal immune network for IgA production,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04936:Alcoholic liver disease,hsa05010:Alzheimer disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,hsa05133:Pertussis,hsa05134:Legionellosis,hsa05135:Yersinia infection,hsa05142:Chagas disease,hsa05143:African trypanosomiasis,hsa05144:Malaria,hsa05146:Amoebiasis,hsa05152:Tuberculosis,hsa05161:Hepatitis B,hsa05162:Measles,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05321:Inflammatory bowel disease,hsa05323:Rheumatoid arthritis,hsa05332:Graft-versus-host disease,hsa05410:Hypertrophic cardiomyopathy,hsa05417:Lipid and atherosclerosis,	108010~Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to,125853~Type 2 diabetes mellitus,148000~Kaposi sarcoma, susceptibility to,222100~Type 1 diabetes mellitus,266600~Crohn disease-associated growth failure,604302~Rheumatoid arthritis, systemic juvenile,	PIRSF001935:interleukin-6,	SM00126:IL6,	KW-0011~Acute phase,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:A->V: Almost no loss of activity.,MUTAGEN:M->T,N,S,R: Loss of activity.,MUTAGEN:R->K,E,Q,T,A,P: Loss of activity.,MUTAGEN:S->P: 87% loss of activity.,MUTAGEN:W->R: No loss of activity.,REGION:Disordered,
IL7	interleukin 7(IL7)	Homo sapiens	GO:0001961~positive regulation of cytokine-mediated signaling pathway,GO:0002360~T cell lineage commitment,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0009887~animal organ morphogenesis,GO:0019221~cytokine-mediated signaling pathway,GO:0030890~positive regulation of B cell proliferation,GO:0032722~positive regulation of chemokine production,GO:0035265~organ growth,GO:0042100~B cell proliferation,GO:0043066~negative regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0045453~bone resorption,GO:0045579~positive regulation of B cell differentiation,GO:0045582~positive regulation of T cell differentiation,GO:0046622~positive regulation of organ growth,GO:0048873~homeostasis of number of cells within a tissue,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0097191~extrinsic apoptotic signaling pathway,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005125~cytokine activity,GO:0005139~interleukin-7 receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,	IPR001181:Interleukin-7,IPR018049:Interleukin-7/-9, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,hsa04640:Hematopoietic cell lineage,hsa05200:Pathways in cancer,	618309~Epidermodysplasia verruciformis, susceptibility to, 5,	PIRSF001942:interleukin-7,	SM00127:IL7,		KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0202~Cytokine,KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,
IRX3	iroquois homeobox 3(IRX3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001656~metanephros development,GO:0003165~Purkinje myocyte development,GO:0003167~atrioventricular bundle cell differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007498~mesoderm development,GO:0030182~neuron differentiation,GO:0045665~negative regulation of neuron differentiation,GO:0045666~positive regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048468~cell development,GO:0060932~His-Purkinje system cell differentiation,GO:0072086~specification of loop of Henle identity,GO:0097009~energy homeostasis,GO:1901844~regulation of cell communication by electrical coupling involved in cardiac conduction,GO:1903598~positive regulation of gap junction assembly,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030424~axon,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001216~bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003893:Iroquois-class homeodomain protein,IPR008422:Homeobox KN domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,SM00548:IRO,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DNA_BIND:Homeobox; TALE-type,REGION:Disordered,
ISM1	isthmin 1(ISM1)	Homo sapiens	GO:0016525~negative regulation of angiogenesis,	GO:0005576~extracellular region,		IPR000884:Thrombospondin, type 1 repeat,IPR005533:AMOP,				SM00209:TSP1,SM00723:AMOP,		KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AMOP,DOMAIN:TSP type-1,REGION:Disordered,
JCHAIN	joining chain of multimeric IgA and IgM(JCHAIN)	Homo sapiens	GO:0001895~retina homeostasis,GO:0002250~adaptive immune response,GO:0003094~glomerular filtration,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0019731~antibacterial humoral response,GO:0045087~innate immune response,GO:0060267~positive regulation of respiratory burst,GO:0065003~macromolecular complex assembly,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0070062~extracellular exosome,GO:0071748~monomeric IgA immunoglobulin complex,GO:0071750~dimeric IgA immunoglobulin complex,GO:0071751~secretory IgA immunoglobulin complex,GO:0071752~secretory dimeric IgA immunoglobulin complex,GO:0071756~pentameric IgM immunoglobulin complex,GO:0072562~blood microparticle,	GO:0003697~single-stranded DNA binding,GO:0003823~antigen binding,GO:0019862~IgA binding,GO:0030674~protein binding, bridging,GO:0031210~phosphatidylcholine binding,GO:0034987~immunoglobulin receptor binding,GO:0042803~protein homodimerization activity,GO:0042834~peptidoglycan binding,	IPR024110:Immunoglobulin J chain,						KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,DISULFID:Interchain (with heavy chain),
JAML	junction adhesion molecule like(JAML)	Homo sapiens	GO:0007157~heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0030593~neutrophil chemotaxis,GO:0035696~monocyte extravasation,GO:0046629~gamma-delta T cell activation,GO:0050900~leukocyte migration,GO:0060054~positive regulation of epithelial cell proliferation involved in wound healing,GO:0072672~neutrophil extravasation,	GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0016021~integral component of membrane,	GO:0005178~integrin binding,GO:0042803~protein homodimerization activity,GO:0050839~cell adhesion molecule binding,	IPR000920:Myelin P0 protein,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0130~Cell adhesion,KW-0391~Immunity,	KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IGv,DOMAIN:Ig-like,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,MUTAGEN:K->E: Loss of the ability to homodimerize, loss of interaction with CXADR and loss of function in cell-cell adhesion.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
KLHDC7A	kelch domain containing 7A(KLHDC7A)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR006652:Kelch repeat type 1,IPR015915:Kelch-type beta propeller,				SM00612:Kelch,		KW-0472~Membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-0880~Kelch repeat,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,TRANSMEM:Helical,
KLHDC7B	kelch domain containing 7B(KLHDC7B)	Homo sapiens			GO:0005515~protein binding,	IPR006652:Kelch repeat type 1,IPR015915:Kelch-type beta propeller,				SM00612:Kelch,				KW-0677~Repeat,KW-0880~Kelch repeat,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,
KLHDC8A	kelch domain containing 8A(KLHDC8A)	Homo sapiens			GO:0005515~protein binding,	IPR006652:Kelch repeat type 1,IPR011043:Galactose oxidase/kelch, beta-propeller,IPR015915:Kelch-type beta propeller,				SM00612:Kelch,				KW-0677~Repeat,KW-0880~Kelch repeat,				REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,REPEAT:Kelch 7,
KLHL32	kelch like family member 32(KLHL32)	Homo sapiens			GO:0005515~protein binding,	IPR000210:BTB/POZ-like,IPR006652:Kelch repeat type 1,IPR011333:BTB/POZ fold,IPR011705:BTB/Kelch-associated,IPR015915:Kelch-type beta propeller,IPR017096:Kelch-like protein, gigaxonin,			PIRSF037037:kelch-like protein, gigaxonin type,	SM00225:BTB,SM00612:Kelch,SM00875:SM00875,				KW-0677~Repeat,KW-0880~Kelch repeat,				DOMAIN:BACK,DOMAIN:BTB,REPEAT:Kelch 1,REPEAT:Kelch 2,REPEAT:Kelch 3,REPEAT:Kelch 4,REPEAT:Kelch 5,REPEAT:Kelch 6,
KRT75	keratin 75(KRT75)	Homo sapiens	GO:0002244~hematopoietic progenitor cell differentiation,GO:0031424~keratinization,GO:0045109~intermediate filament organization,	GO:0001533~cornified envelope,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0045095~keratin filament,GO:0070062~extracellular exosome,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,	IPR003054:Type II keratin,IPR018039:Intermediate filament protein, conserved site,		612318~Pseudofolliculitis barbae, susceptibility to,		SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,	KW-0225~Disease variant,	KW-0175~Coiled coil,				DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KRT80	keratin 80(KRT80)	Homo sapiens	GO:0031424~keratinization,GO:0045109~intermediate filament organization,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005882~intermediate filament,GO:0045095~keratin filament,GO:0045111~intermediate filament cytoskeleton,	GO:0005515~protein binding,GO:0030280~structural constituent of epidermis,	IPR003054:Type II keratin,				SM01391:SM01391,		KW-0403~Intermediate filament,KW-0416~Keratin,		KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	DOMAIN:IF rod,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
KSR2	kinase suppressor of ras 2(KSR2)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007265~Ras protein signal transduction,GO:0019722~calcium-mediated signaling,GO:0035556~intracellular signal transduction,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR013761:Sterile alpha motif/pointed domain,IPR025561:Kinase suppressor of RAS, SAM-like domain,	hsa04014:Ras signaling pathway,			SM00109:C1,SM00220:S_TKc,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,MUTAGEN:A->L: Impairs MAP2K1 binding.,MUTAGEN:D->A: Loss of kinase activity.,MUTAGEN:R->H: Impairs formation of heterotetramers with MAP2K1, but not the formation of heterodimers.,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
KIF15	kinesin family member 15(KIF15)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0007018~microtubule-based movement,GO:1901673~regulation of mitotic spindle assembly,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005873~plus-end kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,	GO:0003774~motor activity,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00129:KISc,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:HMMR_C,DOMAIN:Kinesin motor,REGION:Disordered,
KIF18A	kinesin family member 18A(KIF18A)	Homo sapiens	GO:0000070~mitotic sister chromatid segregation,GO:0007018~microtubule-based movement,GO:0007019~microtubule depolymerization,GO:0007080~mitotic metaphase plate congression,GO:0007140~male meiosis,GO:0015031~protein transport,GO:0070507~regulation of microtubule cytoskeleton organization,GO:0071392~cellular response to estradiol stimulus,GO:0072520~seminiferous tubule development,	GO:0000776~kinetochore,GO:0001726~ruffle,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005815~microtubule organizing center,GO:0005828~kinetochore microtubule,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005901~caveola,GO:0015630~microtubule cytoskeleton,GO:0061673~mitotic spindle astral microtubule,GO:1990023~mitotic spindle midzone,	GO:0003777~microtubule motor activity,GO:0003779~actin binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:0051010~microtubule plus-end binding,GO:0070463~tubulin-dependent ATPase activity,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00129:KISc,	KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Kinesin motor,REGION:Disordered,
KIF1A	kinesin family member 1A(KIF1A)	Homo sapiens	GO:0007018~microtubule-based movement,GO:0008089~anterograde axonal transport,GO:0016192~vesicle-mediated transport,GO:0022027~interkinetic nuclear migration,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0060998~regulation of dendritic spine development,GO:0061001~regulation of dendritic spine morphogenesis,GO:0098840~protein transport along microtubule,GO:0099519~dense core granule cytoskeletal transport,GO:1990048~anterograde neuronal dense core vesicle transport,GO:1990049~retrograde neuronal dense core vesicle transport,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0008021~synaptic vesicle,GO:0030424~axon,GO:0030425~dendrite,GO:0043025~neuronal cell body,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098674~extrinsic component of neuronal dense core vesicle membrane,GO:0098794~postsynapse,GO:0098992~neuronal dense core vesicle,GO:1904115~axon cytoplasm,	GO:0003774~motor activity,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:0042802~identical protein binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR000253:Forkhead-associated (FHA) domain,IPR001752:Kinesin, motor domain,IPR001849:Pleckstrin homology domain,IPR008984:SMAD/FHA domain,IPR011993:Pleckstrin homology-like domain,IPR019821:Kinesin, motor region, conserved site,IPR022140:Kinesin protein 1B,IPR022164:Kinesin-like,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		610357~Spastic paraplegia 30, autosomal dominant,610357~Spastic paraplegia 30, autosomal recessive,614213~Neuropathy, hereditary sensory, type IIC,614255~NESCAV syndrome,		SM00129:KISc,SM00233:PH,SM00240:FHA,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0493~Microtubule,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,KW-0890~Hereditary spastic paraplegia,KW-0991~Intellectual disability,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,DOMAIN:FHA,DOMAIN:Kinesin motor,DOMAIN:Kinesin_assoc,DOMAIN:PH,REGION:Disordered,
KIF20A	kinesin family member 20A(KIF20A)	Homo sapiens	GO:0000281~mitotic cytokinesis,GO:0001578~microtubule bundle formation,GO:0007018~microtubule-based movement,GO:0015031~protein transport,GO:0032465~regulation of cytokinesis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005794~Golgi apparatus,GO:0005819~spindle,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0030496~midbody,GO:0032154~cleavage furrow,GO:0045171~intercellular bridge,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:0019901~protein kinase binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027326:Kinesin-like protein KIF20A,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		619433~Cardiomyopathy, familial restrictive, 6,		SM00129:KISc,	KW-0653~Protein transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Kinesin motor,MUTAGEN:S->A: Impairs phosphorylation by PLK1 and recruitment of PLK1 to the spindle.,REGION:Disordered,REGION:Globular,
KIF2C	kinesin family member 2C(KIF2C)	Homo sapiens	GO:0007018~microtubule-based movement,GO:0007019~microtubule depolymerization,GO:0007080~mitotic metaphase plate congression,GO:0030951~establishment or maintenance of microtubule cytoskeleton polarity,GO:0051301~cell division,GO:0051310~metaphase plate congression,GO:0051315~attachment of mitotic spindle microtubules to kinetochore,GO:0051983~regulation of chromosome segregation,	GO:0000775~chromosome, centromeric region,GO:0000776~kinetochore,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005819~spindle,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0015630~microtubule cytoskeleton,GO:0016020~membrane,GO:0035371~microtubule plus-end,	GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:0019237~centromeric DNA binding,GO:0051010~microtubule plus-end binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0159~Chromosome partition,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	DOMAIN:Kinesin motor,MOTIF:Microtubule tip localization signal,MOTIF:Nuclear localization signal,MUTAGEN:IP->NN: Loss of interaction with MAPRE1 and association with microtubule growing ends.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-109 and E-111.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-95 and E-109.,MUTAGEN:S->E: Alters interaction with MAPRE1 and association with microtubule growing ends; when associated with E-95 and E-111.,REGION:Disordered,REGION:Globular,REGION:Negative regulator of microtubule-binding,
KIF4A	kinesin family member 4A(KIF4A)	Homo sapiens	GO:0000281~mitotic cytokinesis,GO:0006996~organelle organization,GO:0007018~microtubule-based movement,GO:0007052~mitotic spindle organization,GO:0008089~anterograde axonal transport,GO:0051231~spindle elongation,GO:0051256~mitotic spindle midzone assembly,	GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005875~microtubule associated complex,GO:0005876~spindle microtubule,GO:0016020~membrane,GO:0016363~nuclear matrix,GO:0030496~midbody,GO:1904115~axon cytoplasm,	GO:0003677~DNA binding,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0046872~metal ion binding,GO:0051536~iron-sulfur cluster binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		300923~Intellectual developmental disorder, X-linked 100,		SM00129:KISc,		KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0991~Intellectual disability,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0408~Iron,KW-0411~Iron-sulfur,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,KW-0505~Motor protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Kinesin motor,MOTIF:Nuclear localization signal,MUTAGEN:C->A: Abolishes chromatin localization; in association with A-1106 and A-1110.,MUTAGEN:C->A: Abolishes chromatin localization; in association with A-1106 and A-1112.,MUTAGEN:C->A: Abolishes chromatin localization; in association with A-1110 and A-1112.,MUTAGEN:Missing: Diffuse localization and does not localize to the spindle midzone or midbody during anaphase and telophase. Does not affect the interaction with PRC1.,REGION:CRD; required for [4Fe-4S] cluster binding and localization to the spindle midzone and midbody during anaphase and telophase,REGION:Disordered,REGION:Globular,REGION:Required for the interaction with PRC1,
KIF5A	kinesin family member 5A(KIF5A)	Homo sapiens	GO:0007018~microtubule-based movement,GO:0007268~chemical synaptic transmission,GO:0007411~axon guidance,GO:0016192~vesicle-mediated transport,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0048489~synaptic vesicle transport,GO:0098971~anterograde dendritic transport of neurotransmitter receptor complex,GO:0099641~anterograde axonal protein transport,GO:1990049~retrograde neuronal dense core vesicle transport,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0032839~dendrite cytoplasm,GO:0035253~ciliary rootlet,GO:0043204~perikaryon,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:1904115~axon cytoplasm,	GO:0003774~motor activity,GO:0003777~microtubule motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0008574~ATP-dependent microtubule motor activity, plus-end-directed,GO:0016887~ATPase activity,GO:0019894~kinesin binding,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04144:Endocytosis,hsa04728:Dopaminergic synapse,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05132:Salmonella infection,hsa05223:Non-small cell lung cancer,	604187~Spastic paraplegia 10, autosomal dominant,617235~Myoclonus, intractable, neonatal,617921~Amyotrophic lateral sclerosis, susceptibility to, 25,		SM00129:KISc,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0036~Amyotrophic lateral sclerosis,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0887~Epilepsy,KW-0890~Hereditary spastic paraplegia,	KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Kinesin motor,MUTAGEN:R->S: Strongly reduces microtubule affinity; slightly reduces gliding velocity.,REGION:Disordered,REGION:Globular,REGION:Interaction with BICD2,REGION:Microtubule-binding,REGION:Necessary for interaction with ZFYVE27,
KIFC1	kinesin family member C1(KIFC1)	Homo sapiens	GO:0000070~mitotic sister chromatid segregation,GO:0007018~microtubule-based movement,GO:0007080~mitotic metaphase plate congression,GO:0007283~spermatogenesis,GO:0051301~cell division,GO:0090307~mitotic spindle assembly,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005815~microtubule organizing center,GO:0005871~kinesin complex,GO:0005874~microtubule,GO:0016020~membrane,GO:0072686~mitotic spindle,	GO:0003777~microtubule motor activity,GO:0005524~ATP binding,GO:0008017~microtubule binding,GO:0016887~ATPase activity,GO:1990939~ATP-dependent microtubule motor activity,	IPR001752:Kinesin, motor domain,IPR019821:Kinesin, motor region, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00129:KISc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0505~Motor protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Kinesin motor,REGION:Disordered,
LCT	lactase(LCT)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0005990~lactose catabolic process,GO:0046477~glycosylceramide catabolic process,GO:1901733~quercetin catabolic process,GO:2000892~cellobiose catabolic process,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016324~apical plasma membrane,GO:0098591~external side of apical plasma membrane,	GO:0000016~lactase activity,GO:0004336~galactosylceramidase activity,GO:0004348~glucosylceramidase activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0008422~beta-glucosidase activity,GO:0017042~glycosylceramidase activity,GO:0042803~protein homodimerization activity,GO:0080079~cellobiose glucosidase activity,	IPR001360:Glycoside hydrolase, family 1,IPR017853:Glycoside hydrolase, superfamily,IPR018120:Glycoside hydrolase, family 1, active site,	hsa00052:Galactose metabolism,hsa01100:Metabolic pathways,hsa04973:Carbohydrate digestion and absorption,	223000~Lactase deficiency, congenital,				KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,	KW-0325~Glycoprotein,KW-0865~Zymogen,	ACT_SITE:Nucleophile,ACT_SITE:Nucleophile; for lactase activity,ACT_SITE:Nucleophile; for phlorizin hydrolase/Glycosylceramidase activity,ACT_SITE:Proton donor; for lactase activity,ACT_SITE:Proton donor; for phlorizin hydrolase/Glycosylceramidase activity,CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:E->G: Loss of lactase activity. No effect on phlorizin hydrolase activity. No effect on localization to the plasma membrane.,MUTAGEN:E->G: No effect on lactase activity. Decreased phlorizin hydrolase activity. No effect on localization to the plasma membrane.,PROPEP:XBetaGly,REGION:Disordered,REGION:Glycosyl hydrolase-1 1; Region I,REGION:Glycosyl hydrolase-1 2; Region II,REGION:Glycosyl hydrolase-1 3; Region III. Phlorizin hydrolase/glycosylceramidase activity,REGION:Glycosyl hydrolase-1 4; Region IV. Lactase activity,REGION:Required for homodimerization and transport to the plasma membrane,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LTF	lactotransferrin(LTF)	Homo sapiens	GO:0001503~ossification,GO:0001817~regulation of cytokine production,GO:0001895~retina homeostasis,GO:0002227~innate immune response in mucosa,GO:0006508~proteolysis,GO:0006826~iron ion transport,GO:0006959~humoral immune response,GO:0019731~antibacterial humoral response,GO:0019732~antifungal humoral response,GO:0031640~killing of cells of other organism,GO:0031665~negative regulation of lipopolysaccharide-mediated signaling pathway,GO:0032680~regulation of tumor necrosis factor production,GO:0032780~negative regulation of ATPase activity,GO:0033690~positive regulation of osteoblast proliferation,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044793~negative regulation by host of viral process,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,GO:0045669~positive regulation of osteoblast differentiation,GO:0045837~negative regulation of membrane potential,GO:0048525~negative regulation of viral process,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051673~membrane disruption in other organism,GO:0055072~iron ion homeostasis,GO:0060349~bone morphogenesis,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:1900159~positive regulation of bone mineralization involved in bone maturation,GO:1900229~negative regulation of single-species biofilm formation in or on host organism,GO:1902732~positive regulation of chondrocyte proliferation,GO:2000117~negative regulation of cysteine-type endopeptidase activity,GO:2000308~negative regulation of tumor necrosis factor (ligand) superfamily member 11 production,GO:2001205~negative regulation of osteoclast development,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005769~early endosome,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0030141~secretory granule,GO:0032991~macromolecular complex,GO:0035580~specific granule lumen,GO:0042581~specific granule,GO:0055037~recycling endosome,GO:0070062~extracellular exosome,GO:0097013~phagocytic vesicle lumen,GO:1904724~tertiary granule lumen,	GO:0001530~lipopolysaccharide binding,GO:0003677~DNA binding,GO:0004252~serine-type endopeptidase activity,GO:0004869~cysteine-type endopeptidase inhibitor activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0043539~protein serine/threonine kinase activator activity,	IPR001156:Transferrin family,IPR016357:Transferrin,IPR018195:Transferrin family, iron binding site,			PIRSF002549:transferrin,PIRSF500683:lactoferrin [Parent=PIRSF002549],	SM00094:TR_FER,	KW-0391~Immunity,KW-0406~Ion transport,KW-0410~Iron transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0892~Osteogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0044~Antibiotic,KW-0238~DNA-binding,KW-0358~Heparin-binding,KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,KW-0929~Antimicrobial,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GlcNAc) serine; alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Transferrin-like,DOMAIN:Transferrin-like 1,DOMAIN:Transferrin-like 2,MUTAGEN:D->S: Impairs iron binding and changes domain closure.,MUTAGEN:H->A,C,G,E,F,L,M,P,Q,T,Y: Destabilizes iron binding.,MUTAGEN:K->A: Almost no protease activity.,MUTAGEN:Missing: Abolishes binding to heparin, lipid A, lysozyme and DNA.,MUTAGEN:Missing: Greatly impairs binding to heparin, lipid A, lysozyme and DNA. Impairs antibacterial activity.,MUTAGEN:Missing: Impairs binding to heparin, lipid A, lysozyme and DNA.,MUTAGEN:P->V: No effect.,MUTAGEN:R->D,E,S: Disrupts anion binding site and destabilizes iron binding.,MUTAGEN:R->G,E: Destabilizes iron binding slightly.,MUTAGEN:R->K,L: Destabilizes iron binding significantly.,MUTAGEN:S->A: No protease activity.,PEPTIDE:Kaliocin-1,PEPTIDE:Lactoferricin-H,PEPTIDE:Lactoferroxin-A,PEPTIDE:Lactoferroxin-B,PEPTIDE:Lactoferroxin-C,REGION:Bactericidal and antifungal activity,REGION:Critical for glycosaminoglycan, lipid A, lysozyme and DNA binding,REGION:Important for full bactericidal and antifungal activities,REGION:Interaction with PspA,REGION:Interaction with lipopolysaccharide,REGION:Involved in glycosaminoglycan binding,SITE:Important for iron binding,SITE:Interaction with PspA,
LMNTD2	lamin tail domain containing 2(LMNTD2)	Homo sapiens		GO:0005638~lamin filament,	GO:0005515~protein binding,GO:0030527~structural constituent of chromatin,	IPR001322:Lamin Tail Domain,								KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:LTD,REGION:Disordered,
LAMA2	laminin subunit alpha 2(LAMA2)	Homo sapiens	GO:0007155~cell adhesion,GO:0007411~axon guidance,GO:0007517~muscle organ development,GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0014037~Schwann cell differentiation,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0032224~positive regulation of synaptic transmission, cholinergic,GO:0035633~maintenance of permeability of blood-brain barrier,GO:0045785~positive regulation of cell adhesion,GO:0045995~regulation of embryonic development,GO:0051149~positive regulation of muscle cell differentiation,GO:2001046~positive regulation of integrin-mediated signaling pathway,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0016020~membrane,GO:0031594~neuromuscular junction,GO:0042383~sarcolemma,GO:0043083~synaptic cleft,GO:0043197~dendritic spine,GO:0098637~protein complex involved in cell-matrix adhesion,	GO:0005102~receptor binding,GO:0005198~structural molecule activity,GO:0005201~extracellular matrix structural constituent,	IPR000034:Laminin B type IV,IPR000742:Epidermal growth factor-like domain,IPR001791:Laminin G domain,IPR002049:EGF-like, laminin,IPR008211:Laminin, N-terminal,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR009254:Laminin I,IPR010307:Laminin II,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05145:Toxoplasmosis,hsa05146:Amoebiasis,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05222:Small cell lung cancer,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05416:Viral myocarditis,	607855~Muscular dystrophy, congenital, merosin deficient or partially deficient,618138~Muscular dystrophy, limb-girdle, autosomal recessive 23,		SM00136:LamNT,SM00180:EGF_Lam,SM00181:EGF,SM00281:LamB,SM00282:LamG,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0912~Congenital muscular dystrophy,KW-0947~Limb-girdle muscular dystrophy,	KW-0175~Coiled coil,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:LAM_G_DOMAIN,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 10,DOMAIN:Laminin EGF-like 11,DOMAIN:Laminin EGF-like 12,DOMAIN:Laminin EGF-like 13,DOMAIN:Laminin EGF-like 14; first part,DOMAIN:Laminin EGF-like 14; second part,DOMAIN:Laminin EGF-like 15,DOMAIN:Laminin EGF-like 16,DOMAIN:Laminin EGF-like 17,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin EGF-like 3,DOMAIN:Laminin EGF-like 4,DOMAIN:Laminin EGF-like 5; first part,DOMAIN:Laminin EGF-like 5; second part,DOMAIN:Laminin EGF-like 6,DOMAIN:Laminin EGF-like 7,DOMAIN:Laminin EGF-like 8,DOMAIN:Laminin EGF-like 9,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:Laminin G-like 4,DOMAIN:Laminin G-like 5,DOMAIN:Laminin IV type A,DOMAIN:Laminin IV type A 1,DOMAIN:Laminin IV type A 2,DOMAIN:Laminin N-terminal,REGION:Disordered,REGION:Domain II and I,
LATS2	large tumor suppressor kinase 2(LATS2)	Homo sapiens	GO:0000082~G1/S transition of mitotic cell cycle,GO:0001827~inner cell mass cell fate commitment,GO:0001828~inner cell mass cellular morphogenesis,GO:0006468~protein phosphorylation,GO:0008104~protein localization,GO:0009755~hormone-mediated signaling pathway,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0018105~peptidyl-serine phosphorylation,GO:0030216~keratinocyte differentiation,GO:0035329~hippo signaling,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0045736~negative regulation of cyclin-dependent protein serine/threonine kinase activity,GO:0046620~regulation of organ growth,GO:0051301~cell division,GO:0060070~canonical Wnt signaling pathway,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1900181~negative regulation of protein localization to nucleus,	GO:0000922~spindle pole,GO:0005634~nucleus,GO:0005829~cytosol,GO:0034451~centriolar satellite,	GO:0004674~protein serine/threonine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR008271:Serine/threonine-protein kinase, active site,IPR009060:UBA-like,IPR011009:Protein kinase-like domain,IPR015940:Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,	hsa04390:Hippo signaling pathway,hsa04392:Hippo signaling pathway - multiple species,			SM00133:S_TK_X,SM00220:S_TKc,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,		KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:Protein kinase,DOMAIN:UBA,MOTIF:PPxY motif,MUTAGEN:K->A: Loss of kinase activity, autophosphorylation and tumor suppressor activity.,MUTAGEN:S->A: Loss of tumor suppressor activity.,MUTAGEN:S->C: Fails to localize at the centromere during interphase.,MUTAGEN:S->E: Fails to localize at the centromere during interphase.,REGION:Disordered,
LTBP2	latent transforming growth factor beta binding protein 2(LTBP2)	Homo sapiens	GO:0006605~protein targeting,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0009306~protein secretion,GO:0097435~supramolecular fiber organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0019838~growth factor binding,GO:0050436~microfibril binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR017878:TB domain,IPR018097:EGF-like calcium-binding, conserved site,		251750~Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma,613086~Glaucoma 3, primary congenital, D,614819~Weill-Marchesani syndrome 3, recessive,		SM00179:EGF_CA,SM00181:EGF,		KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,KW-0955~Glaucoma,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,		KW-0340~Growth factor binding,KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10; calcium-binding,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16; calcium-binding,DOMAIN:EGF-like 17; calcium-binding,DOMAIN:EGF-like 18; calcium-binding,DOMAIN:EGF-like 19; calcium-binding,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6; calcium-binding,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:TB,DOMAIN:TB 1,DOMAIN:TB 2,DOMAIN:TB 3,DOMAIN:TB 4,MOTIF:Cell attachment site,MUTAGEN:DL->EIFP: Gain-of-function. Forms a complex with TGFB1.,REGION:C-terminal domain,REGION:Disordered,REGION:Heparin-binding,
LEFTY2	left-right determination factor 2(LEFTY2)	Homo sapiens	GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0007275~multicellular organism development,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030509~BMP signaling pathway,GO:0060395~SMAD protein signal transduction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031093~platelet alpha granule lumen,	GO:0005125~cytokine activity,GO:0005160~transforming growth factor beta receptor binding,GO:0008083~growth factor activity,	IPR001111:Transforming growth factor-beta, N-terminal,IPR001839:Transforming growth factor-beta, C-terminal,IPR003942:Left- Right determination factor,IPR015615:Transforming growth factor-beta-related,IPR017948:Transforming growth factor beta, conserved site,	hsa04350:TGF-beta signaling pathway,hsa04550:Signaling pathways regulating pluripotency of stem cells,		PIRSF037402:lefty protein [Parent=PIRSF800009],	SM00204:TGFB,		KW-0964~Secreted,	KW-0225~Disease variant,KW-1056~Heterotaxy,	KW-0732~Signal,		KW-0202~Cytokine,KW-0217~Developmental protein,KW-0339~Growth factor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TGF_BETA_2,PROPEP:Or 135,
LRRC15	leucine rich repeat containing 15(LRRC15)	Homo sapiens	GO:0030335~positive regulation of cell migration,GO:0046813~receptor-mediated virion attachment to host cell,GO:1903077~negative regulation of protein localization to plasma membrane,	GO:0005615~extracellular space,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0001968~fibronectin binding,GO:0005518~collagen binding,GO:0043236~laminin binding,	IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00082:LRRCT,SM00369:LRR_TYP,		KW-0472~Membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:LRRCT,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRRC32	leucine rich repeat containing 32(LRRC32)	Homo sapiens	GO:0001818~negative regulation of cytokine production,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0046007~negative regulation of activated T cell proliferation,GO:1901388~regulation of transforming growth factor beta activation,GO:1901398~regulation of transforming growth factor beta3 activation,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,	GO:0005515~protein binding,GO:0050431~transforming growth factor beta binding,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,		619074~Cleft palate, proliferative retinopathy, and developmental delay,		SM00013:LRRNT,SM00369:LRR_TYP,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0340~Growth factor binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with C-33 in TGFB1); in linked form,DOMAIN:LRRCT,DOMAIN:LRRNT,MUTAGEN:C->A: Abolishes Cell surface localization without affecting interaction with Latency-associated peptide (LAP) of TGFB1.,MUTAGEN:C->A: Abolishes interaction with Latency-associated peptide (LAP) of TGFB1; when associated with A-211.,MUTAGEN:C->A: Abolishes interaction with Latency-associated peptide (LAP) of TGFB1; when associated with A-350.,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LRRC46	leucine rich repeat containing 46(LRRC46)	Homo sapiens	GO:0035307~positive regulation of protein dephosphorylation,GO:0043086~negative regulation of catalytic activity,	GO:0000164~protein phosphatase type 1 complex,	GO:0004865~protein serine/threonine phosphatase inhibitor activity,	IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00369:LRR_TYP,				KW-0175~Coiled coil,KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LRRCT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,
LGR6	leucine rich repeat containing G protein-coupled receptor 6(LGR6)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007411~axon guidance,GO:0016055~Wnt signaling pathway,GO:0030177~positive regulation of Wnt signaling pathway,GO:0030335~positive regulation of cell migration,GO:0050919~negative chemotaxis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1990523~bone regeneration,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0031982~vesicle,GO:0032588~trans-Golgi network membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0016500~protein-hormone receptor activity,GO:0048495~Roundabout binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000372:Leucine-rich repeat-containing N-terminal,IPR001611:Leucine-rich repeat,IPR002131:Glycoprotein hormone receptor,IPR003591:Leucine-rich repeat, typical subtype,	hsa04310:Wnt signaling pathway,			SM00013:LRRNT,SM00369:LRR_TYP,	KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRNT,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
LRGUK	leucine rich repeats and guanylate kinase domain containing(LRGUK)	Homo sapiens	GO:0007283~spermatogenesis,GO:0016310~phosphorylation,GO:0030154~cell differentiation,GO:0035082~axoneme assembly,GO:0046037~GMP metabolic process,GO:0046710~GDP metabolic process,	GO:0001669~acrosomal vesicle,GO:0002177~manchette,GO:0005829~cytosol,GO:0042995~cell projection,	GO:0004385~guanylate kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR001611:Leucine-rich repeat,IPR008144:Guanylate kinase,IPR008145:Guanylate kinase/L-type calcium channel,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00072:GuKc,	KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,		COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Guanylate kinase-like,DOMAIN:LRRCT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
LAIR1	leukocyte associated immunoglobulin like receptor 1(LAIR1)	Homo sapiens	GO:0002250~adaptive immune response,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0035579~specific granule membrane,GO:0070821~tertiary granule membrane,	GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IG,DOMAIN:Ig-like C2-type,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MUTAGEN:Y->F: Reduced tyrosine phosphorylation and loss of binding to PTPN6 and CSK as well as complete loss of inhibitory activity. Loss of phosphorylation and of inhibition of calcium mobilization; when associated with F-281.,MUTAGEN:Y->F: Reduced tyrosine phosphorylation and loss of binding to PTPN6. Partial inhibition of cytotoxic activity.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRA1	leukocyte immunoglobulin like receptor A1(LILRA1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006952~defense response,GO:0007166~cell surface receptor signaling pathway,GO:0019221~cytokine-mediated signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0003823~antigen binding,GO:0004888~transmembrane signaling receptor activity,GO:0032396~inhibitory MHC class I receptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRA6	leukocyte immunoglobulin like receptor A6(LILRA6)	Homo sapiens	GO:0002250~adaptive immune response,GO:0019221~cytokine-mediated signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0032396~inhibitory MHC class I receptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IG,DOMAIN:IGc2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRB1	leukocyte immunoglobulin like receptor B1(LILRB1)	Homo sapiens	GO:0001915~negative regulation of T cell mediated cytotoxicity,GO:0002230~positive regulation of defense response to virus by host,GO:0002250~adaptive immune response,GO:0002309~T cell proliferation involved in immune response,GO:0002719~negative regulation of cytokine production involved in immune response,GO:0002767~immune response-inhibiting cell surface receptor signaling pathway,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0007165~signal transduction,GO:0009615~response to virus,GO:0010628~positive regulation of gene expression,GO:0014063~negative regulation of serotonin secretion,GO:0019221~cytokine-mediated signaling pathway,GO:0031623~receptor internalization,GO:0032688~negative regulation of interferon-beta production,GO:0032689~negative regulation of interferon-gamma production,GO:0032693~negative regulation of interleukin-10 production,GO:0032695~negative regulation of interleukin-12 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032945~negative regulation of mononuclear cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0043065~positive regulation of apoptotic process,GO:0045786~negative regulation of cell cycle,GO:0045806~negative regulation of endocytosis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0046636~negative regulation of alpha-beta T cell activation,GO:0051607~defense response to virus,GO:0051926~negative regulation of calcium ion transport,GO:0060907~positive regulation of macrophage cytokine production,GO:0071222~cellular response to lipopolysaccharide,GO:0071635~negative regulation of transforming growth factor beta production,GO:0097028~dendritic cell differentiation,GO:2000669~negative regulation of dendritic cell apoptotic process,GO:2001186~negative regulation of CD8-positive, alpha-beta T cell activation,GO:2001189~negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,GO:2001193~positive regulation of gamma-delta T cell activation involved in immune response,GO:2001199~negative regulation of dendritic cell differentiation,GO:2001205~negative regulation of osteoclast development,	GO:0005576~extracellular region,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0023025~MHC class Ib protein complex binding,GO:0023029~MHC class Ib protein binding,GO:0030107~HLA-A specific inhibitory MHC class I receptor activity,GO:0030109~HLA-B specific inhibitory MHC class I receptor activity,GO:0032393~MHC class I receptor activity,GO:0032394~MHC class Ib receptor activity,GO:0032396~inhibitory MHC class I receptor activity,GO:0042169~SH2 domain binding,GO:0042288~MHC class I protein binding,GO:0042803~protein homodimerization activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,MOTIF:ITIM motif 4,MUTAGEN:Y->F: Impairs receptor phosphorylation and abolishes inhibition of serotonin release. No effect on PTPN6 binding; when associated with F-562.,MUTAGEN:Y->F: No effect on PTPN6 binding. Abolishes PTPN6 binding; when associated with F-644.,MUTAGEN:Y->F: No effect on PTPN6 binding; when associated with F-533.,MUTAGEN:Y->F: Reduces PTPN6 binding. Abolishes PTPN6 binding; when associated with F-614.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRB2	leukocyte immunoglobulin like receptor B2(LILRB2)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002578~negative regulation of antigen processing and presentation,GO:0002645~positive regulation of tolerance induction,GO:0002666~positive regulation of T cell tolerance induction,GO:0002767~immune response-inhibiting cell surface receptor signaling pathway,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0006955~immune response,GO:0006968~cellular defense response,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007267~cell-cell signaling,GO:0007611~learning or memory,GO:0019221~cytokine-mediated signaling pathway,GO:0032755~positive regulation of interleukin-6 production,GO:0034113~heterotypic cell-cell adhesion,GO:0035307~positive regulation of protein dephosphorylation,GO:0042102~positive regulation of T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0051248~negative regulation of protein metabolic process,GO:0051926~negative regulation of calcium ion transport,GO:0071222~cellular response to lipopolysaccharide,GO:1900271~regulation of long-term synaptic potentiation,GO:1900454~positive regulation of long term synaptic depression,GO:1905875~negative regulation of postsynaptic density organization,GO:2000524~negative regulation of T cell costimulation,GO:2001198~regulation of dendritic cell differentiation,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0001540~beta-amyloid binding,GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0023025~MHC class Ib protein complex binding,GO:0023029~MHC class Ib protein binding,GO:0032396~inhibitory MHC class I receptor activity,GO:0042288~MHC class I protein binding,GO:0042803~protein homodimerization activity,GO:0044877~macromolecular complex binding,GO:0050839~cell adhesion molecule binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:IG,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRB3	leukocyte immunoglobulin like receptor B3(LILRB3)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006952~defense response,GO:0007166~cell surface receptor signaling pathway,GO:0019221~cytokine-mediated signaling pathway,GO:0045671~negative regulation of osteoclast differentiation,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0004888~transmembrane signaling receptor activity,GO:0005515~protein binding,GO:0032396~inhibitory MHC class I receptor activity,GO:0038023~signaling receptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,IPR016332:Alpha-1B-glycoprotein/leukocyte immunoglobulin-like receptor,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,		PIRSF001979:alpha-1B-glycoprotein,	SM00408:IGc2,SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IG,DOMAIN:IGc2,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LILRB4	leukocyte immunoglobulin like receptor B4(LILRB4)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002507~tolerance induction,GO:0002669~positive regulation of T cell anergy,GO:0002725~negative regulation of T cell cytokine production,GO:0002774~Fc receptor mediated inhibitory signaling pathway,GO:0031623~receptor internalization,GO:0032682~negative regulation of chemokine production,GO:0032689~negative regulation of interferon-gamma production,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032693~negative regulation of interleukin-10 production,GO:0032703~negative regulation of interleukin-2 production,GO:0032714~negative regulation of interleukin-5 production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0042130~negative regulation of T cell proliferation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043378~positive regulation of CD8-positive, alpha-beta T cell differentiation,GO:0043409~negative regulation of MAPK cascade,GO:0045584~negative regulation of cytotoxic T cell differentiation,GO:0045591~positive regulation of regulatory T cell differentiation,GO:0045671~negative regulation of osteoclast differentiation,GO:0046007~negative regulation of activated T cell proliferation,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0061099~negative regulation of protein tyrosine kinase activity,GO:0071659~negative regulation of IP-10 production,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1900181~negative regulation of protein localization to nucleus,GO:1902894~negative regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:2000272~negative regulation of receptor activity,GO:2000524~negative regulation of T cell costimulation,	GO:0005886~plasma membrane,GO:0009898~cytoplasmic side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,GO:0098752~integral component of the cytoplasmic side of the plasma membrane,	GO:0001968~fibronectin binding,GO:0005515~protein binding,GO:0019903~protein phosphatase binding,GO:0030293~transmembrane receptor protein tyrosine kinase inhibitor activity,GO:0030547~receptor inhibitor activity,GO:0034185~apolipoprotein binding,	IPR007110:Immunoglobulin-like domain,IPR013151:Immunoglobulin,IPR013783:Immunoglobulin-like fold,	hsa04380:Osteoclast differentiation,hsa04662:B cell receptor signaling pathway,				KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,MOTIF:ITIM motif 1,MOTIF:ITIM motif 2,MOTIF:ITIM motif 3,MUTAGEN:D->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:E->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:F->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:H->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:L->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:P->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:P->A: Significant reduction in APOE-mediated activation of LILRB4.,MUTAGEN:R->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:S->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:T->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:V->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:W->A: No significant change in APOE-mediated activation of LILRB4.,MUTAGEN:W->A: Significant reduction in APOE-mediated activation of LILRB4.,MUTAGEN:Y->A: Significant reduction in APOE-mediated activation of LILRB4.,REGION:Disordered,SITE:Required for APOE-mediated activation of LILRB4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LENG1	leukocyte receptor cluster member 1(LENG1)	Homo sapiens			GO:0005515~protein binding,	IPR019339:CBF1-interacting co-repressor CIR, N-terminal domain,				SM01083:SM01083,				KW-0175~Coiled coil,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,REGION:Disordered,
LDLRAD2	low density lipoprotein receptor class A domain containing 2(LDLRAD2)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,				SM00192:LDLa,		KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:LDL-receptor class A,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LUM	lumican(LUM)	Homo sapiens	GO:0007601~visual perception,GO:0014070~response to organic cyclic compound,GO:0030199~collagen fibril organization,GO:0032914~positive regulation of transforming growth factor beta1 production,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051216~cartilage development,GO:0070848~response to growth factor,	GO:0005576~extracellular region,GO:0005583~fibrillar collagen trimer,GO:0005615~extracellular space,GO:0005796~Golgi lumen,GO:0031012~extracellular matrix,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0030021~extracellular matrix structural constituent conferring compression resistance,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR027219:Lumican,	hsa05205:Proteoglycans in cancer,			SM00013:LRRNT,SM00369:LRR_TYP,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-0765~Sulfation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (keratan sulfate) asparagine,DOMAIN:LRRNT,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
LY6G5B	lymphocyte antigen 6 family member G5B(LY6G5B)	Homo sapiens		GO:0005576~extracellular region,GO:0005956~protein kinase CK2 complex,GO:0009897~external side of plasma membrane,GO:0032991~macromolecular complex,	GO:0019887~protein kinase regulator activity,GO:0042802~identical protein binding,	IPR000704:Casein kinase II, regulatory subunit,						KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:UPAR/Ly6,REGION:Disordered,
LAMP5	lysosomal associated membrane protein family member 5(LAMP5)	Homo sapiens	GO:0072594~establishment of protein localization to organelle,	GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032584~growth cone membrane,GO:0032590~dendrite membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0055038~recycling endosome membrane,		IPR002000:Lysosome-associated membrane glycoprotein,						KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:Y->A: Cell surface localization.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
LOXL1	lysyl oxidase like 1(LOXL1)	Homo sapiens	GO:0018057~peptidyl-lysine oxidation,GO:0018277~protein deamination,GO:0030199~collagen fibril organization,GO:0032496~response to lipopolysaccharide,GO:0035904~aorta development,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,	IPR001695:Lysyl oxidase,IPR019828:Lysyl oxidase, conserved site,		177650~Exfoliation syndrome, susceptibility to,				KW-0964~Secreted,	KW-0955~Glaucoma,	KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0165~Cleavage on pair of basic residues,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr); alternate,REGION:Disordered,REGION:Lysyl-oxidase like,
LOXL2	lysyl oxidase like 2(LOXL2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001666~response to hypoxia,GO:0001837~epithelial to mesenchymal transition,GO:0001935~endothelial cell proliferation,GO:0002040~sprouting angiogenesis,GO:0006464~cellular protein modification process,GO:0006897~endocytosis,GO:0007155~cell adhesion,GO:0007568~aging,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0018057~peptidyl-lysine oxidation,GO:0022900~electron transport chain,GO:0030199~collagen fibril organization,GO:0032332~positive regulation of chondrocyte differentiation,GO:0036211~protein modification process,GO:0043542~endothelial cell migration,GO:0045892~negative regulation of transcription, DNA-templated,GO:0046688~response to copper ion,GO:0070828~heterochromatin organization,GO:1902455~negative regulation of stem cell population maintenance,	GO:0000785~chromatin,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0016020~membrane,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005044~scavenger receptor activity,GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0009055~electron carrier activity,GO:0070492~oligosaccharide binding,	IPR001190:Speract/scavenger receptor,IPR001695:Lysyl oxidase,IPR017448:Speract/scavenger receptor-related,IPR019828:Lysyl oxidase, conserved site,				SM00202:SR,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0084~Basement membrane,KW-0158~Chromosome,KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0539~Nucleus,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0186~Copper,KW-0479~Metal-binding,	KW-0156~Chromatin regulator,KW-0560~Oxidoreductase,KW-0678~Repressor,	KW-0325~Glycoprotein,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr),DOMAIN:SRCR,DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,DOMAIN:SRCR 4,MUTAGEN:H->A: Loss of enzyme activity.,MUTAGEN:HRH->ARA: Abolishes oxidase activity and oxidation of trimethylated 'Lys-4' of histone H3 but does not affect secretion, interaction with SNAI1, binding to the CDH1 promoter, repression of CDH1 transcription or ability to induce EMT.,MUTAGEN:K->A: Loss of enzyme activity.,MUTAGEN:N->Q: Inhibits secretion.,MUTAGEN:Y->A: Loss of enzyme activity.,MUTAGEN:Y->F: Does not affect ability to inhibit keratinocyte differentiation.,REGION:Disordered,REGION:Lysyl-oxidase like,
LOXL4	lysyl oxidase like 4(LOXL4)	Homo sapiens	GO:0006897~endocytosis,GO:0018057~peptidyl-lysine oxidation,GO:0030199~collagen fibril organization,	GO:0005615~extracellular space,GO:0016020~membrane,GO:0043235~receptor complex,GO:0070062~extracellular exosome,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005044~scavenger receptor activity,GO:0005507~copper ion binding,GO:0005515~protein binding,	IPR001190:Speract/scavenger receptor,IPR001695:Lysyl oxidase,IPR017448:Speract/scavenger receptor-related,IPR019828:Lysyl oxidase, conserved site,				SM00202:SR,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr),DOMAIN:SRCR 1,DOMAIN:SRCR 2,DOMAIN:SRCR 3,DOMAIN:SRCR 4,REGION:Lysyl-oxidase like,
LOX	lysyl oxidase(LOX)	Homo sapiens	GO:0001649~osteoblast differentiation,GO:0001932~regulation of protein phosphorylation,GO:0006464~cellular protein modification process,GO:0007507~heart development,GO:0009410~response to xenobiotic stimulus,GO:0010468~regulation of gene expression,GO:0016202~regulation of striated muscle tissue development,GO:0017015~regulation of transforming growth factor beta receptor signaling pathway,GO:0018057~peptidyl-lysine oxidation,GO:0030199~collagen fibril organization,GO:0030282~bone mineralization,GO:0030324~lung development,GO:0035791~platelet-derived growth factor receptor-beta signaling pathway,GO:0035905~ascending aorta development,GO:0035906~descending aorta development,GO:0036211~protein modification process,GO:0042060~wound healing,GO:0042493~response to drug,GO:0042981~regulation of apoptotic process,GO:0043491~protein kinase B signaling,GO:0045652~regulation of megakaryocyte differentiation,GO:0046716~muscle cell cellular homeostasis,GO:0048251~elastic fiber assembly,GO:0048514~blood vessel morphogenesis,GO:0048545~response to steroid hormone,GO:0055001~muscle cell development,GO:0060326~cell chemotaxis,GO:0061448~connective tissue development,GO:0071897~DNA biosynthetic process,GO:1900120~regulation of receptor binding,GO:1903010~regulation of bone development,GO:1990869~cellular response to chemokine,GO:2000586~regulation of platelet-derived growth factor receptor-beta signaling pathway,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0031012~extracellular matrix,	GO:0004720~protein-lysine 6-oxidase activity,GO:0005507~copper ion binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0036094~small molecule binding,GO:0060090~binding, bridging,	IPR001695:Lysyl oxidase,IPR013783:Immunoglobulin-like fold,IPR019828:Lysyl oxidase, conserved site,		617168~Aortic aneurysm, familial thoracic 10,				KW-0964~Secreted,	KW-0225~Disease variant,KW-0993~Aortic aneurysm,	KW-0732~Signal,	KW-0186~Copper,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-0801~TPQ,KW-0886~LTQ,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Lysine tyrosylquinone (Lys-Tyr),MUTAGEN:Y->F: Abolishes sulfation and reduces binding to collagen; when associated with 183-F-F-184 and 186-F-F-187.,MUTAGEN:YY->FF: Abolishes sulfation and reduces binding to collagen; when associated with 183-F-F-184 and F-190.,MUTAGEN:YY->FF: Abolishes sulfation and reduces binding to collagen; when associated with 186-F-F-187 and F-190.,PROPEP:Removed by BMP1,REGION:Disordered,REGION:Lysyl-oxidase like,SITE:Cleavage; by ADAMTS2 and ADAMTS14,
MARCO	macrophage receptor with collagenous structure(MARCO)	Homo sapiens	GO:0001934~positive regulation of protein phosphorylation,GO:0006897~endocytosis,GO:0006898~receptor-mediated endocytosis,GO:0006911~phagocytosis, engulfment,GO:0007166~cell surface receptor signaling pathway,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0043277~apoptotic cell clearance,GO:0045087~innate immune response,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0097242~beta-amyloid clearance,	GO:0005581~collagen trimer,GO:0005622~intracellular,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,	GO:0001540~beta-amyloid binding,GO:0001664~G-protein coupled receptor binding,GO:0004888~transmembrane signaling receptor activity,GO:0005044~scavenger receptor activity,GO:0038024~cargo receptor activity,GO:0038187~pattern recognition receptor activity,	IPR001190:Speract/scavenger receptor,IPR008160:Collagen triple helix repeat,IPR017448:Speract/scavenger receptor-related,	hsa04145:Phagosome,			SM00202:SR,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0176~Collagen,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Collagen-like,DOMAIN:SRCR,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MSR1	macrophage scavenger receptor 1(MSR1)	Homo sapiens	GO:0006898~receptor-mediated endocytosis,GO:0006911~phagocytosis, engulfment,GO:0010629~negative regulation of gene expression,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0010886~positive regulation of cholesterol storage,GO:0030301~cholesterol transport,GO:0034381~plasma lipoprotein particle clearance,GO:0042953~lipoprotein transport,GO:0051649~establishment of localization in cell,GO:0071407~cellular response to organic cyclic compound,GO:0097242~beta-amyloid clearance,	GO:0005581~collagen trimer,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,GO:0034362~low-density lipoprotein particle,	GO:0001540~beta-amyloid binding,GO:0005044~scavenger receptor activity,GO:0005515~protein binding,GO:0030169~low-density lipoprotein particle binding,GO:0038024~cargo receptor activity,	IPR001190:Speract/scavenger receptor,IPR003543:Macrophage scavenger receptor,IPR008160:Collagen triple helix repeat,IPR017448:Speract/scavenger receptor-related,	hsa04145:Phagosome,	614266~Barrett esophagus/esophageal adenocarcinoma,		SM00202:SR,	KW-0254~Endocytosis,	KW-0427~LDL,KW-0472~Membrane,		KW-0175~Coiled coil,KW-0176~Collagen,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Collagen-like,DOMAIN:SRCR,REGION:Disordered,REGION:Spacer,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MST1L	macrophage stimulating 1 like (pseudogene)(MST1L)	Homo sapiens	GO:0006508~proteolysis,GO:0010758~regulation of macrophage chemotaxis,GO:0033601~positive regulation of mammary gland epithelial cell proliferation,GO:0046425~regulation of JAK-STAT cascade,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0004252~serine-type endopeptidase activity,GO:0005102~receptor binding,GO:0030971~receptor tyrosine kinase binding,	IPR000001:Kringle,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR003609:Apple-like,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR024174:Hepatocyte growth factor/macrophage stimulating protein 1,			PIRSF001152:hepatocyte growth factor/macrophage stimulating protein 1,	SM00020:Tryp_SPc,SM00130:KR,SM00473:PAN_AP,		KW-0964~Secreted,		KW-0420~Kringle,KW-0677~Repeat,KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0721~Serine protease homolog,	KW-1015~Disulfide bond,	DOMAIN:Kringle 1,DOMAIN:Kringle 2,DOMAIN:Kringle 3,DOMAIN:Kringle 4,DOMAIN:PAN,DOMAIN:Peptidase S1,
HLA-A	major histocompatibility complex, class I, A(HLA-A)	Homo sapiens	GO:0001913~T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002419~T cell mediated cytotoxicity directed against tumor cell target,GO:0002485~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002726~positive regulation of T cell cytokine production,GO:0006955~immune response,GO:0016045~detection of bacterium,GO:0019731~antibacterial humoral response,GO:0019882~antigen processing and presentation,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0032729~positive regulation of interferon-gamma production,GO:0036037~CD8-positive, alpha-beta T cell activation,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0042590~antigen processing and presentation of exogenous peptide antigen via MHC class I,GO:0045087~innate immune response,GO:0050830~defense response to Gram-positive bacterium,GO:0050852~T cell receptor signaling pathway,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,GO:2000568~positive regulation of memory T cell activation,GO:2001187~positive regulation of CD8-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005797~Golgi medial cisterna,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0042824~MHC class I peptide loading complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0070971~endoplasmic reticulum exit site,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0003723~RNA binding,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0042610~CD8 receptor binding,GO:0046977~TAP binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	608579~Hypersensitivity syndrome, carbamazepine-induced, susceptibility to,		SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0765~Sulfation,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,DOMAIN:MHC_II_beta,DOMAIN:MHC_I_C,MUTAGEN:N->Q: Impairs the recruitment of HLA-A*02 in the peptide-loading complex.,MUTAGEN:S->C: Impairs the maturation of a peptide-receptive HLA-A*02-B2M complex.,MUTAGEN:T->K: Impairs binding to TAP1-TAP2 transporter, resulting in impaired presentation of intracellular peptides.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:I or L,
HLA-B	major histocompatibility complex, class I, B(HLA-B)	Homo sapiens	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002667~regulation of T cell anergy,GO:0006952~defense response,GO:0006955~immune response,GO:0016045~detection of bacterium,GO:0019882~antigen processing and presentation,GO:0032655~regulation of interleukin-12 production,GO:0032675~regulation of interleukin-6 production,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0045087~innate immune response,GO:2001198~regulation of dendritic cell differentiation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0042605~peptide antigen binding,GO:0046977~TAP binding,GO:0051087~chaperone binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	106300~Spondyloarthropathy, susceptibility to, 1,608579~Stevens-Johnson syndrome, susceptibility to,608579~Toxic epidermal necrolysis, susceptibility to,Abacavir hypersensitivity, susceptibility to~Abacavir hypersensitivity, susceptibility to,Drug-induced liver injury due to flucloxacillin~Drug-induced liver injury due to flucloxacillin,Synovitis, chronic, susceptibility to~Synovitis, chronic, susceptibility to,		SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,DOMAIN:MHC_I_C,MOTIF:Bw6 motif,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:D or N,
HLA-C	major histocompatibility complex, class I, C(HLA-C)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0045087~innate immune response,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0042612~MHC class I protein complex,GO:0042613~MHC class II protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046977~TAP binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	177900~Psoriasis susceptibility 1,609423~HIV-1 viremia, susceptibility to,		SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0490~MHC I,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,DOMAIN:MHC_II_beta,DOMAIN:MHC_I_C,MUTAGEN:S->G: Impairs N-linked glycosylation resulting in impaired interaction with CANX and CALR chaperones as well as TAPBPL.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-E	major histocompatibility complex, class I, E(HLA-E)	Homo sapiens	GO:0001815~positive regulation of antibody-dependent cellular cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002474~antigen processing and presentation of peptide antigen via MHC class I,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002477~antigen processing and presentation of exogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002519~natural killer cell tolerance induction,GO:0002639~positive regulation of immunoglobulin production,GO:0002715~regulation of natural killer cell mediated immunity,GO:0002717~positive regulation of natural killer cell mediated immunity,GO:0002729~positive regulation of natural killer cell cytokine production,GO:0006955~immune response,GO:0019731~antibacterial humoral response,GO:0019882~antigen processing and presentation,GO:0032736~positive regulation of interleukin-13 production,GO:0032753~positive regulation of interleukin-4 production,GO:0032759~positive regulation of TRAIL production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032819~positive regulation of natural killer cell proliferation,GO:0036037~CD8-positive, alpha-beta T cell activation,GO:0042270~protection from natural killer cell mediated cytotoxicity,GO:0045087~innate immune response,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:0045954~positive regulation of natural killer cell mediated cytotoxicity,GO:0050830~defense response to Gram-positive bacterium,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,GO:2001187~positive regulation of CD8-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0032398~MHC class Ib protein complex,GO:0042612~MHC class I protein complex,GO:0055038~recycling endosome membrane,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0046703~natural killer cell lectin-like receptor binding,	IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,	KW-0391~Immunity,KW-0399~Innate immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0490~MHC I,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,MUTAGEN:D->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:D->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:E->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:E->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:E->A: Reduces the affinity for KLRD1-KLRC1.,MUTAGEN:H->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:K->A: Impairs folding.,MUTAGEN:Q->A: Impairs the recognition by KLRD1-KLRC1.,MUTAGEN:R->A: Abolishes the recognition by KLRD1-KLRC1.,MUTAGEN:R->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:R->A: Reduces the affinity for KLRD1-KLRC1.,MUTAGEN:T->A: Has no impact on the affinity for KLRD1-KLRC1.,MUTAGEN:V->A: Impairs the recognition by KLRD1-KLRC1.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-F	major histocompatibility complex, class I, F(HLA-F)	Homo sapiens	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002474~antigen processing and presentation of peptide antigen via MHC class I,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002477~antigen processing and presentation of exogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0002725~negative regulation of T cell cytokine production,GO:0002728~negative regulation of natural killer cell cytokine production,GO:0002729~positive regulation of natural killer cell cytokine production,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0043322~negative regulation of natural killer cell degranulation,GO:0043323~positive regulation of natural killer cell degranulation,GO:0045953~negative regulation of natural killer cell mediated cytotoxicity,GO:1901215~negative regulation of neuron death,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0032398~MHC class Ib protein complex,GO:0042612~MHC class I protein complex,GO:0055038~recycling endosome membrane,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042605~peptide antigen binding,GO:0046978~TAP1 binding,GO:0046979~TAP2 binding,GO:0071889~14-3-3 protein binding,	IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,	hsa04144:Endocytosis,hsa04145:Phagosome,hsa04218:Cellular senescence,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04940:Type I diabetes mellitus,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05166:Human T-cell leukemia virus 1 infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05203:Viral carcinogenesis,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,	KW-0391~Immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0490~MHC I,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,MOTIF:Sorting signal sequence; Golgi-retention signal; ER-retention signal,MUTAGEN:Missing: Impairs the interaction with coat protein complex II; impairs the anterograde ER-to-Golgi transport.,MUTAGEN:RNR->AAA: Impairs the interaction with 14-3-3 proteins.,MUTAGEN:RNR->GKG: Impairs the anterograde ER-to-Golgi transport.,MUTAGEN:V->S: Impairs the anterograde ER-to-Golgi transport.,MUTAGEN:W->R: Impairs peptide binding.,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-H	major histocompatibility complex, class I, H (pseudogene)(HLA-H)	Homo sapiens	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002474~antigen processing and presentation of peptide antigen via MHC class I,GO:0002476~antigen processing and presentation of endogenous peptide antigen via MHC class Ib,GO:0002486~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent,GO:0006955~immune response,	GO:0000139~Golgi membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0012507~ER to Golgi transport vesicle membrane,GO:0030670~phagocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0035577~azurophil granule membrane,GO:0042612~MHC class I protein complex,GO:0055038~recycling endosome membrane,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0030881~beta-2-microglobulin binding,GO:0042605~peptide antigen binding,	IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,				SM00407:IGc1,	KW-0391~Immunity,	KW-0472~Membrane,KW-0490~MHC I,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,REGION:Alpha-1,REGION:Alpha-2,REGION:Alpha-3,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DMA	major histocompatibility complex, class II, DM alpha(HLA-DMA)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050870~positive regulation of T cell activation,	GO:0005765~lysosomal membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031902~late endosome membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,MUTAGEN:F->A: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:I->N: Decreases the interaction with MHCII and peptide exchange.,MUTAGEN:N->A,R: Abrogates the interaction with MHCII and peptide exchange.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-124.,MUTAGEN:R->A: Decreases the interaction with MHCII and peptide exchange; when associated with A-220.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
HLA-DOB	major histocompatibility complex, class II, DO beta(HLA-DOB)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002587~negative regulation of antigen processing and presentation of peptide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050870~positive regulation of T cell activation,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0042613~MHC class II protein complex,	GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,	IPR000353:MHC class II, beta chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_beta,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DPA1	major histocompatibility complex, class II, DP alpha 1(HLA-DPA1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032729~positive regulation of interferon-gamma production,GO:0042102~positive regulation of T cell proliferation,GO:0050870~positive regulation of T cell activation,GO:0071346~cellular response to interferon-gamma,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0043231~intracellular membrane-bounded organelle,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DPB1	major histocompatibility complex, class II, DP beta 1(HLA-DPB1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032729~positive regulation of interferon-gamma production,GO:0042102~positive regulation of T cell proliferation,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001003:MHC class II, alpha chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	Beryllium disease, chronic, susceptibility to~Beryllium disease, chronic, susceptibility to,		SM00407:IGc1,SM00920:SM00920,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_beta,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1(HLA-DQA1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046872~metal ion binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	212750~Celiac disease, susceptibility to,		SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DQB1	major histocompatibility complex, class II, DQ beta 1(HLA-DQB1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002344~B cell affinity maturation,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002579~positive regulation of antigen processing and presentation,GO:0002827~positive regulation of T-helper 1 type immune response,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0046635~positive regulation of alpha-beta T cell activation,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0071346~cellular response to interferon-gamma,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005769~early endosome,GO:0005771~multivesicular body,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0015643~toxic substance binding,GO:0023026~MHC class II protein complex binding,GO:0031625~ubiquitin protein ligase binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0046872~metal ion binding,GO:1990405~protein antigen binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR010579:MHC class I, alpha chain, C-terminal,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	123400~Creutzfeldt-Jakob disease, variant, resistance to,126200~Multiple sclerosis, susceptibility to, 1,212750~Celiac disease, susceptibility to,		SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_beta,REGION:Beta-1,REGION:Beta-2,REGION:Connecting peptide,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,UNSURE:E or Q,
HLA-DRA	major histocompatibility complex, class II, DR alpha(HLA-DRA)	Homo sapiens	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002491~antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0043382~positive regulation of memory T cell differentiation,GO:0045622~regulation of T-helper cell differentiation,GO:0050870~positive regulation of T cell activation,GO:0050890~cognition,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0001772~immunological synapse,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031901~early endosome membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0030247~polysaccharide binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,	IPR001003:MHC class II, alpha chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00920:SM00920,	KW-0391~Immunity,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:IGc1,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_alpha,MUTAGEN:A->L: Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->A: Increases the interaction with HLA-DM complex and peptide exchange. Decreases the affinity of the interaction with TCR by more than five-fold.,MUTAGEN:E->K: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->A,C: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:F->A,S,V,L: Impairs the interaction with HLA-DM complex, CLIP dissociation and peptide exchange.,MUTAGEN:F->W: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:G->S: Increases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:K->R: Almost no change in down-regulation of MHCII. No ubiquitination and complete loss of down-regulation of MHCII; when associated with 'R-254' of HLA-DRB.,MUTAGEN:L->R: Decreases the interaction with CD4.,MUTAGEN:P->S: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:Q->A: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:R->A: Impairs the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:S->D,H: Decreases the interaction with HLA-DM complex and peptide exchange.,MUTAGEN:T->R: Decreases the interaction with CD4.,MUTAGEN:W->F: Decreases the interaction with HLA-DM complex and peptide exchange.,REGION:Alpha-1,REGION:Alpha-2,REGION:Connecting peptide,SITE:Pathogen-derived peptide antigen,SITE:Self- and pathogen-derived peptide antigen,SITE:Self-peptide antigen,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DRB1	major histocompatibility complex, class II, DR beta 1(HLA-DRB1)	Homo sapiens	GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0001934~positive regulation of protein phosphorylation,GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002437~inflammatory response to antigenic stimulus,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002491~antigen processing and presentation of endogenous peptide antigen via MHC class II,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002842~positive regulation of T cell mediated immune response to tumor cell,GO:0002862~negative regulation of inflammatory response to antigenic stimulus,GO:0006955~immune response,GO:0006959~humoral immune response,GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0008544~epidermis development,GO:0016045~detection of bacterium,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0030225~macrophage differentiation,GO:0032653~regulation of interleukin-10 production,GO:0032673~regulation of interleukin-4 production,GO:0032689~negative regulation of interferon-gamma production,GO:0032831~positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation,GO:0033674~positive regulation of kinase activity,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042088~T-helper 1 type immune response,GO:0042130~negative regulation of T cell proliferation,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043382~positive regulation of memory T cell differentiation,GO:0043410~positive regulation of MAPK cascade,GO:0045622~regulation of T-helper cell differentiation,GO:0045657~positive regulation of monocyte differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046598~positive regulation of viral entry into host cell,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:0051262~protein tetramerization,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0001772~immunological synapse,GO:0005615~extracellular space,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0030247~polysaccharide binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,GO:0042608~T cell receptor binding,GO:0042609~CD4 receptor binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR001039:MHC class I, alpha chain, alpha1/alpha2,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011161:MHC class I-like antigen recognition,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	126200~Multiple sclerosis, susceptibility to, 1,181000~Sarcoidosis, susceptibility to, 1,		SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_I-like_Ag-recog,DOMAIN:MHC_II_beta,MUTAGEN:D->N: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:E->A: Decreases the interaction with CD4; when assocated with A-172.,MUTAGEN:E->K: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:I->R: Decreases the interaction with CD4.,MUTAGEN:K->A: Impairs MARCHF1-dependent down-regulation through ubiquitination.,MUTAGEN:L->H: Reduces the interaction with HLA-DM complex that results in impaired dissociation of CLIP from MHCII.,MUTAGEN:L->R: Decreases the interaction with CD4.,MUTAGEN:V->A: Decreases the interaction with CD4; when assocated with A-166.,REGION:Beta-1,REGION:Beta-2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DRB3	major histocompatibility complex, class II, DR beta 3(HLA-DRB3)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002469~myeloid dendritic cell antigen processing and presentation,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002842~positive regulation of T cell mediated immune response to tumor cell,GO:0006955~immune response,GO:0007165~signal transduction,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050852~T cell receptor signaling pathway,GO:0050870~positive regulation of T cell activation,GO:2000516~positive regulation of CD4-positive, alpha-beta T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0005515~protein binding,GO:0023026~MHC class II protein complex binding,GO:0032395~MHC class II receptor activity,GO:0042605~peptide antigen binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_beta,REGION:Beta-1,REGION:Beta-2,SITE:Self-peptide antigen,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
HLA-DRB5	major histocompatibility complex, class II, DR beta 5(HLA-DRB5)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002381~immunoglobulin production involved in immunoglobulin mediated immune response,GO:0002503~peptide antigen assembly with MHC class II protein complex,GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0006955~immune response,GO:0019882~antigen processing and presentation,GO:0019886~antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0050870~positive regulation of T cell activation,	GO:0000139~Golgi membrane,GO:0005765~lysosomal membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0010008~endosome membrane,GO:0012507~ER to Golgi transport vesicle membrane,GO:0016021~integral component of membrane,GO:0030658~transport vesicle membrane,GO:0030666~endocytic vesicle membrane,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0032588~trans-Golgi network membrane,GO:0042613~MHC class II protein complex,GO:0070062~extracellular exosome,GO:0071556~integral component of lumenal side of endoplasmic reticulum membrane,	GO:0023026~MHC class II protein complex binding,GO:0042605~peptide antigen binding,	IPR000353:MHC class II, beta chain, N-terminal,IPR003006:Immunoglobulin/major histocompatibility complex, conserved site,IPR003597:Immunoglobulin C1-set,IPR007110:Immunoglobulin-like domain,IPR011162:MHC classes I/II-like antigen recognition protein,IPR013783:Immunoglobulin-like fold,IPR014745:MHC class II, alpha/beta chain, N-terminal,	hsa04145:Phagosome,hsa04514:Cell adhesion molecules,hsa04612:Antigen processing and presentation,hsa04640:Hematopoietic cell lineage,hsa04658:Th1 and Th2 cell differentiation,hsa04659:Th17 cell differentiation,hsa04672:Intestinal immune network for IgA production,hsa04940:Type I diabetes mellitus,hsa05140:Leishmaniasis,hsa05145:Toxoplasmosis,hsa05150:Staphylococcus aureus infection,hsa05152:Tuberculosis,hsa05164:Influenza A,hsa05166:Human T-cell leukemia virus 1 infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05310:Asthma,hsa05320:Autoimmune thyroid disease,hsa05321:Inflammatory bowel disease,hsa05322:Systemic lupus erythematosus,hsa05323:Rheumatoid arthritis,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,			SM00407:IGc1,SM00921:SM00921,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0458~Lysosome,KW-0472~Membrane,KW-0491~MHC II,KW-0967~Endosome,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C1-type,DOMAIN:MHC_II_beta,REGION:Beta-1,REGION:Beta-2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MGAM2	maltase-glucoamylase 2 (putative)(MGAM2)	Homo sapiens	GO:0005975~carbohydrate metabolic process,	GO:0016021~integral component of membrane,	GO:0004339~glucan 1,4-alpha-glucosidase activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004558~alpha-1,4-glucosidase activity,GO:0030246~carbohydrate binding,	IPR000322:Glycoside hydrolase, family 31,IPR000519:P-type trefoil,IPR011013:Galactose mutarotase-like domain,IPR013780:Glycosyl hydrolase, family 13, all-beta,IPR017853:Glycoside hydrolase, superfamily,IPR025887:Glycoside hydrolase family 31, N-terminal domain,	hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,hsa04973:Carbohydrate digestion and absorption,			SM00018:PD,		KW-0472~Membrane,		KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:P-type 1,DOMAIN:P-type 2,REGION:Disordered,REGION:Glucoamylase,REGION:Maltase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MGAM	maltase-glucoamylase(MGAM)	Homo sapiens	GO:0000025~maltose catabolic process,GO:0005975~carbohydrate metabolic process,GO:0005983~starch catabolic process,GO:1901027~dextrin catabolic process,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0003824~catalytic activity,GO:0004339~glucan 1,4-alpha-glucosidase activity,GO:0004553~hydrolase activity, hydrolyzing O-glycosyl compounds,GO:0004558~alpha-1,4-glucosidase activity,GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0032450~maltose alpha-glucosidase activity,	IPR000322:Glycoside hydrolase, family 31,IPR000519:P-type trefoil,IPR011013:Galactose mutarotase-like domain,IPR013780:Glycosyl hydrolase, family 13, all-beta,IPR017853:Glycoside hydrolase, superfamily,IPR017957:P-type trefoil, conserved site,	hsa00052:Galactose metabolism,hsa00500:Starch and sucrose metabolism,hsa01100:Metabolic pathways,hsa04973:Carbohydrate digestion and absorption,			SM00018:PD,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0326~Glycosidase,KW-0378~Hydrolase,KW-0511~Multifunctional enzyme,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:P-type,DOMAIN:P-type 1,DOMAIN:P-type 2,DOMAIN:P-type 3,MUTAGEN:D->A: Loss of alpha-1,4-glucosidase activity toward maltose.,MUTAGEN:Missing: Decreases alpha-1,4-glucosidase activity toward long oligomaltose substrates having four to seven D-glucose residues.,MUTAGEN:Y->W: Decreases alpha-1,4-glucosidase activity toward maltose.,REGION:Disordered,REGION:Glucoamylase,REGION:Maltase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MRC2	mannose receptor C type 2(MRC2)	Homo sapiens	GO:0001649~osteoblast differentiation,GO:0006897~endocytosis,GO:0030574~collagen catabolic process,	GO:0005925~focal adhesion,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0005518~collagen binding,GO:0030246~carbohydrate binding,GO:0038023~signaling receptor activity,	IPR000562:Fibronectin, type II, collagen-binding,IPR000772:Ricin B lectin domain,IPR001304:C-type lectin,IPR013806:Kringle-like fold,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR018378:C-type lectin, conserved site,	hsa04145:Phagosome,hsa05152:Tuberculosis,			SM00034:CLECT,SM00059:FN2,SM00458:RICIN,	KW-0254~Endocytosis,	KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:C-type lectin,DOMAIN:C-type lectin 1,DOMAIN:C-type lectin 2,DOMAIN:C-type lectin 3,DOMAIN:C-type lectin 4,DOMAIN:C-type lectin 5,DOMAIN:C-type lectin 6,DOMAIN:C-type lectin 7,DOMAIN:C-type lectin 8,DOMAIN:Fibronectin type-II,DOMAIN:Ricin B-type lectin,MUTAGEN:E->A: Increased cell surface distribution.,MUTAGEN:LV->AA: Reduction of endocytotic activity; distribution almost restricted to the cell surface.,MUTAGEN:N->D: Reduced sugar-binding activity.,MUTAGEN:Y->A: No alteration of distribution and trafficking.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MKI67	marker of proliferation Ki-67(MKI67)	Homo sapiens	GO:0007049~cell cycle,GO:0007088~regulation of mitotic nuclear division,GO:0008283~cell proliferation,GO:0051983~regulation of chromosome segregation,GO:1902275~regulation of chromatin organization,	GO:0000793~condensed chromosome,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005730~nucleolus,GO:0016020~membrane,GO:0016604~nuclear body,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,	IPR000253:Forkhead-associated (FHA) domain,IPR008984:SMAD/FHA domain,IPR012568:K167R,				SM00240:FHA,SM01295:SM01295,	KW-0131~Cell cycle,	KW-0158~Chromosome,KW-0539~Nucleus,		KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:FHA,DOMAIN:PP1-binding,REGION:16 X 122 AA approximate repeats,REGION:Disordered,REPEAT:K167R 1,REPEAT:K167R 10,REPEAT:K167R 11,REPEAT:K167R 12,REPEAT:K167R 13,REPEAT:K167R 14,REPEAT:K167R 15,REPEAT:K167R 16,REPEAT:K167R 2,REPEAT:K167R 3,REPEAT:K167R 4,REPEAT:K167R 5,REPEAT:K167R 6,REPEAT:K167R 7,REPEAT:K167R 8,REPEAT:K167R 9,
MELK	maternal embryonic leucine zipper kinase(MELK)	Homo sapiens	GO:0000086~G2/M transition of mitotic cell cycle,GO:0006468~protein phosphorylation,GO:0006915~apoptotic process,GO:0008283~cell proliferation,GO:0008631~intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030097~hemopoiesis,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0046777~protein autophosphorylation,GO:0061351~neural precursor cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0016020~membrane,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008289~lipid binding,	IPR000719:Protein kinase, catalytic domain,IPR001772:Kinase associated domain 1 (KA1),IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,	KW-0053~Apoptosis,KW-0131~Cell cycle,	KW-0472~Membrane,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0106~Calcium,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,DOMAIN:KA1,DOMAIN:Protein kinase,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204 and A-286.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-204; and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-169; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-168; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-154; A-169; A-204; A-286 and A-339.,MUTAGEN:C->A: Abolishes dependence to reducing agents; when associated with V-29; V-70; A-89; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->V: Abolishes dependence to reducing agents; when associated with V-29; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:C->V: Abolishes dependence to reducing agents; when associated with V-70; A-89; A-154; A-168; A-169; A-204; A-286 and A-339.,MUTAGEN:D->A: Abolishes enzymatic activity.,MUTAGEN:DDD->KKK: Inactive.,MUTAGEN:S->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.,MUTAGEN:S->D: Inactive.,MUTAGEN:T->A: Abolishes activation of serine/threonine-protein kinase activity and has only weak activity.,MUTAGEN:T->A: Inhibits interaction with PPP1R8.,MUTAGEN:T->A: No effect on interaction with PPP1R8.,MUTAGEN:T->A: Strongly inhibits interaction with PPP1R8. Enhances enzymatic activity.,MUTAGEN:T->D,E: Phosphomimetic mutant that has similar kinase activity as wild-type.,MUTAGEN:Y->F: Abolishes autophosphorylation on tyrosine but still active on exogenous substrates.,REGION:Autoinhibitory region,REGION:UBA-like,
MMP11	matrix metallopeptidase 11(MMP11)	Homo sapiens	GO:0006508~proteolysis,GO:0007275~multicellular organism development,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030574~collagen catabolic process,GO:0045599~negative regulation of fat cell differentiation,GO:0071711~basement membrane organization,	GO:0005576~extracellular region,GO:0005796~Golgi lumen,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0008270~zinc ion binding,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR006026:Peptidase, metallopeptidase,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,			PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,DOMAIN:Peptidase_M10,DOMAIN:ZnMc,MOTIF:Cysteine switch,PROPEP:Activation peptide,REGION:Disordered,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,
MMP13	matrix metallopeptidase 13(MMP13)	Homo sapiens	GO:0001958~endochondral ossification,GO:0003417~growth plate cartilage development,GO:0006508~proteolysis,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030282~bone mineralization,GO:0030574~collagen catabolic process,GO:0044267~cellular protein metabolic process,GO:0060349~bone morphogenesis,GO:1904645~response to beta-amyloid,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005518~collagen binding,GO:0008270~zinc ion binding,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,	hsa04657:IL-17 signaling pathway,hsa04926:Relaxin signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,	250400~Metaphyseal dysplasia, Spahr type,602111~Metaphyseal anadysplasia 1,602111~Spondyloepimetaphyseal dysplasia, Missouri type,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0964~Secreted,	KW-0225~Disease variant,KW-0242~Dwarfism,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ZnMc,MOTIF:Cysteine switch,MUTAGEN:E->A: Abolishes enzyme activity.,PROPEP:Activation peptide,REGION:Disordered,REGION:Interaction with TIMP2,REGION:Interaction with collagen,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,TRANSMEM:Helical,
MMP14	matrix metallopeptidase 14(MMP14)	Homo sapiens	GO:0001501~skeletal system development,GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001666~response to hypoxia,GO:0001935~endothelial cell proliferation,GO:0001958~endochondral ossification,GO:0006508~proteolysis,GO:0006979~response to oxidative stress,GO:0008584~male gonad development,GO:0009612~response to mechanical stimulus,GO:0010831~positive regulation of myotube differentiation,GO:0010954~positive regulation of protein processing,GO:0014070~response to organic cyclic compound,GO:0016485~protein processing,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030307~positive regulation of cell growth,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0030574~collagen catabolic process,GO:0031638~zymogen activation,GO:0035987~endodermal cell differentiation,GO:0035988~chondrocyte proliferation,GO:0043615~astrocyte cell migration,GO:0043627~response to estrogen,GO:0045579~positive regulation of B cell differentiation,GO:0045746~negative regulation of Notch signaling pathway,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0048754~branching morphogenesis of an epithelial tube,GO:0048771~tissue remodeling,GO:0048870~cell motility,GO:0051895~negative regulation of focal adhesion assembly,GO:0060322~head development,GO:0097094~craniofacial suture morphogenesis,GO:1903076~regulation of protein localization to plasma membrane,GO:1905523~positive regulation of macrophage migration,GO:1990834~response to odorant,	GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005796~Golgi lumen,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0031410~cytoplasmic vesicle,GO:0042470~melanosome,GO:0044354~macropinosome,GO:0045111~intermediate filament cytoskeleton,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0070006~metalloaminopeptidase activity,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR021805:Peptidase M10A, matrix metallopeptidase, C-terminal,IPR024079:Metallopeptidase, catalytic domain,	hsa04668:TNF signaling pathway,hsa04912:GnRH signaling pathway,hsa04928:Parathyroid hormone synthesis, secretion and action,	277950~Winchester syndrome,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,		KW-0472~Membrane,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0165~Cleavage on pair of basic residues,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,DOMAIN:PG_binding_1,DOMAIN:ZnMc,MOTIF:Cysteine switch,PROPEP:Activation peptide,REGION:Disordered,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MMP19	matrix metallopeptidase 19(MMP19)	Homo sapiens	GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001542~ovulation from ovarian follicle,GO:0001554~luteolysis,GO:0006508~proteolysis,GO:0009725~response to hormone,GO:0022617~extracellular matrix disassembly,GO:0030154~cell differentiation,GO:0030198~extracellular matrix organization,GO:0030574~collagen catabolic process,GO:0051591~response to cAMP,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0008270~zinc ion binding,	IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR018487:Hemopexin-like repeats,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,		611543~Cavitary optic disc anomalies,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00120:HX,SM00235:ZnMc,	KW-0037~Angiogenesis,KW-0177~Collagen degradation,KW-0221~Differentiation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ZnMc,MOTIF:Cysteine switch,MUTAGEN:E->P: Reduced autolysis rate.,MUTAGEN:P->V: Reduced autolysis rate.,REGION:Disordered,REPEAT:Hemopexin,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,
MMP7	matrix metallopeptidase 7(MMP7)	Homo sapiens	GO:0006508~proteolysis,GO:0006509~membrane protein ectodomain proteolysis,GO:0007568~aging,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030335~positive regulation of cell migration,GO:0030574~collagen catabolic process,GO:0031293~membrane protein intracellular domain proteolysis,GO:0031667~response to nutrient levels,GO:0044849~estrous cycle,GO:0060135~maternal process involved in female pregnancy,GO:0071260~cellular response to mechanical stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009986~cell surface,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,	IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,	hsa04310:Wnt signaling pathway,hsa05166:Human T-cell leukemia virus 1 infection,			SM00235:ZnMc,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0865~Zymogen,	BINDING:in inhibited form,DOMAIN:Peptidase_M10,MOTIF:Cysteine switch,PROPEP:Activation peptide,
MMP9	matrix metallopeptidase 9(MMP9)	Homo sapiens	GO:0001501~skeletal system development,GO:0001503~ossification,GO:0001934~positive regulation of protein phosphorylation,GO:0006508~proteolysis,GO:0006915~apoptotic process,GO:0007566~embryo implantation,GO:0016477~cell migration,GO:0022617~extracellular matrix disassembly,GO:0030198~extracellular matrix organization,GO:0030225~macrophage differentiation,GO:0030335~positive regulation of cell migration,GO:0030574~collagen catabolic process,GO:0034614~cellular response to reactive oxygen species,GO:0035987~endodermal cell differentiation,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043388~positive regulation of DNA binding,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0048013~ephrin receptor signaling pathway,GO:0050900~leukocyte migration,GO:0051549~positive regulation of keratinocyte migration,GO:0071276~cellular response to cadmium ion,GO:0071492~cellular response to UV-A,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:1900122~positive regulation of receptor binding,GO:1904645~response to beta-amyloid,GO:1904707~positive regulation of vascular smooth muscle cell proliferation,GO:2000697~negative regulation of epithelial cell differentiation involved in kidney development,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,GO:2001258~negative regulation of cation channel activity,GO:2001268~negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,GO:1904813~ficolin-1-rich granule lumen,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008233~peptidase activity,GO:0008237~metallopeptidase activity,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,	IPR000562:Fibronectin, type II, collagen-binding,IPR000585:Hemopexin-like domain,IPR001818:Peptidase M10, metallopeptidase,IPR002477:Peptidoglycan binding-like,IPR006026:Peptidase, metallopeptidase,IPR013806:Kringle-like fold,IPR018486:Hemopexin, conserved site,IPR018487:Hemopexin-like repeats,IPR021158:Peptidase M10A, cysteine switch, zinc binding site,IPR021190:Peptidase M10A,IPR024079:Metallopeptidase, catalytic domain,	hsa01522:Endocrine resistance,hsa04657:IL-17 signaling pathway,hsa04668:TNF signaling pathway,hsa04670:Leukocyte transendothelial migration,hsa04915:Estrogen signaling pathway,hsa04926:Relaxin signaling pathway,hsa05161:Hepatitis B,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,hsa05219:Bladder cancer,hsa05415:Diabetic cardiomyopathy,hsa05417:Lipid and atherosclerosis,hsa05418:Fluid shear stress and atherosclerosis,	613073~Metaphyseal anadysplasia 2,	PIRSF001191:matrix metalloproteinase, stromelysin type,	SM00059:FN2,SM00120:HX,SM00235:ZnMc,	KW-0177~Collagen degradation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	BINDING:in inhibited form,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:Fibronectin type-II 1,DOMAIN:Fibronectin type-II 2,DOMAIN:Fibronectin type-II 3,MOTIF:Cysteine switch,MUTAGEN:E->Q: Loss of activity.,PROPEP:Activation peptide,PROPEP:Removed in 64 kDa matrix metalloproteinase-9 and 67 kDa matrix metalloproteinase-9,REGION:Disordered,REPEAT:Hemopexin 1,REPEAT:Hemopexin 2,REPEAT:Hemopexin 3,REPEAT:Hemopexin 4,SITE:Cleavage; by MMP3,
MXRA5	matrix remodeling associated 5(MXRA5)	Homo sapiens	GO:0071559~response to transforming growth factor beta,	GO:0005576~extracellular region,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00013:LRRNT,SM00082:LRRCT,SM00369:LRR_TYP,SM00408:IGc2,SM00409:IG,		KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:LRRCT,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,
MXRA8	matrix remodeling associated 8(MXRA8)	Homo sapiens	GO:0007155~cell adhesion,GO:0030154~cell differentiation,GO:0060857~establishment of glial blood-brain barrier,	GO:0005634~nucleus,GO:0005788~endoplasmic reticulum lumen,GO:0005886~plasma membrane,GO:0005923~bicellular tight junction,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0060170~ciliary membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00406:IGv,SM00409:IG,	KW-0130~Cell adhesion,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0796~Tight junction,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type 1,DOMAIN:Ig-like V-type 2,MOTIF:RGD,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MMEL1	membrane metalloendopeptidase like 1(MMEL1)	Homo sapiens	GO:0006508~proteolysis,GO:0016485~protein processing,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004175~endopeptidase activity,GO:0004222~metalloendopeptidase activity,GO:0008270~zinc ion binding,GO:0046872~metal ion binding,	IPR000718:Peptidase M13,IPR008753:Peptidase M13, N-terminal domain,IPR018497:Peptidase M13, C-terminal domain,IPR024079:Metallopeptidase, catalytic domain,						KW-0472~Membrane,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0378~Hydrolase,KW-0482~Metalloprotease,KW-0645~Protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton donor,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Peptidase M13,DOMAIN:Peptidase_M13,DOMAIN:Peptidase_M13_N,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
MS4A14	membrane spanning 4-domains A14(MS4A14)	Homo sapiens	GO:0007166~cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR007237:CD20-like,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
MEOX2	mesenchyme homeobox 2(MEOX2)	Homo sapiens	GO:0001525~angiogenesis,GO:0001757~somite specification,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007275~multicellular organism development,GO:0007519~skeletal muscle tissue development,GO:0008015~blood circulation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0060021~palate development,GO:0060173~limb development,GO:0061053~somite development,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016607~nuclear speck,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,				SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,MUTAGEN:Q->E: Abolishes DNA-binding. Does not affect ability to activate expression of CDKN2A.,REGION:Disordered,
MEDAG	mesenteric estrogen dependent adipogenesis(MEDAG)	Homo sapiens	GO:0045600~positive regulation of fat cell differentiation,	GO:0005737~cytoplasm,	GO:0005515~protein binding,							KW-0963~Cytoplasm,
MT1L	metallothionein 1L, pseudogene(MT1L)	Homo sapiens	GO:0006882~cellular zinc ion homeostasis,GO:0010273~detoxification of copper ion,GO:0045926~negative regulation of growth,GO:0071276~cellular response to cadmium ion,GO:0071280~cellular response to copper ion,GO:0071294~cellular response to zinc ion,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0008270~zinc ion binding,GO:0046872~metal ion binding,	IPR000006:Metallothionein, vertebrate,IPR003019:Metallothionein superfamily, eukaryotic,IPR017854:Metallothionein domain,IPR018064:Metallothionein, vertebrate, metal binding site,IPR023587:Metallothionein domain, vertebrate,									KW-0104~Cadmium,KW-0186~Copper,KW-0479~Metal-binding,KW-0480~Metal-thiolate cluster,KW-0862~Zinc,			REGION:Alpha,REGION:Beta,
METTL7B	methyltransferase like 7B(METTL7B)	Homo sapiens	GO:0032259~methylation,	GO:0005789~endoplasmic reticulum membrane,GO:0005811~lipid particle,	GO:0008168~methyltransferase activity,GO:0008757~S-adenosylmethionine-dependent methyltransferase activity,GO:0018708~thiol S-methyltransferase activity,	IPR013216:Methyltransferase type 11,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,		KW-0732~Signal,	KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,		MUTAGEN:D->A: Loss of catalytic activity.,
MFAP2	microfibril associated protein 2(MFAP2)	Homo sapiens	GO:0048048~embryonic eye morphogenesis,GO:0048050~post-embryonic eye morphogenesis,	GO:0001527~microfibril,GO:0005576~extracellular region,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,	IPR003582:Metridin-like ShK toxin,IPR008673:Microfibril-associated glycoprotein,						KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,KW-0765~Sulfation,KW-0873~Pyrrolidone carboxylic acid,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:ShKT,REGION:Disordered,SIGNAL:Or 19,
MSMP	microseminoprotein, prostate associated(MSMP)	Homo sapiens	GO:0002548~monocyte chemotaxis,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0048247~lymphocyte chemotaxis,	GO:0005615~extracellular space,GO:0005737~cytoplasm,	GO:0005125~cytokine activity,GO:0031727~CCR2 chemokine receptor binding,	IPR008735:Beta-microseminoprotein,					KW-0145~Chemotaxis,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0202~Cytokine,	KW-1015~Disulfide bond,	REGION:Disordered,
MCUB	mitochondrial calcium uniporter dominant negative subunit beta(MCUB)	Homo sapiens	GO:0006851~mitochondrial calcium ion transport,GO:0036444~mitochondrial calcium uptake,GO:0051560~mitochondrial calcium ion homeostasis,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,GO:0016020~membrane,GO:0031224~intrinsic component of membrane,GO:0031305~integral component of mitochondrial inner membrane,GO:0034704~calcium channel complex,GO:0043231~intracellular membrane-bounded organelle,GO:1990246~uniplex complex,	GO:0019855~calcium channel inhibitor activity,	IPR006769:Coiled-coil domain containing protein 109, C-terminal,					KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0175~Coiled coil,KW-0809~Transit peptide,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,			TRANSIT:Mitochondrion,TRANSMEM:Helical,
MAPK8IP2	mitogen-activated protein kinase 8 interacting protein 2(MAPK8IP2)	Homo sapiens	GO:0000165~MAPK cascade,GO:0001662~behavioral fear response,GO:0007172~signal complex assembly,GO:0007254~JNK cascade,GO:0007617~mating behavior,GO:0010469~regulation of receptor activity,GO:0032874~positive regulation of stress-activated MAPK cascade,GO:0035176~social behavior,GO:0046328~regulation of JNK cascade,GO:0046958~nonassociative learning,GO:0048813~dendrite morphogenesis,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0060079~excitatory postsynaptic potential,GO:2000310~regulation of NMDA receptor activity,GO:2000311~regulation of AMPA receptor activity,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005737~cytoplasm,GO:0014069~postsynaptic density,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,	GO:0001540~beta-amyloid binding,GO:0005078~MAP-kinase scaffold activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019894~kinesin binding,GO:0019901~protein kinase binding,GO:0030295~protein kinase activator activity,GO:0044877~macromolecular complex binding,	IPR001452:Src homology-3 domain,IPR006020:Phosphotyrosine interaction domain,IPR011993:Pleckstrin homology-like domain,	hsa04010:MAPK signaling pathway,			SM00326:SH3,SM00462:PTB,		KW-0963~Cytoplasm,		KW-0728~SH3 domain,		KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PID,DOMAIN:SH3,REGION:Disordered,REGION:JNK-binding domain (JBD),REGION:Necessary for interaction with FGF13,
MSN	moesin(MSN)	Homo sapiens	GO:0001771~immunological synapse formation,GO:0007010~cytoskeleton organization,GO:0007159~leukocyte cell-cell adhesion,GO:0008360~regulation of cell shape,GO:0008361~regulation of cell size,GO:0010628~positive regulation of gene expression,GO:0022612~gland morphogenesis,GO:0022614~membrane to membrane docking,GO:0042098~T cell proliferation,GO:0045198~establishment of epithelial cell apical/basal polarity,GO:0045732~positive regulation of protein catabolic process,GO:0050900~leukocyte migration,GO:0061028~establishment of endothelial barrier,GO:0070489~T cell aggregation,GO:0071394~cellular response to testosterone stimulus,GO:0071803~positive regulation of podosome assembly,GO:0072678~T cell migration,GO:1902115~regulation of organelle assembly,GO:1902966~positive regulation of protein localization to early endosome,GO:1903364~positive regulation of cellular protein catabolic process,GO:2000401~regulation of lymphocyte migration,GO:2000643~positive regulation of early endosome to late endosome transport,	GO:0001931~uropod,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0005912~adherens junction,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030175~filopodium,GO:0031143~pseudopodium,GO:0031528~microvillus membrane,GO:0031982~vesicle,GO:0045177~apical part of cell,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:0071944~cell periphery,GO:0072562~blood microparticle,	GO:0003725~double-stranded RNA binding,GO:0003779~actin binding,GO:0005102~receptor binding,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008092~cytoskeletal protein binding,GO:0019899~enzyme binding,GO:0019901~protein kinase binding,GO:0050839~cell adhesion molecule binding,	IPR000299:FERM domain,IPR000798:Ezrin/radixin/moesin like,IPR008954:Moesin,IPR011174:Ezrin/radixin/moesin,IPR011259:Ezrin/radixin/moesin, C-terminal,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR018979:FERM, N-terminal,IPR018980:FERM, C-terminal PH-like domain,IPR019747:FERM conserved site,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,	hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05162:Measles,hsa05205:Proteoglycans in cancer,	300988~Immunodeficiency 50,	PIRSF002305:ezrin/radixin/moesin,	SM00295:B41,SM01196:SM01196,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,				KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,	COMPBIAS:Basic and acidic residues,DOMAIN:FERM,MOTIF:[IL]-x-C-x-x-[DE] motif,MUTAGEN:E->M: Inhibits S-nitrosylation of Cys-117; when associated with M-115.,MUTAGEN:I->M: Inhibits S-nitrosylation of Cys-117; when associated with M-120.,MUTAGEN:T->A: Abolishes phosphorylation by STK10.,MUTAGEN:T->D: Completely abolishes the interaction between N- and C-terminal domains.,MUTAGEN:T->D: Phosphomimetic mutant.,MUTAGEN:Y->R: Impairs phosphorylation by STK10.,REGION:Disordered,
MKX	mohawk homeobox(MKX)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0030279~negative regulation of ossification,GO:0032331~negative regulation of chondrocyte differentiation,GO:0035990~tendon cell differentiation,GO:0036077~intratendonous ossification,GO:0045599~negative regulation of fat cell differentiation,GO:0048468~cell development,GO:0071260~cellular response to mechanical stimulus,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,	IPR001356:Homeodomain,IPR008422:Homeobox KN domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,DNA_BIND:Homeobox; TALE-type,DOMAIN:Homeobox,REGION:Disordered,
MAOA	monoamine oxidase A(MAOA)	Homo sapiens	GO:0006576~cellular biogenic amine metabolic process,GO:0009967~positive regulation of signal transduction,GO:0042135~neurotransmitter catabolic process,GO:0042420~dopamine catabolic process,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008131~primary amine oxidase activity,GO:0016491~oxidoreductase activity,GO:0050660~flavin adenine dinucleotide binding,GO:0052595~aliphatic-amine oxidase activity,GO:0052596~phenethylamine:oxygen oxidoreductase (deaminating) activity,GO:0097621~monoamine oxidase activity,	IPR001613:Flavin amine oxidase,IPR002937:Amine oxidase,	hsa00260:Glycine, serine and threonine metabolism,hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa00380:Tryptophan metabolism,hsa00982:Drug metabolism - cytochrome P450,hsa01100:Metabolic pathways,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,	300615~Antisocial behavior,300615~Brunner syndrome,			KW-0128~Catecholamine metabolism,KW-0531~Neurotransmitter degradation,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:Amino_oxidase,MUTAGEN:C->S: Complete loss of activity.,MUTAGEN:C->S: No loss of activity.,REGION:Interaction with membrane phospholipid headgroups,SITE:Important for catalytic activity,SITE:Important for substrate specificity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical; Anchor for type IV membrane protein,
MAOB	monoamine oxidase B(MAOB)	Homo sapiens	GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010044~response to aluminum ion,GO:0010269~response to selenium ion,GO:0014063~negative regulation of serotonin secretion,GO:0021762~substantia nigra development,GO:0022900~electron transport chain,GO:0032496~response to lipopolysaccharide,GO:0042135~neurotransmitter catabolic process,GO:0042420~dopamine catabolic process,GO:0042493~response to drug,GO:0045471~response to ethanol,GO:0045964~positive regulation of dopamine metabolic process,GO:0050665~hydrogen peroxide biosynthetic process,GO:0051412~response to corticosterone,	GO:0005739~mitochondrion,GO:0005740~mitochondrial envelope,GO:0005741~mitochondrial outer membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008131~primary amine oxidase activity,GO:0009055~electron carrier activity,GO:0016491~oxidoreductase activity,GO:0042802~identical protein binding,GO:0050660~flavin adenine dinucleotide binding,GO:0052595~aliphatic-amine oxidase activity,GO:0052596~phenethylamine:oxygen oxidoreductase (deaminating) activity,GO:0097621~monoamine oxidase activity,	IPR001613:Flavin amine oxidase,IPR002937:Amine oxidase,	hsa00260:Glycine, serine and threonine metabolism,hsa00330:Arginine and proline metabolism,hsa00340:Histidine metabolism,hsa00350:Tyrosine metabolism,hsa00360:Phenylalanine metabolism,hsa00380:Tryptophan metabolism,hsa00982:Drug metabolism - cytochrome P450,hsa01100:Metabolic pathways,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa05012:Parkinson disease,hsa05030:Cocaine addiction,hsa05031:Amphetamine addiction,hsa05034:Alcoholism,					KW-0472~Membrane,KW-0496~Mitochondrion,KW-1000~Mitochondrion outer membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0274~FAD,KW-0285~Flavoprotein,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	DOMAIN:Amino_oxidase,MUTAGEN:C->A: Complete loss of activity.,MUTAGEN:C->S: Complete loss of activity.,MUTAGEN:C->S: No loss of activity.,MUTAGEN:H->R: Significant loss of activity.,MUTAGEN:I->F: Alters specificity towards synthetic inhibitors.,MUTAGEN:K->M: No loss of activity.,MUTAGEN:S->A: No loss of activity.,MUTAGEN:T->A: Dramatic loss of activity.,SITE:Important for catalytic activity,TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
MMD2	monocyte to macrophage differentiation associated 2(MMD2)	Homo sapiens	GO:0032880~regulation of protein localization,GO:0045666~positive regulation of neuron differentiation,GO:0045860~positive regulation of protein kinase activity,GO:0046579~positive regulation of Ras protein signal transduction,	GO:0000139~Golgi membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004672~protein kinase activity,	IPR004254:Hly-III-related,						KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
MSX2	msh homeobox 2(MSX2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0002063~chondrocyte development,GO:0002076~osteoblast development,GO:0003148~outflow tract septum morphogenesis,GO:0003161~cardiac conduction system development,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0003416~endochondral bone growth,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008285~negative regulation of cell proliferation,GO:0009952~anterior/posterior pattern specification,GO:0023019~signal transduction involved in regulation of gene expression,GO:0030513~positive regulation of BMP signaling pathway,GO:0032792~negative regulation of CREB transcription factor activity,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035313~wound healing, spreading of epidermal cells,GO:0035880~embryonic nail plate morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0045599~negative regulation of fat cell differentiation,GO:0045617~negative regulation of keratinocyte differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0048598~embryonic morphogenesis,GO:0048863~stem cell differentiation,GO:0051795~positive regulation of timing of catagen,GO:0060346~bone trabecula formation,GO:0060363~cranial suture morphogenesis,GO:0060364~frontal suture morphogenesis,GO:0060444~branching involved in mammary gland duct morphogenesis,GO:0061312~BMP signaling pathway involved in heart development,GO:0070166~enamel mineralization,GO:0071392~cellular response to estradiol stimulus,GO:0090427~activation of meiosis,GO:0097152~mesenchymal cell apoptotic process,GO:2000678~negative regulation of transcription regulatory region DNA binding,GO:2001055~positive regulation of mesenchymal cell apoptotic process,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005667~transcription factor complex,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR020479:Homeodomain, metazoa,	hsa05166:Human T-cell leukemia virus 1 infection,	168500~Parietal foramina 1,168550~Parietal foramina with cleidocranial dysplasia,604757~Craniosynostosis 2,		SM00389:HOX,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0892~Osteogenesis,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0989~Craniosynostosis,	KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		DNA_BIND:Homeobox,MUTAGEN:T->A: Does not bind DNA but still suppresses OCFRE activation.,REGION:Disordered,
MUC1	mucin 1, cell surface associated(MUC1)	Homo sapiens	GO:0006351~transcription, DNA-templated,GO:0006977~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,GO:0006978~DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,GO:0010944~negative regulation of transcription by competitive promoter binding,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0036003~positive regulation of transcription from RNA polymerase II promoter in response to stress,GO:0043618~regulation of transcription from RNA polymerase II promoter in response to stress,GO:0051179~localization,GO:0090240~positive regulation of histone H4 acetylation,GO:1902166~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,	GO:0000785~chromatin,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0002039~p53 binding,GO:0003712~transcription cofactor activity,GO:0005515~protein binding,	IPR000082:SEA domain,		174000~Tubulointerstitial kidney disease, autosomal dominant, 2,		SM00200:SEA,		KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:SEA,LIPID:S-palmitoyl cysteine,MOTIF:Interaction with GRB2,MOTIF:Interaction with SRC and ESR1,MOTIF:Required for interaction with AP1S2,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited and AP1S1 binding reduced by 30%; when associated with C-1186. Accumulates in intracellular compartments; when associated with C-1186 and N-1203.,MUTAGEN:C->A: S-palmitoylation reduced by 50%. Complete loss of palmitoylation, no effect on endocytosis, recycling inhibited, and AP1S1 binding reduced by 30%; when associated with C-1184. Accumulates in intracellular compartments; when associated with C-1184 and N-1203.,MUTAGEN:D->A: Greatly reduced formation of isoform 5/isoform Y complex.,MUTAGEN:D->E: No effect on formation of isoform 5/isoform Y complex.,MUTAGEN:RRK->AAA: No nuclear targeting of HRG-stimulated MUC1 C-terminal nor JUP/gamma-catenin. No effect on interaction with JUP/gamma-catenin.,MUTAGEN:RRK->QQQ: No effect on palmitoylation.,MUTAGEN:S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y: Completely abrogates cleavage.,MUTAGEN:S->A: No change in PRKCD- nor GSK3B-mediated phosphorylation.,MUTAGEN:S->A: No change in PRKCD-mediated phosphorylation. Loss of GSK3B-mediated phosphorylation. CTNNB1.,MUTAGEN:S->C,T: Almost complete cleavage.,MUTAGEN:T->A: Loss of PRKCD-mediated phosphorylation. Decreased PRKCD binding. No increased binding to CTNNB1 in the presence of autophosphorylated PRKCD. Increases formation of E-cadherin/beta-catenin complex.,MUTAGEN:Y->E: No effect on nuclear colocalization of MUC1CT and CTNNB1. No effect on in vitro PDFGR-induced cell invasiveness.,MUTAGEN:Y->F: Greatly reduced EGFR- and Src-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-mediated phosphorylation. Decreased Src-binding.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear colocalization of MUC1CT and CTNNB1.,MUTAGEN:Y->F: No effect on EGFR-mediated phosphorylation. No nuclear localization of MUC1CT. Reduced in vitro PDGFR-induced cell invasiveness.,MUTAGEN:Y->F: Some reduction in EGFR-mediated phosphorylation.,MUTAGEN:Y->N: No effect on endocytosis.,MUTAGEN:Y->N: Reduced endocytosis by 30%. Greatly reduced binding to AP1S2 and GRB2. Binding AP1S1 reduced by 25%. Reduced endocytosis by 77%; when associated with N-1243. Accumulates in intracellular compartments; when associated with C-1184 and C-1186.,MUTAGEN:Y->N: Reduces binding to AP1S2 by 33%. Greatly reduced binding to GRB2. Reduced endocytosis by 50%. Reduced endocytosis by 77%; when associated with N-1203.,REGION:42 X 20 AA approximate tandem repeats of P-A-P-G-S-T-A-P-P-A-H-G-V-T-S-A-P-D-T-R,REGION:Disordered,REGION:Interaction with P53,REGION:Required for interaction with GSK3B,REGION:Required for interaction with beta- and gamma-catenins,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:1; approximate,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:2; approximate,REPEAT:3,REPEAT:30,REPEAT:31,REPEAT:32,REPEAT:33,REPEAT:34,REPEAT:35,REPEAT:36,REPEAT:37,REPEAT:38,REPEAT:39,REPEAT:4,REPEAT:40,REPEAT:41,REPEAT:42,REPEAT:43,REPEAT:44,REPEAT:45,REPEAT:46; approximate,REPEAT:47; approximate,REPEAT:48; approximate,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,SITE:Cleavage; by autolysis,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MUC20	mucin 20, cell surface associated(MUC20)	Homo sapiens	GO:0000187~activation of MAPK activity,GO:0048012~hepatocyte growth factor receptor signaling pathway,	GO:0005576~extracellular region,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0009925~basal plasma membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0031528~microvillus membrane,	GO:0042802~identical protein binding,							KW-0472~Membrane,KW-0964~Secreted,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:12 X 20 AA approximate tandem repeats of S-S-E-S-S-A-S-S-D-S-P-H-P-V-I-T-P-S-R-A,REGION:Disordered,REGION:Interaction with MET,REGION:Involved in oligomerization,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12; approximate,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
MSH5	mutS homolog 5(MSH5)	Homo sapiens	GO:0000710~meiotic mismatch repair,GO:0006298~mismatch repair,GO:0007131~reciprocal meiotic recombination,GO:0051026~chiasma assembly,	GO:0000228~nuclear chromosome,GO:0005634~nucleus,	GO:0003690~double-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008094~DNA-dependent ATPase activity,GO:0030983~mismatched DNA binding,	IPR000432:DNA mismatch repair protein MutS, C-terminal,IPR007696:DNA mismatch repair protein MutS, core,IPR007861:DNA mismatch repair protein MutS, clamp,IPR011184:DNA mismatch repair protein, MSH2,IPR017261:DNA mismatch repair protein Msh6,IPR027417:P-loop containing nucleoside triphosphate hydrolase,		617442~Premature ovarian failure 13,619937~Spermatogenic failure 74,	PIRSF005813:DNA mismatch repair protein, eukaryotic MSH2 type,PIRSF037677:DNA mismatch repair protein Msh6,	SM00533:MUTSd,SM00534:MUTSac,	KW-0227~DNA damage,KW-0234~DNA repair,KW-0469~Meiosis,		KW-0225~Disease variant,KW-1066~Premature ovarian failure,	KW-0732~Signal,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0238~DNA-binding,		DOMAIN:DNA_MISMATCH_REPAIR_2,DOMAIN:MUTSd,DOMAIN:MutS_IV,REGION:Disordered,
MPZL2	myelin protein zero like 2(MPZL2)	Homo sapiens	GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0009653~anatomical structure morphogenesis,GO:0098609~cell-cell adhesion,	GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR000920:Myelin P0 protein,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,		618145~Deafness, autosomal recessive 111,		SM00406:IGv,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MYZAP	myocardial zonula adherens protein(MYZAP)	Homo sapiens	GO:0035556~intracellular signal transduction,	GO:0005622~intracellular,GO:0005856~cytoskeleton,GO:0030018~Z disc,GO:0030054~cell junction,GO:0030864~cortical actin cytoskeleton,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031674~I band,GO:0070161~anchoring junction,	GO:0005515~protein binding,							KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0732~Signal,				MOTIF:Required for DYNLL1-binding,MUTAGEN:Q->G: No effect on DYNLL1-binding; when associated with G-448.,MUTAGEN:R->G: No effect on DYNLL1-binding; when associated with G-436.,MUTAGEN:Y->G: No effect on DYNLL1-binding.,REGION:Disordered,
MYOF	myoferlin(MYOF)	Homo sapiens	GO:0001778~plasma membrane repair,GO:0006936~muscle contraction,GO:0007009~plasma membrane organization,GO:0007520~myoblast fusion,GO:0008015~blood circulation,GO:0033292~T-tubule organization,GO:0061025~membrane fusion,	GO:0005635~nuclear envelope,GO:0005886~plasma membrane,GO:0005901~caveola,GO:0016021~integral component of membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0031410~cytoplasmic vesicle,GO:0031965~nuclear membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR006614:Peroxin/Ferlin domain,IPR012560:Ferlin A-domain,IPR012561:Ferlin B-domain,IPR012968:FerIin domain,		619366~Angioedema, hereditary, 7,		SM00239:C2,SM00693:DysFN,SM00694:DysFC,SM01200:SM01200,SM01201:SM01201,SM01202:SM01202,		KW-0472~Membrane,KW-0539~Nucleus,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:C2 3,DOMAIN:C2 4,DOMAIN:C2 5,DOMAIN:C2 6,DOMAIN:C2 7,MUTAGEN:NPF->SPL: Reduces interaction with EHD2.,REGION:Disordered,REGION:Necessary for interaction with EHD2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
MB	myoglobin(MB)	Homo sapiens	GO:0001666~response to hypoxia,GO:0007507~heart development,GO:0009725~response to hormone,GO:0015671~oxygen transport,GO:0031444~slow-twitch skeletal muscle fiber contraction,GO:0042542~response to hydrogen peroxide,GO:0043353~enucleate erythrocyte differentiation,GO:0050873~brown fat cell differentiation,	GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0005344~oxygen transporter activity,GO:0005509~calcium ion binding,GO:0019825~oxygen binding,GO:0020037~heme binding,GO:0046872~metal ion binding,	IPR000971:Globin,IPR002048:EF-hand domain,IPR002335:Myoglobin,IPR008080:Parvalbumin,IPR009050:Globin-like,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0561~Oxygen transport,KW-0813~Transport,				KW-0106~Calcium,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0514~Muscle protein,	KW-0597~Phosphoprotein,	BINDING:distal binding residue,BINDING:proximal binding residue,DOMAIN:EF-hand,DOMAIN:GLOBIN,
MYOM1	myomesin 1(MYOM1)	Homo sapiens	GO:0002074~extraocular skeletal muscle development,GO:0006936~muscle contraction,GO:0010628~positive regulation of gene expression,GO:0010737~protein kinase A signaling,GO:0050714~positive regulation of protein secretion,	GO:0005863~striated muscle myosin thick filament,GO:0031430~M band,	GO:0005515~protein binding,GO:0008307~structural constituent of muscle,GO:0019900~kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0051015~actin filament binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,SM00408:IGc2,SM00409:IG,		KW-0787~Thick filament,KW-0963~Cytoplasm,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0514~Muscle protein,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,REGION:6 X 6 AA tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,
MYO1G	myosin IG(MYO1G)	Homo sapiens	GO:0002456~T cell mediated immunity,GO:0006887~exocytosis,GO:0007015~actin filament organization,GO:0030050~vesicle transport along actin filament,GO:0031589~cell-substrate adhesion,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0071976~cell gliding,GO:0072678~T cell migration,	GO:0001891~phagocytic cup,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005902~microvillus,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016459~myosin complex,GO:0030027~lamellipodium,GO:0030175~filopodium,GO:0031256~leading edge membrane,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0000146~microfilament motor activity,GO:0003774~motor activity,GO:0003779~actin binding,GO:0005516~calmodulin binding,GO:0005524~ATP binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0051015~actin filament binding,	IPR001609:Myosin head, motor domain,IPR010926:Myosin tail 2,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa05130:Pathogenic Escherichia coli infection,			SM00242:MYSc,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0067~ATP-binding,KW-0446~Lipid-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0112~Calmodulin-binding,KW-0505~Motor protein,KW-0518~Myosin,	KW-0007~Acetylation,	DOMAIN:IQ,DOMAIN:Myosin motor,DOMAIN:TH1,MUTAGEN:K->A: No effect on membrane localization; when associated with R-885.,MUTAGEN:K->A: Reduced membrane association.,MUTAGEN:R->A: No effect on membrane localization.,MUTAGEN:R->A: No effect on membrane localization; when associated with K-883.,MUTAGEN:R->A: No effect on membrane localization; when associated with R-903.,MUTAGEN:R->A: No effect on membrane localization; when associated with R-906.,MUTAGEN:R->A: Reduced membrane association.,PEPTIDE:Minor histocompatibility antigen HA-2,REGION:Actin-binding,
MYO7B	myosin VIIB(MYO7B)	Homo sapiens	GO:0007015~actin filament organization,GO:0007423~sensory organ development,GO:0007605~sensory perception of sound,GO:0030050~vesicle transport along actin filament,GO:0030154~cell differentiation,GO:1904970~brush border assembly,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005902~microvillus,GO:0005903~brush border,GO:0015629~actin cytoskeleton,GO:0016459~myosin complex,GO:0031982~vesicle,GO:0090651~apical cytoplasm,	GO:0000146~microfilament motor activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0051015~actin filament binding,	IPR000048:IQ motif, EF-hand binding site,IPR000299:FERM domain,IPR000857:MyTH4 domain,IPR001452:Src homology-3 domain,IPR001609:Myosin head, motor domain,IPR011993:Pleckstrin homology-like domain,IPR014352:FERM/acyl-CoA-binding protein, 3-helical bundle,IPR019748:FERM central domain,IPR019749:Band 4.1 domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,				SM00015:IQ,SM00139:MyTH4,SM00242:MYSc,SM00295:B41,SM00326:SH3,	KW-0221~Differentiation,	KW-0206~Cytoskeleton,KW-0963~Cytoplasm,KW-0966~Cell projection,		KW-0677~Repeat,KW-0728~SH3 domain,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0009~Actin-binding,KW-0505~Motor protein,KW-0518~Myosin,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:FERM,DOMAIN:FERM 1,DOMAIN:FERM 2,DOMAIN:IQ 1,DOMAIN:IQ 2,DOMAIN:IQ 3,DOMAIN:IQ 4,DOMAIN:IQ 5,DOMAIN:IQ 6,DOMAIN:MyTH4,DOMAIN:MyTH4 1,DOMAIN:MyTH4 2,DOMAIN:MyTH4 3,DOMAIN:Myosin motor,DOMAIN:SH3,REGION:Actin-binding,REGION:Disordered,REGION:Mediates interaction with ANKS4B,REGION:Mediates interaction with CDHR2, CDHR5 and USH1C,
MYBPC1	myosin binding protein C1(MYBPC1)	Homo sapiens	GO:0006936~muscle contraction,GO:0007155~cell adhesion,	GO:0005829~cytosol,GO:0030016~myofibril,GO:0032982~myosin filament,	GO:0003779~actin binding,GO:0005515~protein binding,GO:0008307~structural constituent of muscle,GO:0017022~myosin binding,GO:0031432~titin binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,		614335~Arthrogryposis, distal, type 1B,614915~Lethal congenital contracture syndrome 4,618524~Myopathy, congenital, with tremor,		SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0787~Thick filament,	KW-0225~Disease variant,	KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,REGION:Disordered,
MYBPH	myosin binding protein H(MYBPH)	Homo sapiens	GO:0006942~regulation of striated muscle contraction,GO:0007155~cell adhesion,	GO:0032982~myosin filament,	GO:0005515~protein binding,GO:0008307~structural constituent of muscle,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,				SM00060:FN3,SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0787~Thick filament,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,		KW-0514~Muscle protein,	KW-0597~Phosphoprotein,	DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,REGION:Disordered,
MYL9	myosin light chain 9(MYL9)	Homo sapiens	GO:0006937~regulation of muscle contraction,GO:0030239~myofibril assembly,GO:0070527~platelet aggregation,	GO:0001725~stress fiber,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005859~muscle myosin complex,GO:0005938~cell cortex,GO:0016460~myosin II complex,GO:0030016~myofibril,GO:0030018~Z disc,	GO:0005509~calcium ion binding,GO:0008307~structural constituent of muscle,GO:0032036~myosin heavy chain binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04360:Axon guidance,hsa04510:Focal adhesion,hsa04530:Tight junction,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa04921:Oxytocin signaling pathway,hsa05131:Shigellosis,hsa05132:Salmonella infection,	619365~Megacystis-microcolon-intestinal hypoperistalsis syndrome 4,		SM00054:EFh,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0505~Motor protein,KW-0514~Muscle protein,KW-0518~Myosin,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,REGION:Disordered,
NPPA	natriuretic peptide A(NPPA)	Homo sapiens	GO:0001666~response to hypoxia,GO:0003085~negative regulation of systemic arterial blood pressure,GO:0003161~cardiac conduction system development,GO:0003180~aortic valve morphogenesis,GO:0006182~cGMP biosynthetic process,GO:0006457~protein folding,GO:0007168~receptor guanylyl cyclase signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007565~female pregnancy,GO:0008217~regulation of blood pressure,GO:0010460~positive regulation of heart rate,GO:0010753~positive regulation of cGMP-mediated signaling,GO:0014898~cardiac muscle hypertrophy in response to stress,GO:0019934~cGMP-mediated signaling,GO:0030308~negative regulation of cell growth,GO:0032868~response to insulin,GO:0035994~response to muscle stretch,GO:0036376~sodium ion export from cell,GO:0042059~negative regulation of epidermal growth factor receptor signaling pathway,GO:0042311~vasodilation,GO:0043508~negative regulation of JUN kinase activity,GO:0060372~regulation of atrial cardiac muscle cell membrane repolarization,GO:0060452~positive regulation of cardiac muscle contraction,GO:0061049~cell growth involved in cardiac muscle cell development,GO:0071260~cellular response to mechanical stimulus,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1901841~regulation of high voltage-gated calcium channel activity,GO:1902261~positive regulation of delayed rectifier potassium channel activity,GO:1902514~regulation of calcium ion transmembrane transport via high voltage-gated calcium channel,GO:1903595~positive regulation of histamine secretion by mast cell,GO:1903766~positive regulation of potassium ion export across plasma membrane,GO:1903815~negative regulation of collecting lymphatic vessel constriction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005903~brush border,GO:0032991~macromolecular complex,GO:0042629~mast cell granule,GO:0042995~cell projection,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,	GO:0005102~receptor binding,GO:0005179~hormone activity,GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0051427~hormone receptor binding,GO:0071855~neuropeptide receptor binding,	IPR000663:Natriuretic peptide,IPR002407:Natriuretic peptide, atrial type,	hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04714:Thermogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,hsa05143:African trypanosomiasis,	612201~Atrial fibrillation, familial, 6,615745~Atrial standstill 2,		SM00183:NAT_PEP,		KW-0964~Secreted,KW-0966~Cell projection,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,KW-1020~Atrial fibrillation,	KW-0732~Signal,		KW-0372~Hormone,KW-0838~Vasoactive,KW-0840~Vasodilator,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	MUTAGEN:Missing: No effect on degradation of atrial natriuretic peptide by IDE.,MUTAGEN:Missing: Reduced degradation of atrial natriuretic peptide by IDE; when associated with N-147--151-Y DEL.,MUTAGEN:Missing: Reduced degradation of atrial natriuretic peptide by IDE; when associated with S-124--126-R DEL.,MUTAGEN:R->G: Loss of cleavage by CORIN.,PEPTIDE:Atrial natriuretic peptide,PEPTIDE:Atriopeptin-1,PEPTIDE:Atriopeptin-2,PEPTIDE:Atriopeptin-3,PEPTIDE:Auriculin-A,PEPTIDE:Auriculin-B,PEPTIDE:Auriculin-C,PEPTIDE:Auriculin-D,PEPTIDE:Kaliuretic peptide,PEPTIDE:Long-acting natriuretic peptide,PEPTIDE:Urodilatin,PEPTIDE:Vessel dilator,REGION:Disordered,REGION:Important for degradation of atrial natriuretic peptide by IDE,SITE:Cleavage; by CORIN,SITE:Cleavage; by MME,
NPR1	natriuretic peptide receptor 1(NPR1)	Homo sapiens	GO:0006182~cGMP biosynthetic process,GO:0006468~protein phosphorylation,GO:0007165~signal transduction,GO:0007166~cell surface receptor signaling pathway,GO:0007168~receptor guanylyl cyclase signaling pathway,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007589~body fluid secretion,GO:0008217~regulation of blood pressure,GO:0009190~cyclic nucleotide biosynthetic process,GO:0010753~positive regulation of cGMP-mediated signaling,GO:0016525~negative regulation of angiogenesis,GO:0019934~cGMP-mediated signaling,GO:0030308~negative regulation of cell growth,GO:0035556~intracellular signal transduction,GO:0035810~positive regulation of urine volume,GO:0035815~positive regulation of renal sodium excretion,GO:0042417~dopamine metabolic process,GO:0043114~regulation of vascular permeability,GO:0048662~negative regulation of smooth muscle cell proliferation,GO:0097746~regulation of blood vessel diameter,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043235~receptor complex,GO:1990620~ANPR-A receptor complex,	GO:0001653~peptide receptor activity,GO:0004383~guanylate cyclase activity,GO:0004672~protein kinase activity,GO:0005524~ATP binding,GO:0005525~GTP binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0016849~phosphorus-oxygen lyase activity,GO:0016941~natriuretic peptide receptor activity,GO:0017046~peptide hormone binding,GO:0042562~hormone binding,	IPR000719:Protein kinase, catalytic domain,IPR001054:Adenylyl cyclase class-3/4/guanylyl cyclase,IPR001170:Natriuretic peptide receptor,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR001828:Extracellular ligand-binding receptor,IPR011009:Protein kinase-like domain,IPR018297:Adenylyl cyclase class-3/4/guanylyl cyclase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04022:cGMP-PKG signaling pathway,hsa04024:cAMP signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04714:Thermogenesis,hsa04921:Oxytocin signaling pathway,hsa04923:Regulation of lipolysis in adipocytes,hsa04924:Renin secretion,hsa04925:Aldosterone synthesis and secretion,			SM00044:CYCc,	KW-0141~cGMP biosynthesis,	KW-0472~Membrane,		KW-0175~Coiled coil,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0342~GTP-binding,KW-0547~Nucleotide-binding,KW-0868~Chloride,	KW-0456~Lyase,KW-0675~Receptor,KW-0838~Vasoactive,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Guanylate cyclase,DOMAIN:Protein kinase,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NPNT	nephronectin(NPNT)	Homo sapiens	GO:0001657~ureteric bud development,GO:0001658~branching involved in ureteric bud morphogenesis,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0007179~transforming growth factor beta receptor signaling pathway,GO:0010694~positive regulation of alkaline phosphatase activity,GO:0010811~positive regulation of cell-substrate adhesion,GO:0030198~extracellular matrix organization,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0033631~cell-cell adhesion mediated by integrin,GO:0045184~establishment of protein localization,GO:0045669~positive regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0045987~positive regulation of smooth muscle contraction,GO:0051145~smooth muscle cell differentiation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071356~cellular response to tumor necrosis factor,GO:0097195~pilomotor reflex,GO:2000721~positive regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0016020~membrane,GO:0030485~smooth muscle contractile fiber,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000998:MAM domain,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR018097:EGF-like calcium-binding, conserved site,	hsa04512:ECM-receptor interaction,			SM00137:MAM,SM00179:EGF_CA,SM00181:EGF,	KW-0130~Cell adhesion,KW-0221~Differentiation,	KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4; calcium-binding,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:MAM,MOTIF:Integrin interaction,REGION:Disordered,
NGFR	nerve growth factor receptor(NGFR)	Homo sapiens	GO:0001678~cellular glucose homeostasis,GO:0006886~intracellular protein transport,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007266~Rho protein signal transduction,GO:0007411~axon guidance,GO:0007417~central nervous system development,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0016048~detection of temperature stimulus,GO:0021675~nerve development,GO:0030336~negative regulation of cell migration,GO:0031069~hair follicle morphogenesis,GO:0032922~circadian regulation of gene expression,GO:0035907~dorsal aorta development,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0042475~odontogenesis of dentin-containing tooth,GO:0042488~positive regulation of odontogenesis of dentin-containing tooth,GO:0042593~glucose homeostasis,GO:0048144~fibroblast proliferation,GO:0048146~positive regulation of fibroblast proliferation,GO:0051402~neuron apoptotic process,GO:0051799~negative regulation of hair follicle development,GO:1900182~positive regulation of protein localization to nucleus,GO:1902895~positive regulation of pri-miRNA transcription from RNA polymerase II promoter,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1904646~cellular response to beta-amyloid,GO:2001235~positive regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,GO:0009986~cell surface,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030426~growth cone,GO:0031594~neuromuscular junction,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0098793~presynapse,	GO:0001540~beta-amyloid binding,GO:0004888~transmembrane signaling receptor activity,GO:0005035~death receptor activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0015026~coreceptor activity,GO:0031267~small GTPase binding,GO:0031625~ubiquitin protein ligase binding,GO:0038023~signaling receptor activity,GO:0043121~neurotrophin binding,GO:0048406~nerve growth factor binding,	IPR000488:Death domain,IPR001368:TNFR/NGFR cysteine-rich region,IPR011029:Death-like domain,IPR022325:Tumour necrosis factor receptor 16,	hsa03265:Virion - Lyssavirus,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04215:Apoptosis - multiple species,hsa04722:Neurotrophin signaling pathway,hsa05202:Transcriptional misregulation in cancer,			SM00005:DEATH,SM00208:TNFR,	KW-0053~Apoptosis,KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0524~Neurogenesis,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Death,MUTAGEN:D->A: Decreased interaction with ARHGDIA.,MUTAGEN:E->A: Decreased interaction with ARHGDIA.,MUTAGEN:K->A: Decreased interaction with ARHGDIA.,REGION:Disordered,REGION:Mediates interaction with KIDINS220,REPEAT:TNFR-Cys 1,REPEAT:TNFR-Cys 2,REPEAT:TNFR-Cys 3,REPEAT:TNFR-Cys 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NRG3	neuregulin 3(NRG3)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0007171~activation of transmembrane receptor protein tyrosine kinase activity,GO:0007389~pattern specification process,GO:0007399~nervous system development,GO:0007416~synapse assembly,GO:0021842~chemorepulsion involved in interneuron migration from the subpallium to the cortex,GO:0035556~intracellular signal transduction,GO:0038130~ERBB4 signaling pathway,GO:0038138~ERBB4-ERBB4 signaling pathway,GO:0048513~animal organ development,GO:0050804~modulation of synaptic transmission,GO:0060596~mammary placode formation,GO:2001223~negative regulation of neuron migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0098978~glutamatergic synapse,	GO:0005102~receptor binding,GO:0008083~growth factor activity,GO:0030297~transmembrane receptor protein tyrosine kinase activator activity,GO:0030971~receptor tyrosine kinase binding,GO:0045499~chemorepellent activity,GO:0048018~receptor agonist activity,	IPR000742:Epidermal growth factor-like domain,	hsa04012:ErbB signaling pathway,hsa05014:Amyotrophic lateral sclerosis,					KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0339~Growth factor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	COMPBIAS:Polar residues,DOMAIN:EGF-like,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Note=Internal signal sequence,
NRSN1	neurensin 1(NRSN1)	Homo sapiens	GO:0007399~nervous system development,	GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030133~transport vesicle,GO:0030426~growth cone,GO:0031410~cytoplasmic vesicle,GO:0043005~neuron projection,GO:0043025~neuronal cell body,	GO:0005515~protein binding,	IPR024883:Neurensin,						KW-0472~Membrane,KW-0966~Cell projection,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
NXPH1	neurexophilin 1(NXPH1)	Homo sapiens		GO:0005576~extracellular region,	GO:0005102~receptor binding,	IPR010450:Neurexophilin,IPR026845:Neurexophilin/NXPE,			PIRSF038019:neurexophilin,			KW-0964~Secreted,		KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:II,REGION:III,REGION:IV (linker domain),REGION:V (Cys-rich),
NET1	neuroepithelial cell transforming 1(NET1)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0007165~signal transduction,GO:0035025~positive regulation of Rho protein signal transduction,GO:0035556~intracellular signal transduction,GO:0043065~positive regulation of apoptotic process,GO:0043547~positive regulation of GTPase activity,GO:0051056~regulation of small GTPase mediated signal transduction,GO:0051451~myoblast migration,GO:0070301~cellular response to hydrogen peroxide,GO:0071479~cellular response to ionizing radiation,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,	IPR000219:Dbl homology (DH) domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,SM00325:RhoGEF,		KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0656~Proto-oncogene,			KW-0344~Guanine-nucleotide releasing factor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:DH,DOMAIN:PH,MOTIF:Nuclear localization signal,REGION:Disordered,REGION:Necessary for nuclear localization,
NEFH	neurofilament heavy chain(NEFH)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,GO:0007409~axonogenesis,GO:0030031~cell projection assembly,GO:0033693~neurofilament bundle assembly,GO:0045110~intermediate filament bundle assembly,GO:0048936~peripheral nervous system neuron axonogenesis,GO:0060052~neurofilament cytoskeleton organization,GO:0061564~axon development,GO:1902513~regulation of organelle transport along microtubule,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005883~neurofilament,GO:0014069~postsynaptic density,GO:0030424~axon,GO:0097418~neurofibrillary tangle,GO:0098685~Schaffer collateral - CA1 synapse,	GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0008017~microtubule binding,GO:0019894~kinesin binding,GO:0019901~protein kinase binding,GO:0030674~protein binding, bridging,GO:0070840~dynein complex binding,	IPR010790:Protein of unknown function DUF1388,IPR018039:Intermediate filament protein, conserved site,	hsa05014:Amyotrophic lateral sclerosis,hsa05022:Pathways of neurodegeneration - multiple diseases,	105400~Amyotrophic lateral sclerosis, susceptibility to,616924~Charcot-Marie-Tooth disease, axonal, type 2CC,		SM01391:SM01391,		KW-0206~Cytoskeleton,KW-0403~Intermediate filament,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0036~Amyotrophic lateral sclerosis,KW-0144~Charcot-Marie-Tooth disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0622~Neuropathy,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:IF rod,REGION:30 X 6 AA repeats of K-S-P-[AEPV]-[EAK]-[AEVK],REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2A,REGION:Coil 2B,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Linker 2,REGION:Tail,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:13,REPEAT:14,REPEAT:15,REPEAT:16,REPEAT:17,REPEAT:18,REPEAT:19,REPEAT:2,REPEAT:20,REPEAT:21,REPEAT:22,REPEAT:23,REPEAT:24,REPEAT:25,REPEAT:26,REPEAT:27,REPEAT:28,REPEAT:29,REPEAT:3,REPEAT:30,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,
NMUR2	neuromedin U receptor 2(NMUR2)	Homo sapiens	GO:0002023~reduction of food intake in response to dietary excess,GO:0006816~calcium ion transport,GO:0006940~regulation of smooth muscle contraction,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007218~neuropeptide signaling pathway,GO:0007267~cell-cell signaling,GO:0007417~central nervous system development,GO:0007625~grooming behavior,GO:0007631~feeding behavior,GO:0019722~calcium-mediated signaling,GO:0043006~activation of phospholipase A2 activity by calcium-mediated signaling,GO:0048016~inositol phosphate-mediated signaling,GO:0048265~response to pain,GO:0050482~arachidonic acid secretion,GO:0051930~regulation of sensory perception of pain,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0001607~neuromedin U receptor activity,GO:0004930~G-protein coupled receptor activity,GO:0005229~intracellular calcium activated chloride channel activity,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0008188~neuropeptide receptor activity,GO:0042924~neuromedin U binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR005390:Neuromedin U receptor,IPR005392:Neuromedin U receptor, type 2,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
NEUROD2	neuronal differentiation 2(NEUROD2)	Homo sapiens	GO:0001662~behavioral fear response,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0008306~associative learning,GO:0016567~protein ubiquitination,GO:0021695~cerebellar cortex development,GO:0030182~neuron differentiation,GO:0031915~positive regulation of synaptic plasticity,GO:0045666~positive regulation of neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048666~neuron development,GO:0050850~positive regulation of calcium-mediated signaling,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0071257~cellular response to electrical stimulus,GO:0071277~cellular response to calcium ion,GO:0090129~positive regulation of synapse maturation,GO:2000297~negative regulation of synapse maturation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0046982~protein heterodimerization activity,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR016637:Transcription factor, basic helix-loop-helix, NeuroD,IPR022575:Neurogenic differentiation factor, domain of unknown function,		618374~Developmental and epileptic encephalopathy 72,	PIRSF015618:basic helix-loop-helix transcription factor NeuroD,	SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0887~Epilepsy,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Pro residues,DOMAIN:bHLH,MOTIF:Nuclear localization signal,REGION:Disordered,
NEUROD6	neuronal differentiation 6(NEUROD6)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0021542~dentate gyrus development,GO:0030154~cell differentiation,GO:0030182~neuron differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0046983~protein dimerization activity,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR016637:Transcription factor, basic helix-loop-helix, NeuroD,IPR022575:Neurogenic differentiation factor, domain of unknown function,			PIRSF015618:basic helix-loop-helix transcription factor NeuroD,	SM00353:HLH,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		DOMAIN:BHLH,DOMAIN:bHLH,MOTIF:Nuclear localization signal,REGION:Disordered,
NCF1C	neutrophil cytosolic factor 1C pseudogene(NCF1C)	Homo sapiens	GO:0006801~superoxide metabolic process,GO:0042554~superoxide anion generation,GO:0045730~respiratory burst,GO:0050790~regulation of catalytic activity,	GO:0005737~cytoplasm,GO:0043020~NADPH oxidase complex,	GO:0016175~superoxide-generating NADPH oxidase activity,GO:0016176~superoxide-generating NADPH oxidase activator activity,GO:0035091~phosphatidylinositol binding,GO:0060090~binding, bridging,	IPR001452:Src homology-3 domain,IPR001655:Neutrophil cytosol factor 1,IPR001683:Phox homologous domain,IPR015039:NADPH oxidase subunit p47Phox, C-terminal,				SM00312:PX,SM00326:SH3,		KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0728~SH3 domain,			KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:PX,DOMAIN:SH3 1,DOMAIN:SH3 2,REGION:Disordered,
NNMT	nicotinamide N-methyltransferase(NNMT)	Homo sapiens	GO:0006769~nicotinamide metabolic process,GO:0009410~response to xenobiotic stimulus,GO:0010243~response to organonitrogen compound,GO:0010967~regulation of polyamine biosynthetic process,GO:0031060~regulation of histone methylation,GO:0031100~animal organ regeneration,GO:0032259~methylation,GO:0034356~NAD biosynthesis via nicotinamide riboside salvage pathway,GO:0042493~response to drug,GO:0045722~positive regulation of gluconeogenesis,GO:0051569~regulation of histone H3-K4 methylation,GO:0090312~positive regulation of protein deacetylation,	GO:0005829~cytosol,	GO:0008112~nicotinamide N-methyltransferase activity,GO:0008170~N-methyltransferase activity,GO:0030760~pyridine N-methyltransferase activity,	IPR000940:Methyltransferase, NNMT/PNMT/TEMT,IPR025820:Methyltransferase NNMT/PNMT/TEMT, conserved site,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,	Homocysteine plasma level~Homocysteine plasma level,	PIRSF000384:phenylethanolamine N-methyltransferase,			KW-0963~Cytoplasm,			KW-0949~S-adenosyl-L-methionine,	KW-0489~Methyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0164~Citrullination,	MUTAGEN:D->A: Loss of N-methyltransferase activity.,MUTAGEN:R->K: Has no effect on N-methyltransferase activity.,MUTAGEN:R->K: Loss of N-methyltransferase activity like its citrullinated counterpart.,MUTAGEN:S->A: Has no effect on N-methyltransferase activity.,MUTAGEN:Y->A: Loss of N-methyltransferase activity.,MUTAGEN:Y->F: Decreases N-methyltransferase activity.,
NAMPT	nicotinamide phosphoribosyltransferase(NAMPT)	Homo sapiens	GO:0001774~microglial cell activation,GO:0007165~signal transduction,GO:0007267~cell-cell signaling,GO:0007565~female pregnancy,GO:0007568~aging,GO:0008284~positive regulation of cell proliferation,GO:0009435~NAD biosynthetic process,GO:0010507~negative regulation of autophagy,GO:0014070~response to organic cyclic compound,GO:0014916~regulation of lung blood pressure,GO:0032922~circadian regulation of gene expression,GO:0034356~NAD biosynthesis via nicotinamide riboside salvage pathway,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051770~positive regulation of nitric-oxide synthase biosynthetic process,GO:0070997~neuron death,GO:0071479~cellular response to ionizing radiation,GO:0090650~cellular response to oxygen-glucose deprivation,GO:1904646~cellular response to beta-amyloid,GO:1905377~response to D-galactose,GO:2000773~negative regulation of cellular senescence,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016607~nuclear speck,GO:0030054~cell junction,GO:0070062~extracellular exosome,	GO:0000166~nucleotide binding,GO:0004514~nicotinate-nucleotide diphosphorylase (carboxylating) activity,GO:0005125~cytokine activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0047280~nicotinamide phosphoribosyltransferase activity,	IPR013785:Aldolase-type TIM barrel,IPR016471:Nicotinamide phosphoribosyl transferase,	hsa00760:Nicotinate and nicotinamide metabolism,hsa01100:Metabolic pathways,hsa04621:NOD-like receptor signaling pathway,		PIRSF005943:nicotinamide phosphoribosyl transferase,		KW-0090~Biological rhythms,KW-0662~Pyridine nucleotide biosynthesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0964~Secreted,				KW-0202~Cytokine,KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:NAMPT_N,DOMAIN:NAPRTase,MUTAGEN:D->N,S: No effect on activity towards nicotinamide. Alters specificity, so that the enzyme acquires activity towards nicotinic acid.,MUTAGEN:H->A: Reduces activity towards nicotinamide.,MUTAGEN:R->D: Reduces activity towards nicotinamide.,
NID2	nidogen 2(NID2)	Homo sapiens	GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0071711~basement membrane organization,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005518~collagen binding,	IPR000033:LDLR class B repeat,IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000716:Thyroglobulin type-1,IPR000742:Epidermal growth factor-like domain,IPR001881:EGF-like calcium-binding,IPR003886:Nidogen, extracellular domain,IPR006605:G2 nidogen/fibulin G2F,IPR009017:Green fluorescent protein,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011042:Six-bladed beta-propeller, TolB-like,IPR018097:EGF-like calcium-binding, conserved site,IPR024731:EGF domain, merozoite surface protein 1-like,IPR026823:Complement Clr-like EGF domain,				SM00135:LY,SM00179:EGF_CA,SM00181:EGF,SM00211:TY,SM00539:NIDO,SM00682:G2F,	KW-0130~Cell adhesion,	KW-0084~Basement membrane,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0488~Methylation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:NIDO,DOMAIN:Nidogen G2 beta-barrel,DOMAIN:Thyroglobulin type-1,DOMAIN:Thyroglobulin type-1 1,DOMAIN:Thyroglobulin type-1 2,REGION:Disordered,REPEAT:LDL-receptor class B,REPEAT:LDL-receptor class B 1,REPEAT:LDL-receptor class B 2,REPEAT:LDL-receptor class B 3,REPEAT:LDL-receptor class B 4,REPEAT:LDL-receptor class B 5,
NOG	noggin(NOG)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001706~endoderm formation,GO:0001707~mesoderm formation,GO:0001837~epithelial to mesenchymal transition,GO:0001839~neural plate morphogenesis,GO:0001843~neural tube closure,GO:0003149~membranous septum morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0003223~ventricular compact myocardium morphogenesis,GO:0007224~smoothened signaling pathway,GO:0007399~nervous system development,GO:0008045~motor neuron axon guidance,GO:0008542~visual learning,GO:0009953~dorsal/ventral pattern formation,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0021510~spinal cord development,GO:0021533~cell differentiation in hindbrain,GO:0021983~pituitary gland development,GO:0030336~negative regulation of cell migration,GO:0030514~negative regulation of BMP signaling pathway,GO:0035019~somatic stem cell population maintenance,GO:0035640~exploration behavior,GO:0042060~wound healing,GO:0042474~middle ear morphogenesis,GO:0042733~embryonic digit morphogenesis,GO:0045668~negative regulation of osteoblast differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048168~regulation of neuronal synaptic plasticity,GO:0048318~axial mesoderm development,GO:0048570~notochord morphogenesis,GO:0048706~embryonic skeletal system development,GO:0048712~negative regulation of astrocyte differentiation,GO:0048863~stem cell differentiation,GO:0050673~epithelial cell proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051216~cartilage development,GO:0055009~atrial cardiac muscle tissue morphogenesis,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:0060173~limb development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060291~long-term synaptic potentiation,GO:0060302~negative regulation of cytokine activity,GO:0060325~face morphogenesis,GO:0060394~negative regulation of pathway-restricted SMAD protein phosphorylation,GO:0060412~ventricular septum morphogenesis,GO:0060425~lung morphogenesis,GO:0060513~prostatic bud formation,GO:0060676~ureteric bud formation,GO:0060825~fibroblast growth factor receptor signaling pathway involved in neural plate anterior/posterior pattern formation,GO:0061037~negative regulation of cartilage development,GO:0061053~somite development,GO:0061312~BMP signaling pathway involved in heart development,GO:0061384~heart trabecula morphogenesis,GO:0061626~pharyngeal arch artery morphogenesis,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0090193~positive regulation of glomerulus development,GO:1904888~cranial skeletal system development,GO:1905006~negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,GO:1990926~short-term synaptic potentiation,GO:2000313~regulation of fibroblast growth factor receptor signaling pathway involved in neural plate anterior/posterior pattern formation,GO:2001234~negative regulation of apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0098793~presynapse,	GO:0005515~protein binding,GO:0019955~cytokine binding,GO:0042803~protein homodimerization activity,	IPR008717:Noggin,	hsa04350:TGF-beta signaling pathway,	184460~Stapes ankylosis with broad thumbs and toes,185800~Symphalangism, proximal, 1A,186500~Multiple synostoses syndrome 1,186570~Tarsal-carpal coalition syndrome,611377~Brachydactyly, type B2,	PIRSF008129:noggin,		KW-0221~Differentiation,KW-0891~Chondrogenesis,	KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,	KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,
NCAPG	non-SMC condensin I complex subunit G(NCAPG)	Homo sapiens	GO:0007076~mitotic chromosome condensation,GO:0051301~cell division,GO:0051984~positive regulation of chromosome segregation,GO:1905820~positive regulation of chromosome separation,GO:1905821~positive regulation of chromosome condensation,	GO:0000779~condensed chromosome, centromeric region,GO:0000793~condensed chromosome,GO:0000794~condensed nuclear chromosome,GO:0000796~condensin complex,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016020~membrane,	GO:0005515~protein binding,	IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR025977:Nuclear condensin complex subunit 3, C-terminal domain,IPR027165:Condensin complex subunit 3,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cnd3,REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 10,REPEAT:HEAT 2,REPEAT:HEAT 3,REPEAT:HEAT 4,REPEAT:HEAT 5,REPEAT:HEAT 6,REPEAT:HEAT 7,REPEAT:HEAT 8,REPEAT:HEAT 9,
NOTCH4	notch receptor 4(NOTCH4)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001709~cell fate determination,GO:0001763~morphogenesis of a branching structure,GO:0001837~epithelial to mesenchymal transition,GO:0001886~endothelial cell morphogenesis,GO:0001944~vasculature development,GO:0006355~regulation of transcription, DNA-templated,GO:0007219~Notch signaling pathway,GO:0007221~positive regulation of transcription of Notch receptor target,GO:0030097~hemopoiesis,GO:0030154~cell differentiation,GO:0030879~mammary gland development,GO:0042060~wound healing,GO:0045596~negative regulation of cell differentiation,GO:0045602~negative regulation of endothelial cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0050793~regulation of developmental process,GO:0060354~negative regulation of cell adhesion molecule production,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,	GO:0005112~Notch binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR000800:Notch domain,IPR001881:EGF-like calcium-binding,IPR002110:Ankyrin repeat,IPR008297:Notch,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR010660:Notch, NOD domain,IPR011656:Notch, NODP domain,IPR013032:EGF-like, conserved site,IPR018097:EGF-like calcium-binding, conserved site,IPR020683:Ankyrin repeat-containing domain,IPR022355:Neurogenic locus Notch 4,	hsa01522:Endocrine resistance,hsa04330:Notch signaling pathway,hsa04919:Thyroid hormone signaling pathway,hsa05165:Human papillomavirus infection,hsa05200:Pathways in cancer,hsa05206:MicroRNAs in cancer,hsa05224:Breast cancer,		PIRSF002279:notch protein,	SM00004:NL,SM00179:EGF_CA,SM00181:EGF,SM00248:ANK,SM01338:SM01338,SM01339:SM01339,	KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0914~Notch signaling pathway,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0010~Activator,KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11; calcium-binding,DOMAIN:EGF-like 12; calcium-binding,DOMAIN:EGF-like 13; calcium-binding,DOMAIN:EGF-like 14; calcium-binding,DOMAIN:EGF-like 15; calcium-binding,DOMAIN:EGF-like 16,DOMAIN:EGF-like 17,DOMAIN:EGF-like 18,DOMAIN:EGF-like 19,DOMAIN:EGF-like 2,DOMAIN:EGF-like 20,DOMAIN:EGF-like 21,DOMAIN:EGF-like 22,DOMAIN:EGF-like 23,DOMAIN:EGF-like 24,DOMAIN:EGF-like 25,DOMAIN:EGF-like 26,DOMAIN:EGF-like 27,DOMAIN:EGF-like 28,DOMAIN:EGF-like 29,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5; calcium-binding,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7; calcium-binding,DOMAIN:EGF-like 8; calcium-binding,DOMAIN:EGF-like 9; calcium-binding,DOMAIN:LNR,REGION:Disordered,REPEAT:ANK,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,REPEAT:LNR 1,REPEAT:LNR 2,REPEAT:LNR 3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
NOD1	nucleotide binding oligomerization domain containing 1(NOD1)	Homo sapiens	GO:0002221~pattern recognition receptor signaling pathway,GO:0002376~immune system process,GO:0002606~positive regulation of dendritic cell antigen processing and presentation,GO:0006915~apoptotic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006952~defense response,GO:0006954~inflammatory response,GO:0007165~signal transduction,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0007254~JNK cascade,GO:0009595~detection of biotic stimulus,GO:0010942~positive regulation of cell death,GO:0016045~detection of bacterium,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0035556~intracellular signal transduction,GO:0042742~defense response to bacterium,GO:0042981~regulation of apoptotic process,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043280~positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0045087~innate immune response,GO:0046330~positive regulation of JNK cascade,GO:0050830~defense response to Gram-positive bacterium,GO:0051000~positive regulation of nitric-oxide synthase activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0060907~positive regulation of macrophage cytokine production,GO:0070371~ERK1 and ERK2 cascade,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071225~cellular response to muramyl dipeptide,GO:0098792~xenophagy,GO:1901224~positive regulation of NIK/NF-kappaB signaling,GO:1904417~positive regulation of xenophagy,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0045335~phagocytic vesicle,GO:0046658~anchored component of plasma membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008656~cysteine-type endopeptidase activator activity involved in apoptotic process,GO:0038187~pattern recognition receptor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0042834~peptidoglycan binding,GO:0044877~macromolecular complex binding,GO:0050700~CARD domain binding,	IPR001315:Caspase Recruitment,IPR001611:Leucine-rich repeat,IPR007111:NACHT nucleoside triphosphatase,IPR011029:Death-like domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04621:NOD-like receptor signaling pathway,hsa05120:Epithelial cell signaling in Helicobacter pylori infection,hsa05131:Shigellosis,hsa05132:Salmonella infection,hsa05133:Pertussis,				KW-0053~Apoptosis,KW-0391~Immunity,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0832~Ubl conjugation,	DOMAIN:CARD,DOMAIN:NACHT,MUTAGEN:D->A: Reduced binding affinity for NLRP10.,MUTAGEN:D->K: Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.,MUTAGEN:D->K: Abolishes activation of NF-kappa-B. No effect on interaction with RIPK2.,MUTAGEN:D->S: Does not associate with cell membrane.,MUTAGEN:E->K: Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.,MUTAGEN:E->K: No effect on activation of NF-kappa-B. Abolishes interaction with RIPK2.,MUTAGEN:G->S: Does not associate with cell membrane.,MUTAGEN:H->A: Loss of activation by sphingosine-1-phosphate.,MUTAGEN:H->S: No effect on association with cell membrane.,MUTAGEN:K->R: Reduces caspase-9 activation. Reduced binding affinity for NLRP10. Does not associate with cell membrane.,MUTAGEN:L->A: Abolishes activation of NF-kappa-B. No effect on interaction with RIPK2.,MUTAGEN:Q->S: Does not associate with cell membrane.,MUTAGEN:R->E: Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.,MUTAGEN:V->A: Abolishes interaction with RIPK2/RICK.,MUTAGEN:V->Q: Abolishes caspase-9 activation.,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
OSR2	odd-skipped related transciption factor 2(OSR2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001655~urogenital system development,GO:0001656~metanephros development,GO:0001823~mesonephros development,GO:0002062~chondrocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0008284~positive regulation of cell proliferation,GO:0009790~embryo development,GO:0009792~embryo development ending in birth or egg hatching,GO:0010628~positive regulation of gene expression,GO:0030154~cell differentiation,GO:0030501~positive regulation of bone mineralization,GO:0033687~osteoblast proliferation,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0036023~embryonic skeletal limb joint morphogenesis,GO:0042474~middle ear morphogenesis,GO:0042476~odontogenesis,GO:0042733~embryonic digit morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048704~embryonic skeletal system morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0060021~palate development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060322~head development,GO:0060349~bone morphogenesis,GO:0061029~eyelid development in camera-type eye,GO:0072089~stem cell proliferation,GO:0072498~embryonic skeletal joint development,GO:2000648~positive regulation of stem cell proliferation,	GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,		KW-0539~Nucleus,		KW-0677~Repeat,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5; degenerate,
OSR1	odd-skipped related transcription factor 1(OSR1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001655~urogenital system development,GO:0001657~ureteric bud development,GO:0001823~mesonephros development,GO:0002062~chondrocyte differentiation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007507~heart development,GO:0008406~gonad development,GO:0009790~embryo development,GO:0010628~positive regulation of gene expression,GO:0030154~cell differentiation,GO:0030501~positive regulation of bone mineralization,GO:0030857~negative regulation of epithelial cell differentiation,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035725~sodium ion transmembrane transport,GO:0036023~embryonic skeletal limb joint morphogenesis,GO:0042474~middle ear morphogenesis,GO:0042476~odontogenesis,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048389~intermediate mesoderm development,GO:0048793~pronephros development,GO:0048863~stem cell differentiation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0060021~palate development,GO:0060272~embryonic skeletal joint morphogenesis,GO:0071300~cellular response to retinoic acid,GO:0072075~metanephric mesenchyme development,GO:0072111~cell proliferation involved in kidney development,GO:0072133~metanephric mesenchyme morphogenesis,GO:0072143~mesangial cell development,GO:0072162~metanephric mesenchymal cell differentiation,GO:0072166~posterior mesonephric tubule development,GO:0072168~specification of anterior mesonephric tubule identity,GO:0072169~specification of posterior mesonephric tubule identity,GO:0072180~mesonephric duct morphogenesis,GO:0072183~negative regulation of nephron tubule epithelial cell differentiation,GO:0072184~renal vesicle progenitor cell differentiation,GO:0072190~ureter urothelium development,GO:0072207~metanephric epithelium development,GO:0072208~metanephric smooth muscle tissue development,GO:0072234~metanephric nephron tubule development,GO:0072239~metanephric glomerulus vasculature development,GO:0072259~metanephric interstitial fibroblast development,GO:0072268~pattern specification involved in metanephros development,GO:0072498~embryonic skeletal joint development,GO:0090094~metanephric cap mesenchymal cell proliferation involved in metanephros development,GO:1905408~negative regulation of creatine transmembrane transporter activity,GO:2000543~positive regulation of gastrulation,GO:2000650~negative regulation of sodium ion transmembrane transporter activity,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005829~cytosol,GO:0019898~extrinsic component of membrane,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0488~Methylation,	ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,
OLFM1	olfactomedin 1(OLFM1)	Homo sapiens	GO:0003190~atrioventricular valve formation,GO:0007165~signal transduction,GO:0007399~nervous system development,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0023041~neuronal signal transduction,GO:0030516~regulation of axon extension,GO:0043065~positive regulation of apoptotic process,GO:0060317~cardiac epithelial to mesenchymal transition,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0044295~axonal growth cone,GO:0045202~synapse,	GO:0005515~protein binding,	IPR003112:Olfactomedin-like,IPR011044:Quinoprotein amine dehydrogenase, beta chain-like,IPR022082:Neurogenesis glycoprotein,				SM00284:OLF,		KW-0256~Endoplasmic reticulum,KW-0770~Synapse,KW-0964~Secreted,KW-0966~Cell projection,		KW-0175~Coiled coil,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Noelin-1,DOMAIN:Olfactomedin-like,REGION:Disordered,
OLFM4	olfactomedin 4(OLFM4)	Homo sapiens	GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:1900026~positive regulation of substrate adhesion-dependent cell spreading,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0032991~macromolecular complex,GO:0035580~specific granule lumen,GO:0042581~specific granule,GO:0045171~intercellular bridge,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0003824~catalytic activity,GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR003112:Olfactomedin-like,IPR011041:Soluble quinoprotein glucose/sorbosone dehydrogenase,				SM00284:OLF,	KW-0130~Cell adhesion,	KW-0496~Mitochondrion,KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Olfactomedin-like,MUTAGEN:C->A: Abolishes secretion. No effect on multimer formation.,MUTAGEN:C->A: No effect on secretion. Affects multimer formation.,
OLFML2B	olfactomedin like 2B(OLFML2B)	Homo sapiens	GO:0007165~signal transduction,GO:0030198~extracellular matrix organization,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0042802~identical protein binding,GO:0050840~extracellular matrix binding,	IPR003112:Olfactomedin-like,				SM00284:OLF,		KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Olfactomedin-like,REGION:Disordered,
OMP	olfactory marker protein(OMP)	Homo sapiens	GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0007608~sensory perception of smell,GO:0022008~neurogenesis,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0042277~peptide binding,	IPR009103:Olfactory marker protein,					KW-0552~Olfaction,KW-0716~Sensory transduction,	KW-0963~Cytoplasm,					KW-0007~Acetylation,
OR2AE1	olfactory receptor family 2 subfamily AE member 1(OR2AE1)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0050911~detection of chemical stimulus involved in sensory perception of smell,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004984~olfactory receptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000725:Olfactory receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04740:Olfactory transduction,				KW-0552~Olfaction,KW-0716~Sensory transduction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
OR51E1	olfactory receptor family 51 subfamily E member 1(OR51E1)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0050911~detection of chemical stimulus involved in sensory perception of smell,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0004984~olfactory receptor activity,GO:0005515~protein binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR000725:Olfactory receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04740:Olfactory transduction,				KW-0552~Olfaction,KW-0716~Sensory transduction,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
OSMR	oncostatin M receptor(OSMR)	Homo sapiens	GO:0002675~positive regulation of acute inflammatory response,GO:0008284~positive regulation of cell proliferation,GO:0019221~cytokine-mediated signaling pathway,GO:0034097~response to cytokine,GO:0038165~oncostatin-M-mediated signaling pathway,GO:0048861~leukemia inhibitory factor signaling pathway,	GO:0005886~plasma membrane,GO:0005900~oncostatin-M receptor complex,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0043235~receptor complex,	GO:0004896~cytokine receptor activity,GO:0004923~leukemia inhibitory factor receptor activity,GO:0004924~oncostatin-M receptor activity,GO:0005127~ciliary neurotrophic factor receptor binding,GO:0005515~protein binding,GO:0019838~growth factor binding,GO:0019955~cytokine binding,	IPR003529:Long hematopoietin receptor, Gp130 family 2, conserved site,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,	hsa04060:Cytokine-cytokine receptor interaction,hsa04151:PI3K-Akt signaling pathway,hsa04630:JAK-STAT signaling pathway,	105250~Amyloidosis, primary localized cutaneous, 1,		SM00060:FN3,		KW-0472~Membrane,	KW-0225~Disease variant,KW-1008~Amyloidosis,	KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,MOTIF:Box 1 motif,MOTIF:WSXWS motif,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
OTX1	orthodenticle homeobox 1(OTX1)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0009952~anterior/posterior pattern specification,GO:0022037~metencephalon development,GO:0030901~midbrain development,GO:0042472~inner ear morphogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048852~diencephalon morphogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003025:Transcription factor Otx,IPR003026:Transcription factor Otx1,IPR009057:Homeodomain-like,IPR013851:Transcription factor Otx, C-terminal,IPR017970:Homeobox, conserved site,	hsa04550:Signaling pathways regulating pluripotency of stem cells,			SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:TF_Otx,REGION:Disordered,
OTP	orthopedia homeobox(OTP)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0002052~positive regulation of neuroblast proliferation,GO:0007405~neuroblast proliferation,GO:0021879~forebrain neuron differentiation,GO:0021979~hypothalamus cell differentiation,GO:0021985~neurohypophysis development,GO:0030182~neuron differentiation,GO:0061101~neuroendocrine cell differentiation,GO:0071542~dopaminergic neuron differentiation,	GO:0000785~chromatin,GO:0001650~fibrillar center,GO:0005654~nucleoplasm,GO:0016604~nuclear body,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003677~DNA binding,GO:0005515~protein binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,	KW-0221~Differentiation,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DNA_BIND:Homeobox,MOTIF:OAR,REGION:Disordered,
OSCAR	osteoclast associated Ig-like receptor(OSCAR)	Homo sapiens	GO:0030316~osteoclast differentiation,GO:0038065~collagen-activated signaling pathway,GO:0038094~Fc-gamma receptor signaling pathway,GO:0045780~positive regulation of bone resorption,GO:0072674~multinuclear osteoclast differentiation,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0035580~specific granule lumen,GO:0070062~extracellular exosome,GO:1904724~tertiary granule lumen,	GO:0038064~collagen receptor activity,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013783:Immunoglobulin-like fold,	hsa04380:Osteoclast differentiation,			SM00409:IG,		KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IG,DOMAIN:Ig-like,DOMAIN:Ig-like 1,DOMAIN:Ig-like 2,REGION:Disordered,
OTOS	otospiralin(OTOS)	Homo sapiens	GO:0007605~sensory perception of sound,	GO:0005576~extracellular region,	GO:0005515~protein binding,							KW-0964~Secreted,		KW-0732~Signal,
ODF3B	outer dense fiber of sperm tails 3B(ODF3B)	Homo sapiens		GO:0005856~cytoskeleton,	GO:0005515~protein binding,	IPR010736:Sperm-tail PG-rich repeat,												COMPBIAS:Polar residues,REGION:Disordered,REPEAT:STPGR,
PAX3	paired box 3(PAX3)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0007399~nervous system development,GO:0007517~muscle organ development,GO:0007605~sensory perception of sound,GO:0009887~animal organ morphogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048856~anatomical structure development,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0071837~HMG box domain binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR001523:Paired domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,IPR022106:Paired box protein 7,	hsa05202:Transcriptional misregulation in cancer,	122880~Craniofacial-deafness-hand syndrome,148820~Waardenburg syndrome, type 3,193500~Waardenburg syndrome, type 1,268220~Rhabdomyosarcoma 2, alveolar,		SM00351:PAX,SM00389:HOX,	KW-0517~Myogenesis,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0209~Deafness,KW-0225~Disease variant,KW-0656~Proto-oncogene,KW-0897~Waardenburg syndrome,	KW-0371~Homeobox,KW-0563~Paired box,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DNA_BIND:Paired,DOMAIN:Homeobox,REGION:Disordered,REGION:PAI subdomain,REGION:RED subdomain,SITE:Breakpoint for translocation to form PAX3-NCOA1 oncogene,
PRRX2	paired related homeobox 2(PRRX2)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:OAR,MOTIF:OAR,REGION:Disordered,
PPT2	palmitoyl-protein thioesterase 2(PPT2)	Homo sapiens	GO:0046949~fatty-acyl-CoA biosynthetic process,GO:0098734~macromolecule depalmitoylation,	GO:0005764~lysosome,GO:0016021~integral component of membrane,GO:0043202~lysosomal lumen,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0008474~palmitoyl-(protein) hydrolase activity,GO:0016790~thiolester hydrolase activity,GO:0098599~palmitoyl hydrolase activity,	IPR002472:Palmitoyl protein thioesterase,	hsa00062:Fatty acid elongation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa04142:Lysosome,					KW-0458~Lysosome,KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Nucleophile,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,MUTAGEN:D->A: Abolishes enzymatic activity.,MUTAGEN:H->A: Abolishes enzymatic activity.,MUTAGEN:H->A: No effect on enzymatic activity.,MUTAGEN:S->A: Abolishes enzymatic activity.,REGION:Disordered,TRANSMEM:Helical,
PANX2	pannexin 2(PANX2)	Homo sapiens	GO:0002931~response to ischemia,GO:0006812~cation transport,GO:0007267~cell-cell signaling,GO:0032732~positive regulation of interleukin-1 production,GO:0055085~transmembrane transport,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005921~gap junction,GO:0016021~integral component of membrane,	GO:0005198~structural molecule activity,GO:0015267~channel activity,GO:0022829~wide pore channel activity,	IPR000990:Innexin,					KW-0406~Ion transport,KW-0813~Transport,	KW-0303~Gap junction,KW-0472~Membrane,KW-0965~Cell junction,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PVALB	parvalbumin(PVALB)	Homo sapiens	GO:0010467~gene expression,GO:0090102~cochlea development,GO:0098976~excitatory chemical synaptic transmission,GO:0098977~inhibitory chemical synaptic transmission,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030424~axon,GO:0032420~stereocilium,GO:0032437~cuticular plate,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0045202~synapse,	GO:0005509~calcium ion binding,GO:0042802~identical protein binding,GO:0044877~macromolecular complex binding,	IPR002048:EF-hand domain,IPR008080:Parvalbumin,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,				KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:EF-hand,DOMAIN:EF-hand 1,DOMAIN:EF-hand 2,MUTAGEN:D->A: Inactivation.,MUTAGEN:E->V: Inactivation.,
PTX3	pentraxin 3(PTX3)	Homo sapiens	GO:0001550~ovarian cumulus expansion,GO:0001878~response to yeast,GO:0006954~inflammatory response,GO:0008228~opsonization,GO:0030198~extracellular matrix organization,GO:0044793~negative regulation by host of viral process,GO:0044869~negative regulation by host of viral exo-alpha-sialidase activity,GO:0044871~negative regulation by host of viral glycoprotein metabolic process,GO:0045087~innate immune response,GO:0045429~positive regulation of nitric oxide biosynthetic process,GO:0046597~negative regulation of viral entry into host cell,GO:0050766~positive regulation of phagocytosis,GO:1903016~negative regulation of exo-alpha-sialidase activity,GO:1903019~negative regulation of glycoprotein metabolic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0035580~specific granule lumen,GO:1904724~tertiary granule lumen,	GO:0001849~complement component C1q binding,GO:0001872~(1->3)-beta-D-glucan binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046790~virion binding,	IPR001759:Pentaxin,IPR006558:LamG-like jellyroll fold,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,				SM00159:PTX,SM00560:LamGL,		KW-0964~Secreted,		KW-0175~Coiled coil,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:Pentraxin (PTX),
PI3	peptidase inhibitor 3(PI3)	Homo sapiens	GO:0007620~copulation,GO:0010951~negative regulation of endopeptidase activity,GO:0018149~peptide cross-linking,GO:0019731~antibacterial humoral response,GO:0045087~innate immune response,	GO:0001533~cornified envelope,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005829~cytosol,GO:0031012~extracellular matrix,	GO:0004866~endopeptidase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0030280~structural constituent of epidermis,	IPR002098:Seminal vesicle protein I,IPR008197:Whey acidic protein-type  4-disulphide core,IPR019541:Trappin protein transglutaminase-binding repeat,				SM00217:WAP,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-1015~Disulfide bond,	DOMAIN:WAP,REGION:2 X tandem repeats of SVP-1 like motif,REPEAT:SVP-1 clotting 1,REPEAT:SVP-1 clotting 2,
PRF1	perforin 1(PRF1)	Homo sapiens	GO:0001771~immunological synapse formation,GO:0001913~T cell mediated cytotoxicity,GO:0002357~defense response to tumor cell,GO:0002418~immune response to tumor cell,GO:0006915~apoptotic process,GO:0006968~cellular defense response,GO:0019835~cytolysis,GO:0051260~protein homooligomerization,GO:0051607~defense response to virus,GO:0051712~positive regulation of killing of cells of other organism,GO:0055085~transmembrane transport,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031904~endosome lumen,GO:0044194~cytolytic granule,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0022829~wide pore channel activity,GO:0042802~identical protein binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR020863:Membrane attack complex component/perforin domain, conserved site,IPR020864:Membrane attack complex component/perforin (MACPF) domain,	hsa04210:Apoptosis,hsa04650:Natural killer cell mediated cytotoxicity,hsa04940:Type I diabetes mellitus,hsa05320:Autoimmune thyroid disease,hsa05330:Allograft rejection,hsa05332:Graft-versus-host disease,hsa05416:Viral myocarditis,	603553~Hemophagocytic lymphohistiocytosis, familial, 2,605027~Lymphoma, non-Hodgkin,609135~Aplastic anemia,		SM00239:C2,SM00457:MACPF,	KW-0204~Cytolysis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0951~Familial hemophagocytic lymphohistiocytosis,	KW-0245~EGF-like domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1134~Transmembrane beta strand,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C2,DOMAIN:EGF-like,DOMAIN:MACPF,SITE:Important for oligomerization,TRANSMEM:Beta stranded; Name=CH1,TRANSMEM:Beta stranded; Name=CH2,
PLIN1	perilipin 1(PLIN1)	Homo sapiens	GO:0006629~lipid metabolic process,GO:0016042~lipid catabolic process,GO:0070417~cellular response to cold,	GO:0005783~endoplasmic reticulum,GO:0005811~lipid particle,GO:0005829~cytosol,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008289~lipid binding,	IPR004279:Perilipin,	hsa03320:PPAR signaling pathway,hsa04371:Apelin signaling pathway,hsa04714:Thermogenesis,hsa04923:Regulation of lipolysis in adipocytes,	613877~Lipodystrophy, familial partial, type 4,	PIRSF036881:lipid droplet-associated protein, perilipin type,		KW-0443~Lipid metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0551~Lipid droplet,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,REGION:Disordered,REGION:Required for interaction with CIDEC,TRANSMEM:Helical,
POSTN	periostin(POSTN)	Homo sapiens	GO:0001666~response to hypoxia,GO:0001953~negative regulation of cell-matrix adhesion,GO:0003073~regulation of systemic arterial blood pressure,GO:0007155~cell adhesion,GO:0008593~regulation of Notch signaling pathway,GO:0009612~response to mechanical stimulus,GO:0009888~tissue development,GO:0014850~response to muscle activity,GO:0014911~positive regulation of smooth muscle cell migration,GO:0030198~extracellular matrix organization,GO:0032355~response to estradiol,GO:0042060~wound healing,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0071307~cellular response to vitamin K,GO:0071356~cellular response to tumor necrosis factor,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:1990138~neuron projection extension,GO:1990523~bone regeneration,GO:2000343~positive regulation of chemokine (C-X-C motif) ligand 2 production,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0031012~extracellular matrix,GO:0031594~neuromuscular junction,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0046872~metal ion binding,GO:0050839~cell adhesion molecule binding,	IPR000782:FAS1 domain,IPR011489:EMI domain,IPR016666:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,			PIRSF016553:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,	SM00554:FAS1,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0333~Golgi apparatus,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0301~Gamma-carboxyglutamic acid,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EMI,DOMAIN:FAS1,DOMAIN:FAS1 1,DOMAIN:FAS1 2,DOMAIN:FAS1 3,DOMAIN:FAS1 4,MUTAGEN:C->A: No effect on homodimerization.,MUTAGEN:RTA->NTS: Loss of homodimerization.,REGION:Disordered,
PXDN	peroxidasin(PXDN)	Homo sapiens	GO:0001525~angiogenesis,GO:0001654~eye development,GO:0001960~negative regulation of cytokine-mediated signaling pathway,GO:0006955~immune response,GO:0006979~response to oxidative stress,GO:0007155~cell adhesion,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0042744~hydrogen peroxide catabolic process,GO:0051260~protein homooligomerization,GO:0070207~protein homotrimerization,GO:0070831~basement membrane assembly,GO:0071711~basement membrane organization,GO:0098869~cellular oxidant detoxification,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0009986~cell surface,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0004601~peroxidase activity,GO:0005152~interleukin-1 receptor antagonist activity,GO:0005201~extracellular matrix structural constituent,GO:0016684~oxidoreductase activity, acting on peroxide as acceptor,GO:0019806~bromide peroxidase activity,GO:0020037~heme binding,GO:0043237~laminin-1 binding,GO:0046872~metal ion binding,	IPR000483:Cysteine-rich flanking region, C-terminal,IPR001007:von Willebrand factor, type C,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR010255:Haem peroxidase,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,IPR019791:Haem peroxidase, animal, subgroup,		269400~Anterior segment dysgenesis 7, with sclerocornea,		SM00082:LRRCT,SM00214:VWC,SM00369:LRR_TYP,SM00408:IGc2,SM00409:IG,	KW-0376~Hydrogen peroxide,	KW-0084~Basement membrane,KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0393~Immunoglobulin domain,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0349~Heme,KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,KW-0575~Peroxidase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,BINDING:axial binding residue,BINDING:covalent,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain (with C-1315); in homotrimer,DISULFID:Interchain (with C-736); in homotrimer,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:LRRCT,DOMAIN:LRRNT,DOMAIN:VWFC,MUTAGEN:C->S: Does not affect protein homooligomerization. Loss of protein homooligomerization; when associated with S-1315 and S-1316.,MUTAGEN:C->S: Does not affect protein homooligomerization. Loss of protein homooligomerization; when associated with S-1315 and S-1319.,MUTAGEN:C->S: Loss of protein homooligomerization. Loss of protein homooligomerization; when associated with S-1315. Does not affect peroxidase activity; when associated with S-1315. Retains the ability to support the collagen IV cross-links; when associated with S-1315. Slightly reduces proteolysis; when associated with S-1315.,MUTAGEN:C->S: Loss of protein homooligomerization. Loss of protein homooligomerization; when associated with S-1316 and S-1319. Loss of protein homooligomerization; when associated with S-736. Does not affect peroxydase activity; when associated with S-736. Affects cell surface location; when associated with S-736. Slightly reduces proteolysis; when associated with S-736.,MUTAGEN:D->E: Loss of peroxidase activity. Does not affect oligomerization. Loss of peroxidase activity; when associated with E-823. Does not support the formation of collagen IV cross-links; when associated with W-823. Reduces the proteolytic processing; when associated with W-823. Loss of collagen IV cross-link; when associated with W-823.,MUTAGEN:Q->A: Loss of bromide oxidation. Loss of tubulogenesis. Does not induce angiogenesis.,MUTAGEN:Q->W: Loss of peroxidase activity. Does not affect oligomerization. Loss of peroxidase activity; when associated with E-826. Does not support the formation of collagen IV cross-links; when associated with E-826. Reduces the proteolytic processing; when associated with E-826. Loss of collagen IV cross-link; when associated with E-826.,MUTAGEN:RK->AA: Does not affect the proteolytic processing.,MUTAGEN:RR->AA: Loss of proteolytic cleavage. Decreases the formation of sulfilimine cross-links in collagen IV. Reduces the proteolytic processing. Affects collagen IV cross-linking.,REGION:Disordered,REGION:Required in homotrimerization,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,SITE:Cleavage; by FURIN,SITE:Transition state stabilizer,
PDE1A	phosphodiesterase 1A(PDE1A)	Homo sapiens	GO:0007165~signal transduction,GO:0034391~regulation of smooth muscle cell apoptotic process,GO:0046069~cGMP catabolic process,GO:0048660~regulation of smooth muscle cell proliferation,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0043025~neuronal cell body,	GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004117~calmodulin-dependent cyclic-nucleotide phosphodiesterase activity,GO:0005516~calmodulin binding,GO:0046872~metal ion binding,GO:0048101~calcium- and calmodulin-regulated 3',5'-cyclic-GMP phosphodiesterase activity,	IPR002073:3'5'-cyclic nucleotide phosphodiesterase, catalytic domain,IPR003607:HD/PDEase domain,IPR013706:3'5'-cyclic nucleotide phosphodiesterase N-terminal,IPR023088:3'5'-cyclic nucleotide phosphodiesterase,IPR023174:3'5'-cyclic nucleotide phosphodiesterase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04020:Calcium signaling pathway,hsa04740:Olfactory transduction,hsa04742:Taste transduction,hsa04924:Renin secretion,hsa05032:Morphine addiction,			SM00471:HDc,					KW-0114~cAMP,KW-0140~cGMP,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0112~Calmodulin-binding,KW-0378~Hydrolase,		ACT_SITE:Proton donor,DOMAIN:PDEase,REGION:Calmodulin-binding,REGION:Disordered,
PDE2A	phosphodiesterase 2A(PDE2A)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0003170~heart valve development,GO:0003281~ventricular septum development,GO:0007165~signal transduction,GO:0007193~adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010752~regulation of cGMP-mediated signaling,GO:0010754~negative regulation of cGMP-mediated signaling,GO:0010821~regulation of mitochondrion organization,GO:0019933~cAMP-mediated signaling,GO:0019934~cGMP-mediated signaling,GO:0030224~monocyte differentiation,GO:0035690~cellular response to drug,GO:0035904~aorta development,GO:0036006~cellular response to macrophage colony-stimulating factor stimulus,GO:0043116~negative regulation of vascular permeability,GO:0043117~positive regulation of vascular permeability,GO:0043949~regulation of cAMP-mediated signaling,GO:0043951~negative regulation of cAMP-mediated signaling,GO:0046069~cGMP catabolic process,GO:0050729~positive regulation of inflammatory response,GO:0061028~establishment of endothelial barrier,GO:0071260~cellular response to mechanical stimulus,GO:0071320~cellular response to cAMP,GO:0071321~cellular response to cGMP,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:0097011~cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:1904613~cellular response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005759~mitochondrial matrix,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0042734~presynaptic membrane,GO:0048471~perinuclear region of cytoplasm,GO:0097060~synaptic membrane,	GO:0000287~magnesium ion binding,GO:0004114~3',5'-cyclic-nucleotide phosphodiesterase activity,GO:0004115~3',5'-cyclic-AMP phosphodiesterase activity,GO:0004118~cGMP-stimulated cyclic-nucleotide phosphodiesterase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0030552~cAMP binding,GO:0030553~cGMP binding,GO:0030911~TPR domain binding,GO:0042301~phosphate ion binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0047555~3',5'-cyclic-GMP phosphodiesterase activity,	IPR002073:3'5'-cyclic nucleotide phosphodiesterase, catalytic domain,IPR003018:GAF domain,IPR003607:HD/PDEase domain,IPR023088:3'5'-cyclic nucleotide phosphodiesterase,IPR023174:3'5'-cyclic nucleotide phosphodiesterase, conserved site,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04022:cGMP-PKG signaling pathway,hsa04740:Olfactory transduction,hsa04925:Aldosterone synthesis and secretion,hsa05032:Morphine addiction,	619150~Intellectual developmental disorder with paroxysmal dyskinesia or seizures,		SM00065:GAF,SM00471:HDc,		KW-0472~Membrane,KW-0496~Mitochondrion,KW-0963~Cytoplasm,KW-0999~Mitochondrion inner membrane,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0732~Signal,	KW-0114~cAMP,KW-0140~cGMP,KW-0142~cGMP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0378~Hydrolase,	KW-0449~Lipoprotein,KW-0519~Myristate,KW-0564~Palmitate,	ACT_SITE:Proton donor,COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:GAF,DOMAIN:GAF 1,DOMAIN:GAF 2,DOMAIN:PDEase,LIPID:N-myristoyl glycine,LIPID:S-palmitoyl cysteine,MUTAGEN:D->A: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. No effect on 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:I->V: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Increased 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:L->A: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:L->M: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Decreased 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:L->S: Loss of 3',5'-cyclic-AMP phosphodiesterase activity. Decreased 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:M->L: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:Q->I: No effect on 3',5'-cyclic-AMP phosphodiesterase activity. Decreased 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:Q->P: Loss of 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:T->Y: Loss of 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:Y->A: Decreased 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:Y->F: Loss of 3',5'-cyclic-AMP phosphodiesterase activity. Decreased 3',5'-cyclic-GMP phosphodiesterase activity.,MUTAGEN:Y->V,M: Loss of 3',5'-cyclic-AMP phosphodiesterase activity. Loss of 3',5'-cyclic-GMP phosphodiesterase activity.,REGION:Disordered,
PDE6G	phosphodiesterase 6G(PDE6G)	Homo sapiens	GO:0000187~activation of MAPK activity,GO:0007601~visual perception,GO:0043086~negative regulation of catalytic activity,GO:0043410~positive regulation of MAPK cascade,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0045745~positive regulation of G-protein coupled receptor protein signaling pathway,GO:0050896~response to stimulus,	GO:0005886~plasma membrane,GO:0042622~photoreceptor outer segment membrane,GO:0097381~photoreceptor disc membrane,	GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0030507~spectrin binding,GO:0030553~cGMP binding,GO:0047555~3',5'-cyclic-GMP phosphodiesterase activity,	IPR006952:Retinal cGMP phosphodiesterase, gamma subunit,	hsa00230:Purine metabolism,hsa01100:Metabolic pathways,hsa04744:Phototransduction,	613582~Retinitis pigmentosa 57,	PIRSF000969:3',5'-cyclic-GMP phosphodiesterase, gamma subunit,		KW-0716~Sensory transduction,KW-0844~Vision,		KW-0682~Retinitis pigmentosa,		KW-0140~cGMP,	KW-0378~Hydrolase,	KW-0007~Acetylation,	REGION:Disordered,
PGAM2	phosphoglycerate mutase 2(PGAM2)	Homo sapiens	GO:0006094~gluconeogenesis,GO:0006096~glycolytic process,GO:0006941~striated muscle contraction,GO:0007219~Notch signaling pathway,GO:0007283~spermatogenesis,GO:0046689~response to mercury ion,GO:0061621~canonical glycolysis,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0070062~extracellular exosome,	GO:0004082~bisphosphoglycerate mutase activity,GO:0004619~phosphoglycerate mutase activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0042802~identical protein binding,GO:0046538~2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity,	IPR001345:Phosphoglycerate/bisphosphoglycerate mutase, active site,IPR005952:Phosphoglycerate mutase 1,IPR013078:Histidine phosphatase superfamily, clade-1,	hsa00010:Glycolysis / Gluconeogenesis,hsa00260:Glycine, serine and threonine metabolism,hsa01100:Metabolic pathways,hsa01200:Carbon metabolism,hsa01230:Biosynthesis of amino acids,hsa04922:Glucagon signaling pathway,hsa05230:Central carbon metabolism in cancer,	261670~Glycogen storage disease X,		SM00855:SM00855,	KW-0324~Glycolysis,		KW-0225~Disease variant,KW-0322~Glycogen storage disease,			KW-0378~Hydrolase,KW-0413~Isomerase,	KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,ACT_SITE:Tele-phosphohistidine intermediate,SITE:Transition state stabilizer,
PLA2G2A	phospholipase A2 group IIA(PLA2G2A)	Homo sapiens	GO:0006644~phospholipid metabolic process,GO:0006954~inflammatory response,GO:0010744~positive regulation of macrophage derived foam cell differentiation,GO:0016042~lipid catabolic process,GO:0019835~cytolysis,GO:0034374~low-density lipoprotein particle remodeling,GO:0036335~intestinal stem cell homeostasis,GO:0046337~phosphatidylethanolamine metabolic process,GO:0046470~phosphatidylcholine metabolic process,GO:0046473~phosphatidic acid metabolic process,GO:0050482~arachidonic acid secretion,GO:0050729~positive regulation of inflammatory response,GO:0050830~defense response to Gram-positive bacterium,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:1902563~regulation of neutrophil activation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0030141~secretory granule,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004623~phospholipase A2 activity,GO:0005509~calcium ion binding,GO:0005543~phospholipid binding,GO:0047498~calcium-dependent phospholipase A2 activity,	IPR001211:Phospholipase A2,IPR016090:Phospholipase A2 domain,	hsa00564:Glycerophospholipid metabolism,hsa00565:Ether lipid metabolism,hsa00590:Arachidonic acid metabolism,hsa00591:Linoleic acid metabolism,hsa00592:alpha-Linolenic acid metabolism,hsa01100:Metabolic pathways,hsa04014:Ras signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04972:Pancreatic secretion,hsa04975:Fat digestion and absorption,	114500~Colorectal cancer, susceptibility to,		SM00085:PA2c,	KW-0395~Inflammatory response,KW-0443~Lipid metabolism,KW-1208~Phospholipid metabolism,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0964~Secreted,KW-1000~Mitochondrion outer membrane,KW-1003~Cell membrane,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0081~Bacteriolytic enzyme,KW-0378~Hydrolase,KW-0929~Antimicrobial,	KW-1015~Disulfide bond,	DOMAIN:PA2c,MUTAGEN:D->K: No effect on integrin binding; when associated with S-49.,MUTAGEN:G->S: No effect on integrin binding; when associated with K-68.,MUTAGEN:H->Q: Catalytically inactive but does not affect integrin binding. Impairs leukotriene B4 synthesis in activated neutrophils.,MUTAGEN:K->E: Complete loss of bactericidal activity; when associated with E-27 and E-30.,MUTAGEN:K->E: Complete loss of bactericidal activity; when associated with E-27 and E-35.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with D-138.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with E-122.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with E-127.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with E-128.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with E-57.,MUTAGEN:K->E: Impairs bactericidal activity; when associated with E-73 and E-77.,MUTAGEN:K->E: Reduces bactericidal activity to 20% against B.subtilis and to 10% against S.aureus. Complete loss of bactericidal activity; when associated with E-99 and E-104.,MUTAGEN:K->E: Reduces bactericidal activity to 25% against B.subtilis and to 10% against S.aureus. Complete loss of bactericidal activity; when associated with E-87 and E-104.,MUTAGEN:R->D: Impairs bactericidal activity; when associated with E-135.,MUTAGEN:R->E: Impairs bactericidal activity; when associated with E-72 and E-73.,MUTAGEN:R->E: Impairs bactericidal activity; when associated with E-72 and E-77.,MUTAGEN:R->E: Moderately reduced integrin binding. Greatly reduced integrin binding but no effect on catalytic activity; when associated with E-120.,MUTAGEN:R->E: Moderately reduced integrin binding. Greatly reduced integrin binding but no effect on catalytic activity; when associated with E-94.,MUTAGEN:R->E: No effect on integrin binding.,MUTAGEN:R->E: Reduces bactericidal activity to 18% against B.subtilis and to 12% against S.aureus. Complete loss of bactericidal activity; when associated with E-87 and E-99.,MUTAGEN:R->E: Reduces bactericidal activity to 20% against B.subtilis and to 4% against S.aureus. Complete loss of bactericidal activity; when associated with E-30 and E-35.,MUTAGEN:R->E: Slightly reduced integrin binding.,SITE:Important for integrin binding,
PLSCR1	phospholipid scramblase 1(PLSCR1)	Homo sapiens	GO:0006659~phosphatidylserine biosynthetic process,GO:0006915~apoptotic process,GO:0006953~acute-phase response,GO:0010288~response to lead ion,GO:0010628~positive regulation of gene expression,GO:0017121~phospholipid scrambling,GO:0030168~platelet activation,GO:0033003~regulation of mast cell activation,GO:0035456~response to interferon-beta,GO:0045071~negative regulation of viral genome replication,GO:0045089~positive regulation of innate immune response,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046718~viral entry into host cell,GO:0050765~negative regulation of phagocytosis,GO:0051607~defense response to virus,GO:0060368~regulation of Fc receptor mediated stimulatory signaling pathway,GO:0070782~phosphatidylserine exposure on apoptotic cell surface,GO:0090305~nucleic acid phosphodiester bond hydrolysis,GO:1905820~positive regulation of chromosome separation,GO:2000373~positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0045121~membrane raft,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0000287~magnesium ion binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0001618~virus receptor activity,GO:0003677~DNA binding,GO:0004518~nuclease activity,GO:0005154~epidermal growth factor receptor binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0017124~SH3 domain binding,GO:0017128~phospholipid scramblase activity,GO:0019899~enzyme binding,GO:0032791~lead ion binding,GO:0042609~CD4 receptor binding,GO:0045340~mercury ion binding,	IPR005552:Scramblase,					KW-0051~Antiviral defense,KW-0445~Lipid transport,KW-0813~Transport,KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0729~SH3-binding,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0460~Magnesium,	KW-0238~DNA-binding,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0675~Receptor,KW-1183~Host cell receptor for virus entry,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,LIPID:S-palmitoyl cysteine,MOTIF:Nuclear localization signal,MOTIF:PPXY motif 1,MOTIF:PPXY motif 2,MOTIF:SH3-binding 1,MOTIF:SH3-binding 2,MOTIF:SH3-binding 3,MUTAGEN:CCCPCC->AAAPAA: No palmitoylation; constitutively localizes in the nucleus.,MUTAGEN:D->A: Complete inactivation of the Ca(2+)-dependent phospholipid scrambling. No effect on its nuclease activity.,MUTAGEN:D->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:F->A: Complete inactivation of the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:F->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-111; A-211 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-111 and A-211.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-111 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-12; A-53; A-211 and A-262.,MUTAGEN:H->A: 60% reduction in nuclease activity; when associated with A-53; A-111; A-211 and A-262.,MUTAGEN:I->A: Reduces the Ca(2+)-dependent phospholipid scrambling.,MUTAGEN:T->A: No induction by PKC/PRKCD.,MUTAGEN:Y->F: Decrease in phosphorylation.,REGION:Disordered,REGION:Interaction with hepatitis C virus E2 glycoprotein,REGION:Proline-rich domain (PRD),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PLSCR2	phospholipid scramblase 2(PLSCR2)	Homo sapiens	GO:0017121~phospholipid scrambling,	GO:0005654~nucleoplasm,GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0017128~phospholipid scramblase activity,	IPR005552:Scramblase,						KW-0472~Membrane,KW-0539~Nucleus,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	LIPID:S-palmitoyl cysteine,REGION:Proline-rich domain (PRD),TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PHYHIPL	phytanoyl-CoA 2-hydroxylase interacting protein like(PHYHIPL)	Homo sapiens		GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,											KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Fibronectin type-III,
PLVAP	plasmalemma vesicle associated protein(PLVAP)	Homo sapiens	GO:0000165~MAPK cascade,GO:0002693~positive regulation of cellular extravasation,GO:0032502~developmental process,GO:0033209~tumor necrosis factor-mediated signaling pathway,GO:0043114~regulation of vascular permeability,	GO:0005901~caveola,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR009538:PV-1,		618183~Diarrhea 10, protein-losing enteropathy type,				KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
PLAT	plasminogen activator, tissue type(PLAT)	Homo sapiens	GO:0001666~response to hypoxia,GO:0006464~cellular protein modification process,GO:0006508~proteolysis,GO:0007596~blood coagulation,GO:0010757~negative regulation of plasminogen activation,GO:0014909~smooth muscle cell migration,GO:0031639~plasminogen activation,GO:0035249~synaptic transmission, glutamatergic,GO:0036211~protein modification process,GO:0042730~fibrinolysis,GO:0045861~negative regulation of proteolysis,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048167~regulation of synaptic plasticity,GO:0051591~response to cAMP,GO:0051918~negative regulation of fibrinolysis,GO:0060279~positive regulation of ovulation,GO:0060468~prevention of polyspermy,GO:0070542~response to fatty acid,GO:0071372~cellular response to follicle-stimulating hormone stimulus,GO:0071373~cellular response to luteinizing hormone stimulus,GO:0071549~cellular response to dexamethasone stimulus,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009986~cell surface,GO:0030141~secretory granule,GO:0045177~apical part of cell,GO:0070062~extracellular exosome,GO:0097180~serine protease inhibitor complex,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:0098992~neuronal dense core vesicle,GO:0099544~perisynaptic space,	GO:0004252~serine-type endopeptidase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0051219~phosphoprotein binding,	IPR000001:Kringle,IPR000083:Fibronectin, type I,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR018114:Peptidase S1, trypsin family, active site,IPR026280:Tissue plasminogen activator,	hsa04371:Apelin signaling pathway,hsa04610:Complement and coagulation cascades,hsa05202:Transcriptional misregulation in cancer,hsa05215:Prostate cancer,hsa05418:Fluid shear stress and atherosclerosis,	612348~Hyperfibrinolysis, familial, due to increased release of PLAT,612348~Thrombophilia, familial, due to decreased release of PLAT,	PIRSF001145:tissue plasminogen activator,	SM00020:Tryp_SPc,SM00058:FN1,SM00130:KR,	KW-0617~Plasminogen activation,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0420~Kringle,KW-0677~Repeat,KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine; partial,CARBOHYD:O-linked (Fuc) threonine,DISULFID:Interchain (between A and B chains),DOMAIN:EGF-like,DOMAIN:Fibronectin type-I,DOMAIN:Kringle,DOMAIN:Kringle 1,DOMAIN:Kringle 2,DOMAIN:Peptidase S1,PROPEP:Removed by plasmin,REGION:Important for binding to annexin A2,SITE:Important for binding to LRP1,SITE:Important for single-chain activity,SITE:Not glycosylated,
PLAUR	plasminogen activator, urokinase receptor(PLAUR)	Homo sapiens	GO:0001934~positive regulation of protein phosphorylation,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007596~blood coagulation,GO:0010755~regulation of plasminogen activation,GO:0030155~regulation of cell adhesion,GO:0030162~regulation of proteolysis,GO:0034112~positive regulation of homotypic cell-cell adhesion,GO:0038195~urokinase plasminogen activator signaling pathway,GO:0043066~negative regulation of apoptotic process,GO:0043388~positive regulation of DNA binding,GO:0045742~positive regulation of epidermal growth factor receptor signaling pathway,GO:0051917~regulation of fibrinolysis,GO:0090200~positive regulation of release of cytochrome c from mitochondria,GO:2001243~negative regulation of intrinsic apoptotic signaling pathway,GO:2001268~negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0019898~extrinsic component of membrane,GO:0031225~anchored component of membrane,GO:0035579~specific granule membrane,GO:0042995~cell projection,GO:0098637~protein complex involved in cell-matrix adhesion,GO:1905370~serine-type endopeptidase complex,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0019899~enzyme binding,GO:0019904~protein domain specific binding,GO:0030377~urokinase plasminogen activator receptor activity,GO:0038023~signaling receptor activity,	IPR016054:Ly-6 antigen / uPA receptor -like,IPR018363:CD59 antigen, conserved site,	hsa04610:Complement and coagulation cascades,hsa05205:Proteoglycans in cancer,			SM00134:LU,		KW-0472~Membrane,KW-0964~Secreted,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,		KW-0418~Kinase,KW-0675~Receptor,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DOMAIN:UPAR/Ly6,DOMAIN:UPAR/Ly6 1,DOMAIN:UPAR/Ly6 2,DOMAIN:UPAR/Ly6 3,LIPID:GPI-anchor amidated glycine,PROPEP:Removed in mature form,REGION:Disordered,SITE:Cleavage; by U-PA,
PLAU	plasminogen activator, urokinase(PLAU)	Homo sapiens	GO:0001666~response to hypoxia,GO:0006508~proteolysis,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0007596~blood coagulation,GO:0010469~regulation of receptor activity,GO:0010755~regulation of plasminogen activation,GO:0010757~negative regulation of plasminogen activation,GO:0014909~smooth muscle cell migration,GO:0014910~regulation of smooth muscle cell migration,GO:0030155~regulation of cell adhesion,GO:0030335~positive regulation of cell migration,GO:0031639~plasminogen activation,GO:0033628~regulation of cell adhesion mediated by integrin,GO:0038195~urokinase plasminogen activator signaling pathway,GO:0042127~regulation of cell proliferation,GO:0042730~fibrinolysis,GO:0051917~regulation of fibrinolysis,GO:0051918~negative regulation of fibrinolysis,GO:0061041~regulation of wound healing,GO:2000097~regulation of smooth muscle cell-matrix adhesion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0009986~cell surface,GO:0035579~specific granule membrane,GO:0070062~extracellular exosome,GO:0070821~tertiary granule membrane,GO:0097180~serine protease inhibitor complex,GO:0098637~protein complex involved in cell-matrix adhesion,GO:1905370~serine-type endopeptidase complex,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,GO:0016301~kinase activity,	IPR000001:Kringle,IPR000742:Epidermal growth factor-like domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR013806:Kringle-like fold,IPR018056:Kringle, conserved site,IPR018114:Peptidase S1, trypsin family, active site,	hsa04064:NF-kappa B signaling pathway,hsa04610:Complement and coagulation cascades,hsa05202:Transcriptional misregulation in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05215:Prostate cancer,	104300~Alzheimer disease, late-onset, susceptibility to,601709~Quebec platelet disorder,		SM00020:Tryp_SPc,SM00130:KR,	KW-0094~Blood coagulation,KW-0280~Fibrinolysis,KW-0356~Hemostasis,KW-0617~Plasminogen activation,	KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0420~Kringle,KW-0732~Signal,		KW-0378~Hydrolase,KW-0418~Kinase,KW-0645~Protease,KW-0720~Serine protease,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc) threonine,DISULFID:Interchain (between A and B chains),DOMAIN:EGF-like,DOMAIN:Kringle,DOMAIN:Peptidase S1,MUTAGEN:S->E: Abolishes phosphorylation, proadhesive function and ability to induce chemotactic response; when associated with E-158.,MUTAGEN:S->E: Abolishes phosphorylation, proadhesive function and ability to induce chemotactic response; when associated with E-323.,REGION:Binds urokinase plasminogen activator surface receptor,REGION:Connecting peptide,SITE:Cleavage; during zymogen activation,
PDGFA	platelet derived growth factor subunit A(PDGFA)	Homo sapiens	GO:0001525~angiogenesis,GO:0001666~response to hypoxia,GO:0001775~cell activation,GO:0001942~hair follicle development,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0007267~cell-cell signaling,GO:0008284~positive regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0009887~animal organ morphogenesis,GO:0010035~response to inorganic substance,GO:0010512~negative regulation of phosphatidylinositol biosynthetic process,GO:0010544~negative regulation of platelet activation,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0014910~regulation of smooth muscle cell migration,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0030335~positive regulation of cell migration,GO:0031954~positive regulation of protein autophosphorylation,GO:0032355~response to estradiol,GO:0032526~response to retinoic acid,GO:0032956~regulation of actin cytoskeleton organization,GO:0035790~platelet-derived growth factor receptor-alpha signaling pathway,GO:0035793~positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway,GO:0042060~wound healing,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043588~skin development,GO:0048008~platelet-derived growth factor receptor signaling pathway,GO:0048146~positive regulation of fibroblast proliferation,GO:0048286~lung alveolus development,GO:0048839~inner ear development,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050919~negative chemotaxis,GO:0051781~positive regulation of cell division,GO:0051897~positive regulation of protein kinase B signaling,GO:0060683~regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071560~cellular response to transforming growth factor beta stimulus,GO:1990401~embryonic lung development,	GO:0000139~Golgi membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005796~Golgi lumen,GO:0005902~microvillus,GO:0009986~cell surface,GO:0016020~membrane,GO:0031093~platelet alpha granule lumen,GO:1990265~platelet-derived growth factor complex,	GO:0005161~platelet-derived growth factor receptor binding,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008083~growth factor activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0048407~platelet-derived growth factor binding,GO:0070851~growth factor receptor binding,	IPR000072:Platelet-derived growth factor (PDGF),IPR006782:Platelet-derived growth factor, N-terminal,IPR023581:Platelet-derived growth factor, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04072:Phospholipase D signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04630:JAK-STAT signaling pathway,hsa04810:Regulation of actin cytoskeleton,hsa05200:Pathways in cancer,hsa05202:Transcriptional misregulation in cancer,hsa05206:MicroRNAs in cancer,hsa05214:Glioma,hsa05215:Prostate cancer,hsa05218:Melanoma,hsa05231:Choline metabolism in cancer,hsa05418:Fluid shear stress and atherosclerosis,			SM00141:PDGF,		KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,DOMAIN:PDGF_2,DOMAIN:PDGF_N,PROPEP:Removed in mature form,REGION:Disordered,REGION:Receptor binding site,
PLEK2	pleckstrin 2(PLEK2)	Homo sapiens	GO:0031532~actin cytoskeleton reorganization,GO:0035556~intracellular signal transduction,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0031258~lamellipodium membrane,	GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,	IPR000591:DEP domain,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00049:DEP,SM00233:PH,		KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:DEP,DOMAIN:PH,DOMAIN:PH 1,DOMAIN:PH 2,
PSD	pleckstrin and Sec7 domain containing(PSD)	Homo sapiens	GO:0007165~signal transduction,GO:0031175~neuron projection development,GO:0032012~regulation of ARF protein signal transduction,GO:0050790~regulation of catalytic activity,	GO:0032154~cleavage furrow,GO:0032587~ruffle membrane,GO:0043197~dendritic spine,GO:0098999~extrinsic component of postsynaptic endosome membrane,GO:0099092~postsynaptic density, intracellular component,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005515~protein binding,GO:0005543~phospholipid binding,	IPR000904:SEC7-like,IPR001605:Pleckstrin homology domain, spectrin-type,IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR023394:SEC7-like, alpha orthogonal bundle,	hsa04144:Endocytosis,			SM00222:Sec7,SM00233:PH,		KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,		KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PH,DOMAIN:SEC7,MUTAGEN:E->K: Loss of GEF activity, loss of ARF6 localization to the cleavage furrow and, later in cytokinesis, to the midbody ring.,MUTAGEN:RK->EE: Loss of localization to the plasma membrane during interphase and to the cleavage furrow during cytokinesis. No effect on ARF6 localization to the cleavage furrow and, later in cytokinesis, to the midbody ring.,REGION:Disordered,
PLEKHM1	pleckstrin homology and RUN domain containing M1(PLEKHM1)	Homo sapiens	GO:0015031~protein transport,GO:0032418~lysosome localization,GO:0035556~intracellular signal transduction,GO:0045780~positive regulation of bone resorption,GO:1900029~positive regulation of ruffle assembly,GO:1902774~late endosome to lysosome transport,	GO:0005730~nucleolus,GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0031902~late endosome membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0044754~autolysosome,	GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR004012:RUN,IPR011993:Pleckstrin homology-like domain,IPR025258:Domain of unknown function DUF4206,	hsa05132:Salmonella infection,	611497~Osteopetrosis, autosomal recessive 6,618107~Osteopetrosis, autosomal dominant 3,		SM00109:C1,SM00233:PH,SM00593:RUN,SM01175:SM01175,	KW-0072~Autophagy,KW-0653~Protein transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0987~Osteopetrosis,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PH 1,DOMAIN:PH 2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:RUN,MOTIF:LIR,MUTAGEN:C->G: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1021, L-1029 and G-1032.,MUTAGEN:C->G: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1024, L-1029 and G-1032.,MUTAGEN:C->G: Disrupts interaction with Rab7and no localization to endososmal membranes; when associated with G-1021, G-1024 and L-1029.,MUTAGEN:E->A: Disrupts interaction with RAB7A.,MUTAGEN:H->A: No effect on interaction with ARL8B. No effect on interaction with RAB7A.,MUTAGEN:H->A: Strongly reduces interaction with ARL8B. No effect on interaction with RAB7A. No effect on late endosome and lysosome clustering. Loss of interaction with ARL8B as well as late endosome and lysosome clustering; when associated with 119-A--A-123.,MUTAGEN:H->L: Disrupts interaction with Rab7 and no localization to endososmal membranes; when associated with G-1021, G-1024 and G-1032.,MUTAGEN:Missing: Disrupts interaction with RAB7A.,MUTAGEN:R->A: Disrupts interaction with RAB7A.,MUTAGEN:RAWLR->AAWLA: Reduces interaction with ARL8B. No effect on interaction with RAB7A. Loss of interaction with ARL8B as well as late endosome and lysosome clustering; when associated with A-60.,REGION:Disordered,REGION:Interaction with RAB7A,ZN_FING:Phorbol-ester/DAG-type,
PLEKHA4	pleckstrin homology domain containing A4(PLEKHA4)	Homo sapiens	GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:2000096~positive regulation of Wnt signaling pathway, planar cell polarity pathway,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0005515~protein binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0032266~phosphatidylinositol-3-phosphate binding,GO:0042802~identical protein binding,GO:0043325~phosphatidylinositol-3,4-bisphosphate binding,GO:0080025~phosphatidylinositol-3,5-bisphosphate binding,	IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,		KW-0472~Membrane,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0446~Lipid-binding,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PH,REGION:Disordered,
PLEKHS1	pleckstrin homology domain containing S1(PLEKHS1)	Homo sapiens				IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,				SM00233:PH,								COMPBIAS:Basic and acidic residues,DOMAIN:PH,REGION:Disordered,
PODNL1	podocan like 1(PODNL1)	Homo sapiens		GO:0005615~extracellular space,		IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR025875:Leucine rich repeat 4,				SM00369:LRR_TYP,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
PDPN	podoplanin(PDPN)	Homo sapiens	GO:0000902~cell morphogenesis,GO:0001946~lymphangiogenesis,GO:0003333~amino acid transmembrane transport,GO:0006833~water transport,GO:0007266~Rho protein signal transduction,GO:0008285~negative regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0015884~folic acid transport,GO:0016477~cell migration,GO:0030168~platelet activation,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0035239~tube morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0044319~wound healing, spreading of cells,GO:0048535~lymph node development,GO:0051272~positive regulation of cellular component movement,GO:0055093~response to hyperoxia,GO:0060838~lymphatic endothelial cell fate commitment,GO:0070252~actin-mediated cell contraction,GO:0090091~positive regulation of extracellular matrix disassembly,GO:0098609~cell-cell adhesion,GO:1900024~regulation of substrate adhesion-dependent cell spreading,GO:1901731~positive regulation of platelet aggregation,GO:1904328~regulation of myofibroblast contraction,GO:2000392~regulation of lamellipodium morphogenesis,	GO:0001726~ruffle,GO:0005739~mitochondrion,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030027~lamellipodium,GO:0030054~cell junction,GO:0030175~filopodium,GO:0031258~lamellipodium membrane,GO:0031410~cytoplasmic vesicle,GO:0031527~filopodium membrane,GO:0031528~microvillus membrane,GO:0032587~ruffle membrane,GO:0042995~cell projection,GO:0045121~membrane raft,GO:0061851~leading edge of lamellipodium,GO:0070161~anchoring junction,GO:0097197~tetraspanin-enriched microdomain,	GO:0005102~receptor binding,GO:0005515~protein binding,GO:0019956~chemokine binding,GO:0051087~chaperone binding,						KW-0133~Cell shape,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-0965~Cell junction,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,	CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Pro residues,MUTAGEN:Missing: Prevents self-assembly and association to lipid rafts. Reduces the recruitment to invadopodium. Disrupts assembly into adhesion rings. Fails invadopodia-mediated ECM degradation.,MUTAGEN:R->N: Highly decreases interaction with the EZR and MSN. Induces an intermediate phenotype between epithelial and mesenchymal. Does not affect localization at cell surface protrusions. Induces reorganization of the actin cytoskeleton oncomitantly with the induced morphological changes. Increases cell migration individually. Increases invasiveness. Enhances RHOA activity. Colocalizes at cell-surface protrusions with RHOA and RAC1.,MUTAGEN:RK->QN: Impairs interaction with the EZR and MSN. Impairs epithelial to mesenchymal transition. Does not affect localization at cell surface protrusions. Does not induce reorganization of the actin cytoskeleton. Increases cell migration collectively.,MUTAGEN:RKMSGR->QNMGSN: Does not affect localization at cell surface protrusions. Does not induce reorganization of the actin cytoskeleton. Increases cell migration collectively. Does not significant change RHOA activation. No effect on interaction with CD44. Impairs interaction with the EZR and MSN. Impairs epithelial to mesenchymal transition. Does not change localization at invadopodium. Fails to assemble into rings. Fails invadopodia-mediated ECM degradation.,MUTAGEN:T->A: Eliminates induction of platelet aggregation.,PEPTIDE:29kDa cytosolic podoplanin intracellular domain,REGION:Disordered,REGION:Requires for dimerization and lipid rafts association,REGION:Requires for interaction with MSN and EZR,SITE:Cleavage; by gamma-secretase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PABPC1L	poly(A) binding protein cytoplasmic 1 like(PABPC1L)	Homo sapiens	GO:0001556~oocyte maturation,GO:0006338~chromatin remodeling,GO:0006378~mRNA polyadenylation,GO:0048096~chromatin-mediated maintenance of transcription,GO:0051647~nucleus localization,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0008143~poly(A) binding,GO:0008266~poly(U) RNA binding,	IPR000504:RNA recognition motif domain,IPR002004:Polyadenylate-binding protein/Hyperplastic disc protein,IPR003954:RNA recognition motif domain, eukaryote,IPR006515:Polyadenylate binding protein, human types 1, 2, 3, 4,IPR012677:Nucleotide-binding, alpha-beta plait,	hsa03015:mRNA surveillance pathway,hsa03018:RNA degradation,			SM00360:RRM,SM00361:RRM_1,SM00517:PolyA,		KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,		COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:PABC,DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,DOMAIN:RRM 4,REGION:Disordered,
GALNT13	polypeptide N-acetylgalactosaminyltransferase 13(GALNT13)	Homo sapiens	GO:0006486~protein glycosylation,GO:0006493~protein O-linked glycosylation,GO:0016266~O-glycan processing,GO:0018242~protein O-linked glycosylation via serine,GO:0018243~protein O-linked glycosylation via threonine,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0004653~polypeptide N-acetylgalactosaminyltransferase activity,GO:0016740~transferase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000772:Ricin B lectin domain,IPR001173:Glycosyl transferase, family 2,	hsa00512:Mucin type O-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,			SM00458:RICIN,		KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glyco_trans_2-like,DOMAIN:RICIN,DOMAIN:Ricin B-type lectin,REGION:Catalytic subdomain A,REGION:Catalytic subdomain B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GALNT3	polypeptide N-acetylgalactosaminyltransferase 3(GALNT3)	Homo sapiens	GO:0005975~carbohydrate metabolic process,GO:0006493~protein O-linked glycosylation,GO:0007283~spermatogenesis,GO:0008543~fibroblast growth factor receptor signaling pathway,GO:0016266~O-glycan processing,GO:0018242~protein O-linked glycosylation via serine,GO:0018243~protein O-linked glycosylation via threonine,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0032580~Golgi cisterna membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0004653~polypeptide N-acetylgalactosaminyltransferase activity,GO:0005509~calcium ion binding,GO:0016740~transferase activity,GO:0030145~manganese ion binding,GO:0030246~carbohydrate binding,	IPR000772:Ricin B lectin domain,IPR001173:Glycosyl transferase, family 2,	hsa00512:Mucin type O-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,	211900~Tumoral calcinosis, hyperphosphatemic, familial, 1,		SM00458:RICIN,		KW-0333~Golgi apparatus,KW-0472~Membrane,	KW-0225~Disease variant,	KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glyco_trans_2-like,DOMAIN:RICIN,DOMAIN:Ricin B-type lectin,REGION:Catalytic subdomain A,REGION:Catalytic subdomain B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
GALNTL6	polypeptide N-acetylgalactosaminyltransferase like 6(GALNTL6)	Homo sapiens	GO:0006486~protein glycosylation,GO:0006493~protein O-linked glycosylation,GO:0018243~protein O-linked glycosylation via threonine,	GO:0000139~Golgi membrane,GO:0005794~Golgi apparatus,GO:0016021~integral component of membrane,	GO:0004653~polypeptide N-acetylgalactosaminyltransferase activity,GO:0030246~carbohydrate binding,GO:0046872~metal ion binding,	IPR000772:Ricin B lectin domain,IPR001173:Glycosyl transferase, family 2,	hsa00512:Mucin type O-glycan biosynthesis,hsa00514:Other types of O-glycan biosynthesis,hsa01100:Metabolic pathways,			SM00458:RICIN,		KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0328~Glycosyltransferase,KW-0808~Transferase,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Glyco_trans_2-like,DOMAIN:RICIN,DOMAIN:Ricin B-type lectin,REGION:Catalytic subdomain A,REGION:Catalytic subdomain B,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
KCNN4	potassium calcium-activated channel subfamily N member 4(KCNN4)	Homo sapiens	GO:0002376~immune system process,GO:0006811~ion transport,GO:0006813~potassium ion transport,GO:0006816~calcium ion transport,GO:0006884~cell volume homeostasis,GO:0006952~defense response,GO:0030322~stabilization of membrane potential,GO:0045332~phospholipid translocation,GO:0046541~saliva secretion,GO:0050714~positive regulation of protein secretion,GO:0050862~positive regulation of T cell receptor signaling pathway,GO:0051649~establishment of localization in cell,GO:0071805~potassium ion transmembrane transport,GO:1901381~positive regulation of potassium ion transmembrane transport,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016021~integral component of membrane,GO:0031982~vesicle,GO:0043005~neuron projection,GO:0043025~neuronal cell body,	GO:0005267~potassium channel activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0015269~calcium-activated potassium channel activity,GO:0016286~small conductance calcium-activated potassium channel activity,GO:0019903~protein phosphatase binding,GO:0022894~Intermediate conductance calcium-activated potassium channel activity,	IPR004178:Calmodulin-binding domain,IPR013099:Ion transport 2,IPR015449:Potassium channel, calcium-activated, SK,	hsa04911:Insulin secretion,hsa04929:GnRH secretion,hsa04970:Salivary secretion,hsa04974:Protein digestion and absorption,	616689~Dehydrated hereditary stomatocytosis 2,		SM01053:SM01053,	KW-0391~Immunity,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0360~Hereditary hemolytic anemia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0112~Calmodulin-binding,KW-0407~Ion channel,	KW-0597~Phosphoprotein,	DOMAIN:CaMBD,INTRAMEM:Pore-forming; Name=Segment H5,MUTAGEN:T->S: Loss of sensitivity to triarylmethanes.,MUTAGEN:V->A: Loss of sensitivity to triarylmethanes.,REGION:Calmodulin-binding,REGION:Disordered,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S4,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,
KCNJ11	potassium inwardly rectifying channel subfamily J member 11(KCNJ11)	Homo sapiens	GO:0002931~response to ischemia,GO:0006006~glucose metabolic process,GO:0009410~response to xenobiotic stimulus,GO:0032355~response to estradiol,GO:0033198~response to ATP,GO:0033574~response to testosterone,GO:0034765~regulation of ion transmembrane transport,GO:0035774~positive regulation of insulin secretion involved in cellular response to glucose stimulus,GO:0042391~regulation of membrane potential,GO:0042493~response to drug,GO:0046676~negative regulation of insulin secretion,GO:0050796~regulation of insulin secretion,GO:0050877~neurological system process,GO:0071316~cellular response to nicotine,GO:0071333~cellular response to glucose stimulus,GO:0071356~cellular response to tumor necrosis factor,GO:0071805~potassium ion transmembrane transport,GO:0098662~inorganic cation transmembrane transport,GO:0099505~regulation of presynaptic membrane potential,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1990573~potassium ion import across plasma membrane,GO:2001259~positive regulation of cation channel activity,	GO:0001669~acrosomal vesicle,GO:0005635~nuclear envelope,GO:0005739~mitochondrion,GO:0005768~endosome,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008282~ATP-sensitive potassium channel complex,GO:0014704~intercalated disc,GO:0016021~integral component of membrane,GO:0030315~T-tubule,GO:0030673~axolemma,GO:0043025~neuronal cell body,GO:0043209~myelin sheath,GO:0070852~cell body fiber,	GO:0005242~inward rectifier potassium channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008022~protein C-terminus binding,GO:0015272~ATP-activated inward rectifier potassium channel activity,GO:0019829~cation-transporting ATPase activity,GO:0030506~ankyrin binding,GO:0030955~potassium ion binding,GO:0031072~heat shock protein binding,GO:0044325~ion channel binding,GO:0099508~voltage-gated ion channel activity involved in regulation of presynaptic membrane potential,	IPR003279:Potassium channel, inwardly rectifying, Kir6.2,IPR013518:Potassium channel, inwardly rectifying, Kir, cytoplasmic,IPR014756:Immunoglobulin E-set,IPR016449:Potassium channel, inwardly rectifying, Kir,	hsa04911:Insulin secretion,hsa04929:GnRH secretion,hsa04930:Type II diabetes mellitus,	125853~Diabetes mellitus, type 2, susceptibility to,601820~Hyperinsulinemic hypoglycemia, familial, 2,610582~Diabetes mellitus, transient neonatal 3,616329~Maturity-onset diabetes of the young, type 13,618856~Diabetes, permanent neonatal 2, with or without neurologic features,	PIRSF005465:G protein-activated inward rectifier potassium channel,		KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,	KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0597~Phosphoprotein,	DOMAIN:IRK,DOMAIN:IRK_C,INTRAMEM:Helical; Pore-forming; Name=H5,INTRAMEM:Pore-forming,MOTIF:Selectivity filter,MUTAGEN:V->M: Displays gain of function; increased open state stability, reduced ATP sensitivity and increased channel activity; almost completely abolishes high affinity sensitivity to glibenclamide, an inhibitor of ATP-sensitive potassium channels.,SITE:Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=M1,TRANSMEM:Helical; Name=M2,
KCNJ12	potassium inwardly rectifying channel subfamily J member 12(KCNJ12)	Homo sapiens	GO:0006813~potassium ion transport,GO:0006936~muscle contraction,GO:0008016~regulation of heart contraction,GO:0034765~regulation of ion transmembrane transport,GO:0051289~protein homotetramerization,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031224~intrinsic component of membrane,	GO:0005242~inward rectifier potassium channel activity,GO:0005515~protein binding,	IPR003272:Potassium channel, inwardly rectifying, Kir2.2,IPR013518:Potassium channel, inwardly rectifying, Kir, cytoplasmic,IPR013673:Potassium channel, inwardly rectifying, Kir, N-terminal,IPR014756:Immunoglobulin E-set,IPR016449:Potassium channel, inwardly rectifying, Kir,	hsa04725:Cholinergic synapse,hsa04921:Oxytocin signaling pathway,				KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0702~S-nitrosylation,KW-1015~Disulfide bond,	DISULFID:Interchain,INTRAMEM:Helical; Pore-forming; Name=H5,INTRAMEM:Pore-forming,MOTIF:Interaction with phosphatidylinositides,MOTIF:PDZ-binding,MOTIF:Selectivity filter,REGION:Disordered,SITE:Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=M1,TRANSMEM:Helical; Name=M2,
KCNJ3	potassium inwardly rectifying channel subfamily J member 3(KCNJ3)	Homo sapiens	GO:0006813~potassium ion transport,GO:0034765~regulation of ion transmembrane transport,GO:0051602~response to electrical stimulus,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098914~membrane repolarization during atrial cardiac muscle cell action potential,GO:0098915~membrane repolarization during ventricular cardiac muscle cell action potential,GO:0099505~regulation of presynaptic membrane potential,GO:0099625~ventricular cardiac muscle cell membrane repolarization,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0030315~T-tubule,GO:0042734~presynaptic membrane,GO:0098688~parallel fiber to Purkinje cell synapse,GO:0099056~integral component of presynaptic membrane,	GO:0005242~inward rectifier potassium channel activity,GO:0005515~protein binding,GO:0015467~G-protein activated inward rectifier potassium channel activity,GO:0086089~voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization,GO:0099508~voltage-gated ion channel activity involved in regulation of presynaptic membrane potential,GO:1902282~voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization,	IPR003274:Potassium channel, inwardly rectifying, Kir3.1,IPR013518:Potassium channel, inwardly rectifying, Kir, cytoplasmic,IPR014756:Immunoglobulin E-set,IPR016449:Potassium channel, inwardly rectifying, Kir,	hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04929:GnRH secretion,hsa05032:Morphine addiction,		PIRSF005465:G protein-activated inward rectifier potassium channel,		KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:IRK,DOMAIN:IRK_C,INTRAMEM:Helical; Pore-forming; Name=H5,INTRAMEM:Pore-forming,MOTIF:Selectivity filter,REGION:Disordered,SITE:Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=M1,TRANSMEM:Helical; Name=M2,
KCNJ9	potassium inwardly rectifying channel subfamily J member 9(KCNJ9)	Homo sapiens	GO:0034765~regulation of ion transmembrane transport,GO:0099505~regulation of presynaptic membrane potential,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0042734~presynaptic membrane,GO:0098688~parallel fiber to Purkinje cell synapse,	GO:0005242~inward rectifier potassium channel activity,GO:0005515~protein binding,GO:0015467~G-protein activated inward rectifier potassium channel activity,	IPR003276:Potassium channel, inwardly rectifying, Kir3.3,IPR013518:Potassium channel, inwardly rectifying, Kir, cytoplasmic,IPR014756:Immunoglobulin E-set,IPR016449:Potassium channel, inwardly rectifying, Kir,	hsa04713:Circadian entrainment,hsa04723:Retrograde endocannabinoid signaling,hsa04726:Serotonergic synapse,hsa04728:Dopaminergic synapse,hsa04915:Estrogen signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04929:GnRH secretion,hsa05032:Morphine addiction,		PIRSF005465:G protein-activated inward rectifier potassium channel,		KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,		INTRAMEM:Helical; Pore-forming; Name=H5,INTRAMEM:Pore-forming,MOTIF:PDZ-binding,MOTIF:Selectivity filter,REGION:Disordered,SITE:Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=M1,TRANSMEM:Helical; Name=M2,
KCNK12	potassium two pore domain channel subfamily K member 12(KCNK12)	Homo sapiens	GO:0030322~stabilization of membrane potential,GO:0034765~regulation of ion transmembrane transport,GO:0071805~potassium ion transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005244~voltage-gated ion channel activity,GO:0015271~outward rectifier potassium channel activity,GO:0022841~potassium ion leak channel activity,	IPR003280:Two pore domain potassium channel,IPR005410:Two pore domain potassium channel, THIK,IPR013099:Ion transport 2,					KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,INTRAMEM:Pore-forming; Name=Pore-forming 1,INTRAMEM:Pore-forming; Name=Pore-forming 2,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
KCNK5	potassium two pore domain channel subfamily K member 5(KCNK5)	Homo sapiens	GO:0006813~potassium ion transport,GO:0007588~excretion,GO:0030322~stabilization of membrane potential,GO:0034765~regulation of ion transmembrane transport,GO:0060075~regulation of resting membrane potential,GO:0071805~potassium ion transmembrane transport,GO:0097623~potassium ion export across plasma membrane,GO:1990573~potassium ion import across plasma membrane,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005244~voltage-gated ion channel activity,GO:0005267~potassium channel activity,GO:0005515~protein binding,GO:0015271~outward rectifier potassium channel activity,GO:0022841~potassium ion leak channel activity,	IPR003092:Two pore domain potassium channel, TASK family,IPR003280:Two pore domain potassium channel,IPR013099:Ion transport 2,	hsa04742:Taste transduction,hsa04974:Protein digestion and absorption,				KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain,DOMAIN:Ion_trans_2,INTRAMEM:Pore-forming; Name=Pore-forming 1,INTRAMEM:Pore-forming; Name=Pore-forming 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
KCNIP2	potassium voltage-gated channel interacting protein 2(KCNIP2)	Homo sapiens	GO:0005513~detection of calcium ion,GO:0006813~potassium ion transport,GO:0006936~muscle contraction,GO:0007165~signal transduction,GO:0007268~chemical synaptic transmission,GO:0008016~regulation of heart contraction,GO:0045163~clustering of voltage-gated potassium channels,GO:0086009~membrane repolarization,GO:0086013~membrane repolarization during cardiac muscle cell action potential,GO:0097623~potassium ion export across plasma membrane,GO:1901379~regulation of potassium ion transmembrane transport,GO:1903766~positive regulation of potassium ion export across plasma membrane,GO:1903818~positive regulation of voltage-gated potassium channel activity,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0030425~dendrite,GO:0034705~potassium channel complex,GO:0045202~synapse,	GO:0005244~voltage-gated ion channel activity,GO:0005250~A-type (transient outward) potassium channel activity,GO:0005267~potassium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0042802~identical protein binding,GO:0044325~ion channel binding,GO:0044877~macromolecular complex binding,GO:0046923~ER retention sequence binding,GO:0047485~protein N-terminus binding,GO:0086008~voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:EF-hand,DOMAIN:EF-hand 1; degenerate,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:S-palmitoyl cysteine,REGION:Disordered,REGION:Interaction with KCND2,
KCNIP3	potassium voltage-gated channel interacting protein 3(KCNIP3)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006886~intracellular protein transport,GO:0006915~apoptotic process,GO:0007165~signal transduction,GO:0071805~potassium ion transmembrane transport,GO:0072659~protein localization to plasma membrane,GO:1901379~regulation of potassium ion transmembrane transport,	GO:0005634~nucleus,GO:0005783~endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0030425~dendrite,GO:0032993~protein-DNA complex,GO:0043679~axon terminus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0005244~voltage-gated ion channel activity,GO:0005267~potassium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0044325~ion channel binding,	IPR002048:EF-hand domain,IPR011992:EF-hand-like domain,IPR018247:EF-Hand 1, calcium-binding site,				SM00054:EFh,	KW-0053~Apoptosis,KW-0406~Ion transport,KW-0633~Potassium transport,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0677~Repeat,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0678~Repressor,KW-0851~Voltage-gated channel,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1),DOMAIN:EF-hand,DOMAIN:EF-hand 1; degenerate,DOMAIN:EF-hand 2,DOMAIN:EF-hand 3,DOMAIN:EF-hand 4,LIPID:S-palmitoyl cysteine,MUTAGEN:D->A: Abolishes cleavage by caspase-3.,REGION:Disordered,REGION:Interaction with KCND2,
KCNS1	potassium voltage-gated channel modifier subfamily S member 1(KCNS1)	Homo sapiens	GO:0006813~potassium ion transport,GO:0051260~protein homooligomerization,GO:0071805~potassium ion transmembrane transport,GO:1902259~regulation of delayed rectifier potassium channel activity,	GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003971:Potassium channel, voltage dependent, Kv9,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,				SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,		COMPBIAS:Polar residues,DOMAIN:BTB,INTRAMEM:Helical; Name=Pore helix,MOTIF:Selectivity filter,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNA1	potassium voltage-gated channel subfamily A member 1(KCNA1)	Homo sapiens	GO:0001964~startle response,GO:0006813~potassium ion transport,GO:0006937~regulation of muscle contraction,GO:0007268~chemical synaptic transmission,GO:0007405~neuroblast proliferation,GO:0008104~protein localization,GO:0010644~cell communication by electrical coupling,GO:0010960~magnesium ion homeostasis,GO:0019228~neuronal action potential,GO:0021554~optic nerve development,GO:0021766~hippocampus development,GO:0021987~cerebral cortex development,GO:0022038~corpus callosum development,GO:0023041~neuronal signal transduction,GO:0034613~cellular protein localization,GO:0034765~regulation of ion transmembrane transport,GO:0042391~regulation of membrane potential,GO:0050905~neuromuscular process,GO:0050966~detection of mechanical stimulus involved in sensory perception of pain,GO:0050976~detection of mechanical stimulus involved in sensory perception of touch,GO:0051260~protein homooligomerization,GO:0060078~regulation of postsynaptic membrane potential,GO:0061564~axon development,GO:0071286~cellular response to magnesium ion,GO:0071805~potassium ion transmembrane transport,GO:0099505~regulation of presynaptic membrane potential,GO:1903818~positive regulation of voltage-gated potassium channel activity,	GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030054~cell junction,GO:0030425~dendrite,GO:0031410~cytoplasmic vesicle,GO:0033270~paranode region of axon,GO:0042734~presynaptic membrane,GO:0043025~neuronal cell body,GO:0043194~axon initial segment,GO:0043204~perikaryon,GO:0043679~axon terminus,GO:0044224~juxtaparanode region of axon,GO:0044305~calyx of Held,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0070161~anchoring junction,GO:0098978~glutamatergic synapse,GO:0099055~integral component of postsynaptic membrane,GO:0099056~integral component of presynaptic membrane,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005267~potassium channel activity,GO:0005515~protein binding,GO:0015079~potassium ion transmembrane transporter activity,GO:0097718~disordered domain specific binding,GO:0099508~voltage-gated ion channel activity involved in regulation of presynaptic membrane potential,GO:1905030~voltage-gated ion channel activity involved in regulation of postsynaptic membrane potential,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003972:Potassium channel, voltage dependent, Kv1,IPR004048:Potassium channel, voltage dependent, Kv1.1,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,		160120~Episodic ataxia/myokymia syndrome,		SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0770~Synapse,KW-0965~Cell junction,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BTB_2,DOMAIN:Ion_trans,INTRAMEM:Helical; Name=Pore helix,LIPID:S-palmitoyl cysteine,MOTIF:PDZ-binding,MOTIF:Selectivity filter,MUTAGEN:C->A: Strongly decreases palmitoylation and alters current kinetics.,MUTAGEN:CC->AA: No effect on palmitoylation, no effect on current kinetics.,MUTAGEN:I->N: Slows down N-type inactivation of heteromeric channels formed by KCNA1 and KCNA4.,MUTAGEN:N->A,H,T: Slightly increases channel activity, but does not affect expression at the cell membrane.,MUTAGEN:N->E: Abolishes channel activity, but does not affect expression at the cell membrane.,MUTAGEN:N->Q: Strongly reduces channel activity, but does not affect expression at the cell membrane.,MUTAGEN:N->V: No effect on channel activity.,MUTAGEN:S->A: Impairs phosphorylation by PKA.,MUTAGEN:S->E: Impairs expression at the cell membrane.,REGION:Disordered,REGION:S4-S5 linker,REGION:Tetramerization domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNA4	potassium voltage-gated channel subfamily A member 4(KCNA4)	Homo sapiens	GO:0006813~potassium ion transport,GO:0034765~regulation of ion transmembrane transport,GO:0051260~protein homooligomerization,GO:0071805~potassium ion transmembrane transport,GO:0099505~regulation of presynaptic membrane potential,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0043194~axon initial segment,GO:0043197~dendritic spine,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0005515~protein binding,GO:0030955~potassium ion binding,GO:0099508~voltage-gated ion channel activity involved in regulation of presynaptic membrane potential,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003972:Potassium channel, voltage dependent, Kv1,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR012897:Potassium channel, voltage dependent, Kv1.4, tandem inactivation domain,IPR020467:Potassium channel, voltage dependent, Kv1.4,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,	hsa04927:Cortisol synthesis and secretion,hsa04934:Cushing syndrome,	618284~Microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum,		SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0898~Cataract,KW-0991~Intellectual disability,KW-1023~Dystonia,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic residues,INTRAMEM:Helical; Name=Pore helix,MOTIF:PDZ-binding,MOTIF:Selectivity filter,REGION:Disordered,REGION:S4-S5 linker,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
KCNAB1	potassium voltage-gated channel subfamily A regulatory beta subunit 1(KCNAB1)	Homo sapiens	GO:0006813~potassium ion transport,GO:0007420~brain development,GO:0007507~heart development,GO:0007519~skeletal muscle tissue development,GO:0034765~regulation of ion transmembrane transport,GO:0045445~myoblast differentiation,GO:0060539~diaphragm development,GO:0071805~potassium ion transmembrane transport,GO:1901379~regulation of potassium ion transmembrane transport,GO:1902259~regulation of delayed rectifier potassium channel activity,GO:1902260~negative regulation of delayed rectifier potassium channel activity,GO:1903817~negative regulation of voltage-gated potassium channel activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016021~integral component of membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0032839~dendrite cytoplasm,GO:0034705~potassium channel complex,GO:0043204~perikaryon,GO:0044224~juxtaparanode region of axon,GO:1990635~proximal dendrite,	GO:0004033~aldo-keto reductase (NADP) activity,GO:0005244~voltage-gated ion channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0015459~potassium channel regulator activity,GO:0019904~protein domain specific binding,GO:0044325~ion channel binding,GO:0047834~D-threo-aldose 1-dehydrogenase activity,GO:0070402~NADPH binding,	IPR005399:Potassium channel, voltage-dependent, beta subunit, KCNAB-related,IPR005400:Potassium channel, voltage-dependent, beta subunit, KCNAB1,IPR005983:Potassium channel, voltage-dependent, beta subunit, KCNAB,IPR023210:NADP-dependent oxidoreductase domain,					KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,			KW-0521~NADP,KW-0630~Potassium,	KW-0407~Ion channel,KW-0560~Oxidoreductase,KW-0851~Voltage-gated channel,		ACT_SITE:Proton donor/acceptor,COMPBIAS:Polar residues,DOMAIN:Aldo_ket_red,MUTAGEN:R->E: Nearly abolishes NADPH binding.,MUTAGEN:Y->F: Reduces affinity for NADPH.,REGION:Disordered,
KCNAB2	potassium voltage-gated channel subfamily A regulatory beta subunit 2(KCNAB2)	Homo sapiens	GO:0006813~potassium ion transport,GO:0034765~regulation of ion transmembrane transport,GO:0070995~NADPH oxidation,GO:0071805~potassium ion transmembrane transport,GO:0098900~regulation of action potential,GO:1901379~regulation of potassium ion transmembrane transport,GO:2000008~regulation of protein localization to cell surface,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0005886~plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0035579~specific granule membrane,GO:0044224~juxtaparanode region of axon,GO:0045202~synapse,GO:0070821~tertiary granule membrane,GO:1990031~pinceau fiber,	GO:0004033~aldo-keto reductase (NADP) activity,GO:0005244~voltage-gated ion channel activity,GO:0005249~voltage-gated potassium channel activity,GO:0005515~protein binding,GO:0015459~potassium channel regulator activity,GO:0044325~ion channel binding,GO:0047834~D-threo-aldose 1-dehydrogenase activity,	IPR005399:Potassium channel, voltage-dependent, beta subunit, KCNAB-related,IPR005401:Potassium channel, voltage-dependent, beta subunit, KCNAB2,IPR005983:Potassium channel, voltage-dependent, beta subunit, KCNAB,IPR023210:NADP-dependent oxidoreductase domain,					KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,			KW-0521~NADP,KW-0630~Potassium,	KW-0407~Ion channel,KW-0560~Oxidoreductase,KW-0851~Voltage-gated channel,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton donor/acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Aldo_ket_red,MUTAGEN:Y->F: No effect on its activity in promoting KCNA4 channel closure.,REGION:Disordered,
KCNC2	potassium voltage-gated channel subfamily C member 2(KCNC2)	Homo sapiens	GO:0001508~action potential,GO:0009642~response to light intensity,GO:0014070~response to organic cyclic compound,GO:0014075~response to amine,GO:0021554~optic nerve development,GO:0021759~globus pallidus development,GO:0032026~response to magnesium ion,GO:0034765~regulation of ion transmembrane transport,GO:0038060~nitric oxide-cGMP-mediated signaling pathway,GO:0045471~response to ethanol,GO:0051260~protein homooligomerization,GO:0051291~protein heterooligomerization,GO:0071242~cellular response to ammonium ion,GO:0071732~cellular response to nitric oxide,GO:0071805~potassium ion transmembrane transport,GO:0097237~cellular response to toxic substance,GO:0099505~regulation of presynaptic membrane potential,GO:1903818~positive regulation of voltage-gated potassium channel activity,GO:1990089~response to nerve growth factor,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008076~voltage-gated potassium channel complex,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0030673~axolemma,GO:0031982~vesicle,GO:0032590~dendrite membrane,GO:0032809~neuronal cell body membrane,GO:0042734~presynaptic membrane,GO:0043195~terminal bouton,GO:0043204~perikaryon,GO:0045202~synapse,GO:0045211~postsynaptic membrane,GO:0098982~GABA-ergic synapse,	GO:0005249~voltage-gated potassium channel activity,GO:0005251~delayed rectifier potassium channel activity,GO:0044325~ion channel binding,GO:0099508~voltage-gated ion channel activity involved in regulation of presynaptic membrane potential,	IPR000210:BTB/POZ-like,IPR003131:Potassium channel tetramerisation-type BTB domain,IPR003968:Potassium channel, voltage dependent, Kv,IPR003974:Potassium channel, voltage dependent, Kv3,IPR005821:Ion transport domain,IPR011333:BTB/POZ fold,IPR027359:Voltage-dependent potassium channel, four helix bundle domain,		619913~Developmental and epileptic encephalopathy 103,		SM00225:BTB,	KW-0406~Ion transport,KW-0633~Potassium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0628~Postsynaptic cell membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0630~Potassium,	KW-0407~Ion channel,KW-0631~Potassium channel,KW-0851~Voltage-gated channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Pro residues,DOMAIN:BTB,REGION:Disordered,REGION:Selectivity filter,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,TRANSMEM:Helical; Name=Segment S1,TRANSMEM:Helical; Name=Segment S2,TRANSMEM:Helical; Name=Segment S3,TRANSMEM:Helical; Name=Segment S5,TRANSMEM:Helical; Name=Segment S6,TRANSMEM:Helical; Voltage-sensor; Name=Segment S4,
PTCRA	pre T cell antigen receptor alpha(PTCRA)	Homo sapiens	GO:0070244~negative regulation of thymocyte apoptotic process,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR013783:Immunoglobulin-like fold,	hsa04330:Notch signaling pathway,hsa05202:Transcriptional misregulation in cancer,					KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (with TCRB),REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PMEL	premelanosome protein(PMEL)	Homo sapiens	GO:0032438~melanosome organization,GO:0042438~melanin biosynthetic process,	GO:0005576~extracellular region,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0032585~multivesicular body membrane,GO:0033106~cis-Golgi network membrane,GO:0033162~melanosome membrane,GO:0042470~melanosome,GO:0070062~extracellular exosome,GO:0097487~multivesicular body, internal vesicle,	GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000601:PKD domain,IPR013783:Immunoglobulin-like fold,IPR022409:PKD/Chitinase domain,				SM00089:PKD,	KW-0470~Melanin biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,KW-0964~Secreted,KW-0967~Endosome,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0730~Sialic acid,		KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DISULFID:Interchain (in monomeric form),DISULFID:Intrachain (in dimeric form),DOMAIN:PKD,MUTAGEN:C->S: Abolishes disulfide linkage rearrangement that converts dimer to monomer.,MUTAGEN:C->S: Abolishes interchain and intrachain disulfide linkage formation.,MUTAGEN:C->S: Does not affect dimer formation.,MUTAGEN:D->A: Forms fibrils at normal levels.,MUTAGEN:F->A: Loss-of-function. Abolishes fibrillar amyloid formation. Does not exert dominant negative effect and retains the amyloidogenic potential; when associated with A-211.,MUTAGEN:F->A: Loss-of-function. Retained in the endoplasmic reticulum likely due to misfolding.,MUTAGEN:F->A: Reduces fibril formation.,MUTAGEN:F->L: Has normal fibril formation. Reduces fibril formation; when associated with L-207.,MUTAGEN:F->L: Has normal fibril formation. Reduces fibril formation; when associated with L-215.,MUTAGEN:F->L: Reduces fibril formation.,MUTAGEN:G->A: Reduces fibril formation.,MUTAGEN:I->A: Loss-of-function. Abolishes fibrillar amyloid formation. Does not exert dominant negative effect and retains the amyloidogenic potential; when associated with A-211.,MUTAGEN:I->A: Loss-of-function. Likely misfolded and rapidly degraded.,MUTAGEN:K->A: Reduces fibril formation.,MUTAGEN:KR->QQ: Loss of proteolytic cleavage.,MUTAGEN:L->A: Loss-of-function. Abolishes fibrillar amyloid formation. Does not exert dominant negative effect and retains the amyloidogenic potential; when associated with A-211.,MUTAGEN:L->A: Reduces fibril formation.,MUTAGEN:LL->AA: Leads to inefficient endocytic trafficking.,MUTAGEN:Missing: Impairs the cleavage of the C-terminal fragment.,MUTAGEN:Missing: Leads to inefficient ER exit, endocytic trafficking and protein maturation.,MUTAGEN:P->A: Reduces fibril formation.,MUTAGEN:Q->A: Reduces fibril formation.,MUTAGEN:QL->DD: Impairs the cleavage of the C-terminal fragment.,MUTAGEN:R->A: Reduces fibril formation.,MUTAGEN:T->A: Markedly reduces fibril formation. Does not exert dominant negative effect; when associated with A-211.,MUTAGEN:T->A: Reduces fibril formation.,MUTAGEN:TQLI->DDDD: Impairs the cleavage of the C-terminal fragment.,MUTAGEN:V->A: Markedly reduces fibril formation.,MUTAGEN:V->A: Reduces fibril formation.,MUTAGEN:V->D: Leads to inefficient ER exit.,MUTAGEN:W->A,F: Loss-of-function. Abolishes fibril formation. Does not exert dominant negative effect; when associated with A-211.,MUTAGEN:W->A,F: Loss-of-function. Abolishes fibrillar amyloid formation. Does not exert dominant negative effect and retains the amyloidogenic potential; when associated with A-211.,MUTAGEN:W->A: Reduces fibril formation.,MUTAGEN:Y->A,L: Loss-of-function. Abolishes fibril formation. Does not exert dominant negative effect; when associated with A-211.,MUTAGEN:Y->A,L: Loss-of-function. Abolishes fibrillar amyloid formation. Does not exert dominant negative effect and retains the amyloidogenic potential; when associated with A-211.,MUTAGEN:Y->A: Reduces fibril formation.,MUTAGEN:Y->F: Has normal fibril formation.,REGION:12 X 13 AA approximate tandem repeats, RPT domain,REGION:Amyloidogenic unit,REGION:Antigenic peptide; presented by A*02:01,REGION:Disordered,REGION:Kringle-like fold,REPEAT:1,REPEAT:10,REPEAT:11,REPEAT:12,REPEAT:2,REPEAT:3,REPEAT:4,REPEAT:5,REPEAT:6,REPEAT:7,REPEAT:8,REPEAT:9,SITE:Cleavage; by ADAM metalloproteinases,SITE:Cleavage; by furin-like proprotein convertase,SITE:ER exit signal,SITE:Endocytosis signal,SITE:Essential for fibril formation,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
PPBP	pro-platelet basic protein(PPBP)	Homo sapiens	GO:0006954~inflammatory response,GO:0030593~neutrophil chemotaxis,GO:0031640~killing of cells of other organism,GO:0042742~defense response to bacterium,GO:0051781~positive regulation of cell division,GO:0061844~antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0070098~chemokine-mediated signaling pathway,GO:0071222~cellular response to lipopolysaccharide,GO:1904659~glucose transmembrane transport,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031091~platelet alpha granule,GO:0031093~platelet alpha granule lumen,GO:1904724~tertiary granule lumen,	GO:0005355~glucose transmembrane transporter activity,GO:0005515~protein binding,GO:0008009~chemokine activity,GO:0008083~growth factor activity,GO:0045236~CXCR chemokine receptor binding,	IPR001089:CXC chemokine,IPR001811:Chemokine interleukin-8-like domain,IPR018048:CXC chemokine, conserved site,	hsa04060:Cytokine-cytokine receptor interaction,hsa04061:Viral protein interaction with cytokine and cytokine receptor,hsa04062:Chemokine signaling pathway,			SM00199:SCY,	KW-0145~Chemotaxis,	KW-0964~Secreted,		KW-0732~Signal,		KW-0044~Antibiotic,KW-0202~Cytokine,KW-0339~Growth factor,KW-0497~Mitogen,KW-0929~Antimicrobial,	KW-0165~Cleavage on pair of basic residues,KW-1015~Disulfide bond,
PCOLCE2	procollagen C-endopeptidase enhancer 2(PCOLCE2)	Homo sapiens	GO:0010952~positive regulation of peptidase activity,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005576~extracellular region,	GO:0005518~collagen binding,GO:0008201~heparin binding,GO:0016504~peptidase activator activity,	IPR000859:CUB domain,IPR001134:Netrin domain,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR018933:Netrin module, non-TIMP type,				SM00042:CUB,SM00643:C345C,		KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:NTR,REGION:Disordered,
PCOLCE	procollagen C-endopeptidase enhancer(PCOLCE)	Homo sapiens	GO:0006508~proteolysis,GO:0007275~multicellular organism development,GO:0010952~positive regulation of peptidase activity,GO:0032964~collagen biosynthetic process,	GO:0005576~extracellular region,GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0070062~extracellular exosome,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008201~heparin binding,GO:0016504~peptidase activator activity,	IPR000859:CUB domain,IPR001134:Netrin domain,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR018933:Netrin module, non-TIMP type,				SM00042:CUB,SM00643:C345C,		KW-0964~Secreted,		KW-0176~Collagen,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:NTR,REGION:Disordered,SITE:Cleavage,
PDCD1LG2	programmed cell death 1 ligand 2(PDCD1LG2)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006955~immune response,GO:0007166~cell surface receptor signaling pathway,GO:0031295~T cell costimulation,GO:0032689~negative regulation of interferon-gamma production,GO:0032693~negative regulation of interleukin-10 production,GO:0042102~positive regulation of T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0046007~negative regulation of activated T cell proliferation,GO:0071222~cellular response to lipopolysaccharide,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0012505~endomembrane system,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,			SM00409:IG,	KW-0391~Immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PRLHR	prolactin releasing hormone receptor(PRLHR)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007218~neuropeptide signaling pathway,GO:0007565~female pregnancy,GO:0007631~feeding behavior,GO:0042445~hormone metabolic process,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005929~cilium,GO:0016021~integral component of membrane,GO:0043005~neuron projection,	GO:0004930~G-protein coupled receptor activity,GO:0004983~neuropeptide Y receptor activity,GO:0005515~protein binding,GO:0008188~neuropeptide receptor activity,GO:0042923~neuropeptide binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001402:Prolactin-releasing peptide receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04080:Neuroactive ligand-receptor interaction,			SM01381:SM01381,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,MUTAGEN:I->A: Abolishes binding to GRIP1.,MUTAGEN:Missing: Abolishes binding to GRIP1 and PICK1.,MUTAGEN:S->A: Abolishes binding to GRIP1.,MUTAGEN:T->A: No effect on binding to GRIP1.,MUTAGEN:V->A: Abolishes binding to GRIP1.,MUTAGEN:V->A: No effect on binding to GRIP1.,REGION:Required for interaction with GRIP1, GRIP2 and PICK1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PEA15	proliferation and apoptosis adaptor protein 15(PEA15)	Homo sapiens	GO:0000165~MAPK cascade,GO:0006915~apoptotic process,GO:0008643~carbohydrate transport,GO:0042981~regulation of apoptotic process,GO:0043278~response to morphine,GO:0046325~negative regulation of glucose import,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902043~positive regulation of extrinsic apoptotic signaling pathway via death domain receptors,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005875~microtubule associated complex,	GO:0005515~protein binding,	IPR001875:Death effector domain,IPR011029:Death-like domain,				SM00031:DED,	KW-0053~Apoptosis,KW-0762~Sugar transport,KW-0813~Transport,	KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	DOMAIN:DED,REGION:Microtubule-binding,
PRR3	proline rich 3(PRR3)	Homo sapiens			GO:0003723~RNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000571:Zinc finger, CCCH-type,				SM00356:ZnF_C3H1,				KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Pro residues,DOMAIN:C3H1-type,REGION:Disordered,ZN_FING:C3H1-type,
PRRC2A	proline rich coiled-coil 2A(PRRC2A)	Homo sapiens	GO:0030154~cell differentiation,	GO:0005654~nucleoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR009738:BAT2, N-terminal,						KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:BAT2_N,REGION:2 X type B repeats,REGION:3 X 50 AA type C repeats,REGION:4 X 57 AA type A repeats,REGION:Disordered,REPEAT:1-1,REPEAT:1-2,REPEAT:1-3,REPEAT:1-4,REPEAT:2-1,REPEAT:2-2,REPEAT:3-1,REPEAT:3-2,REPEAT:3-3,
PCSK2	proprotein convertase subtilisin/kexin type 2(PCSK2)	Homo sapiens	GO:0006508~proteolysis,GO:0007399~nervous system development,GO:0016485~protein processing,GO:0016486~peptide hormone processing,GO:0016540~protein autoprocessing,GO:0030070~insulin processing,GO:0034230~enkephalin processing,GO:0034231~islet amyloid polypeptide processing,	GO:0005615~extracellular space,GO:0005654~nucleoplasm,GO:0016020~membrane,GO:0030133~transport vesicle,GO:0030141~secretory granule,GO:0030425~dendrite,GO:0043005~neuron projection,GO:0043204~perikaryon,GO:0043231~intracellular membrane-bounded organelle,	GO:0004252~serine-type endopeptidase activity,GO:0005515~protein binding,	IPR000209:Peptidase S8/S53 domain,IPR002884:Proprotein convertase, P,IPR008979:Galactose-binding domain-like,IPR015500:Peptidase S8, subtilisin-related,IPR022398:Peptidase S8, subtilisin, His-active site,IPR023827:Peptidase S8, subtilisin,  Asp-active site,IPR023828:Peptidase S8, subtilisin, Ser-active site,						KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:P/Homo B,DOMAIN:Peptidase S8,
PTGER3	prostaglandin E receptor 3(PTGER3)	Homo sapiens	GO:0006954~inflammatory response,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0008219~cell death,GO:0014827~intestine smooth muscle contraction,GO:0031622~positive regulation of fever generation,GO:0060455~negative regulation of gastric acid secretion,	GO:0005635~nuclear envelope,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004957~prostaglandin E receptor activity,	IPR000265:Prostanoid EP3 receptor,IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001244:Prostaglandin DP receptor,IPR001481:Prostanoid EP3 receptor, type 2,IPR008365:Prostanoid receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,hsa04923:Regulation of lipolysis in adipocytes,hsa05163:Human cytomegalovirus infection,hsa05200:Pathways in cancer,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
PSMB9	proteasome 20S subunit beta 9(PSMB9)	Homo sapiens	GO:0002376~immune system process,GO:0010498~proteasomal protein catabolic process,GO:0010499~proteasomal ubiquitin-independent protein catabolic process,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0051603~proteolysis involved in cellular protein catabolic process,GO:2000116~regulation of cysteine-type endopeptidase activity,	GO:0000502~proteasome complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005839~proteasome core complex,GO:0019774~proteasome core complex, beta-subunit complex,GO:0070062~extracellular exosome,GO:1990111~spermatoproteasome complex,	GO:0004175~endopeptidase activity,GO:0004298~threonine-type endopeptidase activity,GO:0005515~protein binding,	IPR000243:Peptidase T1A, proteasome beta-subunit,IPR001353:Proteasome, subunit alpha/beta,IPR016050:Proteasome, beta-type subunit, conserved site,IPR023333:Proteasome B-type subunit,	hsa03050:Proteasome,	617591~Proteasome-associated autoinflammatory syndrome 3, digenic,			KW-0391~Immunity,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0647~Proteasome,KW-0963~Cytoplasm,				KW-0378~Hydrolase,KW-0645~Protease,KW-0888~Threonine protease,	KW-0007~Acetylation,KW-0865~Zymogen,	ACT_SITE:Nucleophile,MUTAGEN:G->A: Impairs correct processing at the consensus site.,MUTAGEN:K->A: Impairs correct processing at the consensus site.,MUTAGEN:T->A: Impairs correct processing at the consensus site.,PROPEP:Removed in mature form,SITE:Cleavage; by autolysis,
PACSIN1	protein kinase C and casein kinase substrate in neurons 1(PACSIN1)	Homo sapiens	GO:0007010~cytoskeleton organization,GO:0007015~actin filament organization,GO:0030100~regulation of endocytosis,GO:0045806~negative regulation of endocytosis,GO:0048488~synaptic vesicle endocytosis,GO:0048666~neuron development,GO:0048812~neuron projection morphogenesis,GO:0072657~protein localization to membrane,GO:0072659~protein localization to plasma membrane,GO:0097320~plasma membrane tubulation,GO:1900006~positive regulation of dendrite development,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0030137~COPI-coated vesicle,GO:0030659~cytoplasmic vesicle membrane,GO:0032587~ruffle membrane,GO:0043005~neuron projection,GO:0043679~axon terminus,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098684~photoreceptor ribbon synapse,GO:0098833~presynaptic endocytic zone,	GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008092~cytoskeletal protein binding,GO:0016301~kinase activity,GO:0042802~identical protein binding,	IPR001060:FCH domain,IPR001452:Src homology-3 domain,IPR027267:Arfaptin homology (AH) domain/BAR domain,				SM00055:FCH,SM00326:SH3,	KW-0254~Endocytosis,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0728~SH3 domain,	KW-0446~Lipid-binding,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:F-BAR,DOMAIN:SH3,MUTAGEN:I->E: Reduces membrane-binding. Abolishes membrane tubulation.,MUTAGEN:M->E: Reduces membrane-binding. Abolishes membrane tubulation.,REGION:Disordered,
PRKCB	protein kinase C beta(PRKCB)	Homo sapiens	GO:0002250~adaptive immune response,GO:0006325~chromatin organization,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006468~protein phosphorylation,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0006915~apoptotic process,GO:0007077~mitotic nuclear envelope disassembly,GO:0007165~signal transduction,GO:0010827~regulation of glucose transport,GO:0010829~negative regulation of glucose transport,GO:0016570~histone modification,GO:0018105~peptidyl-serine phosphorylation,GO:0030949~positive regulation of vascular endothelial growth factor receptor signaling pathway,GO:0035408~histone H3-T6 phosphorylation,GO:0035556~intracellular signal transduction,GO:0042113~B cell activation,GO:0042953~lipoprotein transport,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0043687~post-translational protein modification,GO:0045766~positive regulation of angiogenesis,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0050853~B cell receptor signaling pathway,GO:0050861~positive regulation of B cell receptor signaling pathway,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0071322~cellular response to carbohydrate stimulus,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008091~spectrin,GO:0044305~calyx of Held,GO:0070062~extracellular exosome,GO:0099523~presynaptic cytosol,	GO:0003682~chromatin binding,GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0005080~protein kinase C binding,GO:0005246~calcium channel regulator activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0030374~ligand-dependent nuclear receptor transcription coactivator activity,GO:0035403~histone kinase activity (H3-T6 specific),GO:0042393~histone binding,GO:0050681~androgen receptor binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014375:Protein kinase C, alpha/beta/gamma types,IPR015727:Protein kinase C mu-related,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04062:Chemokine signaling pathway,hsa04064:NF-kappa B signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04150:mTOR signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04662:B cell receptor signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04912:GnRH signaling pathway,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04931:Insulin resistance,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa04973:Carbohydrate digestion and absorption,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05140:Leishmaniasis,hsa05143:African trypanosomiasis,hsa05146:Amoebiasis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05164:Influenza A,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05214:Glioma,hsa05223:Non-small cell lung cancer,hsa05225:Hepatocellular carcinoma,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,		PIRSF000550:protein kinase C, alpha/beta/gamma types,	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,SM00239:C2,	KW-0053~Apoptosis,KW-0391~Immunity,KW-0804~Transcription,KW-0805~Transcription regulation,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0156~Chromatin regulator,KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Protein kinase,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PRKCG	protein kinase C gamma(PRKCG)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0007268~chemical synaptic transmission,GO:0007611~learning or memory,GO:0007635~chemosensory behavior,GO:0009636~response to toxic substance,GO:0016310~phosphorylation,GO:0018105~peptidyl-serine phosphorylation,GO:0031397~negative regulation of protein ubiquitination,GO:0032095~regulation of response to food,GO:0032425~positive regulation of mismatch repair,GO:0035556~intracellular signal transduction,GO:0042177~negative regulation of protein catabolic process,GO:0042752~regulation of circadian rhythm,GO:0043278~response to morphine,GO:0043524~negative regulation of neuron apoptotic process,GO:0046777~protein autophosphorylation,GO:0048265~response to pain,GO:0048511~rhythmic process,GO:0050764~regulation of phagocytosis,GO:0060291~long-term synaptic potentiation,GO:0060384~innervation,GO:1901799~negative regulation of proteasomal protein catabolic process,GO:1990911~response to psychosocial stress,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005911~cell-cell junction,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0030425~dendrite,GO:0044305~calyx of Held,GO:0048471~perinuclear region of cytoplasm,GO:0097060~synaptic membrane,GO:0099523~presynaptic cytosol,GO:0099524~postsynaptic cytosol,	GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0004697~protein kinase C activity,GO:0004698~calcium-dependent protein kinase C activity,GO:0004712~protein serine/threonine/tyrosine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR000719:Protein kinase, catalytic domain,IPR000961:AGC-kinase, C-terminal,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR014375:Protein kinase C, alpha/beta/gamma types,IPR015727:Protein kinase C mu-related,IPR017441:Protein kinase, ATP binding site,IPR017892:Protein kinase, C-terminal,IPR020454:Diacylglycerol/phorbol-ester binding,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04012:ErbB signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04070:Phosphatidylinositol signaling system,hsa04071:Sphingolipid signaling pathway,hsa04150:mTOR signaling pathway,hsa04270:Vascular smooth muscle contraction,hsa04310:Wnt signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04540:Gap junction,hsa04613:Neutrophil extracellular trap formation,hsa04650:Natural killer cell mediated cytotoxicity,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04713:Circadian entrainment,hsa04720:Long-term potentiation,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa04725:Cholinergic synapse,hsa04726:Serotonergic synapse,hsa04727:GABAergic synapse,hsa04728:Dopaminergic synapse,hsa04730:Long-term depression,hsa04750:Inflammatory mediator regulation of TRP channels,hsa04911:Insulin secretion,hsa04916:Melanogenesis,hsa04918:Thyroid hormone synthesis,hsa04919:Thyroid hormone signaling pathway,hsa04921:Oxytocin signaling pathway,hsa04925:Aldosterone synthesis and secretion,hsa04928:Parathyroid hormone synthesis, secretion and action,hsa04929:GnRH secretion,hsa04935:Growth hormone synthesis, secretion and action,hsa04960:Aldosterone-regulated sodium reabsorption,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04970:Salivary secretion,hsa04971:Gastric acid secretion,hsa04972:Pancreatic secretion,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,hsa05032:Morphine addiction,hsa05143:African trypanosomiasis,hsa05146:Amoebiasis,hsa05161:Hepatitis B,hsa05163:Human cytomegalovirus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05171:Coronavirus disease - COVID-19,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05214:Glioma,hsa05223:Non-small cell lung cancer,hsa05225:Hepatocellular carcinoma,hsa05231:Choline metabolism in cancer,hsa05415:Diabetic cardiomyopathy,	605361~Spinocerebellar ataxia 14,	PIRSF000550:protein kinase C, alpha/beta/gamma types,	SM00109:C1,SM00133:S_TK_X,SM00220:S_TKc,SM00239:C2,	KW-0090~Biological rhythms,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0067~ATP-binding,KW-0106~Calcium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,DOMAIN:AGC-kinase C-terminal,DOMAIN:C2,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:Protein kinase,ZN_FING:Phorbol-ester/DAG-type 1,ZN_FING:Phorbol-ester/DAG-type 2,
PPP1R1A	protein phosphatase 1 regulatory inhibitor subunit 1A(PPP1R1A)	Homo sapiens	GO:0005977~glycogen metabolic process,GO:0007165~signal transduction,GO:0035556~intracellular signal transduction,GO:0043086~negative regulation of catalytic activity,	GO:0005737~cytoplasm,	GO:0004864~protein phosphatase inhibitor activity,GO:0004865~protein serine/threonine phosphatase inhibitor activity,GO:0005515~protein binding,	IPR008466:Protein phosphatase inhibitor, 1DARPP-32,	hsa04261:Adrenergic signaling in cardiomyocytes,hsa04720:Long-term potentiation,				KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,					KW-0650~Protein phosphatase inhibitor,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:T->A: No activity.,MUTAGEN:T->D: 1000-fold reduction in activity, inhibits equally PP1 and PP2A.,REGION:Disordered,REGION:Essential for activity,REGION:Interaction with PPP1R15A,
PPP1R10	protein phosphatase 1 regulatory subunit 10(PPP1R10)	Homo sapiens	GO:0006606~protein import into nucleus,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0032206~positive regulation of telomere maintenance,GO:0043086~negative regulation of catalytic activity,GO:1904290~negative regulation of mitotic DNA damage checkpoint,	GO:0000781~chromosome, telomeric region,GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0016604~nuclear body,GO:0072357~PTW/PP1 phosphatase complex,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0004864~protein phosphatase inhibitor activity,GO:0005515~protein binding,GO:0008157~protein phosphatase 1 binding,GO:0046872~metal ion binding,	IPR000571:Zinc finger, CCCH-type,IPR003617:Transcription elongation factor, TFIIS/CRSP70, N-terminal, sub-type,IPR017923:Transcription factor IIS, N-terminal,				SM00356:ZnF_C3H1,SM00509:TFS2N,		KW-0539~Nucleus,		KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0650~Protein phosphatase inhibitor,KW-0694~RNA-binding,	KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C3H1-type,DOMAIN:TFIIS N-terminal,MOTIF:PP1-binding motif,REGION:Disordered,REGION:Essential for PPP1CA inhibition,REGION:Interaction with TOX4,REGION:Interaction with WDR82,REGION:Necessary for interaction with PPP1CA,REGION:Necessary for interaction with PPP1CC,ZN_FING:C3H1-type,
PPP2R2C	protein phosphatase 2 regulatory subunit Bgamma(PPP2R2C)	Homo sapiens	GO:0050790~regulation of catalytic activity,GO:0070262~peptidyl-serine dephosphorylation,	GO:0000159~protein phosphatase type 2A complex,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,	IPR000009:Protein phosphatase 2A, regulatory subunit PR55,IPR001680:WD40 repeat,IPR015943:WD40/YVTN repeat-like-containing domain,IPR018067:Protein phosphatase 2A, regulatory subunit PR55, conserved site,	hsa03015:mRNA surveillance pathway,hsa04071:Sphingolipid signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04152:AMPK signaling pathway,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04390:Hippo signaling pathway,hsa04530:Tight junction,hsa04728:Dopaminergic synapse,hsa05142:Chagas disease,hsa05160:Hepatitis C,hsa05165:Human papillomavirus infection,		PIRSF037309:serine/threonine-protein phosphatase 2A, subunit B55,	SM00320:WD40,				KW-0677~Repeat,KW-0853~WD repeat,				REGION:Disordered,REPEAT:WD 1,REPEAT:WD 2,REPEAT:WD 3,REPEAT:WD 4,REPEAT:WD 5,REPEAT:WD 6,REPEAT:WD 7,
PPP4R4	protein phosphatase 4 regulatory subunit 4(PPP4R4)	Homo sapiens	GO:0001835~blastocyst hatching,GO:0032515~negative regulation of phosphoprotein phosphatase activity,GO:0080163~regulation of protein serine/threonine phosphatase activity,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0008287~protein serine/threonine phosphatase complex,	GO:0005515~protein binding,GO:0019888~protein phosphatase regulator activity,	IPR011989:Armadillo-like helical,IPR016024:Armadillo-type fold,IPR021133:HEAT, type 2,						KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:R->W: Abolishes interaction with PPP4C.,MUTAGEN:V->A: Diminishes interaction with PPP4C.,MUTAGEN:V->D: Abolishes interaction with PPP4C.,REGION:Disordered,REPEAT:HEAT 1,REPEAT:HEAT 2,REPEAT:HEAT 3,
PPM1L	protein phosphatase, Mg2+/Mn2+ dependent 1L(PPM1L)	Homo sapiens	GO:0000165~MAPK cascade,GO:0006470~protein dephosphorylation,GO:0007178~transmembrane receptor protein serine/threonine kinase signaling pathway,GO:0030148~sphingolipid biosynthetic process,	GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0004722~protein serine/threonine phosphatase activity,GO:0017018~myosin phosphatase activity,GO:0046872~metal ion binding,	IPR000222:Protein phosphatase 2C, manganese/magnesium aspartate binding site,IPR001932:Protein phosphatase 2C (PP2C)-like,IPR015655:Protein phosphatase 2C,				SM00331:PP2C_SIG,SM00332:PP2Cc,		KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0460~Magnesium,KW-0464~Manganese,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0904~Protein phosphatase,		DOMAIN:PPM-type phosphatase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPN22	protein tyrosine phosphatase non-receptor type 22(PTPN22)	Homo sapiens	GO:0002230~positive regulation of defense response to virus by host,GO:0002685~regulation of leukocyte migration,GO:0006470~protein dephosphorylation,GO:0006629~lipid metabolic process,GO:0006914~autophagy,GO:0010507~negative regulation of autophagy,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0030217~T cell differentiation,GO:0031663~lipopolysaccharide-mediated signaling pathway,GO:0032481~positive regulation of type I interferon production,GO:0032496~response to lipopolysaccharide,GO:0032715~negative regulation of interleukin-6 production,GO:0032717~negative regulation of interleukin-8 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0032729~positive regulation of interferon-gamma production,GO:0032817~regulation of natural killer cell proliferation,GO:0034141~positive regulation of toll-like receptor 3 signaling pathway,GO:0034145~positive regulation of toll-like receptor 4 signaling pathway,GO:0034157~positive regulation of toll-like receptor 7 signaling pathway,GO:0034165~positive regulation of toll-like receptor 9 signaling pathway,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0035644~phosphoanandamide dephosphorylation,GO:0042307~positive regulation of protein import into nucleus,GO:0043508~negative regulation of JUN kinase activity,GO:0045088~regulation of innate immune response,GO:0050730~regulation of peptidyl-tyrosine phosphorylation,GO:0050852~T cell receptor signaling pathway,GO:0050855~regulation of B cell receptor signaling pathway,GO:0050856~regulation of T cell receptor signaling pathway,GO:0050860~negative regulation of T cell receptor signaling pathway,GO:0050868~negative regulation of T cell activation,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0070433~negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,GO:0071225~cellular response to muramyl dipeptide,GO:0071663~positive regulation of granzyme B production,GO:1901222~regulation of NIK/NF-kappaB signaling,GO:1902523~positive regulation of protein K63-linked ubiquitination,GO:1903169~regulation of calcium ion transmembrane transport,GO:1903753~negative regulation of p38MAPK cascade,GO:2000566~positive regulation of CD8-positive, alpha-beta T cell proliferation,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0009898~cytoplasmic side of plasma membrane,GO:0048471~perinuclear region of cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0004726~non-membrane spanning protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0016791~phosphatase activity,GO:0017124~SH3 domain binding,GO:0019900~kinase binding,GO:0031625~ubiquitin protein ligase binding,GO:1990782~protein tyrosine kinase binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR016130:Protein-tyrosine phosphatase, active site,IPR016276:Non-receptor tyrosine-protein phosphatase, 8/22,		152700~Systemic lupus erythematosus susceptibility to,180300~Rheumatoid arthritis, susceptibility to,222100~Diabetes, type 1, susceptibility to,	PIRSF000930:non-receptor tyrosine-protein phosphatase, 8/22 types,	SM00194:PTPc,SM00404:PTPc_motif,	KW-0072~Autophagy,KW-0391~Immunity,KW-0443~Lipid metabolism,	KW-0963~Cytoplasm,	KW-0219~Diabetes mellitus,KW-0225~Disease variant,KW-0772~Systemic lupus erythematosus,			KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,MUTAGEN:C->S: Decreases activity 2 fold.,MUTAGEN:C->S: Decreases activity 7 fold.,MUTAGEN:S->E: Loss of phosphorylation by PKC/PRKCD.,MUTAGEN:T->E: No effect on phosphorylation by PKC/PRKCD.,REGION:Disordered,
PTPRR	protein tyrosine phosphatase receptor type R(PTPRR)	Homo sapiens	GO:0001701~in utero embryonic development,GO:0006470~protein dephosphorylation,GO:0007165~signal transduction,GO:0010633~negative regulation of epithelial cell migration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0038128~ERBB2 signaling pathway,GO:0070373~negative regulation of ERK1 and ERK2 cascade,	GO:0005615~extracellular space,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030054~cell junction,GO:0048471~perinuclear region of cytoplasm,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR008356:Protein-tyrosine phosphatase, KIM-containing,IPR016130:Protein-tyrosine phosphatase, active site,IPR016334:Protein-tyrosine phosphatase, receptor type R/non-receptor type 5,	hsa04010:MAPK signaling pathway,		PIRSF001997:receptor tyrosine-protein phosphatase, types R/5,	SM00194:PTPc,SM00404:PTPc_motif,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PTPRT	protein tyrosine phosphatase receptor type T(PTPRT)	Homo sapiens	GO:0006470~protein dephosphorylation,GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007165~signal transduction,GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0030336~negative regulation of cell migration,GO:0035335~peptidyl-tyrosine dephosphorylation,GO:0050807~regulation of synapse organization,GO:0071354~cellular response to interleukin-6,GO:1904893~negative regulation of STAT cascade,GO:1990264~peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0098978~glutamatergic synapse,GO:0099061~integral component of postsynaptic density membrane,	GO:0004725~protein tyrosine phosphatase activity,GO:0005001~transmembrane receptor protein tyrosine phosphatase activity,GO:0005515~protein binding,GO:0008013~beta-catenin binding,GO:0016790~thiolester hydrolase activity,GO:0019903~protein phosphatase binding,GO:0042803~protein homodimerization activity,GO:0045294~alpha-catenin binding,GO:0045295~gamma-catenin binding,GO:0045296~cadherin binding,GO:0051393~alpha-actinin binding,GO:0070097~delta-catenin binding,GO:0097677~STAT family protein binding,	IPR000242:Protein-tyrosine phosphatase, receptor/non-receptor type,IPR000387:Protein-tyrosine/Dual specificity phosphatase,IPR000998:MAM domain,IPR003595:Protein-tyrosine phosphatase, catalytic,IPR003961:Fibronectin, type III,IPR007110:Immunoglobulin-like domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR016130:Protein-tyrosine phosphatase, active site,				SM00060:FN3,SM00137:MAM,SM00194:PTPc,SM00404:PTPc_motif,		KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0675~Receptor,KW-0904~Protein phosphatase,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	ACT_SITE:Phosphocysteine intermediate,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:MAM,DOMAIN:TYR_PHOSPHATASE_2,DOMAIN:Tyrosine-protein phosphatase,DOMAIN:Tyrosine-protein phosphatase 1,DOMAIN:Tyrosine-protein phosphatase 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PLP2	proteolipid protein 2(PLP2)	Homo sapiens	GO:0006811~ion transport,GO:0006935~chemotaxis,GO:0019221~cytokine-mediated signaling pathway,GO:0034220~ion transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0015075~ion transmembrane transporter activity,GO:0019956~chemokine binding,	IPR008253:Marvel,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:MARVEL,TRANSMEM:Helical,
PCDH7	protocadherin 7(PCDH7)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0031092~platelet alpha granule membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR013585:Protocadherin,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,DOMAIN:Cadherin 7,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHA7	protocadherin alpha 7(PCDHA7)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,GO:0009988~cell-cell recognition,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005509~calcium ion binding,GO:0042802~identical protein binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:5 X 4 AA repeats of P-X-X-P,REGION:Disordered,REPEAT:PXXP 1,REPEAT:PXXP 2,REPEAT:PXXP 3,REPEAT:PXXP 4,REPEAT:PXXP 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHA8	protocadherin alpha 8(PCDHA8)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Cadherin,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:5 X 4 AA repeats of P-X-X-P,REGION:Disordered,REPEAT:PXXP 1,REPEAT:PXXP 2,REPEAT:PXXP 3,REPEAT:PXXP 4,REPEAT:PXXP 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHGA1	protocadherin gamma subfamily A, 1(PCDHGA1)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHGA11	protocadherin gamma subfamily A, 11(PCDHGA11)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHGA12	protocadherin gamma subfamily A, 12(PCDHGA12)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005911~cell-cell junction,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PCDHGB7	protocadherin gamma subfamily B, 7(PCDHGB7)	Homo sapiens	GO:0007155~cell adhesion,GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules,GO:0007399~nervous system development,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005509~calcium ion binding,	IPR002126:Cadherin,IPR013164:Cadherin, N-terminal,IPR015919:Cadherin-like,IPR020894:Cadherin conserved site,				SM00112:CA,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:Cadherin 1,DOMAIN:Cadherin 2,DOMAIN:Cadherin 3,DOMAIN:Cadherin 4,DOMAIN:Cadherin 5,DOMAIN:Cadherin 6,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PSORS1C1	psoriasis susceptibility 1 candidate 1(PSORS1C1)	Homo sapiens																COMPBIAS:Polar residues,REGION:Disordered,
RHOD	ras homolog family member D(RHOD)	Homo sapiens	GO:0007015~actin filament organization,GO:0007163~establishment or maintenance of cell polarity,GO:0007266~Rho protein signal transduction,GO:0008360~regulation of cell shape,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030335~positive regulation of cell migration,GO:0030865~cortical cytoskeleton organization,GO:0032956~regulation of actin cytoskeleton organization,GO:0045785~positive regulation of cell adhesion,GO:0048041~focal adhesion assembly,GO:0050790~regulation of catalytic activity,GO:0051017~actin filament bundle assembly,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0000139~Golgi membrane,GO:0005741~mitochondrial outer membrane,GO:0005769~early endosome,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0010008~endosome membrane,GO:0031410~cytoplasmic vesicle,GO:0042995~cell projection,GO:0043231~intracellular membrane-bounded organelle,	GO:0003924~GTPase activity,GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005525~GTP binding,GO:0019901~protein kinase binding,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa04360:Axon guidance,					KW-0472~Membrane,KW-0967~Endosome,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0636~Prenylation,	LIPID:S-geranylgeranyl cysteine,MOTIF:Effector region,MUTAGEN:C->S: Abolishes endosomal localization.,PROPEP:Removed in mature form,
RHOJ	ras homolog family member J(RHOJ)	Homo sapiens	GO:0001525~angiogenesis,GO:0006897~endocytosis,GO:0007163~establishment or maintenance of cell polarity,GO:0007264~small GTPase mediated signal transduction,GO:0007266~Rho protein signal transduction,GO:0008360~regulation of cell shape,GO:0010594~regulation of endothelial cell migration,GO:0016477~cell migration,GO:0030031~cell projection assembly,GO:0030036~actin cytoskeleton organization,GO:0032488~Cdc42 protein signal transduction,GO:0061299~retina vasculature morphogenesis in camera-type eye,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:1903670~regulation of sprouting angiogenesis,	GO:0005886~plasma membrane,GO:0070062~extracellular exosome,	GO:0003924~GTPase activity,GO:0005515~protein binding,GO:0005525~GTP binding,	IPR001806:Small GTPase superfamily,IPR003578:Small GTPase superfamily, Rho type,IPR005225:Small GTP-binding protein domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa05132:Salmonella infection,				KW-0037~Angiogenesis,	KW-0472~Membrane,KW-1003~Cell membrane,			KW-0342~GTP-binding,KW-0547~Nucleotide-binding,		KW-0449~Lipoprotein,KW-0488~Methylation,KW-0564~Palmitate,KW-0636~Prenylation,	LIPID:S-farnesyl cysteine,LIPID:S-palmitoyl cysteine,MOTIF:Effector region,MUTAGEN:C->A: Impaired localization to the plasma membrane.,MUTAGEN:DE->AA: Does not affect localization to the plasma membrane.,MUTAGEN:DEKK->AAAA: Impaired localization to the plasma membrane.,MUTAGEN:G->V: Causes constitutive activation.,MUTAGEN:KK->AA: Impaired localization to the plasma membrane.,MUTAGEN:Q->L: Causes constitutive activation.,MUTAGEN:T->N: Dominant negative mutant.,PROPEP:Removed in mature form,REGION:Disordered,
RAMP3	receptor activity modifying protein 3(RAMP3)	Homo sapiens	GO:0001525~angiogenesis,GO:0001921~positive regulation of receptor recycling,GO:0006816~calcium ion transport,GO:0006886~intracellular protein transport,GO:0007186~G-protein coupled receptor signaling pathway,GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0010628~positive regulation of gene expression,GO:0010739~positive regulation of protein kinase A signaling,GO:0010942~positive regulation of cell death,GO:0015031~protein transport,GO:0031623~receptor internalization,GO:0032870~cellular response to hormone stimulus,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0038041~cross-receptor inhibition within G-protein coupled receptor heterodimer,GO:0051897~positive regulation of protein kinase B signaling,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071392~cellular response to estradiol stimulus,GO:0072659~protein localization to plasma membrane,GO:0086103~G-protein coupled receptor signaling pathway involved in heart process,GO:0097647~amylin receptor signaling pathway,GO:1903078~positive regulation of protein localization to plasma membrane,GO:1904645~response to beta-amyloid,GO:1905665~positive regulation of calcium ion import across plasma membrane,GO:1990410~adrenomedullin receptor signaling pathway,	GO:0005764~lysosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0043235~receptor complex,GO:1903143~adrenomedullin receptor complex,	GO:0001540~beta-amyloid binding,GO:0001605~adrenomedullin receptor activity,GO:0005515~protein binding,GO:0015026~coreceptor activity,GO:0097643~amylin receptor activity,	IPR006985:Receptor activity modifying protein,	hsa04270:Vascular smooth muscle contraction,				KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
RTP5	receptor transporter protein 5 (putative)(RTP5)	Homo sapiens	GO:0001580~detection of chemical stimulus involved in sensory perception of bitter taste,GO:0006612~protein targeting to membrane,GO:0051205~protein insertion into membrane,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0031849~olfactory receptor binding,	IPR026096:Receptor-transporting protein/CXXC-type zinc finger protein 11,IPR026689:CXXC-type zinc finger protein 11,IPR027377:Zinc-binding domain,				SM01328:SM01328,		KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
RIMS1	regulating synaptic membrane exocytosis 1(RIMS1)	Homo sapiens	GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0007601~visual perception,GO:0010628~positive regulation of gene expression,GO:0016079~synaptic vesicle exocytosis,GO:0017156~calcium ion regulated exocytosis,GO:0030154~cell differentiation,GO:0042391~regulation of membrane potential,GO:0045055~regulated exocytosis,GO:0046903~secretion,GO:0046928~regulation of neurotransmitter secretion,GO:0048167~regulation of synaptic plasticity,GO:0048791~calcium ion-regulated exocytosis of neurotransmitter,GO:0050790~regulation of catalytic activity,GO:0050806~positive regulation of synaptic transmission,GO:0050896~response to stimulus,GO:0060478~acrosomal vesicle exocytosis,GO:0061025~membrane fusion,GO:0065003~macromolecular complex assembly,GO:0097151~positive regulation of inhibitory postsynaptic potential,GO:1903861~positive regulation of dendrite extension,GO:2000300~regulation of synaptic vesicle exocytosis,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0042734~presynaptic membrane,GO:0042995~cell projection,GO:0048786~presynaptic active zone,GO:0048788~cytoskeleton of presynaptic active zone,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0030695~GTPase regulator activity,GO:0031267~small GTPase binding,GO:0044325~ion channel binding,GO:0046872~metal ion binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR001478:PDZ domain,IPR010911:Rab-binding domain,IPR011011:Zinc finger, FYVE/PHD-type,IPR017455:Zinc finger, FYVE-related,	hsa04721:Synaptic vesicle cycle,hsa04723:Retrograde endocannabinoid signaling,	603649~Cone-rod dystrophy 7,		SM00228:PDZ,SM00239:C2,	KW-0221~Differentiation,KW-0268~Exocytosis,KW-0532~Neurotransmitter transport,KW-0716~Sensory transduction,KW-0813~Transport,KW-0844~Vision,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,	KW-0677~Repeat,KW-0732~Signal,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:PDZ,DOMAIN:RabBD,MUTAGEN:KK->AA: Abolishes interaction with SYT1 and CACNA1B.,MUTAGEN:RR->AA: Abolishes interaction with SYT1 and CACNA1B.,REGION:Disordered,ZN_FING:FYVE-type,
RIMS3	regulating synaptic membrane exocytosis 3(RIMS3)	Homo sapiens	GO:0006887~exocytosis,GO:0017156~calcium ion regulated exocytosis,GO:0042391~regulation of membrane potential,GO:0048167~regulation of synaptic plasticity,GO:0048791~calcium ion-regulated exocytosis of neurotransmitter,GO:0050806~positive regulation of synaptic transmission,GO:2000300~regulation of synaptic vesicle exocytosis,	GO:0016020~membrane,GO:0042734~presynaptic membrane,GO:0048786~presynaptic active zone,GO:0048788~cytoskeleton of presynaptic active zone,	GO:0005515~protein binding,GO:0031267~small GTPase binding,GO:0044325~ion channel binding,	IPR000008:C2 calcium-dependent membrane targeting,				SM00239:C2,	KW-0268~Exocytosis,KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0770~Synapse,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:C2,REGION:Disordered,
RGS16	regulator of G protein signaling 16(RGS16)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007601~visual perception,GO:0008277~regulation of G-protein coupled receptor protein signaling pathway,GO:0009968~negative regulation of signal transduction,GO:0043547~positive regulation of GTPase activity,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0031224~intrinsic component of membrane,	GO:0003924~GTPase activity,GO:0005096~GTPase activator activity,GO:0005515~protein binding,GO:0005516~calmodulin binding,	IPR016137:Regulator of G protein signalling superfamily,IPR024066:Regulator of G-protein signaling, domain 1,				SM00315:RGS,		KW-0472~Membrane,				KW-0343~GTPase activation,KW-0734~Signal transduction inhibitor,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:RGS,LIPID:S-palmitoyl cysteine,MUTAGEN:Y->F: 30% decrease in GAP activity.,MUTAGEN:Y->F: No effect on GAP activity.,
RGS7BP	regulator of G protein signaling 7 binding protein(RGS7BP)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0009968~negative regulation of signal transduction,GO:0060078~regulation of postsynaptic membrane potential,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0030424~axon,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0043198~dendritic shaft,GO:0043204~perikaryon,GO:0044327~dendritic spine head,GO:0098794~postsynapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099026~anchored component of presynaptic membrane,GO:0099031~anchored component of postsynaptic density membrane,		IPR026512:RGS7BP/RGS9BP family,						KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,				KW-0734~Signal transduction inhibitor,	KW-0449~Lipoprotein,KW-0564~Palmitate,	COMPBIAS:Polar residues,LIPID:S-palmitoyl cysteine,MOTIF:Nuclear localization signal,REGION:Disordered,
RXFP1	relaxin family peptide receptor 1(RXFP1)	Homo sapiens	GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007190~activation of adenylate cyclase activity,GO:0007567~parturition,GO:0009755~hormone-mediated signaling pathway,GO:0030154~cell differentiation,GO:0030198~extracellular matrix organization,GO:0036446~myofibroblast differentiation,GO:0060427~lung connective tissue development,GO:0060658~nipple morphogenesis,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008528~G-protein coupled peptide receptor activity,GO:0042562~hormone binding,GO:0046872~metal ion binding,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001611:Leucine-rich repeat,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR008112:Relaxin receptor,IPR017452:GPCR, rhodopsin-like, 7TM,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04926:Relaxin signaling pathway,			SM00192:LDLa,SM00369:LRR_TYP,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,DOMAIN:LDL-receptor class A,DOMAIN:LRRNT,MUTAGEN:D->Y: Leads to constitutive increase of basal cAMP.,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
RPRML	reprimo like(RPRML)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TRANSMEM:Helical,
RTN4RL1	reticulon 4 receptor like 1(RTN4RL1)	Homo sapiens	GO:0010977~negative regulation of neuron projection development,GO:0022038~corpus callosum development,GO:0031103~axon regeneration,GO:0048681~negative regulation of axon regeneration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0031012~extracellular matrix,GO:0042995~cell projection,GO:0043204~perikaryon,GO:0045121~membrane raft,GO:0046658~anchored component of plasma membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008201~heparin binding,GO:0035374~chondroitin sulfate binding,GO:0038023~signaling receptor activity,	IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,				SM00082:LRRCT,SM00369:LRR_TYP,		KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,	COMPBIAS:Basic residues,DOMAIN:LRRCT,DOMAIN:LRRNT,LIPID:GPI-anchor amidated serine,PROPEP:Removed in mature form,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,
RTN4R	reticulon 4 receptor(RTN4R)	Homo sapiens	GO:0007166~cell surface receptor signaling pathway,GO:0007409~axonogenesis,GO:0010977~negative regulation of neuron projection development,GO:0022038~corpus callosum development,GO:0023041~neuronal signal transduction,GO:0030517~negative regulation of axon extension,GO:0035025~positive regulation of Rho protein signal transduction,GO:0043547~positive regulation of GTPase activity,GO:0048681~negative regulation of axon regeneration,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0031362~anchored component of external side of plasma membrane,GO:0043005~neuron projection,GO:0043025~neuronal cell body,GO:0043198~dendritic shaft,GO:0043204~perikaryon,GO:0044295~axonal growth cone,GO:0045121~membrane raft,GO:0070062~extracellular exosome,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0008201~heparin binding,GO:0035374~chondroitin sulfate binding,GO:0038023~signaling receptor activity,GO:0038131~neuregulin receptor activity,GO:0044877~macromolecular complex binding,GO:1905573~ganglioside GM1 binding,GO:1905576~ganglioside GT1b binding,	IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,		181500~Schizophrenia, susceptibility to,		SM00082:LRRCT,SM00369:LRR_TYP,		KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1211~Schizophrenia,	KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,	KW-0446~Lipid-binding,	KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0336~GPI-anchor,KW-0449~Lipoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRCT,DOMAIN:LRRNT,LIPID:GPI-anchor amidated serine,MUTAGEN:K->A: No effect on interaction with MAG.,MUTAGEN:K->D: Decreases interaction with MAG; when associated with D-279.,MUTAGEN:R->A: Mildly decreases interaction with MAG.,MUTAGEN:R->D: Decreases interaction with MAG; when associated with D-277.,MUTAGEN:R->E: Impaired ganglioside binding.,PROPEP:Removed in mature form,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
RGR	retinal G protein coupled receptor(RGR)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0007601~visual perception,GO:0007602~phototransduction,GO:0009584~detection of visible light,GO:0018298~protein-chromophore linkage,GO:0071482~cellular response to light stimulus,	GO:0001750~photoreceptor outer segment,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0005515~protein binding,GO:0008020~G-protein coupled photoreceptor activity,GO:0009881~photoreceptor activity,	IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001793:Retinal pigment epithelium GPCR,IPR017452:GPCR, rhodopsin-like, 7TM,IPR027430:Visual pigments (opsins) retinal binding site,		613769~Retinitis pigmentosa 44,			KW-0716~Sensory transduction,KW-0844~Vision,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0157~Chromophore,	KW-0297~G-protein coupled receptor,KW-0600~Photoreceptor protein,KW-0675~Receptor,KW-0681~Retinal protein,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:G_PROTEIN_RECEP_F1_2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
RARRES2	retinoic acid receptor responder 2(RARRES2)	Homo sapiens	GO:0001523~retinoid metabolic process,GO:0001934~positive regulation of protein phosphorylation,GO:0003084~positive regulation of systemic arterial blood pressure,GO:0006935~chemotaxis,GO:0006954~inflammatory response,GO:0008286~insulin receptor signaling pathway,GO:0010759~positive regulation of macrophage chemotaxis,GO:0014823~response to activity,GO:0019732~antifungal humoral response,GO:0030154~cell differentiation,GO:0032869~cellular response to insulin stimulus,GO:0045087~innate immune response,GO:0045600~positive regulation of fat cell differentiation,GO:0048566~embryonic digestive tract development,GO:0050829~defense response to Gram-negative bacterium,GO:0050830~defense response to Gram-positive bacterium,GO:0050921~positive regulation of chemotaxis,GO:0050994~regulation of lipid catabolic process,GO:0061760~antifungal innate immune response,GO:0061771~response to caloric restriction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0031089~platelet dense granule lumen,	GO:0005102~receptor binding,GO:0005515~protein binding,						KW-0145~Chemotaxis,KW-0221~Differentiation,KW-0395~Inflammatory response,	KW-0964~Secreted,		KW-0732~Signal,		KW-0675~Receptor,	KW-1015~Disulfide bond,	REGION:Disordered,
RNASE2	ribonuclease A family member 2(RNASE2)	Homo sapiens	GO:0002227~innate immune response in mucosa,GO:0006401~RNA catabolic process,GO:0006935~chemotaxis,GO:0051607~defense response to virus,GO:0090501~RNA phosphodiester bond hydrolysis,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,	GO:0003676~nucleic acid binding,GO:0004519~endonuclease activity,GO:0004522~ribonuclease A activity,GO:0004540~ribonuclease activity,GO:0005515~protein binding,GO:0016829~lyase activity,	IPR001427:Ribonuclease A,IPR023411:Ribonuclease A, active site,IPR023412:Ribonuclease A-domain,				SM00092:RNAse_Pc,	KW-0145~Chemotaxis,	KW-0458~Lysosome,		KW-0732~Signal,		KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0456~Lyase,KW-0528~Neurotoxin,KW-0540~Nuclease,KW-0800~Toxin,	KW-0325~Glycoprotein,KW-0944~Nitration,KW-1015~Disulfide bond,	ACT_SITE:Proton acceptor,ACT_SITE:Proton donor,CARBOHYD:C-linked (Man) tryptophan,CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:RNAse_Pc,
RNH1	ribonuclease/angiogenin inhibitor 1(RNH1)	Homo sapiens	GO:0006402~mRNA catabolic process,GO:0043086~negative regulation of catalytic activity,GO:0045765~regulation of angiogenesis,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032311~angiogenin-PRI complex,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008428~ribonuclease inhibitor activity,	IPR001611:Leucine-rich repeat,IPR006553:Leucine-rich repeat, cysteine-containing subtype,				SM00367:LRR_CC,		KW-0963~Cytoplasm,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	MUTAGEN:Missing: A significant decrease in binding affinity with RNASE1, slight decrease for the ANG ligand, no real change in binding affinity for RNASE2.,MUTAGEN:R->A: 25-fold reduction in binding affinity for RNASE2.,MUTAGEN:W->A: 40-fold reduction in binding affinity for RNASE2.,MUTAGEN:W->A: Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-264 and A-319.,MUTAGEN:W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-264.,MUTAGEN:W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-319.,MUTAGEN:YD->AA: Substantially decreases binding affinity for RNASE1, ANG and RNASE2.,REGION:2 X 5 AA tandem repeats of S-L-D-I-Q,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,
RPS18	ribosomal protein S18(RPS18)	Homo sapiens	GO:0002181~cytoplasmic translation,GO:0006412~translation,	GO:0005581~collagen trimer,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0014069~postsynaptic density,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0070062~extracellular exosome,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,	IPR001892:Ribosomal protein S13,IPR010979:Ribosomal protein S13-like, H2TH,IPR018269:Ribosomal protein S13, conserved site,IPR027437:30s ribosomal protein S13, C-terminal,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,		PIRSF002134:ribosomal protein, S13p/S13a/S18e/organellar S13 types,			KW-0963~Cytoplasm,		KW-0176~Collagen,		KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,
RPS9	ribosomal protein S9(RPS9)	Homo sapiens	GO:0002181~cytoplasmic translation,GO:0006412~translation,GO:0008284~positive regulation of cell proliferation,GO:0042274~ribosomal small subunit biogenesis,GO:0045903~positive regulation of translational fidelity,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005925~focal adhesion,GO:0015935~small ribosomal subunit,GO:0016020~membrane,GO:0022626~cytosolic ribosome,GO:0022627~cytosolic small ribosomal subunit,GO:0045202~synapse,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003735~structural constituent of ribosome,GO:0005515~protein binding,GO:0019843~rRNA binding,GO:0045182~translation regulator activity,GO:1990932~5.8S rRNA binding,	IPR001912:Ribosomal protein S4/S9, N-terminal,IPR002942:RNA-binding S4 domain,IPR005710:Ribosomal protein S4/S9, eukaryotic/archaeal,IPR018079:Ribosomal protein S4, conserved site,IPR022801:Ribosomal protein S4/S9,	hsa03010:Ribosome,hsa05171:Coronavirus disease - COVID-19,			SM00363:S4,SM01390:SM01390,		KW-0963~Cytoplasm,				KW-0687~Ribonucleoprotein,KW-0689~Ribosomal protein,KW-0694~RNA-binding,KW-0699~rRNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Ribosomal_S4,DOMAIN:S4,DOMAIN:S4 RNA-binding,REGION:Disordered,
RNF5	ring finger protein 5(RNF5)	Homo sapiens	GO:0006511~ubiquitin-dependent protein catabolic process,GO:0009617~response to bacterium,GO:0010507~negative regulation of autophagy,GO:0016567~protein ubiquitination,GO:0030163~protein catabolic process,GO:0030433~ubiquitin-dependent ERAD pathway,GO:0031648~protein destabilization,GO:0036503~ERAD pathway,GO:0044257~cellular protein catabolic process,GO:0055085~transmembrane transport,GO:0070534~protein K63-linked ubiquitination,GO:0070936~protein K48-linked ubiquitination,GO:0071712~ER-associated misfolded protein catabolic process,GO:1904380~endoplasmic reticulum mannose trimming,GO:2000785~regulation of autophagosome assembly,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,GO:0044322~endoplasmic reticulum quality control compartment,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0044390~ubiquitin-like protein conjugating enzyme binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,	hsa04141:Protein processing in endoplasmic reticulum,			SM00184:RING,	KW-0833~Ubl conjugation pathway,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0496~Mitochondrion,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-0863~Zinc-finger,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	DOMAIN:RING-type,MUTAGEN:C->S: Loss of E3 ubiquitin-protein ligase activity.,REGION:Disordered,TRANSMEM:Helical,ZN_FING:RING-type,
RYR2	ryanodine receptor 2(RYR2)	Homo sapiens	GO:0001666~response to hypoxia,GO:0002027~regulation of heart rate,GO:0003143~embryonic heart tube morphogenesis,GO:0003220~left ventricular cardiac muscle tissue morphogenesis,GO:0003300~cardiac muscle hypertrophy,GO:0005513~detection of calcium ion,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0010460~positive regulation of heart rate,GO:0010881~regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion,GO:0010882~regulation of cardiac muscle contraction by calcium ion signaling,GO:0014808~release of sequestered calcium ion into cytosol by sarcoplasmic reticulum,GO:0014850~response to muscle activity,GO:0019722~calcium-mediated signaling,GO:0031000~response to caffeine,GO:0035584~calcium-mediated signaling using intracellular calcium source,GO:0035994~response to muscle stretch,GO:0051209~release of sequestered calcium ion into cytosol,GO:0051284~positive regulation of sequestering of calcium ion,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051649~establishment of localization in cell,GO:0051775~response to redox state,GO:0055117~regulation of cardiac muscle contraction,GO:0060048~cardiac muscle contraction,GO:0060402~calcium ion transport into cytosol,GO:0070296~sarcoplasmic reticulum calcium ion transport,GO:0071313~cellular response to caffeine,GO:0071872~cellular response to epinephrine stimulus,GO:0072599~establishment of protein localization to endoplasmic reticulum,GO:0086005~ventricular cardiac muscle cell action potential,GO:0086029~Purkinje myocyte to ventricular cardiac muscle cell signaling,GO:0086064~cell communication by electrical coupling involved in cardiac conduction,GO:0097050~type B pancreatic cell apoptotic process,GO:0098735~positive regulation of the force of heart contraction,GO:0098904~regulation of AV node cell action potential,GO:0098907~regulation of SA node cell action potential,GO:0098910~regulation of atrial cardiac muscle cell action potential,GO:0098911~regulation of ventricular cardiac muscle cell action potential,GO:1901896~positive regulation of calcium-transporting ATPase activity,	GO:0005790~smooth endoplasmic reticulum,GO:0005886~plasma membrane,GO:0014701~junctional sarcoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0030018~Z disc,GO:0030659~cytoplasmic vesicle membrane,GO:0032991~macromolecular complex,GO:0033017~sarcoplasmic reticulum membrane,GO:0034704~calcium channel complex,GO:0042383~sarcolemma,	GO:0005219~ryanodine-sensitive calcium-release channel activity,GO:0005262~calcium channel activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0015278~calcium-release channel activity,GO:0019899~enzyme binding,GO:0034236~protein kinase A catalytic subunit binding,GO:0034237~protein kinase A regulatory subunit binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0043924~suramin binding,GO:0044325~ion channel binding,GO:0048763~calcium-induced calcium release activity,	IPR000699:Intracellular calcium-release channel,IPR001870:B30.2/SPRY domain,IPR002048:EF-hand domain,IPR003032:Ryanodine receptor Ryr,IPR003877:SPla/RYanodine receptor SPRY,IPR005821:Ion transport domain,IPR009460:Ryanodine Receptor TM 4-6,IPR011992:EF-hand-like domain,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013333:Ryanodine receptor,IPR013662:RyR/IP3R Homology associated domain,IPR014821:Inositol 1,4,5-trisphosphate/ryanodine receptor,IPR016093:MIR motif,	hsa04020:Calcium signaling pathway,hsa04024:cAMP signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04371:Apelin signaling pathway,hsa04713:Circadian entrainment,hsa04911:Insulin secretion,hsa04921:Oxytocin signaling pathway,hsa04972:Pancreatic secretion,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,hsa05415:Diabetic cardiomyopathy,	115000~Ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome,600996~Arrhythmogenic right ventricular dysplasia 2,604772~Ventricular tachycardia, catecholaminergic polymorphic, 1,		SM00449:SPRY,SM00472:MIR,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,	KW-0122~Cardiomyopathy,KW-0225~Disease variant,	KW-0175~Coiled coil,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0112~Calmodulin-binding,KW-0217~Developmental protein,KW-0407~Ion channel,KW-0675~Receptor,KW-1071~Ligand-gated ion channel,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:B30.2/SPRY 1,DOMAIN:B30.2/SPRY 2,DOMAIN:B30.2/SPRY 3,DOMAIN:EF-hand,DOMAIN:MIR 1,DOMAIN:MIR 2,DOMAIN:MIR 3,DOMAIN:MIR 4,DOMAIN:MIR 5,INTRAMEM:Pore-forming,MUTAGEN:D->N: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:G->A: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:H->N: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:H->Q: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:I->M: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:I->V: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:M->I: Changed ryanodine-sensitive calcium-release channel activity characterized by increased sensitivity to cytosolic calcium activation.,MUTAGEN:Q->H: Decreased function in release of sequestered calcium ion into cytosol by sarcoplasmic reticulum. Changed ryanodine-sensitive calcium-release channel activity. Mutant channels are less resposive to activation by caffeine and store calcium overload. Affects channel sensitivity to cytosolic and luminal calcium activation.,MUTAGEN:S->A: Abolishes phosphorylation by PKA.,REGION:4 X approximate repeats,REGION:Disordered,REGION:Interaction with CALM,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
SLN	sarcolipin(SLN)	Homo sapiens	GO:0006816~calcium ion transport,GO:0043086~negative regulation of catalytic activity,GO:0043242~negative regulation of protein complex disassembly,GO:0051924~regulation of calcium ion transport,GO:0070296~sarcoplasmic reticulum calcium ion transport,GO:0090281~negative regulation of calcium ion import,GO:1901020~negative regulation of calcium ion transmembrane transporter activity,GO:1901077~regulation of relaxation of muscle,GO:1901877~negative regulation of calcium ion binding,GO:1901881~positive regulation of protein depolymerization,GO:1901894~regulation of calcium-transporting ATPase activity,GO:1901895~negative regulation of calcium-transporting ATPase activity,	GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016529~sarcoplasmic reticulum,GO:0033017~sarcoplasmic reticulum membrane,	GO:0004857~enzyme inhibitor activity,GO:0005515~protein binding,GO:0030234~enzyme regulator activity,GO:0051117~ATPase binding,	IPR008028:Sarcolipin,						KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0703~Sarcoplasmic reticulum,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				PEPTIDE:Sarcolipin,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SECTM1	secreted and transmembrane 1(SECTM1)	Homo sapiens	GO:0006955~immune response,GO:0007165~signal transduction,GO:0007498~mesoderm development,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,	GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005515~protein binding,	IPR013783:Immunoglobulin-like fold,						KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SFRP2	secreted frizzled related protein 2(SFRP2)	Homo sapiens	GO:0001569~branching involved in blood vessel morphogenesis,GO:0002063~chondrocyte development,GO:0003151~outflow tract morphogenesis,GO:0003214~cardiac left ventricle morphogenesis,GO:0003402~planar cell polarity pathway involved in axis elongation,GO:0006915~apoptotic process,GO:0007267~cell-cell signaling,GO:0007501~mesodermal cell fate specification,GO:0007584~response to nutrient,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0008584~male gonad development,GO:0009410~response to xenobiotic stimulus,GO:0010629~negative regulation of gene expression,GO:0010659~cardiac muscle cell apoptotic process,GO:0010667~negative regulation of cardiac muscle cell apoptotic process,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0010950~positive regulation of endopeptidase activity,GO:0010975~regulation of neuron projection development,GO:0016055~Wnt signaling pathway,GO:0030154~cell differentiation,GO:0030178~negative regulation of Wnt signaling pathway,GO:0030199~collagen fibril organization,GO:0030307~positive regulation of cell growth,GO:0030308~negative regulation of cell growth,GO:0030336~negative regulation of cell migration,GO:0030509~BMP signaling pathway,GO:0030514~negative regulation of BMP signaling pathway,GO:0031668~cellular response to extracellular stimulus,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0033630~positive regulation of cell adhesion mediated by integrin,GO:0035567~non-canonical Wnt signaling pathway,GO:0036342~post-anal tail morphogenesis,GO:0042493~response to drug,GO:0042662~negative regulation of mesodermal cell fate specification,GO:0042733~embryonic digit morphogenesis,GO:0043065~positive regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043508~negative regulation of JUN kinase activity,GO:0045600~positive regulation of fat cell differentiation,GO:0045669~positive regulation of osteoblast differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048546~digestive tract morphogenesis,GO:0048866~stem cell fate specification,GO:0050680~negative regulation of epithelial cell proliferation,GO:0050732~negative regulation of peptidyl-tyrosine phosphorylation,GO:0060028~convergent extension involved in axis elongation,GO:0060070~canonical Wnt signaling pathway,GO:0060349~bone morphogenesis,GO:0061056~sclerotome development,GO:0061185~negative regulation of dermatome development,GO:0071425~hematopoietic stem cell proliferation,GO:0071481~cellular response to X-ray,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0090179~planar cell polarity pathway involved in neural tube closure,GO:0090244~Wnt signaling pathway involved in somitogenesis,GO:0090263~positive regulation of canonical Wnt signaling pathway,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:1904956~regulation of midbrain dopaminergic neuron differentiation,GO:2000035~regulation of stem cell division,GO:2000041~negative regulation of planar cell polarity pathway involved in axis elongation,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0001968~fibronectin binding,GO:0005178~integrin binding,GO:0017147~Wnt-protein binding,GO:0048018~receptor agonist activity,GO:0061133~endopeptidase activator activity,	IPR001134:Netrin domain,IPR008993:Tissue inhibitor of metalloproteinases-like, OB-fold,IPR015526:Frizzled/secreted frizzled-related protein,IPR018933:Netrin module, non-TIMP type,IPR020067:Frizzled domain,IPR026558:Secreted frizzled-related protein 2,	hsa04310:Wnt signaling pathway,			SM00063:FRI,SM00643:C345C,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-1015~Disulfide bond,	DOMAIN:FZ,DOMAIN:NTR,
SPP1	secreted phosphoprotein 1(SPP1)	Homo sapiens	GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0006710~androgen catabolic process,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007165~signal transduction,GO:0007566~embryo implantation,GO:0031214~biomineral tissue development,GO:0033280~response to vitamin D,GO:0036005~response to macrophage colony-stimulating factor,GO:0045780~positive regulation of bone resorption,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046697~decidualization,GO:0048545~response to steroid hormone,GO:0048685~negative regulation of collateral sprouting of intact axon in response to injury,GO:0071394~cellular response to testosterone stimulus,GO:2000866~positive regulation of estradiol secretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0031982~vesicle,GO:0042995~cell projection,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005125~cytokine activity,GO:0005178~integrin binding,GO:0005515~protein binding,GO:0036094~small molecule binding,GO:0043167~ion binding,GO:0050840~extracellular matrix binding,	IPR002038:Osteopontin,IPR019841:Osteopontin, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04371:Apelin signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa04620:Toll-like receptor signaling pathway,hsa04929:GnRH secretion,hsa05165:Human papillomavirus infection,			SM00017:OSTEO,	KW-0091~Biomineralization,KW-0130~Cell adhesion,	KW-0964~Secreted,		KW-0732~Signal,	KW-0730~Sialic acid,	KW-0202~Cytokine,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MOTIF:Cell attachment site,REGION:Disordered,
SCG3	secretogranin III(SCG3)	Homo sapiens	GO:0033366~protein localization to secretory granule,	GO:0005576~extracellular region,GO:0005788~endoplasmic reticulum lumen,GO:0030658~transport vesicle membrane,GO:0030667~secretory granule membrane,GO:0034774~secretory granule lumen,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR026197:Secretogranin III,						KW-0472~Membrane,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,			KW-0165~Cleavage on pair of basic residues,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:O-linked (GalNAc...) serine,CARBOHYD:O-linked (GalNAc...) threonine,COMPBIAS:Basic and acidic residues,REGION:Disordered,
SLPI	secretory leukocyte peptidase inhibitor(SLPI)	Homo sapiens	GO:0006955~immune response,GO:0010951~negative regulation of endopeptidase activity,GO:0019731~antibacterial humoral response,GO:0032091~negative regulation of protein binding,GO:0032496~response to lipopolysaccharide,GO:0035821~modification of morphology or physiology of other organism,GO:0045071~negative regulation of viral genome replication,GO:0045087~innate immune response,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005794~Golgi apparatus,GO:0035580~specific granule lumen,GO:0070062~extracellular exosome,	GO:0003677~DNA binding,GO:0003729~mRNA binding,GO:0004866~endopeptidase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0019899~enzyme binding,	IPR008197:Whey acidic protein-type  4-disulphide core,				SM00217:WAP,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0044~Antibiotic,KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,KW-0929~Antimicrobial,	KW-1015~Disulfide bond,	DOMAIN:WAP 1,DOMAIN:WAP 2,MUTAGEN:L->F: Increases inhibition of chymotrypsin.,MUTAGEN:L->G: No significant effect on inhibition of elastase, trypsin and chymotrypsin.,MUTAGEN:L->G: Reduced inhibition of elastase. Strongly reduced inhibition of chymotrypsin and trypsin.,MUTAGEN:L->K,R: Strongly reduced inhibition of elastase. Abolishes inhibition of trypsin.,MUTAGEN:M->G: No significant effect on inhibition of elastase, trypsin and chymotrypsin.,MUTAGEN:R->G: No significant effect on inhibition of elastase, trypsin and chymotrypsin.,MUTAGEN:R->M,V: No significant effect on inhibition of elastase, trypsin and chymotrypsin.,REGION:Elastase inhibitory domain,SITE:Reactive bond for chymotrypsin, trypsin and elastase,
SEZ6L	seizure related 6 homolog like(SEZ6L)	Homo sapiens	GO:0060074~synapse maturation,GO:0090036~regulation of protein kinase C signaling,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0043025~neuronal cell body,		IPR000436:Sushi/SCR/CCP,IPR000859:CUB domain,				SM00032:CCP,SM00042:CUB,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) serine,COMPBIAS:Polar residues,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:CUB 3,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,DOMAIN:Sushi 4,DOMAIN:Sushi 5,REGION:Disordered,REGION:O-glycosylated at one site,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SEZ6	seizure related 6 homolog(SEZ6)	Homo sapiens	GO:0008344~adult locomotory behavior,GO:0021680~cerebellar Purkinje cell layer development,GO:0050773~regulation of dendrite development,GO:0060074~synapse maturation,GO:0060079~excitatory postsynaptic potential,GO:0090036~regulation of protein kinase C signaling,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043198~dendritic shaft,GO:0048471~perinuclear region of cytoplasm,GO:0097440~apical dendrite,	GO:0005515~protein binding,	IPR000436:Sushi/SCR/CCP,IPR000859:CUB domain,				SM00032:CCP,SM00042:CUB,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:CUB,DOMAIN:CUB 1,DOMAIN:CUB 2,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,DOMAIN:Sushi 4,DOMAIN:Sushi 5,REGION:Disordered,REGION:O-glycosylated at two sites,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SELL	selectin L(SELL)	Homo sapiens	GO:0007155~cell adhesion,GO:0007159~leukocyte cell-cell adhesion,GO:0016339~calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,GO:0050900~leukocyte migration,GO:0050901~leukocyte tethering or rolling,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0002020~protease binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0030246~carbohydrate binding,GO:0043208~glycosphingolipid binding,GO:0046872~metal ion binding,GO:0070492~oligosaccharide binding,	IPR000436:Sushi/SCR/CCP,IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR002396:Selectin superfamily,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR016348:L-selectin,IPR018378:C-type lectin, conserved site,	hsa04514:Cell adhesion molecules,		PIRSF002421:L-selectin,	SM00032:CCP,SM00034:CLECT,SM00181:EGF,	KW-0130~Cell adhesion,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0430~Lectin,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:C-type lectin,DOMAIN:EGF-like,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,MUTAGEN:E->D: Impairs interaction with cognate oligosaccharide. Abolishes cell rolling on glycan ligands.,MUTAGEN:N->Q: Loss of one glycosylation site.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SEMA4A	semaphorin 4A(SEMA4A)	Homo sapiens	GO:0001525~angiogenesis,GO:0001755~neural crest cell migration,GO:0007399~nervous system development,GO:0007411~axon guidance,GO:0008360~regulation of cell shape,GO:0010594~regulation of endothelial cell migration,GO:0016525~negative regulation of angiogenesis,GO:0030154~cell differentiation,GO:0030335~positive regulation of cell migration,GO:0045063~T-helper 1 cell differentiation,GO:0048843~negative regulation of axon extension involved in axon guidance,GO:0050919~negative chemotaxis,GO:0071526~semaphorin-plexin signaling pathway,GO:1904891~positive regulation of excitatory synapse assembly,GO:1905704~positive regulation of inhibitory synapse assembly,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0030215~semaphorin receptor binding,GO:0045499~chemorepellent activity,	IPR001627:Semaphorin/CD100 antigen,IPR002165:Plexin,IPR015943:WD40/YVTN repeat-like-containing domain,IPR016201:Plexin-like fold,IPR027231:Semaphorin,	hsa04360:Axon guidance,	610282~Retinitis pigmentosa 35,610283~Cone-rod dystrophy 10,		SM00423:PSI,SM00630:Sema,	KW-0037~Angiogenesis,KW-0221~Differentiation,KW-0391~Immunity,KW-0524~Neurogenesis,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0182~Cone-rod dystrophy,KW-0225~Disease variant,KW-0682~Retinitis pigmentosa,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like C2-type,DOMAIN:PSI,DOMAIN:Sema,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
PRSS3	serine protease 3(PRSS3)	Homo sapiens	GO:0006508~proteolysis,GO:0007586~digestion,GO:0019730~antimicrobial humoral response,GO:0031638~zymogen activation,GO:0043542~endothelial cell migration,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:1904724~tertiary granule lumen,	GO:0004252~serine-type endopeptidase activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,	IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR018114:Peptidase S1, trypsin family, active site,	hsa04080:Neuroactive ligand-receptor interaction,hsa04972:Pancreatic secretion,hsa04974:Protein digestion and absorption,hsa05164:Influenza A,			SM00020:Tryp_SPc,	KW-0222~Digestion,	KW-0964~Secreted,		KW-0732~Signal,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0765~Sulfation,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,DOMAIN:Peptidase S1,MUTAGEN:S->A: Loss of catalytic activity.,PROPEP:Activation peptide,SITE:Required for specificity,
SERTM1	serine rich and transmembrane domain containing 1(SERTM1)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,							KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				TRANSMEM:Helical,
SRRM3	serine/arginine repetitive matrix 3(SRRM3)	Homo sapiens		GO:0005634~nucleus,	GO:0003729~mRNA binding,	IPR013170:mRNA splicing factor, Cwf21,				SM01115:SM01115,								COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:cwf21,REGION:Disordered,
SRRM4	serine/arginine repetitive matrix 4(SRRM4)	Homo sapiens	GO:0000381~regulation of alternative mRNA splicing, via spliceosome,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0007605~sensory perception of sound,GO:0008380~RNA splicing,GO:0030154~cell differentiation,GO:0042551~neuron maturation,GO:0043484~regulation of RNA splicing,	GO:0005634~nucleus,	GO:0003729~mRNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,						KW-0221~Differentiation,KW-0507~mRNA processing,KW-0508~mRNA splicing,	KW-0539~Nucleus,				KW-0694~RNA-binding,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:SRRM_C,REGION:Disordered,
STK19	serine/threonine kinase 19(STK19)	Homo sapiens	GO:0006468~protein phosphorylation,GO:0046579~positive regulation of Ras protein signal transduction,	GO:0005634~nucleus,GO:0016607~nuclear speck,	GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,GO:0016301~kinase activity,GO:0031267~small GTPase binding,	IPR018865:Serine-threonine protein kinase 19,						KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0464~Manganese,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		COMPBIAS:Basic and acidic residues,MUTAGEN:K->P: Complete loss of activity.,MUTAGEN:K->P: Partial loss of activity.,MUTAGEN:L->V: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.,MUTAGEN:V->Y: Prevents inhibition by ZT-12-037-01 (1a) without affecting much the serine/threonine-protein kinase activity.,REGION:Disordered,
STK32B	serine/threonine kinase 32B(STK32B)	Homo sapiens	GO:0018105~peptidyl-serine phosphorylation,GO:0035556~intracellular signal transduction,		GO:0004672~protein kinase activity,GO:0004674~protein serine/threonine kinase activity,GO:0005524~ATP binding,GO:0046872~metal ion binding,	IPR000719:Protein kinase, catalytic domain,IPR008271:Serine/threonine-protein kinase, active site,IPR011009:Protein kinase-like domain,IPR017441:Protein kinase, ATP binding site,				SM00220:S_TKc,					KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0723~Serine/threonine-protein kinase,KW-0808~Transferase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,REGION:Disordered,
STYK1	serine/threonine/tyrosine kinase 1(STYK1)	Homo sapiens	GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway,GO:0018108~peptidyl-tyrosine phosphorylation,GO:0030154~cell differentiation,GO:0045087~innate immune response,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,	GO:0004672~protein kinase activity,GO:0004713~protein tyrosine kinase activity,GO:0004714~transmembrane receptor protein tyrosine kinase activity,GO:0004715~non-membrane spanning protein tyrosine kinase activity,GO:0005102~receptor binding,GO:0005515~protein binding,GO:0005524~ATP binding,	IPR000719:Protein kinase, catalytic domain,IPR001245:Serine-threonine/tyrosine-protein kinase catalytic domain,IPR008266:Tyrosine-protein kinase, active site,IPR011009:Protein kinase-like domain,						KW-0472~Membrane,	KW-0656~Proto-oncogene,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0418~Kinase,KW-0808~Transferase,KW-0829~Tyrosine-protein kinase,		ACT_SITE:Proton acceptor,DOMAIN:Protein kinase,REGION:Disordered,TRANSMEM:Helical,
SERPINA1	serpin family A member 1(SERPINA1)	Homo sapiens	GO:0006953~acute-phase response,GO:0007596~blood coagulation,GO:0010951~negative regulation of endopeptidase activity,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005794~Golgi apparatus,GO:0030134~ER to Golgi transport vesicle,GO:0031093~platelet alpha granule lumen,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,GO:1904813~ficolin-1-rich granule lumen,	GO:0002020~protease binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04610:Complement and coagulation cascades,	613490~Emphysema due to AAT deficiency,613490~Emphysema-cirrhosis, due to AAT deficiency,613490~Hemorrhagic diathesis due to antithrombin Pittsburgh,		SM00093:SERPIN,	KW-0011~Acute phase,KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:SERPIN,MUTAGEN:M->V: Oxidation-resistant inhibitor of therapeutic importance.,PEPTIDE:Short peptide from AAT,REGION:Disordered,REGION:RCL,SITE:(Microbial infection) Cleavage; by Staphylococcus aureus aureolysin/Aur,SITE:(Microbial infection) Cleavage; by Staphylococcus aureus serine and cysteine proteinases,SITE:Reactive bond,
SERPINA3	serpin family A member 3(SERPINA3)	Homo sapiens	GO:0006953~acute-phase response,GO:0006954~inflammatory response,GO:0010951~negative regulation of endopeptidase activity,GO:0019216~regulation of lipid metabolic process,GO:0030277~maintenance of gastrointestinal epithelium,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0031093~platelet alpha granule lumen,GO:0034774~secretory granule lumen,GO:0035578~azurophil granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0003677~DNA binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,		Alpha-1-antichymotrypsin deficiency~Alpha-1-antichymotrypsin deficiency,Cerebrovascular disease, occlusive~Cerebrovascular disease, occlusive,		SM00093:SERPIN,	KW-0011~Acute phase,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SERPIN,REGION:O-glycosylated at one site,REGION:RCL,SITE:Reactive bond,
SERPINA5	serpin family A member 5(SERPINA5)	Homo sapiens	GO:0006869~lipid transport,GO:0007283~spermatogenesis,GO:0007342~fusion of sperm to egg plasma membrane,GO:0010951~negative regulation of endopeptidase activity,GO:0051346~negative regulation of hydrolase activity,GO:0061107~seminal vesicle development,	GO:0002080~acrosomal membrane,GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0009897~external side of plasma membrane,GO:0016020~membrane,GO:0031091~platelet alpha granule,GO:0031094~platelet dense tubular network,GO:0032991~macromolecular complex,GO:0036024~protein C inhibitor-TMPRSS7 complex,GO:0036025~protein C inhibitor-TMPRSS11E complex,GO:0036026~protein C inhibitor-PLAT complex,GO:0036027~protein C inhibitor-PLAU complex,GO:0036028~protein C inhibitor-thrombin complex,GO:0036029~protein C inhibitor-KLK3 complex,GO:0036030~protein C inhibitor-plasma kallikrein complex,GO:0070062~extracellular exosome,GO:0097181~protein C inhibitor-coagulation factor V complex,GO:0097182~protein C inhibitor-coagulation factor Xa complex,GO:0097183~protein C inhibitor-coagulation factor XI complex,	GO:0001972~retinoic acid binding,GO:0002020~protease binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0005539~glycosaminoglycan binding,GO:0008201~heparin binding,GO:0031210~phosphatidylcholine binding,GO:0032190~acrosin binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04610:Complement and coagulation cascades,			SM00093:SERPIN,	KW-0278~Fertilization,KW-0445~Lipid transport,KW-0813~Transport,	KW-0964~Secreted,		KW-0732~Signal,		KW-0358~Heparin-binding,KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (GalNAc...) threonine,DOMAIN:SERPIN,MUTAGEN:E->K: Does not inhibit thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:F->P,G: Increases inhibition of thrombin activity.,MUTAGEN:K->E: Does not change the rate of thrombin or activated protein C/F5 inhibition in the presence or absence of heparin. Slightly reduces the rate of thrombin inhibition in the presence of heparin. Does not inhibit thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:K->E: Does not change the rate of thrombin or activated protein C/F5 inhibition in the presence or absence of heparin. Slightly reduces the rate of thrombin inhibition in the presence of heparin. Inhibits weakly thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:K->E: Does not inhibit thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:R->E: Does not change the rate of thrombin or activated protein C/F5 inhibition in the presence or absence of heparin. Slightly reduces the rate of thrombin inhibition in the presence of heparin. Does not inhibit thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:R->E: Does not change the rate of thrombin or activated protein C/F5 inhibition in the presence or absence of heparin. Strongly reduces the rate of thrombin inhibition in the presence of heparin.,MUTAGEN:R->E: Does not inhibit thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:R->E: Inhibits strongly thrombomodulin-enhanced rate of thrombin inhibition in presence of heparin.,MUTAGEN:R->P: Does not change inhibition of thrombin, activated protein C/F5 and factor XI/F11 activities.,MUTAGEN:R->P: Increases inhibition of thrombin activity. Inhibits heterodimer formation with TMPRSS11E.,MUTAGEN:T->R: Increases inhibition of activated protein C/F5 and factor XI/F11 activities. Decreases inhibition of thrombin activity.,MUTAGEN:T->R: Inhibits heterodimer formation with TMPRSS11E.,PROPEP:Removed in mature form,SITE:Reactive bond,
SERPINE1	serpin family E member 1(SERPINE1)	Homo sapiens	GO:0001525~angiogenesis,GO:0010469~regulation of receptor activity,GO:0010757~negative regulation of plasminogen activation,GO:0010951~negative regulation of endopeptidase activity,GO:0014912~negative regulation of smooth muscle cell migration,GO:0030194~positive regulation of blood coagulation,GO:0030195~negative regulation of blood coagulation,GO:0030336~negative regulation of cell migration,GO:0032757~positive regulation of interleukin-8 production,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0035491~positive regulation of leukotriene production involved in inflammatory response,GO:0042730~fibrinolysis,GO:0045766~positive regulation of angiogenesis,GO:0048260~positive regulation of receptor-mediated endocytosis,GO:0050729~positive regulation of inflammatory response,GO:0050829~defense response to Gram-negative bacterium,GO:0051918~negative regulation of fibrinolysis,GO:0061044~negative regulation of vascular wound healing,GO:0061045~negative regulation of wound healing,GO:0071222~cellular response to lipopolysaccharide,GO:0090026~positive regulation of monocyte chemotaxis,GO:0090399~replicative senescence,GO:0097187~dentinogenesis,GO:1901331~positive regulation of odontoblast differentiation,GO:1902042~negative regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:2000098~negative regulation of smooth muscle cell-matrix adhesion,GO:2000352~negative regulation of endothelial cell apoptotic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0097180~serine protease inhibitor complex,GO:1904090~peptidase inhibitor complex,	GO:0002020~protease binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005102~receptor binding,GO:0005515~protein binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04066:HIF-1 signaling pathway,hsa04115:p53 signaling pathway,hsa04218:Cellular senescence,hsa04371:Apelin signaling pathway,hsa04390:Hippo signaling pathway,hsa04610:Complement and coagulation cascades,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05142:Chagas disease,	613329~Plasminogen activator inhibitor-1 deficiency,Transcription of plasminogen activator inhibitor, modulator of~Transcription of plasminogen activator inhibitor, modulator of,		SM00093:SERPIN,		KW-0964~Secreted,		KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SERPIN,MUTAGEN:G->C: Increased half-life of the active form when associated with C-197.,MUTAGEN:Q->C: Increased half-life of the active form when associated with C-355.,SITE:Reactive bond,
SERPINF2	serpin family F member 2(SERPINF2)	Homo sapiens	GO:0002034~regulation of blood vessel diameter by renin-angiotensin,GO:0006953~acute-phase response,GO:0010033~response to organic substance,GO:0010757~negative regulation of plasminogen activation,GO:0010951~negative regulation of endopeptidase activity,GO:0030199~collagen fibril organization,GO:0032967~positive regulation of collagen biosynthetic process,GO:0042730~fibrinolysis,GO:0045597~positive regulation of cell differentiation,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0046330~positive regulation of JNK cascade,GO:0048514~blood vessel morphogenesis,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0051496~positive regulation of stress fiber assembly,GO:0051918~negative regulation of fibrinolysis,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071636~positive regulation of transforming growth factor beta production,GO:2000049~positive regulation of cell-cell adhesion mediated by cadherin,	GO:0005576~extracellular region,GO:0005577~fibrinogen complex,GO:0005615~extracellular space,GO:0009986~cell surface,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,GO:0072562~blood microparticle,	GO:0002020~protease binding,GO:0004866~endopeptidase inhibitor activity,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,	hsa04610:Complement and coagulation cascades,	262850~Alpha-2-plasmin inhibitor deficiency,		SM00093:SERPIN,	KW-0011~Acute phase,	KW-0964~Secreted,	KW-0225~Disease variant,	KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-0765~Sulfation,KW-1015~Disulfide bond,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-322 in alpha-fibrinogen),DOMAIN:SERPIN,REGION:Disordered,SITE:Cleavage; by prolyl endopeptidase FAP, antiplasmin-cleaving enzyme FAP soluble form,SITE:Reactive bond for chymotrypsin,SITE:Reactive bond for plasmin,
SERPINH1	serpin family H member 1(SERPINH1)	Homo sapiens	GO:0003433~chondrocyte development involved in endochondral bone morphogenesis,GO:0006986~response to unfolded protein,GO:0010951~negative regulation of endopeptidase activity,GO:0030199~collagen fibril organization,GO:0032964~collagen biosynthetic process,GO:0051604~protein maturation,	GO:0005581~collagen trimer,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0005793~endoplasmic reticulum-Golgi intermediate compartment,GO:0045121~membrane raft,	GO:0003723~RNA binding,GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0051082~unfolded protein binding,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,		610504~Preterm premature rupture of the membranes, susceptibility to,613848~Osteogenesis imperfecta, type X,		SM00093:SERPIN,	KW-0346~Stress response,	KW-0256~Endoplasmic reticulum,	KW-1065~Osteogenesis imperfecta,	KW-0176~Collagen,KW-0732~Signal,		KW-0143~Chaperone,	KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SERPIN,MOTIF:Prevents secretion from ER,SITE:Reactive bond homolog,
SERPINI1	serpin family I member 1(SERPINI1)	Homo sapiens	GO:0007417~central nervous system development,GO:0007422~peripheral nervous system development,GO:0010951~negative regulation of endopeptidase activity,GO:0010976~positive regulation of neuron projection development,GO:0030155~regulation of cell adhesion,	GO:0005615~extracellular space,GO:0034774~secretory granule lumen,GO:0043025~neuronal cell body,GO:0043204~perikaryon,GO:0060205~cytoplasmic vesicle lumen,GO:0070062~extracellular exosome,	GO:0004867~serine-type endopeptidase inhibitor activity,	IPR000215:Serpin family,IPR023795:Protease inhibitor I4, serpin, conserved site,IPR023796:Serpin domain,		604218~Encephalopathy, familial, with neuroserpin inclusion bodies,		SM00093:SERPIN,		KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-0523~Neurodegeneration,	KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:SERPIN,MUTAGEN:E->A: Slightly decreases inhibitory activity. No effect on thermal stability.,MUTAGEN:L->K: Increases protein stability and abolishes tendency to form polymers. No effect on inhibitory activity.,MUTAGEN:N->G: Increases protein stability and abolishes tendency to form polymers. No effect on inhibitory activity.,MUTAGEN:S->A: Increases protein stability and decreases tendency to form polymers. No effect on inhibitory activity.,MUTAGEN:V->I: Increases protein stability and decreases tendency to form polymers. No effect on inhibitory activity.,SITE:Reactive bond,
SAA1	serum amyloid A1(SAA1)	Homo sapiens	GO:0000187~activation of MAPK activity,GO:0001819~positive regulation of cytokine production,GO:0006953~acute-phase response,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0030168~platelet activation,GO:0030593~neutrophil chemotaxis,GO:0032732~positive regulation of interleukin-1 production,GO:0045785~positive regulation of cell adhesion,GO:0048246~macrophage chemotaxis,GO:0048247~lymphocyte chemotaxis,GO:0050708~regulation of protein secretion,GO:0050728~negative regulation of inflammatory response,	GO:0005576~extracellular region,GO:0005881~cytoplasmic microtubule,GO:0034364~high-density lipoprotein particle,GO:0070062~extracellular exosome,GO:0071682~endocytic vesicle lumen,	GO:0001664~G-protein coupled receptor binding,GO:0008201~heparin binding,	IPR000096:Serum amyloid A protein,			PIRSF002472:amyloid protein, SAA type,	SM00197:SAA,	KW-0011~Acute phase,	KW-0034~Amyloid,KW-0345~HDL,KW-0964~Secreted,	KW-1008~Amyloidosis,	KW-0732~Signal,		KW-0358~Heparin-binding,	KW-0488~Methylation,	MUTAGEN:H->A: Reduces affinity for heparin and nearly abolishes association with HDL; when associated with A-18 and A-80.,MUTAGEN:R->A: Reduces affinity for heparin and nearly abolishes association with HDL; when associated with A-18 and A-89.,MUTAGEN:R->A: Reduces affinity for heparin and nearly abolishes association with HDL; when associated with A-80 and A-89.,MUTAGEN:R->A: Reduces affinity for heparin; when associated with A-33 and A-37.,MUTAGEN:R->A: Reduces affinity for heparin; when associated with A-33 and A-65.,MUTAGEN:R->A: Reduces affinity for heparin; when associated with A-37 and A-65.,PROPEP:Often cleaved during amyloidogenesis,REGION:Disordered,REGION:Important for amyloid formation; forms amyloid fibrils in vitro,
SHISA6	shisa family member 6(SHISA6)	Homo sapiens	GO:0007283~spermatogenesis,GO:0016055~Wnt signaling pathway,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:0098962~regulation of postsynaptic neurotransmitter receptor activity,GO:0098970~postsynaptic neurotransmitter receptor diffusion trapping,GO:0098976~excitatory chemical synaptic transmission,GO:1904717~regulation of AMPA glutamate receptor clustering,GO:2000311~regulation of AMPA receptor activity,	GO:0014069~postsynaptic density,GO:0016021~integral component of membrane,GO:0032281~AMPA glutamate receptor complex,GO:0032591~dendritic spine membrane,GO:0045211~postsynaptic membrane,GO:0098839~postsynaptic density membrane,GO:0098985~asymmetric, glutamatergic, excitatory synapse,GO:0099061~integral component of postsynaptic density membrane,	GO:0005515~protein binding,GO:0030165~PDZ domain binding,GO:0035255~ionotropic glutamate receptor binding,	IPR026910:Shisa family,					KW-0879~Wnt signaling pathway,	KW-0472~Membrane,KW-0770~Synapse,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,MOTIF:PDZ-binding,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SHOX2	short stature homeobox 2(SHOX2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001501~skeletal system development,GO:0001649~osteoblast differentiation,GO:0002027~regulation of heart rate,GO:0002053~positive regulation of mesenchymal cell proliferation,GO:0002063~chondrocyte development,GO:0003163~sinoatrial node development,GO:0003172~sinoatrial valve development,GO:0003213~cardiac right atrium morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007224~smoothened signaling pathway,GO:0007399~nervous system development,GO:0010463~mesenchymal cell proliferation,GO:0032330~regulation of chondrocyte differentiation,GO:0035115~embryonic forelimb morphogenesis,GO:0045880~positive regulation of smoothened signaling pathway,GO:0048557~embryonic digestive tract morphogenesis,GO:0048743~positive regulation of skeletal muscle fiber development,GO:0050772~positive regulation of axonogenesis,GO:0060272~embryonic skeletal joint morphogenesis,GO:0060351~cartilage development involved in endochondral bone morphogenesis,GO:0060415~muscle tissue morphogenesis,GO:0060920~cardiac pacemaker cell differentiation,GO:0060931~sinoatrial node cell development,GO:0072089~stem cell proliferation,GO:2000172~regulation of branching morphogenesis of a nerve,GO:2000648~positive regulation of stem cell proliferation,	GO:0000785~chromatin,GO:0005634~nucleus,	GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0003677~DNA binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000047:Helix-turn-helix motif,IPR001356:Homeodomain,IPR003654:OAR domain,IPR009057:Homeodomain-like,IPR017970:Homeobox, conserved site,				SM00389:HOX,		KW-0539~Nucleus,		KW-0371~Homeobox,		KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,DNA_BIND:Homeobox,DOMAIN:Homeobox,DOMAIN:OAR,MOTIF:OAR,REGION:Disordered,
SIGLEC1	sialic acid binding Ig like lectin 1(SIGLEC1)	Homo sapiens	GO:0006954~inflammatory response,GO:0007160~cell-matrix adhesion,GO:0075512~clathrin-dependent endocytosis of virus by host cell,GO:0098609~cell-cell adhesion,	GO:0005576~extracellular region,GO:0005769~early endosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0030246~carbohydrate binding,GO:0046790~virion binding,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013098:Immunoglobulin I-set,IPR013106:Immunoglobulin V-set,IPR013162:CD80-like, immunoglobulin C2-set,IPR013783:Immunoglobulin-like fold,	hsa04514:Cell adhesion molecules,			SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,KW-0254~Endocytosis,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 10,DOMAIN:Ig-like C2-type 11,DOMAIN:Ig-like C2-type 12,DOMAIN:Ig-like C2-type 13,DOMAIN:Ig-like C2-type 14,DOMAIN:Ig-like C2-type 15,DOMAIN:Ig-like C2-type 16,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like C2-type 3,DOMAIN:Ig-like C2-type 4,DOMAIN:Ig-like C2-type 5,DOMAIN:Ig-like C2-type 6,DOMAIN:Ig-like C2-type 7,DOMAIN:Ig-like C2-type 8,DOMAIN:Ig-like C2-type 9,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SIGLEC7	sialic acid binding Ig like lectin 7(SIGLEC7)	Homo sapiens	GO:0007155~cell adhesion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0033691~sialic acid binding,GO:0038023~signaling receptor activity,	IPR003598:Immunoglobulin subtype 2,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00408:IGc2,SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:IG,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,MOTIF:ITIM motif,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SIGLEC9	sialic acid binding Ig like lectin 9(SIGLEC9)	Homo sapiens	GO:0007155~cell adhesion,GO:0007166~cell surface receptor signaling pathway,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030667~secretory granule membrane,	GO:0005515~protein binding,GO:0030246~carbohydrate binding,GO:0033691~sialic acid binding,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,	hsa04613:Neutrophil extracellular trap formation,			SM00409:IG,	KW-0130~Cell adhesion,	KW-0472~Membrane,		KW-0393~Immunoglobulin domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0430~Lectin,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type 1,DOMAIN:Ig-like C2-type 2,DOMAIN:Ig-like V-type,MOTIF:ITIM motif,MOTIF:SLAM-like motif,MUTAGEN:R->K: Loss of sialic acid binding.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SERF1B	small EDRK-rich factor 1B(SERF1B)	Homo sapiens	GO:0007399~nervous system development,GO:0031648~protein destabilization,GO:1990000~amyloid fibril formation,	GO:0005634~nucleus,GO:0005829~cytosol,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,	GO:0005515~protein binding,	IPR007513:Uncharacterised protein family SERF,						KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Basic and acidic residues,DOMAIN:4F5,MUTAGEN:K->A: Decreases SNCA binding.,MUTAGEN:K->A: Drastically decreases SNCA binding.,MUTAGEN:K->E: Inhibits SNCA binding.,MUTAGEN:N->A: Decreases SNCA binding.,MUTAGEN:Q->A: Slightly decreases SNCA binding.,MUTAGEN:R->A: No effect on SNCA binding.,MUTAGEN:R->E: Decreases SNCA binding.,MUTAGEN:T->A: No effect on SNCA binding.,REGION:Disordered,REGION:Required for SNCA binding,TRANSMEM:Helical,
SMIM3	small integral membrane protein 3(SMIM3)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0042802~identical protein binding,							KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				SITE:Cleavage,TRANSMEM:Helical,
SNAI1	snail family transcriptional repressor 1(SNAI1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001707~mesoderm formation,GO:0001837~epithelial to mesenchymal transition,GO:0003180~aortic valve morphogenesis,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0010631~epithelial cell migration,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010957~negative regulation of vitamin D biosynthetic process,GO:0016477~cell migration,GO:0030335~positive regulation of cell migration,GO:0031069~hair follicle morphogenesis,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045893~positive regulation of transcription, DNA-templated,GO:0060021~palate development,GO:0060536~cartilage morphogenesis,GO:0060707~trophoblast giant cell differentiation,GO:0060806~negative regulation of cell differentiation involved in embryonic placenta development,GO:0060972~left/right pattern formation,GO:0061314~Notch signaling involved in heart development,GO:0070828~heterochromatin organization,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000810~regulation of bicellular tight junction assembly,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005721~pericentric heterochromatin,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0043231~intracellular membrane-bounded organelle,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0019900~kinase binding,GO:0046872~metal ion binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04520:Adherens junction,			SM00355:ZnF_C2H2,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,	KW-0013~ADP-ribosylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),MOTIF:Destruction motif,MUTAGEN:C->A: Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization.,MUTAGEN:C->A: Impairs binding to KPNB1 and IPO7 and abolishes binding to KPNA2 and TNPO1 and nuclear localization.,MUTAGEN:C->A: Impairs binding to KPNB1, IPO7 and TNPO1 and abolishes binding to KPNA2. Localizes to cytoplasm and nucleus.,MUTAGEN:DVKK->KVEE: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1.,MUTAGEN:F->A: Loss of interaction with KDM1A.,MUTAGEN:K->A: Loss of interaction with KDM1A.,MUTAGEN:K->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-191. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-161 and/or E-220.,MUTAGEN:K->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-161.,MUTAGEN:K->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-170. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-187 and/or E-220.,MUTAGEN:K->R: Does not affect E-cadherin repression; when associated with R-9.,MUTAGEN:K->R: Does not affect E-cadherin/CDH1 repression; when associated with R-16.,MUTAGEN:K->R: Lower sensitivity to FBXL14-triggered degradation. Lower sensitivity to FBXL14-triggered degradation; when associated with R-137. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation; when associated with R-98 and R-137.,MUTAGEN:K->R: Lower sensitivity to FBXL14-triggered degradation. Lower sensitivity to FBXL14-triggered degradation; when associated with R-146. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation and loss of ability to repress E-cadherin; when associated with R-98 and R-146.,MUTAGEN:K->R: No change. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation and loss of ability to repress E-cadherin/CDH1; when associated with R-137 and R-146.,MUTAGEN:N->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-220 and E-224.,MUTAGEN:P->A: Abolishes repressor activity on E-cadherin/CDH1 promoter and binding to KDM1A.,MUTAGEN:Q->A: Loss of binding to KPNB1 and nuclear import; when associated with E-191 and A-193.,MUTAGEN:Q->A: Very minor effect on binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with E-224.,MUTAGEN:Q->E: Does not affect binding to KPNB1, KPNA2, IPO7, TNPO1 or DNA.,MUTAGEN:R->A: Loss of interaction with KDM1A.,MUTAGEN:R->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-220 and E-222. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-220.,MUTAGEN:R->E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-222 and E-224. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-224. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-161 and/or E-187.,MUTAGEN:R->E: Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1. No change in subcellular localization.,MUTAGEN:R->E: Mildly reduces binding to KPNB1 and nuclear import.,MUTAGEN:R->E: Mildly reduces binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with A-193. Loss of binding to KPNB1 and nuclear import; when associated with A-193 and A-196.,MUTAGEN:R->E: Mildly reduces binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with A-228.,MUTAGEN:R->E: Mildly reduces binding to KPNB1. Does not affect binding to KPNA2, IPO7 or TNPO1.,MUTAGEN:RK->EE: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1.,MUTAGEN:S->A: Abolishes CK2 phosphorylation. Strongly decreases repressor activity on E-cadherin/CDH1 and CLDN1 promoters. Increases protein stability. Affects function in cell survival. Abolishes phosphorylation in the serine-rich region; when associated with A-104 and A-107.,MUTAGEN:S->A: Abolishes PKA phosphorylation. Strongly decreases repressor activity on E-cadherin/CDH1 and CLDN1 promoters. Increases protein stability. Affects function in EMT.,MUTAGEN:S->A: Abolishes recognition and ubiquitination by BTRC which increases steady state level and half-life. Preferentially localizes to the nucleus. Induces a more aggressive tissue invasion program. Lower sensitivity to BTRC-triggered degradation, impairs phosphorylation by GSK3B and does not affect NOTCH1-induced degradation; when associated with A-100. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-100; A-107; A-111; A-115 and A-119.,MUTAGEN:S->A: Decreases repression activity on E-cadherin/CDH1, occludin and aromatase promoters. Preferentially localizes to the cytoplasm. Abolishes phosphorylation by PAK1.,MUTAGEN:S->A: Increases protein stability, does not affect repressor activity on E-cadherin/CDH1 promoter, preferentially localizes to the nucleus, induces a more aggressive tissue invasion program and impairs phosphorylation by GSK3B, binding to BTRC and ubiquitination; when associated with A-107. Impairs phosphorylation in the serine-rich domain/region; when associated with A-92 and A-107. Abolishes phosphorylation at S-96.,MUTAGEN:S->A: Loss of interaction with KDM1A.,MUTAGEN:S->A: Lower sensitivity to BTRC-triggered degradation and impaired phosphorylation by GSK3B; when associated with A-96. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-107; A-111; A-115 and A-119. Does not affect NOTCH1-induced degradation; when associated with A-96. Abolishes phosphorylation at S-96.,MUTAGEN:S->A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-111 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-111 and A-115.,MUTAGEN:S->A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-111 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-111 and A-119.,MUTAGEN:S->A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-115 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-115 and A-119.,MUTAGEN:S->A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-111; A-115 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-111; A-115 and A-119. Increases protein stability, does not affect repressor activity on E-cadherin promoter, preferentially localizes to the nucleus, induces a more aggressive tissue invasion program and impairs phosphorylation by GSK3B, binding to BTRC and ubiquitination; when associated with A-104. Impairs phosphorylation in the serine-rich region; when associated with A-92 and A-104. Abolishes phosphorylation at S-96.,MUTAGEN:S->E: Does not affect repressor activity on E-cadherin/CDH1 promoter.,MUTAGEN:S->E: Predominantly localized to the cytoplasm; when associated with E-107; E-111 and E-115.,MUTAGEN:S->E: Predominantly localized to the cytoplasm; when associated with E-107; E-111 and E-119.,MUTAGEN:S->E: Predominantly localized to the cytoplasm; when associated with E-107; E-115 and E-119.,MUTAGEN:S->E: Predominantly localized to the cytoplasm; when associated with E-111; E-115 and E-119.,MUTAGEN:T->A: Abolishes LATS2 phosphorylation. Does not affect binding to LATS2. Reduces protein stability. Equally distributed between nucleus and cytoplasm. Increases capacity to associate with nuclear pore importins. Unable to accumulate in the nucleus. Does not abrogate function.,MUTAGEN:T->E: Exclusively localizes to the cytoplasm. Reduces capacity to associate with nuclear pore importins. Unable to enter the nucleus. Does not abrogate function.,MUTAGEN:W->A: Mildly reduces binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with E-191. Loss of binding to KPNB1 and nuclear import; when associated with E-191 and A-196.,REGION:Disordered,REGION:LATS2 binding,REGION:Required and sufficient for interaction with KDM1A,REGION:Required for FBXL14-triggered degradation,REGION:Required for nuclear localization and interaction with KPNB1, NOTCH1 and PARP1,REGION:SNAG domain,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4; atypical,
SNAI2	snail family transcriptional repressor 2(SNAI2)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001649~osteoblast differentiation,GO:0001837~epithelial to mesenchymal transition,GO:0003180~aortic valve morphogenesis,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0003273~cell migration involved in endocardial cushion formation,GO:0006355~regulation of transcription, DNA-templated,GO:0006933~negative regulation of cell adhesion involved in substrate-bound cell migration,GO:0007219~Notch signaling pathway,GO:0007605~sensory perception of sound,GO:0010839~negative regulation of keratinocyte proliferation,GO:0010957~negative regulation of vitamin D biosynthetic process,GO:0014032~neural crest cell development,GO:0030335~positive regulation of cell migration,GO:0032331~negative regulation of chondrocyte differentiation,GO:0032642~regulation of chemokine production,GO:0033028~myeloid cell apoptotic process,GO:0033033~negative regulation of myeloid cell apoptotic process,GO:0033629~negative regulation of cell adhesion mediated by integrin,GO:0035066~positive regulation of histone acetylation,GO:0035921~desmosome disassembly,GO:0043473~pigmentation,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0043542~endothelial cell migration,GO:0045600~positive regulation of fat cell differentiation,GO:0045667~regulation of osteoblast differentiation,GO:0050872~white fat cell differentiation,GO:0060021~palate development,GO:0060429~epithelium development,GO:0060536~cartilage morphogenesis,GO:0060693~regulation of branching involved in salivary gland morphogenesis,GO:0061314~Notch signaling involved in heart development,GO:0070563~negative regulation of vitamin D receptor signaling pathway,GO:0071364~cellular response to epidermal growth factor stimulus,GO:0071425~hematopoietic stem cell proliferation,GO:0071479~cellular response to ionizing radiation,GO:0090090~negative regulation of canonical Wnt signaling pathway,GO:1902034~negative regulation of hematopoietic stem cell proliferation,GO:1902230~negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage,GO:2000810~regulation of bicellular tight junction assembly,GO:2000811~negative regulation of anoikis,GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003682~chromatin binding,GO:0005515~protein binding,GO:0043565~sequence-specific DNA binding,GO:0046872~metal ion binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa04390:Hippo signaling pathway,hsa04520:Adherens junction,	172800~Piebaldism,608890~Waardenburg syndrome, type 2D,		SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0209~Deafness,KW-0897~Waardenburg syndrome,	KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,MUTAGEN:K->E: Abolishes binding to KPNA2 and impairs binding to KPNB1, IPO7 and TMPO1; when associated with E-196.,MUTAGEN:K->E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-166.,MUTAGEN:K->E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-175.,MUTAGEN:R->E: Abolishes binding to KPNA2 and impairs binding to KPNB1, IPO7 and TMPO1; when associated with E-192.,MUTAGEN:R->E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-225.,MUTAGEN:R->E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-229.,MUTAGEN:S->A: Increases protein stability and half-life, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-100.,MUTAGEN:S->A: Increases protein stability and half-life, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-104.,MUTAGEN:S->A: Increases protein stability, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-92.,MUTAGEN:S->A: Increases protein stability, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-96.,MUTAGEN:S->A: Increases protein stability. Does not affect repressor activity on E-cadherin/CDH1 promoter.,REGION:Disordered,REGION:SNAG domain,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5; atypical,
SCNN1B	sodium channel epithelial 1 subunit beta(SCNN1B)	Homo sapiens	GO:0002269~leukocyte activation involved in inflammatory response,GO:0002283~neutrophil activation involved in immune response,GO:0006814~sodium ion transport,GO:0006883~cellular sodium ion homeostasis,GO:0007588~excretion,GO:0008217~regulation of blood pressure,GO:0009410~response to xenobiotic stimulus,GO:0010467~gene expression,GO:0014824~artery smooth muscle contraction,GO:0032094~response to food,GO:0032341~aldosterone metabolic process,GO:0034101~erythrocyte homeostasis,GO:0035264~multicellular organism growth,GO:0035725~sodium ion transmembrane transport,GO:0036254~cellular response to amiloride,GO:0042045~epithelial fluid transport,GO:0042493~response to drug,GO:0050891~multicellular organismal water homeostasis,GO:0050909~sensory perception of taste,GO:0050914~sensory perception of salty taste,GO:0050915~sensory perception of sour taste,GO:0055075~potassium ion homeostasis,GO:0055078~sodium ion homeostasis,GO:0070254~mucus secretion,GO:0070944~neutrophil mediated killing of bacterium,GO:0071468~cellular response to acidic pH,GO:0097274~urea homeostasis,GO:0098719~sodium ion import across plasma membrane,GO:1904045~cellular response to aldosterone,GO:1904117~cellular response to vasopressin,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,GO:0030659~cytoplasmic vesicle membrane,GO:0034706~sodium channel complex,GO:0070062~extracellular exosome,GO:0098797~plasma membrane protein complex,	GO:0005272~sodium channel activity,GO:0005515~protein binding,GO:0015280~ligand-gated sodium channel activity,GO:0050699~WW domain binding,	IPR001873:Na+ channel, amiloride-sensitive,IPR004724:Epithelial sodium channel,IPR020903:Na+ channel, amiloride-sensitive, conserved site,	hsa04742:Taste transduction,hsa04960:Aldosterone-regulated sodium reabsorption,	177200~Liddle syndrome 1,211400~Bronchiectasis with or without elevated sweat chloride 1,264350~Pseudohypoaldosteronism, type I,			KW-0406~Ion transport,KW-0716~Sensory transduction,KW-0739~Sodium transport,KW-0813~Transport,KW-0919~Taste,	KW-0472~Membrane,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,	KW-0407~Ion channel,KW-0894~Sodium channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,
SCN2B	sodium voltage-gated channel beta subunit 2(SCN2B)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0007399~nervous system development,GO:0009408~response to heat,GO:0010467~gene expression,GO:0035725~sodium ion transmembrane transport,GO:0046684~response to pyrethroid,GO:0060048~cardiac muscle contraction,GO:0060371~regulation of atrial cardiac muscle cell membrane depolarization,GO:0086002~cardiac muscle cell action potential involved in contraction,GO:0086012~membrane depolarization during cardiac muscle cell action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:0098915~membrane repolarization during ventricular cardiac muscle cell action potential,GO:2000649~regulation of sodium ion transmembrane transporter activity,	GO:0001518~voltage-gated sodium channel complex,GO:0005886~plasma membrane,GO:0030315~T-tubule,GO:0045202~synapse,	GO:0005244~voltage-gated ion channel activity,GO:0005248~voltage-gated sodium channel activity,GO:0017080~sodium channel regulator activity,GO:0086006~voltage-gated sodium channel activity involved in cardiac muscle cell action potential,GO:1902282~voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization,	IPR000920:Myelin P0 protein,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,		615378~Atrial fibrillation, familial, 14,		SM00409:IG,	KW-0406~Ion transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0992~Brugada syndrome,KW-1020~Atrial fibrillation,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,KW-0894~Sodium channel,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain; with alpha subunit,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,MUTAGEN:C->A,S: Does not bind alpha subunit. Loss of ability to protect alpha subunit from inhibition by the spider protoxin-II.,REGION:Disordered,SITE:Binds SCN2A,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SCN3B	sodium voltage-gated channel beta subunit 3(SCN3B)	Homo sapiens	GO:0006814~sodium ion transport,GO:0007399~nervous system development,GO:0010460~positive regulation of heart rate,GO:0010765~positive regulation of sodium ion transport,GO:0019233~sensory perception of pain,GO:0034765~regulation of ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0051899~membrane depolarization,GO:0060048~cardiac muscle contraction,GO:0060371~regulation of atrial cardiac muscle cell membrane depolarization,GO:0060373~regulation of ventricular cardiac muscle cell membrane depolarization,GO:0072659~protein localization to plasma membrane,GO:0086002~cardiac muscle cell action potential involved in contraction,GO:0086005~ventricular cardiac muscle cell action potential,GO:0086010~membrane depolarization during action potential,GO:0086012~membrane depolarization during cardiac muscle cell action potential,GO:0086014~atrial cardiac muscle cell action potential,GO:0086015~SA node cell action potential,GO:0086091~regulation of heart rate by cardiac conduction,GO:2000649~regulation of sodium ion transmembrane transporter activity,	GO:0001518~voltage-gated sodium channel complex,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030018~Z disc,	GO:0005244~voltage-gated ion channel activity,GO:0005272~sodium channel activity,GO:0005515~protein binding,GO:0017080~sodium channel regulator activity,GO:0019871~sodium channel inhibitor activity,GO:0044325~ion channel binding,GO:0086006~voltage-gated sodium channel activity involved in cardiac muscle cell action potential,	IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,IPR027096:Sodium channel subunit beta-3,IPR027098:Sodium channel subunit beta-1/beta-3,		613120~Atrial fibrillation, familial, 16,613120~Brugada syndrome 7,		SM00409:IG,	KW-0406~Ion transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0992~Brugada syndrome,KW-1020~Atrial fibrillation,	KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,	KW-0407~Ion channel,KW-0851~Voltage-gated channel,KW-0894~Sodium channel,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC1A2	solute carrier family 1 member 2(SLC1A2)	Homo sapiens	GO:0006750~glutathione biosynthetic process,GO:0006811~ion transport,GO:0006836~neurotransmitter transport,GO:0007268~chemical synaptic transmission,GO:0007632~visual behavior,GO:0009410~response to xenobiotic stimulus,GO:0009611~response to wounding,GO:0010259~multicellular organism aging,GO:0015813~L-glutamate transport,GO:0021537~telencephalon development,GO:0030534~adult behavior,GO:0031668~cellular response to extracellular stimulus,GO:0035264~multicellular organism growth,GO:0042493~response to drug,GO:0043200~response to amino acid,GO:0046326~positive regulation of glucose import,GO:0070207~protein homotrimerization,GO:0070633~transepithelial transport,GO:0070778~L-aspartate transport,GO:0070779~D-aspartate import,GO:0071314~cellular response to cocaine,GO:0098712~L-glutamate import across plasma membrane,GO:0098810~neurotransmitter reuptake,GO:1903712~cysteine transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030673~axolemma,GO:0031982~vesicle,GO:0042734~presynaptic membrane,GO:0044297~cell body,GO:0044306~neuron projection terminus,GO:0045121~membrane raft,GO:0097449~astrocyte projection,GO:0098796~membrane protein complex,GO:0098978~glutamatergic synapse,GO:0099056~integral component of presynaptic membrane,	GO:0005313~L-glutamate transmembrane transporter activity,GO:0005314~high-affinity glutamate transmembrane transporter activity,GO:0005515~protein binding,GO:0015175~neutral amino acid transmembrane transporter activity,GO:0015293~symporter activity,GO:0015501~glutamate:sodium symporter activity,GO:0033229~cysteine transmembrane transporter activity,GO:0046872~metal ion binding,	IPR001991:Sodium:dicarboxylate symporter,IPR018107:Sodium:dicarboxylate symporter, conserved site,	hsa04721:Synaptic vesicle cycle,hsa04724:Glutamatergic synapse,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,	617105~Developmental and epileptic encephalopathy 41,			KW-0029~Amino-acid transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0630~Potassium,KW-0868~Chloride,KW-0915~Sodium,		KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,INTRAMEM:Discontinuously helical,LIPID:S-palmitoyl cysteine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,
SLC10A6	solute carrier family 10 member 6(SLC10A6)	Homo sapiens	GO:0006814~sodium ion transport,GO:0015721~bile acid and bile salt transport,GO:0043251~sodium-dependent organic anion transport,GO:0055085~transmembrane transport,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0008508~bile acid:sodium symporter activity,GO:0043250~sodium-dependent organic anion transmembrane transporter activity,	IPR002657:Bile acid:sodium symporter,IPR004710:Bile acid transporter,					KW-0406~Ion transport,KW-0445~Lipid transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0915~Sodium,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC11A1	solute carrier family 11 member 1(SLC11A1)	Homo sapiens	GO:0001818~negative regulation of cytokine production,GO:0001819~positive regulation of cytokine production,GO:0002309~T cell proliferation involved in immune response,GO:0002606~positive regulation of dendritic cell antigen processing and presentation,GO:0002827~positive regulation of T-helper 1 type immune response,GO:0006826~iron ion transport,GO:0006828~manganese ion transport,GO:0006876~cellular cadmium ion homeostasis,GO:0006879~cellular iron ion homeostasis,GO:0006909~phagocytosis,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007035~vacuolar acidification,GO:0009617~response to bacterium,GO:0010628~positive regulation of gene expression,GO:0015707~nitrite transport,GO:0019730~antimicrobial humoral response,GO:0030001~metal ion transport,GO:0032147~activation of protein kinase activity,GO:0032496~response to lipopolysaccharide,GO:0032729~positive regulation of interferon-gamma production,GO:0034341~response to interferon-gamma,GO:0034755~iron ion transmembrane transport,GO:0042060~wound healing,GO:0042116~macrophage activation,GO:0042742~defense response to bacterium,GO:0042832~defense response to protozoan,GO:0045342~MHC class II biosynthetic process,GO:0045454~cell redox homeostasis,GO:0045730~respiratory burst,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048002~antigen processing and presentation of peptide antigen,GO:0048255~mRNA stabilization,GO:0050766~positive regulation of phagocytosis,GO:0050829~defense response to Gram-negative bacterium,GO:0051649~establishment of localization in cell,GO:0055072~iron ion homeostasis,GO:0060586~multicellular organismal iron ion homeostasis,GO:0070574~cadmium ion transmembrane transport,GO:0070839~divalent metal ion export,GO:0071421~manganese ion transmembrane transport,GO:1902023~L-arginine transport,GO:1902600~hydrogen ion transmembrane transport,GO:1903826~arginine transmembrane transport,	GO:0005764~lysosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0031902~late endosome membrane,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005381~iron ion transmembrane transporter activity,GO:0005384~manganese ion transmembrane transporter activity,GO:0015086~cadmium ion transmembrane transporter activity,GO:0042803~protein homodimerization activity,GO:0046873~metal ion transmembrane transporter activity,GO:0046915~transition metal ion transmembrane transporter activity,GO:0051139~metal ion:proton antiporter activity,	IPR001046:Natural resistance-associated macrophage like,	hsa04142:Lysosome,	607948~Mycobacterium tuberculosis, susceptibility to infection by,610446~Buruli ulcer, susceptibility to,			KW-0406~Ion transport,KW-0410~Iron transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,		KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC16A3	solute carrier family 16 member 3(SLC16A3)	Homo sapiens	GO:0015718~monocarboxylic acid transport,GO:0030163~protein catabolic process,GO:0035873~lactate transmembrane transport,GO:0035879~plasma membrane lactate transport,GO:1901475~pyruvate transmembrane transport,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0016324~apical plasma membrane,GO:0016328~lateral plasma membrane,GO:0031965~nuclear membrane,GO:0045202~synapse,GO:0098688~parallel fiber to Purkinje cell synapse,GO:0098839~postsynaptic density membrane,GO:0099061~integral component of postsynaptic density membrane,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0008028~monocarboxylic acid transmembrane transporter activity,GO:0015129~lactate transmembrane transporter activity,GO:0015293~symporter activity,GO:0015650~lactate:proton symporter activity,GO:0050833~pyruvate transmembrane transporter activity,	IPR004743:Monocarboxylate transporter,IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,	hsa05230:Central carbon metabolism in cancer,				KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:MFS,MUTAGEN:E->A: Affects subcellular localization leading to apical localization. Affects subcellular localization leading to apical localization; when associated with A-425 and A-426.,MUTAGEN:E->A: Affects subcellular localization leading to apical localization. Affects subcellular localization leading to apical localization; when associated with A-426 and A-427.,MUTAGEN:E->A: Leads to a nonpolar expression pattern. Affects subcellular localization leading to apical localization; when associated with A-425 and A-427.,MUTAGEN:P->A: Does not affect basolateral plasma membrane localization. Intracellular accumulation. Affects subcellular localization leading to apical localization; when associated with A-432.,MUTAGEN:P->A: Does not affect basolateral plasma membrane localization. Intracellular accumulation. Affects subcellular localization leading to apical localization; when associated with A-433.,MUTAGEN:R->Q,K: Abolishes lactate transmembrane transporter activity. Does not affect cell membrane localization.,MUTAGEN:R->Q: Does not affect lactate transmembrane transporter activity.,REGION:Basolateral sorting signal,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC17A7	solute carrier family 17 member 7(SLC17A7)	Homo sapiens	GO:0003407~neural retina development,GO:0006811~ion transport,GO:0006813~potassium ion transport,GO:0006817~phosphate ion transport,GO:0006820~anion transport,GO:0006821~chloride transport,GO:0006836~neurotransmitter transport,GO:0007420~brain development,GO:0015813~L-glutamate transport,GO:0035249~synaptic transmission, glutamatergic,GO:0035435~phosphate ion transmembrane transport,GO:0035725~sodium ion transmembrane transport,GO:0044341~sodium-dependent phosphate transport,GO:0050803~regulation of synapse structure or activity,GO:0055062~phosphate ion homeostasis,GO:0071805~potassium ion transmembrane transport,GO:0098700~neurotransmitter loading into synaptic vesicle,GO:1900242~regulation of synaptic vesicle endocytosis,GO:1902476~chloride transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030285~integral component of synaptic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0034707~chloride channel complex,GO:0043005~neuron projection,GO:0048786~presynaptic active zone,GO:0060076~excitatory synapse,GO:0060203~clathrin-sculpted glutamate transport vesicle membrane,	GO:0005254~chloride channel activity,GO:0005313~L-glutamate transmembrane transporter activity,GO:0005326~neurotransmitter transporter activity,GO:0005436~sodium:phosphate symporter activity,GO:0015319~sodium:inorganic phosphate symporter activity,GO:0015386~potassium:proton antiporter activity,GO:0022857~transmembrane transporter activity,	IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,	hsa04721:Synaptic vesicle cycle,hsa04723:Retrograde endocannabinoid signaling,hsa04724:Glutamatergic synapse,hsa05033:Nicotine addiction,				KW-0050~Antiport,KW-0406~Ion transport,KW-0532~Neurotransmitter transport,KW-0592~Phosphate transport,KW-0739~Sodium transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0868~Chloride,KW-0915~Sodium,	KW-0407~Ion channel,KW-0869~Chloride channel,	KW-0597~Phosphoprotein,	DOMAIN:MFS,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC18A3	solute carrier family 18 member A3(SLC18A3)	Homo sapiens	GO:0006836~neurotransmitter transport,GO:0006837~serotonin transport,GO:0007268~chemical synaptic transmission,GO:0014057~positive regulation of acetylcholine secretion, neurotransmission,GO:0015870~acetylcholine transport,GO:0051630~acetylcholine uptake,GO:0055085~transmembrane transport,GO:1900273~positive regulation of long-term synaptic potentiation,GO:1904398~positive regulation of neuromuscular junction development,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030121~AP-1 adaptor complex,GO:0030122~AP-2 adaptor complex,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0043195~terminal bouton,GO:0060201~clathrin-sculpted acetylcholine transport vesicle membrane,	GO:0005277~acetylcholine transmembrane transporter activity,GO:0005278~acetylcholine:proton antiporter activity,GO:0005515~protein binding,GO:0015311~monoamine:proton antiporter activity,GO:0022857~transmembrane transporter activity,	IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,	hsa04721:Synaptic vesicle cycle,hsa04725:Cholinergic synapse,	617239~Myasthenic syndrome, congenital, 21, presynaptic,			KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,	KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,REGION:Mediates interaction with SEC14L1,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal, vesicle,TRANSMEM:Helical,
SLC22A18	solute carrier family 22 member 18(SLC22A18)	Homo sapiens	GO:0007588~excretion,GO:0015695~organic cation transport,GO:0042908~xenobiotic transport,GO:1902600~hydrogen ion transmembrane transport,GO:1990961~drug transmembrane export,	GO:0005635~nuclear envelope,GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,	GO:0005515~protein binding,GO:0015293~symporter activity,GO:0015299~solute:proton antiporter activity,GO:0022857~transmembrane transporter activity,GO:0031625~ubiquitin protein ligase binding,	IPR001958:Tetracycline resistance protein, TetA/multidrug resistance protein MdtG,IPR011701:Major facilitator superfamily,IPR020846:Major facilitator superfamily domain,		114480~Breast cancer, somatic,211980~Lung cancer, somatic,268210~Rhabdomyosarcoma, somatic,			KW-0406~Ion transport,KW-0769~Symport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:MFS,TRANSMEM:Helical,
SLC22A6	solute carrier family 22 member 6(SLC22A6)	Homo sapiens	GO:0014070~response to organic cyclic compound,GO:0015698~inorganic anion transport,GO:0015711~organic anion transport,GO:0015732~prostaglandin transport,GO:0015742~alpha-ketoglutarate transport,GO:0031427~response to methotrexate,GO:0043252~sodium-independent organic anion transport,GO:0055085~transmembrane transport,GO:0097254~renal tubular secretion,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0005901~caveola,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0032991~macromolecular complex,GO:0070062~extracellular exosome,	GO:0005452~inorganic anion exchanger activity,GO:0005515~protein binding,GO:0008514~organic anion transmembrane transporter activity,GO:0015132~prostaglandin transmembrane transporter activity,GO:0015301~anion:anion antiporter activity,GO:0015347~sodium-independent organic anion transmembrane transporter activity,GO:0031404~chloride ion binding,GO:0042802~identical protein binding,	IPR004749:Organic cation transport protein,IPR005828:General substrate transporter,IPR020846:Major facilitator superfamily domain,						KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,MUTAGEN:F->A: Decrease in the level of membrane protein expression, 70 % loss of PAH uptake, increased affinity for cidofovir, lower Vmax for PAH, and lower Km and Vmax for cidofovir.,MUTAGEN:K->A: Decrease in the level of membrane protein expression and 70 % loss of PAH uptake.,MUTAGEN:L->A: Complete loss of PAH transport activity.,MUTAGEN:N->Q: Complete loss of PAH transport activity.,MUTAGEN:T->A: Complete loss of PAH transport activity.,MUTAGEN:Y->A: Loss of membrane protein expression and little uptake of cidofovir.,REGION:Disordered,SITE:Important for interaction with cidofovir,SITE:Important for interaction with cidofovir and PAH,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC26A7	solute carrier family 26 member 7(SLC26A7)	Homo sapiens	GO:0001696~gastric acid secretion,GO:0006811~ion transport,GO:0006820~anion transport,GO:0006821~chloride transport,GO:0008272~sulfate transport,GO:0015701~bicarbonate transport,GO:0019532~oxalate transport,GO:1902358~sulfate transmembrane transport,GO:1902476~chloride transmembrane transport,	GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0055038~recycling endosome membrane,	GO:0005254~chloride channel activity,GO:0008271~secondary active sulfate transmembrane transporter activity,GO:0015106~bicarbonate transmembrane transporter activity,GO:0015108~chloride transmembrane transporter activity,GO:0015116~sulfate transmembrane transporter activity,GO:0015301~anion:anion antiporter activity,GO:0019531~oxalate transmembrane transporter activity,	IPR001902:Sulphate anion transporter,IPR002645:STAS domain,IPR011547:Sulphate transporter,	hsa04971:Gastric acid secretion,				KW-0039~Anion exchange,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0967~Endosome,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				DOMAIN:STAS,DOMAIN:Sulfate_transp,REGION:Membrane targeting,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC28A1	solute carrier family 28 member 1(SLC28A1)	Homo sapiens	GO:0006139~nucleobase-containing compound metabolic process,GO:0015855~pyrimidine nucleobase transport,GO:0015858~nucleoside transport,GO:0015861~cytidine transport,GO:0015862~uridine transport,GO:0045117~azole transport,GO:0072531~pyrimidine-containing compound transmembrane transport,GO:1901642~nucleoside transmembrane transport,GO:1904823~purine nucleobase transmembrane transport,	GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016607~nuclear speck,GO:0031526~brush border membrane,	GO:0005337~nucleoside transmembrane transporter activity,GO:0005345~purine nucleobase transmembrane transporter activity,GO:0005415~nucleoside:sodium symporter activity,GO:0015212~cytidine transmembrane transporter activity,GO:0015213~uridine transmembrane transporter activity,GO:0015293~symporter activity,GO:0015389~pyrimidine- and adenine-specific:sodium symporter activity,GO:1901474~azole transmembrane transporter activity,	IPR002668:Na dependent nucleoside transporter,IPR008276:Concentrative nucleoside transporter,IPR011642:Nucleoside recognition Gate,IPR011657:Na dependent nucleoside transporter, C-terminal,IPR018270:Concentrative nucleoside transporter, metazoan/bacterial,		618477~Uridine-cytidineuria,			KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Gate,DOMAIN:Nucleos_tra2_C,DOMAIN:Nucleos_tra2_N,MUTAGEN:Missing: Unable to mediate sodium-dependent transport of uridine.,MUTAGEN:Q->M: Increases transport of purine nucleosides; when associated with Gly-319.,MUTAGEN:S->A,C,R,T: Unable to mediate sodium-dependent transport of uridine.,MUTAGEN:S->G: Enables transport of purine nucleosides.,MUTAGEN:S->T: Produces a full purine-type transporter; when associated with Gly-319 and Met-320.,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC30A3	solute carrier family 30 member 3(SLC30A3)	Homo sapiens	GO:0006829~zinc II ion transport,GO:0010043~response to zinc ion,GO:0051050~positive regulation of transport,GO:0061088~regulation of sequestering of zinc ion,GO:0071577~zinc II ion transmembrane transport,	GO:0005737~cytoplasm,GO:0005765~lysosomal membrane,GO:0005768~endosome,GO:0005770~late endosome,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030285~integral component of synaptic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0031902~late endosome membrane,GO:0043005~neuron projection,GO:0097457~hippocampal mossy fiber,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0098978~glutamatergic synapse,	GO:0005385~zinc ion transmembrane transporter activity,GO:0005515~protein binding,GO:0008324~cation transmembrane transporter activity,GO:0046872~metal ion binding,	IPR002524:Cation efflux protein,IPR027469:Cation efflux protein transmembrane domain,					KW-0406~Ion transport,KW-0813~Transport,KW-0864~Zinc transport,	KW-0458~Lysosome,KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0967~Endosome,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,CROSSLNK:Dityrosine (Tyr-Tyr) (interchain with Y-357),CROSSLNK:Dityrosine (Tyr-Tyr) (interchain with Y-372),MUTAGEN:Y->F: Decreased homodimerization. Decreased localization to intracellular vesicles. Loss of zinc transporter activity.,MUTAGEN:Y->F: Increased homodimerization. Increased localization to intracellular vesicles.,MUTAGEN:Y->F: No effect on homodimerization.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SLC43A3	solute carrier family 43 member 3(SLC43A3)	Homo sapiens	GO:0015853~adenine transport,GO:0015908~fatty acid transport,GO:0035344~hypoxanthine transport,GO:0042908~xenobiotic transport,GO:1903716~guanine transmembrane transport,	GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,	GO:0005515~protein binding,GO:0015207~adenine transmembrane transporter activity,GO:0015208~guanine transmembrane transporter activity,GO:0015245~fatty acid transporter activity,GO:0022857~transmembrane transporter activity,GO:0042910~xenobiotic transporter activity,	IPR011701:Major facilitator superfamily,IPR027197:Solute carrier family 43 member 3,					KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,REGION:Disordered,TRANSMEM:Helical,
SLC47A2	solute carrier family 47 member 2(SLC47A2)	Homo sapiens	GO:0015695~organic cation transport,GO:0055085~transmembrane transport,GO:1902600~hydrogen ion transmembrane transport,GO:1990961~drug transmembrane export,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0015101~organic cation transmembrane transporter activity,GO:0015297~antiporter activity,GO:0015299~solute:proton antiporter activity,GO:0022857~transmembrane transporter activity,GO:0042910~xenobiotic transporter activity,	IPR002528:Multi antimicrobial extrusion protein,					KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SLC7A14	solute carrier family 7 member 14(SLC7A14)	Homo sapiens	GO:0003333~amino acid transmembrane transport,GO:0006865~amino acid transport,	GO:0005654~nucleoplasm,GO:0005765~lysosomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043231~intracellular membrane-bounded organelle,	GO:0005515~protein binding,GO:0015171~amino acid transmembrane transporter activity,	IPR002293:Amino acid/polyamine transporter I,		615725~Retinitis pigmentosa 68,			KW-0029~Amino-acid transport,KW-0813~Transport,	KW-0458~Lysosome,KW-0472~Membrane,	KW-0682~Retinitis pigmentosa,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
SLC7A4	solute carrier family 7 member 4(SLC7A4)	Homo sapiens	GO:0006865~amino acid transport,GO:1990822~basic amino acid transmembrane transport,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0015171~amino acid transmembrane transporter activity,GO:0015174~basic amino acid transmembrane transporter activity,	IPR002293:Amino acid/polyamine transporter I,					KW-0029~Amino-acid transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TRANSMEM:Helical,
SLC8A2	solute carrier family 8 member A2(SLC8A2)	Homo sapiens	GO:0002931~response to ischemia,GO:0006811~ion transport,GO:0006816~calcium ion transport,GO:0006874~cellular calcium ion homeostasis,GO:0007154~cell communication,GO:0007611~learning or memory,GO:0007612~learning,GO:0007613~memory,GO:0010468~regulation of gene expression,GO:0030001~metal ion transport,GO:0035725~sodium ion transmembrane transport,GO:0048172~regulation of short-term neuronal synaptic plasticity,GO:0050808~synapse organization,GO:0050890~cognition,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0060291~long-term synaptic potentiation,GO:0070050~neuron cellular homeostasis,GO:0070588~calcium ion transmembrane transport,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0098703~calcium ion import across plasma membrane,GO:0098815~modulation of excitatory postsynaptic potential,GO:0099566~regulation of postsynaptic cytosolic calcium ion concentration,GO:0099608~regulation of action potential firing pattern,GO:1903779~regulation of cardiac conduction,GO:1990034~calcium ion export from cell,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016323~basolateral plasma membrane,GO:0030424~axon,GO:0030425~dendrite,GO:0042383~sarcolemma,GO:0043025~neuronal cell body,GO:0043197~dendritic spine,GO:0043204~perikaryon,GO:0043679~axon terminus,GO:0045202~synapse,GO:0098793~presynapse,GO:0098794~postsynapse,	GO:0005432~calcium:sodium antiporter activity,GO:0005516~calmodulin binding,GO:0015081~sodium ion transmembrane transporter activity,GO:0015085~calcium ion transmembrane transporter activity,GO:0015297~antiporter activity,GO:0015491~cation:cation antiporter activity,GO:0046872~metal ion binding,GO:1905060~calcium:cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration,	IPR003644:Na-Ca exchanger/integrin-beta4,IPR004836:Sodium/calcium exchanger protein,IPR004837:Sodium/calcium exchanger membrane region,	hsa04020:Calcium signaling pathway,hsa04022:cGMP-PKG signaling pathway,hsa04260:Cardiac muscle contraction,hsa04261:Adrenergic signaling in cardiomyocytes,hsa04371:Apelin signaling pathway,hsa04740:Olfactory transduction,hsa04961:Endocrine and other factor-regulated calcium reabsorption,hsa04974:Protein digestion and absorption,hsa04978:Mineral absorption,hsa05410:Hypertrophic cardiomyopathy,hsa05412:Arrhythmogenic right ventricular cardiomyopathy,hsa05414:Dilated cardiomyopathy,			SM00237:Calx_beta,	KW-0050~Antiport,KW-0109~Calcium transport,KW-0406~Ion transport,KW-0739~Sodium transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0915~Sodium,	KW-0112~Calmodulin-binding,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Calx-beta,DOMAIN:Calx-beta 1,DOMAIN:Calx-beta 2,DOMAIN:Na_Ca_ex,REGION:Disordered,REGION:Putative calmodulin-binding region,REPEAT:Alpha-1,REPEAT:Alpha-2,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SOWAHD	sosondowah ankyrin repeat domain family member D(SOWAHD)	Homo sapiens				IPR002110:Ankyrin repeat,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,				KW-0040~ANK repeat,KW-0677~Repeat,				COMPBIAS:Polar residues,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,
SPTBN5	spectrin beta, non-erythrocytic 5(SPTBN5)	Homo sapiens	GO:0007030~Golgi organization,GO:0007041~lysosomal transport,GO:0030036~actin cytoskeleton organization,GO:0051693~actin filament capping,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005875~microtubule associated complex,GO:0008091~spectrin,GO:0016020~membrane,GO:0032391~photoreceptor connecting cilium,GO:0045179~apical cortex,GO:0097381~photoreceptor disc membrane,	GO:0002046~opsin binding,GO:0003779~actin binding,GO:0008022~protein C-terminus binding,GO:0019894~kinesin binding,GO:0030507~spectrin binding,GO:0032029~myosin tail binding,GO:0034452~dynactin binding,GO:0042802~identical protein binding,GO:0043621~protein self-association,GO:0045505~dynein intermediate chain binding,GO:0051015~actin filament binding,	IPR001589:Actinin-type, actin-binding, conserved site,IPR001715:Calponin homology domain,IPR001849:Pleckstrin homology domain,IPR002017:Spectrin repeat,IPR011993:Pleckstrin homology-like domain,IPR018159:Spectrin/alpha-actinin,				SM00033:CH,SM00150:SPEC,SM00233:PH,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0009~Actin-binding,KW-0117~Actin capping,		COMPBIAS:Basic and acidic residues,DOMAIN:Calponin-homology (CH) 1,DOMAIN:Calponin-homology (CH) 2,DOMAIN:PH,REGION:Actin-binding,REGION:Disordered,REPEAT:Spectrin 1,REPEAT:Spectrin 10,REPEAT:Spectrin 11,REPEAT:Spectrin 12,REPEAT:Spectrin 13,REPEAT:Spectrin 14,REPEAT:Spectrin 15,REPEAT:Spectrin 16,REPEAT:Spectrin 17,REPEAT:Spectrin 18,REPEAT:Spectrin 19,REPEAT:Spectrin 2,REPEAT:Spectrin 20,REPEAT:Spectrin 21,REPEAT:Spectrin 22,REPEAT:Spectrin 23,REPEAT:Spectrin 24,REPEAT:Spectrin 25,REPEAT:Spectrin 26,REPEAT:Spectrin 27,REPEAT:Spectrin 3,REPEAT:Spectrin 4,REPEAT:Spectrin 5,REPEAT:Spectrin 6,REPEAT:Spectrin 7,REPEAT:Spectrin 8,REPEAT:Spectrin 9,
SPAG17	sperm associated antigen 17(SPAG17)	Homo sapiens	GO:0003351~epithelial cilium movement,GO:0007283~spermatogenesis,GO:0044458~motile cilium assembly,GO:1904158~axonemal central apparatus assembly,GO:1905198~manchette assembly,GO:1990953~intramanchette transport,	GO:0001669~acrosomal vesicle,GO:0002177~manchette,GO:0005576~extracellular region,GO:0005794~Golgi apparatus,GO:0005874~microtubule,GO:0031514~motile cilium,GO:1990716~axonemal central apparatus,		IPR026173:Sperm-associated antigen 17,		619380~Spermatogenic failure 55,			KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0970~Cilium biogenesis/degradation,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0333~Golgi apparatus,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-0969~Cilium,		KW-0175~Coiled coil,				COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,REGION:Disordered,
SPAG4	sperm associated antigen 4(SPAG4)	Homo sapiens	GO:0006998~nuclear envelope organization,GO:0007283~spermatogenesis,GO:0030154~cell differentiation,	GO:0005635~nuclear envelope,GO:0005637~nuclear inner membrane,GO:0005737~cytoplasm,GO:0005856~cytoskeleton,GO:0016021~integral component of membrane,GO:0031514~motile cilium,GO:0034993~LINC complex,	GO:0005198~structural molecule activity,GO:0005515~protein binding,GO:0043495~protein anchor,	IPR012919:Sad1/UNC-like, C-terminal,					KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0206~Cytoskeleton,KW-0282~Flagellum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-0969~Cilium,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,DOMAIN:SUN,REGION:Disordered,TRANSMEM:Helical,
SOHLH1	spermatogenesis and oogenesis specific basic helix-loop-helix 1(SOHLH1)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007283~spermatogenesis,GO:0009994~oocyte differentiation,GO:0030154~cell differentiation,GO:0048477~oogenesis,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,		617690~Ovarian dysgenesis 5,618115~Spermatogenic failure 32,		SM00353:HLH,	KW-0221~Differentiation,KW-0744~Spermatogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,			KW-0217~Developmental protein,KW-0238~DNA-binding,KW-9996~Developmental protein,		COMPBIAS:Pro residues,DOMAIN:bHLH,REGION:Disordered,
SPATA6	spermatogenesis associated 6(SPATA6)	Homo sapiens	GO:0007283~spermatogenesis,GO:0030154~cell differentiation,GO:0044458~motile cilium assembly,	GO:0005576~extracellular region,GO:0097224~sperm connecting piece,	GO:0032027~myosin light chain binding,	IPR027207:Spermatogenesis-associated protein 6,					KW-0221~Differentiation,KW-0744~Spermatogenesis,	KW-0282~Flagellum,KW-0964~Secreted,KW-0966~Cell projection,KW-0969~Cilium,		KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SPATA6,REGION:Disordered,
SPX	spexin hormone(SPX)	Homo sapiens	GO:0003084~positive regulation of systemic arterial blood pressure,GO:0007165~signal transduction,GO:0010459~negative regulation of heart rate,GO:0032099~negative regulation of appetite,GO:0035814~negative regulation of renal sodium excretion,GO:0044539~long-chain fatty acid import,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0051930~regulation of sensory perception of pain,GO:1904306~positive regulation of gastro-intestinal system smooth muscle contraction,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0030133~transport vesicle,GO:0031045~dense core granule,	GO:0005184~neuropeptide hormone activity,GO:0005515~protein binding,GO:0031765~type 2 galanin receptor binding,GO:0031766~type 3 galanin receptor binding,		hsa04080:Neuroactive ligand-receptor interaction,					KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,		KW-0732~Signal,		KW-0372~Hormone,	KW-0027~Amidation,KW-0165~Cleavage on pair of basic residues,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,PEPTIDE:Spexin-1,PEPTIDE:Spexin-2,REGION:Disordered,SITE:Cleavage; by prohormone convertase 2,
SGMS2	sphingomyelin synthase 2(SGMS2)	Homo sapiens	GO:0006665~sphingolipid metabolic process,GO:0006686~sphingomyelin biosynthetic process,GO:0016310~phosphorylation,GO:0030148~sphingolipid biosynthetic process,GO:0030500~regulation of bone mineralization,GO:0046513~ceramide biosynthetic process,GO:1905373~ceramide phosphoethanolamine biosynthetic process,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030173~integral component of Golgi membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0002950~ceramide phosphoethanolamine synthase activity,GO:0005515~protein binding,GO:0016301~kinase activity,GO:0016740~transferase activity,GO:0033188~sphingomyelin synthase activity,GO:0047493~ceramide cholinephosphotransferase activity,	IPR025749:Sphingomyelin synthase-like domain,	hsa00600:Sphingolipid metabolism,hsa01100:Metabolic pathways,hsa04071:Sphingolipid signaling pathway,	126550~Calvarial doughnut lesions with bone fragility with or without spondylometaphyseal dysplasia,			KW-0443~Lipid metabolism,KW-0746~Sphingolipid metabolism,	KW-0333~Golgi apparatus,KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,	KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0418~Kinase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,	COMPBIAS:Basic and acidic residues,DOMAIN:PAP2_C,LIPID:S-palmitoyl cysteine,MUTAGEN:C->A: Strongly decreases palmitoylation; when associated with A-343. Abolishes palmitoylation and dramatically reduces plasma membrane localization; when associated with 331-A-A-332 and A-343.,MUTAGEN:C->A: Strongly decreases palmitoylation; when associated with A-348. Abolishes palmitoylation and dramatically reduces plasma membrane localization; when associated with 331-A-A-332 and A-348.,MUTAGEN:CC->AA: Little effect on palmitoylation; when associated with A-343 or A-348. Abolishes palmitoylation and dramatically reduces plasma membrane localization; when associated with A-343 and A-348.,MUTAGEN:D->E,A: Completely abolishes enzyme activity. No change in subcellular location.,MUTAGEN:H->A: Completely abolishes enzyme activity. No change in subcellular location.,MUTAGEN:S->A: Abolishes enzyme activity by about 70%. No change in subcellular location.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical,
SKA1	spindle and kinetochore associated complex subunit 1(SKA1)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0007059~chromosome segregation,GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0051301~cell division,	GO:0000776~kinetochore,GO:0000940~condensed chromosome outer kinetochore,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0015630~microtubule cytoskeleton,GO:0034451~centriolar satellite,GO:0045171~intercellular bridge,GO:0072686~mitotic spindle,	GO:0005515~protein binding,GO:0008017~microtubule binding,	IPR009829:Protein of unknown function DUF1395,					KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,		KW-0175~Coiled coil,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,MUTAGEN:R->A: Abolishes microtubule binding; when associated with A-155 and A-236.,MUTAGEN:R->A: Abolishes microtubule binding; when associated with A-155 and A-245.,MUTAGEN:R->A: Abolishes microtubule binding; when associated with A-236 and A-245.,MUTAGEN:S->D: Phosphomimetic mutant which strongly reduces microtubule binding; when associated with D-185.,MUTAGEN:S->D: Phosphomimetic mutant which strongly reduces microtubule binding; when associated with D-242.,REGION:Disordered,REGION:Microtubule binding,
SKA3	spindle and kinetochore associated complex subunit 3(SKA3)	Homo sapiens	GO:0000278~mitotic cell cycle,GO:0007059~chromosome segregation,GO:0031110~regulation of microtubule polymerization or depolymerization,GO:0051301~cell division,	GO:0000776~kinetochore,GO:0000940~condensed chromosome outer kinetochore,GO:0005813~centrosome,GO:0005829~cytosol,GO:0005876~spindle microtubule,GO:0072686~mitotic spindle,	GO:0005515~protein binding,						KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,	KW-0137~Centromere,KW-0158~Chromosome,KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,KW-0995~Kinetochore,					KW-0597~Phosphoprotein,	REGION:Disordered,
SPRY1	sprouty RTK signaling antagonist 1(SPRY1)	Homo sapiens	GO:0000132~establishment of mitotic spindle orientation,GO:0001656~metanephros development,GO:0001657~ureteric bud development,GO:0001759~organ induction,GO:0008285~negative regulation of cell proliferation,GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0034260~negative regulation of GTPase activity,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0043065~positive regulation of apoptotic process,GO:0043407~negative regulation of MAP kinase activity,GO:0046580~negative regulation of Ras protein signal transduction,GO:0048513~animal organ development,GO:0051387~negative regulation of neurotrophin TRK receptor signaling pathway,GO:0060449~bud elongation involved in lung branching,GO:0060940~epithelial to mesenchymal transition involved in cardiac fibroblast development,GO:0070371~ERK1 and ERK2 cascade,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1902747~negative regulation of lens fiber cell differentiation,	GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0016020~membrane,	GO:0005515~protein binding,	IPR007875:Sprouty,						KW-0472~Membrane,KW-0963~Cytoplasm,				KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,	COMPBIAS:Polar residues,DOMAIN:SPR,REGION:Disordered,
SPRY4	sprouty RTK signaling antagonist 4(SPRY4)	Homo sapiens	GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0043407~negative regulation of MAP kinase activity,GO:0046580~negative regulation of Ras protein signal transduction,GO:0048513~animal organ development,GO:0070373~negative regulation of ERK1 and ERK2 cascade,GO:1900025~negative regulation of substrate adhesion-dependent cell spreading,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0032587~ruffle membrane,	GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,	IPR007875:Sprouty,		615266~Hypogonadotropic hypogonadism 17 with or without anosmia,				KW-0472~Membrane,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0956~Kallmann syndrome,KW-1016~Hypogonadotropic hypogonadism,			KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:SPR,REGION:Disordered,REGION:Required for interaction with TESK1. Required for colocalization with TESK1 at vesicular spots in the cytoplasm and inhibition of TESK1 kinase activity, resulting in inhibition of cell spreading,
STAB1	stabilin 1(STAB1)	Homo sapiens	GO:0006898~receptor-mediated endocytosis,GO:0006954~inflammatory response,GO:0007155~cell adhesion,GO:0007267~cell-cell signaling,GO:0016525~negative regulation of angiogenesis,GO:0042742~defense response to bacterium,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0030666~endocytic vesicle membrane,	GO:0005041~low-density lipoprotein receptor activity,GO:0005044~scavenger receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005540~hyaluronic acid binding,GO:0015035~protein disulfide oxidoreductase activity,GO:0030169~low-density lipoprotein particle binding,	IPR000538:Link,IPR000742:Epidermal growth factor-like domain,IPR000782:FAS1 domain,IPR001881:EGF-like calcium-binding,IPR002049:EGF-like, laminin,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR024731:EGF domain, merozoite surface protein 1-like,				SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00445:LINK,SM00554:FAS1,	KW-0395~Inflammatory response,	KW-0472~Membrane,		KW-0245~EGF-like domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like 1,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11,DOMAIN:EGF-like 12,DOMAIN:EGF-like 13,DOMAIN:EGF-like 14,DOMAIN:EGF-like 15,DOMAIN:EGF-like 16,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8,DOMAIN:EGF-like 9,DOMAIN:FAS1 1,DOMAIN:FAS1 2,DOMAIN:FAS1 3,DOMAIN:FAS1 4,DOMAIN:FAS1 5,DOMAIN:FAS1 6,DOMAIN:FAS1 7,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Link,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
STC1	stanniocalcin 1(STC1)	Homo sapiens	GO:0001503~ossification,GO:0001886~endothelial cell morphogenesis,GO:0003421~growth plate cartilage axis specification,GO:0006874~cellular calcium ion homeostasis,GO:0007165~signal transduction,GO:0007566~embryo implantation,GO:0010596~negative regulation of endothelial cell migration,GO:0030336~negative regulation of cell migration,GO:0033280~response to vitamin D,GO:0035988~chondrocyte proliferation,GO:0044070~regulation of anion transport,GO:0046697~decidualization,GO:0051926~negative regulation of calcium ion transport,GO:0060348~bone development,GO:0071320~cellular response to cAMP,GO:0071385~cellular response to glucocorticoid stimulus,GO:0071456~cellular response to hypoxia,GO:0086004~regulation of cardiac muscle cell contraction,GO:0090280~positive regulation of calcium ion import,GO:1903403~negative regulation of renal phosphate excretion,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016324~apical plasma membrane,	GO:0005179~hormone activity,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR004978:Stanniocalcin,						KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain,
STBD1	starch binding domain 1(STBD1)	Homo sapiens	GO:0005980~glycogen catabolic process,GO:0006897~endocytosis,GO:0046907~intracellular transport,GO:0061723~glycophagy,GO:0061753~substrate localization to autophagosome,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0030315~T-tubule,GO:0034045~pre-autophagosomal structure membrane,GO:0048471~perinuclear region of cytoplasm,GO:0070821~tertiary granule membrane,GO:0101003~ficolin-1-rich granule membrane,	GO:0005515~protein binding,GO:0019899~enzyme binding,GO:0030247~polysaccharide binding,GO:0038024~cargo receptor activity,GO:2001069~glycogen binding,GO:2001070~starch binding,	IPR002044:Carbohydrate binding module family 20,IPR013783:Immunoglobulin-like fold,IPR013784:Carbohydrate-binding-like fold,				SM01065:SM01065,	KW-0072~Autophagy,KW-0119~Carbohydrate metabolism,KW-0321~Glycogen metabolism,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:CBM20,MOTIF:LIR,MUTAGEN:V->A: Abolishes interaction with GABARAPL1.,MUTAGEN:W->A: Abolishes interaction with GABARAPL1.,MUTAGEN:W->G,L: Abolishes GYS2- and glycogen-binding, and leads to rapid degradation.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SCD	stearoyl-CoA desaturase(SCD)	Homo sapiens	GO:0006636~unsaturated fatty acid biosynthetic process,GO:0070542~response to fatty acid,GO:1903966~monounsaturated fatty acid biosynthetic process,	GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,	GO:0004768~stearoyl-CoA 9-desaturase activity,GO:0005506~iron ion binding,GO:0005515~protein binding,GO:0016491~oxidoreductase activity,GO:0032896~palmitoyl-CoA 9-desaturase activity,	IPR001522:Fatty acid desaturase, type 1, C-terminal,IPR015876:Fatty acid desaturase, type 1, core,	hsa01040:Biosynthesis of unsaturated fatty acids,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,hsa03320:PPAR signaling pathway,hsa04152:AMPK signaling pathway,hsa04936:Alcoholic liver disease,				KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0408~Iron,KW-0479~Metal-binding,	KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	MOTIF:Histidine box-1,MOTIF:Histidine box-2,MOTIF:Histidine box-3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
SBNO2	strawberry notch homolog 2(SBNO2)	Homo sapiens	GO:0002281~macrophage activation involved in immune response,GO:0006355~regulation of transcription, DNA-templated,GO:0030282~bone mineralization,GO:0030316~osteoclast differentiation,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050727~regulation of inflammatory response,GO:0061430~bone trabecula morphogenesis,GO:0071222~cellular response to lipopolysaccharide,GO:0071348~cellular response to interleukin-11,GO:0071354~cellular response to interleukin-6,GO:0072675~osteoclast fusion,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005634~nucleus,	GO:0031490~chromatin DNA binding,GO:0042393~histone binding,	IPR026741:Protein strawberry notch-like,IPR026937:Strawberry notch, helicase C domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0221~Differentiation,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0892~Osteogenesis,					KW-0010~Activator,KW-0678~Repressor,		COMPBIAS:Acidic residues,COMPBIAS:Basic residues,DOMAIN:AAA_34,DOMAIN:Helicase_C_4,REGION:Disordered,
SMC4	structural maintenance of chromosomes 4(SMC4)	Homo sapiens	GO:0000070~mitotic sister chromatid segregation,GO:0007049~cell cycle,GO:0007076~mitotic chromosome condensation,GO:0010032~meiotic chromosome condensation,GO:0045132~meiotic chromosome segregation,GO:0051276~chromosome organization,GO:0051301~cell division,GO:0051383~kinetochore organization,GO:0051984~positive regulation of chromosome segregation,GO:1905820~positive regulation of chromosome separation,GO:1905821~positive regulation of chromosome condensation,	GO:0000775~chromosome, centromeric region,GO:0000794~condensed nuclear chromosome,GO:0000796~condensin complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005694~chromosome,GO:0005829~cytosol,GO:0016607~nuclear speck,	GO:0003682~chromatin binding,GO:0003697~single-stranded DNA binding,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016887~ATPase activity,	IPR003395:RecF/RecN/SMC,IPR010935:SMCs flexible hinge,IPR024704:Structural maintenance of chromosomes protein,IPR027417:P-loop containing nucleoside triphosphate hydrolase,			PIRSF005719:structural maintenance of chromosomes protein,	SM00968:SM00968,	KW-0131~Cell cycle,KW-0132~Cell division,KW-0226~DNA condensation,KW-0498~Mitosis,	KW-0158~Chromosome,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0175~Coiled coil,	KW-0067~ATP-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Pro residues,DOMAIN:SMC hinge,DOMAIN:SMC_N,REGION:Disordered,
STUM	stum, mechanosensory transduction mediator homolog(STUM)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR026673:SPEC3/C1orf95,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	TRANSMEM:Helical,
SULT4A1	sulfotransferase family 4A member 1(SULT4A1)	Homo sapiens	GO:0008202~steroid metabolic process,GO:0051923~sulfation,	GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005829~cytosol,	GO:0005515~protein binding,GO:0008146~sulfotransferase activity,GO:0042802~identical protein binding,	IPR000863:Sulfotransferase domain,IPR027417:P-loop containing nucleoside triphosphate hydrolase,					KW-0443~Lipid metabolism,KW-0753~Steroid metabolism,	KW-0963~Cytoplasm,				KW-0808~Transferase,	KW-0597~Phosphoprotein,	DOMAIN:Sulfotransfer_1,REGION:Disordered,
SOCS2	suppressor of cytokine signaling 2(SOCS2)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0007259~JAK-STAT cascade,GO:0007595~lactation,GO:0009966~regulation of signal transduction,GO:0016567~protein ubiquitination,GO:0032355~response to estradiol,GO:0032870~cellular response to hormone stimulus,GO:0035556~intracellular signal transduction,GO:0040015~negative regulation of multicellular organism growth,GO:0043066~negative regulation of apoptotic process,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0045666~positive regulation of neuron differentiation,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046854~phosphatidylinositol phosphorylation,GO:0060396~growth hormone receptor signaling pathway,GO:0060749~mammary gland alveolus development,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005942~phosphatidylinositol 3-kinase complex,	GO:0005131~growth hormone receptor binding,GO:0005159~insulin-like growth factor receptor binding,GO:0005515~protein binding,GO:0008269~JAK pathway signal transduction adaptor activity,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2 domain,IPR001496:SOCS protein, C-terminal,	hsa04630:JAK-STAT signaling pathway,hsa04910:Insulin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04930:Type II diabetes mellitus,hsa04935:Growth hormone synthesis, secretion and action,			SM00252:SH2,SM00253:SOCS,SM00969:SM00969,	KW-0341~Growth regulation,KW-0833~Ubl conjugation pathway,			KW-0727~SH2 domain,		KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),DOMAIN:SH2,DOMAIN:SOCS box,MUTAGEN:K->R: Increased protein half-life.,MUTAGEN:K->R: No effect on protein half-life.,REGION:Disordered,REGION:Interaction with AREL1,
SOCS3	suppressor of cytokine signaling 3(SOCS3)	Homo sapiens	GO:0001932~regulation of protein phosphorylation,GO:0007259~JAK-STAT cascade,GO:0016567~protein ubiquitination,GO:0030154~cell differentiation,GO:0035556~intracellular signal transduction,GO:0040008~regulation of growth,GO:0042532~negative regulation of tyrosine phosphorylation of STAT protein,GO:0043066~negative regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0043551~regulation of phosphatidylinositol 3-kinase activity,GO:0045597~positive regulation of cell differentiation,GO:0046426~negative regulation of JAK-STAT cascade,GO:0046627~negative regulation of insulin receptor signaling pathway,GO:0046854~phosphatidylinositol phosphorylation,GO:0050728~negative regulation of inflammatory response,GO:0060670~branching involved in labyrinthine layer morphogenesis,GO:0060674~placenta blood vessel development,GO:0060707~trophoblast giant cell differentiation,GO:0060708~spongiotrophoblast differentiation,GO:0097398~cellular response to interleukin-17,GO:1990830~cellular response to leukemia inhibitory factor,	GO:0005829~cytosol,GO:0005942~phosphatidylinositol 3-kinase complex,	GO:0001784~phosphotyrosine binding,GO:0004860~protein kinase inhibitor activity,GO:0005515~protein binding,GO:0035198~miRNA binding,GO:0046935~1-phosphatidylinositol-3-kinase regulator activity,	IPR000980:SH2 domain,IPR001496:SOCS protein, C-terminal,	hsa04120:Ubiquitin mediated proteolysis,hsa04380:Osteoclast differentiation,hsa04630:JAK-STAT signaling pathway,hsa04668:TNF signaling pathway,hsa04910:Insulin signaling pathway,hsa04917:Prolactin signaling pathway,hsa04920:Adipocytokine signaling pathway,hsa04930:Type II diabetes mellitus,hsa04931:Insulin resistance,hsa04932:Non-alcoholic fatty liver disease,hsa04935:Growth hormone synthesis, secretion and action,hsa05160:Hepatitis C,hsa05164:Influenza A,hsa05168:Herpes simplex virus 1 infection,			SM00252:SH2,SM00253:SOCS,SM00969:SM00969,	KW-0341~Growth regulation,KW-0833~Ubl conjugation pathway,			KW-0727~SH2 domain,		KW-0734~Signal transduction inhibitor,	KW-0597~Phosphoprotein,	COMPBIAS:Pro residues,DOMAIN:SH2,DOMAIN:SOCS box,MUTAGEN:E->R: Partial loss of EPO-induced STAT5 signaling suppression. No effect on LIF-induced signaling suppression. Abolishes binding to JH1. Inhibits JAK2 phosphorylation.,MUTAGEN:F->A: Complete loss of EPO-induced STAT5 signaling suppression. Abolishes binding to JH1.,MUTAGEN:G->A: Little effect on EPO/LIF signaling.,MUTAGEN:G->V: No effect on binding to Y429/Y431 phosphorylated EPOR.,MUTAGEN:L->A,F: Little effect on EPO-induced STAT5 signaling suppression.,MUTAGEN:L->A: Impaired binding to Y429/Y431 phosphorylated EPOR.,MUTAGEN:L->D: Complete loss of EPO-induced STAT5 signaling suppression. No suppression of JAK2 phosphorylation.,MUTAGEN:L->R: Complete loss of EPO/LIF-induced signaling inhibition. Abolishes binding to JH1.,MUTAGEN:R->E: Complete loss of EPO/LIF-induced signaling suppression. No inhibition of JAK2 phosphorylation.,MUTAGEN:R->E: Greatly impaired binding to Y429/Y431 phosphorylated EPOR.,MUTAGEN:R->K: No effect on EPO/LIF-induced signaling suppression. Partial suppression of JAK2 phosphorylation. No effect on binding to JH1. Loss of binding to IL12RB2.,MUTAGEN:V->E: Complete loss of EPO/LIF-induced signaling suppression.,MUTAGEN:Y->A: Complete loss of EPO-induced STAT5 signaling suppression. No effect on LIF-induced STAT3 signaling. Abolishes binding to JH1.,MUTAGEN:Y->F: Little effect on EPO-induced signaling suppression.,REGION:Disordered,REGION:Extended SH2 subdomain (ESS),REGION:Kinase inhibitory region (KIR),
SMN2	survival of motor neuron 2, centromeric(SMN2)	Homo sapiens	GO:0000245~spliceosomal complex assembly,GO:0000387~spliceosomal snRNP assembly,GO:0006353~DNA-templated transcription, termination,GO:0006397~mRNA processing,GO:0007399~nervous system development,GO:0008380~RNA splicing,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0015030~Cajal body,GO:0016604~nuclear body,GO:0030018~Z disc,GO:0030424~axon,GO:0032797~SMN complex,GO:0034719~SMN-Sm protein complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0043005~neuron projection,GO:0043204~perikaryon,GO:0097504~Gemini of coiled bodies,	GO:0003723~RNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,	IPR002999:Tudor domain,IPR010304:Survival motor neuron,		253400~Spinal muscular atrophy, type III, modifier of,		SM00333:TUDOR,	KW-0507~mRNA processing,KW-0508~mRNA splicing,KW-0524~Neurogenesis,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0966~Cell projection,	KW-0225~Disease variant,KW-0523~Neurodegeneration,			KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:SMN,DOMAIN:Tudor,MUTAGEN:A->N: Impairs GEMIN2 binding.,MUTAGEN:D->A: Impairs GEMIN2 binding.,MUTAGEN:E->K: Impairs SMN binding to RPP20/POP7. Abolishes the interaction with ELAVL4. Abolishes interaction with SNRPD1 and SNRPD3. Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:EEQ->SEV: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:G->A: Impairs homooligomerization.,MUTAGEN:G->E: Impairs homooligomerization.,MUTAGEN:H->R: Impairs GEMIN8 binding.,MUTAGEN:L->A: Impairs GEMIN2 binding.,MUTAGEN:L->A: Impairs homooligomerization.,MUTAGEN:L->S: Impairs homooligomerization.,MUTAGEN:M->R,T,A: Impairs homooligomerization and GEMIN8 binding.,MUTAGEN:N->D,S: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:Q->E: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:S->P: Impairs homooligomerization and GEMIN8 binding.,MUTAGEN:T->A: Impairs homooligomerization.,MUTAGEN:W->A: Impairs GEMIN2 binding.,MUTAGEN:W->A: Impairs homooligomerization.,MUTAGEN:W->L,V: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:W->S: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:Y->A: Impairs GEMIN2 binding.,MUTAGEN:Y->A: Impairs homooligomerization.,MUTAGEN:Y->D: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:Y->H: Impairs binding to substrate containing dimethylated arginine.,MUTAGEN:Y->L,F: Impairs binding to substrate containing dimethylated arginine.,REGION:Disordered,REGION:Interacts with GEMIN2,REGION:Involved in homooligomerization,REGION:P2 (binding site for SNRPB),REGION:Required for interaction with RPP20/POP7,REGION:Required for interaction with SYNCRIP,
SUSD2	sushi domain containing 2(SUSD2)	Homo sapiens	GO:0051782~negative regulation of cell division,GO:1902807~negative regulation of cell cycle G1/S phase transition,	GO:0005615~extracellular space,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0005515~protein binding,	IPR000436:Sushi/SCR/CCP,IPR001212:Somatomedin B domain,IPR001846:von Willebrand factor, type D domain,IPR005533:AMOP,				SM00032:CCP,SM00216:VWD,SM00723:AMOP,		KW-0472~Membrane,KW-1003~Cell membrane,	KW-0043~Tumor suppressor,	KW-0732~Signal,KW-0768~Sushi,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Alternate,DOMAIN:AMOP,DOMAIN:SMB,DOMAIN:Sushi,DOMAIN:VWFD,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
SRPX2	sushi repeat containing protein X-linked 2(SRPX2)	Homo sapiens	GO:0001525~angiogenesis,GO:0042325~regulation of phosphorylation,GO:0048870~cell motility,GO:0051965~positive regulation of synapse assembly,GO:0071625~vocalization behavior,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0098609~cell-cell adhesion,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009986~cell surface,GO:0045202~synapse,GO:0060076~excitatory synapse,GO:0097060~synaptic membrane,	GO:0005102~receptor binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0036458~hepatocyte growth factor binding,GO:0042802~identical protein binding,	IPR000436:Sushi/SCR/CCP,IPR003410:Hyalin,IPR025232:Domain of unknown function DUF4174,		300643~Rolandic epilepsy, impaired intellectual development, and speech dyspraxia,		SM00032:CCP,	KW-0037~Angiogenesis,KW-0130~Cell adhesion,	KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,	KW-0225~Disease variant,KW-0887~Epilepsy,KW-0991~Intellectual disability,	KW-0677~Repeat,KW-0732~Signal,KW-0768~Sushi,			KW-0325~Glycoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	DOMAIN:DUF4174,DOMAIN:HYR,DOMAIN:Sushi,DOMAIN:Sushi 1,DOMAIN:Sushi 2,DOMAIN:Sushi 3,
SYN2	synapsin II(SYN2)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0007269~neurotransmitter secretion,GO:0017156~calcium ion regulated exocytosis,GO:0097091~synaptic vesicle clustering,	GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0014069~postsynaptic density,GO:0030672~synaptic vesicle membrane,GO:0031201~SNARE complex,GO:0045202~synapse,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098793~presynapse,GO:0098978~glutamatergic synapse,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0042802~identical protein binding,	IPR001359:Synapsin,IPR013815:ATP-grasp fold, subdomain 1,IPR016185:Pre-ATP-grasp domain,IPR019735:Synapsin, conserved site,IPR019736:Synapsin, phosphorylation site,IPR020897:Synapsin, pre-ATP-grasp domain,IPR020898:Synapsin, ATP-binding domain,		181500~Schizophrenia, susceptibility to,				KW-0770~Synapse,	KW-1211~Schizophrenia,				KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:Synapsin,DOMAIN:Synapsin_C,REGION:A,REGION:B; linker,REGION:C; actin-binding and synaptic-vesicle binding,REGION:Disordered,REGION:E,REGION:G; Pro-rich linker,REGION:H; Pro/Ser-rich linker,
SYNGR3	synaptogyrin 3(SYNGR3)	Homo sapiens	GO:0001504~neurotransmitter uptake,GO:0021762~substantia nigra development,GO:0032411~positive regulation of transporter activity,GO:0045055~regulated exocytosis,GO:0051580~regulation of neurotransmitter uptake,	GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,	GO:0005515~protein binding,GO:0042169~SH2 domain binding,GO:0047485~protein N-terminus binding,	IPR008253:Marvel,IPR016579:Synaptogyrin,			PIRSF011282:synaptogyrin,			KW-0472~Membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,COMPBIAS:Polar residues,DOMAIN:MARVEL,REGION:Disordered,TRANSMEM:Helical,
SYCE1L	synaptonemal complex central element protein 1 like(SYCE1L)	Homo sapiens	GO:0007130~synaptonemal complex assembly,	GO:0000795~synaptonemal complex,GO:0045111~intermediate filament cytoskeleton,		IPR026676:Synaptonemal complex central element protein 1,					KW-0469~Meiosis,			KW-0175~Coiled coil,				REGION:Disordered,
SNAP25	synaptosome associated protein 25(SNAP25)	Homo sapiens	GO:0001504~neurotransmitter uptake,GO:0006887~exocytosis,GO:0006906~vesicle fusion,GO:0007268~chemical synaptic transmission,GO:0007626~locomotory behavior,GO:0008306~associative learning,GO:0010975~regulation of neuron projection development,GO:0016079~synaptic vesicle exocytosis,GO:0016081~synaptic vesicle docking,GO:0016082~synaptic vesicle priming,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0050796~regulation of insulin secretion,GO:0051179~localization,GO:0060291~long-term synaptic potentiation,GO:0071805~potassium ion transmembrane transport,GO:0098967~exocytic insertion of neurotransmitter receptor to postsynaptic membrane,GO:0099525~presynaptic dense core vesicle exocytosis,GO:0099590~neurotransmitter receptor internalization,	GO:0001917~photoreceptor inner segment,GO:0005737~cytoplasm,GO:0005802~trans-Golgi network,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0030426~growth cone,GO:0031201~SNARE complex,GO:0031234~extrinsic component of cytoplasmic side of plasma membrane,GO:0031982~vesicle,GO:0035579~specific granule membrane,GO:0036477~somatodendritic compartment,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070032~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex,GO:0070821~tertiary granule membrane,GO:0097470~ribbon synapse,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,	GO:0005249~voltage-gated potassium channel activity,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0008289~lipid binding,GO:0017075~syntaxin-1 binding,GO:0019905~syntaxin binding,GO:0048306~calcium-dependent protein binding,GO:0060090~binding, bridging,	IPR000727:Target SNARE coiled-coil domain,IPR000928:SNAP-25,	hsa04721:Synaptic vesicle cycle,hsa04911:Insulin secretion,	616330~Myasthenic syndrome, congenital, 18,		SM00397:t_SNARE,		KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0991~Intellectual disability,KW-1004~Congenital myasthenic syndrome,	KW-0175~Coiled coil,KW-0677~Repeat,			KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology 1,DOMAIN:t-SNARE coiled-coil homology 2,LIPID:S-palmitoyl cysteine,MUTAGEN:A->R: Not cleaved by BoNT/C.,MUTAGEN:D->A: Decreased cleavage by BoNT/C, no change in cleavage by BoNT/A.,MUTAGEN:I->E: Small decrease in affinity for C.botulinum BoNT/A, increased efficiency of BoNT/C cleavage.,MUTAGEN:M->E: Small decrease in affinity for C.botulinum BoNT/A.,MUTAGEN:M->Y: Slight decrease in affinity for BoNT/A, increases kcat for BoNT/A.,MUTAGEN:P->A: Decreased binding affinity for ZDHHC17.,MUTAGEN:Q->A: Decreased binding affinity for ZDHHC17.,MUTAGEN:Q->A: Decreased cleavage by C.botulinum BoNT/C, no change in cleavage by C.botulinum BoNT/A (botA).,MUTAGEN:R->A: No effect on ZDHHC17 binding.,MUTAGEN:S->A: No effect on ZDHHC17 binding.,MUTAGEN:V->A: Mildly decreased binding affinity for ZDHHC17.,REGION:Disordered,REGION:Interaction with CENPF,REGION:Interaction with ZDHHC17,SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type A (BoNT/A, botA),SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type C (BoNT/C),SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type E (BoNT/E),
SYT2	synaptotagmin 2(SYT2)	Homo sapiens	GO:0007269~neurotransmitter secretion,GO:0014059~regulation of dopamine secretion,GO:0016192~vesicle-mediated transport,GO:0017156~calcium ion regulated exocytosis,GO:0017158~regulation of calcium ion-dependent exocytosis,GO:0030154~cell differentiation,GO:0048488~synaptic vesicle endocytosis,GO:0048791~calcium ion-regulated exocytosis of neurotransmitter,GO:0071277~cellular response to calcium ion,GO:1903861~positive regulation of dendrite extension,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0030669~clathrin-coated endocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0031045~dense core granule,GO:0042584~chromaffin granule membrane,GO:0070382~exocytic vesicle,	GO:0000149~SNARE binding,GO:0001786~phosphatidylserine binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005544~calcium-dependent phospholipid binding,GO:0019905~syntaxin binding,GO:0030276~clathrin binding,GO:0043533~inositol 1,3,4,5 tetrakisphosphate binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR001565:Synaptotagmin,IPR015428:Synaptotagmin 1,		616040~Myasthenic syndrome, congenital, 7A, presynaptic, and distal motor neuropathy, autosomal dominant,619461~Myasthenic syndrome, congenital, 7B, presynaptic, autosomal recessive,		SM00239:C2,	KW-0221~Differentiation,	KW-0472~Membrane,KW-0770~Synapse,KW-0968~Cytoplasmic vesicle,	KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,	KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,		KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,REGION:Disordered,REGION:Phospholipid binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,
SYT7	synaptotagmin 7(SYT7)	Homo sapiens	GO:0001778~plasma membrane repair,GO:0006887~exocytosis,GO:0006909~phagocytosis,GO:0014059~regulation of dopamine secretion,GO:0016192~vesicle-mediated transport,GO:0017156~calcium ion regulated exocytosis,GO:0017158~regulation of calcium ion-dependent exocytosis,GO:0036465~synaptic vesicle recycling,GO:0045956~positive regulation of calcium ion-dependent exocytosis,GO:0046850~regulation of bone remodeling,GO:0048791~calcium ion-regulated exocytosis of neurotransmitter,GO:0050764~regulation of phagocytosis,GO:0050796~regulation of insulin secretion,GO:0070092~regulation of glucagon secretion,GO:0071277~cellular response to calcium ion,GO:0090119~vesicle-mediated cholesterol transport,GO:0090385~phagosome-lysosome fusion,GO:1900242~regulation of synaptic vesicle endocytosis,GO:1990926~short-term synaptic potentiation,GO:1990927~calcium ion regulated lysosome exocytosis,	GO:0005764~lysosome,GO:0005765~lysosomal membrane,GO:0005777~peroxisome,GO:0005778~peroxisomal membrane,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030670~phagocytic vesicle membrane,GO:0030672~synaptic vesicle membrane,GO:0031045~dense core granule,GO:0032009~early phagosome,GO:0042734~presynaptic membrane,GO:0042995~cell projection,GO:0070062~extracellular exosome,GO:0070382~exocytic vesicle,GO:0098686~hippocampal mossy fiber to CA3 synapse,GO:0099056~integral component of presynaptic membrane,	GO:0000149~SNARE binding,GO:0001786~phosphatidylserine binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005516~calmodulin binding,GO:0005544~calcium-dependent phospholipid binding,GO:0005546~phosphatidylinositol-4,5-bisphosphate binding,GO:0019905~syntaxin binding,GO:0030276~clathrin binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR001565:Synaptotagmin,IPR015427:Synaptotagmin 7,				SM00239:C2,	KW-0268~Exocytosis,	KW-0458~Lysosome,KW-0472~Membrane,KW-0576~Peroxisome,KW-0770~Synapse,KW-0966~Cell projection,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0112~Calmodulin-binding,	KW-0449~Lipoprotein,KW-0564~Palmitate,KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Vesicular,TRANSMEM:Helical,
SDC1	syndecan 1(SDC1)	Homo sapiens	GO:0001657~ureteric bud development,GO:0006898~receptor-mediated endocytosis,GO:0006954~inflammatory response,GO:0009636~response to toxic substance,GO:0016477~cell migration,GO:0042060~wound healing,GO:0042476~odontogenesis,GO:0042542~response to hydrogen peroxide,GO:0048627~myoblast development,GO:0051384~response to glucocorticoid,GO:0051591~response to cAMP,GO:0051592~response to calcium ion,GO:0055002~striated muscle cell development,GO:0060009~Sertoli cell development,GO:0060070~canonical Wnt signaling pathway,GO:1903543~positive regulation of exosomal secretion,GO:1903553~positive regulation of extracellular exosome assembly,	GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0032991~macromolecular complex,GO:0043202~lysosomal lumen,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0008022~protein C-terminus binding,GO:0038024~cargo receptor activity,GO:0042802~identical protein binding,	IPR001050:Syndecan,IPR003585:Neurexin/syndecan/glycophorin C,	hsa04512:ECM-receptor interaction,hsa04514:Cell adhesion molecules,hsa05144:Malaria,hsa05205:Proteoglycans in cancer,hsa05418:Fluid shear stress and atherosclerosis,			SM00294:4.1m,		KW-0472~Membrane,KW-0964~Secreted,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine,COMPBIAS:Polar residues,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
STX1A	syntaxin 1A(STX1A)	Homo sapiens	GO:0001956~positive regulation of neurotransmitter secretion,GO:0006836~neurotransmitter transport,GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006906~vesicle fusion,GO:0009629~response to gravity,GO:0010701~positive regulation of norepinephrine secretion,GO:0010807~regulation of synaptic vesicle priming,GO:0016079~synaptic vesicle exocytosis,GO:0016081~synaptic vesicle docking,GO:0016192~vesicle-mediated transport,GO:0016925~protein sumoylation,GO:0017156~calcium ion regulated exocytosis,GO:0017157~regulation of exocytosis,GO:0030073~insulin secretion,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0032940~secretion by cell,GO:0033605~positive regulation of catecholamine secretion,GO:0035493~SNARE complex assembly,GO:0045956~positive regulation of calcium ion-dependent exocytosis,GO:0048278~vesicle docking,GO:0048488~synaptic vesicle endocytosis,GO:0050796~regulation of insulin secretion,GO:0072657~protein localization to membrane,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0001669~acrosomal vesicle,GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0008076~voltage-gated potassium channel complex,GO:0012505~endomembrane system,GO:0014069~postsynaptic density,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030141~secretory granule,GO:0030285~integral component of synaptic vesicle membrane,GO:0030424~axon,GO:0030672~synaptic vesicle membrane,GO:0031201~SNARE complex,GO:0031965~nuclear membrane,GO:0042641~actomyosin,GO:0043005~neuron projection,GO:0048787~presynaptic active zone membrane,GO:0070032~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex,GO:0070033~synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex,GO:0070044~synaptobrevin 2-SNAP-25-syntaxin-1a complex,GO:0098685~Schaffer collateral - CA1 synapse,GO:0098839~postsynaptic density membrane,GO:0098978~glutamatergic synapse,GO:0099056~integral component of presynaptic membrane,	GO:0000149~SNARE binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019855~calcium channel inhibitor activity,GO:0019869~chloride channel inhibitor activity,GO:0019900~kinase binding,GO:0019904~protein domain specific binding,GO:0032028~myosin head/neck binding,GO:0042802~identical protein binding,GO:0043008~ATP-dependent protein binding,GO:0044325~ion channel binding,GO:0044877~macromolecular complex binding,GO:0047485~protein N-terminus binding,GO:0048306~calcium-dependent protein binding,	IPR000727:Target SNARE coiled-coil domain,IPR006011:Syntaxin, N-terminal,IPR006012:Syntaxin/epimorphin, conserved site,IPR010989:t-SNARE,	hsa04130:SNARE interactions in vesicular transport,hsa04721:Synaptic vesicle cycle,hsa04911:Insulin secretion,hsa05016:Huntington disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05031:Amphetamine addiction,			SM00397:t_SNARE,SM00503:SynN,	KW-0268~Exocytosis,KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0472~Membrane,KW-0770~Synapse,KW-0771~Synaptosome,KW-0964~Secreted,KW-0968~Cytoplasmic vesicle,KW-1003~Cell membrane,	KW-0856~Williams-Beuren syndrome,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO),DOMAIN:T-SNARE coiled-coil homology,DOMAIN:t-SNARE coiled-coil homology,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-252 and R-253.,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-252 and R-256.,MUTAGEN:K->R: Complete loss of sumoylation; when associated with R-253 and R-256.,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Anchor for type IV membrane protein,
STX1B	syntaxin 1B(STX1B)	Homo sapiens	GO:0001956~positive regulation of neurotransmitter secretion,GO:0006886~intracellular protein transport,GO:0006887~exocytosis,GO:0006904~vesicle docking involved in exocytosis,GO:0006906~vesicle fusion,GO:0010468~regulation of gene expression,GO:0010807~regulation of synaptic vesicle priming,GO:0010977~negative regulation of neuron projection development,GO:0016081~synaptic vesicle docking,GO:0017157~regulation of exocytosis,GO:0031629~synaptic vesicle fusion to presynaptic active zone membrane,GO:0048278~vesicle docking,GO:0048791~calcium ion-regulated exocytosis of neurotransmitter,GO:0060025~regulation of synaptic activity,GO:0061669~spontaneous neurotransmitter secretion,GO:0098967~exocytic insertion of neurotransmitter receptor to postsynaptic membrane,GO:1903422~negative regulation of synaptic vesicle recycling,GO:1904050~positive regulation of spontaneous neurotransmitter secretion,GO:1905302~negative regulation of macropinocytosis,GO:2000463~positive regulation of excitatory postsynaptic potential,	GO:0005634~nucleus,GO:0005652~nuclear lamina,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0005829~cytosol,GO:0005886~plasma membrane,GO:0008021~synaptic vesicle,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030424~axon,GO:0031201~SNARE complex,GO:0031594~neuromuscular junction,GO:0048787~presynaptic active zone membrane,	GO:0000149~SNARE binding,GO:0005102~receptor binding,GO:0005484~SNAP receptor activity,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0019904~protein domain specific binding,	IPR000727:Target SNARE coiled-coil domain,IPR006011:Syntaxin, N-terminal,IPR006012:Syntaxin/epimorphin, conserved site,IPR010989:t-SNARE,	hsa04130:SNARE interactions in vesicular transport,hsa04721:Synaptic vesicle cycle,	616172~Generalized epilepsy with febrile seizures plus, type 9,		SM00397:t_SNARE,SM00503:SynN,	KW-0532~Neurotransmitter transport,KW-0813~Transport,	KW-0206~Cytoskeleton,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-0887~Epilepsy,	KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	DOMAIN:t-SNARE coiled-coil homology,REGION:Disordered,TOPO_DOM:Cytoplasmic,TRANSMEM:Helical; Anchor for type IV membrane protein,
SNCA	synuclein alpha(SNCA)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001774~microglial cell activation,GO:0001921~positive regulation of receptor recycling,GO:0001956~positive regulation of neurotransmitter secretion,GO:0006469~negative regulation of protein kinase activity,GO:0006631~fatty acid metabolic process,GO:0006638~neutral lipid metabolic process,GO:0006644~phospholipid metabolic process,GO:0006919~activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0007006~mitochondrial membrane organization,GO:0007268~chemical synaptic transmission,GO:0007568~aging,GO:0008344~adult locomotory behavior,GO:0009410~response to xenobiotic stimulus,GO:0010040~response to iron(II) ion,GO:0010517~regulation of phospholipase activity,GO:0010642~negative regulation of platelet-derived growth factor receptor signaling pathway,GO:0014048~regulation of glutamate secretion,GO:0014059~regulation of dopamine secretion,GO:0016079~synaptic vesicle exocytosis,GO:0016082~synaptic vesicle priming,GO:0022898~regulation of transmembrane transporter activity,GO:0031115~negative regulation of microtubule polymerization,GO:0031623~receptor internalization,GO:0031648~protein destabilization,GO:0032026~response to magnesium ion,GO:0032410~negative regulation of transporter activity,GO:0032496~response to lipopolysaccharide,GO:0032769~negative regulation of monooxygenase activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0034341~response to interferon-gamma,GO:0034599~cellular response to oxidative stress,GO:0035067~negative regulation of histone acetylation,GO:0035493~SNARE complex assembly,GO:0035543~positive regulation of SNARE complex assembly,GO:0040012~regulation of locomotion,GO:0042416~dopamine biosynthetic process,GO:0042493~response to drug,GO:0042775~mitochondrial ATP synthesis coupled electron transport,GO:0043030~regulation of macrophage activation,GO:0043065~positive regulation of apoptotic process,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043524~negative regulation of neuron apoptotic process,GO:0044344~cellular response to fibroblast growth factor stimulus,GO:0045807~positive regulation of endocytosis,GO:0045920~negative regulation of exocytosis,GO:0045921~positive regulation of exocytosis,GO:0045963~negative regulation of dopamine metabolic process,GO:0048148~behavioral response to cocaine,GO:0048169~regulation of long-term neuronal synaptic plasticity,GO:0048488~synaptic vesicle endocytosis,GO:0048489~synaptic vesicle transport,GO:0050729~positive regulation of inflammatory response,GO:0050808~synapse organization,GO:0050812~regulation of acyl-CoA biosynthetic process,GO:0051179~localization,GO:0051262~protein tetramerization,GO:0051281~positive regulation of release of sequestered calcium ion into cytosol,GO:0051402~neuron apoptotic process,GO:0051583~dopamine uptake involved in synaptic transmission,GO:0051585~negative regulation of dopamine uptake involved in synaptic transmission,GO:0051612~negative regulation of serotonin uptake,GO:0051621~regulation of norepinephrine uptake,GO:0051622~negative regulation of norepinephrine uptake,GO:0060079~excitatory postsynaptic potential,GO:0060291~long-term synaptic potentiation,GO:0060732~positive regulation of inositol phosphate biosynthetic process,GO:0070495~negative regulation of thrombin-activated receptor signaling pathway,GO:0070555~response to interleukin-1,GO:0071280~cellular response to copper ion,GO:0071872~cellular response to epinephrine stimulus,GO:0071902~positive regulation of protein serine/threonine kinase activity,GO:0097435~supramolecular fiber organization,GO:1901214~regulation of neuron death,GO:1901215~negative regulation of neuron death,GO:1901216~positive regulation of neuron death,GO:1902957~negative regulation of mitochondrial electron transport, NADH to ubiquinone,GO:1903284~positive regulation of glutathione peroxidase activity,GO:1903285~positive regulation of hydrogen peroxide catabolic process,GO:1903421~regulation of synaptic vesicle recycling,GO:1903426~regulation of reactive oxygen species biosynthetic process,GO:1904307~response to desipramine,GO:1904715~negative regulation of chaperone-mediated autophagy,GO:1905606~regulation of presynapse assembly,GO:1990000~amyloid fibril formation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005634~nucleus,GO:0005640~nuclear outer membrane,GO:0005737~cytoplasm,GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005743~mitochondrial inner membrane,GO:0005758~mitochondrial intermembrane space,GO:0005759~mitochondrial matrix,GO:0005764~lysosome,GO:0005791~rough endoplasmic reticulum,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0005840~ribosome,GO:0005886~plasma membrane,GO:0005938~cell cortex,GO:0015629~actin cytoskeleton,GO:0016020~membrane,GO:0016234~inclusion body,GO:0030424~axon,GO:0030426~growth cone,GO:0030672~synaptic vesicle membrane,GO:0031092~platelet alpha granule membrane,GO:0032991~macromolecular complex,GO:0043025~neuronal cell body,GO:0043195~terminal bouton,GO:0043679~axon terminus,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0098794~postsynapse,GO:0099512~supramolecular fiber,	GO:0000149~SNARE binding,GO:0000287~magnesium ion binding,GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0003779~actin binding,GO:0004860~protein kinase inhibitor activity,GO:0005507~copper ion binding,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0005543~phospholipid binding,GO:0008017~microtubule binding,GO:0008198~ferrous iron binding,GO:0008270~zinc ion binding,GO:0008289~lipid binding,GO:0016491~oxidoreductase activity,GO:0019894~kinesin binding,GO:0019904~protein domain specific binding,GO:0030544~Hsp70 protein binding,GO:0042393~histone binding,GO:0042802~identical protein binding,GO:0043014~alpha-tubulin binding,GO:0043027~cysteine-type endopeptidase inhibitor activity involved in apoptotic process,GO:0043274~phospholipase binding,GO:0047485~protein N-terminus binding,GO:0048156~tau protein binding,GO:0048487~beta-tubulin binding,GO:0051219~phosphoprotein binding,GO:0060090~binding, bridging,GO:0070840~dynein complex binding,GO:1903136~cuprous ion binding,	IPR001058:Synuclein,IPR002460:Alpha-synuclein,	hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05022:Pathways of neurodegeneration - multiple diseases,	127750~Dementia, Lewy body,168601~Parkinson disease 1,605543~Parkinson disease 4,				KW-0034~Amyloid,KW-0472~Membrane,KW-0539~Nucleus,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0964~Secreted,KW-0966~Cell projection,	KW-0026~Alzheimer disease,KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0907~Parkinson disease,KW-0908~Parkinsonism,	KW-0677~Repeat,	KW-0186~Copper,KW-0479~Metal-binding,		KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,MUTAGEN:D->A: Impairs copper-binding.,MUTAGEN:E->K: Increases oligomerization.,MUTAGEN:E->K: No effect on oligomerization.,MUTAGEN:H->A: Impairs copper-binding.,MUTAGEN:Missing: Does not affect polymerization into amyloid fibrils.,MUTAGEN:Missing: Impairs polymerization into amyloid fibrils.,MUTAGEN:Missing: Reduces polymerization into amyloid fibrils.,MUTAGEN:Y->F: Abolishes osmotic stress-induced phosphorylation.,MUTAGEN:Y->F: No effect on osmotic stress-induced phosphorylation.,REGION:4 X 11 AA tandem repeats of [EGS]-K-T-K-[EQ]-[GQ]-V-X(4),REGION:Disordered,REGION:Interaction with SERF1A,REPEAT:1,REPEAT:2,REPEAT:3; approximate,REPEAT:4,
SNCB	synuclein beta(SNCB)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0042417~dopamine metabolic process,GO:0043086~negative regulation of catalytic activity,GO:0043524~negative regulation of neuron apoptotic process,GO:0048488~synaptic vesicle endocytosis,GO:0050808~synapse organization,GO:0051402~neuron apoptotic process,GO:1901214~regulation of neuron death,	GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0016234~inclusion body,GO:0043025~neuronal cell body,GO:0043679~axon terminus,	GO:0004859~phospholipase inhibitor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0046914~transition metal ion binding,GO:1903136~cuprous ion binding,	IPR001058:Synuclein,IPR002461:Beta-synuclein,		127750~Dementia, Lewy body,				KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,REGION:4 X 11 AA tandem repeats of [EGS]-K-T-K-[EQ]-[GQ]-V-X(4),REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3; approximate,REPEAT:4,
SNCG	synuclein gamma(SNCG)	Homo sapiens	GO:0007268~chemical synaptic transmission,GO:0008344~adult locomotory behavior,GO:0009306~protein secretion,GO:0014059~regulation of dopamine secretion,GO:0046928~regulation of neurotransmitter secretion,GO:0048488~synaptic vesicle endocytosis,GO:0050808~synapse organization,GO:1901214~regulation of neuron death,	GO:0005737~cytoplasm,GO:0005813~centrosome,GO:0005815~microtubule organizing center,GO:0005819~spindle,GO:0030424~axon,GO:0043025~neuronal cell body,GO:0043679~axon terminus,GO:0045202~synapse,GO:0048471~perinuclear region of cytoplasm,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:1903136~cuprous ion binding,	IPR001058:Synuclein,IPR002462:Gamma-synuclein,						KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,REGION:4 X 11 AA tandem repeats of [EGSA]-K-T-K-[EQ]-[GQ]-V-X(4),REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3; approximate,REPEAT:4,
TACR1	tachykinin receptor 1(TACR1)	Homo sapiens	GO:0002118~aggressive behavior,GO:0002526~acute inflammatory response,GO:0002687~positive regulation of leukocyte migration,GO:0003051~angiotensin-mediated drinking behavior,GO:0006954~inflammatory response,GO:0007200~phospholipase C-activating G-protein coupled receptor signaling pathway,GO:0007204~positive regulation of cytosolic calcium ion concentration,GO:0007217~tachykinin receptor signaling pathway,GO:0007616~long-term memory,GO:0008306~associative learning,GO:0009408~response to heat,GO:0009582~detection of abiotic stimulus,GO:0010193~response to ozone,GO:0010634~positive regulation of epithelial cell migration,GO:0010996~response to auditory stimulus,GO:0014910~regulation of smooth muscle cell migration,GO:0019233~sensory perception of pain,GO:0032224~positive regulation of synaptic transmission, cholinergic,GO:0032230~positive regulation of synaptic transmission, GABAergic,GO:0032355~response to estradiol,GO:0032570~response to progesterone,GO:0035094~response to nicotine,GO:0035106~operant conditioning,GO:0035815~positive regulation of renal sodium excretion,GO:0042713~sperm ejaculation,GO:0042755~eating behavior,GO:0043117~positive regulation of vascular permeability,GO:0043278~response to morphine,GO:0045471~response to ethanol,GO:0045760~positive regulation of action potential,GO:0045777~positive regulation of blood pressure,GO:0045778~positive regulation of ossification,GO:0045907~positive regulation of vasoconstriction,GO:0046878~positive regulation of saliva secretion,GO:0046887~positive regulation of hormone secretion,GO:0048265~response to pain,GO:0048266~behavioral response to pain,GO:0048660~regulation of smooth muscle cell proliferation,GO:0050671~positive regulation of lymphocyte proliferation,GO:0050679~positive regulation of epithelial cell proliferation,GO:0051496~positive regulation of stress fiber assembly,GO:0051602~response to electrical stimulus,GO:0060083~smooth muscle contraction involved in micturition,GO:0070472~regulation of uterine smooth muscle contraction,GO:0070474~positive regulation of uterine smooth muscle contraction,GO:1902093~positive regulation of flagellated sperm motility,	GO:0005737~cytoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0030425~dendrite,GO:0036126~sperm flagellum,GO:0044297~cell body,GO:0061827~sperm head,GO:0097225~sperm midpiece,	GO:0004995~tachykinin receptor activity,GO:0005515~protein binding,GO:0016496~substance P receptor activity,	IPR000046:Neurokinin NK1 receptor,IPR000276:G protein-coupled receptor, rhodopsin-like,IPR001681:Neurokinin receptor,IPR017452:GPCR, rhodopsin-like, 7TM,	hsa04020:Calcium signaling pathway,hsa04080:Neuroactive ligand-receptor interaction,					KW-0472~Membrane,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,KW-0449~Lipoprotein,KW-0564~Palmitate,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:G_PROTEIN_RECEP_F1_2,LIPID:S-palmitoyl cysteine,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TAS1R1	taste 1 receptor member 1(TAS1R1)	Homo sapiens	GO:0007186~G-protein coupled receptor signaling pathway,GO:0050912~detection of chemical stimulus involved in sensory perception of taste,GO:0050917~sensory perception of umami taste,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0008527~taste receptor activity,	IPR000337:GPCR, family 3,IPR001828:Extracellular ligand-binding receptor,IPR011500:GPCR, family 3, nine cysteines domain,IPR017978:GPCR, family 3, C-terminal,IPR017979:GPCR, family 3, conserved site,	hsa04742:Taste transduction,				KW-0716~Sensory transduction,KW-0919~Taste,	KW-0472~Membrane,KW-1003~Cell membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:ANF_receptor,DOMAIN:G_PROTEIN_RECEP_F3_4,DOMAIN:NCD3G,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TAS2R31	taste 2 receptor member 31(TAS2R31)	Homo sapiens	GO:0001580~detection of chemical stimulus involved in sensory perception of bitter taste,GO:0007186~G-protein coupled receptor signaling pathway,GO:0050909~sensory perception of taste,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0004930~G-protein coupled receptor activity,GO:0033038~bitter taste receptor activity,	IPR007960:Mammalian taste receptor,	hsa04742:Taste transduction,				KW-0716~Sensory transduction,KW-0919~Taste,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TAS2R46	taste 2 receptor member 46(TAS2R46)	Homo sapiens	GO:0001580~detection of chemical stimulus involved in sensory perception of bitter taste,GO:0007186~G-protein coupled receptor signaling pathway,GO:0050909~sensory perception of taste,	GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0060170~ciliary membrane,	GO:0004930~G-protein coupled receptor activity,GO:0033038~bitter taste receptor activity,	IPR007960:Mammalian taste receptor,	hsa04742:Taste transduction,				KW-0716~Sensory transduction,KW-0919~Taste,	KW-0472~Membrane,KW-0966~Cell projection,KW-0969~Cilium,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0297~G-protein coupled receptor,KW-0675~Receptor,KW-0807~Transducer,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,
TNC	tenascin C(TNC)	Homo sapiens	GO:0001558~regulation of cell growth,GO:0001649~osteoblast differentiation,GO:0002009~morphogenesis of an epithelium,GO:0007155~cell adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007528~neuromuscular junction development,GO:0008284~positive regulation of cell proliferation,GO:0009611~response to wounding,GO:0009612~response to mechanical stimulus,GO:0010628~positive regulation of gene expression,GO:0014012~peripheral nervous system axon regeneration,GO:0030155~regulation of cell adhesion,GO:0030334~regulation of cell migration,GO:0031175~neuron projection development,GO:0042060~wound healing,GO:0042127~regulation of cell proliferation,GO:0042475~odontogenesis of dentin-containing tooth,GO:0045471~response to ethanol,GO:0050727~regulation of inflammatory response,GO:0060447~bud outgrowth involved in lung branching,GO:0060739~mesenchymal-epithelial cell signaling involved in prostate gland development,GO:0060740~prostate gland epithelium morphogenesis,GO:0071300~cellular response to retinoic acid,GO:0071305~cellular response to vitamin D,GO:0071774~response to fibroblast growth factor,GO:0071799~cellular response to prostaglandin D stimulus,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005614~interstitial matrix,GO:0005615~extracellular space,GO:0005788~endoplasmic reticulum lumen,GO:0005925~focal adhesion,GO:0016020~membrane,GO:0090733~tenascin complex,GO:0098966~perisynaptic extracellular matrix,	GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0045545~syndecan binding,	IPR000742:Epidermal growth factor-like domain,IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR003961:Fibronectin, type III,IPR013111:EGF, extracellular,IPR013783:Immunoglobulin-like fold,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05165:Human papillomavirus infection,hsa05206:MicroRNAs in cancer,	615629~Deafness, autosomal dominant 56,		SM00060:FN3,SM00181:EGF,SM00186:FBG,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0209~Deafness,KW-0225~Disease variant,KW-1010~Non-syndromic deafness,	KW-0175~Coiled coil,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:EGF-like,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11,DOMAIN:EGF-like 12,DOMAIN:EGF-like 13,DOMAIN:EGF-like 14,DOMAIN:EGF-like 15,DOMAIN:EGF-like 1; incomplete,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8,DOMAIN:EGF-like 9,DOMAIN:Fibrinogen C-terminal,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 10,DOMAIN:Fibronectin type-III 11,DOMAIN:Fibronectin type-III 12,DOMAIN:Fibronectin type-III 13,DOMAIN:Fibronectin type-III 14,DOMAIN:Fibronectin type-III 15,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Fibronectin type-III 9,REGION:Disordered,
TNXB	tenascin XB(TNXB)	Homo sapiens	GO:0006631~fatty acid metabolic process,GO:0006641~triglyceride metabolic process,GO:0007155~cell adhesion,GO:0007160~cell-matrix adhesion,GO:0008284~positive regulation of cell proliferation,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010862~positive regulation of pathway-restricted SMAD protein phosphorylation,GO:0030036~actin cytoskeleton organization,GO:0030155~regulation of cell adhesion,GO:0030198~extracellular matrix organization,GO:0030199~collagen fibril organization,GO:0030334~regulation of cell migration,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0032963~collagen metabolic process,GO:0043506~regulation of JUN kinase activity,GO:0045595~regulation of cell differentiation,GO:0048251~elastic fiber assembly,GO:0098609~cell-cell adhesion,GO:1900748~positive regulation of vascular endothelial growth factor signaling pathway,GO:1901390~positive regulation of transforming growth factor beta activation,GO:1904028~positive regulation of collagen fibril organization,GO:1905935~positive regulation of cell fate determination,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,GO:0090733~tenascin complex,	GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0008201~heparin binding,GO:0098633~collagen fibril binding,	IPR000742:Epidermal growth factor-like domain,IPR002181:Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain,IPR003961:Fibronectin, type III,IPR013111:EGF, extracellular,IPR013783:Immunoglobulin-like fold,IPR014716:Fibrinogen, alpha/beta/gamma chain, C-terminal globular, subdomain 1,IPR020837:Fibrinogen, conserved site,	hsa04151:PI3K-Akt signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05165:Human papillomavirus infection,hsa05206:MicroRNAs in cancer,	615963~Vesicoureteral reflux 8,Ehlers-Danlos syndrome, classic-like, 1 606408~Ehlers-Danlos syndrome, classic-like, 1 606408,		SM00060:FN3,SM00181:EGF,SM00186:FBG,	KW-0130~Cell adhesion,	KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-0248~Ehlers-Danlos syndrome,	KW-0175~Coiled coil,KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:EGF-like 10,DOMAIN:EGF-like 11,DOMAIN:EGF-like 12,DOMAIN:EGF-like 13,DOMAIN:EGF-like 14,DOMAIN:EGF-like 15,DOMAIN:EGF-like 16,DOMAIN:EGF-like 17,DOMAIN:EGF-like 18,DOMAIN:EGF-like 19,DOMAIN:EGF-like 1; incomplete,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6,DOMAIN:EGF-like 7,DOMAIN:EGF-like 8,DOMAIN:EGF-like 9,DOMAIN:Fibrinogen C-terminal,DOMAIN:Fibronectin type-III,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 10,DOMAIN:Fibronectin type-III 11,DOMAIN:Fibronectin type-III 12,DOMAIN:Fibronectin type-III 13,DOMAIN:Fibronectin type-III 14,DOMAIN:Fibronectin type-III 15,DOMAIN:Fibronectin type-III 16,DOMAIN:Fibronectin type-III 17,DOMAIN:Fibronectin type-III 18,DOMAIN:Fibronectin type-III 19,DOMAIN:Fibronectin type-III 2,DOMAIN:Fibronectin type-III 20,DOMAIN:Fibronectin type-III 21,DOMAIN:Fibronectin type-III 22,DOMAIN:Fibronectin type-III 23,DOMAIN:Fibronectin type-III 24,DOMAIN:Fibronectin type-III 25,DOMAIN:Fibronectin type-III 26,DOMAIN:Fibronectin type-III 27,DOMAIN:Fibronectin type-III 28,DOMAIN:Fibronectin type-III 29,DOMAIN:Fibronectin type-III 3,DOMAIN:Fibronectin type-III 30,DOMAIN:Fibronectin type-III 4,DOMAIN:Fibronectin type-III 5,DOMAIN:Fibronectin type-III 6,DOMAIN:Fibronectin type-III 7,DOMAIN:Fibronectin type-III 8,DOMAIN:Fibronectin type-III 9,MOTIF:Cell attachment site,REGION:Disordered,
TEX26	testis expressed 26(TEX26)	Homo sapiens		GO:0005737~cytoplasm,														REGION:Disordered,
TSPAN32	tetraspanin 32(TSPAN32)	Homo sapiens	GO:0007010~cytoskeleton organization,GO:0007229~integrin-mediated signaling pathway,GO:0007267~cell-cell signaling,GO:0008285~negative regulation of cell proliferation,GO:0030886~negative regulation of myeloid dendritic cell activation,GO:0042098~T cell proliferation,GO:0042130~negative regulation of T cell proliferation,GO:0042832~defense response to protozoan,GO:0050688~regulation of defense response to virus,GO:0051604~protein maturation,GO:0070527~platelet aggregation,GO:0072659~protein localization to plasma membrane,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0070442~integrin alphaIIb-beta3 complex,		IPR008952:Tetraspanin, EC2 domain,IPR018499:Tetraspanin/Peripherin,						KW-0472~Membrane,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,				REGION:Disordered,TRANSMEM:Helical,
THBD	thrombomodulin(THBD)	Homo sapiens	GO:0006508~proteolysis,GO:0007565~female pregnancy,GO:0007596~blood coagulation,GO:0010165~response to X-ray,GO:0010544~negative regulation of platelet activation,GO:0030195~negative regulation of blood coagulation,GO:0031638~zymogen activation,GO:0032496~response to lipopolysaccharide,GO:0051591~response to cAMP,GO:0051918~negative regulation of fibrinolysis,GO:0072377~blood coagulation, common pathway,	GO:0005615~extracellular space,GO:0005774~vacuolar membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016327~apicolateral plasma membrane,GO:1905370~serine-type endopeptidase complex,	GO:0004888~transmembrane signaling receptor activity,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0038023~signaling receptor activity,	IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001304:C-type lectin,IPR001881:EGF-like calcium-binding,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR015149:Thrombomodulin-like, EGF-like,IPR016186:C-type lectin-like,IPR016187:C-type lectin fold,IPR016316:Complement component C1q/Thrombomodulin,IPR018097:EGF-like calcium-binding, conserved site,IPR026823:Complement Clr-like EGF domain,	hsa04610:Complement and coagulation cascades,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05418:Fluid shear stress and atherosclerosis,	612926~Hemolytic uremic syndrome, atypical, susceptibility to, 6,614486~Thrombophilia 12 due to thrombomodulin defect,		SM00034:CLECT,SM00179:EGF_CA,SM00181:EGF,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0472~Membrane,	KW-0225~Disease variant,KW-0792~Thrombophilia,KW-1068~Hemolytic uremic syndrome,	KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0379~Hydroxylation,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine,DOMAIN:C-type lectin,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF-like 4,DOMAIN:EGF-like 5,DOMAIN:EGF-like 6; calcium-binding,REGION:Disordered,REGION:Involved in alpha-L/beta-2 and alpha-M/beta-2 integrin binding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
THBS1	thrombospondin 1(THBS1)	Homo sapiens	GO:0001666~response to hypoxia,GO:0001937~negative regulation of endothelial cell proliferation,GO:0001953~negative regulation of cell-matrix adhesion,GO:0002040~sprouting angiogenesis,GO:0002544~chronic inflammatory response,GO:0002581~negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,GO:0002605~negative regulation of dendritic cell antigen processing and presentation,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0006986~response to unfolded protein,GO:0007155~cell adhesion,GO:0008284~positive regulation of cell proliferation,GO:0008285~negative regulation of cell proliferation,GO:0009410~response to xenobiotic stimulus,GO:0009612~response to mechanical stimulus,GO:0009749~response to glucose,GO:0010595~positive regulation of endothelial cell migration,GO:0010596~negative regulation of endothelial cell migration,GO:0010748~negative regulation of plasma membrane long-chain fatty acid transport,GO:0010751~negative regulation of nitric oxide mediated signal transduction,GO:0010754~negative regulation of cGMP-mediated signaling,GO:0010757~negative regulation of plasminogen activation,GO:0010759~positive regulation of macrophage chemotaxis,GO:0010763~positive regulation of fibroblast migration,GO:0016477~cell migration,GO:0016525~negative regulation of angiogenesis,GO:0018149~peptide cross-linking,GO:0030194~positive regulation of blood coagulation,GO:0030335~positive regulation of cell migration,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0032026~response to magnesium ion,GO:0032570~response to progesterone,GO:0032695~negative regulation of interleukin-12 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0032914~positive regulation of transforming growth factor beta1 production,GO:0033574~response to testosterone,GO:0034605~cellular response to heat,GO:0034976~response to endoplasmic reticulum stress,GO:0040037~negative regulation of fibroblast growth factor receptor signaling pathway,GO:0042327~positive regulation of phosphorylation,GO:0042493~response to drug,GO:0043032~positive regulation of macrophage activation,GO:0043066~negative regulation of apoptotic process,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0043537~negative regulation of blood vessel endothelial cell migration,GO:0043652~engulfment of apoptotic cell,GO:0045727~positive regulation of translation,GO:0045766~positive regulation of angiogenesis,GO:0048266~behavioral response to pain,GO:0048661~positive regulation of smooth muscle cell proliferation,GO:0050921~positive regulation of chemotaxis,GO:0051592~response to calcium ion,GO:0051726~regulation of cell cycle,GO:0051895~negative regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0051918~negative regulation of fibrinolysis,GO:0071356~cellular response to tumor necrosis factor,GO:0071363~cellular response to growth factor stimulus,GO:0090051~negative regulation of cell migration involved in sprouting angiogenesis,GO:1902043~positive regulation of extrinsic apoptotic signaling pathway via death domain receptors,GO:1903588~negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903671~negative regulation of sprouting angiogenesis,GO:2000353~positive regulation of endothelial cell apoptotic process,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2001027~negative regulation of endothelial cell chemotaxis,GO:2001237~negative regulation of extrinsic apoptotic signaling pathway,	GO:0005576~extracellular region,GO:0005577~fibrinogen complex,GO:0005615~extracellular space,GO:0005783~endoplasmic reticulum,GO:0005788~endoplasmic reticulum lumen,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016529~sarcoplasmic reticulum,GO:0030141~secretory granule,GO:0031012~extracellular matrix,GO:0031091~platelet alpha granule,GO:0031093~platelet alpha granule lumen,GO:0070062~extracellular exosome,	GO:0001786~phosphatidylserine binding,GO:0001968~fibronectin binding,GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0008201~heparin binding,GO:0017134~fibroblast growth factor binding,GO:0030169~low-density lipoprotein particle binding,GO:0042802~identical protein binding,GO:0043236~laminin binding,GO:0043394~proteoglycan binding,GO:0050431~transforming growth factor beta binding,GO:0050840~extracellular matrix binding,GO:0070051~fibrinogen binding,GO:0070052~collagen V binding,	IPR000742:Epidermal growth factor-like domain,IPR000884:Thrombospondin, type 1 repeat,IPR001007:von Willebrand factor, type C,IPR001791:Laminin G domain,IPR001881:EGF-like calcium-binding,IPR003367:Thrombospondin, type 3-like repeat,IPR008859:Thrombospondin, C-terminal,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR017897:Thrombospondin, type 3 repeat,	hsa04015:Rap1 signaling pathway,hsa04115:p53 signaling pathway,hsa04145:Phagosome,hsa04151:PI3K-Akt signaling pathway,hsa04350:TGF-beta signaling pathway,hsa04510:Focal adhesion,hsa04512:ECM-receptor interaction,hsa05144:Malaria,hsa05165:Human papillomavirus infection,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05219:Bladder cancer,			SM00179:EGF_CA,SM00181:EGF,SM00209:TSP1,SM00210:TSPN,SM00214:VWC,	KW-0130~Cell adhesion,KW-0834~Unfolded protein response,	KW-0256~Endoplasmic reticulum,KW-0272~Extracellular matrix,KW-0703~Sarcoplasmic reticulum,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,	KW-0106~Calcium,	KW-0358~Heparin-binding,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:C-linked (Man) tryptophan,CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc...) serine,CARBOHYD:O-linked (Fuc...) threonine,COMPBIAS:Basic and acidic residues,DISULFID:Interchain,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:Laminin G-like,DOMAIN:TSP C-terminal,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:VWFC,MOTIF:Cell attachment site,MUTAGEN:N->K: Loss of N-glycosylation site.,REGION:Disordered,REGION:Heparin-binding,REPEAT:TSP type-3,REPEAT:TSP type-3 1,REPEAT:TSP type-3 2,REPEAT:TSP type-3 3,REPEAT:TSP type-3 4,REPEAT:TSP type-3 5,REPEAT:TSP type-3 6,REPEAT:TSP type-3 7,REPEAT:TSP type-3 8,
THSD4	thrombospondin type 1 domain containing 4(THSD4)	Homo sapiens	GO:0030198~extracellular matrix organization,GO:0048251~elastic fiber assembly,	GO:0001527~microfibril,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0004222~metalloendopeptidase activity,GO:0005201~extracellular matrix structural constituent,GO:0016787~hydrolase activity,	IPR000884:Thrombospondin, type 1 repeat,IPR010294:ADAM-TS Spacer 1,IPR010909:PLAC,	hsa04350:TGF-beta signaling pathway,	619825~Aortic aneurysm, familial thoracic 12,		SM00209:TSP1,		KW-0272~Extracellular matrix,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0378~Hydrolase,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:PLAC,DOMAIN:TSP type-1 1,DOMAIN:TSP type-1 2,DOMAIN:TSP type-1 3,DOMAIN:TSP type-1 4,DOMAIN:TSP type-1 5,DOMAIN:TSP type-1 6,REGION:Disordered,
TK1	thymidine kinase 1(TK1)	Homo sapiens	GO:0006139~nucleobase-containing compound metabolic process,GO:0009157~deoxyribonucleoside monophosphate biosynthetic process,GO:0016310~phosphorylation,GO:0046104~thymidine metabolic process,GO:0051289~protein homotetramerization,GO:0071897~DNA biosynthetic process,	GO:0005829~cytosol,	GO:0004797~thymidine kinase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0008270~zinc ion binding,GO:0019136~deoxynucleoside kinase activity,GO:0042802~identical protein binding,	IPR001267:Thymidine kinase,IPR002624:Deoxynucleoside kinase,IPR020633:Thymidine kinase, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,		PIRSF000705:deoxynucleoside kinase,PIRSF035805:thymidine kinase,		KW-0237~DNA synthesis,	KW-0963~Cytoplasm,			KW-0067~ATP-binding,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Proton acceptor,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:dNK,MOTIF:KEN box,MUTAGEN:K->A: Resistant to degradation in the mitotic exit phase.,MUTAGEN:KE->AA: Resistant to degradation in the mitotic exit phase.,MUTAGEN:KEN->AAA: Resistant to degradation in the mitotic exit phase.,MUTAGEN:L->A: 30-fold higher KM for thymidine.,MUTAGEN:M->I,A: 300-fold higher KM for thymidine.,MUTAGEN:S->A: Loss of phosphorylation. Constant expression during cell cycle. No effect on ATP-induced tetramerization.,MUTAGEN:S->D: Perturbes ATP-induced tetramerization. Retaines the enzymatic function with decreased thymidine affinity and catalytic efficiency.,MUTAGEN:S->P: No effect on phosphorylation.,MUTAGEN:T->S: 50-fold higher KM for thymidine.,REGION:Disordered,
TYMP	thymidine phosphorylase(TYMP)	Homo sapiens	GO:0000002~mitochondrial genome maintenance,GO:0001525~angiogenesis,GO:0006206~pyrimidine nucleobase metabolic process,GO:0006213~pyrimidine nucleoside metabolic process,GO:0006935~chemotaxis,GO:0007165~signal transduction,GO:0030154~cell differentiation,GO:0031641~regulation of myelination,GO:0046074~dTMP catabolic process,GO:0051969~regulation of transmission of nerve impulse,GO:1905333~regulation of gastric motility,	GO:0005829~cytosol,	GO:0004645~phosphorylase activity,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0009032~thymidine phosphorylase activity,GO:0016154~pyrimidine-nucleoside phosphorylase activity,GO:0016740~transferase activity,GO:0016757~transferase activity, transferring glycosyl groups,GO:0016763~transferase activity, transferring pentosyl groups,GO:0042803~protein homodimerization activity,	IPR000053:Pyrimidine-nucleoside phosphorylase,IPR000312:Glycosyl transferase, family 3,IPR013102:Pyrimidine nucleoside phosphorylase, C-terminal,IPR017459:Glycosyl transferase family 3, N-terminal domain,IPR017872:Pyrimidine-nucleoside phosphorylase, conserved site,IPR018090:Pyrimidine-nucleoside phosphorylase, bacterial/eukaryotic,	hsa00240:Pyrimidine metabolism,hsa00983:Drug metabolism - other enzymes,hsa01100:Metabolic pathways,hsa01232:Nucleotide metabolism,hsa05219:Bladder cancer,	603041~Mitochondrial DNA depletion syndrome 1 (MNGIE type),	PIRSF000478:thymidine phosphorylase/pyrimidine-nucleoside phosphorylase,	SM00941:SM00941,	KW-0037~Angiogenesis,KW-0145~Chemotaxis,KW-0221~Differentiation,		KW-0225~Disease variant,KW-0622~Neuropathy,KW-0935~Progressive external ophthalmoplegia,KW-1274~Primary mitochondrial disease,	KW-0677~Repeat,		KW-0217~Developmental protein,KW-0328~Glycosyltransferase,KW-0339~Growth factor,KW-0808~Transferase,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	DOMAIN:Glycos_trans_3N,DOMAIN:Glycos_transf_3,DOMAIN:PYNP_C,MUTAGEN:Y->A: Abolishes catalytic activity.,MUTAGEN:Y->F: Reduced catalytic activity.,MUTAGEN:Y->L: Reduced catalytic activity.,REGION:Disordered,REPEAT:R-A-L-X-X-A-L-V-L,REPEAT:R-V-A-A-A-L-X(5,6)-L-G-R,
TESPA1	thymocyte expressed, positive selection associated 1(TESPA1)	Homo sapiens	GO:0008104~protein localization,GO:0010387~COP9 signalosome assembly,GO:0033077~T cell differentiation in thymus,GO:0033089~positive regulation of T cell differentiation in thymus,GO:0036399~TCR signalosome assembly,GO:0050862~positive regulation of T cell receptor signaling pathway,	GO:0005737~cytoplasm,GO:0005789~endoplasmic reticulum membrane,GO:0005829~cytosol,GO:0008180~COP9 signalosome,GO:0036398~TCR signalosome,	GO:0005102~receptor binding,GO:0043274~phospholipase binding,	IPR026647:Thymocyte-expressed positive selection-associated protein 1,				SM01257:SM01257,		KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0736~Signalosome,KW-0963~Cytoplasm,					KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:KRAP_IP3R_bind,MUTAGEN:F->A: Loss of ITPR1-binding.,MUTAGEN:F->A: Strong decrease in ITPR1-binding. Complete loss of ITPR1-binding; when associated with A-185.,REGION:Disordered,
TFPI2	tissue factor pathway inhibitor 2(TFPI2)	Homo sapiens	GO:0007596~blood coagulation,GO:0010951~negative regulation of endopeptidase activity,GO:0071498~cellular response to fluid shear stress,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0031012~extracellular matrix,	GO:0004867~serine-type endopeptidase inhibitor activity,GO:0005201~extracellular matrix structural constituent,	IPR002223:Proteinase inhibitor I2, Kunitz metazoa,IPR008296:Proteinase inhibitor I2, tissue factor pathway inhibitor,IPR020901:Proteinase inhibitor I2, Kunitz, conserved site,			PIRSF001620:tissue factor pathway inhibitor,	SM00131:KU,	KW-0094~Blood coagulation,KW-0356~Hemostasis,	KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0646~Protease inhibitor,KW-0722~Serine protease inhibitor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:BPTI/Kunitz inhibitor,DOMAIN:BPTI/Kunitz inhibitor 1,DOMAIN:BPTI/Kunitz inhibitor 2,DOMAIN:BPTI/Kunitz inhibitor 3,SITE:Reactive bond,
TLR8	toll like receptor 8(TLR8)	Homo sapiens	GO:0001817~regulation of cytokine production,GO:0001932~regulation of protein phosphorylation,GO:0002224~toll-like receptor signaling pathway,GO:0002755~MyD88-dependent toll-like receptor signaling pathway,GO:0006954~inflammatory response,GO:0006955~immune response,GO:0007249~I-kappaB kinase/NF-kappaB signaling,GO:0009615~response to virus,GO:0016064~immunoglobulin mediated immune response,GO:0032695~negative regulation of interleukin-12 production,GO:0032727~positive regulation of interferon-alpha production,GO:0032728~positive regulation of interferon-beta production,GO:0032729~positive regulation of interferon-gamma production,GO:0032731~positive regulation of interleukin-1 beta production,GO:0032755~positive regulation of interleukin-6 production,GO:0032757~positive regulation of interleukin-8 production,GO:0034158~toll-like receptor 8 signaling pathway,GO:0045087~innate immune response,GO:0045089~positive regulation of innate immune response,GO:0051607~defense response to virus,GO:0071260~cellular response to mechanical stimulus,	GO:0000139~Golgi membrane,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0009897~external side of plasma membrane,GO:0010008~endosome membrane,GO:0016021~integral component of membrane,GO:0036020~endolysosome membrane,	GO:0003677~DNA binding,GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003727~single-stranded RNA binding,GO:0004888~transmembrane signaling receptor activity,GO:0038023~signaling receptor activity,GO:0038187~pattern recognition receptor activity,GO:0042802~identical protein binding,	IPR000157:Toll/interleukin-1 receptor homology (TIR) domain,IPR000483:Cysteine-rich flanking region, C-terminal,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR027175:Toll-like receptor 8,	hsa04613:Neutrophil extracellular trap formation,hsa04620:Toll-like receptor signaling pathway,hsa05171:Coronavirus disease - COVID-19,	301078~Immunodeficiency 98 with autoinflammation, X-linked,		SM00082:LRRCT,SM00255:TIR,SM00369:LRR_TYP,	KW-0391~Immunity,KW-0395~Inflammatory response,KW-0399~Innate immunity,	KW-0472~Membrane,KW-0967~Endosome,		KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0832~Ubl conjugation,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:LRRCT,DOMAIN:TIR,MUTAGEN:D->A: Abolishes activation of NF-kappa-B.,MUTAGEN:D->A: Abolishes responses to both ssRNA and chemical ligands.,MUTAGEN:F->A: Abolishes activation of NF-kappa-B.,MUTAGEN:F->A: Abolishes responses to both ssRNA and chemical ligands.,MUTAGEN:RKRR->NQSN: Monomeric and inactive.,MUTAGEN:T->A: Abolishes responses to both ssRNA and chemical ligands.,MUTAGEN:T->A: Strongly decreases activation of NF-kappa-B.,MUTAGEN:V->A: Increases activation of NF-kappa-B.,MUTAGEN:V->A: Strongly decreases activation of NF-kappa-B.,MUTAGEN:Y->A: Abolishes activation of NF-kappa-B.,MUTAGEN:Y->A: Abolishes responses to both ssRNA and chemical ligands.,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 11,REPEAT:LRR 12,REPEAT:LRR 13,REPEAT:LRR 14,REPEAT:LRR 15,REPEAT:LRR 16,REPEAT:LRR 17,REPEAT:LRR 18,REPEAT:LRR 19,REPEAT:LRR 2,REPEAT:LRR 20,REPEAT:LRR 21,REPEAT:LRR 22,REPEAT:LRR 23,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TFCP2L1	transcription factor CP2 like 1(TFCP2L1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000902~cell morphogenesis,GO:0002070~epithelial cell maturation,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007028~cytoplasm organization,GO:0007431~salivary gland development,GO:0008340~determination of adult lifespan,GO:0045927~positive regulation of growth,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0016020~membrane,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR007604:CP2 transcription factor,IPR013761:Sterile alpha motif/pointed domain,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,				KW-0238~DNA-binding,		COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:Grh/CP2 DB,MUTAGEN:D->G: Impairs the formation of oligomeric homo-complexes in solution.,REGION:Disordered,REGION:SAM2-like domain,
TGFB1I1	transforming growth factor beta 1 induced transcript 1(TGFB1I1)	Homo sapiens	GO:0006351~transcription, DNA-templated,GO:0007155~cell adhesion,GO:0008285~negative regulation of cell proliferation,GO:0009408~response to heat,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0016055~Wnt signaling pathway,GO:0016331~morphogenesis of embryonic epithelium,GO:0030511~positive regulation of transforming growth factor beta receptor signaling pathway,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0030579~ubiquitin-dependent SMAD protein catabolic process,GO:0030855~epithelial cell differentiation,GO:0045165~cell fate commitment,GO:0045444~fat cell differentiation,GO:0045599~negative regulation of fat cell differentiation,GO:0045893~positive regulation of transcription, DNA-templated,	GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016363~nuclear matrix,	GO:0003712~transcription cofactor activity,GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0046872~metal ion binding,GO:0048495~Roundabout binding,GO:0050681~androgen receptor binding,GO:0070411~I-SMAD binding,	IPR001781:Zinc finger, LIM-type,IPR017305:Leupaxin,			PIRSF037881:leupaxin ,	SM00132:LIM,	KW-0221~Differentiation,KW-0879~Wnt signaling pathway,	KW-0206~Cytoskeleton,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0965~Cell junction,		KW-0440~LIM domain,KW-0677~Repeat,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,	KW-0007~Acetylation,KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:LIM zinc-binding,DOMAIN:LIM zinc-binding 1,DOMAIN:LIM zinc-binding 2,DOMAIN:LIM zinc-binding 3,DOMAIN:LIM zinc-binding 4,MOTIF:LD motif 1,MOTIF:LD motif 2,MOTIF:LD motif 3,MOTIF:LD motif 4,MUTAGEN:C->A: Abolishes interaction with CBLC and enhancement of CBLC E3 ubiquitin-protein ligase activity.,MUTAGEN:C->A: No effect on interaction with CBLC.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-369.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-372.,MUTAGEN:C->S: Loss of AR coactivation; when associated with S-428.,MUTAGEN:FLKLF->ALKAA: Loss of interaction with AR; when associated with 338-A--A-342.,MUTAGEN:FLQLF->ALQAA: Loss of interaction with AR; when associated with 456-A--A-460.,MUTAGEN:H->S: Loss of AR coactivation; when associated with S-431.,MUTAGEN:Y->F: Prevents phosphorylation by FAK2 and FYN. Prevents interaction with CSK.,REGION:Disordered,REGION:Interaction with PTK2/FAK1,REGION:Interaction with PTK2B/PYK2,REGION:Transcription activation,
TGFBI	transforming growth factor beta induced(TGFBI)	Homo sapiens	GO:0001525~angiogenesis,GO:0002062~chondrocyte differentiation,GO:0007155~cell adhesion,GO:0007162~negative regulation of cell adhesion,GO:0007601~visual perception,GO:0008283~cell proliferation,GO:0030198~extracellular matrix organization,GO:0050896~response to stimulus,GO:0051179~localization,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005615~extracellular space,GO:0005802~trans-Golgi network,GO:0005886~plasma membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005178~integrin binding,GO:0005201~extracellular matrix structural constituent,GO:0005515~protein binding,GO:0005518~collagen binding,GO:0042802~identical protein binding,GO:0050839~cell adhesion molecule binding,GO:0050840~extracellular matrix binding,	IPR000782:FAS1 domain,IPR011489:EMI domain,IPR016666:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,		121820~Corneal dystrophy, epithelial basement membrane,121900~Corneal dystrophy, Groenouw type I,122200~Corneal dystrophy, lattice type I,602082~Corneal dystrophy, Thiel-Behnke type,607541~Corneal dystrophy, Avellino type,608470~Corneal dystrophy, Reis-Bucklers type,608471~Corneal dystrophy, lattice type IIIA,	PIRSF016553:TGF beta-induced protein bIGH3/osteoblast-specific factor 2,	SM00554:FAS1,	KW-0130~Cell adhesion,KW-0716~Sensory transduction,KW-0844~Vision,	KW-0034~Amyloid,KW-0272~Extracellular matrix,KW-0964~Secreted,	KW-0225~Disease variant,KW-1008~Amyloidosis,KW-1212~Corneal dystrophy,	KW-0677~Repeat,KW-0732~Signal,			KW-0301~Gamma-carboxyglutamic acid,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	DOMAIN:EMI,DOMAIN:FAS1,DOMAIN:FAS1 1,DOMAIN:FAS1 2,DOMAIN:FAS1 3,DOMAIN:FAS1 4,MOTIF:Cell attachment site,
TAGLN2	transgelin 2(TAGLN2)	Homo sapiens	GO:0030855~epithelial cell differentiation,	GO:0005576~extracellular region,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0031982~vesicle,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0045296~cadherin binding,	IPR000557:Calponin repeat,IPR001061:Transgelin,IPR001715:Calponin homology domain,IPR003096:Smooth muscle protein/calponin,				SM00033:CH,							KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:Calponin-homology (CH),REGION:Disordered,REPEAT:Calponin-like,
TAGLN	transgelin(TAGLN)	Homo sapiens	GO:0007517~muscle organ development,GO:0030855~epithelial cell differentiation,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,	GO:0005515~protein binding,GO:0051015~actin filament binding,	IPR000557:Calponin repeat,IPR001715:Calponin homology domain,IPR003096:Smooth muscle protein/calponin,				SM00033:CH,		KW-0963~Cytoplasm,				KW-0009~Actin-binding,KW-0514~Muscle protein,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),REPEAT:Calponin-like,
TRPC3	transient receptor potential cation channel subfamily C member 3(TRPC3)	Homo sapiens	GO:0006816~calcium ion transport,GO:0006828~manganese ion transport,GO:0007338~single fertilization,GO:0007602~phototransduction,GO:0010524~positive regulation of calcium ion transport into cytosol,GO:0033198~response to ATP,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0051592~response to calcium ion,GO:0070588~calcium ion transmembrane transport,GO:1903244~positive regulation of cardiac muscle hypertrophy in response to stress,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0034703~cation channel complex,	GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0015279~store-operated calcium channel activity,GO:0046872~metal ion binding,GO:0070679~inositol 1,4,5 trisphosphate binding,	IPR002110:Ankyrin repeat,IPR002153:Transient receptor potential channel, canonical,IPR005459:Transient receptor potential channel, canonical  3,IPR005821:Ion transport domain,IPR013555:Transient receptor ion channel domain,IPR020683:Ankyrin repeat-containing domain,	hsa04360:Axon guidance,hsa05017:Spinocerebellar ataxia,hsa05022:Pathways of neurodegeneration - multiple diseases,	616410~Spinocerebellar ataxia 41,		SM00248:ANK,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0523~Neurodegeneration,KW-0950~Spinocerebellar ataxia,	KW-0040~ANK repeat,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ion_trans,DOMAIN:TRP_2,MUTAGEN:D->A: Loss of inhibition by intracellular Ca(2+) and loss of Ca(2+)-induced thermostability. Impaired extracellular Ca(2+) inhibition at a holding potential of -60 mV. No effect on activation by diacylglycerol (DAG) analog; when associated with A-525 and A-874.,MUTAGEN:E->A: No effect on inhibition by Ca(2+) or thermostability. No effect on activation by diacylglycerol (DAG) analog; when associated with A-874 and A-883.,MUTAGEN:E->A: Retains robust Ca(2+) inhibition with moderate enhancement of thermostability in low-Ca(2+) conditions. No effect on activation by diacylglycerol (DAG) analog; when associated with A-525 and A-883.,MUTAGEN:R->C: Loss of inhibition by intracellular Ca(2+) and loss of Ca(2+)-induced thermostability.,REGION:Binds to IP3R3,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,REPEAT:ANK 5,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRPC7	transient receptor potential cation channel subfamily C member 7(TRPC7)	Homo sapiens	GO:0006828~manganese ion transport,GO:0007338~single fertilization,GO:0051480~regulation of cytosolic calcium ion concentration,GO:0070588~calcium ion transmembrane transport,	GO:0005635~nuclear envelope,GO:0005801~cis-Golgi network,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,GO:0034703~cation channel complex,GO:0048471~perinuclear region of cytoplasm,	GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0015279~store-operated calcium channel activity,GO:0070679~inositol 1,4,5 trisphosphate binding,	IPR002110:Ankyrin repeat,IPR002153:Transient receptor potential channel, canonical,IPR005463:Transient receptor potential channel, canonical 7,IPR005821:Ion transport domain,IPR013555:Transient receptor ion channel domain,IPR020683:Ankyrin repeat-containing domain,				SM00248:ANK,	KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,KW-0539~Nucleus,KW-1003~Cell membrane,		KW-0040~ANK repeat,KW-0677~Repeat,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0675~Receptor,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Ion_trans,DOMAIN:TRP_2,REGION:Disordered,REPEAT:ANK 1,REPEAT:ANK 2,REPEAT:ANK 3,REPEAT:ANK 4,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRPM8	transient receptor potential cation channel subfamily M member 8(TRPM8)	Homo sapiens	GO:0006812~cation transport,GO:0006874~cellular calcium ion homeostasis,GO:0009409~response to cold,GO:0016048~detection of temperature stimulus,GO:0019722~calcium-mediated signaling,GO:0050951~sensory perception of temperature stimulus,GO:0050955~thermoception,GO:0070588~calcium ion transmembrane transport,GO:0098655~cation transmembrane transport,	GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0009897~external side of plasma membrane,GO:0016021~integral component of membrane,GO:0045121~membrane raft,	GO:0005216~ion channel activity,GO:0005261~cation channel activity,GO:0005262~calcium channel activity,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0099604~ligand-gated calcium channel activity,	IPR005821:Ion transport domain,	hsa04750:Inflammatory mediator regulation of TRP channels,				KW-0406~Ion transport,KW-0716~Sensory transduction,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0407~Ion channel,KW-0675~Receptor,	KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,COMPBIAS:Basic and acidic residues,DOMAIN:Ion_trans,DOMAIN:LSDAT_euk,MUTAGEN:H->N: No effect on glycosylation or channel activity.,MUTAGEN:L->P: Abolishes multimerization and channel activity. Reduces cell surface expression.,MUTAGEN:N->Q: Abolishes glycosylation.,MUTAGEN:N->Q: No effect on glycosylation or ability to form functional channels.,REGION:Disordered,REGION:Epitope; activates specific cytotoxic T lymphocytes,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,
TSPO	translocator protein(TSPO)	Homo sapiens	GO:0006626~protein targeting to mitochondrion,GO:0006700~C21-steroid hormone biosynthetic process,GO:0006783~heme biosynthetic process,GO:0006820~anion transport,GO:0006821~chloride transport,GO:0006869~lipid transport,GO:0007568~aging,GO:0008202~steroid metabolic process,GO:0008347~glial cell migration,GO:0009410~response to xenobiotic stimulus,GO:0010042~response to manganese ion,GO:0010266~response to vitamin B1,GO:0010940~positive regulation of necrotic cell death,GO:0014012~peripheral nervous system axon regeneration,GO:0015918~sterol transport,GO:0030325~adrenal gland development,GO:0031397~negative regulation of protein ubiquitination,GO:0032374~regulation of cholesterol transport,GO:0032570~response to progesterone,GO:0032720~negative regulation of tumor necrosis factor production,GO:0033574~response to testosterone,GO:0042127~regulation of cell proliferation,GO:0042493~response to drug,GO:0042632~cholesterol homeostasis,GO:0043065~positive regulation of apoptotic process,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0048266~behavioral response to pain,GO:0050810~regulation of steroid biosynthetic process,GO:0051901~positive regulation of mitochondrial depolarization,GO:0051928~positive regulation of calcium ion transport,GO:0060242~contact inhibition,GO:0060252~positive regulation of glial cell proliferation,GO:0060253~negative regulation of glial cell proliferation,GO:0071222~cellular response to lipopolysaccharide,GO:0071294~cellular response to zinc ion,GO:0071476~cellular hypotonic response,GO:0072656~maintenance of protein location in mitochondrion,GO:1903147~negative regulation of mitophagy,GO:1903579~negative regulation of ATP metabolic process,GO:1905144~response to acetylcholine,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000853~negative regulation of corticosterone secretion,	GO:0005739~mitochondrion,GO:0005741~mitochondrial outer membrane,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0031966~mitochondrial membrane,GO:0043231~intracellular membrane-bounded organelle,GO:0070062~extracellular exosome,	GO:0005497~androgen binding,GO:0005515~protein binding,GO:0008503~benzodiazepine receptor activity,GO:0015485~cholesterol binding,GO:0044325~ion channel binding,	IPR004307:TspO/MBR-related protein,	hsa04080:Neuroactive ligand-receptor interaction,hsa04979:Cholesterol metabolism,hsa05166:Human T-cell leukemia virus 1 infection,		PIRSF005859:peripheral-type benzodiazepine receptor/signal transduction protein TspO,		KW-0445~Lipid transport,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,		KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,		TOPO_DOM:Cytoplasmic,TOPO_DOM:Mitochondrial intermembrane,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,
TMEM100	transmembrane protein 100(TMEM100)	Homo sapiens	GO:0001525~angiogenesis,GO:0001570~vasculogenesis,GO:0001701~in utero embryonic development,GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation,GO:0007219~Notch signaling pathway,GO:0030509~BMP signaling pathway,GO:0043491~protein kinase B signaling,GO:0045603~positive regulation of endothelial cell differentiation,GO:0050848~regulation of calcium-mediated signaling,GO:0051930~regulation of sensory perception of pain,GO:0060842~arterial endothelial cell differentiation,GO:0071773~cellular response to BMP stimulus,GO:2001214~positive regulation of vasculogenesis,	GO:0005783~endoplasmic reticulum,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0043204~perikaryon,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,						KW-0221~Differentiation,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,	TRANSMEM:Helical,
TMEM151B	transmembrane protein 151B(TMEM151B)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,		IPR026767:Transmembrane protein 151,						KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
TMEM179	transmembrane protein 179(TMEM179)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,	CARBOHYD:N-linked (GlcNAc...) asparagine,REGION:Disordered,TRANSMEM:Helical,
TMEM238	transmembrane protein 238(TMEM238)	Homo sapiens		GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0597~Phosphoprotein,	REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMEM35A	transmembrane protein 35A(TMEM35A)	Homo sapiens	GO:0051131~chaperone-mediated protein complex assembly,GO:2000010~positive regulation of protein localization to cell surface,	GO:0005778~peroxisomal membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016021~integral component of membrane,GO:0031410~cytoplasmic vesicle,	GO:0005515~protein binding,GO:0030548~acetylcholine receptor regulator activity,							KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0576~Peroxisome,KW-0968~Cytoplasmic vesicle,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0143~Chaperone,		REGION:Disordered,REGION:Interaction with NGFR,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,
TMEM37	transmembrane protein 37(TMEM37)	Homo sapiens	GO:0034765~regulation of ion transmembrane transport,GO:0070588~calcium ion transmembrane transport,	GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005244~voltage-gated ion channel activity,GO:0005262~calcium channel activity,						KW-0109~Calcium transport,KW-0406~Ion transport,KW-0813~Transport,	KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,	KW-0107~Calcium channel,KW-0407~Ion channel,KW-0851~Voltage-gated channel,		REGION:Disordered,TRANSMEM:Helical,
TMEM71	transmembrane protein 71(TMEM71)	Homo sapiens		GO:0005739~mitochondrion,GO:0016020~membrane,GO:0016021~integral component of membrane,								KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,				COMPBIAS:Polar residues,REGION:Disordered,TRANSMEM:Helical,
TMEFF2	transmembrane protein with EGF like and two follistatin like domains 2(TMEFF2)	Homo sapiens	GO:0009887~animal organ morphogenesis,GO:0009888~tissue development,GO:0016477~cell migration,GO:0030336~negative regulation of cell migration,GO:0034446~substrate adhesion-dependent cell spreading,GO:0044319~wound healing, spreading of cells,GO:0045720~negative regulation of integrin biosynthetic process,GO:0051497~negative regulation of stress fiber assembly,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,	IPR000742:Epidermal growth factor-like domain,IPR002350:Kazal domain,				SM00280:KAZAL,		KW-0472~Membrane,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine; atypical,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EGF-like,DOMAIN:Kazal-like 1,DOMAIN:Kazal-like 2,REGION:Disordered,REGION:Required for shedding,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TMPRSS2	transmembrane serine protease 2(TMPRSS2)	Homo sapiens	GO:0006508~proteolysis,GO:0006897~endocytosis,GO:0016540~protein autoprocessing,GO:0046598~positive regulation of viral entry into host cell,	GO:0005576~extracellular region,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0070062~extracellular exosome,	GO:0004252~serine-type endopeptidase activity,GO:0005044~scavenger receptor activity,GO:0005515~protein binding,GO:0008236~serine-type peptidase activity,	IPR001190:Speract/scavenger receptor,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR017448:Speract/scavenger receptor-related,IPR018114:Peptidase S1, trypsin family, active site,IPR023415:Low-density lipoprotein (LDL) receptor class A, conserved site,	hsa05164:Influenza A,hsa05171:Coronavirus disease - COVID-19,hsa05202:Transcriptional misregulation in cancer,hsa05215:Prostate cancer,			SM00020:Tryp_SPc,SM00192:LDLa,SM00202:SR,	KW-0945~Host-virus interaction,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0068~Autocatalytic cleavage,KW-0325~Glycoprotein,KW-0865~Zymogen,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,DISULFID:Interchain (between non-catalytic and catalytic chains),DOMAIN:LDL-receptor class A,DOMAIN:Peptidase S1,DOMAIN:SRCR,MUTAGEN:R->Q: Loss of cleavage.,MUTAGEN:S->A: Loss of activity.,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
TMPRSS9	transmembrane serine protease 9(TMPRSS9)	Homo sapiens	GO:0006508~proteolysis,	GO:0005886~plasma membrane,GO:0005887~integral component of plasma membrane,GO:0016021~integral component of membrane,	GO:0004252~serine-type endopeptidase activity,	IPR000082:SEA domain,IPR001254:Peptidase S1,IPR001314:Peptidase S1A, chymotrypsin-type,IPR002172:Low-density lipoprotein (LDL) receptor class A repeat,IPR009003:Trypsin-like cysteine/serine peptidase domain,IPR017324:Peptidase S1A, polyserase-1,IPR018114:Peptidase S1, trypsin family, active site,			PIRSF037931:transmembrane serine protease, TMPRSS9 type,	SM00020:Tryp_SPc,SM00192:LDLa,		KW-0472~Membrane,KW-1003~Cell membrane,		KW-0677~Repeat,KW-0735~Signal-anchor,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0378~Hydrolase,KW-0645~Protease,KW-0720~Serine protease,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	ACT_SITE:Charge relay system,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:LDL-receptor class A,DOMAIN:Peptidase S1,DOMAIN:Peptidase S1 1,DOMAIN:Peptidase S1 2,DOMAIN:Peptidase S1 3,DOMAIN:SEA,REGION:Disordered,SITE:Cleavage,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,TRANSMEM:Helical; Signal-anchor for type II membrane protein,
TAP1	transporter 1, ATP binding cassette subfamily B member(TAP1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent,GO:0006952~defense response,GO:0015031~protein transport,GO:0015833~peptide transport,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0046967~cytosol to ER transport,GO:0055085~transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005887~integral component of plasma membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0030670~phagocytic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0034451~centriolar satellite,GO:0042824~MHC class I peptide loading complex,GO:0042825~TAP complex,	GO:0005215~transporter activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015433~peptide antigen-transporting ATPase activity,GO:0015440~peptide-transporting ATPase activity,GO:0023029~MHC class Ib protein binding,GO:0042287~MHC protein binding,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0042803~protein homodimerization activity,GO:0043531~ADP binding,GO:0046872~metal ion binding,GO:0046978~TAP1 binding,GO:0046979~TAP2 binding,GO:1904680~peptide transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR011527:ABC transporter, transmembrane domain, type 1,IPR013305:ABC transporter, ABCB2,IPR013306:ABC transporter, B3,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,hsa04145:Phagosome,hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05340:Primary immunodeficiency,	604571~Bare lymphocyte syndrome, type I,		SM00382:AAA,	KW-0391~Immunity,KW-0571~Peptide transport,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,		COMPBIAS:Basic and acidic residues,DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transporter,MUTAGEN:D->A: Impairs allosteric coupling of peptide transport to ATP hydrolysis, converting the unidirectional active pump into a passive bidirectional nucleotide-gated facilitator. Inactive in peptide transport when associated with 'A-638' of TAP2.,MUTAGEN:D->K: Complete loss of interaction with TAPBP, resulting in impaired PLC assembly and antigen presentation.,REGION:Disordered,REGION:Part of the peptide-binding site,SITE:Inter-subunit salt bridge with TAPBP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=10,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
TAP2	transporter 2, ATP binding cassette subfamily B member(TAP2)	Homo sapiens	GO:0001913~T cell mediated cytotoxicity,GO:0001916~positive regulation of T cell mediated cytotoxicity,GO:0002237~response to molecule of bacterial origin,GO:0002250~adaptive immune response,GO:0002481~antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent,GO:0002485~antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent,GO:0002489~antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent,GO:0015031~protein transport,GO:0015833~peptide transport,GO:0019885~antigen processing and presentation of endogenous peptide antigen via MHC class I,GO:0046967~cytosol to ER transport,GO:0046968~peptide antigen transport,GO:0055085~transmembrane transport,	GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0016607~nuclear speck,GO:0030176~integral component of endoplasmic reticulum membrane,GO:0030670~phagocytic vesicle membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,GO:0042824~MHC class I peptide loading complex,GO:0042825~TAP complex,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0015433~peptide antigen-transporting ATPase activity,GO:0015440~peptide-transporting ATPase activity,GO:0023029~MHC class Ib protein binding,GO:0042287~MHC protein binding,GO:0042288~MHC class I protein binding,GO:0042605~peptide antigen binding,GO:0042626~ATPase activity, coupled to transmembrane movement of substances,GO:0046872~metal ion binding,GO:0046978~TAP1 binding,GO:0046980~tapasin binding,GO:1904680~peptide transmembrane transporter activity,	IPR003439:ABC transporter-like,IPR003593:AAA+ ATPase domain,IPR005293:Antigen peptide transporter 2,IPR011527:ABC transporter, transmembrane domain, type 1,IPR013305:ABC transporter, ABCB2,IPR017871:ABC transporter, conserved site,IPR027417:P-loop containing nucleoside triphosphate hydrolase,	hsa02010:ABC transporters,hsa04145:Phagosome,hsa04612:Antigen processing and presentation,hsa05163:Human cytomegalovirus infection,hsa05168:Herpes simplex virus 1 infection,hsa05169:Epstein-Barr virus infection,hsa05170:Human immunodeficiency virus 1 infection,hsa05340:Primary immunodeficiency,	604571~Bare lymphocyte syndrome, type I, due to TAP2 deficiency,		SM00382:AAA,	KW-0391~Immunity,KW-0571~Peptide transport,KW-0653~Protein transport,KW-0813~Transport,KW-0945~Host-virus interaction,KW-1064~Adaptive immunity,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0067~ATP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-1278~Translocase,		DOMAIN:ABC transmembrane type-1,DOMAIN:ABC transporter,MUTAGEN:D->A: Inactive in peptide transport when associated with 'A-734' of TAP1.,MUTAGEN:D->K: Complete loss of interaction with TAPBP, resulting in impaired PLC assembly and antigen presentation.,REGION:Part of the peptide-binding site,SITE:Inter-subunit salt bridge with TAPBP,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,TRANSMEM:Helical; Name=1,TRANSMEM:Helical; Name=2,TRANSMEM:Helical; Name=3,TRANSMEM:Helical; Name=4,TRANSMEM:Helical; Name=5,TRANSMEM:Helical; Name=6,TRANSMEM:Helical; Name=7,TRANSMEM:Helical; Name=8,TRANSMEM:Helical; Name=9,
TREM1	triggering receptor expressed on myeloid cells 1(TREM1)	Homo sapiens	GO:0002250~adaptive immune response,GO:0002367~cytokine production involved in immune response,GO:0002526~acute inflammatory response,GO:0006959~humoral immune response,GO:0030593~neutrophil chemotaxis,GO:0032602~chemokine production,GO:0035556~intracellular signal transduction,GO:0045087~innate immune response,GO:0070945~neutrophil mediated killing of gram-negative bacterium,	GO:0005576~extracellular region,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0038023~signaling receptor activity,GO:0097110~scaffold protein binding,	IPR003599:Immunoglobulin subtype,IPR013106:Immunoglobulin V-set,IPR013783:Immunoglobulin-like fold,				SM00409:IG,	KW-0391~Immunity,KW-0399~Innate immunity,KW-1064~Adaptive immunity,	KW-0472~Membrane,KW-0964~Secreted,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0675~Receptor,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:IG,DOMAIN:Ig-like V-type,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
TRIM27	tripartite motif containing 27(TRIM27)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0000209~protein polyubiquitination,GO:0002820~negative regulation of adaptive immune response,GO:0006469~negative regulation of protein kinase activity,GO:0007283~spermatogenesis,GO:0010468~regulation of gene expression,GO:0010508~positive regulation of autophagy,GO:0016567~protein ubiquitination,GO:0016925~protein sumoylation,GO:0032703~negative regulation of interleukin-2 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032729~positive regulation of interferon-gamma production,GO:0032880~regulation of protein localization,GO:0032897~negative regulation of viral transcription,GO:0034314~Arp2/3 complex-mediated actin nucleation,GO:0042147~retrograde transport, endosome to Golgi,GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044790~negative regulation by host of viral release from host cell,GO:0045087~innate immune response,GO:0045814~negative regulation of gene expression, epigenetic,GO:0045893~positive regulation of transcription, DNA-templated,GO:0046596~regulation of viral entry into host cell,GO:0051091~positive regulation of sequence-specific DNA binding transcription factor activity,GO:0051092~positive regulation of NF-kappaB transcription factor activity,GO:0051127~positive regulation of actin nucleation,GO:0070534~protein K63-linked ubiquitination,GO:0090281~negative regulation of calcium ion import,	GO:0001650~fibrillar center,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005768~endosome,GO:0005769~early endosome,GO:0005829~cytosol,GO:0016605~PML body,GO:0031965~nuclear membrane,	GO:0003676~nucleic acid binding,GO:0003677~DNA binding,GO:0003713~transcription coactivator activity,GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0019789~SUMO transferase activity,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0046872~metal ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR001870:B30.2/SPRY domain,IPR003877:SPla/RYanodine receptor SPRY,IPR003879:Butyrophylin-like,IPR006574:SPRY-associated,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR017907:Zinc finger, RING-type, conserved site,IPR020457:Zinc finger, B-box, chordata,				SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00589:PRY,	KW-0804~Transcription,KW-0805~Transcription regulation,KW-0813~Transport,KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,KW-0963~Cytoplasm,KW-0967~Endosome,	KW-0656~Proto-oncogene,	KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,KW-0808~Transferase,		DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:PRY,DOMAIN:RING-type,SITE:Breakpoint for translocation to form the TRIM27/RET oncogene,ZN_FING:B box-type,ZN_FING:RING-type,
TRIM29	tripartite motif containing 29(TRIM29)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0045087~innate immune response,GO:0098609~cell-cell adhesion,GO:1900181~negative regulation of protein localization to nucleus,	GO:0005737~cytoplasm,GO:0005764~lysosome,GO:0005912~adherens junction,	GO:0002039~p53 binding,GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0042802~identical protein binding,GO:0098641~cadherin binding involved in cell-cell adhesion,	IPR000315:Zinc finger, B-box,				SM00336:BBOX,	KW-0391~Immunity,KW-0399~Innate immunity,	KW-0458~Lysosome,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Polar residues,DOMAIN:B box-type,REGION:Disordered,ZN_FING:B box-type,
TRIM67	tripartite motif containing 67(TRIM67)	Homo sapiens	GO:0010976~positive regulation of neuron projection development,GO:0032880~regulation of protein localization,GO:0046580~negative regulation of Ras protein signal transduction,GO:1903827~regulation of cellular protein localization,GO:2000060~positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,	GO:0005737~cytoplasm,GO:0005856~cytoskeleton,	GO:0008270~zinc ion binding,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR001870:B30.2/SPRY domain,IPR003649:B-box, C-terminal,IPR003877:SPla/RYanodine receptor SPRY,IPR003961:Fibronectin, type III,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR013320:Concanavalin A-like lectin/glucanase, subgroup,IPR013783:Immunoglobulin-like fold,IPR017903:COS domain,IPR017907:Zinc finger, RING-type, conserved site,IPR018957:Zinc finger, C3HC4 RING-type,				SM00060:FN3,SM00184:RING,SM00336:BBOX,SM00449:SPRY,SM00502:BBC,		KW-0206~Cytoskeleton,KW-0963~Cytoplasm,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:B box-type,DOMAIN:B30.2/SPRY,DOMAIN:COS,DOMAIN:Fibronectin type-III,REGION:Disordered,ZN_FING:B box-type 1; degenerate,ZN_FING:B box-type 2,ZN_FING:RING-type; degenerate,
TRIM74	tripartite motif containing 74(TRIM74)	Homo sapiens	GO:0016567~protein ubiquitination,	GO:0005737~cytoplasm,GO:0005829~cytosol,	GO:0008270~zinc ion binding,GO:0061630~ubiquitin protein ligase activity,	IPR000315:Zinc finger, B-box,IPR001841:Zinc finger, RING-type,IPR013083:Zinc finger, RING/FYVE/PHD-type,IPR017907:Zinc finger, RING-type, conserved site,IPR027370:RING-type zinc-finger, LisH dimerisation motif,				SM00184:RING,SM00336:BBOX,				KW-0175~Coiled coil,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			ZN_FING:B box-type,ZN_FING:RING-type,
TROAP	trophinin associated protein(TROAP)	Homo sapiens	GO:0007155~cell adhesion,	GO:0005737~cytoplasm,	GO:0005515~protein binding,	IPR026133:Tastin,					KW-0130~Cell adhesion,	KW-0963~Cytoplasm,		KW-0677~Repeat,			KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:4 X 33 AA approximate tandem repeats,REGION:Disordered,REPEAT:1,REPEAT:2,REPEAT:3,REPEAT:4,
TUBA1C	tubulin alpha 1c(TUBA1C)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0051301~cell division,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0005881~cytoplasmic microtubule,GO:0015630~microtubule cytoskeleton,GO:0031982~vesicle,GO:0045121~membrane raft,	GO:0003924~GTPase activity,GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0016787~hydrolase activity,GO:0046872~metal ion binding,	IPR000217:Tubulin,IPR002452:Alpha tubulin,IPR003008:Tubulin/FtsZ, GTPase domain,IPR008280:Tubulin/FtsZ, C-terminal,IPR017975:Tubulin, conserved site,IPR018316:Tubulin/FtsZ, 2-layer sandwich domain,IPR023123:Tubulin, C-terminal,	hsa04145:Phagosome,hsa04210:Apoptosis,hsa04530:Tight junction,hsa04540:Gap junction,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,			SM00864:SM00864,SM00865:SM00865,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,			KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,	KW-0378~Hydrolase,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0944~Nitration,	DOMAIN:Tubulin,DOMAIN:Tubulin_C,MOTIF:MREC motif,REGION:Disordered,SITE:Involved in polymerization,
TUBB6	tubulin beta 6 class V(TUBB6)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,	GO:0005634~nucleus,GO:0005737~cytoplasm,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0045171~intercellular bridge,GO:0070062~extracellular exosome,GO:0072686~mitotic spindle,	GO:0003924~GTPase activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0046872~metal ion binding,	IPR000217:Tubulin,IPR002453:Beta tubulin,IPR003008:Tubulin/FtsZ, GTPase domain,IPR008280:Tubulin/FtsZ, C-terminal,IPR013838:Beta tubulin, autoregulation binding site,IPR017975:Tubulin, conserved site,IPR018316:Tubulin/FtsZ, 2-layer sandwich domain,IPR023123:Tubulin, C-terminal,	hsa04145:Phagosome,hsa04540:Gap junction,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,	617732~Facial palsy, congenital, with ptosis and velopharyngeal dysfunction,		SM00864:SM00864,SM00865:SM00865,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,		KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0597~Phosphoprotein,KW-1017~Isopeptide bond,	DOMAIN:Tubulin,DOMAIN:Tubulin_C,MOTIF:MREI motif,
TUBB	tubulin beta class I(TUBB)	Homo sapiens	GO:0000226~microtubule cytoskeleton organization,GO:0000278~mitotic cell cycle,GO:0007017~microtubule-based process,GO:0009987~cellular process,GO:0030705~cytoskeleton-dependent intracellular transport,GO:0042267~natural killer cell mediated cytotoxicity,GO:0050807~regulation of synapse organization,GO:0051225~spindle assembly,GO:0051301~cell division,GO:0071895~odontoblast differentiation,	GO:0005576~extracellular region,GO:0005634~nucleus,GO:0005641~nuclear envelope lumen,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005856~cytoskeleton,GO:0005874~microtubule,GO:0015630~microtubule cytoskeleton,GO:0032991~macromolecular complex,GO:0035578~azurophil granule lumen,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0044297~cell body,GO:0045121~membrane raft,GO:0045171~intercellular bridge,GO:0070062~extracellular exosome,GO:0072686~mitotic spindle,	GO:0003924~GTPase activity,GO:0005198~structural molecule activity,GO:0005200~structural constituent of cytoskeleton,GO:0005515~protein binding,GO:0005525~GTP binding,GO:0019904~protein domain specific binding,GO:0031625~ubiquitin protein ligase binding,GO:0032794~GTPase activating protein binding,GO:0042288~MHC class I protein binding,GO:0044877~macromolecular complex binding,GO:0046872~metal ion binding,	IPR000217:Tubulin,IPR002453:Beta tubulin,IPR003008:Tubulin/FtsZ, GTPase domain,IPR008280:Tubulin/FtsZ, C-terminal,IPR013838:Beta tubulin, autoregulation binding site,IPR017975:Tubulin, conserved site,IPR018316:Tubulin/FtsZ, 2-layer sandwich domain,IPR023123:Tubulin, C-terminal,	hsa04145:Phagosome,hsa04540:Gap junction,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05130:Pathogenic Escherichia coli infection,hsa05132:Salmonella infection,	156610~Symmetric circumferential skin creases, congenital, 1,615771~Cortical dysplasia, complex, with other brain malformations 6,		SM00864:SM00864,SM00865:SM00865,		KW-0206~Cytoskeleton,KW-0493~Microtubule,KW-0963~Cytoplasm,	KW-0225~Disease variant,	KW-0175~Coiled coil,	KW-0342~GTP-binding,KW-0460~Magnesium,KW-0479~Metal-binding,KW-0547~Nucleotide-binding,		KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate,DOMAIN:Tubulin,DOMAIN:Tubulin_C,MOTIF:MREI motif,REGION:Disordered,
TP73	tumor protein p73(TP73)	Homo sapiens	GO:0000187~activation of MAPK activity,GO:0001822~kidney development,GO:0006298~mismatch repair,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0006915~apoptotic process,GO:0006974~cellular response to DNA damage stimulus,GO:0007049~cell cycle,GO:0007346~regulation of mitotic cell cycle,GO:0008285~negative regulation of cell proliferation,GO:0008630~intrinsic apoptotic signaling pathway in response to DNA damage,GO:0009410~response to xenobiotic stimulus,GO:0010243~response to organonitrogen compound,GO:0010468~regulation of gene expression,GO:0042493~response to drug,GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0043065~positive regulation of apoptotic process,GO:0043410~positive regulation of MAPK cascade,GO:0045665~negative regulation of neuron differentiation,GO:0045893~positive regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048714~positive regulation of oligodendrocyte differentiation,GO:0051262~protein tetramerization,GO:0051726~regulation of cell cycle,GO:0060044~negative regulation of cardiac muscle cell proliferation,GO:1901248~positive regulation of lung ciliated cell differentiation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005794~Golgi apparatus,GO:0005829~cytosol,GO:0030054~cell junction,GO:0043231~intracellular membrane-bounded organelle,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001228~transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0002039~p53 binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019901~protein kinase binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,GO:0061629~RNA polymerase II sequence-specific DNA binding transcription factor binding,GO:0097371~MDM2/MDM4 family protein binding,	IPR001660:Sterile alpha motif domain,IPR002117:p53 tumour suppressor family,IPR008967:p53-like transcription factor, DNA-binding,IPR010991:p53, tetramerisation domain,IPR011615:p53, DNA-binding domain,IPR012346:p53/RUNT-type transcription factor, DNA-binding domain,IPR013761:Sterile alpha motif/pointed domain,	hsa04115:p53 signaling pathway,hsa04390:Hippo signaling pathway,hsa04722:Neurotrophin signaling pathway,hsa05162:Measles,	619466~Ciliary dyskinesia, primary, 47, and lissencephaly,		SM00454:SAM,	KW-0053~Apoptosis,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0043~Tumor suppressor,KW-0225~Disease variant,KW-0451~Lissencephaly,KW-0990~Primary ciliary dyskinesia,KW-1186~Ciliopathy,		KW-0479~Metal-binding,KW-0862~Zinc,	KW-0010~Activator,KW-0238~DNA-binding,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); in isoform Alpha,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:P53,DOMAIN:P53_tetramer,DOMAIN:SAM,MOTIF:PPxY motif,MUTAGEN:K->R: Strongly diminishes sumoylation but does not affect transcriptional activity.,MUTAGEN:T->A: Impaired phosphorylation.,MUTAGEN:Y->A: Loss of interaction with WWOX.,MUTAGEN:Y->F: Impaired phosphorylation of isoform beta by ABL1.,REGION:DNA-binding,REGION:Disordered,REGION:Interaction with HIPK2,REGION:Oligomerization,REGION:Transactivation,
TWIST1	twist family bHLH transcription factor 1(TWIST1)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001503~ossification,GO:0001649~osteoblast differentiation,GO:0001701~in utero embryonic development,GO:0001764~neuron migration,GO:0001843~neural tube closure,GO:0003180~aortic valve morphogenesis,GO:0003183~mitral valve morphogenesis,GO:0003203~endocardial cushion morphogenesis,GO:0003253~cardiac neural crest cell migration involved in outflow tract morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007517~muscle organ development,GO:0010628~positive regulation of gene expression,GO:0010718~positive regulation of epithelial to mesenchymal transition,GO:0010936~negative regulation of macrophage cytokine production,GO:0014067~negative regulation of phosphatidylinositol 3-kinase signaling,GO:0030335~positive regulation of cell migration,GO:0030500~regulation of bone mineralization,GO:0032000~positive regulation of fatty acid beta-oxidation,GO:0032502~developmental process,GO:0032720~negative regulation of tumor necrosis factor production,GO:0032755~positive regulation of interleukin-6 production,GO:0032760~positive regulation of tumor necrosis factor production,GO:0033128~negative regulation of histone phosphorylation,GO:0035067~negative regulation of histone acetylation,GO:0035115~embryonic forelimb morphogenesis,GO:0035116~embryonic hindlimb morphogenesis,GO:0035359~negative regulation of peroxisome proliferator activated receptor signaling pathway,GO:0042473~outer ear morphogenesis,GO:0042476~odontogenesis,GO:0042733~embryonic digit morphogenesis,GO:0043066~negative regulation of apoptotic process,GO:0043433~negative regulation of sequence-specific DNA binding transcription factor activity,GO:0043518~negative regulation of DNA damage response, signal transduction by p53 class mediator,GO:0045668~negative regulation of osteoblast differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045843~negative regulation of striated muscle tissue development,GO:0045892~negative regulation of transcription, DNA-templated,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048511~rhythmic process,GO:0048642~negative regulation of skeletal muscle tissue development,GO:0048701~embryonic cranial skeleton morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0060021~palate development,GO:0060363~cranial suture morphogenesis,GO:0060900~embryonic camera-type eye formation,GO:0061029~eyelid development in camera-type eye,GO:0071363~cellular response to growth factor stimulus,GO:0071456~cellular response to hypoxia,GO:0071639~positive regulation of monocyte chemotactic protein-1 production,GO:2000144~positive regulation of DNA-templated transcription, initiation,GO:2000147~positive regulation of cell motility,GO:2000276~negative regulation of oxidative phosphorylation uncoupler activity,GO:2000679~positive regulation of transcription regulatory region DNA binding,GO:2000773~negative regulation of cellular senescence,GO:2000780~negative regulation of double-strand break repair,GO:2000793~cell proliferation involved in heart valve development,GO:2000802~positive regulation of endocardial cushion to mesenchymal transition involved in heart valve formation,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001221~transcription cofactor binding,GO:0005515~protein binding,GO:0008134~transcription factor binding,GO:0019904~protein domain specific binding,GO:0042803~protein homodimerization activity,GO:0043425~bHLH transcription factor binding,GO:0046983~protein dimerization activity,GO:0070888~E-box binding,	IPR011598:Myc-type, basic helix-loop-helix (bHLH) domain,IPR015789:Twist-related,	hsa05205:Proteoglycans in cancer,	101400~Saethre-Chotzen syndrome with or without eyelid anomalies,123100~Craniosynostosis 1,180750~Robinow-Sorauf syndrome,617746~Sweeney-Cox syndrome,		SM00353:HLH,	KW-0090~Biological rhythms,KW-0221~Differentiation,KW-0517~Myogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,	KW-0225~Disease variant,KW-0989~Craniosynostosis,			KW-0010~Activator,KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0678~Repressor,KW-9996~Developmental protein,		COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:bHLH,REGION:Disordered,REGION:Sufficient for transactivation activity,
UBE2C	ubiquitin conjugating enzyme E2 C(UBE2C)	Homo sapiens	GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0010458~exit from mitosis,GO:0010994~free ubiquitin chain polymerization,GO:0016567~protein ubiquitination,GO:0030071~regulation of mitotic metaphase/anaphase transition,GO:0031145~anaphase-promoting complex-dependent catabolic process,GO:0031536~positive regulation of exit from mitosis,GO:0051301~cell division,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,GO:1904668~positive regulation of ubiquitin protein ligase activity,	GO:0000151~ubiquitin ligase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005680~anaphase-promoting complex,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0016740~transferase activity,GO:0044389~ubiquitin-like protein ligase binding,GO:0061630~ubiquitin protein ligase activity,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,IPR023313:Ubiquitin-conjugating enzyme, active site,	hsa04120:Ubiquitin mediated proteolysis,				KW-0131~Cell cycle,KW-0132~Cell division,KW-0498~Mitosis,KW-0833~Ubl conjugation pathway,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,MUTAGEN:C->S: Loss of function; inhibition of cyclin-B degradation.,REGION:Disordered,
UBE2QL1	ubiquitin conjugating enzyme E2 Q family like 1(UBE2QL1)	Homo sapiens	GO:0000209~protein polyubiquitination,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0005524~ATP binding,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:Ubiquitin-conjugating enzyme, E2,IPR016135:Ubiquitin-conjugating enzyme/RWD-like,	hsa04120:Ubiquitin mediated proteolysis,				KW-0833~Ubl conjugation pathway,	KW-0539~Nucleus,			KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,		ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,MUTAGEN:C->A: Unable to bind ubiquitin.,MUTAGEN:C->S: Enhanced ubiquitin binding.,
UNC13A	unc-13 homolog A(UNC13A)	Homo sapiens	GO:0007269~neurotransmitter secretion,GO:0007528~neuromuscular junction development,GO:0016081~synaptic vesicle docking,GO:0016082~synaptic vesicle priming,GO:0016188~synaptic vesicle maturation,GO:0030154~cell differentiation,GO:0035249~synaptic transmission, glutamatergic,GO:0035556~intracellular signal transduction,GO:0051966~regulation of synaptic transmission, glutamatergic,GO:0061789~dense core granule priming,GO:0099011~neuronal dense core vesicle exocytosis,GO:0099525~presynaptic dense core vesicle exocytosis,GO:1903861~positive regulation of dendrite extension,	GO:0005886~plasma membrane,GO:0030672~synaptic vesicle membrane,GO:0031594~neuromuscular junction,GO:0042734~presynaptic membrane,GO:0043005~neuron projection,GO:0043195~terminal bouton,GO:0048786~presynaptic active zone,GO:0098793~presynapse,GO:0098831~presynaptic active zone cytoplasmic component,	GO:0005509~calcium ion binding,GO:0005516~calmodulin binding,GO:0005543~phospholipid binding,GO:0017075~syntaxin-1 binding,GO:0019992~diacylglycerol binding,	IPR000008:C2 calcium-dependent membrane targeting,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR010439:Calcium-dependent secretion activator,IPR014770:Munc13 homology 1,IPR014772:Mammalian uncoordinated homology 13, domain 2,IPR019558:Mammalian uncoordinated homology 13, subgroup, domain 2,IPR027080:Uncoordinated protein 13 (Unc-13),IPR027082:Protein Unc-13 homologue A,	hsa04721:Synaptic vesicle cycle,			SM00109:C1,SM00239:C2,SM01145:SM01145,	KW-0221~Differentiation,KW-0268~Exocytosis,	KW-0472~Membrane,KW-0770~Synapse,KW-0963~Cytoplasm,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0106~Calcium,KW-0479~Metal-binding,KW-0862~Zinc,		KW-0597~Phosphoprotein,	COMPBIAS:Acidic residues,COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,DOMAIN:C2,DOMAIN:C2 1,DOMAIN:C2 2,DOMAIN:C2 3,DOMAIN:MHD1,DOMAIN:MHD2,DOMAIN:Phorbol-ester/DAG-type,REGION:Disordered,ZN_FING:Phorbol-ester/DAG-type,
UNC5A	unc-5 netrin receptor A(UNC5A)	Homo sapiens	GO:0006915~apoptotic process,GO:0007411~axon guidance,GO:0031175~neuron projection development,GO:0033564~anterior/posterior axon guidance,GO:0038007~netrin-activated signaling pathway,	GO:0005886~plasma membrane,GO:0016021~integral component of membrane,GO:0031226~intrinsic component of plasma membrane,GO:0032589~neuron projection membrane,GO:0032809~neuronal cell body membrane,GO:0045121~membrane raft,	GO:0005042~netrin receptor activity,	IPR000488:Death domain,IPR000884:Thrombospondin, type 1 repeat,IPR000906:ZU5,IPR003599:Immunoglobulin subtype,IPR007110:Immunoglobulin-like domain,IPR011029:Death-like domain,IPR013098:Immunoglobulin I-set,IPR013783:Immunoglobulin-like fold,	hsa04360:Axon guidance,			SM00005:DEATH,SM00209:TSP1,SM00218:ZU5,SM00409:IG,	KW-0053~Apoptosis,	KW-0472~Membrane,KW-0966~Cell projection,KW-1003~Cell membrane,		KW-0393~Immunoglobulin domain,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0217~Developmental protein,KW-0675~Receptor,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,DOMAIN:Death,DOMAIN:Ig-like,DOMAIN:Ig-like C2-type,DOMAIN:TSP type-1,DOMAIN:ZU5,REGION:Interaction with DCC,SITE:Cleavage; by caspase-3,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
UCN2	urocortin 2(UCN2)	Homo sapiens	GO:0007189~adenylate cyclase-activating G-protein coupled receptor signaling pathway,GO:0007586~digestion,GO:0009755~hormone-mediated signaling pathway,GO:0031669~cellular response to nutrient levels,	GO:0005576~extracellular region,GO:0005615~extracellular space,	GO:0005179~hormone activity,GO:0042562~hormone binding,GO:0051429~corticotropin-releasing hormone receptor binding,GO:0051431~corticotropin-releasing hormone receptor 2 binding,	IPR000187:Corticotropin-releasing factor, CRF,IPR024270:Urocortin II/III,IPR024273:Urocortin II,	hsa04080:Neuroactive ligand-receptor interaction,					KW-0964~Secreted,		KW-0732~Signal,		KW-0372~Hormone,	KW-0325~Glycoprotein,	REGION:Disordered,
UMODL1	uromodulin like 1(UMODL1)	Homo sapiens	GO:0007338~single fertilization,GO:0010468~regulation of gene expression,GO:0042981~regulation of apoptotic process,GO:0043086~negative regulation of catalytic activity,GO:0048609~multicellular organismal reproductive process,GO:0052547~regulation of peptidase activity,GO:0060612~adipose tissue development,GO:0097211~cellular response to gonadotropin-releasing hormone,GO:1904708~regulation of granulosa cell apoptotic process,GO:1990266~neutrophil migration,GO:2000354~regulation of ovarian follicle development,	GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0009897~external side of plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0016324~apical plasma membrane,	GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0030414~peptidase inhibitor activity,	IPR000082:SEA domain,IPR000152:EGF-type aspartate/asparagine hydroxylation site,IPR000742:Epidermal growth factor-like domain,IPR001507:Zona pellucida domain,IPR001881:EGF-like calcium-binding,IPR003961:Fibronectin, type III,IPR008197:Whey acidic protein-type  4-disulphide core,IPR009030:Insulin-like growth factor binding protein, N-terminal,IPR011489:EMI domain,IPR013783:Immunoglobulin-like fold,IPR018097:EGF-like calcium-binding, conserved site,				SM00060:FN3,SM00179:EGF_CA,SM00217:WAP,SM00241:ZP,		KW-0472~Membrane,KW-0963~Cytoplasm,KW-1003~Cell membrane,		KW-0245~EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,		KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,DOMAIN:EGF-like 1; calcium-binding,DOMAIN:EGF-like 2; calcium-binding,DOMAIN:EGF-like 3; calcium-binding,DOMAIN:EGF_CA,DOMAIN:EMI,DOMAIN:Fibronectin type-III 1,DOMAIN:Fibronectin type-III 2,DOMAIN:SEA 1,DOMAIN:SEA 2,DOMAIN:WAP,DOMAIN:ZP,REGION:Disordered,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VMP1	vacuole membrane protein 1(VMP1)	Homo sapiens	GO:0000045~autophagosome assembly,GO:0006914~autophagy,GO:0007030~Golgi organization,GO:0007566~embryo implantation,GO:0016240~autophagosome docking,GO:0017121~phospholipid scrambling,GO:0034329~cell junction assembly,GO:0042953~lipoprotein transport,GO:0098609~cell-cell adhesion,GO:1901896~positive regulation of calcium-transporting ATPase activity,GO:1990456~mitochondrion-ER tethering,	GO:0000407~pre-autophagosomal structure,GO:0000421~autophagosome membrane,GO:0005730~nucleolus,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005886~plasma membrane,GO:0012505~endomembrane system,GO:0016020~membrane,GO:0016021~integral component of membrane,GO:0033116~endoplasmic reticulum-Golgi intermediate compartment membrane,	GO:0005515~protein binding,GO:0017128~phospholipid scramblase activity,		hsa04140:Autophagy - animal,				KW-0072~Autophagy,KW-0130~Cell adhesion,KW-0445~Lipid transport,KW-0813~Transport,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0926~Vacuole,KW-1003~Cell membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,	MUTAGEN:G->E: Decreases interaction with ATP2A2.,MUTAGEN:G->R: Decreases interaction with ATP2A2.,REGION:Disordered,REGION:VTT domain,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VEGFA	vascular endothelial growth factor A(VEGFA)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0001525~angiogenesis,GO:0001541~ovarian follicle development,GO:0001569~branching involved in blood vessel morphogenesis,GO:0001570~vasculogenesis,GO:0001666~response to hypoxia,GO:0001701~in utero embryonic development,GO:0001822~kidney development,GO:0001934~positive regulation of protein phosphorylation,GO:0001938~positive regulation of endothelial cell proliferation,GO:0002040~sprouting angiogenesis,GO:0002042~cell migration involved in sprouting angiogenesis,GO:0002052~positive regulation of neuroblast proliferation,GO:0002092~positive regulation of receptor internalization,GO:0002575~basophil chemotaxis,GO:0002687~positive regulation of leukocyte migration,GO:0003007~heart morphogenesis,GO:0003151~outflow tract morphogenesis,GO:0003169~coronary vein morphogenesis,GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007399~nervous system development,GO:0007498~mesoderm development,GO:0007595~lactation,GO:0008284~positive regulation of cell proliferation,GO:0008360~regulation of cell shape,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010749~regulation of nitric oxide mediated signal transduction,GO:0014068~positive regulation of phosphatidylinositol 3-kinase signaling,GO:0030154~cell differentiation,GO:0030224~monocyte differentiation,GO:0030225~macrophage differentiation,GO:0030324~lung development,GO:0030335~positive regulation of cell migration,GO:0030855~epithelial cell differentiation,GO:0031077~post-embryonic camera-type eye development,GO:0031334~positive regulation of protein complex assembly,GO:0031954~positive regulation of protein autophosphorylation,GO:0032147~activation of protein kinase activity,GO:0032793~positive regulation of CREB transcription factor activity,GO:0033138~positive regulation of peptidyl-serine phosphorylation,GO:0035148~tube formation,GO:0035767~endothelial cell chemotaxis,GO:0035924~cellular response to vascular endothelial growth factor stimulus,GO:0036303~lymph vessel morphogenesis,GO:0036324~vascular endothelial growth factor receptor-2 signaling pathway,GO:0038033~positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway,GO:0038084~vascular endothelial growth factor signaling pathway,GO:0038089~positive regulation of cell migration by vascular endothelial growth factor signaling pathway,GO:0038091~positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,GO:0038190~VEGF-activated neuropilin signaling pathway,GO:0042327~positive regulation of phosphorylation,GO:0042462~eye photoreceptor cell development,GO:0043066~negative regulation of apoptotic process,GO:0043117~positive regulation of vascular permeability,GO:0043129~surfactant homeostasis,GO:0043154~negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0043406~positive regulation of MAP kinase activity,GO:0043410~positive regulation of MAPK cascade,GO:0043536~positive regulation of blood vessel endothelial cell migration,GO:0045766~positive regulation of angiogenesis,GO:0045785~positive regulation of cell adhesion,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0048010~vascular endothelial growth factor receptor signaling pathway,GO:0048469~cell maturation,GO:0048593~camera-type eye morphogenesis,GO:0048842~positive regulation of axon extension involved in axon guidance,GO:0048844~artery morphogenesis,GO:0050679~positive regulation of epithelial cell proliferation,GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation,GO:0050918~positive chemotaxis,GO:0050927~positive regulation of positive chemotaxis,GO:0050930~induction of positive chemotaxis,GO:0051272~positive regulation of cellular component movement,GO:0051781~positive regulation of cell division,GO:0051894~positive regulation of focal adhesion assembly,GO:0051897~positive regulation of protein kinase B signaling,GO:0055013~cardiac muscle cell development,GO:0060319~primitive erythrocyte differentiation,GO:0060749~mammary gland alveolus development,GO:0060754~positive regulation of mast cell chemotaxis,GO:0060948~cardiac vascular smooth muscle cell development,GO:0060982~coronary artery morphogenesis,GO:0061042~vascular wound healing,GO:0061419~positive regulation of transcription from RNA polymerase II promoter in response to hypoxia,GO:0070374~positive regulation of ERK1 and ERK2 cascade,GO:0071456~cellular response to hypoxia,GO:0071542~dopaminergic neuron differentiation,GO:0071679~commissural neuron axon guidance,GO:0090037~positive regulation of protein kinase C signaling,GO:0090050~positive regulation of cell migration involved in sprouting angiogenesis,GO:0090190~positive regulation of branching involved in ureteric bud morphogenesis,GO:0090259~regulation of retinal ganglion cell axon guidance,GO:0097475~motor neuron migration,GO:0097533~cellular stress response to acid chemical,GO:1900086~positive regulation of peptidyl-tyrosine autophosphorylation,GO:1900745~positive regulation of p38MAPK cascade,GO:1900748~positive regulation of vascular endothelial growth factor signaling pathway,GO:1901165~positive regulation of trophoblast cell migration,GO:1901727~positive regulation of histone deacetylase activity,GO:1902336~positive regulation of retinal ganglion cell axon guidance,GO:1902966~positive regulation of protein localization to early endosome,GO:1903141~negative regulation of establishment of endothelial barrier,GO:1903392~negative regulation of adherens junction organization,GO:1903572~positive regulation of protein kinase D signaling,GO:1903589~positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,GO:1903672~positive regulation of sprouting angiogenesis,GO:1905278~positive regulation of epithelial tube formation,GO:1905604~negative regulation of maintenance of permeability of blood-brain barrier,GO:2000048~negative regulation of cell-cell adhesion mediated by cadherin,GO:2000573~positive regulation of DNA biosynthetic process,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0005737~cytoplasm,GO:0005912~adherens junction,GO:0009986~cell surface,GO:0016020~membrane,GO:0030141~secretory granule,GO:0031012~extracellular matrix,GO:0031093~platelet alpha granule lumen,GO:1990150~VEGF-A complex,	GO:0001968~fibronectin binding,GO:0005125~cytokine activity,GO:0005161~platelet-derived growth factor receptor binding,GO:0005172~vascular endothelial growth factor receptor binding,GO:0005515~protein binding,GO:0008083~growth factor activity,GO:0008201~heparin binding,GO:0038191~neuropilin binding,GO:0042056~chemoattractant activity,GO:0042802~identical protein binding,GO:0042803~protein homodimerization activity,GO:0043183~vascular endothelial growth factor receptor 1 binding,GO:0043184~vascular endothelial growth factor receptor 2 binding,GO:0048018~receptor agonist activity,GO:0050840~extracellular matrix binding,	IPR000072:Platelet-derived growth factor (PDGF),IPR023581:Platelet-derived growth factor, conserved site,	hsa01521:EGFR tyrosine kinase inhibitor resistance,hsa04010:MAPK signaling pathway,hsa04014:Ras signaling pathway,hsa04015:Rap1 signaling pathway,hsa04020:Calcium signaling pathway,hsa04066:HIF-1 signaling pathway,hsa04151:PI3K-Akt signaling pathway,hsa04370:VEGF signaling pathway,hsa04510:Focal adhesion,hsa04926:Relaxin signaling pathway,hsa04933:AGE-RAGE signaling pathway in diabetic complications,hsa05163:Human cytomegalovirus infection,hsa05165:Human papillomavirus infection,hsa05167:Kaposi sarcoma-associated herpesvirus infection,hsa05200:Pathways in cancer,hsa05205:Proteoglycans in cancer,hsa05206:MicroRNAs in cancer,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05211:Renal cell carcinoma,hsa05212:Pancreatic cancer,hsa05219:Bladder cancer,hsa05323:Rheumatoid arthritis,hsa05418:Fluid shear stress and atherosclerosis,	603933~Microvascular complications of diabetes 1,		SM00141:PDGF,	KW-0037~Angiogenesis,KW-0221~Differentiation,	KW-0964~Secreted,		KW-0732~Signal,		KW-0217~Developmental protein,KW-0339~Growth factor,KW-0358~Heparin-binding,KW-0497~Mitogen,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Basic residues,DISULFID:Interchain,DOMAIN:PDGF_2,REGION:Disordered,
VASN	vasorin(VASN)	Homo sapiens	GO:0010719~negative regulation of epithelial to mesenchymal transition,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0071456~cellular response to hypoxia,GO:0071461~cellular response to redox state,	GO:0005615~extracellular space,GO:0005739~mitochondrion,GO:0005765~lysosomal membrane,GO:0005886~plasma membrane,GO:0009986~cell surface,GO:0016021~integral component of membrane,GO:0031012~extracellular matrix,GO:0070062~extracellular exosome,	GO:0005515~protein binding,GO:0045296~cadherin binding,GO:0050431~transforming growth factor beta binding,	IPR000372:Leucine-rich repeat-containing N-terminal,IPR000483:Cysteine-rich flanking region, C-terminal,IPR000742:Epidermal growth factor-like domain,IPR001611:Leucine-rich repeat,IPR003591:Leucine-rich repeat, typical subtype,IPR003961:Fibronectin, type III,IPR013783:Immunoglobulin-like fold,				SM00013:LRRNT,SM00082:LRRCT,SM00181:EGF,SM00369:LRR_TYP,		KW-0472~Membrane,KW-0964~Secreted,		KW-0245~EGF-like domain,KW-0433~Leucine-rich repeat,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0325~Glycoprotein,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) (complex) asparagine,CARBOHYD:N-linked (GlcNAc...) asparagine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DOMAIN:EGF-like,DOMAIN:Fibronectin type-III,DOMAIN:LRRCT,DOMAIN:LRRNT,REGION:Disordered,REPEAT:LRR 1,REPEAT:LRR 10,REPEAT:LRR 2,REPEAT:LRR 3,REPEAT:LRR 4,REPEAT:LRR 5,REPEAT:LRR 6,REPEAT:LRR 7,REPEAT:LRR 8,REPEAT:LRR 9,TOPO_DOM:Cytoplasmic,TOPO_DOM:Extracellular,TRANSMEM:Helical,
VAV3	vav guanine nucleotide exchange factor 3(VAV3)	Homo sapiens	GO:0001525~angiogenesis,GO:0006906~vesicle fusion,GO:0006974~cellular response to DNA damage stimulus,GO:0007229~integrin-mediated signaling pathway,GO:0007264~small GTPase mediated signal transduction,GO:0008361~regulation of cell size,GO:0009410~response to xenobiotic stimulus,GO:0016477~cell migration,GO:0030032~lamellipodium assembly,GO:0030168~platelet activation,GO:0030593~neutrophil chemotaxis,GO:0030890~positive regulation of B cell proliferation,GO:0035556~intracellular signal transduction,GO:0038095~Fc-epsilon receptor signaling pathway,GO:0038096~Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0042493~response to drug,GO:0043087~regulation of GTPase activity,GO:0043552~positive regulation of phosphatidylinositol 3-kinase activity,GO:0045785~positive regulation of cell adhesion,GO:0050853~B cell receptor signaling pathway,GO:0051056~regulation of small GTPase mediated signal transduction,	GO:0001772~immunological synapse,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0005886~plasma membrane,	GO:0005085~guanyl-nucleotide exchange factor activity,GO:0005096~GTPase activator activity,GO:0005154~epidermal growth factor receptor binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR000219:Dbl homology (DH) domain,IPR000980:SH2 domain,IPR001331:Guanine-nucleotide dissociation stimulator, CDC24, conserved site,IPR001452:Src homology-3 domain,IPR001715:Calponin homology domain,IPR001849:Pleckstrin homology domain,IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding,IPR003096:Smooth muscle protein/calponin,IPR011993:Pleckstrin homology-like domain,IPR022613:Calmodulin-regulated spectrin-associated protein, CH domain,	hsa04015:Rap1 signaling pathway,hsa04024:cAMP signaling pathway,hsa04062:Chemokine signaling pathway,hsa04510:Focal adhesion,hsa04650:Natural killer cell mediated cytotoxicity,hsa04660:T cell receptor signaling pathway,hsa04662:B cell receptor signaling pathway,hsa04664:Fc epsilon RI signaling pathway,hsa04666:Fc gamma R-mediated phagocytosis,hsa04670:Leukocyte transendothelial migration,hsa04810:Regulation of actin cytoskeleton,hsa05135:Yersinia infection,hsa05205:Proteoglycans in cancer,hsa05417:Lipid and atherosclerosis,			SM00033:CH,SM00109:C1,SM00233:PH,SM00252:SH2,SM00325:RhoGEF,SM00326:SH3,	KW-0037~Angiogenesis,			KW-0677~Repeat,KW-0727~SH2 domain,KW-0728~SH3 domain,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0344~Guanine-nucleotide releasing factor,	KW-0597~Phosphoprotein,	DOMAIN:Calponin-homology (CH),DOMAIN:DH,DOMAIN:PH,DOMAIN:Phorbol-ester/DAG-type,DOMAIN:SH2,DOMAIN:SH3,DOMAIN:SH3 1,DOMAIN:SH3 2,REGION:Sufficient for interaction with ROS1,ZN_FING:Phorbol-ester/DAG-type,
VEPH1	ventricular zone expressed PH domain containing 1(VEPH1)	Homo sapiens	GO:0009966~regulation of signal transduction,GO:0030512~negative regulation of transforming growth factor beta receptor signaling pathway,GO:0060392~negative regulation of SMAD protein import into nucleus,	GO:0005886~plasma membrane,	GO:0005515~protein binding,GO:0010314~phosphatidylinositol-5-phosphate binding,	IPR001849:Pleckstrin homology domain,IPR011993:Pleckstrin homology-like domain,IPR016024:Armadillo-type fold,				SM00233:PH,		KW-0472~Membrane,KW-1003~Cell membrane,						DOMAIN:PH,REGION:Disordered,REGION:Interaction with TGFBR1,
VAT1L	vesicle amine transport 1 like(VAT1L)	Homo sapiens			GO:0005515~protein binding,GO:0008270~zinc ion binding,GO:0016491~oxidoreductase activity,	IPR002364:Quinone oxidoreductase/zeta-crystallin, conserved site,IPR011032:GroES-like,IPR013154:Alcohol dehydrogenase GroES-like,IPR020843:Polyketide synthase, enoylreductase,				SM00829:SM00829,						KW-0560~Oxidoreductase,	KW-0597~Phosphoprotein,	COMPBIAS:Basic and acidic residues,DOMAIN:PKS_ER,REGION:Disordered,
VGLL2	vestigial like family member 2(VGLL2)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,GO:0007519~skeletal muscle tissue development,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,GO:0005737~cytoplasm,	GO:0003713~transcription coactivator activity,GO:0005515~protein binding,GO:0008022~protein C-terminus binding,	IPR011520:Vestigial/tondu,					KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,						COMPBIAS:Polar residues,REGION:Disordered,
VIM	vimentin(VIM)	Homo sapiens	GO:0010628~positive regulation of gene expression,GO:0010977~negative regulation of neuron projection development,GO:0014002~astrocyte development,GO:0031175~neuron projection development,GO:0032967~positive regulation of collagen biosynthetic process,GO:0043488~regulation of mRNA stability,GO:0045109~intermediate filament organization,GO:0045727~positive regulation of translation,GO:0060020~Bergmann glial cell differentiation,GO:0060395~SMAD protein signal transduction,GO:0070307~lens fiber cell development,GO:0071222~cellular response to lipopolysaccharide,GO:0071225~cellular response to muramyl dipeptide,GO:0071346~cellular response to interferon-gamma,	GO:0005737~cytoplasm,GO:0005777~peroxisome,GO:0005815~microtubule organizing center,GO:0005829~cytosol,GO:0005844~polysome,GO:0005856~cytoskeleton,GO:0005882~intermediate filament,GO:0005886~plasma membrane,GO:0005925~focal adhesion,GO:0016363~nuclear matrix,GO:0030424~axon,GO:0031252~cell leading edge,GO:0043005~neuron projection,GO:0045111~intermediate filament cytoskeleton,GO:0045335~phagocytic vesicle,GO:0070062~extracellular exosome,GO:1990904~ribonucleoprotein complex,	GO:0003725~double-stranded RNA binding,GO:0005200~structural constituent of cytoskeleton,GO:0005212~structural constituent of eye lens,GO:0005515~protein binding,GO:0019904~protein domain specific binding,GO:0042802~identical protein binding,GO:0060090~binding, bridging,GO:0097110~scaffold protein binding,GO:1990254~keratin filament binding,	IPR006821:Intermediate filament head, DNA-binding domain,IPR018039:Intermediate filament protein, conserved site,	hsa05169:Epstein-Barr virus infection,hsa05206:MicroRNAs in cancer,	116300~Cataract 30, pulverulent,		SM01391:SM01391,	KW-0945~Host-virus interaction,	KW-0206~Cytoskeleton,KW-0403~Intermediate filament,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-0898~Cataract,	KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0325~Glycoprotein,KW-0597~Phosphoprotein,KW-0702~S-nitrosylation,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CARBOHYD:O-linked (GlcNAc) serine; alternate,CARBOHYD:O-linked (GlcNAc) threonine,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:Filament_head,DOMAIN:IF rod,MOTIF:[IL]-x-C-x-x-[DE] motif,REGION:Coil 1A,REGION:Coil 1B,REGION:Coil 2,REGION:Disordered,REGION:Head,REGION:Linker 1,REGION:Linker 12,REGION:Tail,SITE:Stutter,
VWA5B2	von Willebrand factor A domain containing 5B2(VWA5B2)	Homo sapiens				IPR002035:von Willebrand factor, type A,IPR013694:VIT domain,												COMPBIAS:Polar residues,DOMAIN:VIT,DOMAIN:VWFA,REGION:Disordered,
VWC2L	von Willebrand factor C domain containing 2 like(VWC2L)	Homo sapiens	GO:0030514~negative regulation of BMP signaling pathway,GO:0045666~positive regulation of neuron differentiation,	GO:0005576~extracellular region,GO:0005615~extracellular space,GO:0032281~AMPA glutamate receptor complex,GO:0045202~synapse,	GO:0005515~protein binding,	IPR001007:von Willebrand factor, type C,				SM00214:VWC,		KW-0770~Synapse,KW-0964~Secreted,		KW-0677~Repeat,KW-0732~Signal,		KW-0217~Developmental protein,KW-9996~Developmental protein,		DOMAIN:VWFC 1,DOMAIN:VWFC 2,
ZC3H12A	zinc finger CCCH-type containing 12A(ZC3H12A)	Homo sapiens	GO:0000294~nuclear-transcribed mRNA catabolic process, endonucleolytic cleavage-dependent decay,GO:0001525~angiogenesis,GO:0001933~negative regulation of protein phosphorylation,GO:0002230~positive regulation of defense response to virus by host,GO:0002757~immune response-activating signal transduction,GO:0006915~apoptotic process,GO:0006954~inflammatory response,GO:0006974~cellular response to DNA damage stimulus,GO:0007399~nervous system development,GO:0010468~regulation of gene expression,GO:0010508~positive regulation of autophagy,GO:0010587~miRNA catabolic process,GO:0010595~positive regulation of endothelial cell migration,GO:0010628~positive regulation of gene expression,GO:0010629~negative regulation of gene expression,GO:0010656~negative regulation of muscle cell apoptotic process,GO:0010884~positive regulation of lipid storage,GO:0010942~positive regulation of cell death,GO:0016579~protein deubiquitination,GO:0030154~cell differentiation,GO:0032088~negative regulation of NF-kappaB transcription factor activity,GO:0032689~negative regulation of interferon-gamma production,GO:0032691~negative regulation of interleukin-1 beta production,GO:0032715~negative regulation of interleukin-6 production,GO:0032720~negative regulation of tumor necrosis factor production,GO:0034599~cellular response to oxidative stress,GO:0042149~cellular response to glucose starvation,GO:0042307~positive regulation of protein import into nucleus,GO:0043031~negative regulation of macrophage activation,GO:0043124~negative regulation of I-kappaB kinase/NF-kappaB signaling,GO:0044828~negative regulation by host of viral genome replication,GO:0045019~negative regulation of nitric oxide biosynthetic process,GO:0045600~positive regulation of fat cell differentiation,GO:0045766~positive regulation of angiogenesis,GO:0045944~positive regulation of transcription from RNA polymerase II promoter,GO:0050852~T cell receptor signaling pathway,GO:0051259~protein oligomerization,GO:0051607~defense response to virus,GO:0055118~negative regulation of cardiac muscle contraction,GO:0061014~positive regulation of mRNA catabolic process,GO:0061158~3'-UTR-mediated mRNA destabilization,GO:0071222~cellular response to lipopolysaccharide,GO:0071347~cellular response to interleukin-1,GO:0071356~cellular response to tumor necrosis factor,GO:0090501~RNA phosphodiester bond hydrolysis,GO:0090502~RNA phosphodiester bond hydrolysis, endonucleolytic,GO:0090503~RNA phosphodiester bond hydrolysis, exonucleolytic,GO:0098586~cellular response to virus,GO:1900016~negative regulation of cytokine production involved in inflammatory response,GO:1900119~positive regulation of execution phase of apoptosis,GO:1900745~positive regulation of p38MAPK cascade,GO:1901223~negative regulation of NIK/NF-kappaB signaling,GO:1903003~positive regulation of protein deubiquitination,GO:1903799~negative regulation of production of miRNAs involved in gene silencing by miRNA,GO:1903936~cellular response to sodium arsenite,GO:1904637~cellular response to ionomycin,GO:1990869~cellular response to chemokine,GO:2000320~negative regulation of T-helper 17 cell differentiation,GO:2000379~positive regulation of reactive oxygen species metabolic process,GO:2000627~positive regulation of miRNA catabolic process,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005791~rough endoplasmic reticulum,GO:0005856~cytoskeleton,GO:0030867~rough endoplasmic reticulum membrane,GO:0032991~macromolecular complex,GO:0036464~cytoplasmic ribonucleoprotein granule,GO:0042406~extrinsic component of endoplasmic reticulum membrane,	GO:0003677~DNA binding,GO:0003682~chromatin binding,GO:0003723~RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0004521~endoribonuclease activity,GO:0004532~exoribonuclease activity,GO:0004540~ribonuclease activity,GO:0004843~thiol-dependent ubiquitin-specific protease activity,GO:0005515~protein binding,GO:0016787~hydrolase activity,GO:0035198~miRNA binding,GO:0035613~RNA stem-loop binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0043022~ribosome binding,GO:0046872~metal ion binding,	IPR021869:Ribonuclease Zc3h12a-like,					KW-0037~Angiogenesis,KW-0051~Antiviral defense,KW-0053~Apoptosis,KW-0221~Differentiation,KW-0227~DNA damage,KW-0346~Stress response,KW-0391~Immunity,KW-0395~Inflammatory response,KW-0524~Neurogenesis,KW-0804~Transcription,KW-0805~Transcription regulation,KW-0945~Host-virus interaction,	KW-0256~Endoplasmic reticulum,KW-0472~Membrane,KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0863~Zinc-finger,	KW-0460~Magnesium,KW-0479~Metal-binding,KW-0862~Zinc,	KW-0217~Developmental protein,KW-0238~DNA-binding,KW-0255~Endonuclease,KW-0378~Hydrolase,KW-0540~Nuclease,KW-0678~Repressor,KW-0694~RNA-binding,KW-9996~Developmental protein,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,	COMPBIAS:Polar residues,DOMAIN:RNase NYN,DOMAIN:UBA_6,MUTAGEN:C->A: Does not inhibit antiviral effects.,MUTAGEN:C->G: Inhibits transcriptional activity; when associated with G-311.,MUTAGEN:C->G: Inhibits transcriptional activity; when associated with G-317.,MUTAGEN:C->R: Loss of interleukin IL17A mRNA instability. Reduces weakly pre-miRNA RNase activity. Attenuates miRNA silencing activity. Does not inhibits binding to Japanese encephalitis virus (JEV) and dengue virus (DEN) RNAs and weakly attenuates antiviral effects. Loss of HIV-1 antiviral activity.,MUTAGEN:D->A: Loss of pre-miRNA RNase activity, IL17A mRNA instability and antiviral effects; when associated with A-225. Loss of IL1B mRNA instability; when associated with N-141.,MUTAGEN:D->A: Loss of pre-miRNA RNase activity, IL17A mRNA instability and antiviral effects; when associated with A-226.,MUTAGEN:D->N: Abolishes RNase activity.,MUTAGEN:D->N: Loss of pre-miRNA RNase activity. Attenuates strongly miRNA silencing activity. Loss of interleukin IL17A and IL6 mRNA instabilities. Reduces angiogenic differentiation. Loss of RNase activity on JEV and DEN viral RNAs and antiviral effects. Loss of HIV-1 antiviral activity. Loss of IL1B mRNA instability; when associated with A-226.,MUTAGEN:K->G: Inhibits transcriptional activity; when associated with G-312.,MUTAGEN:K->G: Inhibits transcriptional activity; when associated with G-318.,MUTAGEN:N->A: No change in RNase activity.,MUTAGEN:R->A: Abolishes RNase activity.,REGION:Disordered,REGION:Necessary for interaction with TANK,REGION:Necessary for interaction with ZC3H12D,REGION:RNA binding,REGION:RNase,REGION:Ubiquitin association domain,ZN_FING:C3H1-type,
ZDHHC22	zinc finger DHHC-type palmitoyltransferase 22(ZDHHC22)	Homo sapiens	GO:0006612~protein targeting to membrane,GO:0018230~peptidyl-L-cysteine S-palmitoylation,GO:0018345~protein palmitoylation,GO:0072659~protein localization to plasma membrane,	GO:0000139~Golgi membrane,GO:0005783~endoplasmic reticulum,GO:0005789~endoplasmic reticulum membrane,GO:0005794~Golgi apparatus,GO:0005886~plasma membrane,GO:0016021~integral component of membrane,	GO:0005515~protein binding,GO:0019706~protein-cysteine S-palmitoyltransferase activity,	IPR000731:Sterol-sensing domain,IPR001594:Zinc finger, DHHC-type, palmitoyltransferase,						KW-0256~Endoplasmic reticulum,KW-0333~Golgi apparatus,KW-0472~Membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,		KW-0012~Acyltransferase,KW-0808~Transferase,	KW-0449~Lipoprotein,KW-0564~Palmitate,	ACT_SITE:S-palmitoyl cysteine intermediate,DOMAIN:DHHC,TOPO_DOM:Cytoplasmic,TOPO_DOM:Lumenal,TRANSMEM:Helical,
ZBTB9	zinc finger and BTB domain containing 9(ZBTB9)	Homo sapiens	GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding,GO:0005515~protein binding,GO:0042802~identical protein binding,GO:0046872~metal ion binding,	IPR000210:BTB/POZ-like,IPR011333:BTB/POZ fold,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00225:BTB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,	KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate,DOMAIN:BTB,DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2; atypical,
ZNF217	zinc finger protein 217(ZNF217)	Homo sapiens	GO:0000122~negative regulation of transcription from RNA polymerase II promoter,GO:0006355~regulation of transcription, DNA-templated,GO:0045892~negative regulation of transcription, DNA-templated,	GO:0000118~histone deacetylase complex,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0016607~nuclear speck,	GO:0000976~transcription regulatory region sequence-specific DNA binding,GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0001227~transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding,GO:0003700~transcription factor activity, sequence-specific DNA binding,GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,KW-0678~Repressor,	KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:C2H2-type,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,
ZNF311	zinc finger protein 311(ZNF311)	Homo sapiens	GO:0006355~regulation of transcription, DNA-templated,GO:0006357~regulation of transcription from RNA polymerase II promoter,	GO:0005634~nucleus,	GO:0000978~RNA polymerase II core promoter proximal region sequence-specific DNA binding,GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding,GO:0046872~metal ion binding,	IPR001909:Krueppel-associated box,IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,	hsa05168:Herpes simplex virus 1 infection,			SM00349:KRAB,SM00355:ZnF_C2H2,	KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,		KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,	KW-0238~DNA-binding,		COMPBIAS:Polar residues,DOMAIN:C2H2-type,DOMAIN:KRAB,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 10,ZN_FING:C2H2-type 11,ZN_FING:C2H2-type 12,ZN_FING:C2H2-type 13,ZN_FING:C2H2-type 14,ZN_FING:C2H2-type 2,ZN_FING:C2H2-type 3,ZN_FING:C2H2-type 4,ZN_FING:C2H2-type 5,ZN_FING:C2H2-type 6,ZN_FING:C2H2-type 7,ZN_FING:C2H2-type 8,ZN_FING:C2H2-type 9,
ZNF474	zinc finger protein 474(ZNF474)	Homo sapiens			GO:0005515~protein binding,GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,IPR026319:Zinc finger C2HC domain-containing protein,								KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Polar residues,REGION:Disordered,ZN_FING:C2H2-type; degenerate,
ZNF831	zinc finger protein 831(ZNF831)	Homo sapiens			GO:0046872~metal ion binding,	IPR013087:Zinc finger C2H2-type/integrase DNA-binding domain,				SM00355:ZnF_C2H2,				KW-0175~Coiled coil,KW-0677~Repeat,KW-0863~Zinc-finger,	KW-0479~Metal-binding,KW-0862~Zinc,			COMPBIAS:Basic and acidic residues,COMPBIAS:Polar residues,COMPBIAS:Pro residues,REGION:Disordered,ZN_FING:C2H2-type 1,ZN_FING:C2H2-type 2,
